COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit under 35 U.S.C. § 1 19(e) of U.S. Provisional Patent Application No. 61/362, 135 filed July 7, 2010; and U.S. Provisional Patent Application No. 61/443,634 filed February 16, 201 1 , where these provisional applications are incorporated herein by reference in their entireties.

BACKGROUND Field

The present invention is directed to novel phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, and methods for their preparation and use as therapeutic or prophylactic agents.

Description of the Related Art

Patients with inadequate renal function, hypoparathyroidism, or certain other medical conditions (such as hereditary hyperphosphatemia, Albright hereditary osteodystrophy, amyloidosis, etc.) often have hyperphosphatemia, or elevated serum phosphate levels (wherein the level, for example, is more than about 6 mg/dL). Hyperphosphatemia, especially if present over extended periods of time, leads to severe abnormalities in calcium and phosphorus metabolism, often manifested by secondary hyperparathyroidism, bone disease and ectopic calcification in the cardiovascular system, joints, lungs, eyes and other soft tissues. Higher serum phosphorus levels are strongly associated with the progression of renal failure, cardiovascular calcification and mortality in end-stage renal disease (ESRD) patients. High-normal serum phosphorus levels have been associated with cardiovascular events and mortality among individuals who have chronic kidney disease (CKD) and among those who have normal kidney function (see, e.g. , Joy, M.S., P.C. Karagiannis and F.W. Peyerl, Outcomes of Secondary Hyperparathyroidism in Chronic Kidney Disease and the Direct Costs of Treatment, J. Manag. Care Pharm., 13(5):397-411 (2007)) The progression of kidney disease can be slowed by reducing phosphate retention. Thus, for renal failure patients who are hyperphosphatemic and for chronic kidney disease patients who have serum phosphate levels within the normal range or only slightly elevated, therapy to reduce phosphate retention is beneficial.

For patients who experience hyperphosphatemia, calcium salts have been widely used to bind intestinal phosphate and prevent its absorption. Different types of calcium salts, including calcium carbonate, acetate, citrate, alginate, and ketoacid salts have been utilized for phosphate binding. A problem with all of these therapeutics is the hypercalcemia, which often results from absorption of high amounts of ingested calcium. Hypercalcemia causes serious side effects such as cardiac arrhythmias, renal failure, and skin and vascular calcification. Frequent monitoring of serum calcium levels is required during therapy with calcium-based phosphate binders. Other calcium and aluminum-free phosphate binders, such as sevelamer, a crosslinked polyamine polymer, have drawbacks that include the amount and frequency of dosing required to be therapeutically active. The relatively modest phosphate binding capacity of those drugs in vivo obliges patients to escalate the dose (up to 7 grs per day or more). Such quantities have been shown to produce gastrointestinal discomfort, such as dyspepsia, abdominal pain and, in some extreme cases, bowel perforation.

An alternative approach to the prevention of phosphate absorption from the intestine in patients with elevated phosphate serum levels is through inhibition of the intestinal transport system which mediates phosphate uptake in the intestine. It is understood that phosphate absorption in the upper intestine is mediated at least in part by a carrier-mediated mechanism which couples the absorption of phosphate to that of sodium. Inhibition of intestinal phosphate transport will reduce body phosphorus overload. In patients with advanced kidney disease (e.g. stage 4 and 5), the body phosphorus overload manifests itself by serum phosphate concentration above normal levels, i.e. hyperphosphatemia. Hyperphosphatemia is directly related to mortality and morbidity. Inhibition of intestinal phosphate transport will reduce serum phosphate concentration and therefore improve outcome in those patients. In chronic kidney disease patients stage 2 and 3, the body phosphorus overload does not necessarily lead to hyperphosphatemia, i.e. patients remain normophosphatemic, but there is a need to reduce body phosphorus overload even at those early stages to avoid associated bone and vascular disorders, and ultimately improve mortality rate. Similarly, inhibition of intestinal phosphate transport would be particularly advantageous in patients that have a disease that is treatable by inhibiting the uptake of phosphate from the intestines. Inhibition of phosphate absorption from the glomerular filtrate within the kidneys would also be advantageous for treating chronic renal failure. Furthermore, inhibition of phosphate transport may slow the progression of renal failure and reduce risk of cardiovascular events.

While progress has been made in this field, there remains a need in the art for novel phosphate transport inhibitors. The present invention fulfills this need and provides further related advantages.

BRIEF SUMMARY

In brief, the present invention is directed to compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, and the use of such compounds to inhibit sodium- mediated phosphate uptake and to thereby treat any of a variety of conditions or diseases in which modulation of sodium-mediated phosphate uptake provides a therapeutic benefit.

In one embodiment of the invention, for example, there is provided a compound having (i) a tPSA of at least about 174 A ² or (ii) a tPSA of at least about 174 A ² and a molecular weight of at least about 736 Daltons, wherein the compound is substantially active in the gastrointestinal tract as an inhibitor of Na/phosphate co- transport upon administration to a patient in need thereof, and wherein the compound is substantially non-systemically bioavailable, and wherein the compound has an NaPi2b inhibitory concentration IC50 of less than about 10 uM.

In another embodiment, there is provided a compound having (i) a tPSA of at least about 190 A ² or (ii) a tPSA of at least about 190 A ² and a molecular weight of at least about 736 Daltons, wherein the compound is substantially active in the gastrointestinal tract and is not a competitive inhibitor with respect to phosphate of Na/phosphate co-transport upon administration to a patient in need thereof, wherein the compound is substantially non-systemically bioavailable.

In yet another embodiment, there is provided a compound having (i) a tPSA of at least about 162 A ² or (ii) a tPSA of at least about 162 A ² and a molecular weight of at least about 641 Daltons, wherein the compound is substantially active in the gastrointestinal tract as and is not a competitive inhibitor with respect to phosphate of Na/phosphate co-transport upon administration to a patient in need thereof, wherein the compound is substantially non-systemically bioavailable, wherein greater than about 50% of the compound is recoverable from the feces over a 72 hour period following administration to a patient in need thereof.

In another embodiment of the invention, there is provided a compound having (i) a tPSA of at least about 196 A ² or (ii) a tPSA of at least about 196 A ² and a molecular weight of at least about 736 Daltons, wherein the compound is substantially active in the gastrointestinal tract as an inhibitor of Na/phosphate co-transport upon administration to a patient in need thereof, and wherein the compound is substantially non-systemically bioavailable.

In another embodiment, the Na/phosphate co-transport that is inhibited by a compound of the invention is mediated by NaPi2b.

In another embodiment, a compound of the invention has a tPSA of at least about 190 A ² , 196 A ² , 200 A ² , 225 A ² , 250 A ² , 300 A ² , 350 A ² , 400 A ² , 450 A ² , 500 A ² , 750 A ² or 1000 A ² .

In another embodiment, a compound of the invention has a MW of at least about 545, 550, 575, 600, 625, 650, 675, 700, 725. 750, 775, 800, 900, 1000, 1100, 1200, 1300, 1400 or 1500 Daltons.

In yet another embodiment, greater than about 60%, 70%, 80% or 90% of a compound of the invention is recoverable from the feces over a 72 hour period following administration to a patient in need thereof.

In another embodiment, a compound of the invention has (i) a number of NH and/or OH and/or other potential hydrogen bond donor moieties greater than about 5; (ii) a total number of O atoms and/or N atoms and/or other potential hydrogen bond acceptors greater than about 10; and/or (iii) a Moriguchi partition coefficient greater than about 10 ⁵ or less than about 10.

In still another embodiment, a compound of the invention has a total number of rotatable bonds greater than about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15.

In another embodiment, a compound of the invention has a permeability coefficient, P _app , of less than about 100 x 10 ^"6 cm/s, or less than about 10 x 10 ^"6 cm/s, or less than about 1 x 10 ^"6 cm/s, or less than about 0.1 x 10 ^"6 cm/s.

In another embodiment, a compound of the invention is substantially impermeable to the epithelium of the gastrointestinal tract.

In yet another embodiment, a compound of the invention is substantially stable under physiological conditions in the gastrointestinal tract. For example, in certain embodiments, the compound has a tj ₂ greater than about 3, 4, 5, 6, 7 or 8 hours in simulated intestinal or gastric fluid (e.g., Simulated Gastric Fluid (SGF) standard USP solution with 3 mg/ml pepsin; Simulated Intestinal Fluid (SIF) standard USP solution with 3 mg/ml pancreatin, and/or other simulated fluid as defined, e.g., in U.S. Pharmacopeia-National Formulary). For example, in certain embodiments, the compound may be recovered at greater than about 50%, 60%, 70%, 80%, 90% or 95% following treatment of the compound in a simulated intestinal or gastric fluid for about 6 hours.

In still another embodiment, a compound of the invention is substantially inert with regard to gastrointestinal flora.

In another embodiment, a compound of the invention, upon administration to a patient in need thereof, exhibits a maximum concentration detected in the serum, defined as C _max , that is lower than the NaPi2b inhibitory concentration IC50 of the compound.

In another embodiment, a compound of the present invention is one that does not interfere with a phosphate binding compound.

In yet another embodiment, a compound of the invention has a pIC50 greater than about 4, 5, 6, 7 or 8 for cells expressing rat or human NaPi2b. In still another embodiment, systemic exposure to a compound of the invention is < 10% of IC ₅₀ at PD dose, with fecal recovery of > 80% of the compound and/or its metabolites.

In another embodiment, a compound of the present invention has a NaPi2b inhibitory concentration IC ₅ o of less than about 10 uM, 9 uM, 8 uM, 7 uM, 6 uM, 5 uM, 4 uM, 3 uM, 2 uM or 1 uM.

In still another embodiment, a compound of the invention is a monomeric compound, e.g., the compound comprises only one pharmacophore entity acting as an inhibitor of phosphate transport, distinct from a multimeric compound (e.g. dimer, trimer) where multiple pharmacophores are present in the same molecules.

In another embodiment, a pharmaceutical composition is provided comprising a compound of the invention, as described herein, or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable carrier, diluent or excipient.

In yet another embodiment, the pharmaceutical composition comprising a compound of the invention may further comprise one or more additional biologically active agents of interest. The compound and the one or more additional biologically active agents may be administered as part of a single pharmaceutical preparation or as individual pharmaceutical preparations, which may be administered either sequentially or simultaneously.

In still another embodiment, the additional biologically active agent included in a pharmaceutical composition of the invention is selected, for example, from vitamin D ₂ (ergocalciferol), vitamin D ₃ (cholecalciferol), active vitamin D (calcitriol) and active vitamin D analogs (e.g. doxercalciferol, paricalcitol)

In another embodiment, the additional biologically active agent included in a pharmaceutical composition of the invention is a phosphate binder, such as Renvela, Renagel, Fosrenol, calcium carbonate, calcium acetate (e.g. Phoslo), MCI- 196, Zerenex™, Fermagate, APS1585, SBR-759, PA-21, and the like.

In still another embodiment, a compound or composition of the invention may be used in a method for treating essentially any disease or other condition in a patient which would benefit from phosphate uptake inhibition in the gastrointestinal tract of the patient. For example, in more specific embodiments, a compounds or composition of the invention can be used in a method selected from the group consisting of: (a) a method for treating hyperphosphatemia; (b) a method for treating a renal disease (e.g., chronic kidney disease or end stage renal disease); (c) a method for delaying time to dialysis; (d) a method for attenuating intima localized vascular calcification; (e) a method for reducing the hyperphosphatemic effect of active vitamin D; (f) a method for reducing FGF23 levels; (g) a method for attenuating hyperparathyroidism; (h) a method for improving endothelial dysfunction induced by postprandial serum phosphate; (i) a method for reducing urinary phosphorous; (j) a method for normalizing serum phosphorus levels; (k) a method for treating proteinura; and (1) a method for reducing serum PTH and serum phosphate concentrations or levels.

In yet another embodiment, the methods of the invention may comprise, in addition to the administration of a compound of the invention, one or more additional biologically active agents of interest. The compound and the one or more additional biologically active agents may be administered as part of a single pharmaceutical preparation or as individual pharmaceutical preparations, which may be administered either sequentially or simultaneously.

In another embodiment, the additional biologically active agent included in the methods of the invention is selected, for example, from vitamin D ₂ (ergocalciferol), vitamin D ₃ (cholecalciferol), active vitamin D (calcitriol) and active vitamin D analogs (e.g. doxercalciferol, paricalcitol).

In still another embodiment, the additional biologically active agent included in the methods of the invention is a phosphate binder, such as Renvela, Renagel, Fosrenol, calcium carbonate, calcium acetate (e.g. Phoslo), MCI- 196, Zerenex™, Fermagate, APS1585, SBR-759, PA-21 , or the like.

These and other aspects of the invention will be apparent upon reference to the following detailed description.

DETAILED DESCRIPTION

In the following description, certain specific details are set forth in order to provide a thorough understanding of various embodiments of the invention. However, one skilled in the art will understand that the invention may be practiced without these details.

Unless the context requires otherwise, throughout the present specification and claims, the word "comprise" and variations thereof, such as, "comprises" and "comprising" are to be construed in an open, inclusive sense, that is as "including, but not limited to".

Reference throughout this specification to "one embodiment" or "an embodiment" means that a particular feature, structure or. characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, the appearances of the phrases "in one embodiment" or "in an embodiment" in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.

In accordance with the present disclosure, it has been discovered that phosphate absorption from the intestine in patients with elevated phosphate serum levels may be limited, and preferably substantially prevented, through inhibition of the intestinal transport system which mediates phosphate uptake in the intestine. This inhibition may be achieved by the administration of certain compounds, and/or pharmaceutical compositions comprising them, which may advantageously be designed such that little, or substantially none, of the compound is absorbed into the blood stream (that is, it is designed to be non-systemic or substantially non-systemic). In this regard, the compounds have features that give rise to little or substantially no systemic availability. In other words, the compounds are not absorbed into the bloodstream at meaningful levels and therefore have no activity there, but instead have their activity localized substantially within the GI tract.

Therefore, in certain illustrative embodiments as further described herein, the compounds of the invention generally require a combination of structural and/or functional features relating or contributing to their activity in the GI tract and/or their substantial non-systemic bioavailability. Such features may include, for example, one or more of (i) specific tPSA and/or MW values (e.g., at least about 190 A ² and/or at least about 736 Daltons, respectively), (ii) specific levels of fecal recovery of the compound and/or its metabolites after administration (e.g., greater than 50% at 72 hours); (iii) specific numbers of NH and/or OH and/or potentially hydrogen bond donor moieties (e.g., greater than about five); (iv) specific numbers of rotatable bonds (e.g., greater than about five); (iv) specific permeability features (e.g., P _app less than about 100 x 10 ^"6 cm/s); and/or any of a number of other features and characteristics as described herein.

The compounds of the present invention offer numerous advantages in the treatment of GI tract and other disorders. For example, the compounds are active on the phosphate transporter apically located in the intestine and essentially do not reach other phosphate transporters expressed in other tissues and organs. For instance the NaPi2b transporter is primarily expressed in the apical membrane of intestinal enterocytes, but is also found in salivary glands, mammary glands, lung, kidney, pancreas, ovary, prostate, testis and liver (Feild et al, 1999, Biochem Biophys Res Commun, v. 258, no. 3, p. 578-582; Bai et al, 2000, Am J Physiol Cell Physiol, v. 279, no. 4, p. CI 135-C1143; Virkki et al, 2007, Am J Physiol Renal Physiol, v. 293, no, 3, p. F643-F654). Genome wide single-nucleotide polymorphism analysis in patients with pulmonary alveolar microlithiasis (PAM) has revealed a link between a mutated NaPi2b gene and disorder in which microliths are formed in the lung alveolar space. Homozygous inactivating mutations of pulmonary NaPi2b have also been implicated in the pathophysiology of PAM (Huqun et al, 2007, Am J Respir Crit Care Med, v. 175, no. 3, p. 263-268). Consistent with this human study, calcification nodules were evident in NaPi2b conditional knockout mice but not in wild type animals after NaPi2b deletion. In contrast, analysis of kidney and ileum samples revealed no pathologic abnormalities associated with Npt2b deletion (Sabbagh et al, 2009, J Am Soc.Nephrol., 20: 2348-2358).

The essentially non-systemic NaPi2b inhibitors of the present invention do not interfere with the pulmonary function of NaPi2b and, therefore, potential pulmonary toxicity is minimized. In addition, certain patient populations to whom the compounds of the invention may be administered are expected to have limited kidney clearance rate secondary to a declining kidney function. Thus, systemic compounds with some kidney clearance contribution in their excretion pathway can accumulate in the plasma, potentially leading to undesired side-effects in those patients with chronic kidney disease (Sica, 2008, J Clin Hypertens.(Greenwich.), v. 10, no. 7, p. 541-548). The compounds of the invention do not give rise to these same concerns because of their limited systemic availability.

As further detailed below, phosphate absorption in the upper intestine is mediated, at least in part, by a carrier-mediated mechanism which couples the absorption of phosphate to that of sodium. Accordingly, inhibition of intestinal phosphate transport will reduce body phosphorus overload. In patients with advanced kidney disease (e.g. stage 4 and 5), the body phosphorus overload manifests itself by serum phosphate concentration above normal levels, i.e. hyperphosphatemia. Hyperphosphatemia is directly related to mortality and morbidity. Inhibition of intestinal phosphate transport will reduce serum phosphate concentration and therefore improve outcome in those patients. In stage 2 and 3 chronic kidney disease patients, the body phosphorus overload does not necessarily lead to hyperphosphatemia, i.e. patients remain normophosphatemic, but there is a need to reduce body phosphorus overload even at those early stages to avoid associated bone and vascular disorders, and ultimately improve mortality rate. Similarly, inhibition of intestinal phosphate transport will be particularly advantageous in patients that have a disease that is treatable by inhibiting the uptake of phosphate from the intestines. Inhibition of phosphate absorption from the glomerular filtrate within the kidneys would also be advantageous for treating chronic renal failure. Furthermore, inhibition of phosphate transport may slow the progression of renal failure and reduce risk of cardiovascular events.

Without being held to any particular theory, it is generally believed that, in vertebrates, phosphate (Pi) transporters use the inwardly directed electrochemical gradient of Na+ ions, established by the Na K ATPase transporter, to drive Pi influx. These transporters fall in three distinct and unrelated Pi transporters proteins named type I, II and III. NaPi type I transporters comprise NaPi-I, mainly expressed in the proximal and distal renal tubules. NaPi type II transporters comprise NaPi2a, NaPi2b, and NaPi2c. NaPi2a is localized in the apical membrane of proximal renal tubule, but is also detected in rat brain, osteoclasts and osteoblast-like cells. NaPi2b is expressed in the apical membrane of enterocytes, but also found in lung, colon, testis and liver (see, :g, Virkki, L.Y., et al, Phosphate Transporters: A Tale of Two Solute Carrier ^f amilies, Am. J. Physiol. Renal. Physiol., 293(3):F643-54 (2007)). Type III NaPi ransporters comprise PiT-1 and PiT-2, which are now emerging as important players in >one Pi metabolism and vascular calcification.

NaPi2a is believed to play a key role in phosphorus homeostasis by controlling the reabsorption of Pi in the renal proximal tubule. This is exemplified in faPi2a KO mice, which develop hyperphosphaturia and hypophosphatemia. NaPi2b is relieved responsible for transepithelial absorption in the small intestine and is regulated 3y dietary Pi and vitamin D (Calcitriol (1,25-Dihydroxycholecalciferol)). NaPi2c is jxpressed in renal tubule and other tissues {see, e.g., Virkki, L.V., et al, Id.).

The basic transport mechanism of NaPi2a and NaPi2b is the same {see, z.g, Murer, H., et al, Proximal Tubular Phosphate Reabsorption: Molecular Mechanisms, Physiol. Rev., 80(4).T 373-409 (2000)); both are electrogenic with a stoichiometry of about 3:1 Na ⁺ :HP0 ₄ ^2" , meaning that 3 Na ⁺ are co-transported with one phosphate anion. The additional Na cations translocated are excreted on the basolateral membrane via the K/Na ATPase active transporters to preserve cell polarization. Renal Pi transporter NaPi2a activity is increased in the kidney in response to low dietary Pi {see, e.g., Murer, et al, Id.). This results from an increase in transporter expression on the apical membrane of the kidney tubule. Histochemical analysis suggests a "recruitment" phenomenon. It is to be noted that, in contrast, the type I Na-Pi transporter does not respond to change in dietary P. The change in NaPi2a expression is paralleled by alteration in parathyroid hormone PTH plasma concentration and vice- versa {e.g., injection of PTH in rats leads within minutes to a reduction in brush border membrane transporter content). Acid-base change can also alter expression of NaPi2a. Chronic metabolic acidosis in rats significantly decreases NaPi2a protein and mRNA content. The same is observed in CKD rats induced by 5/6 ^th nephrectomy. The regulation of apical NaPi2a transporters involves complex membrane retrieval and reinsertion mechanisms. Control in transport activity can also be controlled by changes in intra-tubular and intracellular pH, in transmembrane potential difference and posttranslational modification. I. Substantially Impermeable or Substantially Systemically Non-Bioavailable Phosphate Transport Inhibitor Compounds

A. Physical and Performance Properties

In accordance with the present disclosure, the compounds described herein are designed to be substantially active or localized in the gastrointestinal lumen of a human or animal subject. The term "gastrointestinal lumen" is used interchangeably herein with the term "lumen," to refer to the space or cavity within a gastrointestinal tract (GI tract, which can also be referred to as the gut), delimited by the apical membrane of GI epithelial cells of the subject. In some embodiments, the compounds are not absorbed through the layer of epithelial cells of the GI tract (also known as the GI epithelium). "Gastrointestinal mucosa" refers to the layer(s) of cells separating the gastrointestinal lumen from the rest of the body and includes gastric and intestinal mucosa, such as the mucosa of the small intestine. A "gastrointestinal epithelial cell" or a "gut epithelial cell" as used herein refers to any epithelial cell on the surface of the gastrointestinal mucosa that faces the lumen of the gastrointestinal tract, including, for example, an epithelial cell of the stomach, an intestinal epithelial cell, a colonic epithelial cell, and the like.

"Substantially systemically non-bioavailable" and/or "substantially impermeable" as used herein (as well as variations thereof) generally refer to situations in which a statistically significant amount, and in some embodiments essentially all of the compound of the present disclosure, remains in the gastrointestinal lumen. For example, in accordance with one or more embodiments of the present disclosure, preferably at least about 70%, about 80%, about 90%, about 95%, about 98%, about 99%, or even about 99.5%, of the compound remains in the gastrointestinal lumen. In such cases, localization to the gastrointestinal lumen refers to reducing net movement across a gastrointestinal layer of epithelial cells, for example, by way of both transcellular and paracellular transport, as well as by active and/or passive transport. The compound in such embodiments is hindered from net permeation of a layer of gastrointestinal epithelial cells in transcellular transport, for example, through an apical membrane of an epithelial cell of the small intestine. The compound in these embodiments is also hindered from net permeation through the "tight junctions" in paracellular transport between gastrointestinal epithelial cells lining the lumen.

In this regard it is to be noted that, in one particular embodiment, the compound is essentially not absorbed at all by the GI tract or gastrointestinal lumen. As used herein, the terms "substantially impermeable" or "substantially systemically non- bioavailable" refers to embodiments wherein no detectable amount of absorption or permeation or systemic exposure of the compound is detected, using means generally known in the art.

In this regard it is to be further noted, however, that in alternative embodiments "substantially impermeable" or "substantially systemically non- bioavailable" provides or allows for some limited absorption in the GI tract, and more particularly the gut epithelium, to occur (e.g., some detectable amount of absorption, such as for example at least about 0.1%, 0.5%, 1% or more and less than about 30%, 20%, 10%, 5%, etc., the range of absorption being for example between about 1% and 30%, or 5% and 20%, etc.); stated another way, "substantially impermeable" or "substantially systemically non-bioavailable" may refer to compounds that exhibit some detectable permeability to an epithelial layer of cells in the GI tract of less than about 20% of the administered compound (e.g., less than about 15%, about 10%, or even about 5%, and for example greater than about 0.5%, or 1%), but then are cleared by the liver (i.e., hepatic extraction) and/or the kidney (i.e., renal excretion).

In this regard it is to be further noted, that in certain embodiments, due to the substantial impermeability and/or substantial systemic non-bioavailability of the compounds of the present invention, greater than about 50%, 60%, 70%, 80% or 90% of a compound of the invention is recoverable from the feces over, for example, a 24, 48 or 72 hour period following administration to a patient in need thereof. In this respect, it is understood that a recovered compound can include the sum of the parent compound and its metabolites derived from the parent compound, e.g., by means of hydrolysis, conjugation, reduction, oxidation, N-alkylation, glUcuronidation, acetylation, methylation, sulfation, phosphorylation, or any other modification that adds atoms to or removes atoms from the parent compound, wherein the metabolites are generated via the action of any enzyme or exposure to any physiological environment including, pH, temperature, pressure, or interactions with foodstuffs as they exist in the digestive milieu. Measurement of fecal recovery of compound and metabolites can be carried out using standard methodology. For example, compound can be administered orally at a suitable dose (e.g., 10 mg/kg) and feces are then collected at predetermined times after dosing (e.g., 24 hours, 48 hours, 72 hours). Parent compound and metabolites can be extracted with organic solvent and analyzed quantitatively using mass spectrometry. A mass balance analysis of the parent compound and metabolites (including, parent = M, metabolite 1 [M+16], and metabolite 2 [M+32]) can be used to determine the percent recovery in the feces.

In certain preferred embodiments, the phosphate transport inhibitors of the present invention are not competitive inhibitors with respect to phosphate of Na/phosphate co-transport. In certain other preferred embodiments, the phosphate transport inhibitors of the invention are non-competitive inhibitors. Non-competitive inhibitors maintain their degree of inhibition irrespective of the local phosphate concentration. This feature is an important aspect in providing an efficient blockade of intestinal transport in postprandial state, where the local concentration of dietary phosphate can attain concentration as high as 10 mM. It is believed that competitive inhibitors are too sensitive to local phosphate concentration and unable to block phosphate uptake following a high phosphorus meal. Various methods are available for determining whether a phosphate transport inhibitor is non-competitive or competitive. For example, a phosphate uptake assay can be peformed and the IC ₅₀ values for a compound at different phosphate concentrations can be determined (e.g., "Enzyme kinetics", I.Segel, 1975, John- Wiley & Sons, p.123). IC ₅₀ values for non-competitive inhibitors will remain the same or similar with respect to the phosphate concentration, whereas IC ₅₀ values for competitive inhibitors will increase (i.e lose potency) as phosphate concentration increases.

(i) Permeability

In this regard it is to be noted that, in various embodiments, the ability of the compound to be substantially systemically non-bioavailable is based on the compound charge, size, and/or other physicochemical parameters (e.g., polar surface area, number of hydrogen bond donors and/or acceptors therein, number of freely otatable bonds, etc.). More specifically, it is to be noted that the absorption character )f a compound can be selected by applying principles of pharmacokinetics, for jxample, by applying Lipinski's rule, also known as "the rule of five." Although not a ^• ule, but rather a set of guidelines, Lipinski shows that small molecule drugs with (i) a nolecular weight, (ii) a number of hydrogen bond donors, (iii) a number of hydrogen 3ond acceptors, and/or (iv) a water/octanol partition coefficient (Moriguchi Log P), greater than a certain threshold value, generally do not show significant systemic ;oncentration (i.e., are generally not absorbed to any significant degree). (See, e.g., Lipinski et al, Advanced Drug Delivery Reviews, 46, 2001 3-26, incorporated herein by reference.) Accordingly, substantially systemically non-bioavailable compounds {e.g., substantially systemically non-bioavailable phosphate transport inhibitor compounds) can be designed to have molecular structures exceeding one or more of Lipinski's threshold values. ' (See also Lipinski et al, Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings, Adv. Drug Delivery Reviews, 46:3-26 (2001); and Lipinski, Drug-like Properties and the Causes of Poor Solubility and Poor Permeability, J. Pharm. & Toxicol. Methods, 44:235-249 (2000), incorporated herein by reference.)

In some embodiments, for example, a substantially impermeable or substantially systemically non-bioavailable phosphate transport inhibitor compound of the present disclosure can be constructed to feature one or more of the following characteristics: (i) a MW greater than about 500 Da, about 1000 Da, about 2500 Da, about 5000 Da, about 10,000 Da or more (in the non-salt form of the compound); (ii) a total number of NH and/or OH and/or other potential hydrogen bond donors greater than about 5, about 10, about 15 or more; (iii) a total number of O atoms and/or N atoms and/or other potential hydrogen bond acceptors greater than about 5, about 10, about 15 or more; (iv) a Moriguchi partition coefficient greater than about 10 ⁵ (i.e., Log P greater than about 5, about 6, about 7, etc.), or alternatively less than about 10 (i.e., a Log P of less than 1, or even 0); and or (v) a total number of rotatable bonds greater than about 5, about 10 or about 15, or more.

In addition to the parameters noted above, the molecular polar surface area (i.e., "PSA"), which may be characterized as the surface belonging to polar atoms, is a descriptor that has also been shown to correlate well with passive transport through membranes and, therefore, allows prediction of transport properties of drugs. It has been successfully applied for the prediction of intestinal absorption and Caco2 cell monolayer penetration. (For Caco2 cell monolayer penetration test details, see for example the description of the Caco2 Model provided in Example 31 of U.S. Pat. No. 6,737,423, the entire contents of which are incorporated herein by reference, and the text of Example 31 in particular, which may be applied for example to the evaluation or testing of the compounds of the present disclosure.) PSA is expressed in A ² (squared angstroms) and is computed from a three-dimensional molecular representation. A fast calculation method is also available (see, e.g., Ertl et al, Journal of Medicinal Chemistry, 2000, 43, 3714-3717, the entire contents of which are incorporated herein by reference for all relevant and consistent purposes) using a desktop computer and commercially available chemical graphic tools packages, such as ChemDraw. The term "topological PSA" (tPSA) has been coined for this fast-calculation method. tPSA is well correlated with human absorption data with common drugs (see, e.g., Table 1, below):

Table 1 name % FA- TPSA*

metoprolol 102 50.7

nordlazepam 99 41.5

diazepam Θ7 32.7

oxprenolol 97 50.7

pheiiazone 97 26.9

oxazepam 97 61.7

alprenolol 96 41. §

practolol 95 70.6

pindolol 92 57.3

ciprofloxacin 69 74.6

metolazone 64 92.5

tranexamic acid 55 63,3

atenolol 54 84.6

sulpiride 36 101.7

mannltol 26 121.4

f oscar net 17 94.8

sulfasalazine 12 141.3

olsalazine 2.3 139.8

lactulose 0.6 197.4

rafflnose 0.3 268.7 (from Ertl et al, J. Med. Chem., 2000, 43:3714-3717). Accordingly, in some embodiments, the compounds of the present disclosure may be constructed to exhibit a tPSA value greater than about 100 A ² , about 120 A ² , about 130 A ² , or about 140 A ² , and in some instances about 150 A ² , about 160 A ² , about 170 A ² , about 180 A ² , about 190 A ² , about 200 A ² , about 225 A ² ,about 250 A ² , about 270 A ² , about 300 A ² , about 350 A ² ,about 400 A ² , about 450 A ² , about 500 A ² , about 750 A ² , or even about 1000 A ² ,such that the compounds are substantially impermeable or substantially systemically non-bioavailable (as defined elsewhere herein).

Because there are exceptions to Lipinski's "rule," or the tPSA model, the permeability properties of the compounds of the present disclosure may be screened experimentally. The permeability coefficient can be determined by methods known to those of skill in the art, including for example by Caco-2 cell permeability assay and/or using an artificial membrane as a model of a gastrointestinal epithelial cell. A synthetic membrane impregnated with, for example, lecithin and/or dodecane to mimic the net permeability characteristics of a gastrointestinal mucosa may be utilized as a model of a gastrointestinal mucosa. The membrane can be used to separate a compartment containing the compound of the present disclosure from a compartment where the rate of permeation will be monitored. Also, parallel artificial membrane permeability assays (PAMPA) can be performed. Such in vitro measurements can reasonably indicate actual permeability in vivo. (See, for example, Wohnsland et al., J. Med. Chem., 2001, 44:923-930; Schmidt et al, Millipore Corp. Application Note, 2002, n° AN1725EN00, and n° AN1728EN00, incorporated herein by reference.)

Accordingly, in some embodiments, the compounds utilized in the methods of the present disclosure may have a permeability coefficient, P _app , of less than about 100 x 10 ^"6 cm/s, or less than about 10 x 10 ^"6 cm/s, or less than about 1 x 10 ^"6 cm/s, or less than about 0.1 x 10 ^"6 cm/s, when measured using means known in the art (such as for example the permeability experiment described in Wohnsland et al, J. Med. Chem., 2001, 44. 923-930, the contents of which is incorporated herein by reference).

As previously noted, in accordance with the present disclosure, phosphate transport inhibitors may be modified to hinder their net absorption through a layer of gut epithelial cells, rendering them substantially systemically non-bioavailable. In some particular embodiments, the compounds of the present disclosure comprise a phosphate transport inhibitor linked, coupled or otherwise attached to a non-absorbable moiety, which may be an oligomer moiety, a polymer moiety, a hydrophobic moiety, a hydrophilic moiety, and/or a charged moiety, which renders the overall compound substantially impermeable or substantially systemically non-bioavailable. In some preferred embodiments, the phosphate transport inhibitor is coupled to a multimer or polymer portion or moiety, such that the resulting molecule is substantially impermeable or substantially systemically non-bioavailable. The multimer or polymer portion or moiety may be of a molecular weight greater than about 500 Daltons (Da), about 1000 Da, about 2500 Da, about 5000 Da, about 10,000 Da or more, and in particular may have a molecular weight in the range of about 1000 Daltons (Da) to about 500,000 Da, preferably in the range of about 5000 to about 200,000 Da, and more preferably may have a molecular weight that is sufficiently high to essentially preclude any net absorption through a layer of gut epithelial cells of the compound. In these or other particular embodiments, the phosphate transport inhibitor is modified to substantially hinder its net absorption through a layer of gut epithelial cells. fii) Persistent Inhibitory Effect

In other embodiments, the substantially impermeable or substantially systemically non-bioavailable compounds utilized in the treatment methods of the present disclosure may additionally exhibit a persistent inhibitor effect. This effect manifests itself when the inhibitory action of a compound at a certain concentration in equilibrium with epithelial cells (e.g., at or above its inhibitory concentration, IC) does not revert to baseline (i.e., phosphate transport without inhibitor) after the compound is depleted by simple washing of the luminal content.

This effect can be interpreted as a result of the tight binding of the compounds to the phosphate transport protein at the intestinal apical side of the gut epithelial cell. The binding can be considered as quasi-irreversible to the extent that, after the compound has been contacted with the gut epithelial cell and subsequently washed off said gut epithelial cell, the flux of phosphate transport is still significantly lower than in the control without the compound. This persistent inhibitory effect has the clear advantage of maintaining drug activity within the GI tract even though the residence time of the active in the upper GI tract is short, and when no entero-biliary recycling process is effective to replenish the compound concentration near its site of action.

Such a persistent inhibitory effect has an obvious advantage in terms of patient compliance, but also in limiting drug exposure within the GI tract.

The persistence effect can be determined using in vitro methods; in one instance, cell lines expressing phosphate transporters are split in different vials and treated with a phosphate transport inhibiting compound and phosphate solution to measure the rate of phosphate uptake. The cells in one set of vials are washed for different periods of time to remove the inhibitor, and phosphate uptake measurement is repeated after the washing. Compounds that maintain their inhibitory effect after multiple/lengthy washing steps (compared to the inhibitory effect measured in the vials where washing does not occur) are persistent inhibitors. Persistence effect can also be characterized ex vivo by using the everted sac technique, whereby transport of phosphate is monitored using an excised segment of GI perfused with a solution containing the inhibitor and shortly after flushing the bathing solution with a buffer solution free from inhibitor. A persistence effect can also be characterized in vivo by observing the time needed for phosphate balance to return to normal when the inhibitor treatment is discontinued. The limit of the method resides in the fact that apical cells (and therefore apical phosphate transporters) are sloughed off after a period of 3 to 4 days, the typical turnover time of gut epithelial cells. A persistence effect can be achieved by increasing the residence time of the active compound at the apical surface of the gut epithelial cells; this can be obtained by designing phosphate transport inhibitors with several phosphate transport inhibiting moieties built-in the small molecule or oligomer (wherein "several" as used herein typically means at least about 2, about 4, about 6 or more). Examples of such structures in the context of analogs of the antibiotic vancomycin are given in Griffin, et al, J. Am. Chem. Soc, 2003, 125, 6517-6531. Alternatively the compound comprises groups that contribute to increase the affinity towards the gut epithelial cell so as to increase the time of contact with the gut epithelial cell surface. Such groups are referred to as being "mucoadhesive." More specifically, the Core or L moiety can be substituted by such mucoadhesive groups, such as polyacrylates, partially deacetylated chitosan or polyalkylene glycol. (See also Patil, S.B. et al, Curr. Drug. Deliv., 2008, Oct. 5(4), pp. 312-8.)

(in) GI Enzyme Resistance

Because the compounds utilized in the treatment methods of the present disclosure are preferably substantially systemically non-bioavailable, and/or preferably exhibit a persistent inhibitory effect, it is also desirable that, during their prolonged residence time in the gut, these compounds resist the hydrolytic conditions prevailing in the upper GI tract. In such embodiments, compounds of the present disclosure are resistant to phase 1 and phase 2 metabolism. For example, administered compounds are preferably resistant to the activity of P450 enzymes, glucurosyl transferases, sulfotransferases, glutathione S-transferases, and the like, in the intestinal mucosa, as well as gastric (e.g., gastric lipase, and pepsine), pancreatic (e.g., trypsin, triglyceride pancreatic lipase, phospholipase A2, endonucleases, nucleotidases, and alpha-amylase), and brush-border enzymes (e.g., alkaline phosphatase, glycosidases, and proteases) generally known in the art.

The compounds that are utilized in methods of the present disclosure are also preferably resistant to metabolism by the bacterial flora of the gut; that is, the compounds are not substrates for enzymes produced by bacterial flora. In addition, the compounds administered in accordance with the methods of the present disclosure may be substantially inactive towards the gastrointestinal flora, and do not disrupt bacterial growth or survival. As a result, in various embodiments herein, the minimal inhibitory concentration (or "MIC") against GI flora is desirably greater than about 15 μg/ml, about 30 μg/ml, about 60 μ^ηιΐ, about 120 μg/ml, or even about 240 μg/ml, the MIC in various embodiments being for example between about 16 and about 32 μg/ml, or between about 64 and about 128 μg/ml, or greater than about 256 μ^ηιΐ.

To one skilled in the art of medicinal chemistry, metabolic stability can be achieved in a number of ways. Functionality susceptible to P450-mediated oxidation can be protected by, for example, blocking the point of metabolism with a halogen or other functional group. Alternatively, electron withdrawing groups can be added to a conjugated system to generally provide protection to oxidation by reducing the electrophilicity of the compound. Proteolytic stability can be achieved by avoiding secondary amide bonds, or by incorporating changes in stereochemistry or other modifications that prevent the drug from otherwise being recognized as a substrate by the metabolizing enzyme.

It is also to be noted that, in various embodiments of the present disclosure, one or more of the compounds detailed herein, when administered either alone or in combination with one or more additional pharmaceutically active compounds or agents to a patient in need thereof has a C _max that is less than the IC ₅₀ for NaPi2b, more specifically, less than about 10X (10 times) the IC ₅₀ , and, more specifically still, less than about 100X (100 times) the IC ₅₀ .

Additionally, or alternatively, it is also to be noted that, in various embodiments of the present disclosure, one or more of the compounds detailed herein, when administered either alone or in combination with one or more additional pharmaceutically active compounds or agents to a patient in need thereof, may have a Cmax of less than about 10 ng/ml, about 7.5 ng/ml, about 5 ng/ml, about 2.5 ng/ml, about 1 ng/ml, or about 0.5 ng/ml, the C _max being for example within the range of about 1 ng/ml to about 10 ng/ml, or about 2.5 ng ml to about 7.5 ng/ml.

Additionally, or alternatively, it is also to be noted that, in various embodiments of the present disclosure, one or more of the compounds detailed herein, when administered either alone or in combination with one or more additional pharmaceutically active compounds or agents to a patient in need thereof, may have a IC50 of less than about 10 μΜ, about 7.5 μΜ, about 5 μΜ, about 2.5 μΜ, about 1 μΜ, or about 0.5 μΜ, the IC ₅₀ being for example within the range of about 0.5 μΜ to about 10 μΜ, or about 0.5 μΜ to about 7.5 μΜ, or about 0.5 μΜ to about 5 μΜ, or about 0.5 μΜ to about 2.5 μΜ. Additionally, or alternatively, it is also to be noted that, in various embodiments of the present disclosure, one or more of compounds detailed herein, when administered to a patient in need thereof, may have a ratio of IC5o:C _max , wherein IC ₅ o and C _max are expressed in terms of the same units, of at least about 10, about 50, about 100, about 250, about 500, about 750, or about 1000.

Additionally, or alternatively, it is also to be noted that, in various embodiments of the present disclosure, wherein one or more of the compounds as detailed herein is orally administered to a patent in need thereof, within the therapeutic range or concentration, the maximum compound concentration detected in the serum, defined as C _max , is lower than the NaPi2b inhibitory concentration IC50 of said compound. As previously noted, as used herein, IC ₅₀ is defined as the quantitative measure indicating the concentration of the compound required to inhibit 50% of the NaPi2b transport activity in a cell based assay.

B. Illustrative Small Molecule Embodiments

In various representative embodiments of the present disclosure, the compounds of the present disclosure have one of the following structures (I), (II), (III), (IV) and (V), as set forth below.

1. Compounds of Structure (T)

In one embodiment of the present invention, the compounds have the following structure (I):

(I)

or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof,

wherein:

A is -CRi- or -N-; X is substituted aryl or substituted heteroaryl;

Y is halogen, optionally substituted alkylamino, optionally substituted alkoxy, optionally substituted thioalkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, -0(optionally substituted cycloalkyl), -0(optionally substituted heterocyclyl) or -0(optionally substituted aryl);

each R] is, independently, hydrogen, halogen, C _1-6 alkyl or C _1-6 haloalkyl;

R ₂ is -C(=0)NR _2a R _2b , -NR _2a C(=0)R _2b , -C(=0)R _2b , -NR _2a R _2b , -OR _2b or

-R _2b ;

R _2a is hydrogen or optionally substituted C _1-6 alkyl; and

R _2b is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl.

In further embodiments, Y is halogen, such as chloro.

In other further embodiments, Y is alkylamino, such as diethylamino.

In other further embodiments, Y is alkoxy.

In other further embodiments, Y is heterocyclyl, such as 1-piperidinyl and the compound has the

In other further embodiments, Y is -O(cycloalkyl).

In other further embodiments, X is -ZR ₃ , where Z is aryl or heteroaryl and R ₃ represents a non-hydrogen substituent as defined above, or as more specifically defined below.

In more specific embodiments, Z is aryl, such as phenyl and the compound has the structure:

In other more specific embodiments, Z is heteroaryl, such as pyridinyl compound has the structure:

In more specific embodiments of the foregoing, ₃ is:

(a) -(optionally substituted Ci _-6 alkyl)-S(0)o-2(optionally substituted C _1-6 alkyl)C(=0)NR ₇ R ,

(b) -(optionally substituted Ci _-6 alkyl)-S(O) _0- 2(optionally substituted C _1-6 alkyl)NR ₇ R ,

(c) -(optionally substituted C _1-6 alkyl)-S(O) _0-2 (optionally substituted C _1-6 alkyl)C(=0)OR ₅ ,

(d) -(optionally substituted C _1-6 alkyl)-S(O) _0-2 (optionally substituted C _1-6 alkyl)OR ₅ ,

(e) -(optionally substituted C _1-6 alkyl)-S(0)o _-2 (optionally substituted d-ealky^ ^,

(f) -(optionally substituted C _1-6 alkyl)-S(O) _0-2 R ₆ ,

(g) -(optionally substituted C _1-6 alkyl)-S(O) _0-2 NR ₇ R ₄ ,

(h) -(optionally substituted C _1-6 alkyl)-S(O) _0-2 (CH ₂ CH ₂ O) _* R ₅ , or

(i) -(optionally substituted C _1-6 alkyl)-S(O) _0-

2(CH ₂ CH ₂ 0) _¾ (CH ₂ ) ₂ NHS0 ₂ (phenyl)R ₅ ,

wherein: R is hydrogen, hydroxyl, alkoxy, optionally substituted C _\ . ₆ alkyl, optionally substituted aryl, optionally substituted heterocyclyl or optionally substituted heteroaryl;

R ₅ is hydrogen, optionally substituted Ci. ₆ alkyl, optionally substituted aryl, optionally substituted heterocyclyl or optionally substituted heteroaryl;

Re is optionally substituted aryl, optionally substituted heterocyclyl or optionally substituted heteroaryl;

R ₇ is hydrogen or optionally substituted C _1-6 alkyl; and

x is an integer from 2 to 10.

For example, in certain embodiments, R ₃ is:

(a) -CH ₂ S(0)o _-2 (optionally substituted C _1-6 alkyl)C(=0)NR ₇ R4,

(b) -CH ₂ S(O) _0-2 (optionally substituted d-ealky^NR^,

(c) -CH ₂ S(0)o _-2 (optionally substituted C _1-6 alkyl)C(=0)OR ₅ ,

(d) -CH ₂ S(O) _0-2 (optionally substituted C _1-6 alkyl)OR ₅ ,

(e) -CH ₂ S(O) _0-2 (optionally substituted C _1-6 alkyl)R ₆ ,

(f) -CH ₂ S(O) _0-2 R6,

(g) -CH ₂ S(0)o _-2 NR ₇ R ₄ ,

(h) -CH ₂ S(O) _0-2 (CH ₂ CH ₂ O) _¾ R ₅ , or

(i) -CH ₂ S(0)o _-2 (CH ₂ CH ₂ O CH ₂ ) ₂ NHS0 ₂ (phenyl)R ₅ .

In other more specific embodiments of the foregoing, R ₃ is:

(a) -(optionally substituted Ci _-6 alkyl)-CH ₂ NR ₇ (CH ₂ CH ₂ 0) _x R ₅ , or

(b) -(optionally substituted Ci _-6 alkyl)-CH ₂ NR ₇ (CH ₂ CH ₂ 0) _¾ (CH ₂ ) ₂ NHS0 ₂ (phenyl)R ₅ ,

wherein:

R ₅ is hydrogen, optionally substituted C _1-6 alkyl, optionally substituted aryl, optionally substituted heterocyclyl or optionally substituted heteroaryl;

R ₇ is hydrogen or optionally substituted C _1-6 alkyl; and x is an integer from 2 to 10.

For example, in certain embodiments, R ₃ is:

(a) -CH ₂ NR ₇ (CH ₂ CH ₂ 0) _x R ₅ , or

(b) -CH ₂ NR ₇ (CH ₂ CH ₂ 0)^(CH ₂ ) ₂ NHS0 ₂ (phenyl)R ₅ . In other more specific embodiments of the foregoing, R ₃ is:

(a) -C(=0)NR ₇ (optionally substituted C _1-6 alkyl)C(=0)NR ₇ R ₄ ,

(b) -C(=0)NR ₇ (optionally substituted C _1-6 alkyl)NR ₇ R4,

(c) -C(=0)NR ₇ (optionally substituted C _1-6 alkyl)C(=0)OR ₅ ,

(d) -C(=0)NR ₇ (optionally substituted Ci _-6 alkyl)OR ₅ ,

(e) -C(=0)NR ₇ (optionally substituted C _1-6 alkyl)R<;,

(f) -C(=0)NR ₇ (CH ₂ CH ₂ 0) _x R ₅ , or

(g) -C(=0)NR ₇ (CH ₂ CH ₂ OUCH ₂ ) ₂ NHS0 ₂ (phenyl)R ₅ , wherein:

R ₄ is hydrogen, hydroxyl, alkoxy, optionally substituted C _\ . ₆ alkyl, optionally substituted aryl, optionally substituted heterocyclyl or optionally substituted heteroaryl;

R ₅ is hydrogen, optionally substituted Ci _-6 alkyl, optionally substituted aryl, optionally substituted heterocyclyl or optionally substituted heteroaryl;

Re is optionally substituted aryl, optionally substituted heterocyclyl or optionally substituted heteroaryl;

R ₇ is hydrogen or optionally substituted C _1-6 alkyl; and

x is an integer from 2 to 10.

In other more specific embodiments of the foregoing, R ₃ is:

(a) -0(optionally substituted C _1-6 alkyl)C(=0)NR ₇ R4,

(b) -0(optionally substituted Ci _-6 alkyl)NR ₇ R ₄ ,

(c) -0(optionally substituted C _1-6 alkyl)C(=0)OR ₅ ,

(d) -O(optionally substituted C _1-6 alkyl)OR ₅ ,

(e) -0(optionally substituted Ci-ealky^Re,

(f) -0(CH ₂ CH ₂ 0) _X R ₅ , or

(g) -0(CH ₂ CH ₂ 0),(CH ₂ ) ₂ NHS0 ₂ (phenyl)R ₅ , wherein:

R ₄ is hydrogen, hydroxyl, alkoxy, optionally substituted Ci. ₆ alkyl, optionally substituted aryl, optionally substituted heterocyclyl or optionally substituted heteroaryl; R ₅ is hydrogen, optionally substituted Ci _-6 alkyl, optionally substituted aryl, optionally substituted heterocyclyl or optionally substituted heteroaryl;

is optionally substituted aryl, optionally substituted heterocyclyl or optionally substituted heteroaryl;

R ₇ is hydrogen or optionally substituted Ci _-6 alkyl; and

x is an integer from 2 to 10.

In other more specific embodiments of the foregoing, R ₃ is:

(a) -S(optionally substituted Ci _-6 alkyl)C(=0)NR ₇ R4,

(b) -S(optionally substituted C _1-6 alkyl)NR ₇ R ₄ ,

(c) -S(optionally substituted Ci _-6 alkyl)C(=0)OR ₅ ,

(d) -S(optionally substituted C _1-6 alkyl)OR5,

(e) -S (optionally substituted Ci _-6 alkyl)R0,

(f) -S(CH ₂ CH ₂ 0) _x R ₅ , or

(g) -S(CH ₂ CH ₂ OyCH ₂ ) ₂ NHS0 ₂ (phenyl)R ₅ , wherein:

R ₄ is hydrogen, hydroxyl, alkoxy, optionally substituted Q. ₆ alkyl, optionally substituted aryl, optionally substituted heterocyclyl or optionally substituted heteroaryl;

R ₅ is hydrogen, optionally substituted Ci _-6 alkyl, optionally substituted aryl, optionally substituted heterocyclyl or optionally substituted heteroaryl;

R^ is optionally substituted aryl, optionally substituted heterocyclyl or optionally substituted heteroaryl;

R ₇ is hydrogen or optionally substituted Ci _-6 alkyl; and

x is an integer from 2 to 10.

In other more specific embodiments of the foregoing, R ₃ is:

(a) -NR ₇ (optionally substituted C _1-6 alkyl)C(=0)NR ₇ R ₄ ,

(b) -NR ₇ (optionally substituted C _1-6 alkyl)NR ₇ R4,

(c) -NR ₇ (optionally substituted Ci. ₆ alkyl)C(=0)OR ₅ , .

(d) -NR ₇ (optionally substituted C _1-6 alkyl)OR ₅ ,

(e) -NR ₇ (optionally substituted C _1-6 alkyl)R<3,

(f) -NR ₇ (CH ₂ CH ₂ 0) _x R ₅ , or (g) -NR ₇ (CH ₂ CH ₂ 0),(CH ₂ ) ₂ NHS0 ₂ (phenyl)R ₅ ,

wherein:

R4 is hydrogen, hydroxyl, alkoxy, optionally substituted C _\ . ₆ alkyl, optionally substituted aryl, optionally substituted heterocyclyl or optionally substituted heteroaryl;

R ₅ is hydrogen, optionally substituted C _1-6 alkyl, optionally substituted aryl, optionally substituted heterocyclyl or optionally substituted heteroaryl;

R is optionally substituted aryl, optionally substituted heterocyclyl or optionally substituted heteroaryl;

R ₇ is hydrogen or optionally substituted C _1-6 alkyl; and

x is an integer from 2 to 10.

In other more specific embodiments of the foregoing, R ₃ is:

(a) -(optionally substituted Ci _-6 alkyl)-(OCH ₂ CH ₂ ) _y OR ₅ , or

(b) -(optionally substituted C _1-6 alkyl)-(OCH ₂ CH ₂ ) 0(CH ₂ ) ₂

NHS0 ₂ (phenyl)R ₅ ,

wherein:

R ₅ is hydrogen, optionally substituted C _1-6 alkyl, optionally substituted aryl, optionally substituted heterocyclyl or optionally substituted heteroaryl; and

y is an integer from 1 to 10.

For example, in certain embodiments, R ₃ is:

(a) -(CH ₂ ) ₃ (OCH ₂ CH ₂ )^OR ₅ , or

(b) -(CH ₂ ) ₃ (OCH ₂ CH ₂ )^0(CH ₂ ) ₂ NHS0 ₂ (phenyl)R ₅ .

In other further embodiments, A is -CH-.

In other further embodiments, A is N.

In other further embodiments, each R _\ is hydrogen.

In other further embodiments, R ₂ is -C(=0)NR _2a R ₂ b. In more specific embodiments, R _2a is hydrogen and R _¾ is:

or It is understood that any embodiment of the compounds of structure (I), as set forth above, and any specific substituent set forth herein for a X, Y, Z, A, R _1? R ₂ , R2a> R2t» R3, R4, R _5» ¾ or R ₇ group in the compounds of structure (I), as set forth above, may be independently combined with other embodiments and/or substituents of compounds of structure (I) to form embodiments of the inventions not specifically set forth above. In addition, in the event that a list of substitutents is listed for any particular substituent in a particular embodiment and/or claim, it is understood that each individual substituent may be deleted from the particular embodment and/or claim and that the remaining list of substituents will be considered to be within the scope of the invention.

2. Compounds of Structure (I

In another embodiment of the present invention, the compounds have the following structure (II):

(II)

or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof,

wherein:

A is:

X is substituted aryl or substituted heteroaryl;

Y is halogen, optionally substituted alkylamino, optionally substituted alkoxy, optionally substituted thioalkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, -0(optionally substituted cycloalkyl), -0(optionally substituted heterocyclyl) or -0(optionally substituted aryl); and

Ri is optionally substituted aryl or optionally substituted heteroaryl. In further embodiments, Y is halogen, such as chloro.

In other further embodiments, Y is alkylamino, such as diethylamino. In other further embodiments, Y is alkoxy.

In other further embodiments, Y is heterocyclyl, such as 1-piperidinyl and the compound has the stru

In other further embodiments, Y is -O(cycloalkyl).

In other further embodiments, X is -ZR ₂ . where Z is aryl or heteroaryl and R ₂ represents a non-hydrogen substituent as defined above, or as more specifically defined below.

In more specific embodiments, Z is aryl, such as phenyl and the compound has the structure:

In other more specific embodiments, Z is heteroaryl, such as pyridinyl and the compound has the structure:

In more specific embodiments of the foregoing, R ₂ is:

(a) -CH ₂ S(O) _0-2 (optionally substituted C _1-6 alkyl)C(=0)NR ₆ R ₃ ,

(b) -CH ₂ S(O) _0-2 (optionally substituted C _1-6 alkyl)NR ₆ R ₃ ,

(c) -CH ₂ S(0)o _-2 (optionally substituted

(d) -CH ₂ S(O) _0-2 (optionally substituted C _1-6 alkyl)OR4,

(e) -CH ₂ S(O) _0-2 (optionally substituted Ci _-6 alkyl)R ₅ ,

(f) -CH ₂ S(0)o. ₂ R ₅ ,

(g) -CH ₂ S(0)o _-2 NR ₆ R ₃ ,

(h) -CH ₂ S(O) _0-2 (CH ₂ CH ₂ O) _x R4,

(i) -CH ₂ NR ₆ (CH ₂ CH ₂ 0),R ₄₎

G) -C(=0)NR ₆ (optionally substituted C ₁ . ₆ alkyl)C(=0)NR ₆ R ₃ , (k) -C(=0)NR ₆ (optionally substituted d-ealky^NReRs,

(1) -C(=0)NR ₆ (optionally substituted C _1-6 alkyl)C(=0)OR ₄ , (m) -C(=0)NR ₆ (optionally substituted d-ealky OR^

(n) -C(=0)NR ₆ (optionally substituted C _1-6 alkyl)R ₅ , or

(o) -C(=0)NR ₆ (CH ₂ CH ₂ 0) _x R ₄ ;

wherein,

R ₃ is hydrogen, hydroxyl, alkoxy, optionally substituted Q. ₆ alkyl, optionally substituted aryl, optionally substituted heterocyclyl or optionally substituted heteroaryl;

R4 is hydrogen, optionally substituted C _1-6 alkyl, optionally substituted aryl, optionally substituted heterocyclyl or optionally substituted heteroaryl;

R ₅ is optionally substituted aryl, optionally substituted heterocyclyl or optionally substituted heteroaryl;

R _$ is hydrogen or optionally substituted C _{1 -} alkyl; and

x is an integer from 2 to 10. In other further embodiments, A is:

In other further embodiments, A is:

In other further embodiments, A is:

In other further embodiments, A is:

In other further embodiments, A is:

In other further embodiments, A is:

In other further embodiments, R _\ is optionally substituted aryl. In more specific embodiments, R _\ is phenyl. In other more specific embodiments, R\ is substituted phenyl, such as trifluoromethylphenyl.

It is understood that any embodiment of the compounds of structure (II), as set forth above, and any specific substituent set forth herein for a X, Y, A, Ri, R ₂ , R ₃ , R4, R ₅ or R group in the compounds of structure (II), as set forth above, may be independently combined with other embodiments and/or substituents of compounds of structure (II) to form embodiments of the inventions not specifically set forth above. In addition, in the event that a list of substitutents is listed for any particular substituent in a particular embodiment and/or claim, it is understood that each individual substituent may be deleted from the particular embodment and/or claim and that the remaining list of substituents will be considered to be within the scope of the invention.

3. Compounds of Structure (III)

In another embodiment of the present invention, the compounds have the following structure (III):

(III)

or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof,

wherein:

X is substituted aryl or substituted heteroaryl;

Y is halogen, optionally substituted alkylamino, optionally substituted alkoxy, optionally substituted thioalkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, -0(optionally substituted cycloalkyl), -0(optionally substituted heterocyclyl) or -0(optionally substituted aryl);

each Ri is, independently, hydrogen, C _1-6 alkyl or C _1-6 haloalkyl; and R ₂ is optionally substituted aryl or optionally substituted heteroaryl. In further embodiments, Y is halogen, such as chloro.

In other further embodiments, Y is alkylamino, such as diethylamino In other further embodiments, Y is alkoxy. In other further embodiments, Y is heterocyclyl, such as 1 -piperidinyl and the compound has the

In other further embodiments, Y is -O(cycloalkyl).

In other further embodiments, X is -ZR ₃ , where Z is aryl or heteroaryl and R ₃ represents a non-hydrogen substituent as defined above, or as more specifically defined below.

In more specific embodiments, Z is aryl, such as phenyl and the compound has the structure:

In other more specific embodiments, Z is heteroaryl, such as pyridinyl and the compound has the

In more specific embodiments of the foregoing, R ₃ is:

(a) -CH ₂ S(O) _0- 2(optionally substituted C _1-6 alkyl)C(=0)NR ₇ R ₄ ,

(b) -CH ₂ S(O) _0-2 (optionally substituted C _1-6 alkyl)NR ₇ R ₄ ,

(c) -CH ₂ S(O) _0-2 (optionally substituted C _1-6 alkyl)C(=0)OR ₅ ,

(d) -CH ₂ S(O) _0-2 (optionally substituted C _1-6 alkyl)OR ₅ , (e) -CH ₂ S(0)o _-2 (optionally substituted d _-6 alkyl)R ₆ ,

(f) -CH ₂ S(O) _0-2 R6,

(g) -CH ₂ S(O) _0-2 NR ₇ R4,

(h) -CH ₂ S(O) _0-2 (CH ₂ CH ₂ O) _¾ R ₅ ,

(i) -CH ₂ NR ₇ (CH ₂ CH ₂ 0) _x R ₅ ,

(j) -C(=0)NR ₇ (optionally substituted C _1-6 alkyl)C(=0)NR ₇ R ₄ , (k) -C(=0)NR ₇ (optionally substituted Ci _-6 alkyl)NR ₇ R4,

(1) -C(=0)NR ₇ (optionally substituted C _1-6 alkyl)C(=0)OR ₅ , (m) -C(=0)NR ₇ (optionally substituted C _1-6 alkyl)OR ₅ ,

(n) -C(=0)NR ₇ (optionally substituted Ci-ealky^Re, or

(o) -C(=0)NR ₇ (CH ₂ CH ₂ 0),R ₅ ;

wherein,

¾ is hydrogen, hydroxyl, alkoxy, optionally substituted Q. ₆ alkyl, optionally substituted aryl, optionally substituted heterocyclyl or optionally substituted heteroaryl;

R ₅ is hydrogen, optionally substituted C _1-6 alkyl, optionally substituted aryl, optionally substituted heterocyclyl or optionally substituted heteroaryl;

R^ is optionally substituted aryl, optionally substituted heterocyclyl or optionally substituted heteroaryl;

R ₇ is hydrogen or optionally substituted C _1-6 alkyl; and

x is an integer from 2 to 10.

In other further embodiments, A is:

In other further embodiments, A is:

In other further embodiments, A is:

In other further embodiments, each R _\ is hydrogen.

In other further embodiments, R ₂ is optionally substituted aryl. In more specific embodiments, R ₂ is phenyl or R ₂ is substituted phenyl, such as trifluoromethylphenyl.

It is understood that any embodiment of the compounds of structure (III), as set forth above, and any specific substituent set forth herein for a X, Y, A, R _1? R ₂ , R ₃ , R4, R ₅ , R6 or R ₇ group in the compounds of structure (III), as set forth above, may be independently combined with other embodiments and/or substituents of compounds of structure (III) to form embodiments of the inventions not specifically set forth above. In addition, in the event that a list of substitutents is listed for any particular substituent in a particular embodiment and/or claim, it is understood that each individual substituent may be deleted from the particular embodment and/or claim and that the remaining list of substituents will be considered to be within the scope of the invention.

4. Compounds of Structure (IV)

In another embodiment of the present invention, the compounds have the following structure (IV):

or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof,

wherein:

X is substituted aryl or substituted heteroaryl;

Y is halogen, optionally substituted alkylamino, optionally substituted alkoxy, optionally substituted thioalkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, -0(optionally substituted cycloalkyl), -0(optionally substituted heterocyclyl) or -0(optionally substituted aryl);

each Ri is, independently, hydrogen, halogen, C _1- alkyl or C _1-6 haloalkyl; and

R ₂ is hydrogen or optionally substituted Ci _-6 alkyl.

In further embodiments, Y is halogen, such as chloro.

In other further embodiments, Y is alkylamino, such as diethylamino.

In other further embodiments, Y is alkoxy.

In other further embodiments, Y is heterocyclyl, such as 1-piperidinyl and the compound has the structure:

In other further embodiments, Y is -O(cycloalkyl).

In other further embodiments, X is -ZR ₃ , where Z is aryl or heteroaryl and R ₃ represents a non-hydrogen substituent as defined above, or as more specifically defined below.

In more specific embodiments, Z is aryl, such as phenyl and the compound has the structure:

In other more specific embodiments, Z is heteroaryl, such as pyridinyl and the compound has the structure:

In more specific embodiments of the foregoing, R ₃ is:

(a) -CH ₂ S(0)o. ₂ (optionally substituted C _1-6 alkyl)C(=0)NR ₇ R ₄ ,

(b) -CH ₂ S(O) _0-2 (optionally substituted C _1-6 alkyl)NR ₇ R4,

(c) -CH ₂ S(O) _0-2 (optionally substituted Ci _-6 alkyl)C(=0)OR ₅ ,

(d) -CH ₂ S(O) _0-2 (optionally substituted Ci _-6 alkyl)OR ₅ ,

(e) -CH ₂ S(O) ₀ - ₂ (optionally substituted Ci _-6 alkyl)R ₆ ,

(f) -CH.SCO),,^,

(g) -CH ₂ S(O) _0-2 NR ₇ R ₄ ,

(h) -CH ₂ S(O) _0-2 (CH ₂ CH ₂ O) _JC R ₅ ,

(i) -CH ₂ NR ₇ (CH ₂ CH ₂ 0) _¾ R ₅ ,

0) -C(=0)NR ₇ (optionally substituted C _1-6 alkyl)C(=0)NR ₇ R4, (k) -C(=0)NR ₇ (optionally substituted Ci _-6 alkyl)NR ₇ R ₄ ,

(1) -C(=0)NR ₇ (optionally substituted C _1-6 alkyl)C(=0)OR ₅ , (m) -C(=0)NR ₇ (optionally substituted C _1-6 alkyl)OR ₅ ,

(n) -C(=0)NR ₇ (optionally substituted Ci _-6 alkyl)R6, or

(o) -C(=0)NR ₇ (CH ₂ CH ₂ 0) _x R ₅ ;

wherein

R ₄ is hydrogen, hydroxyl, alkoxy, optionally substituted C\. ₆ alkyl, optionally substituted aryl, optionally substituted heterocyclyl or optionally substituted heteroaryl;

R ₅ is hydrogen, optionally substituted C _1-6 alkyl, optionally substituted aryl, optionally substituted heterocyclyl or optionally substituted heteroaryl;

is optionally substituted aryl, optionally substituted heterocyclyl or optionally substituted heteroaryl; R-7 is hydrogen or optionally substituted C _1-6 alkyl; and

x is an integer from 2 to 10.

In other further embodiments, each R _\ is hydrogen.

In other further embodiments, R ₂ is hydrogen.

In other further embodiments, R ₂ is an optionally substituted Ci _-6 alkyl, such as trifluoromethyl.

It is understood that any embodiment of the compounds of structure (IV), as set forth above, and any specific substituent set forth herein for a X, Y, Rj, R ₂ , R ₃ , j, R ₅ , Re or R ₇ group in the compounds of structure (IV), as set forth above, may be independently combined with other embodiments and/or substituents of compounds of structure (IV) to form embodiments of the inventions not specifically set forth above. In addition, in the event that a list of substitutents is listed for any particular substituent in a particular embodiment and/or claim, it is understood that each individual substituent may be deleted from the particular embodment and/or claim and that the remaining list of substituents will be considered to be within the scope of the invention.

5. Compounds of Structure (V)

In another embodiment of the present invention, the compounds have the following structure (V):

(V)

or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof,

wherein:

Z is optionally substituted aryl or optionally substituted heteroaryl; Y is chloro or 1-piperidinyl; Ri is:

(a) optionally substituted alkenyl,

(b) optionally substituted alkynyl,

(c) -CH ₂ (substituted heteroaryl),

(d) -CH ₂ (heterocycle)(CH ₂ )^C(=0)NH(CH2CH ₂ 0)^R ₃ ,

(e) -CH ₂ S(O) _0-2 (optionally substituted

(f) -CH ₂ S(O) _0-2 (CH ₂ CH ₂ (¾R ₃ ,

(g) -CH ₂ NH(CH ₂ CH ₂ 0),R ₃ ,

(h) -C(=0)NR ₄ (optionally substituted C _1-6 alkyl)OR ₃ ,

(i) -C(=0)NR (optionally substituted C _1-6 alkyl)R ₅ , or

(j) -CEbNR^optionally substituted Ci _-6 alkyl)(phenyl)B(OH) ₂ ; hydrogen, hydroxyl, alkoxy, optionally substituted C _1-6 alkyl, optionally substituted aryl;

R ₃ is hydrogen, optionally substituted Ci _-6 alkyl, or optionally substituted aryl;

R4 is hydrogen or optionally substituted C _1-6 alkyl;

R ₅ is optionally substituted heterocycle or optionally substituted heteroaryl;

x is an integer from 2 to 10; and

y is 0 or an integer from 1 to 6.

In further embodiments, Z is aryl. In particular, in certain embodiments,

Z is phenyl. In such embodiments, for example, the compound may have the structure:

In other further embodiments, Z is heteroaryl. In particular, in certain embodiments, Z is pyridinyl. In such embodiments, for example, the compound may have the structure:

In other further embodiments, Y is chloro and the compound has the structure:

In other further embodiments, Y is 1-piperidinyl and the compound has the structure:

In other further embodiments, R\ is optionally substituted alkenyl.

In other further embodiments, Ri is optionally substituted alkynyl.

In other further embodiments, R\ is -CH ₂ (substituted heteroaryl). In )articular, in certain embodiments, R _\ is -CH ₂ (heteroaryl)(CH ₂ CH ₂ 0) _x R3.

In other further embodiments, is

•CH ₂ (heterocycle)(CH ₂ ) _y C(=0)NH(CH ₂ CH ₂ 0) _¾ R ₃ .

In other further embodiment, ] is -CH ₂ S(O) _0-2 (optionally substituted 3i _-6 ai _j !) ^r ^O /iNJi . ₂ . m particular, in certain embodiments, Ri is -CH ₂ S(0)o- >(optionally substituted C _1-6 alkyl)C(=0)NH(CH ₂ CH ₂ 0) _* R ₃ .

In other further embodiments, R is -CH ₂ S(O) _0-2 (CH ₂ CH ₂ O) _* R ₃ .

In other further embodiments, R _\ is -CH ₂ NH(CH ₂ CH ₂ 0) _x R ₃ .

In other further embodiments, Ri is -C(=0)NR4(optionally substituted C _1-6 alkyl)OR ₃ . In particular, in certain embodiments, R _t is -C(=0)NH(CH ₂ CH ₂ 0) _x R ₃ .

In other further embodiments, Ri is -C(=0)NR (optionally substituted

C _1-6 alkyl)R ₅ .

In other further embodiments, R _\ is -CH ₂ NR ₄ (optionally substituted C\. ₆ alkyl)(phenyl)B(OH) ₂ .

It is understood that any embodiment of the compounds of structure (V), as set forth above, and any specific substituent set forth herein for a Z, Y, R\, R ₂ , R ₃ , R ₄ , R ₅ , x and y group in the compounds of structure (V), as set forth above, may be independently combined with other embodiments and/or substituents of compounds of structure (V) to form embodiments of the inventions not specifically set forth above. In addition, in the event that a list of substitutents is listed for any particular substituent in a particular embodiment and/or claim, it is understood that each individual substituent may be deleted from the particular embodment and/or claim and that the remaining list of substituents will be considered to be within the scope of the invention.

II. Pharmaceutical Compositions and Methods of Treatment

For the purposes of administration, the compounds of the present invention may be administered to a patient or subject as a raw chemical or may be formulated as pharmaceutical compositions. Pharmaceutical compositions of the present invention generally comprise a compound of the invention and a pharmaceutically acceptable carrier, diluent or excipient. The compound is present in the composition in an amount which is effective to treat a particular disease or condition of interest, as described herein, and preferably with acceptable toxicity to the patient. The activity of compounds can be determined by one skilled in the art, for example, as described in the Example below. Appropriate concentrations and dosages can be readily determined by one skilled in the art.

A compound or composition of the invention may be used in a method for treating essentially any disease or other condition in a patient which would benefit from phosphate uptake inhibition in the gastrointestinal tract.

For example, by way of explanation, but not limitation, kidney damage reduces the production and activity of renal 1 -alpha hydroxylase, leading to lower 1,25- dihydroxy vitamin D. Decreased vitamin D levels limit gastrointestinal calcium absorption, leading to a decline in serum calcium levels. The combination of lower 1,25- dihydroxy vitamin D and lower serum calcium levels synergistically stimulate parathyroid tissue to produce and secrete PTH. A loss of nephrons also impairs Pi excretion, but serum P levels are actively defended by the actions of PTH and FGF-23, and by higher serum P levels, which considerably enhance urinary P0 ₄ excretion. However, tubular actions of PTH and FGF-23 cannot maintain serum P levels in the face of continual nephron loss. Once renal insufficiency progresses to the loss of about 40-50% of renal function, the decrease in the amount of functioning renal tissue does not allow excretion of the full amount of ingested phosphate required to maintain homeostasis. As a result, hyperphosphatemia develops. In addition, a rise in serum P levels impedes renal 1 -alpha hydroxylase activity, further suppressing activated vitamin D levels, and further stimulating PTH, leading to secondary hyperparathyroidism (sHPTH).

Phosphorus imbalance, however, does not necessarily equate with hyperphosphatemia. In fact, the vast majority of CKD patients not yet on dialysis are normophosphatemic but their phosphorus balance is positive with the excess phosphorus being disposed in the vasculature in the form of ectopic calcification, e.g. intima localized vascular calcification. Clinically, patients with CKD have elevated levels of FGF-23 that are significantly associated with deteriorating renal function and with decreased calcitriol levels, and it has been hypothesized that the synthesis of FGF- 23 is induced by the presence of excess P in the body consecutive to renal failure.

Furthermore, an unrecognized effect on cardiovascular disease is postprandial phosphatemia, i.e. serum P excursion secondary to meal intake. Further still, studies have investigated the acute effect of phosphorus loading on endothelial function in vitro and in vivo. Exposing bovine arotic endothelial cells to a phosphorus load increased production of reactive oxygen species and decreased nitric oxide, a known vasodilator agent. In the acute P loading study in healthy volunteers described above, it was found that the flow mediated dilation correlated inversely with postprandial serum P (Shuto et al., 2009b, J.Am.Soc.NephroL, v. 20, no. 7, p. 1504-1512).

Accoringly, in certain more specific embodiments, a compounds or composition of the invention can be used in a method selected from the group consisting of: (a) a method for treating hyperphosphatemia; (b) a method for treating a renal disease (e.g., chronic kidney disease or end stage renal disease); (c) a method for delaying time to dialysis; (d) a method for attenuating intima localized vascular calcification; (e) a method for reducing the hyperphosphatemic effect of active vitamin D; (f) a method for reducing FGF23 levels; (g) a method for attenuating hyperparathyroidism; (h) a method for improving endothelial dysfunction induced by postprandial serum phosphate; (i) a method for reducing urinary phosphorous; (j) a method for normalizing serum phosphorus levels; (k) a method for treating proteinura; and (1) a method for reducing serum PTH, calcium, calcitriol and/or phosphate concentrations or levels.

Administration of the compounds of the invention, or their pharmaceutically acceptable salts, in pure form or in an appropriate pharmaceutical composition, can be carried out via any of the accepted modes of administration of agents for serving similar utilities. The pharmaceutical compositions of the invention can be prepared by combining a compound of the invention with an appropriate pharmaceutically acceptable carrier, diluent or excipient, and may be formulated into preparations in solid, semi-solid, liquid or gaseous forms, such as tablets, capsules, powders, granules, ointments, solutions, suppositories, injections, inhalants, gels, microspheres, and aerosols. Typical routes of administering such pharmaceutical compositions include, without limitation, oral, topical, transdermal, inhalation, parenteral, sublingual, buccal, rectal, vaginal, and intranasal. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. Pharmaceutical compositions of the invention are formulated so as to allow the active ingredients contained therein to be bioavailable upon administration of the composition to a patient. Compositions that will be administered to a subject or patient take the form of one or more dosage units, where for example, a tablet may be a single dosage unit, and a container of a compound of the invention in aerosol form may hold a plurality of dosage units. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington: The Science and Practice of Pharmacy, 20th Edition (Philadelphia College of Pharmacy and Science, 2000). The composition to be administered will, in any event, contain a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, for treatment of a disease or condition of interest in accordance with the teachings of this invention.

A pharmaceutical composition of the invention may be in the form of a solid or liquid. In one aspect, the carrier(s) are particulate, so that the compositions are, for example, in tablet or powder form. The carrier(s) may be liquid, with the compositions being, for example, an oral syrup, injectable liquid or an aerosol, which is useful in, for example, inhalatory administration.

When intended for oral administration, the pharmaceutical composition is preferably in either solid or liquid form, where semi-solid, semi-liquid, suspension and gel forms are included within the forms considered herein as either solid or liquid.

As a solid composition for oral administration, the pharmaceutical composition may be formulated into a powder, granule, compressed tablet, pill, capsule, chewing gum, wafer or the like form. Such a solid composition will typically contain one or more inert diluents or edible carriers. In addition, one or more of the following may be present: binders such as carboxymethylcellulose, ethyl cellulose, microcrystalline cellulose, gum tragacanth or gelatin; excipients such as starch, lactose or dextrins, disintegrating agents such as alginic acid, sodium alginate, Primogel, corn starch and the like; lubricants such as magnesium stearate or Sterotex; glidants such as colloidal silicon dioxide; sweetening agents such as sucrose or saccharin; a flavoring agent such as peppermint, methyl salicylate or orange flavoring; and a coloring agent.

When the pharmaceutical composition is in the form of a capsule, for example, a gelatin capsule, it may contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol or oil.

The pharmaceutical composition may be in the form of a liquid, for example, an elixir, syrup, solution, emulsion or suspension. The liquid may be for oral administration or for delivery by injection, as two examples. When intended for oral administration, preferred composition contain, in addition to the present compounds, one or more of a sweetening agent, preservatives, dye/colorant and flavor enhancer. In a composition intended to be administered by injection, one or more of a surfactant, preservative, wetting agent, dispersing agent, suspending agent, buffer, stabilizer and isotonic agent may be included.

The liquid pharmaceutical compositions of the invention, whether they be solutions, suspensions or other like form, may include one or more of the following adjuvants: sterile diluents such as water for injection, saline solution, preferably physiological saline, Ringer's solution, isotonic sodium chloride, fixed oils such as synthetic mono or diglycerides which may serve as the solvent or suspending medium, polyethylene glycols, glycerin, propylene glycol or other solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic. Physiological saline is a preferred adjuvant. An injectable pharmaceutical composition is preferably sterile.

A liquid pharmaceutical composition of the invention intended for either parenteral or oral administration should contain an amount of a compound of the invention such that a suitable dosage will be obtained.

The pharmaceutical composition of the invention may be intended for topical administration, in which case the carrier may suitably comprise a solution, emulsion, ointment or gel base. The base, for example, may comprise one or more of the following: petrolatum, lanolin, polyethylene glycols, bee wax, mineral oil, diluents such as water and alcohol, and emulsifiers and stabilizers. Thickening agents may be present in a pharmaceutical composition for topical administration. If intended for transdermal administration, the composition may include a transdermal patch or iontophoresis device.

The pharmaceutical composition of the invention may be intended for rectal administration, in the form, for example, of a suppository, which will melt in the rectum and release the drug. The composition for rectal administration may contain an oleaginous base as a suitable nonirritating excipient. Such bases include, without limitation, lanolin, cocoa butter and polyethylene glycol.

The pharmaceutical composition of the invention may include various materials, which modify the physical form of a solid or liquid dosage unit. For example, the composition may include materials that form a coating shell around the active ingredients. The materials that form the coating shell are typically inert, and may be selected from, for example, sugar, shellac, and other enteric coating agents. Alternatively, the active ingredients may be encased in a gelatin capsule.

The pharmaceutical composition of the invention in solid or liquid form may include an agent that binds to the compound of the invention and thereby assists in the delivery of the compound. Suitable agents that may act in this capacity include a monoclonal or polyclonal antibody, a protein or a liposome.

The pharmaceutical composition of the invention may consist of dosage units that can be administered as an aerosol. The term aerosol is used to denote a variety of systems ranging from those of colloidal nature to systems consisting of pressurized packages. Delivery may be by a liquefied or compressed gas or by a suitable pump system that dispenses the active ingredients. Aerosols of compounds of the invention may be delivered in single phase, bi-phasic, or tri-phasic systems in order to deliver the active ingredient(s). Delivery of the aerosol includes the necessary container, activators, valves, subcontainers, and the like, which together may form a kit. One skilled in the art, without undue experimentation may determine preferred aerosols. The pharmaceutical compositions of the invention may be prepared by methodology well known in the pharmaceutical art. For example, a pharmaceutical composition intended to be administered by injection can be prepared by combining a compound of the invention with sterile, distilled water so as to form a solution. A surfactant may be added to facilitate the formation of a homogeneous solution or suspension. Surfactants are compounds that non-covalently interact with the compound of the invention so as to facilitate dissolution or homogeneous suspension of the compound in the aqueous delivery system.

The compounds of the invention, or their pharmaceutically acceptable salts, are administered in a therapeutically effective amount, which will vary depending upon a variety of factors including the activity of the specific compound employed; the metabolic stability and length of action of the compound; the age, body weight, general health, sex, and diet of the patient; the mode and time of administration; the rate of excretion; the drug combination; the severity of the particular disorder or condition; and the subject undergoing therapy.

In certain embodiments, a typical dosage of the substantially impermeable or substantially systemically non-bioavailable, compound may be between about 0.2 mg per day and about 2 g per day, or between about 1 mg and about 1 g per day, or between about 5 mg and about 500 mg, or between about 10 mg and about 250 mg per day, which is administered to a subject in need of treatment.

The frequency of administration of the compounds and compositions described herein may vary from once-a-day (QD) to twice-a-day (BID) or thrice-a-day (TID), etc., the precise frequency of administration varying with, for example, the patient's condition, the dosage, etc.

Compounds of the invention, or pharmaceutically acceptable derivatives thereof, may also be administered simultaneously with, prior to, or after administration of one or more other therapeutic agents. Such combination therapy includes administration of a single pharmaceutical dosage formulation which contains a compound of the invention and one or more additional active agents, as well as administration of the compound of the invention and each active agent in its own separate pharmaceutical dosage formulation. For example, a compound of the invention and the other active agent can be administered to the patient together in a single oral dosage composition such as a tablet or capsule, or each agent administered in separate oral dosage formulations. Where separate dosage formulations are used, the compounds of the invention and one or more additional active agents can be administered at essentially the same time, i.e., concurrently, or at separately staggered times, i.e., sequentially; combination therapy is understood to include all these regimens.

For example, in certain embodiments, the additional biologically active agent included in a pharmaceutical composition (or method) of the invention is selected, for example, from vitamin D ₂ (ergocalciferol), vitamin D ₃ (cholecalciferol), active vitamin D (calcitriol) and active vitamin D analogs (e.g. doxercalciferol, paricalcitol).

In other specific embodiments, the additional biologically active agent included in a pharmaceutical composition (or method) of the invention is a phosphate binder, such as Renvela, Renagel, Fosrenol, calcium carbonate, calcium acetate (e.g. Phoslo), MCI-196, Zerenex™, Fermagate, APS1585, SBR-759, PA-21, and the like.

The compounds of the invention have been found to act synergistically with phosphate binders by providing a higher efficacy than the sum of the efficacy of a NaPi2b inhibitor and that of a phosphate binder administered alone. Without wishing to be bound by theory, it is believed that the synergy results from the distinct mechanisms of action of a phosphate transport inhibitor and a phosphate binder. More specifically, a phosphate transport inhibitor blocks the epithelial inward transport of phosphate ions whereas phosphate binders sequester free phosphate ions in the lumen of the intestine.

The efficacy of a phosphate binder, as measured by its vivo binding capacity (mole of phosphate ions bound per gram of binder) is essentially dictated by: i) the density of binding sites (i.e. amine groups in Renvela / Sevelamer, a polymeric amine material; or multivalent cations such calcium or lanthanum in Phoslo (Calcium acetate) or Fosrenol (lanthanum carbonate)); and ii) the affinity of said binding sites for phosphate ions. Notably only a fraction of the binding sites is available for phosphate binding in vivo as other anions, such as bile acids and fatty acids compete for the binding sites and therefore lowers efficacy. Bound phosphate ions are in equilibrium with free phosphate in the intestinal lumen and are themselves subject to intense pumping from phosphate transport proteins lining up the epithelia. Experiments have shown that the efficacy of phosphate intestinal uptake is remarkably high, exceeding 95% of the phosphate presented to the epithelia. It is believed that the active transport of phosphate contributes to lower the luminal free phosphate concentration and therefore to drive the binding equilibrium of a phosphate binder to lower binding capacity. It is also believed that by reducing the phosphate intestinal transport using a phosphate transport inhibitor, one restores a higher in vivo binding capacity of phosphate sequestering agents. The synergistic effect is thought to be even more pronounced when the contribution of active phosphate transport is increased as a result of, e.g. vitamin D treatment, an agent promoting NaPi2b expression.

It is understood that in the present description, combinations of substituents and/or variables of the depicted formulae are permissible only if such contributions result in stable compounds.

It will also be appreciated by those skilled in the art that in the process described herein the functional groups of intermediate compounds may need to be protected by suitable protecting groups. Such functional groups include hydroxy, amino, mercapto and carboxylic acid. Suitable protecting groups for hydroxy include trialkylsilyl or diarylalkylsilyl (for example, t-butyldimethylsilyl, t-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl, and the like. Suitable protecting groups for amino, amidino and guanidino include t-butoxycarbonyl, benzyloxycarbonyl, and the like. Suitable protecting groups for mercapto include -C(0)-R" (where R" is alkyl, aryl or arylalkyl), /?-methoxybenzyl, trityl and the like. Suitable protecting groups for carboxylic acid include alkyl, aryl or arylalkyl esters. Protecting groups may be added or removed in accordance with standard techniques, which are known to one skilled in the art and as described herein. The use of protecting groups is described in detail in Green, T.W. and P.G.M. Wutz, Protective Groups in Organic Synthesis (1999), 3rd Ed., Wiley. As one of skill in the art would appreciate, the protecting group may also be a polymer resin such as a Wang resin, Rink resin or a 2-chlorotrityl-chloride resin.

It will also be appreciated by those skilled in the art, although such protected derivatives of compounds of this invention may not possess pharmacological activity as such, they may be administered to a mammal and thereafter metabolized in the body to form compounds of the invention which are pharmacologically active. Such derivatives may therefore be described as "prodrugs". All prodrugs of compounds of this invention are included within the scope of the invention.

Furthermore, all compounds of the invention which exist in free base or acid form can be converted to their pharmaceutically acceptable salts by treatment with the appropriate inorganic or organic base or acid by methods known to one skilled in the art. Salts of the compounds of the invention can be converted to their free base or acid form by standard techniques.

Definitions and Terminology

"Amino" refers to the -NH ₂ radical.

"Cyano" refers to the -CN radical.

"Hydroxy" or "hydroxyl" refers to the -OH radical.

"Imino" refers to the =NH substituent.

"Nitro" refers to the -N0 ₂ radical.

"Oxo" refers to the =0 substituent.

"Thioxo" refers to the =S substituent.

"Alkyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, which is saturated or unsaturated {i.e., contains one or more double and/or triple bonds), having from one to twelve carbon atoms (Cm alkyl), preferably one to eight carbon atoms (Q-Cg alkyl) or one to six carbon atoms (C]-C ₆ alkyl), and which is attached to the rest of the molecule by a single bond, e.g., methyl, ethyl, n-propyl, 1-methylethyl (z ^' sO-propyl), «-butyl, H-pentyl, 1,1-dimethylethyl (t-butyl), 3-methylhexyl, 2-methylhexyl, ethenyl, prop-l-enyl, but-l-enyl, pent-l-enyl, penta-l ,4-dienyl, ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like. Unless stated otherwise specifically in the specification, an alkyl group may be optionally substituted.

"Alkylene" or "alkylene chain" refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, which is saturated or unsaturated (i.e., contains one or more double and/or triple bonds), and having from one to twelve carbon atoms, e.g. , methylene, ethylene, propylene, «-butylene, ethenylene, propenylene, rc-butenylene, propynylene, rc-butynylene, and the like. The alkylene chain is attached to the rest of the molecule through a single or double bond and to the radical group through a single or double bond. The points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkylene chain may be optionally substituted.

"Alkoxy" refers to a radical of the formula -OR _a where R _a is an alkyl radical as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, an alkoxy group may be optionally substituted.

"Alkylamino" refers to a radical of the formula -NHR _a or -NR _a R _a where each R _a is, independently, an alkyl radical as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, an alkylamino group may be optionally substituted.

"Thioalkyl" refers to a radical of the formula -SR _a where R _a is an alkyl radical as defined above containing one to twelve carbon atoms. Unless stated otherwise specifically in the specification, a thioalkyl group may be optionally substituted.

"Aryl" refers to a hydrocarbon ring system radical comprising hydrogen, 6 to 18 carbon atoms and at least one aromatic ring. For purposes of this invention, the aryl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems. Aryl radicals include, but are not limited to, aryl radicals derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, os-indacene, 5-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene. Unless stated otherwise specifically in the specification, the term "aryl" or the prefix "ar-" (such as in "aralkyl") is meant to include aryl radicals that are optionally substituted. "Aralkyl" refers to a radical of the formula -Rb- c where Rb is an alkylene chain as defined above and Rc is one or more aryl radicals as defined above, for example, benzyl, diphenylmethyl and the like. Unless stated otherwise specifically in the specification, an aralkyl group may be optionally substituted.

"Cycloalkyl" or "carbocyclic ring" refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, which may include fused or bridged ring systems, having from three to fifteen carbon atoms, preferably having from three to ten carbon atoms, and which is saturated or unsaturated and attached to the rest of the molecule by a single bond. Monocyclic radicals include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic radicals include, for example, adamantyl, norbornyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like. Unless otherwise stated specifically in the specification, a cycloalkyl group may be optionally substituted.

"Cycloalkylalkyl" refers to a radical of the formula -RbRd where Rd is an alkylene chain as defined above and R _g is a cycloalkyl radical as defined above. Unless stated otherwise specifically in the specification, a cycloalkylalkyl group may be optionally substituted.

"Fused" refers to any ring structure described herein which is fused to an existing ring structure in the compounds of the invention. When the fused ring is a heterocyclyl ring or a heteroaryl ring, any carbon atom on the existing ring structure which becomes part of the fused heterocyclyl ring or the fused heteroaryl ring may be replaced with a nitrogen atom.

"Halo" or "halogen" refers to bromo, chloro, fluoro or iodo.

"Haloalkyl" refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, and the like. Unless stated otherwise specifically in the specification, a haloalkyl group may be optionally substituted.

"Heterocyclyl" or "heterocyclic ring" refers to a stable 3- to 18-membered non-aromatic ring radical which consists of two to twelve carbon atoms and from one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. Unless stated otherwise specifically in the specification, the heterocyclyl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized; and the heterocyclyl radical may be partially or fully saturated. Examples of such heterocyclyl radicals include, but are not limited to, dioxolanyl, thienyl[l,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and l,l-dioxo-thiomoφholinyl. Unless stated otherwise specifically in the specification, Unless stated otherwise specifically in the specification, a heterocyclyl group may be optionally substituted.

"N-heterocyclyl" refers to a heterocyclyl radical as defined above containing at least one nitrogen and where the point of attachment of the heterocyclyl radical to the rest of the molecule is through a nitrogen atom in the heterocyclyl radical. Unless stated otherwise specifically in the specification, a N-heterocyclyl group may be optionally substituted.

"Heterocyclylalkyl" refers to a radical of the formula -RbRe where Rb is an alkylene chain as defined above and ¾ is a heterocyclyl radical as defined above, and if the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl may be attached to the alkyl radical at the nitrogen atom. Unless stated otherwise specifically in the specification, a heterocyclylalkyl group may be optionally substituted.

"Heteroaryl" refers to a 5- to 14-membered ring system radical comprising hydrogen atoms, one to thirteen carbon atoms, one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and at least one aromatic ring. For purposes of this invention, the heteroaryl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized. Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][l,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[l,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 1- oxidopyridinyl, 1-oxidopyrimidinyl, 1 -oxidopyrazinyl, 1-oxidopyridazinyl, 1 -phenyl- lH-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thiophenyl (i.e., thienyl). Unless stated otherwise specifically in the specification, a heteroaryl group may be optionally substituted.

"N-heteroaryl" refers to a heteroaryl radical as defined above containing at least one nitrogen and where the point of attachment of the heteroaryl radical to the rest of the molecule is through a nitrogen atom in the heteroaryl radical. Unless stated otherwise specifically in the specification, an N-heteroaryl group may be optionally substituted.

"Heteroarylalkyl" refers to a radical of the formula -¾Rf where ¾ is an alkylene chain as defined above and Rf is a heteroaryl radical as defined above. Unless stated otherwise specifically in the specification, a heteroarylalkyl group may be optionally substituted.

The term "substituted" used herein means any of the above groups (i.e., alkyl, alkylene, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl) wherein at least one hydrogen atom is replaced by a bond to a non-hydrogen atoms such as, but not limited to: a halogen atom such as F, CI, Br, and I; an oxygen atom in groups such as hydroxyl groups, alkoxy groups, and ester groups; a sulfur atom in groups such as thiol groups, thioalkyl groups, sulfone groups, sulfonyl groups, and sulfoxide groups; a nitrogen atom in groups such as amines, amides, alkylamines, dialkylamines, arylamines, alkylarylamines, diarylamines, N-oxides, imides, and enamines; a silicon atom in groups such as trialkylsilyl groups, dialkylarylsilyl groups, alkyldiarylsilyl groups, and triarylsilyl groups; and other heteroatoms in various other groups. "Substituted" also means any of the above groups in which one or more hydrogen atoms are replaced by a higher-order bond (e.g., a double- or triple-bond) to a heteroatom such as oxygen in oxo, carbonyl, carboxyl, and ester groups; and nitrogen in groups such as imines, oximes, hydrazones, and nitriles. For example, "substituted" includes any of the above groups in which one or more hydrogen atoms are replaced with -NR _g R _h , -NR _g C(=0)R _h , -NR _g C(=0)NR _g R _h , -NRgC(=0)OR _h , -NR _g S0 ₂ R _h , -OC(=0)NR _g R _h , -OR _g , -SR _g , -SOR _g , -S0 ₂ R _g , -OS0 ₂ R _g , -S0 ₂ OR _g , =NS0 ₂ R _g , and -S0 ₂ NR _g R _h . "Substituted" also means any of the above groups in which one or more hydrogen atoms are replaced with -C(=0)R _g , -C(=0)OR _g , -C(=0)NR _g R _h , -CH ₂ S0 ₂ R _g , -CH ₂ S0 ₂ NR _g R _h , -(CH ₂ CH ₂ O) _1-10 R _g , -(CH ₂ CH ₂ O) _2-10 R _g , - (OCH ₂ CH ₂ )i _-10 R _g and -(OCH ₂ CH ₂ ) _2- ioR _g . In the foregoing, R _g and R _h are the same or different and independently hydrogen, alkyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl. "Substituted" further means any of the above groups in which one or more hydrogen atoms are replaced by a bond to an amino, cyano, hydroxyl, imino, nitro, oxo, thioxo, halo, alkyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, 7V-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl group. The above non-hydrogen groups are generally referred to herein as "substituents" or "non-hydrogen substituents". In addition, each of the foregoing substituents may also be optionally substituted with one or more of the above substituents.

"Prodrug" is meant to indicate a compound that may be converted under physiological conditions or by solvolysis to a biologically active compound of the invention. Thus, the term "prodrug" refers to a metabolic precursor of a compound of the invention that is pharmaceutically acceptable. A prodrug may be inactive when administered to a subject in need thereof, but is converted in vivo to an active compound of the invention. Prodrugs are typically rapidly transformed in vivo to yield the parent compound of the invention, for example, by hydrolysis in blood. The prodrug compound often offers advantages of solubility, tissue compatibility or delayed release in a mammalian organism (see, Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier, Amsterdam)). A discussion of prodrugs is provided in Higuchi, T., et al, A.C.S. Symposium Series, Vol. 14, and in Bioreversible Carriers in Drug Design, Ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.

The term "prodrug" is also meant to include any covalently bonded carriers, which release the active compound of the invention in vivo when such prodrug is administered to a mammalian subject. Prodrugs of a compound of the invention may be prepared by modifying functional groups present in the compound of the invention in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound of the invention. Prodrugs include compounds of the invention wherein a hydroxy, amino or mercapto group is bonded to any group that, when the prodrug of the compound of the invention is administered to a mammalian subject, cleaves to form a free hydroxy, free amino or free mercapto group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol or amide derivatives of amine functional groups in the compounds of the invention and the like,

The invention disclosed herein is also meant to encompass the in vivo metabolic products of the disclosed compounds. Such products may result from, for example, the oxidation, reduction, hydrolysis, amidation, esterification, and the like of the administered compound, primarily due to enzymatic processes. Accordingly, the invention includes compounds produced by a process comprising administering a compound of this invention to a mammal for a period of time sufficient to yield a metabolic product thereof. Such products are typically identified by administering a radiolabelled compound of the invention in a detectable dose to an animal, such as rat, mouse, guinea pig, monkey, or to human, allowing sufficient time for metabolism to occur, and isolating its conversion products from the urine, blood or other biological samples.

"Stable compound" and "stable structure" are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.

"Mammal" includes humans and both domestic animals such as laboratory animals and household pets (e.g., cats, dogs, swine, cattle, sheep, goats, horses, rabbits), and non-domestic animals such as wildlife and the like.

"Optional" or "optionally" means that the subsequently described event or circumstances may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. For example, "optionally substituted aryl" means that the aryl radical may or may not be substituted and that the description includes both substituted aryl radicals and aryl radicals having no substitution.

"Pharmaceutically acceptable carrier, diluent or excipient" includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals.

"Pharmaceutically acceptable salt" includes both acid and base addition salts.

"Pharmaceutically acceptable acid addition salt" refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid, camphor- 10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- 1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, 2-oxo-glutaric acid, glycerophosphoric acid, glycolic acid, tiippuric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucic acid, naphthalene- 1, 5 -disulfonic acid, naphthalene-2-sulfonic acid, l-hydroxy-2-naphthoic acid, nicotinic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic acid, pyroglutamic acid, pyruvic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, tartaric acid, thiocyanic acid, -toluenesulfonic acid, trifluoroacetic acid, undecylenic acid, and the like.

"Pharmaceutically acceptable base addition salt" refers to those salts which retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Preferred inorganic salts are the ammonium, sodium, potassium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, deanol, 2-dimethylaminoethanol,

2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, benethamine, benzathine, ethylenediamine, glucosamine, methylglueamine, theobromine, triethanolamine, tromethamine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like. Particularly preferred organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine.

Often crystallizations produce a solvate of the compound of the invention. As used herein, the term "solvate" refers to an aggregate that comprises one or more molecules of a compound of the invention with one or more molecules of solvent. The solvent may be water, in which case the solvate may be a hydrate. Alternatively, the solvent may be an organic solvent. Thus, the compounds of the present invention may exist as a hydrate, including a monohydrate, dihydrate, hemihydrate, sesquihydrate, trihydrate, tetrahydrate and the like, as well as the corresponding solvated forms. The compound of the invention may be true solvates, while in other cases, the compound of the invention may merely retain adventitious water or be a mixture of water plus some adventitious solvent.

A "pharmaceutical composition" refers to a formulation of a compound of the invention and a medium generally accepted in the art for the delivery of the biologically active compound to mammals, e.g., humans. Such a medium includes all pharmaceutically acceptable carriers, diluents or excipients therefor.

"Effective amount" or "therapeutically effective amount" refers to that amount of a compound of the invention which, when administered to a mammal, preferably a human, is sufficient to inhibit phosphate transport, inhibit sodium-mediated phosphate uptake, reduce serum PTH, calcium, calcitriol, and phosphate concentrations or levels, treat renal disease, treat hyperphosphatemia in the mammal, preferably a human, and/or treat any one or more other conditions described herein. The amount of a compound of the invention which constitutes a "therapeutically effective amount" will vary depending on the compound, the condition and its severity, the manner of administration, and the age of the mammal to be treated, but can be determined routinely by one of ordinary skill in the art having regard to his own knowledge and to this disclosure.

"Treating" or "treatment" as used herein covers the treatment of the disease or condition of interest in a mammal, preferably a human, having the disease or condition of interest, and includes:

(i) preventing the disease or condition from occurring in a mammal, in particular, when such mammal is predisposed to the condition but has not yet been diagnosed as having it;

(ii) inhibiting the disease or condition, i.e., arresting its development;

(iii) relieving the disease or condition, i.e., causing regression of the disease or condition; or (iv) relieving the symptoms resulting from the disease or condition, i.e., relieving pain without addressing the underlying disease or condition. As used herein, the terms "disease" and "condition" may be used interchangeably or may be different in that the particular malady or condition may not have a known causative agent (so that etiology has not yet been worked out) and it is therefore not yet recognized as a disease but only as an undesirable condition or syndrome, wherein a more or less specific set of symptoms have been identified by clinicians.

Subjects "in need of treatment" with a compound of the present disclosure, or subjects "in need of inhibition of phosphate transport" include subjects with diseases and/or conditions described herein, particularly diseases and/or conditions that can be treated with substantially impermeable or substantially systemically non- bioavailable phosphate transport-inhibiting compounds of the invention, with or without other active agents, to achieve a beneficial therapeutic and/or prophylactic result. A beneficial outcome includes a decrease in the severity of symptoms or delay in the onset of symptoms, increased longevity and/or more rapid or more complete resolution of the disease or condition.

The compounds of the invention, or their pharmaceutically acceptable salts may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino acids. The present invention is meant to include all such possible isomers, as well as their racemic and optically pure forms. Optically active (+) and (-), (R)- and (S)-, or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, for example, chromatography and fractional crystallization. Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC). When the compounds described herein contain olefinic double bonds or other centres of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included. A "stereoisomer" refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable. The present invention contemplates various stereoisomers and mixtures thereof and includes "enantiomers", which refers to two stereoisomers whose molecules are nonsuperimposeable mirror images of one another.

A "tautomer" refers to a proton shift from one atom of a molecule to another atom of the same molecule. The present invention includes tautomers of any said compounds.

The following Examples, provided for purposes of illustration, not limitation, illustrate various methods of making compounds of this invention., It is understood that one skilled in the art may be able to make these compounds by similar methods or by combining other methods known to one skilled in the art. It is also understood that one skilled in the art would be able to make, in a similar manner as described below, other compounds of the invention not specifically illustrated below by using the appropriate starting components and modifying the parameters of the synthesis as needed. In general, starting components may be obtained from sources such as Sigma Aldrich, Lancaster Synthesis, Inc., Maybridge, Matrix Scientific, TCI, and Fluorochem USA, etc. or synthesized according to sources known to those skilled in the art {see, e.g., Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5th edition (Wiley, December 2000)) or prepared as described in this invention.

EXAMPLES

EXAMPLES FOR COMPOUNDS OF STRUCTURE (I)

EXAMPLE 1.1

3-(3-((2-(4-((3-(TrifluoromethvDbenzyl)carbamovnpyridm-2-yl -4-(piperidin-l- vDphenvDcarbamovDbenzylthio^propanoic acid

Scheme 1. l . KSAc, EtOH; 2. K ₂ C0 ₃ , MeOH; 3. ½rt-butyl acrylate, DBU; 4. piperidine, K ₂ C0 ₃ , 5. 4,4,4',4',5,5,5 ^, ,5'-octamethyl-2,2'-bi(l,3,2-dioxaborolane), PdCl ₂ (dppf); 6. MeOH, SOCl ₂ ; 7. Pd(Ph ₃ P) ₄ , intermediate l.le, DME, Na ₂ C0 ₃ , water; 8. Fe, NH ₄ CL MeOH; 9. EDC HC1, DMAP, intermediate 1.1c; lO. LiOH; l l. EDC HC1, DMAP, 3-(trifluoromethyl)benzylamine; 12. TFA.

Intermediate 1.1a: 3-(acetylthiomethyl)benzoic acid. Into a 250-mL round-bottom flask, was placed a solution of 3-(bromomethyl)benzoic acid (7 g, 32.56 mmol, 1.00 equiv) in ethanol (80 mL), and potassium ethanethioate (9.65 g, 84.65 mmol, 2.60 equiv). The resulting solution was stirred overnight at room temperature. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 80 mL of water and adjusted to pH 3-4 with 10% hydrochloric acid. The resulting solution was extracted with 3x50 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 1x50 mL of brine. The mixture was dried over sodium sulfate and concentrated under vacuum. This resulted in 4.4 g (64%) of 3- (acetylthiomethyl)benzoic acid as a brown solid.

Intermediate 1.1b: 3-(mercaptomethyl)benzoic acid. Into a 500-mL round-bottom flask, was placed a solution of 3-(acetylthiomethyl)benzoic acid (16.4 g, 78.10 mmol, 1.00 equiv) in methanol (150 mL), and a solution of potassium carbonate (26.9 g, 194.93 mmol, 2.50 equiv) in water (70 mL). The resulting solution was stirred for 4 h at 60°C. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 200 mL of water and adjusted to pH 3 with 10% hydrochloric acid. The resulting solution was extracted with 3x (100/20 mL) of ethyl acetate/ tetrahydrofiiran and the organic layers combined. The resulting mixture was washed with 1x100 mL of brine. The mixture was dried over sodium sulfate and concentrated under vacuum. This resulted in 12 g (91%) of 3-(mercaptomethyl)benzoic acid as a brown solid.

Intermediate 1.1c: 3- (3-ΐ6ΐΐ^ηΐοχν-3-οχορΓο ν1ΐΜο^6Φν1^6ηζοίο acid. Into a 500- mL round-bottom flask, was placed a solution of 3-(mercaptomethyl)benzoic acid (12 g, 71.43 mmol, 1.00 equiv) in acetonitrile (200 mL), and tert-butyl acrylate (60 mL), DBU (21.7 g, 142.76 mmol, 2.00 equiv). The resulting solution was stirred overnight at 80°C in an oil bath. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 200 mL of water and adjusted to pH 2-3 with 10% hydrochloric acid. The resulting solution was extracted with 3x200 mL of ethyl acetate and the organic layers combined. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with petroleum ether/ethyl acetate (50:1). This resulted in 10.5 g (47%) of 3-((3- tert-butoxy-3-oxopropylthio)methyl)benzoic acid as red oil. 1H-NMR (300MHz, COC , ppm): δ 8.08 (s, 1H), 8.04 (d, J=7.8Hz, 1H), 7.62 (d, J=7.8Hz, 1H), 7.46 (t, 1H), 3.81 (s, 2H), 2.68 (t, 2H), 2.50 (t, 2H), 1,.48 (s, 9H). MS (ES, m/z): 295 [M-H]\

Intermediate l.ld: l-(3-bromo-4-nitrophenyl piperidine. Into a 1000-mL round- bottom flask, was placed a solution of 2-bromo-4-fluoro-l -nitrobenzene (30 g, 137.61 mmol, 1.00 equiv) in N,N-dimethylformamide (450 mL), piperidine (13.974 g, 162.68 mmol, 1.20 equiv), and potassium carbonate (56.718 g, 411.00 mmol, 2.99 equiv). The resulting solution was stirred overnight at 75°C in an oil bath. The solids were filtered out. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 300 mL of dichloromethane. The resulting mixture was washed with 2x100 mL of water and 2x100 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate/petroleum ether (1 :50). This resulted in 19 g (49%) of l-(3-bromo-4-nitrophenyl)piperidine as a yellow solid.

Intermediate Lie: l-(4-nitro-3-(4,4,5,5-tetramethyl-L3,2-dioxaborolan-2-yl) phenvD- piperidine. Into a 50-mL 3-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of l-(3-bromo-4- nitrophenyl)piperidine (8.00 g, 28.07 mmol, 1.00 equiv) in DMSO (25 mL), PdCl ₂ (dppf) (620 mg, 0.85 mmol, 0.03 equiv), 4,4,5,5-tetramethyl-2-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-l,3,2-dioxaborolane (10.74 g, 42.45 mmol, 1.50 equiv), and potassium acetate (7.09 g, 72.24 mmol, 2.57 equiv). The resulting solution was stirred overnight at 80°C in an oil bath. The mixture was concentrated under vacuum. The resulting solution was diluted with 100 mL of water. The resulting solution was extracted with 2x200 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 2x100 mL of water and 2x100 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate/petroleum ether (1 :50-1 :10). This resulted in 8.0 g (86%) of l-(4-nitro-3-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)phenyl)piperidine as a yellow solid. 1H-NMR (300MHz, CDCI ₃ , ppm): δ 8.047-8.077 (d, J=9.0Hz,lH), 6.770-6.829 (m, 2H), 3.453 (s, 4H), 1.586-1.702(m, 6H), 1.499(s, 12H). MS (ES, m/z): 333.15 [M+H] ⁺ .

Intermediate l.lf: methyl 2-bromoisonicotinate hydrochloride. Into a 500-mL round bottom flask, was placed a solution of 2-bromoisonicotinic acid (10 g, 49.75 mmol, 1.00 equiv) in methanol (200 mL). This was followed by dropwise addition of thionyl chloride (24 g, 203.39 mmol, 4.09 equiv) with stirring at 0°C-5°C. The resulting solution was stirred for 5 h at 70°C in an oil bath. The resulting mixture was concentrated under vacuum, to yield 10 g (80%) of methyl 2-bromoisonicotinate hydrochloride as a white solid.

Intermediate l .l g: methyl 2-(2-nitro-5-(piperidin-l-yl)phenyl isonicotinate. Into a 250-mL 3-neck round bottom flask purged and maintained with an inert atmosphere of nitrogen, were placed a solution of l-(4-nitro-3-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)phenyl)piperidine (4 g, 12.05 mmol, 1.00 equiv) in ethylene glycol dimethyl ether (60 mL), methyl 2-bromoisonicotinate hydrochloride (2.6 g, 12.09 mmol, 1.02 equiv), a solution of sodium carbonate (6.4 g, 60.38 mmol, 5.01 equiv) in water (30 mL), and Pd(PPh ₃ ) ₄ (1.4 g, 1.21 mmol, 0.10 equiv). The resulting solution was stirred for 3 h at 95°C. The resulting solution was diluted with 100 mL of water. The resulting solution was extracted with 3x100 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 3x100 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with petroleum ether/ethyl acetate (10:1). This resulted in 1.8 g (44%) of methyl 2-(2-nitro-5 -(piperidin- 1- yl)phenyl)isonicotinate as a red semi-solid.

Intermediate l.lh: methyl 2-(2-amino-5 -(piperidin- 1 -vDphenvDisonicotinate. Into a 100-mL round bottom flask, was placed a solution of methyl 2-(2-nitro-5-(piperidin-l- yl)phenyl)isonicotinate (1.8 g, 5.28 mmol, 1.00 equiv) in methanol (15 mL), and a solution of NH ₄ CI (850 mg, 15.89 mmol, 3.00 equiv) in water (7.9 mL). This was followed by the addition of iron (2.9 g, 51.79 mmol, 9.99 equiv) in several batches at 70°C. The resulting solution was stirred for 4 h at 70°C in an oil bath. The solids were filtered out. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 10 mL of water, extracted with 3x20 mL of ethyl acetate, and the organic layers combined. The resulting mixture was washed with 3x10 mL of brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. This resulted in 1.4 g (85%) of methyl 2-(2-amino-5 -(piperidin- l-yl)phenyl)isonicotinate as a black semi-solid.

Intermediate l.li: methyl 2-(2-(3-((3-ί6ΐΐ^ίοχν-3-οχορΓορν1ίΜο^6Φν 1 benzamidoV 5 -(piperidin- 1 -vDphenyDisonicotinate. Into a 50-mL round bottom flask, was placed a solution of methyl 2-(2-amino-5 -(piperidin- l-yl)phenyl)isonicotinate (800 mg, 2.57 mmol, 1.00 equiv) in dichloromethane (2 mL), EDC.HC1 (608 mg, 3.09 mmol, 1.20 equiv), 4-dimethylaminopyridine (380 mg, 3.11 mmol, 1.20 equiv), and 3-((3-tert- butoxy-3-oxopropylthio)methyl)benzoic acid (837 mg, 2.83 mmol, 1.00 equiv). The resulting solution was stirred for 4 h at room temperature. The mixture was concentrated under vacuum. The residue was applied onto a silica gel column and eluted with petroleum ether/ethyl acetate (10:1-5:1). This resulted in 600 mg (40%) of methyl 2-(2-(3-((3-tert-butoxy-3-oxopropylthio)methyl)benzamido)-5- (piperidin-l- yl)phenyl)isonicotinate as yellow oil.

Intermediate l.li: 2-(2-(3 -((3 -tert-butoxy-3 -oxopropylthio)methyDbenzarnido)-5 - (piperidin- 1 -vDphenvDisonicotinic acid. Into a 50-mL round bottom flask, was placed a solution of methyl 2-(2-(3-((3-tert-butoxy-3-oxopropylthio)methyl)benzamido)-5- (piperidin-l-yl)phenyl)isonicotinate (160 mg, 0.27 mmol, 1.00 equiv) in tetrahydrofuran (5 mL), and a solution of lithium hydroxide hydrate (160 mg, 3.81 mmol, 14.02 equiv) in water (5 mL). The resulting solution was stirred overnight at room temperature. The resulting mixture was concentrated under vacuum. The solution was adjusted to pH 3 with hydrochloric acid (2 mol/L). The resulting solution was extracted with 3x10 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 3x10 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This resulted in 140 mg (90%) of 2-(2- (3 -((3 -tert-butoxy-3 -oxopropy lthio)methyl)benzamido)-5 -(piperidin- 1 - yl)phenyl)isonicotinic acid as a yellow semi-solid.

Intermediate 1. Ik: tert-butyl 3-(3-((2-(4-((3-(trifluoromethyl)benzyl) carbamoyl) pyridin-2-yl)-4-(piperidin-l-yl)phenyl)carbamovnbenzylthio propanoate. Into a 50 mL round bottom flask, was placed 2-(2-(3-((3-tert-butoxy-3- oxopropylthio)methyl)benzamido)-5 -(piperidin- l-yl)phenyl)isonicotinic acid (220 mg, 0.38 mmol, 1.00 equiv), 3-(trifluoromethyl)benzylamine (134 mg, 0.77 mmol, 2.00 equiv), EDC.HC1 (124 mg, 0.63 mmol, 1.65 equiv), 4-dimethylaminopyridine (76 mg, 0.62 mmol, 1.63 equiv), and dichloromethane (10 mL). The resulting solution was stirred overnight at room temperature. The reaction progress was monitored by LCMS. The resulting mixture was washed with 5x30 mL of aqueous NH ₄ C1. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This resulted in 360 mg (90%) of tert-butyl 3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin- 2-yl)-4-(piperidin-l-yl)phenyl)carbamoyl)benzylthio)propanoa te as yellow oil.

Example 1.1: 3 -(3 -((2-(4-((3 -(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl -4- (piperidin- 1 -yl phenyDcarbamovDbenzylthio)propanoic acid. Into a 50-mL round bottom flask, was placed a solution of tert-butyl 3-(3-((2-(4-((3- (trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin -l-yl)phenyl)carbamoyl)- benzylthio)propanoate (360 mg, 0.49 mmol, 1.00 equiv) ^' in dichloromethane (2 mL), and 2,2,2-trifluoroacetic acid (2 mL). The resulting solution was stirred for 1 h at room temperature. The reaction progress was monitored by LCMS. The resulting mixture was concentrated under vacuum. The crude product was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 217.9 mg (66%) of a white solid. 1H-NMR (300MHz, DMSO-i ₆ +DCl, ppm): δ 9.06-9.04 (d, J=5.7Hz, 1H), 8.86 (s, 1H), 8.75 (s, 1H), 8.74-8.47 (m, 1H), 8÷44~8.10 (m, 2H), 7.88 (s, 2H),7.88~7.84 (d, J=7.8Hz, 2H), 7.75-7.48 (m, 4H), 4.60 (s, 2H), 3.86 (s, 2H), 3.78 (s, 4H), 2.63-2.58(m, 2H), 2.31-1.75 (m, 6H). MS (ES, m/z): 677[M+H] ⁺ .

EXAMPLE 1.2

3 -((3 -(( 4-(Piperidin- 1 - vD-2-(4-( ( ( 6-(trifluoromethvnpyridin-3 - yl)methyl)carbamoyl ^N )pyridin-2-yl)phenyl ^' )carbamoyl)benzyl)thio)propanoic acid

Scheme 2. 1. (6-(trifluoromethyl)pyridin-3-yl)methanamine, HATU, DIEA, DMF; 2. CF ₃ C0 ₂ H.

Intermediate 1.2a: tert-butyl 3-((3-((4-(piperidin-l-ylV2-(4-(((6-(trifluoromethv pyridin-3-vDmethyl ^' )carbamoyl pyridin-2-yl phenvncarbamovnbenzyl thio

propanoate. Into a 8-mL sealed tube, was placed a solution of 2-(2-(3-((3-tert-butoxy- 3-oxopropyltWo)methyl)benzamido)-5-(piperidin-l-yl)phenyl)is onicotinic acid l.lj (90 mg, 0.16 mmol, 1.00 equiv) in N,N-dimethylformamide (2 mL), HATU (90 mg, 0.24 mmol, 1.51 equiv), N,N-diisopropylethylamine (30.6 mg, 0.24 mmol, 1.52 equiv), and (6-(trifluoromethyl)pyridin-3-yl)methanamine (54 mg, 0.31 mmol, 1.96 equiv). The resulting solution was stirred overnight at room temperature. The resulting mixture was concentrated under vacuum. The residue was dissolved in ethyl acetate. The resulting mixture was washed with water and brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum to yield 114.7 mg (crude) of tert-butyl 3 -(3 -((2-(4-(((6-(trifluoromethyl)pyridin-3 -yl)methyl)carbamoyl)pyridin-2-yl)-4- (piperidin-l-yl)phenyl)carbamoyl)benzylthio)propanoate as red oil.

Example 1.2: 3 -(3 -((2-(4-(((6-(trifluoromethyl pyridin-3 -yl methyl carbamoyl pyridin-2-yl)-4-(piperidin-l-yl)phenyl)carbamoyl ^' )benzylthio)propanoic acid, trifluoroacetate salt. Example 1.2 was prepared from intermediate 1.2a using the procedure used to prepare Example 1.1 from intermediate 1.1k. 1H-NMR (300MHz, D ₃ OO, ppm): δ 9.064 (d, J=5.1Hz, 1H), 8.777 (d, J=9.0Hz, 1H), 8.425 (s, 1H), 8.108- 8.163 (m, 2H), 7.997 (s, 1H), 7.896-7.811 (m, 3H), 7.704-7.667 (m, 1H), 7.620-7.595 (m, 1H), 7.547-7.496 (m, 1H), 4.764 (s, 2H), 3.912 (s, 2H), 3.690-3.656 (m, 4H), 2.751- 2.690 (m, 2H), 2.614-2.568 (m, 2H), 2.046 (s, 4H), 1.823 (s, 2H). MS (ES, m/z): 678 [M+H] ⁺ .

EXAMPLE 1.3

3-((3-((2-(4-((4-(Tert-butyl)benzyl)carbamoyl)pyridin-2-y l)-4-(piperidin-l- yl)phenyl)carbamoyl benzyl thio)propanoic acid

Scheme 3. 1. 4-tertbutyl-benzylamine, EDC HC1, DMAP; 2. CF ₃ C0 ₂ H.

Intermediate 1.3 a: methyl tert-butyl 3-(3-((2-(4-((4-tert-butylbenzyl carbamoyl pyridin-2-yl -4-(piperidin-l-yl)phenyl)carbamoyl)benzylthio)propanoate. Into a 50-mL round bottom flask, was placed a solution of 2-(2-(3-((3-tert-butoxy-3- oxopropylthio)methyl)benzamido)-5-( iperidin-l-yl)phenyl)isonicotinic acid l.lj (90.0 mg, 0.16 mmol, 1.00 equiv) in dichloromethane (15 mL), N-(3-dimethylaminopropyl)- N'-ethylcarbodiimide hydrochloride (45.0 mg, 0.23 mmol, 1.50 equiv), N,N-dimethylpyridin-4-amine (28.0 mg, 0.23 mmol, 1.50 equiv), and (4-tert- butylbenzylamine (25.2 mg, 0.15 mmol, 1.00 equiv). The resulting solution was stirred for 8 h at 25°C in an oil bath. The resulting solution was diluted with 10 mL of water. The resulting solution was extracted with 2x20 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with brine, dried over sodium sulfate, and concentrated under vacuum. This resulted in 100 mg (89%) of tert-butyl 3- (3 -((2-(4-((4-tert-butylbenzyl)carbamoyl)pyridin-2-yl)-4-(pipe ridin- 1 - yl)phenyl)carbamoyl)benzylthio)propanoate as a yellow solid.

Example 1.3: 3-((3-((2-(4-(( ^" 4-(tert-butyl)benzvncarbamoyl pyridin-2-yl -4-(piperidin- 1 -yl phenyl carbamoyl benzyl)thio propanoic acid. Into a 50-mL round bottom flask, was placed a solution of tert-butyl 3-(3-((2-(4-((4-tert-butylbenzyl)carbamoyl)pyridin- 2-yl)-4-(piperidin-l-yl)phenyl)carbamoyl) benzyIthio)propanoate (100 mg, 0.14 mmol, 1,00 equiv) in dichloromethane (2 mL), and trifluoroacetic acid (160 mg, 1.40 mmol, 10.00 equiv). The resulting solution was stirred overnight at 25°C in an oil bath. The resulting mixture was concentrated under vacuum. The crude product (95 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 50 mg (46%) of a white solid. 1H-NMR (300MHz, CD ₃ OD, ppm): δ 9.03-9.05 (d, J=5.4Hz, 1H), 8.80-8.83 (d, J=9.3 Hz, 1H), 8.42 (s, 1H), 8.16-8.17 (d, J=2.7 Hz, 1H), 8.00 (s, 1H), 7.90-7.90 (d, J=1.5 Hz, 1H), 7.87-7.89 (m, 2H), 7.71-7.75 (dd, J=9.02Hz, J'=2.7Hz, 1H), 7.60-7.62 (m, 1H), 7.50- 7.55 (m, 1H), 7.40-7.42 (m, 2H), 7.31-7.39 (m, 2H), 4.61 (s, 2H), 3.91 (s, 2H), 3.70- 3.73 (m, 4H), 2.70 (m, 2H), 2.56-2.51 (m, 2H), 2.06-2.09 (m, 4H), 1.84-1.86 (m, 1H), 1.32-1.33 (m, 9H). MS (ES, m/z): 665 [M +H] ⁺ .

EXAMPLES 1.4 THROUGH 1.49

The compounds listed in Table 1 were prepared from intermediate l.lj and the requisite amines or amine hydrochloride salts using the methods described for the preparation of Example 1.1 (Method 1) and Example 1.2 (Method 2). Mass spectral data (ES, positive ion mode) is provided for each compound.

Table 1

Not Applicable (NA): compound isolated as a zwitterion, or free base, or conjugate acid EXAMPLE 2

3.3 '-((((( ((4,4'-( (Oodecane- 1.12-diylbis(azanedivn )bis(carbonyl))bisr yridine-4,2- divD)bis(4-(piperidin- 1 -yl)-2, 1 -phenylene))bis( ^' azanediyl )bis(carbonyl )bis( ^' 3 , 1 - phenylene))bis(methylene ^' )bis(sulfanedivn)dipropanoic acid

2

A stirred mixture of 27 mg of intermediate l.lj, 4.8 mg of 1,12-diaminododecane, and 26 L of diisopropylamine in 0.5 mL of DMF was treated with 21 mg of HATU. After 20 minutes the solvent was evaporated at reduced pressure and the residue was partitioned between ethyl acetate and aqueous sodium bicarbonate solution. The organic extracts were washed twice with water and once with brine. The solution was dried (Na ₂ S0 ₄ ) and the solvent was evaporated. The residue was dissolved in 300 μΐ, of dichloromethane and treated with 300 μΐ, of TFA. The solvent was evaporated and the residue was purified by reverse-phase HPLC to yield 16 mg of 3,3'-(((((((4,4'- ((dodecane- 1 , 12-diylbis(azanediyl))bis(carbonyl))bis(pyridine-4,2-diyl))b is(4- (piperidin- 1 -yl)-2, 1 -phenylene))bis(azanediyl))bis(carbonyl))bis(3 , 1 - phenylene))bis(methylene))bis-(sulfanediyl))dipropanoic acid. Ή-NMR (400MHz, CO ₃ OO, ppm): δ 8.97 (dd, J=5.2 Hz, J'= 0.8 Hz, 2H), 8.79 (d, J=9.0 Hz, 2H), 8.34 (s, 2H), 8.16 (d, J=2.7 Hz, 2H), 7.96 (t, J=1.7 Hz, 2H), 7.84 (dt, J=8.2 Hz, J'=1.3 Hz, 2H), 7.78 (dd, J=5.3 Hz, J'=1.6 Hz, 2H), 7.70 (dd, J=9.2 Hz, J'=2.8 Hz, 2H), 7.56 (dt, J=8.0 Hz, J'=1.2 Hz, 2H), 7.48 (t, J=7.6 Hz, 2H), 3.87 (s, 4H), 3.69 (t, J=5.5 Hz, 8H), 3.39 (t, J=7.2 Hz, 4H), 2.71 (dt, J=7.2 Hz, J'=1.0 Hz, 4H), 2.55 (dt, J=7.1 Hz, J'=1.0 Hz, 4H), 2.05 (m, 8H), 1.81 (m, 4H), 1.62 (m, 4H), 1.40-1.25 (m, 16H). MS (ES, m/z) 1203.6 [M+H] ⁺ . EXAMPLE 3.1

3 -((3 -(Y4-(Piperidin- 1 -ν1)-2-(6-((3 -(trifluoromethyl benzyl amino)pyrimidin-4- yl)phenyl)carbamoyl)benzvDthio propanoic acid

Scheme 4. 1. oxalyl chloride, DMF; 2. Intermediate Lie, Pd(OAc) ₂ , PPh ₃ , Na ₂ C0 ₃ ; 3. 3-(trifiuoromethyl)benzylamine, 50°C; 4. H ₂ , Pd/C; 5. intermediate 3.1a; 6. TFA.

Intemediate 3.1a: tert-butyl 3-((3-(chlorocarbonyl)berizyl thio)propanoate. Into a 100- mL round-bottom flask, was placed a solution of 3-((3-tert-butoxy-3- oxopropylthio)methyl)benzoic acid Lie (3.00 g, 10.14 mmol, 1.00 equiv) in dichloromethane (50 mL). This was followed by the addition of oxalyl dichloride (4.50 g, 35.43 mmol, 3.00 equiv) dropwise with stirring at 0°C. To this was added N,N- dimethylformamide (one drop). The resulting solution was stirred for 1.5 h at room temperature. The resulting mixture was concentrated under vacuum. This resulted in 3.18 g (99%) of tert-butyl 3-(3-(chlorocarbonyl)benzylthio)propanoate as red oil. Intermediate 3.1b. 4-chloro-6-(2-nitro-5-(piperidin- 1 -yl)phenyl)pyrimidine. Into a 250-mL 3 -necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of l-(4-nitro-3-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)phenyl)piperidine (5 g, 15.06 mmol, 1.00 equiv) in 1,4-dioxane (150 mL), water (25 mL), 4,6-dichloropyrimidine (5.54 g, 37.69 mmol, 2.50 equiv), Pd(PPh ₃ ) ₂ Cl ₂ (500 mg, 0.75 mmol, 0.05 equiv), triphenylarsine (460 mg, 1.50 mmol, 0.10 equiv), and K ₃ P0 ₄ (4.79 g, 22.59 mmol, 1.50 equiv). The resulting solution was stirred overnight at 75°C. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate/petroleum ether (1:10). This resulted in 2.5 g (47%) of 4-chloro-6-(2-nitro-5 -(piperidin- 1- yl)phenyl)pyrimidine as a yellow solid.

Intermediate 3.1c: 6-(2-nitro-5-(piperidin-l-yl phenyl -N-(3-(trifluoromethyl) benzyl - pyrimidin-4-amine. Into a 50-mL round-bottom flask, was placed a solution of 4- chlorp-6-(2-nitro-5-(piperidin-l-yl)phenyl)pyrimidine (191 mg) in

N,N-dimethylformamide (10 mL), and 3-(trifluoromethyl)benzylamine (210 mg). The resulting solution was stirred overnight at 50°C. The resulting mixture was dissolved in 50 mL of ethyl acetate and washed with 2x50 mL of water. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified by silica gel chromatograpy to give 186 mg of product as yellow oil.

Intermediate 3.1 d: 6-(2-amino-5-(piperidin- 1 -yl phenyl -N-(3-(trifluoromethyl benzyl)-pyrimidin-4-amine. A mixture of 6-(2-nitro-5 -(piperidin- l-yl)phenyl)-N-(3 - (trifluoromethyl) benzyl)pyrimidin-4-amine (184 mg) and 5% Pd/C (35 mg) in ethanol was stirred for 1 h under an atmosphere of hydrogen. The mixture was filtered and the solvent was evaporated.

Intermediate 31 e: tert-butyl 3 -((3 -((4-(piperidin- 1 -yl -2-(6-((3 -(trifluoromethyl) benzyl) amino)pyrimidin-4-yl)phenyl)carbamoyl)benzyl)thio)propanoate . A solution of 6-(2-amino-5 -(piperidin- 1 -yl)phenyl)-N-(3 -(trifluoromethyl) benzyl)pyrimidin-4-amine (122 mg) in 1.0 mL of dichloromethane was treated with 54 mg of tert-butyl 3-((3- (chlorocarbonyl)benzyl)thio)propanoate. The mixture was stirred overnight. The solvent was evaporated and the residue was purified by silica gel chromatography to give 120 mg of product as a yellow oil.

Example 3.1 : 3 -((3 -((4-(piperidin- 1 - yQ-2-(6-((3 -(trifluoromethyObenzyl) amino - pyrimidin-4-yl phenvf)carbamoyl benzyl ^' )thio ^N )propanoic acid. To a solution of tert- butyl 3-((3-((4-(piperidin-l-yl)-2-(6-((3-(trifluoromethyl) benzyl) amino)pyrimidin-4- yl)phenyl)carbamoyl)benzyl)thio)propanoate in 1 mL of dichloroethane was added 1 mL of TFA. The mixture was stirred 1 h, and then the solvent was evaporated. The residue was purified by chromatography on silica gel to give 100 mg of a yellow solid. 1H NMR (400 MHz, DMSO-i¾) δ 8.82 (s, 1H), 7.82 (s, 1H), 7.78 - 7.60 (m, 4H), 7.59 - 7.50 (m, 4H), 7.45 (t, J= 7.6 Hz, 1H), 7.34 - 7.15 (m, 2H), 6.97 (s, 1H), 4.76 (s, 2H), 3.84 (s, 2H), 3.26 (s, 4H), 2.64 - 2.54 (m, 2H), 2.53-2.45 (m, 2H), 1.73 - 1.62 (m, 4H), 1.62 - 1.50 (m, 2H). MS (ES, m/z): 650.28 [M+H] ⁺ .

EXAMPLE 3.2

3 -((3 -(Y4-(Piperidin- 1 -vD-2-(6-((3 -methylbenzyl¼mino)pyrimidin-4- yl)phenvDcarbamoyl)benzyl thio propanoic acid

Scheme 5. 1. 3-methylbenzylamine, K ₂ C0 _3, 50°C; 2. Zn/HOAc; 3. 3-(((3-(tert-butoxy)- 3-oxopropyl)thio)methyl)benzoic acid 1.1c, EDC HC1; DMAP; 4.TFA.

Intermediate 3.2a: N-(3-methylbenzyl -6-( ^' 2-nitro-5-(piperidin-l-yl ^' )phenyl pyrimidin- 4-amine. Into a 50-mL round-bottom flask, was placed a solution of 4-chloro-6-(2- nitro-5-(piperidin-l-yl)phenyl)pyrimidine 3.1b (500 mg, 1.57 mmol, 1.00 equiv) in N,N-dimethylformamide (10 mL), m-methylbenzylamine (285 mg, 2.36 mmol, 1.50 equiv), and potassium carbonate (650 mg, 4.71 mmol, 3.00 equiv). The resulting solution was stirred overnight at 80°C. The solids were filtered out. The resulting mixture was concentrated under vacuum. The residue was dissolved in 50 mL of ethyl acetate. The resulting mixture was washed with 2x50 mL of water. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate/petroleum ether (1 :5). This resulted in 0.5 g (79%) of N-(3-methylbenzyl)-6-(2-nitro-5-(piperidin-l-yl)phenyl) pyrimidin-4-amine.as yellow oil.

Intermediate 3.2b: 6-(2-amino-5-(piperidin-l-yl phenyl)-N-(3-methylbenzyl) pyrimidin-4-amine. Into a 50-mL round-bottom flask, was placed a solution of 6-(2- amino-5-(piperidin-l-yl)phenyl)-N-(3-methylbenzyl) pyrimidin-4-amine (400 mg, 0.99 mmol, 1.00 equiv) in acetic acid (5 mL). This was followed by the addition of zinc (630 mg, 9.84 mmol, 10.00 equiv) in several batches at 70°C. The resulting solution was stirred for 2 h at 60°C. The solids were filtered out. The resulting mixture was concentrated under vacuum. The solution was adjusted to pH 8 with aqueous ammonia (1 mol/L). The resulting solution was extracted with 2x50 mL of ethyl acetate and the organic layers combined, dried over anhydrous sodium sulfate, and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with dichloromethane:methanol (1 :50). This resulted in 200 mg (49%) of 6-(2-amino-5- (piperidin-l-yl)phenyl)-N-(3-methylbenzyl)pyrimidin-4-amine as a black solid.

Intermediate 3.2c: tert-butyl 3-((3-((4-(piperidin-l-yl -2-(6-((3-methyl benzvDaminoV pyrimidin-4-yl phenyl)carbamoyl)benzyl thio)propanoate. Into a 50-mL round-bottom flask, was placed a solution of 3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid (143 mg, 0.48 mmol, 1.00 equiv) in dichloromethane (10 mL), EDC HC1 (139 mg, 0.72 mmol, 1.50 equiv), 4-dimethylaminopyridine (89 mg, 0.69 mmol, 1.50 equiv), and 6-(2- amino-5-(piperidin-l-yl)phenyl)-N-(3-methylbenzyl) pyrimidin-4-amine (180 mg, 0.48 mmol, 1.00 equiv). The resulting solution was stirred overnight at room temperature. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column and eluted with petroleum ether/ethyl acetate (5:1). This resulted in 200 mg (57%) of product as yellow oil.

Example 3.2: 3-((3-( ^" (2-(6-((3-methylbenzyl)amino)pyrimidin-4-yl)-4-(piperi din-l-yl - phenyl)carbamoyl)benzyl thio)propanoic acid. Into a 100-mL round-bottom flask, was placed a solution of tert-butyl 3-(3-(2-(6-(3-methylbenzylamino)pyrimidin-4-yl)-4- (piperidin-l-yl)phenylcarbamoyl)benzylthio)propanoate (180 mg, 0.28 mmol, 1.00 equiv) in dichloromethane (5 mL), and 2,2,2-trifluoroacetic acid (2 mL). The resulting solution was stirred for 3 h at room temperature. The resulting mixture was concentrated under vacuum. The crude product was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 84 mg (51%) of a yellow solid. 1H-NMR (300MHz, DMSO-J ₆ , ppm): δ 9.42 (s, 1H), 8.84 (s, 1H), 7.80(s, 1H), 7.71(m, 2H), 7.52(m, 1H), 7.45(m, 1H), 7.24(m, 6H), 6.90(s, 1H), 5.42(s, 2H), 4.64(m, 1H), 3.82(s, 2H), 3.26(m, 4H), 2.59(m, 2H), 1.67(m, 6H). MS (ES, m/z): 596 [M+H] ⁺ .

EXAMPLE 3.3

3 -(Y3 -(Y4-(Piperidin- 1 -yP-2-(6-(Y3 -(trifluoromethyl phenethyl amino)pyrimidin-4- vDphenvDcarbamovDbenzvDthio^propanoic acid

This compound was prepared using the procedure described for the preparation of Example 3.2, except that 3-(trifluoromethyl)phenethylamine was used in place of 3- methylbenzylamine. 1H-NMR (300MHz, CD ₃ OD, ppm): 6 8.67(s, 1H), 7.86(s, 1H), 7.76 (m, 2H), 7.47(m, 9H), 6.82(s, 1H), 3.85 (s, 4H), 3.38(m, 4H), 3.01(m, 2H), 2.66(m, 2H), 2.56(m, 2H), 1.83(m, 4H), 1.72(m, 2H). MS (ES,m/z): 664 [M+H] ⁺ .

EXAMPLE 3.4

3 -(Y3 -((2-(6-((3 ,4-Dimethylbenzyl amino pyrimidin-4-yl -4-(piperidin- 1 - yl)phenvDcarbamoyl benzyl thio)propanoic acid

This compound was prepared using the procedure described for the preparation of Example 3.2, except that 3,4-dimethylbenzylamine was used in place of 3- methylbenzylamine. 1H-NMR (300MHz, DMSO-t ₆ , ppm): δ 8.83(s, 1H), 7.79(s, 1H), 7.71(m, 2H), 7.53(m, 1H), 7.47(m, 1H), 7.26(m, 2H), 7.06(m, 2H), 6.96(m, 1H), 6.88(s, 1H), 4.58(s, 2H), 3.82(s, 2H), 3.26(m, 4H), 2.57(m, 2H), 2.18(m, 6H), 1.66(m, 6H). MS (ES, w/z): 610 [M+H] ⁺ .

EXAMPLE 3.5

3-(f3-((2-(6-(i4-CMoro-3 -(trifle

1 -vDphenvDcarbamovDbenzvDthio^propanoic acid

This compound was prepared using the procedure described for the preparation of Example 3.2, except that 4-chloro-3-(trifluoromethyl)benzylamine was used in place of 3-methylbenzylamine. 1H-NMR (300MHz, CD ₃ OD, ppm): δ 8.75(s, 1H), 7.86(s, 1H), 7.77 (m, 3H), 7.48(m, 8H), 6.91(s, 1H), 4.79 (s, 2H), 3.84(s, 2H), 3.42(m, 4H), 2.70(m, 2H), 2.56(m, 2H), 1.85(m, 4H), 1.73(m, 2H). MS (ES, m/z): 684 [M+H] ⁺ .

EXAMPLE 3.6

3-((3-((2-(6-((3,4-Dimethoxybenzvnamino pyrimidin-4-yl)-4-(piperidin-l- vDphenvDcarbamovDbenzvnthio'tpropanoic acid

This compound was prepared using the procedure described for the preparation of Example 3.2, except that 3,4-dimethoxyben2ylamine was used in place of 3- methylbenzylamine. 1H-NMR (400MHz,DMSO-i/ ₆ , ppm): δ 8.85(s, 1H), 7.79(s, 1H), 7.73(m, 2H), 7.54(m, 1H), 7.44(m, 1H), 7.25(m, 1H), 7.23(m, 1H), 6.88(m, 2H), 6.83(m, 1H), 6.76(m, 1H), 4.58(s, 2H), 4.39(s, 1H), 3.82(s, 2H), 3.72(m, 3H), 3.68(s, 3H), 3.25(m, 4H), 2.58(m, 2H), 1.66(m, 4H), 1.58(m, 2H). MS (ES, m/z): 642 [M+H] ⁺ .

EXAMPLE 3.7

3 -((3 -((2-( ^" 6-(Benzylamino pyrimidin-4-ylV4-(piperidin- 1 - yl phenvDcarbamoyl)benzyl)thio)propanoic acid

This compound was prepared using the procedure described for the preparation of Example 3.2, except that benzylamine was used in place of 3-methylbenzylamine. Ή-NMR (400MHz, DMSO d ₆ , ppm): δ 9.55(s, IH), 8.85(s, IH), 7.80 (s, IH), 7.74(m, IH), 7.72(m, IH), 7.55(m,lH), 7.45(m, IH), 7.28(m, 7H), 6.91(s, IH), 4.68(m, 2H), 4.52(s, IH), 3.82(s, 2H), 3.27 (s, 4H), 2.57 (m, 2H), 1.67(m, 4H), 1.58(m, 2H). MS (ES, M/Z): 582 [M+H] ⁺ .

EXAMPLE 3.8

3 -(( 3 -((4-(Piperidin- 1 -yl)-2-(6-(Y3 -(trifluoromethyl)benzyl)oxy)pyrimidin-4- vDphenvDcarbamoyDbenzynthio ^' ipropanoic acid

Scheme 6. 1. 3-(trifluoromethyl)benzyl alcohol, NaH; 2. sodium dithionite; 3. Intermediate 3.1a; 4. TFA.

Intermediate 3.8a: 4-( ^' 2-nitro-5-(piperidin-l-vnphenylV6-(f3-( ^' trifluoromethyl benzylV oxy)pyrimidine. To a solution of 99 mg of 3-(trifluoromethyl)benzyl alcohol in 2 mL of DMF was added 27 mg of a 50% dispersion of sodium hydride in oil. After 15 min the solution was treated with 150 mg of intermediate 3.1b. After an additional 2 h the reaction mixture was partitioned between water and ethyl acetate. The organic extracts were washed with brine and dried (Na ₂ S0 ₄ ). The solvent was evaporated to give a yellow syrup that was used directly in the next step.

Intermediate 3.8b: 4-(piperidin-l-ylV2-(6-(( ^' 3-(trifluoromethyl ^' ) benzyl oxy pyrimidin- 4-yl)aniline. All of the product from the preceding step was dissolved in 4 mL of dioxane and a solution of 410 mg of sodium dithionite and 158 mg of sodium bicarbonate in 4 mL of water was added dropwise. After 3 h a fresh solution of 410 mg of sodium dithionite and 158 mg of sodium bicarbonate in 4 mL of water was added dropwise, and the mixture was stirred an additional 4 h. It was partitioned between ethyl acetate and water, and the aqueous phase was extracted with ethyl acetate. The combined organic extracts were washed with brine and dried (Na ₂ S0 ). The solvent was evaporated and the residue was chromatographed on silica gel to give 75 mg of a yellow syrup.

Intermediate 3.8c: tert-butyl 3-(f3-((4-rpiperidin-l-yl)-2-(6-((3-(trifluoromethyn benzyl) oxy)pyrimidin-4-v phenvncarbamoyl benzvf)thio ^' )propanoate. To a 5°C solution of 75 mg of 4-(piperidin-l-yl)-2-(6-((3-(trifluoromethyl)benzyl)oxy)pyri midin- 4-yl)aniline in dichloromethane was added 65 mg of intermediate 3.1a. The mixture was stirred overnight and then the solvent was evaporated. The residue was purified by chromatography on silica gel to give 75 mg of a yellow syrup.

Example 3.8: 3 -((3 -( (4-ipiperidin- 1 - yl)-2-(6-((3 - ( trifluoromefhvn benzyl)oxy)pyrimidin-4-yDphenyl ^' )carbamoyD benzyl)thio)propanoic acid. This compound was prepared from intermediate 3.8c using the same procedure used to prepare Example 1.1 from intermediate 1.1k. MS (ES, m/z): 651.1 [M+H] ⁺

EXAMPLE 3.9

3 -(Y3 -(Y4-(Piperidin- 1 -νΓ)-2-(6-(3 -(trifluoromethyl)phenoxy ^' )pyrimidin-4- yDphenvDcarbamovDbenzyDthio ^' ipropanoic acid.

Scheme 7. 1. 3-(trifluoromethyl)phenol, K ₂ C0 ₃ ; 2. ¾, PoVC; 3. Intermediate 3.1a, then TFA.

Intermediate 3.9a: 4-( ^' 2-nitro-5-(piperidin-l-yl ^' )phenylV6-(3-(trifluoromethyl)phenoxy - pyrimidine. To a solution of 160 mg of 3-(trifluoromethyl)phenol in 2 mL of DMF was added 104 mg of potassium carbonate and 160 mg of intermediate 3.1b. After stirring overnight at 50° C the reaction mixture was partitioned between water and ethyl acetate. The organic extracts were washed with brine and dried (Na ₂ S0 ₄ ). The solvent was evaporated to give a yellow syrup that was used directly in the next step.

Intermediate 3.9b: 4-(piperidin-l-yl -2-(6-( ^' 3-(trifluoromethvnphenoxy pyrimidin-4- yl)-aniline. A solution of 4-(2-nitro-5-(piperidin-l-yl)phenyl)-6-(3-(trifluoromethyl )phenoxy)pyrimidine in a mixture of methanol and ethyl acetate was treated with 35 mg of 5% Pd/C and stirred for 2 h under a hydrogen atmosphere. The mixture was filtered and the solvent was evaporated. The residue was purified by chromatography to give the product as 170 mg of a yellow syrup.

Example 3.9: 3-(Y3-(Y4-(piperidin-l -ylV2-(6-(3-(trifluoromethyl ^' )phenoxy)pyrimidin-4- yl)-phenyDcarbamovDbenzyl)thio propanoic acid. This compound was prepared from intermediate 3.9 using the procedure described for the conversion of intermediate 1.1k to Example 1.1.

EXAMPLE 3.10

3 -((3 -(Y4-(Piperidin- 1 -vD-2-(6-(T3 -(trifluoromethyl)phenyl amino ^' )pyrimidin-4- vDphenvDcarbamoyl)benzyl)thio propanoic acid

Scheme 8. 1. 3-(trifluoromethyl)aniline, hydrochloric acid; 2. H ₂ , Pd/C; 3. Intermediate 3.1a, then TFA

Intermediate 3.10a: 6-(2-nitro-5 -(piperidin- 1 -vDphenvD-N-O -(trifluoromethyl)phenyl)- pyrimidin-4-amine. A solution of 15 mg of 3-(trifluoromethyl)aniline and 27 mg intermediate 3.1b in 1 mL of DMF was treated with 1 drop of concentrated hydrochloric acid and heated to 90°C for 1 h. The solution was cooled and partitioned between ethyl acetate and water. The organic extracts were washed with brine and dried over Na ₂ S0 ₄ . The solvent was evaporated at reduced pressure to give 28 mg of product. Intermediate 3.10b: 6-(2-amino-5-( ^' piperidin-l-yl ^' )phenylVN-(3- (trifluoromethyl)phenylVpyrimidin-4-amine. This compound was prepared from intermediate 3.10a using the procedure used for the preparation of intermediate 3.9b from intermediate 3.9a.

Example 3.10: 3-((3-((4-( ^' piperidin-l-ylV2-(6-((3-(trifluoromethyl)phenvDaminoV pyrimidin-4-yl)phenyl)carbamoyl benzyl)thio propanoic acid. This compound was prepared from intermediate 3.10b using the procedure described for the preparation of Example 3.8 from intermediate 3.8b. MS (ES, m/z): 636.3 [M+H] ⁺

EXAMPLE 4.1

Nl-( ^, 2-(Diethylamino ethyl -Nl-methyl-N3-r4-(piperidin-l-yl -2-(4-( ^' r3- (trifluoromethyl)benzyncarbamoyl)pyridin-2-vDphenvDisophthal amide

Scheme 9. 1. LiOH, THF, water; 2. EDC HC1, D AP,

3-(trifluoromethyl)benzylamine; 3. H ₂ , Pd/C; 4. isophthalic acid monomethyl ester, EDC HC1, DMAP; 5. LiOH; 6. EDC HC1, DMAP, Et ₂ NC¾CH ₂ NHMe.

Intermediate 4.1a: 2-( ^f 2-nitro-5-(piperidin-l-yl ^' )phenvnisonicotinic acid. Into a 50-mL round-bottom flask, was placed a solution of methyl 2-(2-nitro-5-(piperidin-l- yl)phenyl)isonicotinate l.lg (1 g, 2.93 mmol, 1.00 equiv) in tetrahydrofuran/water(l:l) (20 mL), lithium hydroxide hydrate (1.26 g, 30.00 mmol, 10.23 equiv). The resulting solution was stirred overnight at 25°C in an oil bath. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 10 mL of water. The resulting solution was extracted with 2x20 mL of ethyl acetate and the aqueous layers combined. The solution was adjusted to pH 5 with hydrochloric acid. The resulting solution was extracted with 2x50 mL of ethyl acetate and the organic layers combined, dried over anhydrous sodium sulfate, and concentrated under vacuum. This resulted in 0.8 g (83%) of 2-(2-nitro-5-(piperidin-l-yl)phenyl)isonicotinic acid as a yellow solid.

Intermediate 4.1b: N-(3-(trifluoromethyl)benzylV2-(2-nitro-5-(piperidin-l-yl)ph enylV isonicotinamide. Into a 50-mL round bottom flask, was placed a solution of 2-(2-nitro- 5-(piperidin-l-yl)phenyl)isonicotinic acid (1 g, 3.06 mmol, 1.00 equiv) in dichloromethane (20 mL), EDC.HC1 (970 mg, 5.05 mmol, 1.65 equiv), 4- dimethylaminopyridine (620 mg, 5.08 mmol, 1.66 equiv), and (3- (trifluoromethyl)phenyl)methanamine (590 mg, 3.37 mmol, 1.10 equiv). The resulting solution was stirred overnight at 25°C in an oil bath. The reaction progress was monitored by LCMS. The mixture was concentrated under vacuum. The residue was applied onto a silica gel column and eluted with petroleum ether/ethyl acetate (10:1-3:1). This resulted in 800 mg (51%) of N-(3-(trifluoromethyl)benzyl)-2-(2-nitro- 5-(piperidin-l-yl)phenyl)isonicotinamide as a yellow solid.

Intermediate 4.1c: N-(3-(trifluoromethyl benzyl)-2-(2-amino-5-(piperidin-l- vDphenvD-isonicotinamide. Into a 250 mL round bottom flask, was placed a solution of l-(2-(2-nitro-5-(piperidin-l-yl)phenyl)pyridin-4-yl)ethanone (1 g, 2.07 mmol, 1.00 equiv) in methanol/ethyl acetate(3:2) (35 mL). The mixture was treated with Pd/C (10%) (1 g) and stirred under a hydrogen atmosphere for 1.5 h at room temperature. The solids were filtered out. The resulting mixture was concentrated under vacuum. This resulted in 0.9 g (96%) of N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-(piperidin- l-yl)phenyl)isonicotinamide as a yellow solid.

Intermediate 4.1 d: 3-((2-(4-((3-(trifluoromethyl benzyl carbamoyl)pyridin-2-yl -4- (piperidin- 1 -vDphenyl)carbamoyl benzoate. Into a 50-mL round bottom flask, was placed a solution of N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-(piperidin-l- yl)phenyl)-isonicotinamide (300 mg, 0.66 mmol, 1.00 equiv) in dichloromethane (15 mL), EDC.HC1 (153 mg, 0.80 mmol, 1.21 equiv), 4-dimethylaminopyridine (96.75 mg, 0.79 mmol, 1.20 equiv), and 3-(methoxycarbonyl)benzoic acid (130.8 mg, 0.73 mmol, 1.10 equiv). The resulting solution was stirred overnight at 25°C in an oil bath. The reaction progress was monitored by LCMS. The resulting solution was diluted with 50 mL of dichloromethane. The resulting mixture was washed with 2x50 mL of N¾C1 aq. and 1x50 mL of brine. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column and eluted with petroleum ether/ethyl acetate (3:1-2:1). This resulted in 360 mg (88%) of methyl 3-((2-(4-((3- (trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin - 1 - yl)phenyl)carbamoyl)benzoate as a yellow solid.

Intermediate 4.1 e: 3-((2-(4-((3 -(trifluoromethyl benzyl carbamoyl pyridin-2-yl)-4- (piperidin- 1 -yl phenyl carbamoyl benzoic acid. Into a 50-mL round-bottom flask, was placed a solution of methyl 3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2- yl)-4-(piperidin-l-yl)phenyl)carbamoyl)benzoate (360 mg, 0.58 mmol, 1.00 equiv) in tetrahydrofuran/water(2:3) (35 mL), and lithium hydroxide hydrate (251.2 mg, 5.98 mmol, 10.25 equiv). The resulting solution was stirred overnight at 25°C in an oil bath. The reaction progress was monitored by LCMS. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 50 mL of water adjusted to pH 2-3 with hydrogen chloride (2 mol/L). The resulting solution was extracted with 3x50 mL of ethyl acetate and the organic layers combined. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This resulted in 325 mg (92%) of 3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl) -4- (piperidin-l-yl)phenyl)carbamoyl)-benzoic acid as a yellow oil.

Example 4.1 : Nl-(2-(diethylamino ethvn-Nl-methyl-N3-(4-(piperidm-l-yl)-2-(4-r(3- (trifluoromethyl benzyl)carbamoyl pyridin-2-yl)phenyl isophthalamide. Into a 10-mL round bottom flask, was placed a solution of 3-((2-(4-((3- (trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin -l-yl)phenyl)carbamoyl)- benzoic acid (100 mg, 0.17 mmol, 1.00 equiv) in dichloromethane (5 mL), EDC.HCl (63.75 mg, 0.33 mmol, 2.00 equiv), 4-dimethylaminopyridine (40.5 mg, 0.33 mmol, 2.00 equiv), Nl,Nl-diethyl-N2-methylethane-l,2-diamine (64.8 mg, 0.56 mmol, 3.00 equiv). The resulting solution was stirred overnight at 25°C in an oil bath. The reaction progress was monitored by LCMS. The resulting solution was diluted with 50 mL of dichloromethane. The resulting mixture was washed with 3x70 mL of NH ₄ C1 (aq). The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product (150 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 47.8 mg (34%) of a yellow solid. 1H-NMR (300MHz, OMSO-d ₆ , ppm): δ 12.36(s, 1H), 9.57(t, 1H), 9.28(s, 1H), 8.90(d, J=5.1Hz, 1H), 8.30(m, 2H), 7.98(d, J=7.2Hz, 2H), 7.84(d, J=4.8Hz, 1H), 7.65(m, 7H), 7.28(d, J=8.4 Hz, 1H), 4.66(d, J=6.0Hz, 2H), 3.82(m, 2H), 3.31(m, 9H), 2.97(s, 4H), 1.71(m, 6H),1.24(m, 6H). MS (ES, m/z): 715 [M+H] ⁺ .

EXAMPLE 4.2

N 1 -(2-(4-((3 -(Trifluoromethyl benzyl)carbamovnpyridin-2-yl -4-(piperidin- 1 - yl phenyl -N3-(3-(2-methoxyethylamino)-3-oxopropyl -N3-methylisophthalamide

Into a 10-mL vial, was placed a solution of 3-((2-(4-((3- (trifluoromethyl)berizyl)carbamoyl)pyridin-2-yl)-4-(piperidi n-l-yl)pnenyl)carbamoyl)- benzoic acid 4.1e (80 mg, 0.13 mmol, 1.00 equiv) in dichloromethane (5 mL), EDC.HC1 (51.1 mg, 0.27 mmol), 4-dimethylaminopyridine (32.4 mg, 0.27 mmol, 2.00 equiv), and N-(2-methoxyethyl)-3-(methylamino)propanamide (31.2 mg, 0.20 mmol, 1.47 equiv). The resulting solution was stirred for 6 h at 25°C in an oil bath. The reaction progress was monitored by LCMS. The resulting solution was diluted with 50 mL of dichloromethane. The resulting mixture was washed with 3x70 mL of NH ₄ C1. The mixture was dried over sodium sulfate and concentrated under vacuum. The crude product (100 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TF A. This yielded 50.4 mg (44%) of Nl-(2-(4-((3- (trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin - 1 -yl)phenyl)-N3 -(3 -(2- methoxyethylamino)-3-oxopropyl)-N3-methylisophthalamide as a yellow solid. Ή- NMR (300MHz, DMSO-i¾+D ₂ 0, ppm) δ 8.89 (d, J=5.1Hz ,1H), 8.43 (t, IH), 8.31 (s, IH), 7.94 (t, J=9.3Hz, 4H), 7.83 (m, 7H), 4.58 (s, 2H), 3.32-3.65(m, 7H), 3.07-3.17 (m, 6H), 2.85-2.95 (m, 3H), 2.31 (s, 2H), 1.63-1.85 (m, 6H). MS (ES, m/z): 745 [M+H] ⁺ .

EXAMPLE 4.3

Nl-(2-(2-Hvdroxyethoxy ethvn-Nl-methyl-N3-( ^' 4-rpiperidin-l-vn-2-(4-r(3- (trifluoromethyl)benzyl)carbamovnpyridin-2-yl phenvDisophthalamide

This compound was prepared from 3-((2-(4-((3-

(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperi din-l-yl)phenyl)carbamoyl)- benzoic acid 4.1e using the procedure described for the preparation of Nl-(2-(4-((3- (trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin -l-yl)phenyl)-N3-(3-(2- methoxyethylamino)-3 -oxopropyl)-N3 -methylisophthalamide 4.2. 2-(2- (Methylamino)-ethoxy)ethanol was used as the amine component in this coupling. 1H-NMR: (300MHz, DMSO-i ₆ +D ₂ 0, ppm): δ 9.58 (s, IH), 8.91 (d, J=5.1Hz, IH), 8.46 (d, J=9Hz, IH), 8.36 (s, IH), 7.87-7.96 (m, 4H), 7.545-7.689 (m, 7H), 4.61 (s, 2H), 3.29-3.49 (m, 12H), 2.97 (d, J=21.9Hz, 3H), 1.84 (s, 4H), 1.68 (s, 2H). MS (ES, m/z): 704 [M +H] ⁺ .

EXAMPLE 4.4 N 1 -(2-Morpholinoethyl -N3 -f 4-ipiperidin- 1 -γ\)-2-(4-( ( 3 - (trifluoromethvnbenzyl carbamoyl pyridin-2-yl phenvnisophtlialarnide

This compound was prepared from 3-((2-(4-((3-

(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperi din-l-yl)phenyl)carbamoyl)- benzoic acid 4.1e using the procedure described for the preparation of Nl-(2-(4-((3- (trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin -l-yl)phenyl)-N3-(3-(2- methoxyethylamino)-3-oxopropyl)-N3-methylisophthalamide 4.2. 2-Morpholino- ethanamine was used as the amine component in this coupling. 1H-NMR (300MHz, OMSO-d ₆ , ppm) δ 12.60 (s, IH), 9.68 (s, 1H),9.57 (t, IH), 9.00 (d, J=5.1Hz,lH), 8.95 (t, IH), 8.50 (s, IH), 8.36 (s, 2H),8.09(t, 2H), 7.85 (d, J=5.1Hz, IH), 7.64 (m, 6H), 7.28 (s, IH), 4.63 (d, J=6.0Hz, 2H), 4.02 (m, 4H), 3.69 (m, 6H), 3.43 (m, 8H), 1.65 (m, 6H). MS (ES, m/z): 715 [M+H] ⁺ .

EXAMPLE 4.5

Tert-butyl 4-(2-rN-methyl-3-r(4-(piperidin-l-vn-2-(4-(r3-

( ^" trifluoromethyl ^' )benzyl)carbamoyl pyridin-2- ynphenvDcarbamovfjbenzamidolethvDpiperazine- 1 -carboxylate

This compound was prepared from 3-((2-(4-((3-

(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperi din-l-yl)phenyl)carbamoyl)- benzoic acid 4.1e using the procedure described for the preparation of Nl-(2-(4-((3- (trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin -l-yl)phenyl)-N3-(3-(2- methoxyethylamino)-3-oxopropyl)-N3-methylisophthalamide 4.2. Tert-Butyl 4-(2- (methylamino)ethyl)piperazine-l-carboxylate was used as the amine component in this coupling. 1H-NMR (300MHz, CD ₃ OD, ppm): δ 8.98 (d, J=5.1Hz, 1H), 8.75 (d, J=9.0Hz, 1H), 8.46 (s, 1H), 8.18-8.11 (m, 3H), 7.89-7.53 (m, 8H), 4.72 (s, 2H), 4.00-3.11 (m, 16H), 3.08 (s, 3H), 2.04 (d, J=4.8Hz, 4H), 1.83 (d, J=5.7Hz, 2H), 1.49 (s, 9H). MS (ES, m/z): 828 [M+H] ⁺ .

EXAMPLE 4.6

2-(2-(3 -(4- Acetylpiperazine- 1 -carbonyl)benzamido -5-(piperidin- 1 -vDphenylVN-O - (trifluoromethvDbenzyl)isonicotinamide

This compound was prepared from 3-((2-(4-((3-

(trifluoromethyl)berizyl)carbamoyl)pyridin-2-yl)-4-(piper idin-l-yl)phenyl)carbamoyl)- benzoic acid 4.1e using the procedure described for the preparation of Nl-(2-(4-((3- (trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin - 1 -yl)phenyl)-N3 -(3 -(2- methoxyethylamino)-3-oxopropyl)-N3-methylisophthalamide 4.2. N-Acetylpiperazine was used as the amine component in this coupling. 1H-NMR (400MHz, DMSO-i/ ₆ , ppm): δ 12.48 (s, 1H), 9.57 (m, 1H), 8.93 (d, J=5.2Hz, 1H), 8.39 (d, J=1 1.2Hz, 2H), 7.99-7.46 (m, 1 1H), 4.63 (d, J=6.0Hz, 2H), 3.55-3.42 (m, 12H), 2.21 (s, 3H), 1.79 (s, 4H), 1.62 (s, 2H). MS (ES, m/z): 713 [M+H] ⁺ . EXAMPLE 4.7

2-(2-(3-(4-Acetamidopiperidine- 1 -carbonyl benzamido)-5-(piperidin- 1 -yl phenyl)-N- (3-(trifluoromethvDbenzvnisonicotinamide

This compound was prepared from 3-((2-(4-((3-

(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperi din- 1 - yl)phenyl)carbamoyl)benzoic acid 4.1e using the procedure described for the preparation of Nl -(2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4 - (piperidin-l-yl)phenyl)-N3-(3-(2-methoxyethylamino)-3-oxopro pyl)-N3- methylisophthalamide 4.2. N-(piperidin-4-yl)acetamide was used as the amine component in this coupling. 1H-NMR (300MHz, CD ₃ OD, ppm): δ 8.98 (d, J=3.5Hz, IH), 8.85 (d, J=9.0Hz, IH), 8.47 (s, IH), 8.24 (d, J=2.4Hz, IH), 8.12-8.09 (m, 2H), 7.90-7.88 (m, IH), 7.77-7.68 (m, 5H), 6.62-7.55 (m, 2H), 4.72 (s, 2H), 4.58 (s, IH), 3.99-3.93 (m, IH), 3.73-3.70 (m, 5H), 3.27-3.12 (m, 2H), 2.09-2.02 (m, 5H), 1.94 (s, 3H), 1.85 (d, J=4.8Hz, IH), 1.60-1.35 (m, 2H). MS (ES, m/z): 727 [M+H] ⁺ .

EXAMPLE 4.8

Nl-Ethyl-Nl- -morpholinoethylVN3-( ^' 4-( ^, piperidin-l-vn-2-r4-( ^' n- (trifluoromethyl ^' )benzyl carbamoyl pyridin-2-yl)phenyl)isophthalamide

To a mixture of 25 mg of 3-((4-(piperidin-l-yl)-2-(4-((3- (trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)carbam oyl)benzoic acid 4.1 e, 17 mg of diisopropylethylamine and 9 mg of N-ethyl-2-morpholinoethanamine in 1 mL of DMF was added 17 mg of HATU. The mixture was stirred at 25°C for 1 h. The solution was injected onto a preparative reverse phase HPLC and the product was eluted with 0.5% TFA in a gradient of water and acetonitrile. The yield was 11.2 mg of product. 1H-NMR (400MHz, DMSO- ₆ , ppm) δ 12.46 (s, IH), 9.90 (s, IH), 9.57 (t, J=6.1 Hz, IH), 8.90 (d, J=5.1 Hz, IH), 8.36, (s, 2H), 8.03-7.92 (m, 2H), 7.87 (dd, J=5.1, 1.3 Hz, IH), 7.75-7.53 (m, 26H), 7.39 (s, IH), 4.63 (d, J=5.8 Hz, 2H), 4.03 (s, 2H), 3.82 (s, 2H), 3.60 (s, 4H), 3.40 (d, J=23.1 Hz, 6H), 3.24 (s, 4H), 1.77 (s, 4H), 1.61 (s, 2H), 1.08 (t, J=6.5 Hz, 10H). MS (ES, m/z): 743 [M+H] ⁺ .

EXAMPLE 4.9

(S )-2-(2-(3 -(3 - Acetamidopyrrolidine- 1 -carbonyDbenzamidoV 5-(piperidin- 1 -vDphenylV N-(3-(trifluoromethyl)benzyl isonicotinamide

This compound was prepared from 3-((2-(4-((3-

(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperi din- 1 - yl)phenyl)carbamoyl)benzoic acid 4.1e using the procedure described for the preparation of N 1 -methyl-N 1 -(2-morpholinoethyl)-N3 -(4-(piperidin- 1 -yl)-2-(4-((3- (trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)isopht halamide 4.8, except that CH ₃ CN was substituted for DMF as the reaction solvent and (S)-N-(pyrrolidin-3- yl)acetamide was used as the amine component. ¹ H-NMR (300MHz, CD ₃ OD, ppm): δ 8.88 (d, J=3.5Hz, IH), 8.69-8.663 (m, IH), 8.33 (s, IH), 8.10-8.05 (m, 2H), 8.00-7.97 (m, IH), 7.76 (d, J=5.2Hz, IH), 7.71-7.66 (m, IH), 7.60-7.43 (m, 6H), 4.60 (s, 2H), 4.40-4.16 (m, IH), 3.71-3.21 (m, 8H), 2.22-1.71 (m, 11H). MS (ES, m/z): 713 [M+H] ⁺ .

EXAMPLE 4.10

(SV2-(2-(3-(3-Acetamidopyrrolidine-l-carbonyl benzamido)-5-(piperidin-l-yl phenyl - N-D-CtrifluoromethvDbenzvnisonicotinamide

This compound was prepared from 3-((2-(4-((3-

(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperi din-l-yl)phenyl)carbamoyl)- benzoic acid 4.1e using the procedure described for the preparation of Nl -methyl-N 1- (2-mo holinoethyl)-N3-(4-(piperidin-l-yl)-2-(4-((3-

(trifluoromethyl)benzyl)carbamoyl)-pyridin-2-yl)phenyl)is ophthalamide 4.8, except that CH ₃ CN was substituted for DMF as the reaction solvent and (R)-N-(pyrrolidin-3- yl)acetamide was used as the amine component. Ή-NMR (300MHz, CD ₃ OD, ppm): δ 8.99 (d, J=6.0Hz, 1H), 8.70 (d, J=9.6Hz, 1H), 8.41 (s, 1H), 8.21 (d, J=6.0Hz, 1H), 8.12 (d, J=7.8Hz, 1H), 8.01 (s, 1H), 7.88-7.78 (m, 2H), 7.72-7.54 (m, 6H), 4.72 (s, 1H), 4.51-4.28 (m, 1H), 3.91-3.52 (m, 8H), 2.30-1.79 (m, 11H). MS (ES, m/z): 713 [M+H] ⁺ .

EXAMPLE 4.i l

N 1 -Cvclopropyl-N 1 -(2-morpholinoethyl)-N3 -( 4-(piperidin- 1 -yl>2-( 4-(Y3

( ^' trifluoromethynbenzyl)carbamoyl pyridin-2-vDphenyl)isophthalamide

Scheme 10. 1. CH ₃ CN, 80°C; 2.1ntermediate 4.1e, HATU, DIPEA.

Intermediate 4.11a: N-(2-morpholinoethvDcyclopropanamine, hydrochloride salt. A solution of 100 mg of N-(2-chloroethyl)morpholine and 307 mg of cyclopropylamine in 5 mL of C¾CN was refluxed for 2 h. The mixture was cooled to 25°C and treated with excess K ₂ C0 ₃ . After stirring for 1 h the suspension was filtered and the solvent was evaporated. The residual solvent was removed at high vacuum and the residue was dissolved in a large excess of methanolic HCl. The solvent was evaporated to give 102 mg of the product.

Example 4.11 : Nl-cvclopropyl-Nl-(2-morpholinoethv -N3-( ^f 4-(piperidin-l-vD-2-( ^' 4- ((3-(trifluoromethyl)benzyl)carbamoyl pyridin-2-vDphenvDisophthalamide. This compound was prepared from 3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin- 2-yl)-4-(piperidin-l-yl)phenyl)carbamoyl)benzoic acid 4.1e using the procedure described for the preparation l-yl)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-y l)phenyl)isophthalamide 4.8. N-(2-moφholinoethyl)cyclopro anamine hydrochloride was used as the amine component in this coupling. MS (ES, m/z): 755 [M+H] ⁺

EXAMPLE 4.12

Nl -Benzyl-Nl -f 2-mo^holinoe hylVN3-(4-(piperidin-l -νΠ-2-Γ4-((3- (trifluoromethvnbenzyl)carbamoyl)pyridin-2-yl)phenyl)isophth alamide

Scheme 11. 1. CH ₃ CN, 80°C; 2. Intermediate 4.1e, HATU, DIPEA.

Intermediate 4.12a: N-benzyl-2-morpholinoethanamine, hydrochloride salt. A solution of 100 mg of N-(2-chloroethyl)morpholine and 575 mg of benzylamine in 5 mL of CH ₃ CN was refluxed for 2 h. The mixture was cooled to 25°C and partitioned between dichloromethane and an aqueous sodium bicarbonate solution. The organic extracts were dried and the solvent was evaporated. The residual solvent was removed at high vacuum and the residue was dissolved in a large excess of methanolic HCl. The solvent was evaporated to give 60 mg of the product.

Example 4.12: Nl -benzyl-Nl -(2-morpholinoethylVN3-f4-(piperidin-l -ylV2-(4-((3- (trifluoromethyl)benzvncarbamoyl pyridin-2-yl ^' )phenyl isophthalamide. This compound was prepared from 3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin- 2-yl)-4-(piperidin-l-yl)phenyl)carbamoyl)benzoic acid 4.1e using the procedure described for the preparation of Nl-methyl-Nl-(2-morpholinoethyl)-N3-(4-(piperidin- l-yl)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-y l)phenyl)isophthalamide 4.8. N-benzyl-2-morpholinoethanamine was used as the amine component in this coupling. MS (ES, m/z) 805 [M+H] ⁺

EXAMPLE 4.13

2-(2-(3-(4- Acetyl- 1 ,4-diazepane- 1 -carbonyl)benzamido)-5-(piperidin- 1 -vOphenyQ-N- (3-ftrifluoromethyl)benzvDisonicotinamide

Scheme 12. 1. tert-butyl 1,4-diazepane-l-carboxylate, EDC HC1, DMAP; 2. TFA, then AcCl.

Intermediate 4.13a: tert-butyl 4-(3 -(T 4-rpiperidin- 1 - yl )-2-(4-( (3 -

(trifluoromethyl benzylVcarbamoyl)pyridin-2-vDphenyl)carbamoy benzoyl)-1.4- diazepane- 1 -carboxylate. This compound was prepared from 3-((2-(4-((3- (trifluoromethyl)benzyl)carbamoyl)pyridin-2-yI)-4-(piperidin - 1 - yl)phenyl)carbamoyl)benzoic acid 4.1e and tert-butyl 1,4-diazepane-l-carboxylate using the procedure used to prepare Nl-(2-(diethylamino)ethyl)-Nl-methyl-N3-(4- (piperidin- 1 -yl)-2-(4-((3 -(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)- isophthalamide 4.1.

Example 4.13: 2-(2-(3-(4-acetyl- 1 ,4-diazepane- 1 -carbonvDbenzamido)- 5-(piperidin- 1 - vDphenvD-N-iS-rtrifluoromethvDbenzvDisonicotinamide. The Boc protecting group was removed from 2-(2-(3-(4-acetyl-l,4-diazepane-l-carbonyl)benzamido)-5- (piperidin-l-yl)phenyl)-N-(3-(trifluoromethyl)benzyl)isonico tinamide by treatment with a 1 :1 solution of dichloromethane and TFA. The product was acylated using acetyl chloride and pyridine in dichloromethane as solvent under standard conditions. ^! H- NMR (300MHz, CDC1 ₃ , ppm): δ 14.26(s, 1H), 9.55(s, 1H), 9.31(s, 1H), 9.15(d, J=8.4Hz, 1H), 8.94(s, 1H), 8.87(d, J=4.8Hz, 1H), 8.14~8.06(m, 3H), 7.73(s, 1H), 7.68~7.60(m, 3H), 7.52~7.41(m, 3H), 4.76(d, J=5.7Hz, 2H), 3.93~3.47(m, 10H), 2.19~2.13(m, 10H), 1.73(s, 3H). MS (ES, m/z): 727 [M+H] ⁺ .

EXAMPLE 4.14

( ^' SV2-(2-(3-(3-((2-Methoxyethv carbamovDpiperidine-l-carbonyl)benzamido -5- (piperidin- 1 -yl)phenyl)-N-(3 -(trifluoromethyl benzvnisonicotinamide

Scheme 13. 1. EDC HC1, triethylamine, HOBt, then HC1; 2. HATU, diisopropylethylamine, intermediate 4.1e.

Intermediate 4.14a: (S^-N-^-methoxyethvnpiperidine-S-carboxamide. A 0°C solution of 500 mg of (S)-l-(tert-butoxycarbonyl)piperidine-3-carboxylic acid, 328 mg of 2- methoxyethylamine, 736 mg of HOBt, and 1.82 mL of triethylamine in 9 mL of dichloromethane was treated with 836 mg of EDC HC1. The mixture was stirred at 25°C overnight and the solvent was evaporated at reduced pressure. The residue was dissolved in ethyl acetate, and the solution was sequentially washed with water, an aqueous solution of citric acid, an aqueous sodium bicarbonate solution, and brine. The solution was dried (Na ₂ S0 ₄ ) and the solvent was evaporated. The residue was dissolved in a 4 M solution of HC1 in dioxane. After 1 h the mixture was evaporated to give 406 mg of the product.

Example 4.14: (S)-2-(2-(3-(3-((2-methoxyethyl carbamoy

benzamidoV5-(piperidin-l-yDphenylVN-(3-(rt A solution of 31.4 mg of 3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl) -4- (piperidin-l-yl)phenyl)carbamoyl)benzoic acid 4.1e, 31.1 mg of intermediate 4.14a, 68 μΐ, of diisopropylethylamine, and 22.4 mg of HATU in 150 iL of DMF was stirred for 2 h. The product was isolated by reverse phase chromatography. MS (ES, m/z): 771.8 [M+H] ⁺

EXAMPLE 4.15

(RV2-(2-(3-(3 -ff 2-Methoxyethyl)carbamov0piperidine- 1 -carbonvDbenzamidoVS- (piperidin- 1 -yl)phenyl -N-(3 -(trifluoromethvnbenzvDisonicotinamide

This compound was prepared using the methods described in Example 4.14. MS (ES, m/z): 771.8 [M+H] ⁺

EXAMPLE 4.16 2-(2-(3-(( 3-((2-Mo holinoethyl)amino)-3-o o ropyDthio methyl benzamido)-5- (piperidin-l-yl)phenyl)-N-(3-(trifluoromethvnbenzvDisonicoti namide

A solution of 25 mg of 3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2- yl)-4-(piperidin-l-yl)phenyl)carbamoyl)benzylthio)propanoic acid 1.1, 19 mg of diisopropylethylamine, and 6 mg of 2-morpholinoethylamine in 1 mL of DMF was treated with 15 mg of HATU and stirred for 24 h. The product was isolated by reverse phase HPLC eluting with 0.05% TFA in a water / acetonitrile gradient to give 11.3 mg of product. MS (ES, m/z): 789 [M+H] ⁺

EXAMPLE 4.17

2-(2.-(3 -(((3 -( (2-MethoxyethvDamino)-3 -oxopropyl)thio")methyl benzamido -5 - (piperidm-l-yl)phenyl)-N-(3-(trifluoromethvDben2yl isonicotinamide

This compound was prepared using the procedure described for the preparation of 2-(2- (3-(((3-((2-morpholinoethyl)amino)-3-oxopropyl)thio)methyl)b enzamido)-5-(piperidin- l-yl)-phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide 4.16, using 2- methoxyethylamine in place of 2-morpholinoethylamine. MS (ES, m/z): 734 [M+H] ⁺ EXAMPLE 4.18

2-(3-(Y3-((4-(Piperidin-l-yl>2-(4-(0-(tri

yl)phenyl)carbamoyDbenzylWo)propanamido acetic acid

ert-butyl glycinate was coupled to 3-(3-((2-(4-((3-

(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperi din-l-yl)phenyl)carbamoyl^ benzylthio)propanoic acid 1.1 using the procedure described for the synthesis of 2-(2- (3-(((3-((2-mo holinoethyl)amino)-3-oxopropyl)thio)rnethyl)berlzamido)-5-(p iperidin- l-yl)-phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide 4.16. This material was dissolved in 2 mL of 1 : 1 dichloromethane / TFA and stirred for 1 h. The solvent was evaporated to give 4.6 mg of product. MS (ES, m/z): 734 [M+H] ⁺

EXAMPLE 4.19

2-(2-(3 -(29-Hvdroxy-5-oxo-9.12.15,18.21.24.27-heptaoxa-2-thia-6- azanonacosvDbenzamidoVS-Cpiperidin-l-ynphenylVN-rS- (trifluoromethyl)berizvDisonicotinamide

A solution of 50 mg of 3-(3-((2-(4-((_5-(trifluoromethyl)benzyl)carbamoyl)pyridin-2 - yl)-4-(piperidin-l-yl)phenyl)carbamoyl)benzylthio)propanoic acid 1.1, 57 mg of diisopropylethylamine, 27 mg of 23-amino-3,6,9,12,15,18,21-heptaoxatricosan-l-ol, 18 mg of EDCI, and 19 mg of HOBt in 2 mL of DMF was stirred for 24 h. The product was isolated by reverse phase HPLC eluting with 0.05% TFA in a water / acetonitrile gradient to give 5.1 mg of product. MS (ES, m/z): 1028 [M+H] ⁺

EXAMPLE 4.20.1

N 1 -Methyl-N 1 -i2-morpholinoethyl>N3 -(4-( iperidin- 1 - _ν Γ)-2-(4-( ( 3 - (trifluoromethyl)benzyl ^N )carbamoyl ^' )pyridin-2-yl ^' )phenvnisophthalamide

This compound was prepared by coupling N-methyl-2-morpholinoethylamine to 3-((4- (piperidin- 1 -yl)-2-(4-((3 -(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)- carbamoyl)benzoic acid 4.1e, using the procedure described for the preparation of Nl-

carbamoyl)pyridin-2-yl)phenyl)isophthalamide 4.8. MS (ES, m/z): 743 [M+H] ⁺ EXAMPLE 4.20.2

Nl-i2-((2-MethoxyethylVmethyl¼mm^^

(( ^" 3-(trifluoromethyl)benzyncart

4.20.2

Scheme 14. 1. N-methyl-N-(2-chloroethyl)amine hydrochloride, diisopropylamine, HATU; 2. N-methyl-2-(methoxyethyl)amine.

Intermediate 4.20a: Nl-( ^, 2-chloroethylVNl-methyl-N3-( ^, 4-(piperidin-l-ylV2-( ^' 4-rn- (trifluoromethyl benzyl ^' )carbamoyl ^' )pyridin-2-yl ^' )phenyl)isophthalamide. A solution of 50 mg of 3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl) -4-(piperidin-l- yl)phenyl)carbamoyl)benzoic acid 4.1e, 9.3 mg of N-methyl-N-(2-chloroethyl)amine hydrochloride, 43 μΐ, of diisopropylethylamine, and 35 mg of HATU in 1000 μΐ, of DMF was stirred for 1 h. The mixture was diluted with 20 mL of water, and the resulting precipitate was collected by filtration. It was dissolved in dichloromethane and the solution was washed with water and dried (Na ₂ S0 ₄ ). The solvent was evaporated to give 42 mg of product. Example 4.20.2 : Nl-(2-( (2-methoxyethylXmethyl¼mino)ethylVN 1 -methyl-N3 -(4- (piperidin-l-yl)-2-(4-((3-(trifluoromem^

isophthalamide. A mixture of 21 mg of Nl-(2-chloroethyl)-Nl -methyl -N3 -(4- (piperidin-l-yl)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl) pyridin-2- yl)phenyl)isophthalamide 4.20a and 4.1 mg of N-methyl-2-(methoxyethyl)amine in 1 mL of acetonitrile was refluxed for 2 h. The product was isolated by reverse phase HPLC, eluting with 0.05% TFA in a water / acetonitrile gradient to give 18.8 mg. ^! H NMR (400 MHz, DMSO-ifc) δ 12.34 (s, 1H), 9.55 (t, J = 6.0 Hz, 1H), 9.40 (s, 1H), 8.90 (d, J = 5.0 Hz, 1H), 8.33 (s, 1H), 8.28 (d, J = 7.3 Hz, 1H), 8.05 - 7.93 (m, 2H), 7.84 (d, J = 5.1 Hz, 1H), 7.75 - 7.54 (m, 6H), 7.25 (s, 1H), 4.63 (d, J = 5.9 Hz, 2H), 3.88 - 3.81 (m, 2H), 3.75 - 3.66 (m, 2H), 3.64 - 3.55 (m, 2H), 3.56 - 3.42 (m, 2H), 3.42 - 3.22 (m, 7H), 3.01 - 2.88 (m, 6H), 1.80 - 1.66 (m, 4H), 1.58 (s, 2H). MS (ES, m/z) 727 [M+H] ⁺ .

EXAMPLE 4.21

N 1 -(2-( (2-Hvdroxyethvnrmethyl)amino ethyl VN 1 -methyl-N3 -(4-(piperidin- 1 -νΐν2-(4- ((3-(trifluoromethyl)benzvncarbamoyl pyridin-2-vnphenyl ^' )isophthalamide

This compound was prepared by the procedure described for the preparation of Nl-(2- ((2-methoxyethyl)(methyl)amino)ethyl)-N 1 -methyl-N3 -(4-(piperidin- 1 -yl)-2-(4-((3 - (trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)isopht halamide 4.20.2, using 2- (methylamino) ethanol in place of N-methyl-2-(methoxyethyl)amine. MS (ES, m/z) 111 [M+H] ⁺ . EXAMPLES 4.22 THROUGH 4.30

The compounds in the Table 2 were prepared by the following procedure: A 60°C solution of 20 mg of 3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl) -4- (piperidin-l-yl)phenyl)carbamoyl)benzoic acid 4.1e, 1.2 equivalents of the requisite amine, 14.4 mg of HATU, and 28.3 mg of diisopropylethylamine in 150 μΐ, of DMF was stirred for 1 h. The product was isolated by reverse phase HPLC, eluting with 0.05% TFA in a gradient of water / acetonitrile.

Scheme 14-1. 1. diisopropylethylamine, HATU, DMF.

Table 2

EXAMPLE 4.31

2-Q-(3-(4-(Piperidin-l-yl ^' )-2-(4-(3-(trifluoromethvDbenzylcarbamoyl ^' )pyridin-2- yDphenylcarbamovnbenzoyl ^' )piperidin-4-yl)acetic acid

To a mixture of 20 mg of 3-((4-(piperidin-l-yl)-2-(4-((3-(trifluoromethyl)- benzyl)carbamoyl)pyridin-2-yl)phenyl)carbamoyl)benzoic acid 4.1e, 28 mg of diisopropylethylamine, and 6.5 mg of ethyl 2-(piperidin-4-yl)acetate in 1 mL of DMF was added 17 mg of HATU. The mixture was stirred at 60°C for 1 h. The solution was diluted with water and extracted with ethyl acetate. The organic phase was washed with water, then brine. It was dried and the solvent was evaporated at reduced pressure. It was dissolved in 4 : 1 methanol / water and treated with 19.4 mg of LiOH H ₂ 0. After stirring for 20 h the product was isolated by reverse phase HPLC, eluting with 0.5% TFA in a gradient of water and acetonitrile to give 10.9 mg of product. MS (ES, m/z): 728.7 [M+H] ⁺ . EXAMPLE 4.32

3 -fflSf-Methyl-3-(4-( piperidin- 1 -yl)-2-(4-(3 -(trifluoromethyl)benzylcarbamoyl)pyridin- 2-vDphenylcarbamoyl benzamido methyl benzoic acid

This compound was prepared using the procedure described for the preparation of Example 4.31, using 3-((methylamino)methyl)benzoic acid methyl ester as the amine component. MS (ES, m/z): 750.5 [M+H] ⁺ .

EXAMPLES 5.1 AND 6.1

3 -((3 -((2- 4-(3 -Phenylpropanoyl)pyridin-2-ylV4-(piperidin- 1 - vDphenvDcarbamovDbenzyDthio^propanoic acid and 3-((3-( 2-(4-(l-hydroxy-3- phenylpropyl pyridin-2-ylV4-(piperidin-l-yl ^' )phenvncarbamovDbenzyl)thio)propanoic acid

5.1 6.1

Scheme 15. 1. PhCH ₂ CH ₂ MgCl; 2. Intermediate l.le, Pd(OAc) ₂ , Ph ₃ P, Na ₂ C0 ₃ ; 3. ¾, Pd/C; 4. Intermediate 1.1c, HATU, then TFA.

Intermediate 5.1a: 1 -(2-bromopyridin-4-yl)-3 -phenylpropan- 1 -one. 1.0 mL of 1.0 N phenyethylmagnesium chloride in THF was added dropwise to a -78°C solution of 200 mg of 2-bromo-N-methoxy-N-methylisonicotinamide in 6 mL of THF. The solution was allowed to warm to 25°C. After 10 minutes the solution was cooled back to -78°C and an additional 1.0 mL of 1.0 N phenylmagnesium chloride in THF was added. The mixture was warmed to 25°C and after 10 minutes 10 mL of 1.0 N hydrochloric acid was added. The solution was then made basic with excess aqueous sodium hydroxide solution and the mixture was partitioned between ethyl acetate and water. The aqueous phase was washed with ethyl acetate and the combined organic extracts were dried over sodium sulfate. The solvent was evaporated and the residue was chromatographed on silica gel to give 168 mg of product.

Intermediate 5.1b: 1 -f2-(2-nitro-5-(piperidin- 1 -vDphenyl)pyridin-4-yl>3 - phenylpropan- 1 -one. A solution of 200 mg of l-(4-nitro-3-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl) phenyl)piperidine l.le, 168 mg of l-(2-bromopyridin-4-yl)-3- phenylpropan-l-one 5.1a, 12 mg of Pd(OAc) ₂ , 58 mg of PPh ₃ in 1.25 mL of 2 N aqueous Na ₂ C0 ₃ solution and 3 mL of dimethoxyethane was refluxed for 4 h. The mixture was diluted with ethyl acetate and washed with water twice. The combined organic layer was dried over Na ₂ S0 ₄ and the solvent was evaporated. The residue was chromatographed on silica gel eluting with a gradient of 0% to 7% ethyl acetate in dichloromethane to give 196 mg of product.

Intermediates 5.1c: l-(2-(2-amino-5-ipiperidin-l-vnphenvf)pyridin-4-ylV3- phenylpropan- 1 -one and 1 -(2-(2-amino-5-(piperidin- 1 -yl phenyr)pyridin-4-yl>3 - phenylpropan- 1 -ol. This mixture was prepared using the procedure described for the conversion of 6-(2-nitro-5 -(piperidin- 1 -yl)phenyl)-N-(3 -(trifluoromethyl) benzyl)pyrimidin-4-amine 3.1c to 6-(2-ammo-5-(piperidin-l-yl)phenyl)-N-(3- (trifluoromethyl) benzyl)pyrimidin-4-amine 3.1d. After chromatography on silica gel, 95 mg of a mixture of starting material, l-(2-(2-amino-5-(piperidin-l- yl)phenyl)pyridin-4-yl)-3 -phenylpropan- 1 -one and 1 -(2-(2-amino-5 -(piperidin- 1 - yl)phenyl)pyridin-4-yl)-3 -phenylpropan- l-ol was obtained.

Examples 5.1 and 6.1 : 3-r(3-((2-(4-(3-phenylpropanoynpyridin-2-yl)-4-(piperidin-l- vDphenyl carbamoyl)benzyl)thio)propanoic acid and 3-((3-((2-(4-(l-hydroxy-3- phenylpropyl pyridin-2-yl -4-(piperidin-l-yl phenyl)carbamoyl)benzyl thio propanoic acid. The mixture of products from the previous synthetic step was converted to a mixture containing 3 -((3 -((2-(4-(3 -phenylpropanoyl)pyridin-2-yl)-4-(piperidin- 1 - yl)phenyl)-carbamoyl)benzyl)thio)propanoic acid 5 and 3-((3-((2-(4-(l-hydroxy-3- phenylpropyl)pyridin-2-yl)-4-(piperidin-l-yl)phenyl)carbamoy l)benzyl)thio)propanoic acid 6 using intermediate 3.1a and following procedures described in the preparation of Example 3.1. These two examples were isolated from the mixture by chromatography on silica gel, eluting with a gradient of 0% to 20% ethyl acetate in dichloromethane. Each product was then further purified by reverse phase HPLC. The mass spectrum (ES) of 3 -((3 -((2-(4-(3 -phenylpropanoyl)pyridin-2-yl)-4-(piperidin- 1 - yl)phenyl)carbamoyl)benzyl)-thio)propanoic acid 5 exhibited m/z = 608.3 [M + H] ⁺ . The mass spectrum (ES) of 3-((3-((2-(4-(l-hydroxy-3-phenylpropyl)pyridin-2-yl)-4- (piperidin-l-yl)phenyl)carbamoyl)-benzyl)thio)propanoic acid 6 exhibited m/z = 610.3 [M+H] ⁺ . , EXAMPLE 5.2

Ν1-Β6ηζν1-Ν1-(2-ηΐθ 1ιο1ίηο6ΐ1ινΐνΝ3-(4-( ^' ρίρ6ΓΪ(ϋη-1-ν1 -2-(4-( ^' (3- (trifluoromethvDbenzyl)carbamovnpyridin-2-vnphenyl sophthalamide

Scheme 16. 1. Intermediate 1.1 e, l-(4-nitro-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan- 2-yl) phenyl)piperidine, Pd(OAc) ₂ , PPh ₃ , DME, Na ₂ C0 ₃ ; 2. 3-(trifluoromethyl)phenylmagnesium chloride; 3. H ₂ , Pd/C; 4. Intermediate 1.1c: 3- ((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid, HATU, DMF; 5. Py S0 ₃ ; 6. TFA.

Intermediate 5 ,2a: 2-(2-nitro-5-(piperidin- 1 -vDphenvDisonicotinaldehyde. A mixture of

200 mg of l-(4-nitro-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl) phenyl)piperidine le, 85 mg of 2-chloroisonicotinaldehyde, 6.7 mg of Pd(OAc) ₂ , 31 mg of PPh ₃ , 1.25 mL of 2 N aqueous Na ₂ C0 ₃ solution, and 3 mL of DME were refluxed 2 h. The mixture was diluted with ethyl acetate and washed 3x with water. The organic extracts were washed with brine and dried (Na ₂ S0 ₄ ). The solvent was evaporated and the residue was chromatographed on silica gel eluting with 10% ethyl acetate in dichloromethane. This gave 114 mg of product. MS (ES, m/z): 312.0 [M+H] ⁺ .

Intermediate 5.2b: (2-(2-nitro-5-(piperidin- 1 -vDphenyr)pyridin-4-viy3-

(trifluoromethylVphenvDmethanol. To a -78° solution of 110 mg of 2-(2-nitro-5- (piperidin-l-yl)phenyl)isonicotinaldehyde in 4 mL of THF was added 0.82 mL of a 1.0 M solution of 3-(trifluoromethyl)phenylmagnesium chloride in THF. After 5 min the solution was warmed to 0°C and treated with 10 mL of a saturated aqueous solution of NaHC0 ₃ . The mixture was extracted with ethyl acetate and the organic extracts were washed with water and then with brine. The solution was dried (Na ₂ S0 ₄ ) and the solvent was evaporated. The residue was purified by silica gel chromatography eluting with 1 :1 ethyl acetate / hexanes to give 123 mg of product. MS (ES, m/z) 458.2 [M+H] ⁺ .

(trifluoromethylVphenyl methanol. A mixture of 123 mg of (2-(2-nitro-5-(piperidin-l- yl)phenyl)pyridin-4-yl)(3-(trifluoromethyl)phenyl)methanol 5.2b, 30 mg of moist 10% Pd/C, and 3 mL of methanol was stirred under a hydrogen atmosphere for 5 h. The mixture was filtered and the solvent was evaporated to provide 1.05 mg of product. MS (ES, m/z) 428.2 [M+H] ⁺ .

Intermediate 5.2d: tert-butyl 3-((3-((2-(4-(hvdroxy( ^, 3-(trifluoromethyl)phenvDmethylV pyridin-2-yl)-4-(piperidin-l-yDphenvDcarbamovnbenzv thio)propanoate. A solution of 54 mg of (2-(2-amino-5-(piperidin-l-yl)phenyl)pyridin-4-yl)(3-

(trifluoromethyl)phenyl)-methanol 5.2c, and 41 mg of 3-((3-tert-butoxy-3- oxopropylthio)methyl)benzoic acid 1.1c, 67 mg of diisopropylethylamine in 1.5 mL of DMF was treated with 57 mg of HATU. After stirring at 60° C for 2 h the mixture was diluted with ethyl acetate and washed once with a saturated aqueous solution of sodium bicarbonate, three times with water, and once with brine. After drying (Na ₂ S0 ₄ ) the solvent was evaporated to give 107 mg of product. MS (ES, m/z) 706.2 [M+H] ⁺ .

Intermediate 5.2e: tert-butyl 3-((3-((4-(piperidin-l-ylV2-r4-( ^' 3-

(trifluoromethvnbenzoylVpyridin-2-yl)phenyl)carbamoyl)ben zyl)thio ^' )propanoate. A - 10°C solution of 23 mg of tert-butyl 3-((3-((2-(4-(hydroxy(3- (trifluoromethyl)phenyl)methyl)pyridin-2-yl)-4-(piperidin- 1 - yl)phenyl)carbamoyl)benzyl)thio)propanoate 5.2d, 17 mg of diisopropylethylamine, and 10 mg of DMSO in 0.4 mL of dichloromethane was treated with 10 mg of pyridine sulfur trioxide complex. After stirring for 1 h the reaction mixture was applied directly to a silica gel column and eluted with a gradient of 0% to 10% ethyl acetate in dichloromethane. Evaporation of the solvent yielded 9.5 mg of product. MS (ES, m/z)

704.2 [M+H] ⁺ .

Example 5.2: 3 -((3 -((4-( piperidin- 1 -ylV 2-(4-(3 -(trifluoromethyl benzovDpyridin-2- vDphenvDcarbamovDbenzyDthio^propanoic acid. A solution of 9.5 mg of 3-((3-((4- (piperidin- 1 -yl)-2-(4-(3-(trifluoromethyl)benzoyl)pyridin-2- yl)phenyl)carbamoyl)benzyl)-thio)propanoate. 5.2e in 600 μΐ, of 1 :1 dichloromethane / TFA was stirred 45 minutes and then the solvent was evaporated. The residue was purified by reverse phase chromatography eulting with a water / acetonitrile gradient containing 0.05% TFA to afford 5 mg of product. 1H-NMR (400 MHz, CD ₃ OD, ppm) δ 9.10 (d, J = 5 Hz, 1H), 8.75 (d, J = 9 Hz, 1H), 8.28 (s, 1H), 8.18 (s, 1H), 8.10 - 8.05 (m, 2H), 7.99 - 8.02 (m, 3H), 7.87 (d, J = 8 Hz, 1H), 7.76 - 7.71 (m, 3H), 7.58 (d, J = 8 Hz, 1H), 7.49 (d, J = 8 Hz, 1H), 3.89 (s, 2H), 3.70 - 3.60 (m, 4H), 2.70 (t, J = 7 Hz, 2H), 2.55 (t, J= 7 Hz, 2H), 2.10 - 2.00 (m, 4H), 1.85 - 1.75 (m, 2H). ¹⁹ F-NMR analysis revealed the presence of two peaks at δ-64 and δ -77 in a 1 : 2 ratio, suggesting that the compound was isolated as a salt containing two equivalents of TFA. MS (ES, m/z)

648.3 [M+H] ⁺ . EXAMPLE 6.2

3 -((3 -(Y2-(4-(Hydroxy(3 -( ^' trifluoromethyl ^' )phenyl rnethvDpyridin-2-ylV4-(piperidin- 1 - yDphenyl)carbamoyl benzyl)thio)propanoic acid

This compound was prepared from (2-(2-amino-5-(piperidin-l-yl)phenyl)pyridin-4- yl)(3-(trifluoromethyl)phenyl)methanol 5.2c using the procedures described in Example 5.2, but omitting the oxidation step (Step 5.2e). MS (ESI, m/z) 650.3 [M+H] ⁺ .

EXAMPLE 7

3-( (3-( ( 4-(Piperidin- 1 -viV2-(4-(((3-(trifluoromethvnbenzyl ^' )amino ^' )methyl)pyridin-2- yl)phenyl carbamoyl)benzyl thio)propanoic acid

Scheme 17: 1. 3-(trifluoromethyl)benzylamine, NaBH(OAc) ₃ , then Boc ₂ 0; 2. H ₂ , Pd/C; 3. 3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid 1.1c, HATU, diisopropylamine, then TFA.

Intermediate 7a: tert-butyl (|2-(2-nitro-5 -(piperidin- 1 -yl phenyl pyridin-4- vDmethylX3 -(trifluoromethvDbenzyDcarbamate . A solution of 120 mg of 2-(2-nitro-5- (piperidin-l-yl)phenyl)isonicotinaldehyde 5.2a and 70 mg of 3-

(trifluoromethyl)benzylamine in 4 mL of dichloromethane was treated with 207 mg of NaBH(OAc) ₃ . After 17 h the mixture was diluted with 10 mL of a saturated aqueous solution of sodium bicarbonate. The phases were separated and the aqueous phase was washed 3 times with dichloromethane. The combined organic extracts were dried (Na ₂ S0 ₄ ), and the solvent was evaporated to give 220 mg of a product giving MS (ES, m/z) All.2 [M+H] ⁺ . The product was dissolved in 3 mL of dichloromethane and teated with 109 mg of Boc ₂ 0 and stirred for 17 h. The solvent was evaporated and the product was purified by silica gel chromatography to give 93 mg of tert-butyl ((2-(2-nitro-5- (piperidin- 1 -yl)phenyl)pyridin-4-yl)methyl)(3 -(trifluoromethyl)-benzyl)carbamate 7a. Intermediate 7b: tert-butyl ((2-( ^" 2-amino-5 -(piperidin- 1 -yl phenyl pyridin-4- vDmethyDfS-CtrifluoromethvDbenzvncarbamate. This compound was prepared using the procedure described for the conversion of (2-(2-nitro-5-(piperidin-l- yl)phenyl)pyridin-4-yl)(3-(trifluoromethyl)phenyl)methanol 5.2b to 2-(2-amino-5- (piperidin-l-yl)phenyl)pyridin-4-yl)(3-(trifluoromethyl)phen yl)methanol 5.2c. MS (ES, m/z) 541.2 [M+H] ⁺ .

Example 7: 3-((3-((4-(piperidin-l-vn-2-(4-(((3-( ^" trifluoromethvnbenzyl amino) methyl)-pyridin-2-yl)phenvncarbamoyl)benzyl thio ^' )propanoic acid. This compound was prepared using the procedure described for the preparation of 3-((3-((4-(piperidin- 1 -yl)-2-(6-(3 -(trifluoromethyl)phenoxy)pyrimidin-4- yl)phenyl)carbamoyl)benzyl)thio)propanoic acid 3.9 from 4-(piperidin-l-yl)-2-(6-(3- (trifluoromethyl)phenoxy)pyrimidin-4-yl)aniline 3.9b. MS (ES, m/z) 662.2 [M+H] ⁺ .

EXAMPLE 8,1

3-((3-((4-(Piperidin-l-yl -2-(4-((3-(trifluoromethyl benzyl)carbamovnpyridin-2- vDphenyDcarbamovDbenzvDthio^enzoic acid

Scheme 18: 1. 3-(chloromethyl)benzoyl chloride, diisopropylethylamine;

2. 3-mercaptobenzoic acid, K ₂ C0 ₃ .

Intermediate 8.1 a. 2-(2-(3-(chloromethyl)benzamidoV5-(piperidin-l-yl)phenyl)-N- (3- (trifluoromethvnbenzvDisonicotinamide. 3-(Chloromethyl)benzoyl chloride was added dropwise to a 0°C solution of 900 mg of N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5- (piperidin-l-yl)phenyl)isonicotinamide 4.1c 1.02 g of diisopropylethylamine in 10 mL of a 1 :1 mixture of dichloromethane and THF. The mixture was warmed to 25°C and stirred for 1 h, after which it was washed five times with aqueous hydrochloric acid, once with a saturated aqueous solution of sodium bicarbonate, and once with water. The solution was dried and the solvent was evaporated to give 1.24 g of product as a yellow solid.

Example 8.1 : 3-((3-((4-(piperidin-l-yl -2-(4-((3-(trifluoromethyl)benzvDcarbamoyl)- pyridin-2-yl)phenvDcarbamovf)benzyl thio benzoic acid. A mixture of 250 mg of 2-(2- (3-(chloromethyl)benzamido)-5-(piperidin-l-yl)phenyl)-N-(3-( trifluoromethyl)benzyl)- isonicotinamide 8.1a, 70 mg of 3-mercaptobenzoic acid, 10 mL of acetone, and 171 mg of K ₂ C0 ₃ was stirred for 16 h and then filtered. The solvent was removed by evaporation. The residue was dissolved in dichloromethane and the resulting solution was washed with aqueous hydrochloric acid. The solution was dried, and the solvent was evaporated. The residue was purified by silica gel chromatography to give 113 mg of product. MS (ES, m/z) 725 [M+H] ⁺ .

EXAMPLES 8.2 THROUGH 8.24

The compounds presented in Table 3 were prepared as follows: A mixture of 2-(2-(3- (chloromethyl)benzamido)-5-(piperidin- 1 -yl)phenyl)-N-(3 -(trifluoromethyl)benzyl)- isonicotinamide 8.1a (0.05 mmol), the requisite thiol (0.055 mmol), and K ₂ C0 ₃ in 500xL of DMF were stirred for 18 h under nitrogen. The mixture was filtered, and the filtrate was purified by reverse-phase HPLC eluting with a water / acetonitrile gradient containing 0.1% TFA. The purity and identity of the products was confirmed by LCMS (Table 3) and 1H NMR (data not shown).

Table 3

EXAMPLE 8.25

3-(3-( ^, 4-Chloro-2-(4-(3-(trifluoromethyl benzylcarbamoyl pyridin-2- vDphenylcarbamoyDbenzylthio)benzoic acid

A mixture of 173 mg of 2-(5-chloro-2-(3-(chloromethyl)benzamido)phenyl)-N-(3- (trifluoromethyl)benzyl)isonicotinamide, which was made from intermediate 21b in a similar manner as the synthesis of 8.1a, 52 mg of 3-mercaptobenzoic acid, and 128 mg of K ₂ C0 ₃ in 2 mL of DMF was stirred for 2 h and then poured into 20 mL of water. The solution was acidified with hydrochloric acid. A precipitate formed and was collected by filtration and dried. The resulting solid was dissolved in acetone and filtered. Evaporation of the solvent gave 92 mg of product. MS (ES, m/z) 676 [M+H] ⁺ . EXAMPLE 8.26

3-(Y3-((4-(Piperidin-l-yl)-2-( -((3-(triflu^

yl)phenyl)carbamovDbenzyl)sulfonyl)benzoic acid

A solution of 25 mg of 3-((3-((4-(piperidin-l-yl)-2-(4-((3-

(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)car bamoyl)benzyl)thio)benzoic acid 8.25 in 2 mL of a 2:1 :1 mixture of THF, methanol, and water was treated with 110 mg of Oxone®. The mixture was stirred for 2 h and then it was diluted with ethyl acetate. The organic phase was washed with water, which caused a precipitate to form. The precipitate was redissolved by adding methanol. The organic phase was separated and filtered. Evaporation of the solvent gave a white solid. This solid was dissolved in methanol and treated with 5 mg of 5% Pd/C. The mixture was stirred under a hydrogen atmosphere for 15 minutes, and then it was filtered. The solvent was evaporated and the residue was purified by reverse phase HPLC, eluting with 0.05% TFA in a water / acetonitrile gradient. The process yielded 8.6 mg of product. MS (ES, m/z) 151 [M+H] ⁺ .

EXAMPLE 8.27

3-((3-((4-(Piperidin-l-ylV2-(4-((3-(trifluoromethyl benzv carbamoyl pyridin-2- yl)phenyl carbamoyl benzvDthio)benzoic acid

A mixture of 20 mg of 2-(2-(3-(chloromethyl)benzamido)-5-(piperidin-l-yl)phenyl)-N - (3-(trifluoromethyl)benzyl)isonicotinamide 8.1a, 4.6 mg of 4- (hydroxymethyl)piperidine, and 9.1 mg of K ₂ C0 ₃ in 2 mL of DMF was stirred for 12 h. The product (12 mg) was isolated by reverse phase chromatography eluting with 0.05% TFA in a water / acetonitrile gradient. MS (ES, m/z) 686.3 [M+H] ⁺ .

EXAMPLE 8.28

2-(2-(3-((4-(2-Hvdroxyethyl)piperidin-l-vDmethyl benzamido -5-(piperidin-l- yl)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide

A mixture of 20 mg of 2-(2-(3-(chloromethyl)benzamido)-5-(piperidin-l-yl)phenyl)-N - (3-(trifluoromethyl)benzyl)isonicotinamide 8.1a, 5.2 mg of 2-(piperidin-4-yl)ethanol, and 9.1 mg of K ₂ C0 ₃ in 2 mL of DMF was stirred for 12 h. The product was isolated by reverse phase chromatography eluting with 0.05% TFA in a water / acetonitrile gradient. MS (ES, m/z) 700.27 [M+H] ⁺ . EXAMPLE 9.1 l-(3-((4-(Piperidin-l-yl -2-(4-((3-(trifluoromethyl)benzyl)carbamoyl pyridin-2- vDphenvDcarbamovDbenzylV 1 H-indole-4-carboxylic acid

A mixture of 10.5 mg of methyl lH-indole-4-carboxylate, 18.2 mg of 2-(2-(3- (chloromethyl)benzamido)-5 -(piperidin- 1 -yl)phenyl)-N-(3 -(trifluoromethyl)benzyl)- isonicotinamide 8.1a, and excess potassium carbonate in 300 \iL of DMF was stirred for 24 h. The solvent was evaporated and the residue was purified by silica gel chromatography. The product was dissolved in 1 mL of 4 : 1 THF / water and treated with 10 mg of Li OH ¾0. After stirring 4 days at 70°C the reaction mixture was acidified with 3.0 N hydrochloric acid and then extracted with ethyl acetate. The aqueous phase was washed with ethyl acetate, and the combined organic extracts washed with brine and dried (NaSG ₄ ). The residue was purified by reverse phase HPLC eluting with 0.1% TFA in a water/acetonitrile gradient to give 10.6 mg of product. MS (ES, m/z) 732.4 [M+H] ⁺ .

EXAMPLE 9.2

1 -Oxo- 1 -( 1 -(3 -((4-(piperidin- 1 -ylV2-(4-((3-(trifluoromethyl)benzyl carbamovDpyridin- 2-yDphenyl carbamoyl)benzyiy 1 H-indol-4-yl)-5,8, 1 1 -trioxa-2-azatetradecan- 14-oic acid

A mixture of 3 mg of l-(3-((4-(piperidin-l-yl)-2-(4-((3-(trifluoromethyl)- benzyl)carbamoyl)pyridin-2-yl)phenyl)carbamoyl)berizyl)- 1 H-indole-4-carboxylic acid 9.1, 1.7 mg of 3-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)propanoic acid, and 2.5 mg of HATU in 300 of DMF was treated with 1.5 of diisopropylethylamine. After 2 h the solvent was evaporated and the residue was partitioned between ethyl acetate and water. The aqueous phase was washed with ethyl acetate, and the combined organic extracts were washed with brine and dried (Na ₂ S0 ₄ ). The solvent was evaporated and a fraction of the product was dissolved in 1 : 1 dichloromethane / TFA. After stirring for 1 h the solvent was evaporated and the residue was purified by reverse phase HPLC eluting with 0.05% TFA in a water/acetonitrile gradient to yield 1.4 mg of the title compound. 1H NMR (400 MHz, DMSO- ₆ ) δ 12.62 (s, 1H), 9.57 (t, J = 5.7 Hz, 1H), 8.98 (d, J = 5.1 Hz, 1H), 8.51 (d, J = 8.7 Hz, 1H), 8.40 (s, 1H), 7.93 (s, 1H), 7.89 (d, J = 5.1 Hz, 1H), 7.78 (d, J = 7.4 Hz, 1H), 7.72 (s, 1H), 7.65 (m, 2H), 7.60 - 7.52 (m, 3H), 7.48 (t, J = 7.7 Hz, 1H), 7.24 - 7.14 (m, 3H), 7.03 - 6.94 (m, 1H), 4.64 (d, J = 5.8 Hz, 2H), 4.36 (s, 2H), 3.47 (s, 4H), 2.15 (t, J = 7.3 Hz, 2H), 1.83 (br, 4H), 1.81 - 1.67 (m, 2H), 1.64 (br, 2H). MS (ES, m/z) 935.32 [M+H] ⁺

EXAMPLE 9.3 3 -(((3 -((4-(Piperidin- 1 -νΓ)-2-(4-((3 -(trifluoromethyl ^' )benzyl ^' )carbamoyl)pyridin-2- vDphenvncarbamovDbenzvnthio^methvDbenzoic acid

Scheme 19: 1. Na ₂ S; 2. HATU, diisopropylethylamine.

Intermediate 9.3a: 3,3'-(thiobis(methylene))dibenzoic acid. A mixture of 284 μΐ, of 3- (chloromethyl)benzoyl chloride, 78 mg of Na ₂ S, 36 μΐ, of water, and 276 mg K ₂ C0 ₃ in DMF was stirred 18 h at RT The mixture was filtered and the solvent was evaporated at reduced pressure. The residue was triturated with dichloromethane to give 100 mg of product.

Example 9.3: 3-(((3-((4-( ^" piperidin-l-ylV2-( ^' 4-((3-(trifluoromethyl)benzyl carbamoyl)- pyridin-2-yl)phenyl)carbamoyl)benzyl)thio methyl)benzoic acid. A solution of 15 mg of thiobis(methylene))dibenzoic acid 9.3a, 7.5 mg of N-(3-(trifluoromethyl)benzyl)-2- (2-amino-5-(piperidin-l-yl)phenyl)isonicotinamide.4.1c, and 17 mg of HATU in DMF was treated with 26 μΐ, of diisopropylethylamine. After 18 h the product was isolated by reverse phase HPLC, eluting with 0.05% TFA in a water / acetonitrile gradient. The procedure gave 7.5 mg of product. MS (ES, m/z) 739.3 [M+H] ⁺ .

EXAMPLE 10.1 l-Oxo -(3-ff(3-(f4-fpiperidin-l-ylV2-(4-((3- (trifluoromethyl)benzvncarbamovnpyridin-2- yl phenvncarbamoyl benzyl)thio methyl ^' )phenylV5,8,l l-trioxa-2-azatetradecan-14-oic acid

Scheme 20. 1. H ₂ NCH ₂ CH ₂ (OCH ₂ CH ₂ ) ₃ C0 ₂ (t-Bu), diisopropylethylamme, HATU; 2. TFA.

Intermediate 10.1b: tert-butyl 1 -oxo- 1 - (3 -(3 -f 4-f piperidin- 1 -yl )-2-( 4-f 3 -

(trifluoromethyl -benzylcarbamovnpyridin-2-vnphenylcarbamoyl)benzylthio ^' )phenvn- 5,8,1 1 -trioxa-2-azatetradecan- 14-oate. A solution of 25 mg of 3-(3-(4-(piperidin-l-yl)- 2-(4-(3-(trifluoromethyl)-benzylcarbamoyl)pyridin-2- yl)phenylcarbamoyl)benzylthio)benzoic acid 8.1, 12 mg of tert-butyl 3-(2-(2-(2- aminoethoxy)ethoxy)ethoxy)propanoate, and 17.8 mg of diisopropylethylamme in 1 mL of DMF was treated with 15 mg of HATU. The mixture was stirred for 1 h and then the product was isolated by reverse phase HPLC eluting with 0.05% TFA in a water / acetonitrile gradient.

Example 10.1 : l-oxo-l-(3-(3- 4-(piperidin-l-yl -2-(4-(3-(trifluoromethvnbenzyl- carbamoyl pyridin-2-yl)phenylcarbamoyl)benzylthio phenvn-5,8,l l-trioxa-2- azatetradecan-14-oic acid. tert-Butyl l-oxo-l-(3-(((3-((4-(piperidin-l -yl)-2-(4-((3- (trifluoromethyl)benzyl)-carbamoyl)pyridin-2- yl)phenyl)carbamoyl)benzyl)thio)methyl)-phenyl)-5,8,l l-trioxa-2-azatetradecan-14- oate 10.1b from the previous step was dissolved in 1 mL of 1 : 1 dichloromethane / TFA. After 45 minutes the solvent was evaporated in a stream of nitrogen and the residue was dissolved in 1 :1 acetonitrile / water. Lyophilization gave 18 mg of product. ^! H NMR (400 MHz, CD ₃ OD) δ 8.94 (d, J = 5.2 Hz, 1H), 8.81 (d, J = 9.2 Hz, 1H), 8.43 (s, 1H), 8.15 (s, 1H), 7.96 (s, 1H), 7.88 - 7.83 (m, 2H), 7.82 (t, J = 1.8 Hz, 1H), 7.73 - 7.70 (m, 2H), 7.67 (d, J = 7.4 Hz, 1H), 7.64 - 7.60 (m, 1H), 7.60 - 7.54 (m, 3H), 7.52 - 7.44 (m, 2H), 7.34 (t, J - 7.8 Hz, 1H), 4.72 (d, J = 4.2 Hz, 2H), 4.34 (s, 2H), 3.72 - 3.68 (m, 4H), 3.65 (t, J = 6.3 Hz, 2H), 3.61 - 3.55 (m, 8H), 3.54 - 3.48 (m, 4H), 2.47 (t, J = 6.3 Hz, 2H), 2.10 - 2.02 (m, 4H), 1.82 (s, 2H). MS (ES, m/z) 928 [M+H] ⁺

EXAMPLES 10.2 THROUGH 10.8

The compounds presented in Table 4 were prepared using the procedure described for the preparation of intermediate 10.1

Table 4

EXAMPLES 10.9 THROUGH 10.12

The compounds presented in Table 5 were prepared using the method described for the synthesis of 1 -oxo-1 -(3-(((3-((4-(piperidin-l -yl)-2-(4-((3-(trifluoromethyl)benzyl)- carbamoyl)pyridin-2-yl)phenyl)carbamoyl)benzyl)thio)methyl)p henyl)-5,8, 11 -trioxa-2- azatetradecan-14-oic acid 10.1 from 3-(((3-((4-(piperidin-l-yl)-2-(4-((3- (trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)carbam oyl)benzyl)thio) methyl)-benzoic acid 9.3. The products were assayed by NMR and LCMS to confirm identity and purity.

Table 5

EXAMPLE 11.1

N2-Methyl-N2-i2-morpholinoeth^

(trifluoromethvDberizyl)carbamoy

A solution of 25 mg of N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-(piperidin-l- yl)phenyl)isonicotinamide 4.1c, 28 mg of pyridine-2,6-dicarboxylic acid, and 4.3 mg of diisopropylethylamine in 1 mL of DMF was treated with 21 mg of HATU. After 2 h the mixture was separated by reverse phase HPLC, eluting with 0.05% TFA in a water / acetonitrile gradient. The isolated monoamide adduct of pyridine-2,6-dicarboxylic acid and 4.1c was dissolved in 2 mL of DMF and treated with 10 mg of N-methyl-2- morpholinoethanamine, 28 mg of diisopropylethylamine, and 23 mg of HATU. After 2 h the product was isolated by reverse phase HPLC. MS (ES, m/z) 730 [M+H] ⁺

EXAMPLE 11.2

NL5-Dimethyl-Nl-( ^, 2-morpholinoethvn-N3-( ^, 4-(piperidin-l-ylV2-(4-(( ^' 3- (trifluoromethyl ^' )benzv carbamoyl ^' )pyridin-2-yl phenvnisophthalamide

This compound was prepared using the method described for the preparation of Example 11.2, using 5-methyl-isophthalic acid in place of pyridine-2,6-dicarboxylic acid. MS (ES, m/z) 743 [M+H] ⁺

EXAMPLE 11.3

2-Methoxy-N 1 -methyl-N 1 -(2-morpholinoethylVN3 -(4-( piperidin- 1 -ylV2-( 4-((3- (trifluoromethyl)benzyl carbamoyl ^' )pyridin-2-vf)phenyDisophthalamide

This compound was prepared using the method described for the preparation of Example 11.2, using 2-methoxy-isophthalic acid in place of pyridine-2,6-dicarboxylic acid. MS (ES, m/z) 759 [M+H] ⁺

EXAMPLE 11.4

5-Methoxy-N 1 -methyl-N 1 -( 2-morpholinoethylVN3 -( 4-(piperidin- 1 - vfl-2-( 4-(f 3 - (trifluoromethyl ^' )benzvf)carbamoyl pyridin-2-yl)phenyl isophthalamide

This compound was prepared using the method described for the preparation of Example 11.2, using 5-methoxy-isophthalic acid in place of pyridine-2,6-dicarboxylic acid. MS (ES, m/z) 759 [M+H] ⁺

EXAMPLE 12.1 (S -2-(2-(3-((3-((2-Methoxyethyl carbarnoyl)piperidin-l-vnmethvnbenzamido)-5- (piperidin- 1 -yl)phenyl)-N-(3 -(trifluoromethyl)benzyl)isonicotinamide

A mixture of 20 mg of 2-(2-(3-(chloromethyl)benzamido)-5-(piperidin-l-yl)phenyl)-N - (3-(trifluoromethyl)benzyl)isonicotinamide 8.1a, 8.8 mg of (S)-N-(2- methoxyethyl)piperidine-3-carboxamide and 13.7 mg of K2CO3 in 0.33 mL of DMF was stirred for 2 h. The product was isolate by preparative reverse phase HPLC eluting with 0.05% TFA in a water / acetonitrile gradient to give 23 mg of product. MS (ES, m/z) 757.3 [M+H] ⁺

EXAMPLE 12.2

(R -2-(2-(3-((3-((2-Methoxyethvncarbamovnpiperidin-l-vnmethyl benzamido -5- (piperidin- 1 -yl)phenyl)-N-(3 -(trifluoromethvDbenzvDisonicotinamide

This compound was prepared by the procedure described for the preparation enantiomer. MS (ES, m/z) 757.3 [M+H] ⁺

EXAMPLE 14

3 -((3 -((4-Morpholino-2-(4-((3 -(trifluoromethyl)benzvncarbamovnpyridin-2- yl)phenyl)carbamoyl)benzyl)thio)propanoic acid

Scheme 20. 1. 3-Trif uoromethyl benzylamine, EDC HCl, DMAP; 2. Tf ₂ 0, pyridine; 3. Pd(dppf)Cl ₂ /KOAc, 1,4-dioxane, 4,4,4',4',5,5,5 ^, ,5'-octamethyl-2,2'-bi(l,3,2- dioxaborolane); 4. Pd(dppf)Cl ₂ , X-PHOS, K ₃ P0 ₄ , DME/H ₂ 0, intermediate 14a; 5. K ₂ C0 ₃ , DMF,morpholine; 6. Pd/C, H ₂ , MeOH; 7. EDC HCl, DMAP, DMF, 3-((3- tert-butoxy-3-oxopropylthio)methyl)benzoic acid 1.1c; 8. CF ₃ COOH, DCM. Intermediate 14a: N-(3 -(ΐΓίιΊ^Γοηΐ6ί1ιν1^6ηζνΠ-2-ο1 1θΓθΪ8οηΐοοΐίηαηιϊ(ΐ6. Into a 500- mL round bottom flask, was placed a solution of 2-chloroisonicotinic acid (18 g, 113.92 mmol, 2.00 equiv) in dichloromethane (200 mL), 3-(trifluoromethyl)benzylamine (10 g, 57.14 mmol, 1.00 equiv), EDC ^' HC1 (22 g, 115.18 mmol, 2.00 equiv), and 4- dimethylaminopyridine (14 g, 114.75 mmol, 2.00 equiv). The resulting solution was stirred for 3 h at 25°C. The resulting solution was diluted with 500 mL of dichloromethane. The resulting mixture was washed with 2x50 mL of aqueous NH ₄ C1, 1x50 mL of 10% sodium bicarbonate, and 1x50 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with petroleum ether/ethyl acetate (5:1). The product was obtained as 11.8 g (63%) of a white solid.

Intermediate 14b: 5-fluoro-2-nitrophenyl trifluoromethanesulfonate. Into a 250-mL round bottom flask, was placed a solution of 5-fluoro-2-nitrophenol (5 g, 31.85 mmol, 1.00 equiv) in pyridine (25 mL). This was followed by the addition of trifluoromethanesulfonic anhydride (9.6 g, 34.04 mmol, 1.07 equiv) dropwise with stirring at 0°C. The resulting solution was stirred for 1 h at 0°C, overnight at room temperature. The resulting solution was diluted with 100 mL of water. The resulting solution was extracted with 3x100 mL of dichloromethane and the organic layers combined. The resulting mixture was washed with 3x100 mL of water. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The product was obtained as 5 g (54%) of a yellow oil.

Intermediate 14c: 2-(5-fluoro-2-nitrophenyl -4,4,5,5-tetramethyl-L3,2-dioxaborolane. Into a 250-mL round bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of 5-fluoro-2-nitrophenyl trifluoromethanesulfonate (18 g, 62.28 mmol, 1.00 equiv) in 1,4-dioxane (150 mL), 4,4,4',4 ^, ,5,5,5',5'-octamethyl-2,2'- bi(l,3,2-dioxaborolane) (24 g, 94.49 mmol, 1.50 equiv), Pd(dppf)Cl ₂ (1.5 mg, 0.03 equiv), and potassium acetate (12.6 g, 128.44 mmol, 2.00 equiv). The resulting solution was stirred overnight at 80°C. The mixture was concentrated under vacuum. The residue was applied onto a silica gel column and eluted with petroleum ether/ethyl acetate (1 :5~ethyl acetate). The product was obtained as 10 g (60%) of a yellow solid.

Intermediate 14d: N-(3-(trifluoromethyl benzyl -2-(5-fluoro-2-nitrophenyl)- isonicotinamide. Into a 500-mL round bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of 2-(5-fluoro-2-nitrophenyl)-4,4,5,5- tetramethyl-l,3,2-dioxaborolane (11.8 g, 44.19 mmol, 3.00 equiv) in 330 mL of 10 : 1 DME/H ₂ 0, N-(3-(trifluoromethyl)benzyl)-2-chloroisonicotinamide (5 g, 15.92 mmol, 1.00 equiv), Pd(PPh3) ₂ Cl ₂ (2.54 g, 3.62 mmol, 0.20 equiv), X-PHOS (2.5 g, 6.36 mmol, 0.20 equiv), and K ₃ P0 ₄ (20 g, 59.17 mmol, 4.00 equiv). The resulting solution was stirred overnight at 80°C. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate/petroleum ether (1 :5~1). The product was obtained as 2 g (27%) of a brown oil.

Intermediate 14e: N-(3-(trifluoromethyl ben yl -2-(5-mo holino-2-nitrophenyl - isonicotinamide. Into a 50-mL round bottom flask, was placed a solution of N-(3- (trifluoromethyl)benzyl)-2-(5-fluoro-2-nitrophenyl)isonicoti namide 14d (200 mg, 0.48 mmol, 1.00 equiv) in N,N-dimethylformamide (2 mL), morpholine (80 mg, 0.90 mmol, 1.70 equiv), and potassium carbonate (0.2 g, 3.00 equiv). The resulting solution was stirred overnight at 80°C. The solids were filtered out. The resulting mixture was concentrated under vacuum to yield 0.1 g of crude product as a yellow oil.

Intermediate 14f: N-(3-(trifluoromethyl benzyl)-2-(2-amino-5-morpholinophenylV isonicotinamide. Into a 50-mL round bottom flask, was placed a solution of N-(3- (trifluoromethyl)benzyl)-2-(5-morpholino-2-nitrophenyl)isoni cotinamide (100 mg, 0.21 mmol, 1.00 equiv). in methanol (5 mL). The solution was treated with Pd/C (100 mg), and stirred under an atmosphere of hydrogen overnight at room temperature. The solids were filtered out. The resulting mixture was concentrated under vacuum to yield 50 mg (53%) of product as a yellow oil. Intermediate 14g: tert-butyl 3-(3-( ^" (2-(4-((3-(trifluorometliyl)benzyl)carbamoyl)pyridin- 2-yl)-4-morpholinophenyl)carbamoyl)benzyltliio)propanoate. Into a 50-mL round bottom flask, was placed a solution of N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5- morpholinophenyl)isonicotinamide (200 mg, 0.44 mmol, 1.00 equiv) in N,N- dimethylformamide (5 mL), 3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid 1.1c (200 mg, 0.68 mmol, 1.50 equiv), EDC ^' HC1 (160 mg, 0.84 mmol, 2.00 equiv), and 4-dimethylaminopyridine (60 mg, 0.49 mmol, 1.00 equiv). The resulting solution was stirred for 2 h at room temperature. After a conventational aqueous/organic workup, the resulting mixture was concentrated under vacuum to yield 100 mg of crude product as a yellow oil.

Example 14: 3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl pyridin-2-yl)-4- morpholinophenyl)carbamoyl benzylthio)propanoic acid. Into a 50-mL round bottom flask, was placed a solution of tert-butyl 3-(3-((2-(4-((3- (trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4- morpholinophenyl)carbamoyl)benzylthio)propanoate (100 mg, 0.14 mmol, 1.00 equiv) in dichloromethane (5 mL), and trifluoroacetic acid (0.1 mL). The resulting solution was stirred overnight at room temperature. The reaction progress was monitored by LCMS. The resulting mixture was concentrated under vacuum. The crude product (100 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 14 mg (15%) of a yellow solid. 1H-NMR (300MHz, CDC1 ₃ , ppm): δ 13.55(s, 1H), 9.09(s, 1H), 8.96-8.78(m, 2H), 8.72(s, 1H), 8.65(s, 1H), 8.25-8.09(m, 3H), 8.05-7.90(m, 8H), 4.73(d, J=5.4Hz, 2H), 4.13(s, 4H), 3.82(s, 2H), 3.47(s, 4H), 2.75-2.57(m, 4H). MS (ES, m/z): 679 [M+H] ⁺ .

EXAMPLE 15

3-((3-((4-Isopropoxy-2-(4-((3-(trifluoromethyl)benzyl)car bamoyl pyridin-2- yl phenyl carbamoyl)benzyl)thio)propanoic acid

Scheme 21. 1. isopropanol, NaH, DMF; 2. Pd/C H ₂ , MeOH, DCM; 3. EDC HC1, DMAP/DCM, 3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid 1.1c; 4. TFA, DCM.

Intermediate 15a: N-( ^" 3-(trifluoromethvnbenzyl -2-(5-isopropoxy-2-nitrophenyn- isonicotinamide. Into a 50-mL round bottom flask, was placed a solution of propan-2-ol (2 mL) in N,N-dimethylformamide (5 mL), sodium hydride (72 mg, 3.00 mmol, 5.00 equiv), and N-(3 -(trifluoromethyl)benzyl)-2-(5 -fluoro-2-nitrophenyl)isonicotinamide 14d (250 mg, 0.58 mmol, 1.00 equiv, 98%). The resulting solution was stirred for 3 h at 60°C in an oil bath. The resulting solution was diluted with 200 mL of ethyl acetate and washed with 3x30 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum to yield 280 mg (99%) of product as a brown oil.

Intermediate 15b: N-(3-(trifluoromethvnbenzyl -2-(2-amino-5-isopropoxyphenyl)- isonicotinamide. Into a 100-mL round bottom flask, was placed a solution of N-(3- (trifluoromethyl)benzyl)-2-(5-isopropoxy-2-nitrophenyl)isoni cotinamide (270 mg, 0.53 mmol, 1.00 equiv, 90%) in dichloromethane/methanol (3/6 mL). The solution was treated with Pd/C (270 mg), and stirred under an atmosphere of hydrogen for 2 h at room temperature. The solids were filtered out. The filtrate was concentrated under vacuum to yield 230 mg (91%) of product as a brown oil. Intermediate 15c: tert-butyl 3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamovnpyridin- 2-vn-4-isopropoxyphenyncarbamoyl ^' )benzylthio propanoate. Into a 50-mL round bottom flask, was placed a solution of N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5- isopropoxyphenyl)isonicotinamide (230 mg, 0.48 mmol, 1.00 equiv, 90%) in dichloromethane (8 mL), 3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid 1.1c (317 mg, 0.86 mmol, 2.00 equiv, 80%), EDC HC1 (206 mg, 1.07 mmol, 2.00 equiv), and 4-dimethylaminopyridine (131 mg, 1.07 mmol, 2.00 equiv). The resulting solution was stirred for 2 h at 25°C. The resulting solution was diluted with 100 mL of ethyl acetate and washed with 1x20 mL of aqueous NH ₄ C1, 1x20 mL of 10% sodium bicarbonate, and 1x20 mL of brine. The mixture was dried over sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate/petroleum ether (1 :2). The product was obtained as 240 mg (60%) of a brown oil.

Example 15: 3-(3-((2-(4-(f3-(trifluoromethyl)benzyl carbamoyl pyridin-2-yl -4- isopropoxyphenyl)carbamoyl)benzylthio propanoic acid. Into a 50-mL round bottom flask, was placed a solution of tert-butyl 3-(3-((2-(4-((3- (trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-isopropoxy phenyl)carbamoyl)- benzylthio)propanoate (230 mg, 0.28 mmol, 1.00 equiv, 85%) in dichloromethane (5 mL), and trifluoroacetic acid (1 mL). The resulting solution was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum. The crude product (180 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 139.8 mg (76%) of a white solid. 1H-NMR (400MHz, DMSO- ¾, ppm) δ 12.52 (s, IH), 12.23 (s, IH), 9.57 (t, J=8Hz, IH), 8.96 (d, J=4Hz, IH), 8.41-8.36(m, 2H), 7.88-7.84(m, 2H), 7.79-7.63(m, 2H), 7.60- 7.52(m, 2H), 7.50-7.48(m, 4H), 7.16-7.13(d, J=12Hz, IH), 4.76-4.70(m, IH), 4.62 (d, J=6Hz, 2H), 3.88 (s, 2H), 2.63-2.53 (m, 4H), 1.30 (s, 6H). MS (ES, m/z): 652 [M+H] ⁺ .

EXAMPLE 16 3-((3-((4-f (tetrahvdro-2H-pyran-4-yl)oxyV2-(4-( ( 3 -rtrifluoromethvnbenzyl - carbamoyl)pyridin-2-yl)phenyl)carbamoyl benzyl)thio ^' )propanoic acid

Scheme 22. 1. LAH; 2. NaH, DMF, intermediate N-(3-(trifluoromethyl)benzyl)-2-(5- fluoro-2-nitrophenyl)isonicotinamide 14d; 3. Pd/C H ₂ , MeOH, DCM; 4. EDC HC1, DMAP/DCM, 3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid 1.1c; 5. TFA, DCM.

Intermediate 16a: tetrahydro-2H-pyran-4-ol. Into a 250-mL 3 -necked round bottom flask, was placed a solution of tetrahydropyran-4-one (5 g, 50.00 mmol, 1.00 equiv) in tetrahydrofuran (25 mL). This was followed by dropwise addition of a solution of LiAlH ₄ (3.8 g, 102.70 mmol, 2.00 equiv) in tetrahydrofuran (25 mL) with stirring at 0- 5°C. The resulting solution was stirred for 3 h at 0-5°C in a water/ice bath. The reaction was then quenched by the addition of 3.8 mL of water, 3.8 mL of 15% NaOH, and 11.4 mL of water. The mixture was dried over anhydrous sodium sulfate. The solids were filtered out. The resulting mixture was concentrated under vacuum to yield 5 g (96%) of product as a yellow oil. Intermediate 16b: N-(3-(trifluoromethvnbenzvn-2-(2-nitro-5-(tetrahvdro-2H-pyra n-4- yloxy)phenyl isonicotinamide. Into a 50-mL round bottom flask, was placed a solution of tetrahydro-2H-pyran-4-ol (220 mg, 2.11 mmol, 3.00 equiv, 98%) in N,N- dimethylformamide (5 mL). This was followed by the addition of sodium hydride (86 mg, 3.58 mmol, 5.00 equiv), in portions at room temperature. The resulting solution was stirred for 10 min at room temperature. To this was added N-(3- (trifluoromethyl)benzyl)-2-(5-fluoro-2-nitrophenyl)isonicoti namide (300 mg, 0.70 mmol, 1.00 equiv, 98%). Then the resulting solution was stirred for an additional 2 h at 80°C in an oil bath. The resulting solution was diluted with 200 mL of ethyl acetate, and washed with 2x30 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate/methanol (20/1). The product was obtained as 400 mg (97%) of a brown oil.

Intermediate 16c: N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-(tetrahvdro-2H-py ran-4- yloxy)phenyl)isonicotinamide. Into a 50-mL round bottom flask, was placed a solution of N-(3 -(trifluoromethyl)benzyl)-2-(2-nitro-5 -(tetrahydro-2H-pyran-4- yloxy)phenyl)isonicotinamide (400 mg, 0.76 mmol, 1.00 equiv, 95%) in methanol/dichloromethane (10/5 mL). The solution was treated with Pd/C (400 mg), and stirred under an atmosphere of hydrogen for 2 h at room temperature. The solids were filtered out. The resulting mixture was concentrated under vacuum to yield 270 mg (68%) of product as a brown oil.

Intermediate 16d: tert-butyl 3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl pyridin- 2-yl)-4-(tetrahvdro-2H-pyran-4-yloxy)phenyl carbamoyl benzylthio)propanoate. Into a 50-mL round bottom flask, was placed a solution of N-(3-(trifluoromethyl)benzyl)-2-(2- amino-5-(tetrahydro-2H-pyran-4-yloxy)phenyl)isonicotinamide (270 mg, 0.52 mmol, 1.00 equiv, 90%) in dichloromethane (10 mL), 3-((3-tert-butoxy-3- oxopropylthio)methyl)benzoic acid (339 mg, 0.92 mmol, 2.00 equiv, 80%), EDC HCl (220 mg, 1.15 mmol, 2.00 equiv), and 4-dimethylaminopyridine (140 mg, 1.15 mmol, 2.00 equiv). The resulting solution was stirred for 3 h at 25°C. The resulting solution was diluted with 150 mL of dichloromethane and was washed with 1x20 mL of aqueous NH ₄ C1, 1x20 mL of 10% sodium bicarbonate, and 1x20 mL of brine. The mixture was dried over sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate/petroleum ether (l :l)~dichloromethane:methanol(20:l). The product was obtained as 190 mg (42%) of a brown oil.

Example 16: 3-(3-((2-(4-((3-(trifluoromethyl)benzyl carbamoyl)pyridin-2-yl)-4- (tetTahydro-2H-pyran-4-yloxy phenyl carbamoyl)benzylthio propanoic acid. Into a 50- mL round bottom flask, was placed a solution of tert-butyl 3-(3-((2-(4-((3- (trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(tetrahydr o-2H-pyran-4- yloxy)phenyl)-carbamoyl)benzylthio)propanoate (190 mg, 0.20 mmol, 1.00 equiv, 80%) in dichloromethane (5 mL), and trifluoroacetic acid (1 mL). The resulting solution was stirred for 3 h at room temperature. The resulting mixture was concentrated under vacuum. The crude product (100 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 82.4 mg (57%) of as a yellow solid. 1H-NMR (300MHz, CD ₃ OD, ppm): δ 8.94 (d, J=3Hz, 1H), 8.30 (s, 1H), 8.22 (d, J=9Hz, 1H), 7.89-7.85 (m, 2H), 7.77 (d, J=9Hz, 1H), 7.70 (s, 1H), 7.66-7.52 (m, 4H), 7.48-7.43 (m, 2H), 7.19-7.15 (q, J-9Hz, 1H), 4.69 (s, 3H), 4.01- 3.95(m, 2H), 3.86 (s, 2H), 3.66-3.58 (m, 2H), 2.73-2.68(m, 2H), 2.59-2.54 (m, 2H), 2.06 (m, 2H), 1.80-1.76 (m, 2H). MS (ES, m/z): 694 [M+H] ⁺ .

EXAMPLE 17

3-(3-(( ^' 2-(4-( ^' (3-(trifluoromethyl benzyl carbamoyl ^' )pyridin-2-yl)-4-(bis( ^' 2- methoxyethyl ^' )amino)phenyl carbamoyl)benzylthio propanoic acid

Scheme 23. 1. Diisopropyethylamine, bis(2-methoxyethyl)amine, DMF; 2. Pd/C H ₂ , MeOH, DCM; 3. EDC HC1, DMAP, DCM, 3-((3-tert-butoxy-3- oxopropylthio)methyl)benzoic acid 1.1c; 4. TFA, DCM.

Intermediate 17a: N-(3 -(trifluoromethyl)benzyl -2-( ^' 5-(bis( ^, 2-methoxyethyl)amino -2- nitrophenvDisonicotinamide . Into a 10-mL vial, was placed a solution of bis(2- methoxyethyl)amine (285.6 mg, 2.15 mmol, 3.00 equiv) in N,N-dimethylformamide (3 mL), and N,N-diisopropylethylamine (277 mg, 2.14 mmol, 2.99 equiv). This was followed by the addition of a solution of N-(3-(trifluoromethyl)benzyl)-2-(5-fluoro-2- nitrophenyl)isonicotinamide (300 mg, 0.72 mmol, 1.00 equiv) in N,N- dimethylformamide (2 mL). The resulting solution was stirred for 48 h at 80°C in an oil bath. The reaction progress was monitored by LCMS. The resulting solution was diluted with 50 mL of water. The resulting solution was extracted with 3x50 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 2x70 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate/petroleum ether (1 :5-1). The product was obtained as 270 mg (71 %) of a yellow to green oil.

Intermediate 17b: N-(3-(trifluoromethyl benzyl -2-(2-amino-5-(bis(2-methoxyethylV amino phenyl isonicotinamide. Into a 50-mL round bottom flask, was placed a solution of N-(3-(trifluoromethyl)benzyl)-2-(5-(bis(2-methoxyethyl)amino )-2-nitrophenyl)- isonicotinamide (270 mg, 0.51 mmol, 1.00 equiv) in methanol (10 mL). The solution was treated with Pd/C (300 mg), and stirred under an atmosphere of hydrogen for 2 h at room temperature in a water bath. The solids were filtered out. The resulting mixture was concentrated under vacuum to yield 180 mg (71%) of product as a yellow to green oil.

Intermediate 17c: tert-butyl 3-(3-((2-(4-((3-(trifluoromethyl)benzyl carbamoyl)pyridin- 2-yl)-4-(bis(2-methoxyethyl amino phenyl)carbamoyl)benzylthio)propanoate. Into a 10-mL vial, was placed a solution of 3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid (188.64 mg, 0.64 mmol, 2.00 equiv) in dichloromethane (5 mL), EDC HC1 (120.8 mg, 0.63 mmol, 1.98 equiv), 4-dimethylaminopyridine (77.6 mg, 0.64 mmol, 2.00 equiv), and N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-(bis(2- methoxyethyl)amino)phenyl)-isonicotinamide (160 mg, 0.32 mmol, 1.00 equiv). The resulting solution was stirred for 2 h at 25°C in an oil bath. The reaction progress was monitored by LCMS. The resulting solution was diluted with 50 mL of dichloromethane, and washed with 3x50 mL of aqueous NH ₄ C1. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate/petroleum ether (1 :5-1). The product was obtained as 160 mg (64%) of a yellow solid.

Example 17: 3-(3-((2-(4-((3-(trifluoromethyl benzyl carbamoyl)pyridin-2-yl)-4-(bis(2- methoxyethyl amino)phenyl carbamoyl)benzylthio)propanoic acid. Into a 50-mL round bottom flask, was placed a solution of tert-butyl 3-(3-((2-(4-((3- (trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(bis(2- methoxyethyl)amino)phenyl)-carbamoyl)benzylthio)propanoate (160 mg, 0.21 mmol, 1.00 equiv) in dichloromethane (8 mL), and trifluoroacetic acid (2 mL). The resulting solution was stirred for 4 h at 25°C in an oil bath. The reaction progress was monitored by LCMS. The resulting mixture was concentrated under vacuum. The crude product (125 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TF A. The product was obtained as 81.1 mg (41%) of as a yellow solid. 1H-NMR (300MHz, OMSO, ppm): δ 11.86(s, 1H), 9.49(t, J=5.7Hz, 1H), 8.94(d, J=5.1Hz, 1H), 8.25(s, 1H), 8.12(d, J=6.5Hz, 1H), 7.82(s, 2H), 7.71(m, 2H), 7.62(m, 5H), 7.15(d, J=2.4Hz, 1H), 6.90(m, 1H), 4.61(d, J=6.0Hz, 2H), 3.87(s, 2H), 3.56(m, 8H), 3.27(s, 6H), 2.63(m, 2H), 2.51(m, 2H). MS (ES, m/z): 725 [M+H] ⁺ .

EXAMPLE 18

3 -((3 -(Y4-Fluoro-2-(4-(Y3 -(trifluoromethyl)benzyl)carbamoyl pyridin-2- vDphenvDcarbamoyDbenzvDthio^propanoic acid

Scheme 24. l . Pd/C H ₂ , MeOH; 2. EDC HC1, DMAP, DMF, 3-((3-tert-butoxy-3- oxopropylthio)methyl)benzoic acid 1.1c; 3. CF ₃ COOH, DCM.

Intermediate 18a: N-(3-(trifluoromethyl)benzyl -2-(2-amino-5-fluorophenylV isonicotinamide. Into a 50-mL round bottom flask, was placed a solution of N-(3- (trifluoromethyl)benzyl)-2-(5-fluoro-2-nitrophenyl)isonicoti namide 14d (200 mg, 0.48 mmol, 1.00 equiv) in methanol (5 mL). The solution was treated with Pd/C (0.2 g), and stirred under an atmosphere of hydrogen for 2 h at room temperature. The reaction progress was monitored by LCMS. The solids were filtered out. The resulting mixture was concentrated under vacuum to yield 200 mg of crude product as a yellow oil.

Intermediate 18b: tert-butyl 3-(3-((-2-(4-((3-(trifluoromethvDbenzyl ^' )carbamoyl)pyridin- 2-yl)-4-fluorophenyl)carbamoyl ^' )benzylthio ^' )propanoate. Into a 50-mL round bottom flask, was placed a solution of N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-fluoro- phenyl)isonicotinamide (200 mg, 0.51 mmol, 1.00 equiv) in N,N-dimethylformamide (2 mL), 3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid (200 mg, 0.68 mmol, 1.50 equiv), EDC HC1 (0.18 g, 0.94 mmol, 2.00 equiv), and 4-dimethylaminopyridine (58 mg, 0.48 mmol, 1.00 equiv). The resulting solution was stirred for 2 h at room temperature. The reaction progress was monitored by LCMS. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate/petroleum ether (l :5~ethyl acetate). The product was obtained as 100 mg (29%) of a yellow solid.

Example 18: 3 -(3 -((2-(4-((3 -(trifluoromethyl)benzvncarbamoyl ^' )pyridin-2-yl)-4-fluoro- phenyl)carbamoyl)benzylthio)propanoic acid. Into a 50-mL round bottom flask, was placed a solution of tert-butyl 3-(3-((2-(4-((3-

(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4- fluorophenyl)cafbamoyl)benzylthio)propanoate (100 mg, 0.15 mmol, 1.00 equiv) in dichloromethane (5 mL), and trifluoroacetic acid (1 mL). The resulting solution was stirred overnight at room temperature. The resulting mixture was concentrated under vacuum. The crude product (100 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 22.7 mg (25%) of a yellow solid. 1H-NMR (300MHz, DMSO, ppm): 6 12.78(s, 1H), 9.55- 9.54(m, 1H), 9.00-8.99(m, 1H), 8.58-8.53(m, 1H), 8.43(s, 1H), 7.94-7.39(m, 1 1 H), 4.65-4.63(t, J=3Hz, 2H), 3.89(s, 2H), 2.63-2.59(m, 2H). MS (ES, m/z): 612 [M+H] ⁺ .

EXAMPLE 19 3 -((3 -((4-(Dipropylamino -2-(4-(( ^, 3 -(tri¾oromethyl)benzvDcarbamoyl pyridin-2- yl)phenyl)carbamoyl)benzyl thio propanoic acid

Scheme 25: 1. dipropylamine, 2. Pd/C H ₂ , MeOH; 3. EDC HC1, DMAP, DMF, 3-((3- tert-butoxy-3-oxopropylthio)methyl)benzoic acid 1.1c; 4. CF ₃ COOH, DCM.

Intermediate 19a: N-(3-(trifluoromethyl)benzylV2-( ^' 5-( ^' dipropylaminoV2-nitrophenyl)- isonicotinamide. Into a 10-mL vial, was placed a solution of dipropylamine (216.9 mg, 2.15 mmol, 3.00 equiv) in N,N-dimethylformamide (3 mL), N,N-diisopropylethylamine (277 mg, 2.15 mmol, 3.00 equiv), and a solution of N-(3-(trifluoromethyl)benzyl)-2-(5- fluoro-2-nitrophenyl)isonicotinamide 14d (300 mg, 0.72 mmol, 1.00 equiv) in N,N- dimethylformamide (2 mL). The resulting solution was stirred for 8 h at 90°C to 100°C in an oil bath. The resulting solution was diluted with 50 mL of water. The resulting solution was extracted with 3x50 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 2x70 mL of brine, dried over sodium sulfate, and concentrated under vacuum. The crude product was obtained as 400 mg of a yellow to green oil.

Intermediate 19b: N-(3-(trifluoromethyl benzyl -2-(2-amino-5-

(dipropylamino phenviyisonicotinarnide. Into a 50-mL round bottom flask, was placed a solution of N-(3-(trifluoromethyl)benzyl)-2-(5-(dipropylamino)-2- nitrophenyl)isonicotinamide (400 mg, 0.80 mmol, -1.00 equiv) in methanol (20 mL). The solution was treated with Pd/C (400 mg, 10%), and stirred under an atmosphere of hydrogen for 4 h at room temperature. The solids were filtered out. The resulting mixture was concentrated under vacuum. The product was obtained as 300 mg (80%) of a yellow to green oil.

Intermediate 19c: tert-butyl 3-(3-((2-(4-((3-(trifluoromethyl benzyl carbamoyl)pyridin- 2-yl)-4-(dipropylamino)phenyl carbamoyl)benzylthio)propanoate. Into a 10-mL vial, was placed a solution of 3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid (355.2 mg, 1.20 mmol, 2.00 equiv) in dichloromethane (5 mL), EDC HC1 (228 mg, 1.19 mmol, 2.00 equiv), 4-dimethylaminopyridine (146.4 mg, 2.00 mmol), and N-(3- (trifluoromethyl)benzyl)-2-(2-amino-5-(dipropylamino)phenyl) isonicotinamide (300 mg, 0.64 mmol, 1.00 equiv). The resulting solution was stirred for 2 h at 25°C in an oil bath. The resulting solution was diluted with 50 mL of dichloromethane and washed with 3x50 mL of aqueous NH ₄ C1. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate/petroleum ether (1:5-1:3). The product was obtained as 320 mg (67%) of a yellow to green oil.

Example 19 : 3 -((3 -((4-(dipropylamino)-2-(4-((3 -(trifluoromethvDbenzvDcarbamoyl - pyridin-2-yl)phenyl)carbamoyl)benzyl)thio)propanoic acid. Into a 50-mL round bottom flask, was placed a solution of tert-butyl 3-(3-((2-(4-((3-(trifluoromethyl)- berizyl)carbamoyl)pyridin-2-yl)-4-(dipropylaniino)phenyl)car bamoyl)benzylthio)- propanoate (320 mg, 0.43 mmol, 1.00 equiv) in dichloromethane (10 mL), and trifluoroacetic acid (1 mL). The resulting solution was stirred overnight at 25°C in an oil bath. The reaction progress was monitored by LCMS. The resulting mixture was concentrated under vacuum. The crude product (200 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 108 mg (30%) of a yellow solid. 1H-NMR (300MHz, DMSO, ppm): δ 9.52(t, J=6Hz, 1H), 8.96(d, J=5.1Hz, 1H), 8.27(s, 2H), 7.85(s, 2H), 7.74(m, 2H), 7.53(m, 5H), 7.02(s, 2H), 4.61(d, J=5.7Hz, 2H), 3.87(s, 2H), 3.39(s, 4H), 2.61(m, 2H), 2.50(m, 2H), 1.53(t, J=9.3Hz, 4H), 0.89(t, J=7.2Hz, 6H). MS (ES, m/z): 693 [M+H] ⁺ .

EXAMPLE 20

3-( ^" (3-((4-(Pyrrolidin-l-yl)-2-(4-((3-(trifluoromethyl benzyl carbamoyl)pyridin-2- yl)phenyl carbamoyl)benzvDthio)propanoic acid

Scheme 26: 1. pyrrolidine, 2. Pd/C H ₂ , MeOH; 3. EDC HC1, DMAP, DMF, 3-((3-tert- butoxy-3-oxopropylthio)methyl)benzoic acid 1.1c; 4. CF ₃ COOH, DCM.

Intermediate 20a: N-( ^, 3-( ^' trifluoromethvnbenzyl)-2-(2-nitro-5-(pyrrolidin-l -vDphenylV isonicotinamide. Into a 10-mL vial, was placed a solution of pyrrolidine (152.5 mg, 2.15 mmol, 3.00 equiv) in N,N-dimethylformamide (5 mL), potassium carbonate (296.2 mg, 2.15 mmol, 3.00 equiv), and N-(3-(trifluoromethyl)benzyl)-2-(5-fluoro-2- nitrophenyl)isonicotinamide 14d (300 mg, 0.72 mmol, 1.00 equiv). The resulting solution was stirred for 4 h at 90°C in an oil bath. The resulting solution was diluted with 50 mL of water. The resulting solution was extracted with 3x50 mL of ethyl acetate and the organic layers combined. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum to yield 400 mg of crude product as a yellow to green oil. Intermediate 20b: N-(3-(trifluoromethyl benzyl)-2-(2-amino-5-(pyrrolidin-l- yl)phenyl)-isonicotinamide. Into a 50-mL round bottom flask, was placed a solution of N-(3-(trifluoromethyl)benzyl)-2-(2-nitro-5-(pyrrolidin-l-yl) phenyl)isonicotinamide (400 mg, 0.85 mmol, 1.00 equiv) in methanol (20 mL). The solution was treated with Pd/C (400 mg) and stirred under an atmosphere of hydrogen for 3.5 h at room temperature. The solids were filtered out. The resulting mixture was concentrated under vacuum. The product was obtained as 300 mg (80%) of a yellow to green solid.

Intermediate 20c: tert-butyl 3-(3-((2-(4-((3-(trifluoromethyl benzyl carbamoyl pyridin- 2-yl)-4-(pyrrolidin- 1 -vDphenvDcarbamovDbenzylthio propanoate . Into a 10-mL vial, was placed a solution of 3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid (402.6 mg, 1.36 mmol, 2.00 equiv) in dichloromethane (5 mL), EDC ^' HC1 (258.5 mg, 1.35 mmol, 2.00 equiv), 4-dimethylaminopyridine (165.9 mg, 1.36 mmol, 2.00 equiv), and N-(3 -(trifluoromethyl)benzyl)-2-(2-amino-5 -(pyrrolidin- 1 -yl)phenyl)isonicotinamide (300 mg, 0.68 mmol, 1.00 equiv). The resulting solution was stirred for 5 h at 25°C in an oil bath. The resulting solution was diluted with 50 mL of dichloromethane and washed with 2x70 mL of aqueous NH ₄ C1. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate/petroleum ether (1 :10-1 :3). The crude product was obtained as 600 mg of a yellow solid.

Example 20 : 3 -((3 -((4-(pyrrolidin- 1 -yD-2-(4-((3 -(trifluoromethvDbenzvDcarbamoyl - pyridin-2 -yl phenyl)carbamoyl)benzyl)thio propanoic acid. Into a 50-mL round bottom flask, was placed a solution of tert-butyl 3-(3-((2-(4-((3- (trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(pyrrolidi n-l-yl)phenyl)carbamoyl)- benzylthio)propanoate (600 mg, 0.84 mmol, 1.00 equiv) in dichloromethane (20 mL), and trifluoroacetic acid (2 mL). The resulting solution was stirred for 2.5 h at 25°C in an oil bath. The reaction progress was monitored by LCMS. The resulting mixture was concentrated under vacuum. The crude product (120 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 96.2 mg (15%) of a yellow solid. 1H-NMR (300MHz, DMSO, ppm): 6 1 1.92(s, IH), 9.51(t, J=11.7Hz, IH), 8.95(d, J=5.4Hz, IH), 8.28(s, IH), 8.15(d, J=8.7Hz, IH), 7.82(d, J=5.4Hz, 2H), 7.73(t, J=12.3Hz, 2H), 7.55(m, 5H), 6.96(d, J=2.4Hz, IH), 6.76(m, IH), 4.62(d, J=5.7Hz, 2H), 3.87(s, 2H), 3.33(s, 4H), 2.62(m, 2H), 2.50(m, 2H), 1.99(s, 4H). MS (ES, m/z): 663 [M+H] ⁺ .

EXAMPLE 21

3 -(( ^" 3 -(( ^' 4-Chloro-2-(4-((3 -(trifluoromethyl)benzvncarbamovnpyridin-2- yl phenyl)carbamoyl benzyl)thio propanoic acid

Scheme 27: 1. 3-(trifluormethyl)benzylamine, EDC ^■ HC1, DMAP; 2. 4-chloro-2- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)aniline, (Ph ₃ P) ₄ Pd, Na ₂ C0 ₃ , DME; 3. 3- ((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid 1.1c, EDC HC1, DMAP; 4. TFA.

Intermediate 21a: N-(3 -(trifluoromethyl benzyl)-2-bromoisonicotinamide. Into a 250- mL round bottom flask, was placed a solution of 2-bromoisonicotinic acid (1.4 g, 6.93 mmol, 1.20 equiv) in dichloromethane (50 mL), EDC HC1 (1.64 g, 8.56 mmol, 1.50 equiv), 4-dimethylaminopyridine (1.04 g, 8.51 mmol, 1.50 equiv), and 3- (trifluoromethyl)benzylamine (1.0 g, 5.71 mmol, 1.00 equiv). The resulting solution was stirred overnight at 25°C in an oil bath. The resulting solution was diluted with 100 mL of dichloromethane. The resulting mixture was washed with 2x50 mL of sat. NH4CI, 2x50 mL of sat. Na ₂ C0 ₃ , and 2x50 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate/petroleum ether (1:10-1 :5). The product was obtained as 1.2 g (59%) of a white solid.

Intermediate 21b: N-(3 -(trifluoromethyl benzviy 2-(2-amino-5 -chlorophenyl)- isonicotinamide. Into a 50-mL round bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of 4-chloro-2-(4,4,5,5-tetramethyl-l,3- dioxolan-2-yl)benzenamine (300 mg, 1.17 mmol, 1.00 equiv) in ethylene glycol dimethyl ether (15 mL), N-(3-(trifluoromethyl)benzyl)-2-bromoisonicotinamide (432 mg, 1.20 mmol, 1.00 equiv), a solution of sodium carbonate (636 mg, 6.00 mmol, 5.00 equiv) in water (3.0 mL), and Pd(PPh ₃ ) ₄ (138 mg, 0.12 mmol, 0.10 equiv). The resulting solution was stirred for 2 h at 85°C in an oil bath. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 10 mL of water. The resulting solution was extracted with 3x10 mL of ethyl acetate and the organic layers combined, and washed with brine. The mixture was dried over sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with petroleum ether/ethyl acetate (10:1-5:1). The product was obtained as 260 mg (55%) of a yellow solid.

Intermediate 21c: tert-butyl 3-(3-((2-( ^' 4-((3-(trifluoromethyl)benzyl carbamoyl)pyridin- 2-yl)-4-chlorophenyl)carbamoyl benzylthio ^' )propanoate. Into a 100-mL round bottom flask, was placed a solution of 3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid (210 mg, 0.71 mmol, 1.20 equiv) in dichloromethane (35 mL), EDC HC1 (170.6 mg, 0.89 mmol, 1.50 equiv), 4-dimethylaminopyridine (108.8 mg, 0.89 mmol, 1.50 equiv), and N-(3 -(trifluoromethyl)benzyl)-2-(2-aminO-5 -chlorophenyl)isonicotinamide (240 mg, 0.59 mmol, 1.00 equiv). The resulting solution was stirred for 6 h at 25°C in an oil bath. The resulting solution was diluted with 100 mL of dichloromethane and washed with 2x50 mL of aqueous NH ₄ C1 and brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum to yield 350 mg (86%) of product as a yellow solid.

Example 21 : 3-(3-((2-(4-((3-(trifluoromethyDbenzyl)carbamoyl pyridin-2-ylV4- chlorophenyl)carbamoyl benzylthio propanoic acid. Into a 50-mL round bottom flask, was placed a solution of tert-butyl 3-(3-((2-(4-((3- (trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-chlorophen yl)carbamoyl)

benzylthio)propanoate(350 mg, 0.51 mmol, 1.00 equiv) in dichloromethane (5.0 mL), and trifluoroacetic acid (581.4 mg, 5.10 mmol, 10.00 equiv). The resulting solution was stirred overnight at 15°C. The resulting mixture was concentrated under vacuum. The crude product (340 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TF A. The product was obtained 250 mg (78%) of a white solid. 1H-NMR (300MHz, DMSO-c¾, ppm): δ 12.988(s, IH), 12.228(s, IH), 9.595-9.560 (m, IH), 9.020-9.003(d, J=5.1 Hz, IH), 8.631-8.601(d, J=9.0 Hz, IH), 8.448(s, IH), 8.118-8.126(d, J= 2.4 Hz, IH), 7.917-7.899(d, J= 5.4 Hz, 2H), 7.837-7.812(d, J= 7.5 Hz, IH), 7.727-7.510(m, 6H), 4.662-4.643 (d, J=5.7 Hz, 2H), 3.904(s, 2H), 2.637-2.594(m, 2H), 2.538(m, 2H). MS (ES, m/z): 628 [M+H] ⁺ .

EXAMPLE 22

3 -((3 -((2-(4-((3 -(TrifluoromethvDbenzyl carbamoyl pyridin-2- vDphenvncarbamovDbenzvDthiolpropanoic acid

22e 22

Scheme 28: 1. 2-nitrophenylboronic acid, (Ph ₃ ) ₄ Pd, DME, Na ₂ C0 ₃ ; 2. Fe, CH ₃ COOH; 3. methyl acrylate, DBU, acetonitrile; 4. oxaloyl chloride, DCM; 5. methyl 3-((3- (chlorocarbonyl)benzyl)thio)propanoate, pyridine; 6. LiOH.

Intermediate 22a: N-(3-(trifluoromethvDbenzyl -2-( ^' 2-nitrophenyl) isonicotinamide. Into a 250-mL 3-necked round bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of 2-nitrophenylboronic acid (500 mg, 2.99 mmol, 1.00 equiv) in ethylene glycol dimethyl ether (30 mL), N-(3- (trifluoromethyl)benzyl)-2-bromoisonicotinamide 21a (1.08 g, 3.01 mmol, 1.00 equiv), Pd(PPh ₃ ) ₄ (334.7 mg, 0.30 mmol, 0.10 equiv), and a solution of sodium carbonate (1.6 g, 15.09 mmol, 5.00 equiv) in water (4 mL). The resulting solution was stirred for 1.5 h at 80°C. The reaction progress was monitored by TLC (ethyl acetate/petroleum ether = 1 :1). The resulting solution was diluted with 50 mL of water. The resulting solution was extracted with 2x100 mL of ethyl acetate and the organic layers combined and dried over magnesium sulfate. The solids were filtered out. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column and eluted with petroleum ether / EtOAc (20:1-5:1). The product was obtained as 1.0 g (83%) of a light yellow solid.

Intermediate 22b: N-(3-(trifluoromethyl)benzylV2-(2-aminophenyl)isonicotinamid e. Into a 100-mL round bottom flask, was placed a solution of N-(3- (trifluoromethyl)benzyl)-2-(2-nitrophenyl)isonicotinamide (350 mg, 0.87 mmol, 1.00 equiv) in ethanol/H ₂ 0(l/l) (30 mL), iron (489 mg, 8.73 mmol, 10.00 equiv), and acetic acid (0.1 mL). The resulting solution was heated to reflux for 0.5 h. The solids were filtered out. The resulting solution was extracted with of ethyl acetate and the organic layers combined and dried over magnesium sulfate. The solids were filtered out. The resulting mixture was concentrated under vacuum. The product was obtained as 260 mg (80%) of a yellow solid.

Intermediate 22c: 3-((3-methoxy-3-oxopropylthio methyl benzoic acid. To a solution of 3-(mercaptomethyl)benzoic acid (500 mg, 2.97 mmol, 1.00 equiv) in acetonitrile (10.0 mL) was added methyl acrylate (10.0 mL) and l,8-Diazabicyclo[5.4.0]undec-7- ene (1.0 g, 6.57 mmol, 2.00 equiv) and the resulting solution was heated to reflux overnight. The reaction was concentrated under vacuum and the residue was applied onto a silica gel column with ethyl acetate/petroleum ether (0~1:6) to afford 220 mg (28%) of 3-((3-methoxy-3-oxopropylthio)methyl)benzoic acid as light-red oil.

Intermediate 22d: methyl 3-(3-(chlorocarbonyl)benzylthio)propanoate. To a solution of 3-((3-methoxy-3-oxopropylthio)methyl)benzoic acid (61.6 mg, 0.24 mmol, 1.00 equiv) in dichloromethane (5 mL) was added dropwise oxalyl dichloride (121.76 mg, 0.96 mmol, 4.00 equiv) followed by a few drops of N,N-dimethylformamide. The resulting solution was heated to reflux for 30 min, then concentrated under vacuum to afford 60 mg (crude) of methyl 3-(3-(chlorocarbonyl)benzylthio)propanoate as a yellow oil.

Intermediate 22e: methyl 3-(3-((2-(4-( ^, (3-(trifluoromethyl)benzyl carbamoyl pyridin-2- yl phenvDcarbamoyl)benzylthio)propanoate. Into a 100-mL round bottom flask, was placed a solution of N-(3-(trifluorometliyl)benzyl)-2-(2-aminophenyl)isonicotinam ide (240 mg, 0.65 mmol, 1.00 equiv) in tetrahydrofuran (5 mL), and pyridine (77 mg, 0.97 mmol, 1.50 equiv). This was followed by drop wise addition of a solution of methyl 3- (3-(chlorocarbonyl)benzylthio)propanoate (194 mg, 0.71 mmol, 1.10 equiv) in tetrahydrofuran (5 mL) with stirring. The resulting solution was stirred for 2 h at room temperature. The reaction was then quenched with 30 mL of water. The resulting solution was extracted with 3x10 mL of ethyl acetate and the organic layers combined and dried over magnesium sulfate. The resulting mixture was concentrated under vacuum to yield 250 mg (64%) of product as a light yellow solid.

Example 22: 3-(3-((2-(4-((3-(trifluoromethyl benzyl)carbamoyl ^' )pyridin-2-yl)phenyl - carbamovDbenzylthio) propanoic acid. Into a 100-mL 3 -necked round bottom flask, was placed a solution of methyl 3-(3-((2-(4-((3- (trifluoromethyl)benzyl)carbamoyl)pyridin-2- yl)phenyl)carbamoyl)benzylthio)propanoate (250 mg, 0.41 mmol, 1.00 equiv) in tetrahydrofuran (8 mL), and a solution of LiOH (98 mg, 4.08 mmol, 10.00 equiv) in water (2 mL). The resulting solution was stirred for 2 h at room temperature. The reaction progress was monitored by LCMS. The reaction was then quenched with 50 mL of water. The solution was adjusted to pH 3 with hydrochloric acid. The resulting solution was extracted with of ethyl acetate and the organic layers combined and dried over anhydrous sodium sulfate. The solids were filtered out. The resulting mixture was concentrated under vacuum. The crude product (120 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained 50 mg (20%) of a white solid. 1H-NMR (400MHz, OMSO-d ₆ ,ppm): δ 13.02(s, 1H), 9.60-9.56(t, 1H), 9.01-8.99(d, 1H), 8.60-8.57(d, 1H), 8.42(s, 1H), 8.05-8.03(d, 1H), 7.93-7.82(m, 3H), 7.72-7.51(m, 7H), 7.35-7.30(t, 1H), 4.65-4.63(d, 2H), 3.91 (s, 2H), 2.64-2.59(m, 3H). MS (ES, m/z): 594 [M+H] ⁺ .

EXAMPLE 24 N 1 -( 2-(4-( 1 -Benzyl- 1 H- 1.2.3 -triazol-4-yl idin-l-yl -fpiperidin- 1 - vnphenylVN3 - methyl-NS-Q-morpholinoethvDisophthalamide

Scheme 29: l. TMSC≡CH, Cul, (Ph ₃ P) ₂ PdCl ₂ , triethylamine; 2. boronic ester Lie, Pd(OAc) ₂ , XPHOS, Na ₂ C0 ₃ ; 3. benzyl azide, CuS0 ₄ ; 4. H ₂ , Pd/C; 5. 3-(methyl(2- morpholinoethyl)carbamoyl)benzoic acid, EDC ^' HC1, DMAP.

Intermediate 24a: 2-chloro-4-((trimethylsilyl)ethynyl)pyridine. A solution 0.835 mL of triethylamine in 10 mL of THF was degassed and treated with 16 mg of Ph ₃ P, 70 mg of (Ph ₃ P) ₂ PdCl ₂ , and 479 mg of 2-chloro-4-iodopyridine. The solution was stirred 1 h then treated with 236 mg of TMSC≡CH and 11.4 mg of Cul. After stirring overnight the solvent was evaporated and the residue was dissolved in dichloromethane. The solution was washed with water and then with brine. The solution was dried (Na ₂ S0 ₄ ) and then the solvent was evaporated at reduced pressure. The residue was chromatographed on silica gel eluting with a gradient of 0% to 20% ethyl acetate in hexanes to give 516 mg of product. MS (ESI, m/z) 210.1 [M+H] ⁺ . Intermediate 24b: 4-ethvnyl-2-(2-nitro-5-(piperidin-l -vDphenvDpyridine. A degassed mixture of 2-chloro-4-((trimethylsilyl)ethynyl)pyridine 24a, boronic ester Lie, 4.9 mL of 2 M aqueous Na ₂ C0 ₃ , and 12 mL of DME was treated with 45 mg of XPHOS and 11 mg of Pd(OAc) ₂ . The mixture was stirred at 75°C for 1.5 h. The solvent was evaporated at reduced pressure and the residue was dissolved in 100 mL of dichloromethane. The solution was washed with water and dried over Na ₂ S0 ₄ . The solvent was evaporated and the residue was purified by silica gel chromatography eluting with a 0 - 20% gradient of EtOAc in CH ₂ Cl ₂ to give 275 mg of product. MS (ESI, m/z) 308.1 [M+H] ⁺ .

Intermediate 24c: 4-d -benzyl- 1 H- 1 ,2,3 -triazol-4-yl -2-(2-nitro-5-(piperidin- 1 - vDphenvD-pyridine. A solution of 50 mg of 4-ethynyl-2-(2-nitro-5-(piperidin-l- yl)phenyl)pyridine, 20 of benzyl azide, 16.3 of 1 M aqueous sodium ascorbate solution, 5.4 μΕ of 0.3 M CuS0 ₄ solution, 326 μΐ. of tert-butanol, and 326 μΐ, of water was stirred for 2 days and then the solvent was evaporated at reduced pressure. The residue was dissolved in dichloromethane. The solution was washed with water and dried. The solvent was evaporated at reduced pressure and the residue was chromatographed on silica gel eluting with a 0% to 4% gradient of methanol in dichloromethane. The process yielded 22 mg of product.

Intermediate 24d: 2-(4-( 1 -benzyl- 1 H- 1 ,2,3 -triazol-4-yl)pyridin-2-yl -4-(piperidin- 1 - yD-aniline. A solution of 22 mg of 4-(l-benzyl-lH-l,2,3-triazol-4-yl)-2-(2-nitro-5- (piperidin-l-yl)phenyl)pyridine 24c in 1 mL of methanol was treated with 10 mg of Pd/C and stirred under a hydrogen atmosphere for 1 h. The mixture was filtered through celite and the solvent was evaporated to give 22 mg of product.

Example 24: Nl-i2-(4-ri-benzyl-lH-1.2,3-triazol-4-vnpyridin-2-ylV4-(pipe ridin-l-vD- phenv -N3-methyl-N3-(2-morpholinoethvnisophthalamide. A solution of 22 mg of 2- (4-(l-benzyl-lH-l,2,3-triazol-4-yl)pyridin-2-yl)-4-(piperidi n-l-yl)aniline 24d, 15.2 mg of 3-(methyl(2-morpholinoethyl)carbamoyl)benzoic acid, 22.6 mg of HATU, and 27.9 mg of diisopropylethylamine in 0.3 mL of DMF was stirred for 1 h. The solution was filtered and the product was isolated from the filtrate by reverse phase chromatography eluting with 0.05% TFA in a water / acetonitrile gradient. This procedure gave 13.4 mg of product. 1H NMR (400 MHz, DMSO-i¼, ppm) δ 8.97 (s, 1H), 8.78 (d, J = 5.0 Hz, 1H), 8.35 (s, 1H), 8.32 - 8.26 (m, 1H), 8.03 - 7.94 (m, 2H), 7.91 (d, J = 5.2 Hz, 1H), 7.70 - 7.50 (m, 3H), 7.35 (mj, 4H), 7.28 - 7.19 (m, 1H), 5.69 (s, 2H), 4.09 - 3.90 (m, 3H), 3.85 - 3.76 (m, 2H), 3.71 - 3.53 (m, 4H), 2.91 (s, 3H), 1.69 (s, 4H), 1.55 (s, 2H). MS (ESI, m/z) 685.3 [M+H] ⁺ .

EXAMPLE 25

N 1 -( ^r 4-(Diethylamino)-2-(4-(( ^' 3 -( trifluoromethyl)benzvDcarbamoyl)pyridin-2- vDphenvO-N3 -methyl-N3 -(2-morpholinoethyl isophthalamide

Scheme 30: 1. diethylamine, 2. Pd/C ¾, MeOH; 3. HATU, DIEA, DMF, 3-(methyl(2- mo holinoethyl)carbamoyl)benzoic acid.

Intermediate 25a: N-(3-(trifluoromethyl)benzylV2-( ^' 5-( ^' diethylamino -2-nitrophenylV isonicotinamide. A 25°C mixture of 500 mg of 2-(5-fluoro-2-nitrophenyl)-N-(3- (trifluoromethyl)benzyl)isonicotinamide 14d, 131 mg of diethylamine, and 329 mg of K ₂ C0 ₃ in 4 mL of DMF was stirred for 16 h and then stirred for an additional 24 h at 60°C. The mixture was diluted with ethyl acetate, and the resulting solution was washed with water, and then with brine. The solution was dried (Na ₂ S0 ₄ ) and the solvent was removed at reduced pressure. The residue was purified by chromatography on silica gel to give 500 mg of a yellow solid.

Intermediate 25b: N-(3-( ^, trifluoromethyl benzylV2-(2-amino-5-(diethylamino)phenylV isonicotinamide. A mixture of 500 mg of N-(3-(trifluoromethyl)benzyl)-2-(5- (diethylamino)-2-nitrophenyl)isonicotinamide, 120 mg of 10% Pd/C, and 30 mL of methanol was stirred for 2 h under a hydrogen atmosphere. The mixture was filtered and concentrated to give 0.42 g of product.

Example 25 : N 1 -(4-f diethylamino)-2-(4-(Y3 -

(trifluoromethvnbenzyl)carbamoyl ^' )pyridin-2-yl ^' )phenylVN3-methyl-N3-(2- morpholinoethyl isophthalamide. A mixture of 80 mg of N-(3-(trifluoromethyl)benzyl)- 2-(2-amino-5-(diethylamino)phenyl)isonicotinamide, 64 mg of 3-(methyl(2- morpholinoethyl)carbamoyl)benzoic acid, 83 mg of HATU, and 190 μΐ, of diisopropylethylamine in 0.5 mL of DMF was stirred at 60°C for 2 h. The product was isolated by reverse phase chromatography eluting with 0.05% TFA in a water / acetonitrile gradient. This procedure gave 17.6 mg of product. 1H NMR (400 MHz, CO ₃ OO, ppm): 5 9.54 (t, J= 5.9 Hz, IH), 8.98 (dd, J= 5.2, 0.6 Hz, IH), 8.88 (d, J= 9.0 Hz, IH), 8.49 (s, IH), 8.26 (d, J= 2.6 Hz, IH), 8.20 (s, IH), 8.16 - 8.10 (m, IH), 7.90 (dd, J= 5.2, 1.5 Hz, IH), 7.80 (d, J= 7.8 Hz, IH), 7.75 - 7.63 (m, 4H), 7.63 - 7.50 (m, 2H), 4.74 - 4.67 (m, 2H), 4.21-4.03(m, 2H), 3.99 (t, J= 5.7 Hz, 2H), 3.90-3.69 (m, 4H), 3.76 (q, J= 7.2 Hz, 4H), 3.54 (t, J= 5.9 Hz, 2H), 3.34-3.18 (m, 2H), 3.10 (s, 3H), 1.22 (t, J= 7.2 Hz, 6H). MS (ESI, m/z) 717.24 [M+H] ⁺ .

EXAMPLE 26

N 1 -(4-Cvclobutoxy-2-(4-(Y3 -(trifluoromethyl benzyl)carbamoyl)pyridin-2-yl)phenylV

N3-methyl-N3-(2-morpholinoethyl)isophthalamide

Scheme 31: 1. cyclobutanol, NaH, 2. Pd/C H ₂ , MeOH; 3. HATU, DIEA, DMF, 3- (methyl(2-morpholinoethyl)carbamoyl)benzoic acid;

Intermediate 26a: 2-(5 -cyclobutoxy-2-nitrophenylVN-(3 -(trifluoromethyl)benzylV isonicotinamide. A 25°C solution of 26 mg of cyclobutanol in 0.5 mL of DMF was treated with 10 mg of 60% NaH in oil. After stirring for 15 minutes, 75 mg of 2-(5- fluoro-2-nitrophenyl)-N-(3-(trifluoromethyl)benzyl)isonicoti namide 14d was added. The mixture was stirred overnight and then it was quenched with water. It was diluted with ethyl acetate, and the resulting solution was washed with water, then with brine. The solution was dried (Na ₂ S0 ₄ ) and the solvent was removed at reduced pressure. The residue was purified by chromatography on silica gel to give 62 mg of a syrup.

Intermediate 26b: 2-(2-amino-5-cyclobutoxyphenyl)-N-(3 -(trifluoromethvPbenzylV isonicotinamide. A mixture of 62 mg of 2-(5-cyclobutoxy-2-nitrophenyl)-N-(3- (trifluoromethyl)benzyl)isonicotinamide, 10 mg of 10% Pd/C, and 4 mL of methanol was stirred for 2 h under a hydrogen atmosphere. The mixture was filtered and concentrated to give 46 mg of product. Example 26 : 1 -(4-cyclobutoxy-2-(4-((3 -(trifluoromethvDbenzvDcarbamovDpyridin- 2-yl phenyl)-N3-methyl-N3-( ^' 2-morph.olinoethyl)isophthalamide. A mixture of 26 mg of 2-(2-amino-5-cyclobutoxyphenyl)-N-(3-(trifluoromethyl)benzyl )isonicotinamide, 21 mg of 3-(methyl(2-morpholinoethyl)carbamoyl)benzoic acid, 27 mg of HATU, and 63 μΐ. of DIEA in 0.2 mL of DMF was stirred at 60°C for 2 h. The product was isolated by reverse phase chromatography eluting with 0.05% TF A in a water / acetonitrile gradient. This procedure gave 24 mg of a yellow solid. 1H NMR (400 MHz, CD ₃ OD, ppm): δ 9.46 (t, J= 5.8 Hz, IH), 8.85 (d, J= 5.3 Hz, IH), 8.26 (s, IH), 8.15 (d, J= 9.0 Hz, IH), 8.05 (s, IH), 8.01 (d, J= 7.8 Hz, IH), 7.85 - 7.80 (m, IH), 7.80 - 7.47 (m, 6H), 7.31 (d, J= 2.7 Hz, IH), 7.00 (dd, J= 8.9, 2.6 Hz, IH), 4.83 - 4.71 (m, IH), 4.67 (s, 2H), 4.09 (s, 2H), 3.96 (m, 2H), 3.77 (m, 4H), 3.52 (t, J= 4.9 Hz, 2H), 3.24 (s, 2H), 3.07 (s, 3H), 2.59 - 2.39 (m, 2H), 2.25 - 2.04 (m, 2H), 1.93 - 1.60 (m, 2H). MS (ESI, m/z) 716.26 [M+H] ⁺ .

EXAMPLE 27

3 -((3 -((4-Thiomorpholino-2-f 4-(Y3 -(trifluoromethyl)benzyl)carbamovDpyridin-2- yl phenyDcarbamovDbenzvDthio)propanoic acid

This compound was prepared according to the procedure described for the synthesis of 3-((3-((4-morpholino-2-(4-((3-(trifluoromethyl)benzyl)carbam oyl)pyridin-2- yl)phenyl)carbamoyl)benzyl)thio)propanoic acid 14, using thiomorpholine in place of morpholine. 1H-NMR (300MHz, DMSO-d ₆ , ppm): δ 12.22 (s, IH), 9.54 (t, IH), 8.32 (d, J=3Hz, IH), 8.27 (m, 2H), 7.85 (m, 2H), 7.75 (m, 2H), 7.50 (m, 6H), 7.15 (m, IH), 4.62 (d, J=6Hz, 2H), 3.87 (s, 2H), 3.58 (m, 4H), 2.74 (m, 4H), 2.62 (m, 2H), 2.50 (m, IH). MS (ES, m/z): 695 [M+H] ⁺ .

EXAMPLE 28

3-( ( 3 -i(4-(Hexahvdrocvclopenta[clpyrrol-2( 1 Ή -γ\)-2-(4-(( 3 -qrifluoromethylV benzyl)carbamoyl ^' )pyridin-2-yl)phenyl ^' )carbamoyl)benzyl thio)propanoic acid

This compound was prepared according to the procedure described for the synthesis of 3 -((3 -((4-morpholino-2-(4-((3 -(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)- carbamoyl)benzyl)thio)propanoic acid 14, using octahydrocyclopenta[c]pyrrole in place of morpholine. 1H-NMR (300MHz, DMSO-i/ ₆ +D ₂ 0, ppm): δ 9.54 (s, IH), 8.92 (d, J=3Hz, IH), 8.25 (s, IH), 8.11 (d, J=9Hz, IH), 7.73 (m, 2H), 7.58 (m, 2H), 7.49 (m, 2H), 7.45 (m, 2H), 7.02 (s, IH), 6.80 (d, J=9Hz, IH), 4.60 (s, 2H), 3.84 (s, 2H), 3.05 (d, J=6Hz, 2H), 2.77 (m, 2H), 2.56 (m, 3H), 1.80 (m, 2H), 1.52 (m, 3H). MS (ES, m/z): 703 [M+H] ⁺ .

EXAMPLE 29

3 -((3 -(Y4-Ethoxy-2-(4-((3 -(trifluoromethyl benzyl ^' )carbamovDpyridin-2- yl phenyDcarbamoyl benzyl thio propanoic acid

This compound was prepared according to the procedure described for the synthesis of 3 -((3 -((4-morpholino-2-(4-((3 -(trifluoromethyl)benzyl)carbamoyl)pyridin-2- yl)phenyl)carbamoyl)benzyl)thio)propanoic acid 14, using ethanol in place of morpholine. ^! H-NMR (300MHz, DMSO, ppm): δ 12.49 (s, 1H), 9.57 (m, 1H), 8.98- 8.96 (m, 1H), 8.41-8.38 (m, 2H), 7.88-7.54(m, 10 H), 7.16-7.10 (m, 2H), 4.63 (m, 2H), 4.14-4.12 (m, 2H), 3.88 (s, 2H), 2.60-2.58 (m, 2H), 1.37-1.35 (t, J=3Hz, 3H). MS (ES, m/z) 638 [M+H] ⁺ .

EXAMPLE 30

3-((3-((4-Methoxy-2-(4-((3-(trifluoromethyl)benzvncarbamo yl ^' )pyridin-2- yl)phenyl carbamoyl)benzyl)thio propanoic acid

This compound was prepared according to the procedure described for the synthesis of 3 -((3 -((4-morpholino-2-(4-((3 -(trifluoromethyl)benzyl)carbamoyl)pyridin-2- yl)phenyl)carbamoyl)benzyl)thio)propanoic acid 14, using methanol in place of morpholine. Ή-NMR (300MHz, DMSO-d ₆ , ppm): δ 12.40(s, IH), 9.55 (m, IH), 8.98- 8.96 (m, IH), 8.39-8.36 (m, 2H), 7.87-7.47(m, 10 H), 7.16-7.14 (m, IH), 4.62- 4.61(m, 2H), 3.88 (s, IH), 3.86 (s, 3H), 2.62-2.58 (m, 2H). MS (ES, m/z): 624 [M+H] ⁺ .

EXAMPLE 31

3-((3-((4-(4-Methoxypiperidin-l-yl ^' )-2-(4-((3-( ^' trifluoromethyl ^' )benzyl)carbamoyl - pyridin-2-yl phenyl ^' )carbamovnbenzyl thio)propanoic acid

This compound was prepared according to the procedure described for the synthesis of 3 -((3 -((4-morpholino-2-(4-((3 -(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)- carbamoyl)benzyl)thio)propanoic acid 14, using 4-methoxypiperidine in place of morpholine and using triethylamine in place of potassium carbonate in the nucleophilic aromatic substitution step. 1H-NMR (300MHz, CD ₃ OD, ppm) δ 8.98(d, J=4.1Hz, IH), 8.47(d, J=9Hz, IH) 8.33(s, IH), 7.94(s, IH), 7.84(m, 2H), 7.72-7.46(m, 7H), 7.38(d, J=7.5Hz, IH), 4.71(s, 3H), 3.89(s, 2H), 3.72(m, 2H), 3.55(m, IH), 3.33(s, 3H), 3.26(m, 2H), 2.74(t, 2H), 2.56(t, 2H), 2.20(m, 2H), 1.88(m, 2H). MS (ES, m/z): 707 [M+H] ⁺ . EXAMPLE 32

3 -((3 -((4-(2,2,2-Trifluoroethoxy)-2-(4-(( 3 -(trifluoromethvDbenzvDcarbamovDpyridin- 2-yl phenyl)carbamoyl)benzyl)thio)propanoic acid

Scheme 32: 1. 2,2,2-trifluoroethanol, NaH, THF; 2. H ₂ , Pd/C; 3. 3-((3-tert-butoxy-3- oxopropylthio)methyl)benzoic acid, 1.1c, EDC, DMAP; 4. TFA

Intermediate 32a: N-(3-( ^" trifluoromethyl ^' )benzyl ^' )-2-(2-nitro-5-(2,2,2-trifluoroethoxyV phenyDisonicotinamide. Into a 50-mL round-bottom flask, was placed a solution of 2,2,2-trifluoroethanol (150 mg, 1.50 mmol, 2.00 equiv) in tetrahydrofuran (10 mL). This was followed by the addition of sodium hydride (180 mg, 7.50 mmol, 10.00 equiv), in portions at 0°C. The resulting solution was stirred for 20 min at 0°C in an ice/salt bath. To this was added N-(3-(trifluoromethyl)benzyl)-2-(5-fluoro-2- nitrophenyl)isonicotinamide 14d (300 mg, 0.72 mmol, 1.00 equiv). The resulting solution was stirred overnight at room temperature. The resulting solution was diluted with 20 mL of water. The resulting solution was extracted with 3x20 mL of dichloromethane and the organic layers combined and dried over sodium sulfate and concentrated under vacuum. This resulted in 200 mg (crude) of N-(3- (trifluoromethyl)benzyl)-2-(2-nitro-5-(2,2,2-trifluoroethoxy )phenyl)isonicotinamide as a yellow solid.

Intermediate 32b: N- 3-(trifluoromethyl)benzyl)-2-( ^' 2-amino-5-( ^' 2,2 _< 2-trifluoroethLOxyV phenvDisonicotinamide. Into a 50-mL round-bottom flask, was placed a solution of N- (3-(trifluoromethyl)benzyl)-2-(2-nito

(200 mg, 0.40 mmol, 1.00 equiv) in methanol (5 mL). The solution was treated with Pd/C (0.2 g), and stirred under an atmosphere of hydrogen for 2 h at room temperature. The solids were filtered out. The resulting mixture was concentrated under vacuum. This resulted in 200 mg (crude) of N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-(2,2,2- trifluoroethoxy)phenyl)isonicotinamide as a yellow solid.

Intermediate 32c: tert-butyl 3-(3-((2-(4-((3-(trifluoromethyl)benzyl carbamoyl)pyridin- 2-yl -4-(2,2,2-trifluoroethoxy)phenyl)carbamoyl)benzylthio)propan oate. Into a 50-mL round-bottom flask, was placed a solution of N-(3-(trifluoromethyl)benzyl)-2-(2-amino- 5-(2,2,2-trifluoroethoxy)phenyl)isonicotinamide (200 mg, 0.43 mmol, 1.00 equiv) in N,N-dimethylformamide (3 mL), 3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid (200 mg, 0.74 mmol, 1.50 equiv), EDC HC1 (190 mg, 0.99 mmol, 2.00 equiv), and 4-dimethylaminopyridine (60 mg, 0.49 mmol, 1.00 equiv). The resulting solution was stirred for 2 h at room temperature. This resulted in 300 mg (crude) of tert-butyl 3-(3- ((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4 -(2,2,2- trifluoroethoxy)phenyl)-carbamoyl)benzylthio)propanoate as a yellow solid.

Example 32 : 3 -(3 -((2-(4-((3 -(trifluoromethyl benzyl)carbamoyl pyridin-2-yl)-4-(2,2,2- trifluoroethoxy phenyl carbamoyl)benzylthio propanoic acid. Into a 50-mL round- bottom flask, was placed a solution of tert-butyl 3-(3-((2-(4-((3- (trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(2,2,2-tri fluoroethoxy)phenyl)- carbamoyl)benzylthio)propanoate (200 mg, 0.27 mmol, 1.00 equiv) in dichloromethane (5 mL), and trifluoroacetic acid (2 mL). The resulting solution was stirred overnight at room temperature. The reaction progress was monitored by LCMS. The resulting mixture was concentrated under vacuum. The crude product (200 mg) was purified by reverse phase HPLC eluting with a water/C¾CN gradient containing 0.05% TFA. The product was obtained as 68 mg (37%) of a light yellow solid. 1H-NMR (300MHz, DMSO-i¾, ppm): δ 12.61 (s, IH), 9.57-9.54 (m, IH), 8.99-8.98 (m, IH), 8.49-8.41 (m, 2H), 7.89-7.79 (m, 10 H), 7.30-7.26 (m, IH), 4.92-4.84 (dd, J=18Hz, 9Hz, 2H), 4.65- 4.63 (d, J=5.4Hz, 2H), 3.89 (s, 2H), 2.63-2.59 (m, 4H). MS (ES, m/z): 692 [M+H] ⁺ .

EXAMPLE 33

3 -((3 -((4-Methoxy-2-(4-((3 -rtrifluoromethyl benzyl carbamovnpyridin-2- vDphenvDcarbamoyDbenzvDthio^propanoic acid

This compound was prepared according to the procedure described for the synthesis of 3 -(3 -((2-(4-((3 -(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(2,2,2- trifluoroethoxy)-phenyl)carbamoyl)benzylthio)propanoic acid 32, using isobutanol in place of trifluoroethanol. 1H-NMR (300MHz, DMSO-</ ₆ , ppm): δ 12.44 (s, IH), 9.56 (m, IH), 8.97 (m, IH), 8.36 (m, 2H), 7.87-7.52 (m, 10 H), 7.16 (m, IH), 4.63 (d, 2H), 3.87 (m, 4H), 2.59 (m, 2H), 2.06 (m, 2H), 1.03 (m, 6H). MS (ES, m/z): 666 [M+H] ⁺ .

EXAMPLE 34

3 -((3 -((4-(2-MethoxyethoxyV2-(4-((3 -(trifluoromethvnbenzyl)carbamoyl ^' )pyridin-2- vDphenvDcarbamoyDbenzyl¼hio)propanoic acid

This compound was prepared according to the procedure described for the synthesis of 3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2- yl)-4-(2,2,2- trifluoroethoxy)phenyl)carbamoyl)benzylthio)propanoic acid 32 using 2- methoxyethanol in place of trifluoroethanol. 1H-NMR (400MHz, DMSO-i¾, ppm): δ 12.55(s, 1H), 9.60-9.58(m, 1H), 8.99-8.97(m, 1H), 8.43-8.39(m, 2H), 7.89-7.49(m, 11H), 7.18-7.15(m, 1H), 4.64-4.63(m, 2H), 4.22-4.20(t, J=6Hz, J=3Hz, 2H), 3.89(s, 2H), 3.71-3.69(t, J=6Hz, J=3Hz, 2H), 3.33(s, 3H), 2.63-2.59(m, 2H). MS (ES, m/z): 668 [M+H] ⁺ .

EXAMPLE 35

3-((3-((4-(Ethylthio)-2-(4-((3-(trifluoromethvnbenzyl ^' )carbamoyl ^N )pyridin-2- v phenvDcarbamovDbenzvDthio^propanoic acid

Scheme 33. 1. EtSNa, DMSO; 2. Pd/C H ₂ , MeOH, DCM; 3. EDC HC1, DMAP/DCM, 3-(((3-(tert-butoxy)-3-oxopropyl)thio)methyl)benzoic acid 1.1c; 4. TFA, DCM.

Intermediate 35a: N-( ^, 3-(trifluoromethyl ^' )benzyl)-2-( ^' 5-(ethylthio ^' )-2-nitrophenvn- isonicotinamide. Into a 50-mL round-bottom flask, was placed a solution of N-(3- (trifluoromethyl)benzyl)-2-(5-fluoro-2-nitrophenyl)isonicoti namide 14d (300 mg, 0.72 mmol, 1.00 equiv) in DMSO (5 mL), and sodium ethanethiolate (100 mg, 1.19 mmol, 1.70 equiv). The resulting solution was stirred for overnight at 90°C in an oil bath. The mixture was concentrated under vacuum. The residue was diluted with 20 mL of water. The resulting solution was extracted with 3x20 mL of dichloromethane and the organic layers combined. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This resulted in 300 mg (crude) of N-(3- (trifluoromethyl)benzyl)-2-(5-(ethylthio)-2-nitrophenyl)ison icotinamide as a yellow solid.

Intermediate 35b: N-(3-(trifluoromethyl benzyl -2-( ^' 2-amino-5-(ethylthio phenyl - isonicotinamide. Into a 50-mL round-bottom flask, was placed a solution of N-(3- (trifluoromethyl)benzyl)-2-(5-(ethylthio)-2-nitrophenyl)ison icotinamide (300 mg, 0.65 mmol, 1.00 equiv) in methanol (5 mL). The solution was treated with Pd/C (300 mg), and stirred under an atmosphere of hydrogen for 2 h at room temperature. The solids were filtered out. The resulting mixture was concentrated under vacuum. This resulted in 200 mg (71%) of N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5- (ethylthio)phenyl)isonicotinamide as a yellow solid.

Intermediate 35c: tert-butyl 3-(3-((2-(4-((3-(trifluoromethyl benzyl carbamoyl pyridin- 2-yl -4-(ethylthio phenyl carbamoyl)benzylthio propanoate. Into a 50-mL round- bottom flask, was placed a solution of N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5- (ethylthio)phenyl)isonicotinamide (200 mg, 0.46 mmol, 1.00 equiv) in N,N- dimethylformamide (5 mL), 3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid (200 mg, 0.68 mmol, 1.50 equiv), EDC HC1 (190 mg, 0.99 mmol, 2.00 equiv), and 4- dimethylaminopyridine (60 mg, 0.49 mmol, 1.00 equiv). The resulting solution was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum. This resulted in 300 mg (crude) of tert-butyl 3-(3-((2-(4-((3- (trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(ethylthio )phenyl)carbamoyl)- benzylthio)propanoate as a yellow solid.

Example 35: 3 -(3 -(4-(ethylthio)-2-(4-(3 -(trifluoromethyl benzylcarbamoyl)pyridin-2- yl phenylcarbamoyl)benzylthio propanoic acid. Into a 50-mL round-bottom flask, was placed a solution of tert-butyl 3-(3-(4-(ethylthio)-2-(4-(3- (trifluoromethyl)benzylcarbamoyl)pyridin-2- yl)phenylcarbamoyl)benzylthio)propanoate (200 mg, 0.28 mmol, 1.00 equiv) in dichloromethane (5 mL), and trifluoroacetic acid (2 mL). The resulting solution was stirred overnight at room temperature. The reaction progress was monitored by LCMS. The resulting mixture was concentrated under vacuum. The crude product (0.2 g) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained 40.4 mg (21%) of a light yellow solid. ¹ H-NMR (400MHz, DMSO-c ₆ , ppm): δ 12.85 (s, 1H), 12.28 (s, 1H), 9.60-9.57 (m, 1H), 9.01- 8.99 (m, 1H), 8.55-8.53 (m, 1H), 8.39 (s, 1H), 7.96-7.51 (m, 11 H), 4.65-4.64 (d, J=5.2Hz, 2H), 3.90 (s, 2H), 3.08-3.03 (m, 2H), 2.63-2.59 (t, J=5.1Hz, 2H), 1.28-1.24 (t, J=5.7Hz, 3H). MS (ES, m/z): 654 [M+H] ⁺ .

EXAMPLE 36 3 -((3 -(Y4-Phenoxy-2-(4-(T3 -( ^" trifluoromethyl)benzyl carbamoyl)pyridin-2- yl phenyl)carbamovDbenzyl thio)propanoic acid

This compound was prepared according to the procedure described for the synthesis of 3-(3-((2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2- yl)-4-(2,2,2- trifluoroethoxy)phenyl)carbamoyl)benzylthio)propanoic acid 32 using phenol in place of trifluoroethanol. 1H-NMR- (300MHz, CD ₃ OD, ppm): δ 8.97(m, 1H), 8.47-8.50(d, 1H), 8.24(s, 1H), 7.96(s, 1H), 7.81-7.86(m, 2H), 7.36-7.69(m, 6H), 7.36-7.40(m, 2H), 7.05-7.15(m, 4H), 4.66(s, 2H), 3.89(s, 2H), 2.70-2.74(m, 2H), 2.56-2.61(m, 2H). MS (ES, m/z): 686 [M+H] ⁺ .

EXAMPLE 37

(8 -Ν1-Μ6Φν1-Ν1-(2-ηΐθ ^1ΐηο6Φν1)-Ν3-(4-(ρΐρ6Γίάίη-1-νΐν2-( ^, 4-((1,2,3,4- tetrahvdronaphthalen-l-yl carbamoyl)pyridin-2-yl phenyl)isophthalamide

Scheme 34. 1. 3-(methyl(2-mo holinoethyl)carbamoyl)benzoic acid, HATU, diisoporopylethylamine; 2. LiOH; 3. (S)-l, 2,3, 4-tetrahydronaphthalen-l -amine, HATU, diisopropylethylamine; 4. HC1.

Intermediate 37a: methyl 2-(2-(3-(methyl(2-morpholinoethyl ^' )carbamoyl)benzamido -5- (piperidin- 1 -yPphenyDisonicotinate . A solution of 150 mg of methyl 2-(2-amino-5- (piperidin-l-yl)phenyl)isonicotinate l.lh, 169 mg of 3-(methyl(2- mo holinoethyl)carbamoyl)benzoic acid, and 249 mg of diisopropylethylamine in 3 mL of DMF was treated with 202 mg of HATU. The mixture was stirred for 2 h and then it was diluted with 20 mL of water. The resulting precipitate was collected by filtration and dissolved in dichloromethane. The solution was washed with water and then dried over Na ₂ S0 ₄ . The solvent was evaporated to give the product as 231 mg of an orange oil.

Intermediate 37b: 2-(2-(3 -(methyl(2-morpholinoethv carbamoyl ^' )benzamido)-5- (piperidin- 1 -vDphenyl)isonicotinic acid. A solution of 231 mg of methyl 2-(2-(3- (methyl(2-mo holinoethyl)carbamoyl)benzamido)-5-(piperidin-l- yl)phenyl)isonicotinate in 9 mL of 2 : 1 dioxane / water was treated with 33 mg of lithium hydroxide hydrate. After stirring for 1 h the solvent was evaporated and the residue was partitioned between dichloromethane and 3 N hydrochloric acid. The aqueous phase was evaporated to give the product as 280 mg of a yellow solid.

Example 37c: ( S VN 1 -methyl-N 1 -( 2-morpholinoetfayl VN3-( 4-( piperidin- 1 - ylV 2-C4- (( 1 ,2,3 ,4-tetrahvdronaphthalen- 1 -yl carbamoyl pyridin-2-yl phenyl sophthalamide. A solution of 550 mg of 2-(2-(3-(methyl(2-mo holinoethyl)carbamoyl)benzamido)-5- (piperidin-l-yl)phenyl)isonicotinic acid, 142 mg of (S)- 1,2,3, 4-tetrahydronaphthalen-l- amine, and 497 mg of diisopropylethylamine in 6 mL of DMF was treated with 366 mg of HATU. After stirring for 2 h the product was isolated by reverse phase HPLC, eluting with 0.05% TFA in a water / acetonitrile gradient. The procedure gave 220 mg of product.

Example 37 : SV 1 -methyl-N 1 -(2-morpholinoethylVN3-(4-(piperidin- 1 -yl>2-(4- ( 1 ,2,3 ,4-tetrahvdronaphthalen- 1 -ylcarbamoyl pyridin-2-yl)phenyl)isophthalamide trihydrochloride. Into a 100-mL round-bottom flask, was placed a solution of (S)-Nl- methyl-Nl-(2-morpholinoethyl)-N3-(4-(piperidin-l-yl)-2-(4-(l ,2,3,4- tetrahydronaphthalen-l-yl-carbamoyl)pyridin-2-yl)phenyl)isop hthalamide (1.02 g, 1.46 mmol, 1.00 equiv) in methanol (30 mL). Hydrogen chloride gas was bubbled through the reaction mixture for 15 minutes. The resulting solution was stirred for 2 min at 5°C in a water/ice bath. The resulting mixture was concentrated under vacuum. The resulting mixture was washed with 2x20 mL of diethyl ether. This resulted in 1.12 g (93%) of (S)-Nl-methyl-Nl-(2-morpholinoethyl)-N3-(4-(piperidin-l-yl)- 2-(4-(l,2,3,4- tetrahydronaphthalen-l-yl-carbamoyl)pyridin-2-yl)phenyl)isop hthalamide

trihydrochloride as a yellow solid. Ή-NMR (300MHz, CD ₃ OD, ppm): δ 9.00(d, J=5.4Hz, 1H), 8.60~8.58(m, 2H), 8.51(s, 1H), 8.34(s, 1H), 8.20 ~7.91(m, 3H), 7.84(d, J=7.2Hz, 1H), 7.72~7.67(m, 1H), 7.25~7.16(m, 4H), 5.39~5.37(m, 1H), 4.14~3.88(m, 6H), 3.84~3.76(m, 6H), 3.56~3.55(m, 2H), 3.28~3.24(m, 2H), 3.12(s, 3H), 2.91~2.83(m, 2H), 2.14~1.86(m, 10H). MS (ES, m/z): 701 [M+H] ⁺ .

EXAMPLE 38 Tert-butyl 4-(2-(methyl(3-((4-(piperidin-l^

carbamoyl)pyridin-2-yl phenyl)carbanioyl)benzyl)amino)etliyl piperazine- 1 - carboxylate

Scheme 35. 1. SOCl ₂ ; 2. methylamine; 3. K ₂ C0 ₃ , KI, DMF, acetone, intermediate 38b.

Intermediate 38a: tert-butyl 4-(2-chloroethyl)piperazine-l -carboxylate. Into a 50-mL round-bottom flask, was placed a solution of tert-butyl 4-(2-hydroxyethyl)piperazine-l- carboxylate (2.31 g, 10.03 mmol, 1.00 equiv) in dichloromethane (20 mL) and a solution of thionyl chloride (1.5 mL, 2.00 equiv) in dichloromethane (3 mL) was added dropwise at 0°C. The resulting solution was stirred overnight at 25°C. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 10 mL of water. The resulting solution was extracted with 2x25 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 2x15 mL of sodium bicarbonate aq. and 2x10 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate/petroleum ether (1:5). This resulted in 1.16 g (46%) of tert-butyl 4-(2-chloroethyl)piperazine-l -carboxylate as a off-white solid. Intermediate 38b: tert-butyl 4-(2-(methylamino)ethyl )piperazine-l-carboxylate. Into a 50-mL sealed tube, was placed tert-butyl 4-(2-chloroethyl)piperazine-l-carboxylate (300 mg, 1.21 mmol, 1.00 equiv), methylamine (in ethanol) (10 mL), and Nal (100 mg). The resulting solution was stirred for 12 h at 70°C in an oil bath. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 3 mL of water and adjusted to pH 7-8 with sodium bicarbonate (5 %). The resulting solution was extracted with 2x5 mL of dichloromethane and the organic layers combined. The resulting mixture was washed with 1 3 mL of water and 1x3 mL of brine. The resulting mixture was concentrated under vacuum. This resulted in 180 mg (crude) of tert-butyl 4-(2-(methylamino)ethyl)piperazine-l-carboxylate as brown oil.

Example 38: tert-butyl 4-(2-( methvK 3 -( ( 4-( iperidin- 1 -vi)-2-f 4-( ( 3 -

(trifluoromethyl)benzyl)carbamoyl pyridin-2- yl)phenyl carbamoyl)benzyl amino ethyl -piperazine-l-carboxylate. Into a 50-mL round-bottom flask, was placed a solution of N-(3-(trifluoromethyl)benzyl)-2-(2-(3- (chloromethyl)benzamido)-5-(piperidin-l-yl)phenyl)-isonicoti namide (100 mg, 0.17 mmol, 1.00 equiv) in N,N-dimethylformamide (2.5 mL), acetone (2.5 mL), tert-butyl 4- (2-(methylamino)ethyl)piperazine-l-carboxylate (48 mg, 0.20 mmol, 1.20 equiv), potassium carbonate (68 mg, 0.49 mmol, 3.00 equiv), and potassium iodide (6 mg, 0.04 mmol, 0.20 equiv). The resulting solution was stirred for 2.5 h at 70°C in an oil bath. The resulting mixture was concentrated under vacuum. The crude product (100 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 75.5 mg (49%) of a yellow solid. 1H-NMR (300MHz, DMSO-<¾, ppm): δ 12.28 (s, IH) , 9.58-9.54 (m, IH), 8.94-8.92 (d, J=5.1Hz, IH), 8.33-8.27 (m, 2H), 8.04 (s, IH), 7.96-7.93 (d, J=7.8Hz, IH), 7.85-7.84 (d, J=4.2Hz, IH), 7.71-7.55 (m, 7H), 7.31-7.28 (d, J=8.1Hz, IH), 4.64-4.62 (d, J=5.7Hz, 2H), 4.29 (s, 2H), 3.44-3.31 (m, 8H), 3.20 (s, 2H), 3.06(s, 2H), 3.27-3.26 (m, 6H), 1.73 (s, 4H), 1.60 (s, 2H), 1.39 (s, 9H). MS (ES, m/z): 814 [M+H] ⁺ .

EXAMPLE 39 2-(2-(3 -f (Methyl(2-(4-methylpiperazin- 1 -yl)ethyl amino)methyl)benzarnido)-5 - (piperidin- 1 -vDphenyl VN-(3 -(trifluoromethyl benzyl isonicotinamide

Into a 25-mL round-bottom flask, was placed 160 mg of tert-butyl 4-(2-(methyl(3-((4- (piperidin- 1 -yl)-2-(4-((3 -(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)- carbamoyl)benzyl)amino)ethyl)piperazine-l-carboxylate Example 38 and 10 mL of 1 : 1 dichloromethane / TFA. After stirring for 2 hours, the solvent was evaporated. The residue was partitioned between ethyl acetate and aqueous sodium bicarbonate solution. The organic phase was dried and the solvent was evaporated. The residue was treated with triethylamine (78 mg, 0.77 mmol, 6.00 equiv), and dichloromethane (2 mL). This was followed by dropwise addition of a solution of methanesulfonyl chloride (21.9 mg, 0.19 mmol, 1.50 equiv) in dichloromethane (1 mL) with stirring at 0°C. The resulting solution was stirred for 4 h at 25°C. The resulting mixture was concentrated under vacuum. The crude product (200 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 45 mg

(28%) of a yellow solid. 1H-NMR (300MHz, DMSO-</ ₆ , ppm): δ 12.3 l(s, 1H), 9.55- 9.59(t, J=6.6Hz, 1H), 8.93-8.94(d, J=3Hz, 1H), 8.35(s, 1H), 8.27-8.30(d, J=9Hz, 1H), 8.09(s, 1H), 7.96-7.98(d, J=6Hz, 1H), 7.85-7.86(d, J=3Hz, 1H), 7.56-7.76(m, 7H), 7.31-7.34(d, J=9Hz, 1H), 4.62-4.64(d, J=6Hz, 2H), 4.39(s, 2H), 3.34(s, 4H), 3.22- 3.24(d, J=6Hz, 6H), 2.90(s, 5H), 2.74(s, 3H), 2.69(s, 4H), 1.75(s, 4H), 1.60-1.61(d, J=3Hz, 2H). MS (ES, m/z): 792 [M+H] ⁺ . EXAMPLE 40

2-i2-(3-((Methyl(2-(4-methylpiperazin-l-yl)ethyl¼mino)me thyl benzarnido)-5- (piperidin- 1 -yl)phenylVN-(3 -(trifluoromethvDbenzvDisonicotinaniide

Into a 25-mL round-bottom flask, was placed 190 mg of tert-butyl 4-(2-(methyl(3-((4- (piperidin-l-yl)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl) pyridin-2-yl)phenyl)- carbamoyl)benzyl)amino)ethyl)piperazine-l-carboxylate and 10 mL of 1 : 1 dichloromethane / TFA. After stirring for 2 hours, the solvent was evaporated. The residue was dissolved in 10 mL of aqueous sodium bicarbonate solution. The mixture was stirred for 20 minutes at room temperature. The resulting solution was extracted with 3x10 mL of ethyl acetate and the organic layers combined. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This resulted in 150 mg of N-(3 -(trifluoromethyl)benzyl)-2-(2-(3 -((methyl(2-(piperazin- 1 - yl)ethyl)amino)methyl)-benzamido)-5-(piperidin-l-yl)phenyl)i sonicotinamide.

Into a 50-mL round-bottom flask, was placed a solution of N-(3- (trifluoromethyl)benzyl)-2-(2-(3 -((methyl(2-(piperazin- 1 - yl)ethyl)amino)methyl)benzamido)-5-(piperidin-l-yl)-phenyl)i sonicotinamide (150 mg, 0.21 mmol, 1.00 equiv) in formaldehyde solution (5 mL), sodium cyanoborohydride (16 mg, 0.25 mmol, 1.20 equiv), and acetic acid (cat.). The resulting solution was stirred for 2 h at room temperature. The resulting solution was diluted with 2 mL of water. The resulting solution was extracted with 2x5 mL of ethyl acetate and the organic layers combined and dried over sodium sulfate and concentrated under vacuum. The crude product (150 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 21.3 mg (8%) of a yellow solid. 1H-NMR (300MHz, OMSO-d ₆ , ppm): δ 12.18 (s, 1H), 9.57 (s, 1H), 9.56-9.54 (d, /=6.0Hz, 1H), 8.93-8.91 (d, J=5.1Hz, 1H), 8.32 (s, 1H), 8.23-8.20 (d, J=9.0Hz, 1H), 8.08 (s, 1H), 7.98-7.96 (d, J=7.8Hz, 1H), 7.84-7.82 (m, 6H), 7.50 (s, 1H), 7.22 (s, 1H), 4.81-4.80(m, 1H), 4.68-4.60 (m, 3H), 4.44 (s, 3H), 3.41-3.38 (d, J=10.5Hz, 2H), 3.28- 3.20 (m, 6H), 2.98-2.94 (d, J=12Hz, 4H), 2.78-2.73 (m, 7H), 2.51-2.49 (m, 2H), 1.76 (s, 4H), 1.59-1.57 (d, J=4.5Hz, 2H). MS (ES, m/z):72S [M+H] ⁺ .

EXAMPLE 41

2-(2-(3 -(Y(2-(4- Acetylpiperazin- 1 -yl ethyl)(methyl¼mino)methyl benzamido)-5 - (piperidin- 1 -vf)phenyl)-N-benzylisonicotinamide

The free base of N-benzyl-2-(2-(3-((methyl(2-(piperazin-l- yl)ethyl)amino)methyl)benzamido)-5-(piperidin- 1 -yl)phenyl)isonicotinamide was prepared as described in the preparation of 2-(2-(3-((methyl(2-(4-methylpiperazin-l- yl)ethyl)amino)methyl)benzamido)-5-(piperidin-l-yl)phenyl)-N -(3-(trifluoromethyl)- benzyl)isonicotinamide 40. Into a 50-mL round-bottom flask, was placed a solution of this free base (150 mg, 0.21 mmol, 1.00 equiv) in tetrahydrofuran (5 mL), acetyl acetate (26 mg, 0.25 mmol, 1.20 equiv), and pyridine (33 mg, 0.42 mmol, 2.00 equiv). The resulting solution was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum. The crude product (200 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 44 mg (17%) of a yellow solid. ^-NMR (300MHz, DMSO-<¾, ppm): δ 12.25 (s, 1H), 9.56-9.52 (m, 1H), 8.93-8.91 (d, J=5.1Hz, 1H), 8.33-8.26 (m, 2H), 8.04 (s, 1H), 7.96-7.93 (d, J=7.8Hz, 1H), 7.85-7.83 (d, J=6.3Hz, 1H), 7.70-7.55 (m, 6H),

7.29- 7.26 (d, J=8.7Hz, 1H), 4.64-4.62 (d, J=5.7Hz, 2H), 4.29 (s, 2H), 3.54 (s, 4H),

3.30- 3.21 (m, 6H), 3.03(s, 2H), 2.80-2.73 (m, 3H), 2.66(s, 3H), 1.99 (s, 3H), 1.73 (s, 4H), 1.60-1.59 (d, J=4.8Hz, 1H). MS (ES, m/z): 756 [M+H] ⁺ .

EXAMPLE 42

2-(2-(3 -((N-Methyl-2-morpholinoacetamido methyl benzamido -5 -(piperidin- 1 - yl)phenyl)-N-(3-(trifluoromethyl benzyl)isonicotinamide

Scheme 36. 1. 3-(bromomethyl)benzoyl chloride, pyridine; 2 MeNH ₂ ; 3. EDC · HC1, DMAP, DCM, moφholinoacetic acid.

Intermediate 42a: 2-(2-(3-(bromomethyl)benzamido -5-(piperidin- 1 -vnphenylVN-CS- (trifluoromethvDbenzvDisonicotinamide. This compound was prepared from 3- (bromomethyl)benzoyl chloride and Intermediate 4.1c using the procedure described for the synthesis of 2-(2-(3-(chloromethyl)benzamido)-5-(piperidin-l-yl)phenyl)-N -(3- (trifluoromethyl)benzyl)isonicotinamide 8.1a.

Intermediate 42b: N-(3-(trifluoromethyl ^' )benzyD-2-(2-(3-((methylamino)methvn- benzamidoV 5-(piperidin- 1 -vDphenvDisonicotinamide. Into a 100-mL round-bottom flask, was placed a solution of methylamine in methanol (126 mg, 1.22 mmol, 4.00 equiv, 30%), potassium carbonate (124 mg, 0.90 mmol, 3.00 equiv), potassium iodide (10 mg, 0.06 mmol, 0.20 equiv), and a solution of N-(3-(trifluoromethyl)benzyl)-2-(2- (3-(bromomethyl)benzamido)-5-(piperidin-l-yl)phenyl)isonicot inamide (200 mg, 0.31 mmol, 1.00 equiv) in N,N-dimethylformamide (15 mL). The resulting solution was stirred for 3 h at 70°C in an oil bath. The resulting solution was diluted with 250 mL of water. The resulting solution was extracted with 4x20 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 2x50 mL of brine, dried over sodium sulfate, and concentrated under vacuum. This resulted in 200 mg (crude) of N-(3-(trifluoromethyl)benzyl)-2-(2-(3-((methylamino)methyl)b enzamido)-5- (piperidin- 1 -yl)phenyl)isonicotinamide as a yellow solid.

Example 42: 2-r2-(3-((N-methyl-2-morpholinoacetamido methyl)benzamido)-5- (piperidin- 1 -yl phenyl)-N-(3 -(trifluoromethyl benzyl)isonicotinamide. Into a 50-mL round-bottom flask, was placed a solution of 2-morpholinoacetic acid (25.0 mg, 0.17 mmol, 1.00 equiv) in dichloromethane (10 mL), EDC HC1 (50.0 mg, 0.26 mmol, 1.50 equiv), 4-dimethylaminopyridine (32.0 mg, 0.26 mmol, 1.50 equiv), and N-(3- (trifluoromethyl)benzyl)-2-(2-(3-((methylamino)methyl)benzam ido)-5-(piperidin-l- yl)phenyl)isonicotinamide (1000 mg, 1.66 mmol, 1.00 equiv). The resulting solution was stirred for 6 h at 25°C in an oil bath. The resulting solution was diluted with 50 mL of dichloromethane. The resulting mixture was washed with 2x30 mL of aqueous NH ₄ C1. The resulting mixture was washed with brine. The mixture was dried over sodium sulfate and concentrated under vacuum. The crude product (120 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 47.4 mg (26%) of a pale-yellow solid. 1H- NMR (300MHz, CD ₃ OD, ppm): δ 8.90-8.98(m, 1H), 8.57-8.64(m, 1H), 8.40(s, 1H), 7.84-8.00(m, 4H), 7.54-7.72(m, 7H), 4.72-4.76(m, 4H), 4.36-4.38(m, 2H), 3.96(m, 4H), 3.58-3.61(m, 4H), 3.01(s, 3H), 1.99-2.00(m, 4H), 1.75(m, 2H). MS (ES, m/z) 729 [M+H] ⁺ .

EXAMPLE 43

2-Methyl-l-(3-(( ^, 4-(piperidin-l-vn-2-(4-((3-(trifluoromethvnbenzv carbamoyl) pyridin-2-yl phenyl)carbamoyl)phenviy 5,8, 11 -trioxa-2-azatetradecan- 14-oic acid

Scheme 37. l. tert-butyl 5,8,1 l-trioxa-2-azatetradecan-14-oate, K ₂ C0 ₃ , KI, DMF; 2. CF ₃ COOH, DCM. Intermediate 43 a: tert-butyl 3-(2-(2-(2-((3-((2-(4-(f3-

(trifluoromemyl)berizyl)carbamoyl)-pyrid^

benzylXmethyl)amino)ethoxy)ethoxy)-ethoxy)propanoate. Into a 8-mL round-bottom flask, was placed a solution of tert-butyl 3-(2-(2-(2- (methylamino)ethoxy)ethoxy)ethoxy)propanoate (89.3 mg, 0.31 mmol, 1.00 equiv) in N,N-dimethylformamide (6 mL), potassium carbonate (84.7 mg, 0.61 mmol, 1.99 equiv), potassium iodide (10.2 mg, 0.06 mmol, 0.20 equiv), and N-(3- (trifluoromethyl)benzyl)-2-(2-(3-(bromomethyl)benzamido)-5-( piperidin-l- yl)phenyl)isonicotinamide (200 mg, 0.31 mmol, 1.00 equiv). The resulting solution was stirred overnight at 70°C. The solids were filtered out. The resulting mixture was concentrated under vacuum. The residue was dissolved in 20 mL of dichloromethane. The resulting mixture was washed with 2x20 mL of water. The resulting mixture was washed with 1x20 mL of brine, dried over sodium sulfate, and concentrated under vacuum. This resulted in 264 mg (crude) of product as yellow oil.

Example 43 : 2-methyl- 1 -(3-((4-(piperidin- 1 -yl -2-(4-((3 -(trifluoromethvDbenzyl - carbamoyl pyridin-2-yl)phenyl carbamoyl phenyl -5,8, 11 -trioxa-2-azatetradecan- 14- oic acid. Into a 50-mL round-bottom flask, was placed a solution of tert-butyl 3-(2-(2- (2-((3 -((2-(4-((3 -(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidi n- 1 - yl)phenyl)-carbamoyl)benzyl)(methyl)amino)ethoxy)ethoxy)etho xy)propanoate (264 mg, 0.31 mmol, 1.00 equiv) in dichloromethane (2 mL), and trifluoroacetic acid (1 mL). The resulting solution was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum. The crude product (200 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 46 mg (13%) of as a yellow solid. ¹ H-NMR (300MHz, CD ₃ OD, ppm): 5 8.941-8.924(d, J=5.1Hz, 1H), 8.665-8.635(d, J=9.0Hz, 1H), 8.436(s, 1H), 8.159- 8.081(m, 3H), 7.888-7.863(m, 1H), 7.792-7.563(m, 7H), 4.720(s, 2H), 4.533(s, 2H), 3.895-3.862(m, 6H), 3.685-3.560(m, 14H), 3.410(s, 2H), 2.910(s, 3H), 2.509-2.468(m, 2H), 2.020-2.004(s, 4H), 1.816-1.799(s, 2H). MS (ES, m/z): 806 [M+H] ⁺ . EXAMPLE 44 tert-Butyl 4-(3-((4-(piperidin-l-yl -2-(4-((3-rtrifiuoromethyl benzvn carbamoyl pyridin-2-yl phenyl)carbamoyl benzyl - 1 ,4-diazepane- 1 -carboxylate

Example 44: tert-butyl 4-( ^' 3-(( ^' 2-( ^' 4-((3-(trifluoromethyl benzvncarbamoyl ^' )pyridin-2- ylV4-(piperidin- 1 - yl phenyl carbamoyl)benzyl - 1 ,4-diazepane- 1 -carboxylate. Into a 100-mL round-bottom flask, was placed a solution of N-(3-(trifluoromethyl)benzyl)-2- (2-(3-(bromomethyl)benzamido)-5-(piperidin-l-yl)phenyl)isoni cotinamide (400 mg, 0.61 mmol, 1.00 equiv) in N,N-dimethylformamide (20 mL), potassium carbonate (248 mg, 1.79 mmol, 2.92 equiv), potassium iodide (20 mg, 0.12 mmol, 0.20 equiv), and tert- butyl 1,4-diazepane-l -carboxylate (240 mg, 1.20 mmol, 1.95 equiv). The resulting solution was stirred for 3 h at 70°C in an oil bath. The resulting solution was diluted with 300 mL of water. The resulting solution was extracted with 4x200 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 2x200 mL of brine. The mixture was dried over sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with dichloromethane:methanol (20:1-10:1). The product was obtained as 400 mg (85%) of a yellow solid. 1H-NMR (300MHz, CD ₃ OD, ppm): δ 8.875-8.887(d, J=3.6 Hz, 1H), 8.287-8.298(d, J=3.3 Hz, 1H), 8.253(s, 1H), 7.936(s, 1H), 7.772-7.936(m, 2H), 7.433- 7.71 l(m, 7H), 7.106-7.146(dd, J=2.7 Hz, J=9.0 Hz, 1H), 4.689(s, 2H), 3.740(s, 2H), 3.482(m, 4H), 3.197-3.232(m, 4H), 2.656-2.693(m, 4H), 1.720-1.847(m, 6H), 1.614- 1.649(m, 2H), 1.420-1.459(m, 9H). MS (ES, m/z): 771 [M+H] ⁺ ; 793 [M+Na] ⁺ .

EXAMPLE 45 2-(2-(3 -((4-Methyl- 1 ,4-diazepan- 1 -yl)methyl)benzamido -5-(piperidin- 1 - vDphenyl)-N- (3-(trifluoromethyl)benzyl)is,onicotinamide

Into a 50-mL round-bottom flask, was placed a solution of N-(3- (trifluoromethyl)benzyl)-2-(2-(3 -(bromomethyl)benzamido)-5 -(piperidin- 1 - yl)phenyl)isonicotinamide (100 mg, 0.15 mmol, 1.00 equiv) in N,N-dimethylformamide (2 mL), 1 -methyl- 1,4-diazepane (65.4 mg, 0.57 mmol, 3.74 equiv), KI (12.7 mg, 0.08 mmol, 0.50 equiv), and potassium carbonate (42.4 mg, 0.31 mmol, 2.00 equiv). The resulting solution was stirred for 3 h at 70°C in an oil bath. The reaction progress was monitored by LCMS. The resulting solution was diluted with 20 mL of water. The resulting solution was extracted with 3x20 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 3x20 mL of brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. The crude product was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 40 mg (23%) of a yellow solid. 1H-NMR

(400MHz, CD ₃ OD, ppm): δ 8.95-8.93(d, J=4.2Hz, 1H), 8.75-8.73(d, J=6.6Hz, 1H), 8.46(s, 1H), 8.18-8.17(d, J=4.2Hz, 1H), 8.09(s, 1H), 8.02-8.00(d, J=8Hz, 1H), 7.90- 7.88(m, 1H), 7.75-7.55(m, 1H), 4.72(s, 2H), 4.19(s, 2H), 3.70-3.67(t, J=5.6Hz, 4H), 3.55-3.49(m, 4H), 3.18-3.16(t, J=5.6Hz, 2H), 2.95(s, 3H), 2.22-2.18(m, 2H), 2.07- 2.05(t, J=5.2Hz, 4H), 1.84-1.83(d, J=5.2Hz, 1H). MS (ES, m/z): 685 [M+H] ⁺ .

EXAMPLE 46

2-(2-(3 -((4- Acetamidopiperidin- 1 - yl methyl benzamido -5 -(piperidin- 1 -yl phenyl -N- ^-(trifluoromethvDbenzvDisonicotinamide

Into a 50-mL round-bottom flask, was placed a solution of N-(3- (trifluoromethyl)benzyl)-2-(2-(3 -(bromomethyl)benzamido)-5 -(piperidin- 1 - yl)phenyl)isonicotinamide (100 mg, 0.15 mmol, 1.00 equiv) in N,N-dimethylformamide (2 mL), N-(piperidin-4-yl)acetamide (52.5 mg, 0.37 mmol, 2.41 equiv), potassium iodide (12.7 mg, 0.08 mmol, 0.50 equiv), and potassium carbonate (42.4 mg, 0.31 mmol, 2.00 equiv). The resulting solution was stirred for 3 h at 70°C in an oil bath. The reaction progress was monitored by LCMS. The resulting solution was diluted with 20 mL of water. The resulting solution was extracted with 3x20 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 3x20 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TF A. The product was obtained as 80.4 mg (50%) of a yellow solid. 1H-NMR (400MHz, CD ₃ OD, ppm) δ 8.93-8.92(d, J=5.2Hz, 1H), 8.67- 8.65(d, J=8.8Hz, 1H), 8.44(s, 1H), 8.13-8.09(m, 3H), 7.88-7.87(m, 1H), 7.78-7.67(m, 5H), 7.62-7.54(m, 1H), 4.72(s, 2H), 4.44(s, 2H), 3.91(s, 1H), 3.66-3.63(t, J=5.2Hz, 4H), 3.57-3.54(m, 2H), 3.20-3.14(m, 2H), 2.17-2.13(m, 2H), 2.05-2.00(m, 4H), 1.93(s, 3H), 1.82-1.70(m, 4H). MS (ES, m/z): 713 [M+H] ⁺ .

EXAMPLE 47

( ^, S -2-(2-(3- (3-Acetamidopyrrolidin-l -v0methyl)benzamidoy5-(piperidin- 1 - yllphenvD-N-iS-^rifluoromethvDbenzvnisonicotinamide

Into a 50-mL round-bottom flask, was placed a solution of N-(3- (trifluoromethyl)benzyl)-2-(2-(3-(bromomethyl)benzamido)-5-( piperidin-l- yl)phenyl)isonicotinamide (100 mg, 0.15 mmol, 1.00 equiv) in N,N-dimethylformamide (10 mL), potassium carbonate (62 mg, 0.45 mmol, 2.92 equiv), potassium iodide (5 mg, 0.03 mmol, 0.20 equiv), and (S)-N-(pyrrolidin-3-yl)acetamide (38.5 mg, 0.30 mmol, 1.96 equiv). The resulting solution was stirred for 3 h at 70°C in an oil bath. The resulting solution was diluted with 150 mL of water. The resulting solution was extracted with 4x100 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 2x200 mL of brine. The mixture was dried over sodium sulfate and concentrated under vacuum. The crude product (100 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 38.7 mg (24%) of a light yellow solid. 1H- NMR (300MHz, CD ₃ OO, ppm): δ 8.921-8.938(d, J=5.1 Hz, 1H), 8.623-8.653(d, J=9.0 Hz, 1H), 8.429(s, 1H), 8.070-8.138(m, 3H), 7.859-7.881(m, 1H), 7.536-7.799(m, 7H), 4.719(s, 2H), 4.526-4.593(m, 2H), 4.377-7.420(m, 1H), 3.612-3.648(t, J-5.4 Hz, 4H), 2.500(m, 1H), 2.007-2.022(m, 5H), 1.946(s, 3H), 1.803-1.818(m, 2H). MS (ES, m/z): 699 [M+H] ⁺ .

EXAMPLE 48

(SV2-(2-(3 -((3 - Acetamidopyrrolidin- 1 -yl methyl benzamidoy 5-(piperidin- 1 - yl)phenyl)-N-(3-(trifluoromethyl)benzyl isonicotinamide

[nto a 50-niL round-bottom flask, was placed a solution of N-(3- (trifluoromethyl)benzyl)-2-(2-(3-(bromomethyl)benzamido)-5-( piperidin-l- yl)phenyl)isonicotinamide (100 mg, 0.15 mmol, 1.00 equiv) in N,N-dimethylformamide (10 mL), potassium carbonate (62 mg, 0.45 mmol, 2.92 equiv), potassium iodide (5 mg, 0.03 mmol, 0.20 equiv), and (R)-N-(pyrrolidin-3-yl)acetamide (38.5 mg, 0.30 mmol, 1.96 equiv). The resulting solution was stirred for 3 h at 70°C in an oil bath. The resulting solution was diluted with 150 mL of water. The resulting solution was extracted with 4x100 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 2x200 mL of brine. The mixture was dried over sodium sulfate and concentrated under vacuum. The crude product (100 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 48 mg (30%) of a light yellow solid. 1H-

NMR (300MHz, CD ₃ OD, ppm): δ 8.925-8.942(d, J=5.1 Hz, IH), 8.642-8.672(d, J=9.0 Hz, IH), 8.435(s, IH), 8.075-8.141(m, 3H), 7.863-7.880(m, IH), 7.537-7.801(m, 7H), 4.720(s, 2H), 4.524-4.594(m, 2H), 4.374-4.418(m, IH), 3.628-3.663(m, 4H), 2.501(m, IH), 2.016-2.03 l(m, 5H), 1.947(m, 3H), 1.810-1.826(m, 2H). MS (ES, m/z): 699

[M+H] ⁺ .

EXAMPLE 49

2-(2-(3 -((4- Acetyl- 1 ,4-diazepan- 1 - yl methyl benzamido -5-(piperidin- 1 - yl phenyl -N- (3-(trifluoromethyl)benzyl)isonicotinamide

49

Scheme 38. 1. CF ₃ COOH, DCM; 2. (CH ₃ CO) ₂ 0, Py, THF.

Intermediate 49 : 2-(2-(3 -(( 1 ,4-diazepan- 1 -yl methvDbenzamido -5 -(piperidin- 1 -ylV phenvD-N-O-CtrifluoromethvDbenzvnisonicotinamide. Into a 50-mL round-bottom flask, was placed a solution of tert-butyl 4-(3-((2-(4-((3- (trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin - 1 - yl)phenyl)carbamoyl)benzyl)-l,4-diazepane-l-carboxylate (100 mg, 0.13 mmol, 1.00 equiv) in dichloromethane (15 mL), and trifluoroacetic acid (147.9 mg, 1.30 mmol, 10.00 equiv). The resulting solution was stirred for 3 h at 15°C. The resulting mixture was concentrated under vacuum to yield 130 mg of crude product as a red solid.

Example 49: 2-(2-(3-((4-acetyl- 1 ,4-diazepan- 1 -yl methyl benzamido)-5-(piperidin- 1 - yl)-phenyl -N-(3-(trifluoromethyl benzyl isonicotinamide. Into a 50-mL round-bottom flask, was placed a solution of PH-RDX-002-1161-1 (149 mg, 0.19 mmol, 1.00 equiv) in tetrahydrofuran (15 mL), pyridine (31 mg, 0.39 mmol, 2.00 equiv), and acetyl acetate (33 mg, 0.23 mmol, 1.20 equiv). The resulting solution was stirred for 3 h at room temperature. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 20 mL of water. The resulting solution was extracted with 2x20 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with brine. The mixture was dried over sodium sulfate and concentrated under vacuum. The crude product (160 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 92.2 mg

(46%) of a pale-yellow solid. 1H-NMR (300MHZ, CD ₃ OD, ppm): δ 8.907-8.924(d, J=5.1 Hz, 1H), 8.562-8.592(d, J=9.0 Hz, 1H), 8.402(s, 1H), 8.082-8.146(m, 2H), 7.986- 7.994(d, J=2.4 Hz, 1H), 7.854-7.877(m, 1H ), 7.662-7.79 l(m, 4H), 7.536-7.601(m, 3H), 4.717(s, 2H), 4.508-4.519(d, J=3.3 Hz, 2H), 3.656-3.698(t, J=6.3 Hz, 2H), 3.569- 3.604(t, J=5.3 Hz, 4H), 3.466-3.480(m, 2H), 2.249-2.265(m, 2H), 2.152(s, 3H), 1.993(m, 4H), 1.784-1.802(m, 2H). MS (ES, m/z) 713 [M+H] ⁺ ; 357 [(M+2H)/2] ⁺ .

EXAMPLE 50

2-(2-(3 -((4- Acetylpiperazin- 1 - vDmethyl)benzamido)-5 -(piperidin- 1 -vDphenyD-N-(3 - (trifluoromethyDbenzyl)isonicotinamide

Into a 50-mL round-bottom flask, was placed a solution of N-(3- (trifluoromethyl)benzyl)-2-(2-(3 -(bromomethyl)benzamido)-5 -(piperidin- 1 - yl)phenyl)isonicotinamide (100 mg, 0.15 mmol, 1.00 equiv) in N,N-dimethylformamide (2 mL), l-(piperazin-l-yl)ethanone (59 mg, 0.46 mmol, 3.00 equiv), potassium iodide (12.7 mg, 0.08 mmol, 0.50 equiv), and potassium carbonate (42.4 mg, 0.31 mmol, 2.00 equiv). The resulting solution was stirred for 3 h at 70°C in an oil bath. The reaction progress was monitored by LCMS. The resulting solution was diluted with 20 mL of water. The resulting solution was extracted with 3x20 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 3x20 mL of brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. The crude product was purified by reverse phase HPLC eluting with a water/C¾CN gradient containing 0.05% TFA. The product was obtained as 54.8 mg (34%) of a yellow solid. 1H-NMR (400MHz, CD ₃ OD, ppm): 8.94-8.92(d, J=4.2Hz, 1H), 8.66-8.64(d, J=6.6Hz, 1H), 8.43(s, 1H), 8.14-8.09(m, 3H), 7.88-7.87(m, 1H), 7.79-7.54(m, 7H), 4.72(s, 2H), 4.47(s, 2H), 3.82(s, 3H), 3.65-3.62(t, J=4.2Hz, 1H), 3.33-3.29(m, 5H), 2.15 (s, 3H), 2.04-2.01(t, J=5.2Hz, 4H), 1.82-1.81(d, J=5.2Hz, 1H). MS (ES, m/z): 699 [M+H] ⁺ .

EXAMPLE 51

2-(2-(3-(((3-((2-Methoxyethyl amino)-3-oxopropyl (methvnamino methyl ^' )benzamido - 5-(piperidin-l-yl phenylVN-(3-(trifluoromethyl ^' )benzyl)isonicotinamide

Scheme 39. 1. 2-methoxyethanamine; 2. Pd/C, MeOH; 3. Intermediate 42a, K ₂ C0 ₃ , KI

3-(benzyl(methyl amino -N-(2-methoxyethv propanamide. To methyl 3-

(benzyl(methyl)amino)propanoate (1.5 g, 7.24 mmol, 1.00 equiv) was added 2- methoxyethanamine (11 g, 146.45 mmol, 20.00 equiv) and the mixture was stirred for 2 days at 100°C in sealed tube. The resulting mixture was concentrated under vacuum and purified via silica gel chromatography (dichloromethane/methanol 30:1) to afford 1.1 g (61%) of the product as a yellow oil.

N-(2-methoxyethyl -3-(methylamino propanamide. To a solution of 3- (benzyl(methyl)amino)-N-(2-methoxyethyl)propanamide (1.1 g, 4.39 mmol, 1.00 equiv) in methanol (50 mL) was added 5% palladium-on-carbon (50 mg) and the suspension stirred under a hydrogen atmosphere for 2 h. The solids were filtered out and the mixture was concentrated under vacuum to afford 200 mg (28%) of the product as a white solid.

Example 51. 2-(2-(3-(((3-((2-methoxyethyl amino -3-oxopropyl)(methyl)amino - methyl)benzamido)-5 -(piperidin- 1 -vDphenyl)-N-(3 -(trifluoromethyl)benzyl)- isonicotinamide. Into a 8-mL round-bottom flask, was placed a solution of N-(3- (trifluoromethyl)benzyl)-2-(2-(3-(bromomethyl)benzamido)-5-( piperidin-l-yl)phenyl)- isonicotinamide 42a (250 mg, 0.31 mmol, 1.00 equiv, 80%) in N,N-dimethylformamide (6 mL), N-(2-methoxyethyl)-3-(methylamino)propanamide (185 mg, 1.04 mmol, 3.00 equiv, 90%), potassium carbonate (106 mg, 0.77 mmol, 2.00 equiv), and potassium iodide (32 mg, 0.19 mmol, 0.50 equiv). The resulting solution was stirred for 5 h at 60°C. The resulting solution was diluted with 100 mL of ethyl acetate. The resulting mixture was washed with 1x20 mL of 10% sodium bicarbonate. The resulting mixture was washed with 1x20 mL of brine, dried over sodium sulfate, and concentrated under vacuum. The crude product was purified by Flash-Prep-HPLC with watenmethanol (0.05% TFA) (10:90). The product was obtained as 63.7 mg (23%) of a yellow solid. Ή-ΝΜΡ (300MHz, CD ₃ OD, m): δ 8.87 (d, J=6Hz, 1H), 8.29 (m, 2H), 8.06 (m, 2H), 7.70 (m, 8H), 7.31 (d, J=9Hz, 1H), 4.70 (s, 2H), 4.50 (m, 2H), 3.43 (m, 2H), 3.39 (m, 6H), 2.89 (s, 3H), 2.76 (m, 2H), 1.86 (m, 4H), 1.73 (m, 2H). MS (ES, m/z): 731 [M+H] ⁺ .

EXAMPLE 52 tert-Butyl 4-q-(melhyl((6-((4-(piperidiii- 1 -yl)-2-(4-r(3- itrifluoromethyl benzvDcarbamoyl pyridin-2-yl)phenyl')carbarnoyl)pyridin-2- yl methyl)amino ethyl piperazine- 1 -carboxylate

Scheme 40. 1. 6-(chloromethyl)picolinic acid EDC HC1, DMAP, DCM, 25°C; 2. K ₂ C0 ₃ , KI, DMF, tert-butyl 4-(2-(methylamino)ethyl)piperazine-l -carboxylate, 65°C.

Intermediate 52a: N-(3 -(trifluoromethyl)benzyl)-2-( ^' 2-(2-(chloromethyl)picolinamido ^' )- 5 -(piperidin- 1 -vDphenvDisonicotinamide. Into a 50-mL 1-neck bottle, was placed a solution of N-(3-(trifluoromethyl)benzyl)-2-(2-amino-5-(piperidin-l - yl)phenyl)isonicotinamide (1.83 g, 4.03 mmol, 1.00 equiv) in dichloromethane (30 mL), 6-(chloromethyl)picolinic acid (1.04 g, 6.05 mmol, 1.50 equiv), EDC HC1 (1.54 g, 8.06 mmol, 2.00 equiv), and 4-dimethylaminopyridine (490 mg, 4.02 mmol, 1.00 equiv). The resulting solution was stirred for 4 h at 25 °C. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column and eluted with dichloromethane:methanol (100:1). The product was obtained as 2 g (82%) of a yellow solid. 1H-NMR (300MHz, DMSO-i¾, ppm): δ 13.01 (s, 1H), 9.54 (t, J=8.7Hz, 1H), 9.09 (d, J=5.1Hz, 1H), 8.51 (d, J=9.0Hz, 1H), 8.25 (s, 1H), 8.12-8.04 (m, 2H), 7.87-7.37 (m, 6H), 7.36 (s, 1H), 7.14 (dd, J=9.0Hz, 1H), 4.95 (s, 2H), 4.65 (t, J=4.8Hz, 2H), 3.34-3.20 (m, 4H), 1.67-1.55(m, 6H). MS (ES, m/z): 608 [M+H] ⁺ .

Example 52: N-(3-(trifluoromethyl benzyl)-2-(2-(2-(chloromethyl)picolinamido)-5- (piperidin- 1 -yl)phenyl)isonicotinamide. Into a 8-mL sealed tube, was placed a solution of 6-(chloromethyl)-N-(4-(piperidin- 1 -yl)-2-(4-(3 -

(trifluoromethyl)benzylcarbamoyl)pyridin-2-yl)phenyl)pico linamide (166 mg, 0.27 mmol, 1.00 equiv) in N,N-dimethylformamide (5 mL), tert-butyl 4-(2- (methylamino)ethyl)piperazine-l-carboxylate (100 mg, 0.41 mmol, 1.50 equiv), potassium carbonate (114 mg, 0.82 mmol, 3.00 equiv), and potassium iodide (9 mg, 0.05 mmol, 0.20 equiv). The resulting solution was stirred for 3 h at 65°C. The resulting solution was diluted with 10 mL of water. The resulting solution was extracted with 3x30 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 3x30 mL of brine. The mixture was dried over sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with dichloromethane:methanol (100:1-40:1). This resulted in 180 mg (81%) of tert-butyl 4- (2-(methyl((6-(4-(piperidin- 1 -yl)-2-(4-(3 -(trifluoromethyl)benzylcarbamoyl)pyridin-2- yl)-phenylcarbamoyl)pyridin-2-yl)methyl)amino)ethyl)piperazi ne-l -carboxylate as a yellow solid. 1H-NMR (400MHz, DMSO-i¾, ppm): δ 12.88 (s, 1H), 9.54 (t, J=6.0Hz, 1H), 9.04 (d, J=4.8Hz, 1H), 8.51 (d, J=9.2Hz,lH), 8.24 (s, 1H), 8.01 (d, J=4.0Hz, 2H), 7.88 (dd, J=4.8Hz, 1H), 7.56-7.72 (m, 5H), 7.34(d, J=3.6Hz, 1H), 7.14 (dd, J=9.2Hz, 1H), 4.64 (d, J=5.6Hz, 2H), 3.78 (s, 2H), 3.20-3.78 (m, 8H), 1.67-2.56 (m, 11H), 1.57- 1.66 (m, 6H), 1.35 (s, 9H). MS (ES, m/z): 815 [M+H].

EXAMPLE 53

6-(ΓN-Methyl-2-moφholinoacetamido methyl -N-(4-( ^' piperidin- 1 -yl V2-(4-((3 - (trifluoromethyl benzyl carbamoyl pyridin-2-yl')phenyl)picolinamide

Scheme 41. 1. CH ₃ NH ₂ , DCM; 2. EDC HC1, DMAP, DCM, morpholinoacetic acid.

Intermediate 53 a: N-(3 -(trifluoromethvnbenzyl)-2-(2-(2-( ^' (methylamino methylV picolinamido)-5-(piperidin-l-yl)phenyl ^' )isonicotinamide. Into a 10-mL vial, was placed a solution of N-(3-(trifluoromethyl)benzyl)-2-(2-(2-(chloromethyl)picolina mido)-5- (piperidin-l-yl)phenyl)isonicotinamide (150 mg, 0.25 mmol, 1.00 equiv) in dichloromethane (5 mL), methylamine (2 mL). The resulting solution was stirred for 48 h at 25°C in an oil bath. The reaction progress was monitored by LCMS. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate/petroleum ether (1 :10-1 :5). The product was obtained as 110 mg (74%) of a yellow solid.

Example 53: N-(3-rtrifluoromethyl benzvn-2-(2-(2-(( -methyl-2- morpholinoacetamido -methyl picolinamido -5-(piperidin-l-yl)phenyl isonicotinamide. Into a 50-mL vial, was placed N-(3-(trifluoromethyl)benzyl)-2-(2-(2- ((methylamino)methyl)picolinamido)-5-(piperidin-l -yl)phenyl)isonicotinamide (100 mg, 0.17 mmol, 1.00 equiv) in dichloromethane (10 mL), 2-morpholinoacetic acid (28.9 mg, 0.20 mmol, 1.20 equiv), EDC ^■ HC1 (47.4 mg, 0.25 mmol, 1.50 equiv), and 4- dimethylaminopyridine (30.4 mg, 0.25 mmol, 1.50 equiv). The resulting solution was stirred for 4 h at 25°C in an oil bath. The reaction progress was monitored by LCMS. The resulting solution was diluted with 50 mL of dichloromethane. The resulting mixture was washed with 3x50 mL of aqueous NH ₄ C1, dried over anhydrous sodium sulfate, and concentrated under vacuum. The crude product (200 mg) was purified by reverse phase HPLC eluting with a water/C¾CN gradient containing 0.05% TFA. The product was obtained as 116 mg (59%) of a yellow solid. ¹ H-NMR (400MHz, CD ₃ OD, ppm): 6 9.12(m, 1H), 8.86(d, J=9.2Hz, 1H), 8.34(d, J=2.0Hz, 1H), 8.17(m, 1H), 8.12(m, 1H), 8.01(m, 1H), 7.95(m, 1H), 7.80(m, 3H), 7.60(m, 3H), 4.96(m, 2H), 4.72(s, 2H), 4.50(m, 2H), 3.98(m, 4H), 3.70(m, 4H), 3.1(s, 3H), 2.10(m, 4H), 1.98(s, 2H). MS (ES, m/z): 730 [M+H] ⁺ .

EXAMPLE 54

2-Methyl- 1 -(6-((4-(piperidin- 1 -vP-2-(4-((3 -(trifluoromethvDbenzvDcarbamov pyridin- 2-yl phenyl)carbamoyl pyridin-2-yl)-5,8Jl-trioxa-2-azatetradecan-14-oic acid

Scheme 42. l. K ₂ C0 ₃ , KI, DMF, tert-butyl 5,8,1 l-trioxa-2-azatetradecan-14-oate; 2. CF ₃ COOH, DCM.

Intermediate 54a: tert-butyl 3-(2-(2-(2-(( ^, ( ^' 6-(( ^' 2-(4-((3-

(trifluoromethyl)benzyl)carbamoyl)-pyridin-2-ylV4-(piperi din- 1 - yl)phenvDcarbamoyl ^' )pyridin-2-yl ^' )methyl)(methyl amino)- ethoxy ethoxy ethoxy)propanoate. Into a 10-mL round-bottom flask, was placed a solution of N-(3-(trifluoromethyl)benzyl)-2-(2-(2-(chloromethyl)picolina mido)-5- (piperidin-l-yl)phenyl)isonicotinamide (200 mg, 0.33 mmol, 1.00 equiv) in N,N- dimethylformamide (10 mL), tert-butyl 3-(2-(2-(2-

(methylamino)ethoxy)ethoxy)ethoxy)propanoate (191.7 mg, 0.66 mmol, 2.00 equiv), potassium carbonate (90.9 mg, 0.66 mmol, 2.00 equiv), and potassium iodide (109.4 mg, 0.66 mmol, 2.00 equiv). The resulting solution was stirred overnight at 60°C in an oil bath. The resulting solution was diluted with 50 mL of water. The resulting solution was extracted with 2x50 mL of dichloromethane and the organic layers combined. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product was obtained as 300 mg of a yellow oil. Example 54 : 3-(2-( 2-(2-(( ( 6-((2-(4-( ( 3 -(trifluoromethvnbenzvncarbamovnpyridin-2- yl -4-(piperidin- 1 -v phenvncarbamoyl pyridin-2- vnmethyl (methyl)amino ethoxy ethoxy)-ethoxy)propanoic acid. Into a 50-mL vial, was placed a solution of tert-butyl 3-(2-(2-(2-(((6-((2-(4-((3- (trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin - 1 - yl)phenyl)carbamoyl)pyridin-2-yl)methyl)(methyl)amino)ethoxy )ethoxy)ethoxy)- propanoate (200 mg, 0.23 mmol, 1.00 equiv) in dichloromethane (10 mL), and 2,2,2- trifluoroacetic acid (2 mL). The resulting solution was stirred for 3 h at 25°C in an oil bath. The reaction progress was monitored by LCMS. The resulting mixture was concentrated under vacuum. The residue was dissolved in 50 mL of ethyl acetate. The resulting mixture was washed with 4x30 mL of brine, dried over sodium sulfate, and concentrated under vacuum. The crude product (200 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 84.9 mg (31%) of a yellow solid. 1H-NMR (300MHz, DMSO-i/ ₆ , ppm): δ

12.34(s, 1H), 9.89(s, 1H), 9.54(m, 1H), 9.02(m, 1H), 8.19(m, 4H), 7.84(m, 2H), 7.57(m, 5H), 7.29(s, 1H), 4.60(t, J=5.7Hz, 6H), 3.77(t, J=4.8Hz, 2H), 3.48(m, 16H), 2.84(s, 3H), 2.5 l(m, 2H), 1.9(s, 4H), 1.7(s, 2H). MS (ES, m/z): 807 [M+H] ⁺ .

EXAMPLE 55

(Ρ -6-Γ ( 3 - Acetamidopyrrolidin- 1 -ynmethylVN-f 4-(piperidin- 1 -vD-2-( 4-((3 - (trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)picoli namide

trifluoroacetate

Into a 50-mL round-bottom flask, was placed a solution of N-(3- (trifluoromethyl)benzyl)-2-(2-(2-(chloromethyl)picolinamido) -5 -(piperidin- 1 - yl)phenyl)isonicotinamide (100 mg, 0.15 mmol, 1.00 equiv, 90%) in N,N- dimethylformamide (3 mL), (R)-N-(pyrrolidin-3-yl)acetamide (42 mg, 0.33 mmol, 2.00 equiv), potassium carbonate (45 mg, 0.33 mmol, 2.00 equiv), and potassium iodide (14 mg, 0.08 mmol, 0.50 equiv). The resulting solution was stirred for 3 h at 60°C in an oil bath. The resulting solution was diluted with 100 mL of ethyl acetate. The resulting mixture was washed with 3x20 mL of brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. The crude product (100 mg) was purified by reverse phase HPLC eluting with a water/C¾CN gradient containing 0.05% TFA. The product was obtained as 33.4 mg (27%) of a yellow solid. 1H-NMR (300MHz, CD ₃ OD, ppm): δ 8.90 (d, J=6Hz, 1H), 8.40 (s, 1H), 8.26 (m, 1H), 8.21-8.09 (m, 2H), 7.98 (d, J=3Hz, 1H), 7.82 (d, J=6Hz, 1H), 7.71-7.50 (m, 6H), 4.65 (m, 4H), 4.20 (m, 1H), 3.85 (m, 1H), 3.66-3.63 (m, 4H), 2.50 (m, 1H), 2.00 (m, 4H), 1.80 (m, 3H), 1.68 (m, 3H). MS (ES, m/z): 700 [M+H] ⁺ .

EXAMPLE 56

( S -6-(( 3 - Acetamidopyrrolidin- 1 -yl methylVN-f 4-(piperidin- 1 -yl)-2-(4-( ( 3 - (trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl picolinamide

Into a 50-mL round-bottom flask, was placed a solution of N-(3- (trifluoromethyl)benzyl)-2-(2-(2-(chloromethyl)picolinamido) -5-(piperidin-l- yl)phenyl)isonicotinamide (100 mg, 0.15 mmol, 1.00 equiv, 90%) in N,N- dimethylformamide (3 mL), (S)-N-(pyrrolidin-3-yl)acetamide (42 mg, 0.33 mmol, 2.00 equiv), potassium carbonate (45 mg, 0.33 mmol, 2.00 equiv), and potassium iodide (14 mg, 0.08 mmol, 0.50 equiv). The resulting solution was stirred for 3 h at 60°C in an oil bath. The resulting solution was diluted with 100 mL of ethyl acetate. The resulting mixture was washed with 2x20 mL of brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. The crude product (100 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 47.8 mg (39%) of a yellow solid. 1H-NMR (300MHz , CD ₃ OD, ppm): δ 8.92 (d, J=6Hz, 1H), 8.42 (s, 1H), 8.19 (m, 1H), 8.15 (m, 1H), 8.10 (m, 1H), 8.04 (m, 1H), 7.83 (d, J=6Hz, 1H), 7.74 (m, 3H), 7.61 (m, 2H), 7.52 (m, 1H), 4.65 (m, 4H), 4.22 (m, 1H), 3.80 (m, 1H), 3.69-3.54 (m, 5H), 3.44 (m, 1H), 2.49 (m, 1H), 2.05-2.00 (m, 5H), 1.83-1.66 (m, 5H). MS (ES, m/z): 700 [M+H] ⁺ .

EXAMPLE 57

6-(Y4- Acetamidopiperidin- 1 -v0methviyN-(4-(piperidin- 1 -ylV2-(4-((3- (trifluoromethyl)benzyl carbamovf)pyridin-2-vf)phenyl picolinamide

Into a 50-mL round-bottom flask, was placed a solution of 6-(chloromethyl)-N-(4- (piperidin- 1 -yl)-2-(4-(3 -(trifluoromethyl)benzylcarbamoyl)pyridin-2- yl)phenyl)picolinamide (100 mg, 0.16 mmol, 1.00 equiv) in N,N-dimethylformamide (2 mL), N-(piperidin-4-yl)acetamide (35 mg, 0.25 mmol, 1.50 equiv), potassium carbonate (70 mg, 0.51 mmol, 3.00 equiv), and potassium iodide (6 mg, 0.04 mmol, 0.20 equiv). The resulting solution was stirred overnight at 60°C. The reaction progress was monitored by LCMS. The solids were filtered out. The mixture was concentrated under vacuum. The crude product (200 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 70.8 mg

(51%) of a yellow solid. Ή-NMR (300MHz, DMSO-d ₆ , ppm): δ 12.49 (s, 1H), 9.86 (m, 1H), 9.54 (m, 1H), 9.06 (m, 1H), 8.37-8.19 (d, J=9Hz, 1H), 8.24-8.19 (m, 3H), 7.97- 7.95 (d, J=6Hz, 1H), 7.86-7.83 (m, 2H), 7.70-7.49 (m, 5H), 7.26 (m, 1H), 4.64-4.51 (m, 4H), 3.82 (m, 1H), 3.54-3.24 (m, 8H), 1.95-1.58 (m, 13H). MS (ES, m/z): 714 [M+H] ⁺ .

EXAMPLE 58

6-(( 4- Acetylpiperazin- 1 -vf)methyl)-N-(4-( piperidin- 1 -vD-2-(4-((3 - (trifluoromethyl)benzyl carbamoyl)pyridin-2-yl)phenyl picolinamide

Into a 8-mL sealed tube, was placed a solution of 6-(chloromethyl)-N-(4-(piperidin-l- yl)-2-(4-(3 -(trifluoromethyl)benzylcarbamoyl)pyridin-2-yl)phenyl)picoli namide (120 mg, 0.20 mmol, 1.00 equiv) in Ν,Ν-dimethylformarnide (5 mL), l-(piperazin-l- yl)ethanone (37.9 mg, 0.30 mmol, 1.50 equiv), potassium carbonate (82 mg, 0.59 mmol, 3.00 equiv), and potassium iodide (7 mg, 0.04 mmol, 0.20 equiv). The resulting solution was stirred for 3 h at 65°C. The reaction was then quenched with 10 mL of water. The resulting solution was extracted with 3x30 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 3x30 mL of brine, dried over sodium sulfate, and concentrated under vacuum. The crude product (100 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 89.2 mg (56%) of a yellow solid. 1H-NMR (300MHz, DMSO-< ₆ , ppm): δ 12.56 (s, IH), 9.54 (t, J=6.0Hz, IH), 9.08 (d, J=5.1Hz, IH), 8.38 (d, J=8.7Hz, IH), 8.25-8.17 (m, 3H), 7.84 (d, J=3.9Hz, 2H), 7.71-7.58 (m, 5H), 7.51 (s, IH), 4.63 (d, J=5.7Hz, 2H), 4.49 (s, 2H), 3.31-3.21 (m, 10H), 2.01 (s, 3H), 1.72-1.59 (m, 6H). MS (ES, m/z): 700 [M+H] ⁺ .

EXAMPLE 59

6-( ( 4- Acetyl- 1.4-diazepan- 1 -vDmeth l VN-(4-(piperidin- 1 -ylV2-( 4-((3 - (trifluoromethyl benzyl carbamoyl pyridin-2-yl)phenyl ^' )picolinamide

Scheme 43. l . tert-butyl 1,4-diazepane-l-carboxylate, KI, K ₂ C0 ₃ ; 2 TFA, DMF; 3 TEA, AcCl.

Intermediate 59a: tert-butyl 4-((6-(( 4-( iperidin- 1 -vD-2-ί 4-C(3 -

(trifluoromethyl)benzyl -carbamoyl)pyridin-2-yl ^' )phenvDcarbamovnpyridin-2- yPmethyl)- 1 ,4-diazepane- 1 -carboxylate. This compound was prepared using the procedure described for the preparation of 6-((4-acetylpiperazin-l-yl)methyl)-N-(4- (piperidin- 1 -yl)-2-(4-((3 -(trifluoromethyl)benzyl)carbamoyl)pyridin-2- yl)phenyl)picolinamide 58, substituting tert-butyl 1,4-diazepane-l-carboxylate for - (piperazin- 1 -yl)ethanone.

Intermediate 59b: 6-((l,4-diazepan-l-yl ^' )methyl)-N-(4-(piperidin-l-yl)-2-(4-( ^' 3- (trifluoromethyl ^' )benzylcarbamoyl pyridin-2-yl phenyDpicolinamide. Into a 50-mL round-bottom flask, was placed a solution of tert-butyl 4-((6-(4-(piperidin-l-yl)-2-(4-(3- (trifluoromethyl)benzylcarbamoyl)pyridin-2-yl)phenylcarbamoy l)pyridin-2-yl)methyl)- 1,4-diazepane-l -carboxylate (150 mg, 0.18 mmol, 1.00 equiv, 95%) in dichloromethane (5 mL), and trifluoroacetic acid (1 mL). The resulting solution was stirred overnight at room temperature. The resulting solution was diluted with 50 mL of dichloromethane. The solution was adjusted to pH 9 with aqueous sodium bicarbonate. The resulting solution was extracted with 3x50 mL of dichloromethane and the organic layers combined, dried over anhydrous sodium sulfate, and concentrated under vacuum. The product was obtained as 120 mg (97%) of a yellow solid.

Example 59 : 6-(( 4-acetyl- 1 ,4-diazepan- 1 -yl)methyl -N-( 4-(piperidin- 1 -yl -2-(4-( 3 - (trifluoromethyl benzylcarbamoyl)pyridin-2-yl phenyl)picolinamide. Into a 50-mL round-bottom flask, was placed a solution of 6-((l,4-diazepan-l-yl)methyl)-N-(4- (piperidin-l-yl)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)py ridin-2- yl)phenyl)picolinamide (135 mg, 0.19 mmol, 1.00 equiv, 95%) in dichloromethane (5 mL), triethylamine (40 mg, 0.39 mmol, 2.00 equiv, 99%), and acetyl chloride (18 mg, 0.23 mmol, 1.20 equiv, 99%). The resulting solution was stirred for 3 h at room temperature. The resulting solution was diluted with 50 mL of dichloromethane. The resulting mixture was washed with 1x50 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The resulting mixture was washed with 2x10 mL of hexane. The product was obtained as 120 mg (87%) of a yellow solid. 1H-NMR (400MHz, OMSO-ck, ppm) δ 12.86 (s, 1H), 9.54-9.51 (t, 1H), 9.00 (s, 1H), 8.51-8.49 (d, J=6Hz, 1H), 8.23 (s, 1H), 8.00 (s, 2H), 7.88-7.86 (d, 1H), 7.72-7.55 (m 5H), 7.33 (s, 1H), 7.14-7.11 (d, J=9Hz, 1H), 4.63 (s, 2H), 3.91-3.88 (s, J=9Hz, 2H), 3.52-3.50 (m, 4H), 3.21-3.19 (m, 4H), 2.78-2.63 (m, 4H), 2.01-1.98 (d, J=9Hz, 3H), 1.79-1.55 (m, 8H). MS (ES, m/z) 714 [M+H] ⁺ .

EXAMPLE 60

6-(((2-(4- Acetylpiperazin- 1 -yl)ethylXmethvf)amino methylVN-(4-(piperidin- 1 -yl -2-(4- ((3-(trifluoromethyl)benzyl ^N )carbamovnpyridin-2-vnphenyl picolinamide .

The tert-butoxycarbonyl group of tert-butyl 4-(2-(methyl((6-((4-(piperidin-l-yl)-2-(4- ((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)ca rbamoyl)pyridin-2-yl)- methyl)amino)ethyl)piperazine-l-carboxylate 52 was cleaved by stirring for 1 hour in 1 : 1 dichloromethane / TFA and the resultant amine converted to the free base by partitioning between ethyl acetate and aqueous sodium bicarbonate solution. Into a 50- mL round-bottom flask, was placed a solution of this amine (110 mg, 0.15 mmol, 1.00 equiv) in dichloromethane (5 mL), and N,N-diisopropylethylamine (30 mg, 0.23 mmol, 1.50 equiv). This was followed by dropwise addition of a solution of acetyl chloride (14.4 mg, 0.18 mmol, 1.20 equiv) in dichloromethane (1 mL) with stirring at 0°C. The resulting solution was stirred for 3 h at room temperature. The resulting mixture was concentrated under vacuum. The crude product (200 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 90.3 mg (44%) of as a yellow solid. 1H-NMR (300MHz, DMSO-<¾, ppm): δ 12.77 (s, 1H), 9.56 (t, J=5.7Hz, 1H), 9.06 (d, J=5.1Hz, 1H), 8.49 (d, J=8.7Hz, 1H), 8.28 (s, 1H), 8.15-8.09 (m, 2H), 7.90-7.79 (m, 2H), 7.72-7.56 (m, 5H), 7.34 (s, 1H), 4.64 (d, J=5.7Hz, 2H), 4.20 (s, 2H), 3.56 (s, 4H), 3.34 (s, 4H), 3.18-2.95 (m, 7H), 2.56-2.49 (m, 4H), 1.96 (s, 3H), 1.74 (s, 4H), 1.60 (d, J=4.2Hz, 2H). MS (ES, m/z): 757 [M+H] ⁺ .

EXAMPLE 61

6-((Methyl(2-(4-methylpiperazin-l-yl ethyl amino methyl -N-(4-(piperidin-l-yl)-2-(4- ((3-(trifluoromethyl benzyl carbamoyl)pyridin-2-yl phenyl picolinamide

The tert-butoxycarbonyl group of tert-butyl 4-(2-(methyl((6-((4-(piperidin-l-yl)-2-(4- ((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)ca rbamoyl)pyridin-2- yl)methyl)amino)ethyl)piperazine-l-carboxylate 52 was cleaved by stirring for 1 hour in 1 : 1 dichloromethane / TFA and the resultant amine converted to the free base by partitioning between ethyl acetate and aqueous sodium bicarbonate solution. Into a 8- mL sealed tube, was placed a solution of 6-((methyl(2-(piperazin-l- yl)ethyl)amino)methyl)-N-(4-(piperidin- 1 -yl)-2-(4-(3 -

(trifluoromethyl)benzylcarbamoyl)pyridin-2-yl)phenyl)pico linamide (100 mg, 0.14 mmol, 1.00 equiv) in tetrahydrofuran (3 mL), NaBH(OAc) ₃ (90 mg, 0.42 mmol, 3.00 equiv), and formaldehyde (2 mL). The resulting solution was stirred for overnight at 40°C. The resulting mixture was concentrated under vacuum. The crude product (100 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 53.7 mg (27%) of as a yellow solid. 1H-NMR (300MHz, DMSO-i¾, ppm): δ 12.44 (s, IH), 9.82 (s, IH), 9.58 (t, J=5.4Hz, IH), 9.06 (d, J=5.1Hz, IH), 8.33 (d, J=9.0Hz, IH), 8.26 (s, IH), 8.21-8.15 (m, 2H), 7.90-7.84 (m, 2H), 7.71-7.55 (m, 4H), 7.47 (s, IH), 7.25 (d, J=8.1Hz, IH), 4.64- 4.58 (m, 4H), 3.36-3.29 (m, 8H), 2.97 (s, 4H), 2.86 (s, 3H), 2.76 (s, 5H), 2.33-2.27 (m, 2H), 1.71-1.58 (m, 6H). MS (ES, m/z): 729 [M+H] ⁺ .

EXAMPLE 62

6-((Methyl(2-(4-(methylsulfonyl piperazin-l-vnethyl amino methyl -N-(4-(piperidin- l-yl -2-(4-((3-(trifluoromethyl benzyl carbamoyl pyridin-2-yl phenyl picolinamide

The tert-butoxycarbonyl group of tert-butyl 4-(2-(methyl((6-((4-(piperidin-l-yl)-2-(4- ((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)ca rbamoyl)pyridin-2- yl)methyl)amino)ethyl)piperazine-l-carboxylate 52 was cleaved by stirring for 1 hour in 1 : 1 dichloromethane / TFA and the resultant amine converted to the free base by partitioning between ethyl acetate and aqueous sodium bicarbonate solution. Into a 50- mL round-bottom flask, was placed a solution of 6-((methyl(2-(piperazin-l- yl)ethyl)amino)methyl)-N-(4-(piperidin- 1 -yl)-2-(4-(3 -

(trifluoromethyl)benzylcarbamoyl)pyridin-2-yl)phenyl)-pic olinamide (110 mg, 0.15 mmol, 1.00 equiv) in dichloromethane (5 mL). To this was added triethylamine (23.3 mg, 0.23 mmol, 1.50 equiv). This was followed by dropwise addition of a solution of methanesulfonyl chloride (21.2 mg, 0.18 mmol, 1.20 equiv) in dichloromethane (2 mL) with stirring at 0°C. The resulting solution was stirred for 3 h at room temperature. The resulting mixture was concentrated under vacuum. The crude product (100 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 58.1 mg (28%) of a yellow solid. Ή-NMR (300MHz, OMSO-de, ppm): δ 12.62 (s, 1H), 9.56 (t, J=6.0Hz, 1H), 9.05 (d, J=5.4Hz, 1H), 8.42 (d, J=9.0Hz, 1H), 8.27 (s, 1H), 8.16 (dd, J=4.8Hz, 2H), 7.88-7.81 (m, 2H), 7.71 (s, 1H), 7.67-7.54 (m, 4H), 7.30 (d, J=7.8Hz, 1H), 4.63 (d, J=5.7Hz, 2H), 4.35 (s, 2H), 3.32 (s, 4H), 3.18 (s, 6H), 2.99 (s, 2H), 2.88-2.84 (m,7H), 2.68 (s, 3H), 1.73-1.59 (m, 6H). MS (ES, m/z) 793 [M+H] ⁺ .

EXAMPLE 63

N-r2-Methoxyethvn-4-(2-(methyl((6-((4-(piperidin-l-ylV2-( 4-((3- (trifluoromethyl)benzvncarbamoyl pyridin-2-yl)phenyl)carbamoyl pyridin-2- y Qmethyl amino ethyl piperazine- 1 -carboxamide

Scheme 44. l . TFA, then 4-nitrophenyl chloroformate; 2. DIE A, DMF, methoxyethylamine.

Intermediate 63 a: 4-nitrophenyl 4-(2-(methyl((6-(4-(piperidin-l-yl)-2-(4-(3-

(trifluoromethyDbenzylc-U-bamo

amino thvDpiperazine- 1 -carboxylate. The tert-butoxycarbonyl group of tert-butyl 4-(2- (methyl((6-((4-(piperidin- 1 -yl)-2-(4-((3 -(trifluoromethyl)benzyl)carbamoyl)pyridin-2- yl)-phenyl)carbamoyl)pyridin-2-yl)methyl)amino)ethyl)piperaz ine- 1 -carboxylate 52 was cleaved by stirring for 1 hour in 1 : 1 dichloromethane / TFA and the resultant amine converted to the free base by partitioning between ethyl acetate and aqueous sodium bicarbonate solution. Into a 50-mL round-bottom flask, was placed a solution of 6-((methyl(2-(piperazin- 1 -yl)ethyl)amino)methyl)-N-(4-(piperidin- 1 -yl)-2-(4-(3 - (trifluoromethyl)benzylcarbamoyl)pyridin-2-yl)phenyl)picolin amide (100 mg, 0.14 mmol, 1.00 equiv) in dichloromethane (2 mL), and 4-nitrophenyl chloroformate (28 mg, 0.14 mmol, 1.00 equiv). The resulting solution was stirred for 2 h at room temperature. The mixture was concentrated under vacuum. The crude product was obtained as 0.1 g of a yellow solid. Example 63: N-(2-methoxyethyl -4-( ^' 2-(methyl((6-(4-( ^, piperidin-l-vn-2-(4-( ^, 3- (trifluoromethvnbenzylcarbamoyl ^' )pyridin-2-yl)phenylcarbamovnpyridin-2- yl)methyl)amino)ethyl)piperazine- 1 -carboxamide. Into a 50-mL round-bottom flask, was placed a solution of 4-nitrophenyl 4-(2-(methyl((6-(4-(piperidin-l-yl)-2-(4-(3- (trifluoromethyl)benzylcarbamoyl)pyridin-2-yl)phenylcarbamoy l)pyridin-2-yl)methyl)- amino)ethyl)piperazine-l-carboxylate (100 mg, 0.11 mmol, 1.00 equiv) in N,N- dimethylformamide (5 raL), 2-methoxyethanamine (10 mg, 0.13 mmol, 1.00 equiv), and N,N-diisopropylethylamine (45 mg, 0.35 mmol, 3.00 equiv). The resulting solution was stirred overnight at room temperature. The mixture was concentrated under vacuum. The crude product (0.1 g) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TF A. The product was obtained as 23.2 mg (18%) of a yellow solid. 1H-NMR (300MHz, DMSO-c¾, ppm): δ 12.76 (s, 1H), 9.54- 9.52 (m, 1H), 9.05-9.03 (m, 1H), 8.48-8.45 (m, 1H), 8.26 (m, 1H), 8.14-8.12 (m, 2H), 7.88-7.86 (m, 1H), 7.79-7.24 (m, 7H), 6.71 (m, 1H), 4.65-4.63 (d, J=5.7Hz, 2H), 4.09 (m, 3H), 3.69-3.01 (m, 23H), 1.71-1.59 (m, 6H). MS (ES, m/z): 816 [M+H] ⁺ .

EXAMPLE 64

Nl-(2-r2-Hvdroxyethoxykthvn-N3-(4-(piperidin-l-vn-2-(6-r( 3-

(trifluoromethyl)benzyl)amino)pyrimidin-4-yl phenyl ^' )isophthalamide

Scheme 45. 1. HATU, diisopropylethylamine; 2. LiOH; 3. EDC HC1 /HOBT/TEA, DMF, intermediate 3.1d.

Intermediate 64a: methyl 3-((2-(2-hvdroxyethoxy)ethyl carbamoyl benzoate. Into a 1000-mL round bottom flask, was placed a solution of 3-(methoxycarbonyl)benzoic acid (20 g, 111.11 mmol, 1.00 equiv) in N,N-dimethylformamide (500 mL), HATU (63.2 g, 166.32 mmol, 1.50 equiv), N,N-diisopropylethylamine (21.5 g, 166.67 mmol, 1.50 equiv), 2-(2-aminoethoxy)ethanol (23.3 g, 221.90 mmol, 2.00 equiv). The resulting solution was stirred for overnight at 25°C. The resulting mixture was concentrated under vacuum. The resulting solution was dissolved in 200 mL of ethyl acetate. The resulting mixture was washed with 10x200 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with dichloromethane methanol (100:1). This resulted in 15 g (51%) of methyl 3-((2-(2-hydroxyethoxy)ethyl)carbamoyl)benzoate as red oil.

Intermediate 64b: 3-((2-(2-hvdroxyethoxy ethyl)carbamoyl benzoic acid. Into a 500- mL round bottom flask, was placed a solution of methyl 3-((2-(2- hydroxyethoxy)ethyl)carbamoyl)benzoate (10 g, 37.45 mmol, 1.00 equiv) in tetrahydrofuran (40 mL), and a solution of lithium hydroxide hydrate (23.4 g, 558.33 mmol, 15.00 equiv) in water(30 mL). The resulting solution was stirred for overnight at room temperature. The resulting mixture was concentrated under vacuum. The solution was adjusted to pH 3-4 with hydrochloric acid (2 mol/L). The resulting solution was extracted with 3x10 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with.2x10 mL of brine, dried over anhydrous sodium sulfat,e and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with dichloromethane:methanol (50:1). This resulted in 5 g (53%) of 3-((2-(2- hydroxyethoxy)ethyl)carbamoyl)benzoic acid as a yellowish solid. 1H-NMR (300MHz DMSO-i ₆ , ppm): δ 13.25(s, IH), 8.71(m, IH), 8.48(d, J=8.5Hz IH), 8.06(m, 2H), 7.62(m, IH), 4.59(s, IH), 3.41-3.60 (m, 8H). MS (ES, m/z): 254 [M+H] ⁺ .

Example 64 : N 1 -( 2-(2-hvdroxyethoxy)ethyl>N3 -(4-( piperidin- 1 -y\)-2-(6-( (3- (trifluoromethyl)benzyl amino pyrimidin-4-yl)phenyl)isophthalamide. Into a 100-mL round bottom flask, was placed a solution of 6-(2-amino-5-(piperidin-l-yl)phenyl)-N- (3-(trifluoromethyl)benzyl)pyrimidin-4-amine (300 mg, 0.70 mmol, 1.00 equiv) in N,N- dimethylformamide (6 mL). This was followed by the addition of 3-(2-(2- hydroxyethoxy)ethylcarbamoyl)benzoic acid (302.2 mg, 1.19 mmol, 1.70 equiv) at room temperature. To this was added triethylamine (156 mg, 1.54 mmol, 2.20 equiv). To the mixture was added EDC ^' HC1 (148.2 mg, 0.78 mmol, 1.10 equiv) at room temperature, followed by HOBT (104.4 mg, 0.77 mmol, 1.10 equiv) at room temperature. The resulting solution was stirred overnight at room temperature. The resulting mixture was concentrated under vacuum. The crude product was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 83.6 mg (15%) of a yellow solid. 1H-NMR (300MHz, CD ₃ OD, ppm): δ 8.76(s, IH), 8.40(s, IH), 8.039(t, J=8.1Hz, 2H), 7.74(s, IH), 7.63~7.57(m, 3H), 7.53~7.50(m, 2H), 7.47~7.40(m, 2H), 6.93(s, IH), 4.81(s, 2H), 3.71~3.58(m, 8H), 3.43~3.39(m, 4H), 1.84~1.81(m, 6H). MS (ES, m/z) 663 [M+H] ⁺ .

EXAMPLE 65

Nl-(4-Chloro-2-(6-((3-(trifluoromethyl)benzyl amino)pyrimidin-4-yl)phenyl)-N3-(2-

(2-hydroxyethoxy thyl)isophthalamide

Scheme 46. 1. Pd(PhP ₃ ) ₂ Cl ₂ , AsPh ₃ , K ₃ P0 ₄ , dioxane/HCl; 2. 3-(trifluromethyl)- benzylamine; 3. monomethyl isophthalate, EDC, DMAP/DCM; 4. LiOH, THF, H ₂ 0; 5. HATU/DIPEA, DMF, 2-(2-aminoethoxy)ethanol.

Intermediate 65a: 4-chloro-2-(6-chloropyrimidin-4-yl)aniline. Into a 250-mL round bottom flask, was placed a solution of 4-chloro-2-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)benzenamine (3 g, 11.83 mmol, 1.00 equiv) in dioxane (120 mL), water(20 mL), 4,6-dichloropyrimidine (4.4 g, 29.53 mmol, 2.50 equiv), triphenylarsine (360 mg, 1.18 mmol, 0.10 equiv), K ₃ P0 ₄ (3.8 g, 17.90 mmol, 1.50 equiv), Pd(PPh ₃ ) ₂ Cl ₂ (390 mg, 0.56 mmol, 0.05 equiv). The resulting solution was stirred for 3 h at 75°C in an oil bath. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:50-1:10). This resulted in 1.5 g (53%) of 4-chloro-2-(6-chloropyrimidin-4-yl)benzenamine as a yellow solid.

Intermediate 65b: 6-( ^' 2-amino-5-chlorophenyl -N-(3-

(trifluoromethyl)benzyl pyrimidin-4-amine. Into a 50-mL round bottom flask, was placed a solution of 4-chloro-2-(6-chloropyrimidin-4-yl)benzenamine (1.5 g, 6.25 mmol, 1.00 equiv) in N,N-dimethylformamide (30 mL), potassium carbonate (2.7 g, 19.54 mmol, 3.00 equiv), 3-(trifluoromethyl)benzylamine (1.7 g, 9.70 mmol, 1.50 equiv). The resulting solution was stirred overnight at 80°C in an oil bath. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 20 mL of ethyl acetate. The resulting mixture was washed with 2x20 mL of water. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:2). This resulted in 1 g (42%) of N-(3-(trifluoromethyl)benzyl)-6-(2-amino-5- chlorophenyl)pyrimidin-4-amine as yellow oil

Intermediate 65c: methyl 3-((2-(6-( ^' 3-(trifluoromethyl)benzylamino)pyrimidin-4-yl -4- chlorophenvDcarbamovDbenzoate. Into a 100-mL round bottom flask, was placed a solution of N-(3-(trifluoromethyl)benzyl)-6-(2-amino-5-chlorophenyl)pyri midin-4- amine (500 mg, 1.32 mmol, 1.00 equiv) in dichloromethane (30 mL), EDC HC1 (380 mg, 1.98 mmol, 1.50 equiv), N,N-dimethylpyridin-4-amine (242 mg, 1.98 mmol, 1.50 equiv), and 3-(methoxycarbonyl)benzoic acid (357 mg, 1.98 mmol, 1.50 equiv). The resulting solution was stirred for 2 h at 30°C in an oil bath. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column and eluted with petroleum ether/ethyl acetate (2:1). The product was obtained as 400 mg (56%) of a yellow solid.

Intermediate 65d: 3-(( ^' 2-(6-(3-(trifluoromethyl ^' )benzylamino)pyrimidin-4-yl -4- chlorophenvDcarbamovDbenzoic acid. Into a 100-mL round bottom flask, was placed a solution of methyl 3-((2-(6-(3-(trifluoromethyl)benzylamino)pyrimidin-4-yl)-4- chlorophenyl)carbamoyl)benzoate (400 mg, 0.74 mmol, 1.00 equiv) in tetrahydrofuran (30 mL), water(30 mL), and lithium hydroxide hydrate (317 mg, 7.55 mmol, 10.00 equiv). The resulting solution was stirred for 4 h at 30°C in an oil bath. The solution was adjusted to pH 1 with hydrochloric acid (1 mol/L). The resulting solution was extracted with 20 mL of ethyl acetate and the organic layers combined, dried over anhydrous sodium sulfate, and concentrated under vacuum. The product was obtained as 350 mg (90%) of a white solid.

Example 65 : N 1 -(2-(6-(3 -(trifluoromethvnbenzylamino)pyrimidin-4-yl)-4- chlorophenyl -N3-(2-( ^' 2-hydroxyethoxy)ethvnisophthalamide. Into a 50-mL round bottom flask, was placed a solution of N-(3-(trifluoromethyl)benzyl)-6-(2-amino-5- chlorophenyl)pyrimidin-4-amine (200 mg, 0.53 mmol, 1.00 equiv) in N,N- dimethylformamide (20 mL), HATU (290 mg, 0.76 mmol, 2.00 equiv), N,N- diisopropylethylamine (200 mg, 1.55 mmol, 4.00 equiv), and Nl-(2-(6-(3- (trifluoromethyl)benzylamino)pyrimidin-4-yl)-4-chlorophenyl) -N3-(2-(2- hydroxyethoxy)ethyl)isophthalamide (60 mg, 0.10 mmol, 1.50 equiv). The resulting solution was stirred overnight at 30°C in an oil bath. The reaction progress was monitored by LCMS. The resulting mixture was concentrated under vacuum. The crude product was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 105.9 mg (33%) of a yellow solid. 1H-NMR (300MHz, DMSO- ₆ , ppm): δ 8.87(s, 1H), 8.71(t, J=4.8Hz, 9.9Hz, 1H), 8.49(s, 1H), 8.07(t, J=7.5Hz,15.3Hz, 2H), 7.83(s, 1H), 7.58(m, 6H), 7.07(s, 1H), 4.75(s, 2H), 3.57(m, 2H), 3.49(m, 6H). MS (ES, m/z): 614 [M+H] ⁺ .

EXAMPLE 66

3 -((3 -((4-Chloro-2-(6-((3 -(trifluoromethyl benzyl amino pyrimidin-4- yl phenyl)carbamoyl benzyl)thio)propanoic acid

This compound was prepared from 6-(2-amino-5-chlorophenyl)-N-(3- (trifluoromethyl)benzyl)pyrimidin-4-amine 65b using the procedure described for the preparation of 3 -((3 -((4-(piperidin- 1 -yl)-2-(6-((3 -methylbenzyl)amino)pyrimidin-4- yl)phenyl)carbamoyl)benzyl)thio)propanoic acid 3.2 from 6-(2-amino-5-(piperidin-l- yl)phenyl)-N-(3-methylbenzyl) pyrimidin-4-amine 3.2b. 1H-NMR (400MHz, DMSO- d ₆ , ppm): δ 8.79(s, 1H), 8.48(s, 1H), 7.91(s, 1H), 7.81(d, J=5.7Hz, 2H), 7.63(s, 1H), 7.56(m, 6H), 7.09(s, 1H), 4.74(s, 2H), 3.88(s, 2H), 2.57(d, J=4.8Hz, 2H). MS (ES, m/z): 601 [M+H] ⁺ .

EXAMPLE 67

N-(4-Chloro-2-(6-(3-( ^, trifluoromethyl)benzylamino)pyrimidin-4-yl ^s )phenyl)-3-(4- (dimethylamino)but- 1 - ynyHbenzamide 2,2,2-trifluoroacetate

Scheme 47. 1. homopropargyl alcohol, Pd(Ph ₃ P ₎₂ Cl ₂ , Cul, Et ₃ N; 2. methanesulfonic anhydride, Et N; 3. dimethylamine; 4. intermediate 67c, EDC HC1, DMAP, DCM.

Intermediate 67a: 3-(4-hydroxybut-l-yn-l-yl benzoic acid. Into a 500-mL round bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of 3-bromobenzoic acid (10 g, 49.75 mmol, 1.00 equiv) in triethylamine/ N,N- dimethylformamide (100/20 mL), but-3-yn-l-ol (6.98 g, 99.57 mmol, 2.00 equiv), copper(I) iodide (1.90 g, 9.97 mmol, 0.20 equiv), Pd(PPh ₃ ) ₂ Cl ₂ (6.98 g, 9.94 mmol, 0.20 equiv). The resulting solution was stirred overnight at 80°C. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 100 mL of water. The pH value of the solution was adjusted to 11-12 with sodium hydroxide (1 mol/L). The resulting solution was extracted with 3x300 mL of dichloromethane and the aqueous layers combined. The solution was adjusted to pH 1-2 with hydrochloric acid (1 mol/L). The resulting solution was extracted with 5x300 mL of dichloromethane and the organic layers combined, dried over sodium sulfate, and concentrated under vacuum. This resulted in 10 g crude product as brown oil.

Intermediate 67b: 3-(4-((methylsulfonyl oxy)but-l-yn-l-yl benzoic acid. Into a 250- mL round bottom flask, was placed a solution of 3-(4-hydroxybut-l-ynyl)benzoic acid (2 g, 10.52 mmol, 1.00 equiv) in dichloromethane (100 mL), triethylamine (3200 mg, 31.68 mmol, 3.00 equiv), and methanesulfonic anhydride (3700 mg, 21.24 mmol, 2.00 equiv). The resulting solution was stirred for 5 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column and eluted with dichloromethane/methanol (100:1). This resulted in 3 g crude product as a brown oil.

Example 67c: 3-(4-(dimethylamino but-l-vn-l-yl benzoic acid trifluoroacetic acid salt. Into a 250-mL round bottom flask, was placed a solution of 3-(4- (methylsulfonyloxy)but-l-ynyl)benzoic acid (8.23 g, 30.67 mmol, 1.00 equiv) in ethanol (50 mL), dimethylamine 33% water solution (50 mL). The resulting solution was stirred overnight at 30°C in an oil bath. The resulting mixture was concentrated under vacuum. The crude product (10 g) was purified by reverse phase HPLC eluting with a water/C¾CN gradient containing 0.05% TFA. 3-(4-(dimethylamino)but-l- ynyl)benzoic acid trifluoroacetic acid salt was obtained as 2.68 g (40%) of as yellow oil

Example 67 : N-(4-chloro-2-(6-(3 -(trifluoromethyDbenzylamino)pyrimidin-4- yl phenyl)-3-(4-(dimethylamino)but-l-vnyl)benzamide 2,2,2-trifluoroacetate. Into a 50- mL round bottom flask, was placed a solution of 6-(2-amino-5-chlorophenyl)-N-(3- (trifluoromethyl)benzyl)pyrimidin-4-amine 57b (100 mg, 0.26 mmol, 1.00 equiv) in dichloromethane (2 mL), 3-(4-(dimethylamino)but-l-ynyl)benzoic acid (57 mg, 0.26 mmol, 1.00 equiv), EDC ^■ HC1 (76 mg, 0.40 mmol, 1.50 equiv), and 4- dimethylaminopyridine (48 mg, 0.39 mmol, 1.50 equiv). The resulting solution was stirred overnight at 25°C. The crude product (100 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 7.4 mg (4%) of a light yellow solid. ¹ H-NMR (300MHz, OMSO-d ₆ , ppm): δ 8.666(s, 1H), 8.5385(d, J=2.9Hz, 1H), 8.430(s, 1H), 8.1125(d, J=6.9Hz, 1H), 8.008(s, 1H), 7.866(s, 1H), 7.819(m, 2H), 7.769(m, 1H), 7.623(m, 4H), 7.120(s, 1H), 6.491(s, 1H), 4.7285(d, J=5.7Hz, 2H), 4.090(t, J=6.9Hz, 2H), 3.169(m, 6H), 2.930(m, 2H). MS (ES, m/z): 578 [M +H] ⁺ .

EXAMPLE 68 N-(4-Chloro-2-(6-((3-(trifluoromethyl)benzyl amino pyrimidin-4-yl)phenyl)-3-(((2- (diethylamino^ethvnimethvnamino ^' jmethvDbenzamide

65b 68

Scheme 48. 1. N,N-diethyl-N'-methylethylenediamine; 2. HATU, DIPEA, DMF, intermediate 68a.

Intermediate 68a: 3-(((2-(diethylamino)ethylXmethyl amino methyl ^' )benzoic acid. Into a 1000-mL round bottom flask, was placed a solution of ΝΙ,ΝΙ -diethyl -N2- methylethane-l,2-diamine (9.1 g, 63.00 mmol, 1.50 equiv, 90%) in N,N- dimethylformamide (500 mL), 3-(bromomethyl)benzoic acid (10 g, 46.51 mmol, 1.00 equiv), potassium carbonate (7.8 g, 56.12 mmol, 1.20 equiv), and potassium iodide (1.55 g, 9.34 mmol, 0.20 equiv). The resulting solution was stirred for 2 h at 90°C in an oil bath. The solids were filtered out. The resulting mixture was concentrated under vacuum. The crude product (10 g) was purified by reverse phase HPLC eluting with 0.05% TFA in a water/CH ₃ CN gradient. The product was obtained as 6 g (46%) of a white solid. 1H-NMR (300MHz, CDC1 ₃ , ppm): δ 8.01(m, 1H), 7.89-7.87(m, 1H), 7.28- 7.22(m, 2H), 3.99(s, 2H), 2.97-2.72(m, 8H), 2.28(s, 3H), 1.13-1.01(m, 6H). MS (ES, m/z): 265 [M+H] ⁺ . Example 68: N-f4-chloro-2-(6-((3-(trifluorornethyl)benzyl¼mino)pyrirnid in-4- yl)phenvn-3-(((2-(diethylamino ethvD( ^' metliyl ^' )amino ^' )methyl ^' )benzamide. Into a 50-mL round bottom flask, was placed a solution of 6-(2-amino-5-chlorophenyl)-N-(3- (trifluoromethyl)benzyl)pyrimidin-4-amine 65b (200 mg, 0.53 mmol, 1.00 equiv) in N,N-dimethylformamide (5 mL), 3 -(((2-

(diethylamino)ethyl)(methyl)amino)methyl)benzoic acid (130 mg, 0.49 mmol, 1.00 equiv), HATU (300 mg, 0.79 mmol, 1.50 equiv), and N,N-diisopropylethylamine (270 mg, 2.09 mmol, 5.00 equiv). The resulting solution was stirred for 2 days at 25°C in an oil bath. The reaction was then quenched with 50 mL of water. The resulting solution was extracted with 2x100 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 2x50 mL of saturated NH ₄ C1, dried over anhydrous sodium sulfate, and concentrated under vacuum. The crude product (200 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 36.1 mg (9%) of a yellow solid. 1H-NMR (300MHz, DMSO-<¾, ppm): δ 8.73(s, 1H), 8.60(d, J=9.3Hz, 1H), 8.41(s, 1H), 8.19(m, 1H), 7.92(m, 3H), 7.64(m, 7H), 7.14(s, 1H), 4.73 (d, J=5.7Hz, 2H), 3.35(s, 2H), 3.14 (d, J=6.9Hz, 4H), 1.18(t, J=7.2Hz, 6H). MS (ES, m/z): 625 [M +H] ⁺ .

EXAMPLE 69

3-((3-((4-(Piperidin-l-yl)-2-(4-((3-(trifluoromethyl)benz yl)amino pyridin-2- yl)phenyl)carbamoyl)benzyl)thio propanoic acid

Scheme 49. 1. 2-chloro-4-fluoropyridine, K ₃ P0 ₄ , SPhos, Pd(PPh ₃ ) ₄ , DME/H ₂ 0; 2. 3-(trifluoromethyl)benzylamine, K ₂ C0 ₃ , DMF; 3. (Boc) ₂ 0, DCM; 4. DCM, Zn, AcOH; 5. DCM/THF, pyridine, methyl 3-(3-(chlorocarbonyl)benzylthio)propanoate 22d; 6. TFA, DCM; 7. THF/H ₂ 0, LiOH.

Intermediate 69a: 4-fluoro-2-(2-nitro-5-(piperidin- 1 -vDphenvDpyridine. Into a 500-mL 3 -necked round bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of l-(4-nitro-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan- 2-yl)phenyl) piperidine (15 g, 45.18 mmol, 1.00 equiv) in DME/H ₂ 0 (100/5 mL), 2- chloro-4-fluoropyridine (7.80 g, 60.00 mmol, 1.20 equiv), K ₃ P0 ₄ (31 g, 146.23 mmol, 3.00 equiv), 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (SPhos) (2.00 g, 4.88 mmol, 0.10 equiv), and Pd(PPh ₃ ) ₄ (2800 mg, 2.42 mmol, 0.05 equiv). The resulting solution was stirred for 1 overnight at 80°C in an oil bath. The reaction progress was monitored by LCMS. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 200 mL of H ₂ 0, extracted with 3x300 mL of dichloromethane, and the organic layers combined. The resulting mixture was washed with 1x20 mL of brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate/petroleum ether (10:1). The product was obtained as 8 g of a yellow solid.

Intermediate 69b: 2-(2-nitro-5-(piperidin-l-vnphenyl -N-( ^' 3-(trifluoromethvnbenzyl)- pyridin-4-amine. Into a 30-mL round bottom flask, was placed a solution of 4-fluoro-2- (2-nitro-5-(piperidin-l-yl) phenyl)pyridine (500 mg, 1.66 mmol, 1.00 equiv) in N,N- dimethylformamide (10 mL), (3-(trifluoromethyl)benzylamine (581 mg, 3.32 mmol, 2.00 equiv), and potassium carbonate (985 mg, 7.14 mmol, 4.00 equiv). The resulting solution was stirred overnight at 100°C in an oil bath. The resulting solution was diluted with 30 mL of water. The resulting solution was extracted with 3x30 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 2x20 mL of brine and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate/hexane (1 :1). The product was obtained as 500 mg (66%) of a yellow oil.

Intermediate 69c: tert-butyl 2-(2-nitro-5 -(piperidin- 1 -vOphenyl pyridin-4-yl(3 -

(trifluoro-methvDbenzv carbamate. Into a 100-mL round bottom flask, was placed a solution of 2-(2-nitro-5-(piperidin- 1 -yl)phenyl)-N-(3-(trifluoromethyl)benzyl)pyridin-4- amine (670 mg, 1.47 mmol, 1.00 equiv) in dichloromethane (40 mL), (Boc) ₂ 0 (960 mg, 4.40 mmol, 3.00 equiv), and 4-dimethylaminopyridine (268 mg, 2.20 mmol, 1.50 equiv). The resulting solution was stirred overnight at 35°C in an oil bath. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 30/30 mL of H ₂ 0/DCM, and adjusted to pH 7 with sulfuric acid (1 N). The resulting solution was extracted with 3x50 mL of dichloromethane and the organic layers combined, dried over sodium sulfate, and concentrated under vacuum. The product was obtained as 760 mg (93%) of a yellow solid. Intermediate 69d: tert-butyl 2-(2-amino-5-(piperidin-l-yl)phenyl pyridin-4-yl( ^, 3-

(trifluoro-methyl)benzyl)carbamate. Into a 100-mL 3 -necked round bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of tert-butyl 2-(2-nitro-5-( iperidin-l-yl)phenyl)pyridin-4-yl(3-(trifluoromethyl)benzyl) carbamate (760 mg, 1.37 mmol, 1.00 equiv) in dichloromethane (10 mL), and Zn (500 mg). This was followed by dropwise addition of acetic acid (0.7 mL) with stirring. The resulting solution was stirred for 3 h at room temperature. The reaction progress was monitored by LCMS. The solids were removed by filtration. The solution was adjusted to pH 8-9 with NaHC0 ₃ (aq). The resulting solution was extracted with 3x50 mL of dichloromethane and the organic layers combined. The resulting mixture was washed with 1x50 mL of brine, dried over sodium sulfate, and concentrated under vacuum. The product was obtained as 600 mg (83%) of a black solid.

Intermediate 69e: methyl 3-(3-(2-(4-(tert-butoxycarbonyl(3-(trifluoromethyl)benzylV amino pyridin-2-yl -4-(piperidin-l-yl)phenylcarbamoyl)benzylthio)propanoate. Into a 50-mL round bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of tert-butyl 2-(2-amino-5-(piperidin-l-yl)phenyl)pyridin-4-yl(3- (trifluoromethyl)benzyl) carbamate (600 mg, 1.14 mmol, 1.00 equiv) in DCM/THF (5/20 mL), methyl 3-(3-(chlorocarbonyl) benzylthio)propanoate (580 mg, 2.13 mmol, 1.40 equiv), and pyridine (750 mg, 9.49 mmol, 3.00 equiv). The resulting solution was stirred for 3 h at room temperature. The reaction progress was monitored by LCMS. The resulting solution was diluted with 30 mL of H ₂ 0 and adjusted to pH 6-7 with H ₂ S0 ₄ (1 N). The resulting solution was extracted with 3x40 mL of dichloromethane and the organic layers combined. The resulting mixture was washed with 1x30 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum to yield 800 mg (92%) of product as a yellow oil.

Intermediate 69f: methyl 3-r3-r4-rpiperidin-l-ylV2-r4-(3-

(trifluoromethyl benzylamino -pyridin-2-yl)phenylcarbamoyl)benzylthio propanoate. Into a 50-mL round bottom flask, was placed a solution of methyl 3-(3-(2-(4-(tert- butoxycarbonyl(3-(trifluoromethyl)benzyl)amino)pyridin-2-yl) -4-(piperidin-l- yl)phenylcarbamoyl)-benzylthio)propanoate (800 mg, 1.05 mmol, 1.00 equiv) in dichloromethane (2 mL), and 2,2,2-trifluoroacetic acid (5 mL). The resulting solution was stirred for 3 h at room temperature. The reaction progress was monitored by LCMS. The resulting solution was diluted with 20 mL of NaHC0 ₃ (aq), extracted with 3x50 mL of dichloromethane, and the organic layers combined. The resulting mixture was washed with 1x50 mL of brine. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column and eluted with petroleum ethenethyl acetate (5:1). The product was obtained as 200 mg (29%) of a yellow solid.

Example 69: 3-(3-(4-(piperidin-l-yl -2-(4-(3-(trifluoromethyl benzylamino pyridin-2- vDphenylcarbamovDbenzylthio ^' ipropanoic acid. Into a 50-mL round bottom flask, was placed a solution of methyl 3-(3-(4-(piperidin-l-yl)-2-(4-(3-(trifluoromethyl)- benzylamino)pyridin-2-yl)phenylcarbamoyl)benzylthio)propanoa te (300 mg, 0.35 mmol, 1.00 equiv, 78%) in tetrahydrofuran/H ₂ 0 (20/5 mL), and LiOH (150 mg, 10.00 equiv, 40%). The resulting solution was stirred for 2 h at room temperature. The reaction progress was monitored by LCMS. The solution was adjusted to pH 6-7 with hydrochloric acid (1 N). The resulting solution was extracted with 3x50 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 1x20 mL of ethoxyethane. The resulting mixture was concentrated under vacuum. The crude product (250 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA to afford the product (27 mg, 10%) as a yellow oil. 1H- NMR (300MHz, DMSO-i¾, ppm) δ 13.49(s, 1H), 10.05(m, 1H), 8.89(m, 1H), 8.02(m, 1H), 7.68(m, 4H), 7.37(m, 5H), 7.08(m, 1H), 6.91(m, 2H), 6.28(m, 1H), 3.80(s, 2H), 3.23(s, 4H), 2.27(m, 2H), 1.63(s, 6H). MS (ES, m/z): 649 [M+H] ⁺ .

EXAMPLE 70

3-((3-((4-(Piperidin-l-yl)-2-(4-((3-(trifluoromethvDphene thyl amino pyridin-2- yl)phenyl)carbamovDbenzyDthio)propanoic acid

This compound was prepared by the route used to prepare 3-(3-(4-(piperidin-l-yl)-2-(4- (3-(trifluoromethyl)benzylamino) pyridin-2-yl)phenylcarbamoyl)benzylthio)propanoic acid 69, substituting 3-(trifluromethyl)phenethylamine for 3- (trifluoromethyl)benzylamine. 1H-NMR (300MHz, DMSO-i ₆ , ppm): δ 13.37(s, IH), 12.23(s, IH), 8.22(s, IH), 7.82-7.74(m, 2H), 7.64-7.50(m, 6H), 7.12(m, 3H), 6.99(s, IH), 6.70(s, IH), 3.82(s, 2H), 3.47(s, 2H), 3.21(t, 4H), 2.92(t, 2H), 2.58-2.50(m, 4H), 1.66(m, 4H), 1.58(m, 2H). MS (ES, m/z): 663 [M+H] ⁺ .

EXAMPLE 71

3-(Y3 -((2-(4-((3 ,4-Dimethylphenvnamino ^{^} )pyridin-2-yl V4-(piperidin- 1 - yl)phenyl carbamovDbenzvDthio propanoic acid

Scheme 50. 1. 3,4-dimethylaninline, NaH, DMF; 2. Zn/HOAc, EtOH/THF; 3. methyl 3-(3-(chlorocarbonyl)benzylthio)propanoate 22d; 4. LiOH, H ₂ 0/THF.

Intermediate 71 a: N-(3 ,4-dimethylphenyl)-2-(2-nitro-5-(piperidin- 1 -vDphenvDpyridin- 4-amine. Into a 100-mL 3 -necked round bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of 3,4-dimethylbenzenamine (2 g, 16.53 mmol, 4.98 equiv) in N,N-dimethylformamide (50 mL), and sodium hydride (660 mg, 16.50 mmol, 4.97 equiv, 60%).The resulting solution was stirred for 1 h at room temperature. To this was added 4-fluoro-2-(2-nitro-5-(piperidin-l-yl)phenyl)pyridine (1 g, 3.32 mmol, 1.00 equiv). The resulting solution stirred for an additional 1 h at 50- 80°C in an oil bath. The reaction mixture was cooled. The reaction was then quenched with 150 mL of H ₂ 0. The resulting solution was extracted with 3x60 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 1x60 mL of brine, dried over sodium sulfate, and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate .-petroleum ether (1 :1). The product was obtained as 500 mg (37%) of a yellow solid.

Intermediate 71b: 2-(2-amino-5-(piperidin-l-yl)phenyl -N-(3,4- dimethylphenyl pyridm-4-amine. Into a 50-mL 3 -necked round bottom flask, was placed a solution of N-(3,4-dimethylphenyl)-2-(2-nitro-5-(piperidin-l- yl)phenyl)pyridin-4-amine (300 mg, 0.75 mmol, 1.00 equiv) in tetrahydrofuran/EtOH (10/1 mL), Zn (485 mg, 7.46 mmol, 10.00 equiv), and acetic acid (1 mL). The resulting solution was stirred for 30 min at room temperature. The solids were filtered out. The solution was adjusted to pH 7-8 with sodium bicarbonate (aq). The resulting solution was extracted with 3x25 mL of dichloromethane and the organic layers combined. The resulting mixture was washed with 1x25 mL of brine, dried over sodium sulfate, and concentrated under vacuum. The product was obtained as 270 mg (97%) of a yellow solid.

Intermediate 71c: methyl 3-(3-((2-(4-(3,4-dimethylphenylamino pyridin-2-yl)-4- (piperidin- 1 -yl phenyl)carbamoyl benzylthio propanoate. Into a 50-mL 3-necked round bottom flask, was placed a solution of 2-(2-amino-5-(piperidin-l-yl)phenyl)-N- (3,4-dimethylphenyl)pyridin-4-amine (270 mg, 0.72 mmol, 1.00 equiv) in tetrahydrofuran (10 mL), pyridine (170 mg, 2.15 mmol, 2.97 equiv), and methyl 3-(3- (chlorocarbonyl)benzylthio)propanoate (197.6 mg, 0.72 mmol, 1.00 equiv). The resulting solution was stirred for 1.5 h at room temperature. This reaction was used directly in next step without workup.

Example 71 : 3 -(3 -((2-(4-(3 ,4-dimethylphenylamino)pyridin-2-yl -4-(piperidin- 1 -ylV phenvDcarbamovD benzylthio ^' lpropanoic acid. Into a 50-mL 3-necked round bottom flask, was placed a solution of methyl 3-(3-((2-(4-(3,4-dimethylphenylamino)pyridin-2- yl)-4-(piperidin-l-yl)phenyl)carbamoyl)benzylthio)propanoate (440 mg, 0.72 mmol, 1.00 equiv) in tetrahydrofuran (10 mL), and a solution of LiOH H ₂ 0 (300 mg, 7.14 mmol, 9.89 equiv) in water (2 mL). The resulting solution was stirred for 18 h at room temperature. The reaction was then quenched with 30 mL of water. The solution was adjusted to pH 6-7 with hydrochloric acid (1 N). The resulting solution was extracted with 3x30 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 1x30 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product (250 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 237.2 mg (55%) of as a yellow solid. ^-NMR (300MHz, DMSO-< ₆ , ppm): δ 13.76(s, 1H), 10.22(s, 1H), 10.11(s, 1H), 8.21 (d, J=6Hz, 1H), 7.71(s, IH), 7.61(d, J=6.6Hz, IH), 7.51(d, J=7.5Hz, IH), 7.42(m, IH), 7.32(d, J=8.1Hz, IH), 7.16(d, J=9Hz, IH), 7.08(s, 2H), 6.94 (m, 3H), 6.81 (s, IH), 3.80(s, 2H), 3.24(s, 4H), 2.55(m, 3H), 2.17(d, 6H), 1.63(s, 6H). MS (ES, m/z): 595 [M+H] ⁺ .

EXAMPLE 72

3 -((3 -((4-(Piperidin- 1 - vD-2-(4-(Y3 -(trifiuoromethvnphenyl)amino pyridin-2- vDphenvDcarbamovDbenzvQthio^propanoic acid

This compound was prepared by the route used to prepare 3-((3-((2-(4-((3,4- dimethylphenyl)amino)pyridin-2-yl)-4-(piperidin-l-yl)phenyl) carbamoyl)benzyl)thi propanoic acid 71, substituting 3-(trifluoromethyl)aniline for 3,4-dimethylaniline. 1H- NMR (300MHz, DMSO-i&, ppm) δ 13.08(s, IH), 9.36(s, IH), 8.54-8.52(d, IH), 8.43- 8.40(d, IH), 7.89(s, IH), 7.81-7.78(d, IH), 7.56-7.39(m, 7H), 7.24-7.23(d, IH), 7.10- 7.04(m, 2H), 3.89(s, 2H), 3.17-3.15(d, 4H), 2.62-2.58(m, 2H), 1.66-1.56(d, 6H). MS (ES, m/z): 635 [M+H] ⁺ .

EXAMPLE 73

3 -((3 -((4-(Piperidin- 1 - vD-2-(4-(3 -(trifluoromethyP)benzamido ^' )pyridin-2- yl>phenyl carbamovDbenzyl thio propanoic acid

Scheme 51. 1. H2, Pd/C; 2.3-(trifluoromethyl)benzoyl chloride; 3. Intermediate 73a, (Ph ₃ P) ₂ PdCl ₂ , X-PHOS, K ₃ P0 ₄ ; 4 DCM, DIEA, methyl 3-((3-

(chlorocarbonyl)benzyl)thio)propanoate 22d; 5 LiOH H ₂ 0, THF/H ₂ 0.

Intermediate 73 a: 4-(piperidin- 1 -vD-2-(4,4,5 ,5 -tetramethyl- 1 ,3 ,2-dioxaborolan-2- ylV aniline. Into a 50-mL round-bottom flask, was placed a solution of l-(4-nitro-3-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl)piperidine (600.0 mg, 1.81 mmol, 1.00 equiv) in ethyl acetate (30.0 mL), then Palladium carbon(10%) (150 mg) was added next. The gas of ¾ was introduced in. The resulting solution was stirred for 1 h at 0~5°C. The Pd/C was filtered out and the filtrate was collected and concentrated under vacuum. This resulted in 545.8 mg (99%) of 4-(piperidin-l-yl)-2-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)benzenamine as a green to yellow solid. The target product was unstable, it was used to the next reaction step rapidly Intermediate 73b: N-(2-chloropyridin-4-yl)-3-(trifluoromethvnbenzamide. Into a 100- mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of 2-chloropyridin-4-amine (1.0 g, 7.78 mmol, 1.00 equiv) and N,N-Diisopropylethylamine (1.0 mL) in dichloromethane (30.0 mL). This was followed by the addition of a solution of 3-(trifluoromethyl)benzoyl chloride (2.6 g, crude) in dichloromethane (5.0 mL) dropwise with stirring at 0°C. The resulting solution was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (0-1:2). This resulted in 2.2 g (92%) of N-(2-chloropyridin-4-yl)-3- (trifluoromethyl)benzamide as a light-yellow syrup

Intermediate 73c: N-(2-(2-amino-5-(piperidin-l-yl phenvDpyridin-4-yl)-3- (trifluoromethyl)benzamide. Into a 50-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of N-(2-chloropyridin-4-yl)- 3-(trifluoromethyl)benzamide (350 mg, 1.16 mmol, 1.00 equiv), 4-(piperidin-l-yl)-2- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzenamine (430 mg, 1.42 mmol, 1.20 equiv), Pd(PPh ₃ ) ₂ Cl ₂ (81.7 mg, 0.12 mmol, 0.10 equiv), K ₃ P0 ₄ .7H ₂ 0 (790 mg, 2.33 mmol, 2.00 equiv), X-PHOS (91.6 mg, 0.23 mmol, 0.20 equiv) in DME/H ₂ O(10:l) (30/3 mL). The resulting solution was stirred for 2 h at 80°C. The reaction progress was monitored by LCMS. The resulting mixture was concentrated under vacuum. The residual solution was diluted with 50 mL of water. The resulting solution was extracted with 2x50 mL of dichloromethane and the organic layers combined and dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with dichloromethane/methanol (100-100:1-40:1). This resulted in 350 mg (67%) of N-(2-(2-amino-5-(piperidin-l-yl)phenyl)pyridin-4-yl)-3- (trifluoromethyl)benzamide as a yellow solid

Intermediate 73d: methyl 3-(3-((4-(piperidin-l-yl -2-(4-(3-

(trifluoromethyl)benzamido -pyridin-2-ynphenvncarbamoyl benzylthio)propanoate. Into a 50-mL round bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of N-(2-(2-amino-5-(piperidin-l-yl)phenyl)pyridin-4- yl)-3-(trifluoromethyl)benzamide (100.0 mg, 0.23 mmol, 1.00 equiv) and N,N- diisopropylethylamine (0.2 mL) in dichloromethane (20 mL). This was followed by dropwise addition of a solution of methyl 3-(3-(chlorocarbonyl)benzylthio)propanoate 22d (74.0 mg, 0.27 mmol, 1.20 equiv) in dichloromethane (2.0 mL) with stirring at 0°C. The resulting solution was stirred for 2 h at room temperature. The resulting mixture was combined with the solution of the previous batch and then concentrated under vacuum. The residue was applied onto a silica gel column and eluted with dichloromethane:methanol (100~100:1~50:1). The product was obtained as 170 mg (70%) of a yellow solid.

Example 73 : 3-((3-((4-(piperidin-l-yl)-2-(4-(3-(trifluoromethyl benzamido)pyridin-2- yl -phenyl carbamoyl)benzyl thio propanoic acid. Into a 50-mL round bottom flask, was placed a solution of methyl 3-(3-((4-(piperidin-l-yl)-2-(4-(3- (trifluoromethyl)benzamido)pyridin-2-yl)phenyl)carbamoyl)ben zylthio)propanoate (100 mg, 0.15 mmol, 1.00 equiv) and lithium hydroxide hydrate (62.0 mg, 1.48 mmol, 10.00 equiv) in tetrahydrofuran/water(l :l) (10/10 mL). The resulting solution was stirred for 2 h at room temperature. The resulting mixture was combined with the solution of the previous batch and then concentrated under vacuum. The residual solution was adjusted to pH 5~6 with 1 N acetic acid. The resulting solution was extracted with 2x30 mL of dichloromethane and the organic layers combined and dried over anhydrous sodium sulfate. The solvent was removed under vacuum. The crude product (140 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The fractions were collected and lyophilized to yield 100 mg (58%) of product as an off-white solid. 1H-NMR (300MHz, DMSO-d ₆ , ppm): δ 11.29 (br, 1H), 8.79 (d, J=6.0Hz, 1H), 8.42 (s, 1H), 8.31- 8.27 (m, 2H), 8.07-7.97 (m, 2H), 7.87-7.74(m, 3H), 7.53-7.44 (m, 3H), 7.38-7.37 (m, 1H), 3.83 (s, 2H), 3.35 (s, 4H), 2.56 (t, J=6.3Hz, 2H), 1.74-1.61 (m, 6H). MS (ES, m/z): 663 [M+H] ⁺ .

EXAMPLE 74 3-((3-((2-(4-n^-Dimethylbenzamido pyridin-2-yl)-4-(piperidin-l- vDphenvDcarbamoyDbenzyDthio^propanoic acid

This compound was prepared by the route used to prepare 3-((3-((4-(piperidin- (4-(3-(trifluoromethyl)benzamido)pyridin-2- yl)phenyl)carbamoyl)benzyl)thio)propanoic acid 73, substituting 3,4-dimethylbenzoyl chloride for 3-(trifluoromethyl)benzoyl chloride. 1H-NMR (300MHz, CD ₃ OD, ppm): δ 8.71-8.65 (m, 2H), 7.96-7.84(m, 3H), 7.77-7.70(m, 3H), 7.55-7.41 (m, 4H), 7.33 (d, J=8.1Hz, 1H), 2.63 (s, 2H), 2.60 (d, J=6.9Hz, 4H), 2.63-2.58(m, 2H), 2.52-2.46(m, 2H), 2.38 (s, 6H), 1.90-1.74 (m, 6H). MS (ES, m/z): 623 [M+H] ⁺ .

EXAMPLE 75

2-f 2-(3 -(( 4-(2-Hvdroxyethyl - 1 H- 1.2.3 -triazol- 1 -vnmethyl benzamido)-5-( piperidin- 1 - yl phenyl -N-( ^' 3-(trifluoromethyl ^' )benzyl)isonicotinamide

Scheme 52. 1. NaN ₃ , DMF; 2. Cul, DMSO, homopropargyl alcohol.

Intermediate 75a: N-C3 -(trifluoromethyl benzyiy2-(2-(3 -(azidomethyl)benzamido>5- (piperidin- 1 -vDphenvDisonicotinamide. Into a 50-mL round-bottom flask, was placed a solution of N-(3-(trifluoromethyl)benzyl)-2-(2-(3-(bromomethyl)benzamido )-5- (piperidin-l-yl)phenyl)isonicotinamide (200 mg, 0.18 mmol, 1.00 equiv, 60%) in N,N- dimethylformamide (5 mL), and NaN ₃ (70 mg, 1.08 mmol, 5.00 equiv). The resulting solution was stirred for 2 h at 80°C in an oil bath. The resulting solution was diluted with 25 mL of water. The resulting solution was extracted with 3x50 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 1x50 mL of brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate/petroleum ether (1 :2). The product was obtained as 55 mg (49%) a yellow solid.

Example 75 : 2-(2-(3 - ( (4-(2-hvdroxyethylV 1 H- 1 ,2.3-triazol- 1 -vnmethvnbenzamido>5- piperidin- 1 -yl)phenyl -N-(3 -CtrifluoromethyDbenzyDisonicotinamide. Into a 50-mL round-bottom flask, was placed a solution of N-(3-(trifluoromethyl)benzyl)-2-(2-(3- (azidomethyl)benzamido)-5-(piperidin-l-yl)phenyl)isonicotina mide (55 mg, 0.09 mmol, 1.00 equiv, 95%) in DMSO (3 mL), but-3-yn-l-ol (19 mg, 0.27 mmol, 3.00 equiv), and copper(I) iodide (0.84 mg, 0.05 equiv). The resulting solution was stirred overnight at room temperature. The resulting solution was diluted with 10 mL of 10% ΝΙ¾.Η ₂ 0. The resulting solution was extracted with 5x30 mL of ethyl acetate and the organic layers combined, dried over anhydrous sodium sulfate, and concentrated under vacuum. The crude product (60 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 10 mg (14%) of a yellow to green solid. 1H-NMR (300MHz, DMSO- ₆ , ppm): δ 12.48 (s, 1H), 9.55-9.58 (t, J=6 Hz, 1H), 8.93 (s, 1H), 8.36 (s, 2H), 7.96 (s, 1H), 7.85-7.96 (s, 1H), 7.71-7.77 (m, 3H) 7.64 (s, 1H), 7.55-7.60 (m, 5H), 7.44 (s, 1H), 5.67 (s, 2H), 4.63 (t, 2H), 3.58-3.61 (t, 2H), 3.40 (s, 4H), 2.75-2.77 (t, J=9 Hz, 2H), 1.61-1.78 (d, 6H). MS (ES, m/z): 684 [M+H] ⁺ .

EXAMPLE 76

3 -((3 -((4-(Piperidin- 1 -yl)-2-(6-(( 1 -(3 -(trifluoromethyl)phenyl ethyl amino pyrimidin-4- yl)phenyl)carbamovDbenzyl)thio propanoic acid

Scheme 53. 1. Ti[OCH(CH ₃ ) ₂ ] ₄ , NH ₃ , EtOH, NaBH ₄ ; 2. Intermediate 76a, toluene, ΒΓΝΑΡ, Cs ₂ C0 ₃ , Pd(dba) ₃ CHCl ₃ ; 3. CH ₃ COOH, Zn; 4. 3-((3-tert-butoxy-3- oxopropylthio)methyl)benzoic acid 1.1c, DCM, DMAP, EDC HC1 ; 5. TFA, DCM.

Intermediate 76a: 1 -(3 -(trifluoromethyl)phenvnethanamine. Into a 150 mL 3 -necked round bottom flask, was placed ethanol (25 mL). NH ₃ gas was added at 0°C. The mixture was stirred for 1 h at 0°C. Into a 150-mL sealed tube, was placed a solution of l-(3-(trifluoromethyl)phenyl)ethanone (2 g, 10.64 mmol, 1.00 equiv) in ethanol (5 mL), and Ti[OCH(CH ₃ ) ₂ ] (6.04 g, 21.13 mmol, 2.00 equiv). This was followed by the addition of the above solution of NH ₃ (gas) in ethanol (25 mL). The mixture was stirred overnight at 48°C. To this was added NaBH ₄ (600 mg, 15.79 mmol, 1.48 equiv). The resulting solution was stirred for 3 h at room temperature. The resulting solution was diluted with 10 mL of ammonia and the solids were filtered out. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column and eluted with dichloromethane/methanol (50:1). The product was obtained as 1 g (50%) of a yellow oil. Intermediate 76b : 6-(2-nitro-5 -(piperidin- 1 -yl)phenyl)-N-( 1 -(3 - (trifluoromethyl)phenyl)-ethyl)pyrimidin-4-amine. Into a 100 mL round bottom flask, was placed a solution of 4-chloro-6-(2-nitro-5-(piperidin-l-yl)phenyl)pyrimidine (100 mg, 0.31 mmol, 1.00 equiv) in toluene (10 mL), l-(3- (trifluoromethyl)phenyl)ethanamine (71 mg, 0.38 mmol, 1.20 equiv), ΒΓΝΑΡ (9 mg, 0.01 mmol, 0.05 equiv), Cs ₂ C0 ₃ (144 mg, 0.44 mmol, 1.40 equiv), and Pd(dba) ₃ CHC1 ₃ (6.5 mg, 0.01 mmol, 0.02 equiv). The resulting solution was stirred for 3 h at 120°C. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate/petroleum ether (1:5). The product was obtained as 80 mg (54%) of a yellow oil.

Intermediate 76c: 6-(2-amino-5 -(piperidin- l-vPphenvD-N-O -(3- (trifluoromethyl phenyl -ethyl)pyrimidin-4-amine. Into a 100-mL round-bottom flask, was placed a solution of 6-(2-nitro-5-(piperidin-l-yl)phenyl)-N-(l-(3- (trifluoromethyl)phenyl)ethyl)pyrimidin-4-amine (400 mg, 0.85 mmol, 1.00 equiv) in acetic acid (5 mL). To this was added zinc (552 mg, 8.62 mmol, 10.00 equiv) in several batches at 70°C. The resulting solution was stirred for 1 h at 70°C. The solids were filtered out. The resulting mixture was concentrated under vacuum. The solution was adjusted to pH 8 with ammonia (1 mol/L). The resulting solution was extracted with 4x50 ml of ethyl acetate and the organic layers combined, dried over sodium sulfate, and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with methanol :dichloromethane (1 :50). The product was obtained as 200 mg (53%) of a black solid.

Intermediate 76d: tert-butyl 3 -(3 -(4-(piperidin- 1 -yl V2-(6-( 1 -(3 -

(trifluoromethyl phenyl -ethylamino pyrimidin-4- yl)phenylcarbamoyl)benzylthio propanoate. Into a 100-mL round-bottom flask, was placed a solution of 3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid (147 mg, 0.50 mmol, 1.10 equiv) in dichloromethane (5 mL), EDC HC1 (143 mg, 0.74 mmol, 1.50 equiv), 4-dimethylaminopyridine (92 mg, 0.71 mmol, 1.50 equiv), and 6-(2-amino- 5-(^iperidin-l -yl)phenyl)-N-(l -(3-(tri

(200 mg, 0.45 mmol, 1.00 equiv). The resulting solution was stirred for 3 h at 30°C. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column and eluted with petroleum ether/ethyl acetate (5: 1). The product was obtained as 100 mg (31%) of a yellow oil.

Example 76: 3-(3-(4-(piperidin-l-yl)-2-(6-(l-(3-(trifluoromethyl)phenyl ethylamino - pyrimidin-4-yl)phenylcarbamoyl benzylthio)propanoic acid. Into a 100-mL round- bottom flask, was placed a solution of tert-butyl 3-(3-(4-(piperidin-l-yl)-2-(6-(l-(3- (trifluoromethyl)phenyl)ethylamino)pyrimidin-4-yl)phenylcarb amoyl)benzylthio)- propanoate (90 mg, 0.13 mmol, 1.00 equiv) in dichloromethane (4 mL), and 2,2,2- trifluoroacetic acid (2 mL). The resulting solution was stirred for 2 h at 30°C. The resulting mixture was concentrated under vacuum. The crude product (80 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 46.1 mg (55%) of as a yellow solid. ^-NMR (300MHz, DMSO-c , ppm): δ 8.78(s, 1H), 7.71(m, 4H), 7.53(m, 6H), 7.27(m, 2H), 6.93(s, 1H), 5.40(s, 1H), 3.92(s, 2H), 3.48(m, 4H), 2.61(m, 4H), 1.59(m, 10H). MS (ES, m/z): 663 [M+H] ⁺ .

EXAMPLE 77

3-(3-(4-(piperidin- 1 -yl)-2-(4-(l -(3-(trifluoromethyl)phenyl ethylcarbamoyl pyridin-2- yDphenylcarbamo yl benzylthio propano ic acid

This compound was prepared using the procedure used to prepare 3-(3-((2-(4-((3- (trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-( iperidin-l-yl)phenyl)carbamoyl)- benzylthio)propanoic acid 1.1, using l-(3-(trifluoromethyl)phenyl)ethanamine in place of 3-(trifluoromethyl)benzylamine. 1H-NMR (300MHz, CD ₃ OD, ppm): δ 9.044- 9.062(d, J=5.4 Hz, IH), 8.786-8.816(d, J=9.0 Hz, IH), 8.378(s, IH), 8.125-8.133(d, J=2.4 Hz, IH), 8.003(s, IH), 7.875-7.905(m, 2H), 7.707-7.754(m, 3H), 7.499-7.623(m, 4H), 5.324-5.393(m, IH), 3.913(s, 2H), 3.678-3.714(m, 4H), 2.709-2.754(m, 2H), 2.574-2.618(m, 2H), 2.043-2.060(m, 4H), 1.831-1.846(m, 2H), 1.641-1.664(d, J= 6.9 Hz, 3H). MS (ES, m/z): 692 [M+H] ⁺ .

EXAMPLE 78

3 -(3 -(2-(4-( 4-Morpholinobenzylcarbamoyl ^' )pyridin-2-ylV4-(piperidin- 1 -yP)- phenylcarbamovDbenzylthio) propanoic acid

Scheme 54. 1. DMSO, morpholine 2. LiAlH ₄ , THF; 3. DCM, oxalyl chloride; 4. THF, Intermediate 78b; 5. TFA, DCM.

Intermediate 78 a: 4-morpholinobenzonitrile. Into a 50-mL 3 -necked round-bottom flask, was placed a solution of 4-fluorobenzonitrile (500 mg, 4.13 mmol, 1.00 equiv) in DMSO (5 mL), and morpholine (1070 mg, 12.30 mmol, 3.00 equiv). The resulting solution was stirred for 4 h at 120°C in an oil bath. The resulting solution was diluted with 100 mL of H ₂ 0. The solids were collected by filtration. The product was obtained as 617 mg (79%) of a yellow solid.

Intermediate 78b: (4-morpholinophenyl methanamine. Into a 50-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of 4-morpholinobenzonitrile (200 mg, 1.06 mmol, 1.00 equiv) in tetrahydrofuran (10 mL), and LiAlH ₄ (400 mg, 10.53 mmol, 10.00 equiv). The resulting solution was stirred for 3 h at 60°C. The reaction was then quenched with 1 N NaOH. The solids were removed by filtration. The resulting solution was extracted with 3x20 mL of dichloromethane and the organic layers combined, dried over NaS0 ₄ , and concentrated under vacuum. The product was obtained as 120 mg (58%) of a yellow solid. 1H-NMR (300MHz, CDC ,ppm): δ 7.26(m, 2H). 6.91(m, 2H), 3.87(m, 6H), 3.16(m, 4H).

Intermediate 78c: tert-butyl 3-(3-(2-(4-(chlorocarbonyl)pyridin-2-yl -4-( ^' piperidin-l- yl)phenylcarbamoyl)benzylthio propanoate. Into a 50-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of 2-(2-(3- ((3-tert-butoxy-3-oxopropylthio)methyl)benzamido)-5-(piperid in-l-yl)phenyl) isonicotinic acid (170 mg, 0.30 mmol, 1.00 equiv) in dichloromethane (10 mL), and oxalyl dichloride (112 mg, 0.88 mmol, 3.00 equiv). The resulting solution was stirred for 4 h at room temperature. The resulting mixture was concentrated under vacuum to yield 200 mg of crude product a yellow solid.

Intermediate 78d: tert-butyl 3-(3-(2-(4-(4-morpholinobenzylcarbamoyl pyridin-2-yl)-4- (piperidin- 1 -yl phenylcarbamoyl benzylthio propanoate. Into a 50-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of tert-butyl 3 -(3 -(2-(4-(chlorocarbonyl)pyridin-2-yl)-4-(piperidin- 1 - yl)phenylcarbamoyl)-benzylthio)-propanoate (120 mg, 0.20 mmol, 1.00 equiv) in tetrahydrofuran (10 mL), (4-morpholinophenyl)methanamine (68 mg, 0.35 mmol, 1.50 equiv), and DIPEA (32 mg, 0.25 mmol, 3.00 equiv). The resulting solution was stirred for 4 h at room temperature. An additional 68 mg of 4-morpholinophenyl)methanamine was added. The resulting solution was stirred for an additional 2 h at room temperature. The resulting solution was diluted with 10 mL of H ₂ 0. The resulting solution was extracted with 3x50 mL of dichloromethane and the organic layers combined. The resulting mixture was washed with 1x50 mL of brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. This resulted in 200 mg of crude product as a yellow oil. Example 78: 3-(3-(2-(4-(4-nlO holinobenzylcaΓbamoyl)pyridin-2-yl -4-(pi eridin-l- ylVphenylcarbamoyl benzylthio propanoic acid. Into a 50-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of tert-butyl 3-(3-(2-(4-(4-morpholinobenzylcarbamoyl)pyridin-2-yl)-4-(pip eridin-l- yl)phenylcarbamoyl)-benzylthio)propanoate (170 mg, 0.20 mmol, 1.00 equiv, 86%) in dichloromethane (20 mL), and trifluoroacetic acid (2 mL). The resulting solution was stirred overnight at room temperature. The reaction progress was monitored by LCMS. The solution was adjusted to pH 7-8 with NaHC0 ₃ (aq). The resulting solution was extracted with 3x30 mL of dichloromethane and the organic layers combined. The resulting mixture was washed with 1x30 mL of brine, dried over NaS0 ₄ and concentrated under vacuum. The crude product (120 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 17 mg (13%) of a yellow solid. 1H-NMR (300MHz, DMSO- ₆ , ppm): 5 8.96(s, 1H), 8.49(m, 1H), 8.34(s, 1H), 7.79(m, 4H), 7.54(m, 3H), 7.16(m, 2H), 6.89(m, 2H), 4.42(s, 2H), 3.86(s, 2H), 3.70(m, 5H), 3.49(s, 4H), 3.04(m, 4H), 2.60(m, 2H), 1.78(m, 6H). MS (ES, m/z): 694 [M+H] ⁺ .

EXAMPLE 79

3 -(3 -((2-(4-((4-( 1 H-Pyrazol- 1 -yl)benzyl carbamoyl pyridin-2-yl V4-(piperidin- 1 -vD phenyl carbamoyl benzylthio propanoic acid

Scheme 55. 1. DMF, NaOH, lH-pyrazole; 2. LiAlH ₄ , THF; 3. EDC HCL, DMAP, DCM, intermediate 79b; 4. TF A, DCM.

Intermediate 79a: 4-dH-pyrazol-l-yl)benzonitrile. Into a 50-mL 3-necked round- bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed lH-pyrazole (422 mg, 6.21 mmol, 1.50 equiv), sodium hydroxide (248 mg, 6.20 mmol, 1.50 equiv), and N,N-dimethylformamide (20 mL). The mixture was stirred and heated to 80°C for 30 min, then to this was added 4-fluorobenzonitrile (500 mg, 4.13 mmol, 1.00 equiv). The resulting solution was stirred for 3 h at 110°C in an oil bath. The resulting solution was diluted with 50 mL of H ₂ 0. The solids were collected by filtration and dried in an oven. The product was obtained as 0.43 g (62%) of a white solid.

Intermediate 79b: ^-( ^" lH-pyrazol-l-vDphenvDmethanamine. Into a 50-mL 3-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed tetrahydrofuran (15 mL). This was followed by dropwise addition of a 4-(lH- pyrazol-l-yl)benzonitrile (250 mg, 1.48 mmol, 1.00 equiv) in tetrahydrofuran (5 mL) with stirring at 0°C. To this was added LiAlH ₄ (337 mg, 8.87 mmol, 6.00 equiv). The resulting solution was stirred for 3 h at room temperature. The reaction was then quenched by the addition of NaOH (15%, aq). The resulting solution was extracted with 3x50 mL of dichloromethane and the organic layers were combined, dried over anhydrous sodium sulfate, and concentrated under vacuum. The product was obtained as 0.251 mg of a white crude solid.

Intermediate 79c: tert-butyl 3 - (3 - ((2-(4-((4-( 1 H-pyrazol- 1 - yl benzyl earbamoyl pyridin-2-ylV4-(piperidin- 1 - yl)phenyl carbamoyl)benzylthio propanoate. Into a 50-mL 3 -necked round-bottom flask, was placed 2-(2-(3-((3-tert-butoxy-3-oxopropylthio) methyl)benzamido)-5- (piperidin-l-yl)phenyl)isonicotinic acid (125 mg, 0.22 mmol, 1.00 equiv), (4-(lH- pyrazol-l-yl)phenyl)methanamine (41 mg, 0.24 mmol, 1.10 equiv), EDC HC1 (62 mg, 0.32 mmol, 1.50 equiv), 4-dimethylaminopyridine (40 mg, 0.33 mmol, 1.51 equiv), and dichloromethane (15 mL). The resulting solution was stirred overnight at room temperature. The resulting solution was extracted with 40 mL of dichloromethane and the organic layers combined. The resulting mixture was washed with 2x15 mL of H ₂ 0. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The product was obtained as 0.132 g (83%) of a yellow crude solid.

Example 79 : 3 -(3 - f (2-(4-((4-( 1 H-pyrazol- 1 -vnbenzyl carbamoyl pyridin-2-yl -4- (piperidin- 1 -yl)phenyl carbamoyl)benzylthio propanoic acid. Into a 50-mL 3 -necked round bottom flask, was placed tert-butyl 3-(3-((2-(4-((4-(lH-pyrazol-l- yl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin-l-yl)phenyl)c arbamoyl)benzylthio)- propanoate (130 mg, 0.18 mmol, 1.00 equiv), and dichloromethane (2 mL). This was followed by dropwise addition of trifluoroacetic acid (3 mL) with stirring. The resulting solution was stirred for 60 min at room temperature. The solution was adjusted to pH 7 with sodium bicarbonate (aq). The resulting solution was diluted with 30 mL of dichloromethane and washed with 2x10 mL of H ₂ 0. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product (300 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 86.9 mg (72%) of a yellow solid. 1H-NMR: (300MHz, DMSO-i¾+D ₂ 0, ppm): δ 1.63(m, 2H), 1.82(m, 4H), 2.58-2.62(m, 4H), 3.47(t, 4H), 3.87(s, 2H), 4.56(d, 2H), 6.53(s, 1H), 7.44-7.54(m, 4H), 7.72-7.79(m, 3H), 7.87-7.89(m, 2H), 8.36(s, 1H), 8.42(s, 1H), 8.99(d, 1H), 9.53(s, 1H), 11.97(s, 1H). MS (ES, m/z): 675 [M+H] ⁺ .

EXAMPLE 80

Nl-Methyl-Nl-( ^, 2-morpholinoethyl -N3-(4-rpiperidin-l-yl -2-(4-((3- (trifluoromethyl benzyl ^' )carbamovnpyridin-2-yl phenyl)isophthalamide

80a Scheme 56. l.oxalyl chloride; 2. Boc ₂ 0; 3. LAH; 4. Intermediate 80a; 5. LiOH ' H ₂ 0; 6. EDC HC1, DMAP, DCM, 3-(methyl(2-morpholinoethyl)carbamoyl)benzoic acid.

Intermediate 80a: methyl 3-(chlorocarbonyl)benzoate. Into a 250-mL round-bottom flask, was placed a solution of 3-(methoxycarbonyl)benzoic acid (6.2 g, 34.44 mmol, 1.00 equiv) in dichloromethane (50 mL), oxalyl dichloride (8.74 g, 69.37 mmol, 2.00 equiv), and N,N-dimethylformamide (cat.). The resulting solution was stirred for 1 h at 40°C in an oil bath. The resulting mixture was concentrated under vacuum. This resulted in 6.6 g (87%) of methyl 3-(chlorocarbonyl)benzoate as brown oil

Intermediate 80b: tert-butyl (2-morpholinoethyl carbamate. Into a 250-mL round- bottom flask, was placed a solution of 2-morpholinoethanamine (10 g, 76.92 mmol, 1.00 equiv) in dichloromethane (50 mL). To this was added triethylamine (5.83 g, 57.72 mmol, 0.50 equiv). This was followed by the addition of di-tert-butyl dicarbonate (18.44 g, 84.59 mmol, 1.10 equiv) at 0-5°C. The resulting solution was stirred overnight at 25°C. The resulting solution was diluted with 200 mL of dichloromethane. The resulting mixture was washed with 1x30 mL of 10% sodium bicarbonate and 1x30 mL of brine. The mixture was dried over sodium sulfate and concentrated under vacuum. This resulted in 16 g (81%) of tert-butyl 2-morpholinoethylcarbamate as an off-white solid.

Intermediate 80c: N-methyl-2-morpholinoethanamine. Into a 250-mL 3-necked round- bottom flask, was placed a solution of LiAl¾ (7.72 g, 208.65 mmol, 3.00 equiv) in tetrahydrofuran (60 mL). This was followed by the addition of a solution of tert-butyl 2- morpholinoethylcarbamate (16 g, 62.61 mmol, 1.00 equiv, 90%) in tetrahydrofuran (40 mL) dropwise with stirring at 0-5°C. The resulting solution was stirred for 2 h at 70°C in a oil bath bath. The reaction was then quenched by the addition of 7.7 mL of water, 7.7 mL of 15% sodium hydroxide, and 23.1 mL of water. The solids were filtered out. The mixture was dried over sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with dichloromethane:methanol(0.5% triethylamine) (20:1). This resulted in 4.2 g (42%) of N-methyl-2-morpholinoethanamine as brown oil.

Intermediate 80d: methyl 3-( ^" methyl(2-morpholinoethyl carbamoyl)benzoate. Into a 100-mL round-bottom flask, was placed a solution of N-methyl-2- morpholinoethanamine (2.1 g, 13.12 mmol, 1.00 equiv, 90%) in dichloromethane (20 mL), and triethylamine (1.47 g, 14.55 mmol, 1.00 equiv). This was followed by the addition of a solution of methyl 3-(chlorocarbonyl)benzoate (3.3 g, 15.00 mmol, 1.20 equiv, 90%) in dichloromethane (10 mL) dropwise with stirring at 0-5°C. The resulting solution was stirred for 3 h at room temperature. The resulting solution was diluted with 100 mL of dichloromethane. The resulting mixture was washed with 1x30 mL of 10% sodium bicarbonate. The resulting mixture was washed with 1x30 mL of brine. The mixture was dried over sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with dichloromethane:methanol (20: 1). This resulted in 4.4 g (99%) of methyl 3-(methyl(2-morpholinoethyl)carbamoyl)benzoate as a brown solid.

Intermediate 80e: 3-(methyl(2-morpholinoethyl carbamoyl)benzoic acid. Into a 100- mL round-bottom flask, was placed a solution of methyl 3-(methyl(2- morpholinoethyl)carbamoyl)benzoate (4.4 g, 13.66 mmol, 1.00 equiv, 95%) in tetrahydrofuran/water (15/10 mL), and lithium hydroxide hydrate (1.77 g, 43.17 mmol, 3.00 equiv). The resulting solution was stirred for 1 h at 25°C. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 10 mL of water and adjusted to pH 2-3 with hydrochloric acid. The resulting mixture was washed with 2x30 mL of ethyl acetate. The aqueous layers were concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate:methanol (4: 1). This resulted in 2.7 g (65%) of 3-(methyl(2-morpholinoethyl)carbamoyl)benzoic acid as a white solid. 1H-NMR (300MHz, CD ₃ OD, ppm): δ 8.17 (m, 2H), 7.78 (m, 1H), 7.61 (m, 1H), 3.98 (m, 6H), 3.56 (m, 5H), 3.47 (m, 1H), 3.10 (s, 3H). MS (ES, m/z): 293 [M+H] ⁺ . Example 80 : N 1 -(2-(4-(Y3 -(trifiuoromethyl)benzvncarbamoyl pyridin-2-yl ^' )-4- (piperidin- 1 -yl)phenyl)-N3 -methyl-N3 -(2-morpholinoethyl isophthalamide

hydrochloride. Into a 250-mL round bottom flask, was placed a solution of N-(3- (trifluoromethyl)benzyl)-2-(2-amino-5-(piperidin- 1 -yl)phenyl)isonicotinamide (1 g, 2.09 mmol, 1.00 equiv, 95%) in dichloromethane (30 mL), 3-(methyl(2- morpholinoethyl)carbamoyl)benzoic acid (960 mg, 3.12 mmol, 1.50 equiv, 95%), EDC HCl (840 mg, 4.38 mmol, 2.00 equiv), and 4-dimethylaminopyridine (540 mg, 4.43 mmol, 2.00 equiv). The resulting solution was stirred for 3 h at 25°C. The resulting solution was diluted with 200 mL of ethyl acetate. The resulting mixture was washed with 2x30 mL of NH ₄ C1 (aq), 1x30 mL of 10% sodium bicarbonate, and 1x30 mL of brine. The mixture was dried over sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate:methanol (20:1). This resulted in 1.30 g of Nl-(2-(4-((3- (trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin -l-yl)phenyl)-N3-methyl- N3-(2-morpholinoethyl)isophthalamide as a brown oil. The brown oil was dissolved in 40 mL of methanol. HCl gas was added at 0°C. The mixture was stirred for 20 min at 0°C. The mixture was concentrated under vacuum. The product was obtained as 1.40 g (86%) of a yellow solid. 1H-NMR (300MHz, DMSO- ₆ +D ₂ 0, ppm): δ 9.96 (m, 1H), 8.94 (d, J=6Hz, 1H), 8.59 (m, 2H), 8.49 (s, 1H), 7.93-8.07 (m, 2H), 7.87-8.03 (m, 2H), 7.54-7.80 (m, 7H), 4.59 (s, 2H), 4.12 (m, lH), 3.99-4.03 (m, 2H), 3.88 (m, 2H), 3.76- 3.79 (m, 2H), 3.58 (m, 2H), 3.43 (m, 2H), 3.15-3.17 (m, 3H), 2.96 (s, 3H), 1.97 (m, 4H), 1.71 (m, 2H). MS (ES, m/z): 729 [M+H] ⁺ .

EXAMPLE 81

Nl -(2-(4-Acetv iperazin- 1 -yl)ethyl)-N 1 -methyl-N3-(4-(piperidin- 1 -yl)-2-( 4-(3- (trifluoromethyl)benzylcarbamoyl)pyridin-2-yl)phenyl isophthalamide

Scheme 57. 1. SOCl ₂ ; 2. MeNH ₂ ; 3. NaHC0 ₃ , then Et ₃ N, DCM; 4. TFA; 5. AcCl

Intermediate 81a: tert-butyl 4-(2-chloroethyl piperazine-l-carboxylate. Into a 50-mL round-bottom flask, was placed a solution of tert-butyl 4-(2-hydroxyethyl)piperazine-l- carboxylate (2.31 g, 10.03 mmol, 1.00 equiv) in dichloromethane (20 mL) and a solution of thionyl chloride (1.5 mL, 2.00 equiv)in dichloromethane (3 mL) was added dropwise under ice-bath. The resulting solution was stirred overnight at 25°C. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 10 mL of water. The resulting solution was extracted with 2x25 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 2x15 mL of sodium bicarbonate aq. and 2x10 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:5). This resulted in 1.16 g (46%) of tert-butyl 4-(2-chloroethyl)piperazine-l-carboxylate as a off-white solid

Intermediate 81b: tert-butyl 4-(2-( ^' methylamino ethyl)piperazine-l-carboxylate. Into a 50-mL sealed tube, was placed tert-butyl 4-(2-chloroethyl)piperazine-l-carboxylate (300 mg, 1.21 mmol, 1.00 equiv), methanamine (in ethanol) (10 mL), Nal (100 mg). The resulting solution was stirred for 12 h at 70°C in an oil bath. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 3 mL of water. The pH value of the solution was adjusted to 7-8 with sodium bicarbonate (5 %). The resulting solution was extracted with 2x5 mL of dichloromethane and the organic layers combined. The resulting mixture was washed with 1x3 mL of water and 1x3 mL of brine. The resulting mixture was concentrated under vacuum. This resulted in 180 mg (crude) of tert-butyl 4-(2-(methylamino)ethyl)piperazine-l-carboxylate as brown oil Intermediate 81c: tert-butyl 4-(2-(N-methyl-3-((4-(piperidin-l-yl)-2-(4-((3- (trifluoromethyl benzyl)carbamoyl)pyridin-2-yl)phenyl)carbamoyl ^' )benzamido)ethyl)- piperazine- 1 -carboxylate. Into a 50-mL round-bottom flask, was placed a solution of 3- (4-(piperidin-l-yl)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl )pyridin-2- yl)phenylcarbamoyl)-benzoic acid (100 mg, 0.17 mmol, 1.00 equiv) in dichloromethane (5 mL), EDC HC1 (48 mg, 0.25 mmol, 1.50 equiv), 4-dimethylaminopyridine (31 mg, 0.25 mmol, 1.50 equiv). The mixture was stirred for 5 min at room temperature. To the above was added tert-butyl 4-(2-(methylamino)ethyl)piperazine-l -carboxylate (53 mg, 0.22 mmol, 1.30 equiv). The resulting solution was stirred for 2 h at 25°C. The resulting solution was diluted with 5 mL of water. The resulting solution was extracted with 2x5 mL of dichloromethane and the organic layers combined. The resulting mixture was washed with 1x5 mL of water and 2x5 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product (100 mg) was purified by Prep-HPLC with the following conditions (1#-Waters 2767-3): Column, SunFire Prep CI 8, 19* 150mm 5um; mobile phase, WATER WITH 0.05%TFA and CH ₃ CN (25% CH ₃ CN up to 45% in 6 min); Detector, Waters2545 UvDector 254&220nm. 33.6 mg product was obtained. This resulted in 33.6 mg (21%) of PH-RDX-002-1129-0 as a light yellow solid. MS (ES, m/z): 828 [M- +H] ⁺ . H-NMR (300MHz, CD ₃ OD, ppm) 8.98(d, J=5.1Hz, 1H), 8.75(d, J=9.0Hz, 1H), 8.46(s, 1H), 8.18~8.11(m, 3H), 7.89~7.53(m, 8H), 4.72(s, 2H), 4.00~3.11(m, 16H), 3.08(s, 3H), 2.04(d, J=4.8Hz, 4H), 1.83(d, J=5.7Hz, 2H), 1.49(s, 9H) Intermediate 81d: Nl-(2-(4-r(3-(trifluoromethyl)benzyl carbamoyl)pyridin-2-ylV4- (piperidin- 1 -yl phenvO-N3 -methyl -N3 -(2 -(piperazin- 1 - vDethvQisophthalamide .

Compound 81c was dissolved in 1 : 1 dichloromethane / TFA and stirred for 1 hour. The solvent was evaporated and 250 mg of the residue was placed into a 50-mL round bottom flask with a saturated aqueous solution of sodium bicarbonate aq. (10 mL). The mixture was stirred for 20 minutes at room temperature. The resulting solution was extracted with 3x10 mL of ethyl acetate and the organic layers combined. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum to yield 150 mg of product.

Example 81 : Nl -(2-(4-acetyrpiperazin- 1 -vDethylVN 1 -methyl-N3 -(4-fpiperidin- 1 -yl -2- (4-( ^, 3-( ^" trifluoromethvDbenzylcarbamoyl ^' )pyridin-2-vDphenyl ^' )isophthalamide. Into a 50- mL round-bottom flask, was placed a solution of N 1 -methyl -Nl-(2-(piperazin- 1- yl)ethyl)-N3-(4-(piperidin-l-yl)-2-(4-(3-(trifluoromethyl)be nzylcarbamoyl)pyridin-2- yl)phenyl)-isophthalamide (150 mg, 0.21 mmol, 1.00 equiv) in dichloromethane (3 mL), and triethylamine (63 mg, 0.62 mmol, 3.00 equiv). This was followed by dropwise addition of acetyl chloride (25 mg, 0.32 mmol, 1.50 equiv) with stirring at 0°C. The resulting solution was stirred for 2 h at 25°C. The reaction was then quenched with 3 mL of water. The resulting solution was extracted with 2x5 mL of dichloromethane and the organic layers combined. The resulting mixture was washed with 1x5 mL of sodium bicarbonate and 2x5 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product (130 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 56.5 mg (38%) of a light yellow solid. 1H-NMR (300MHz, CD ₃ OD, pptn) δ 8.96(d, J=5.1Hz, 1H), 8.70(d, J=9.0Hz, 1H), 8.43(s, 1H), 8.16~8.08(m, 3H), 7.87~7.86(m, 1H), 7.79~7.56(m, 7H), 4.71(s, 2H), 4.00~3.89(m, 5H), 3.63~3.52(m, 11H), 3.23(s ,3H), 2.17(s, 3H), 2.01(s, 1H), 1.81(d, J=4.8Hz, 1H). MS (ES, m/z): 770 [M+H] ⁺ .

EXAMPLE 82 N 1 -Methyl-N 1 -(2-(4-methyrpiperazin- 1 -yl ethyl -N3 -(4-f piperidin- 1 - ylV2-( 4-(T 3 - (trifluoromethyl)benzvncarbamoyl pyridin-2-yl)phenyl)isophthalarnide

Into a 50-mL round bottom flask, was placed a solution of l-methyl-Nl-(2-(piperazin- 1 -yl)ethyl)-N3 -(4-(piperidin- 1 -yl)-2-(4-(3 -(trifluoromethyl)benzylcarbamoyl)pyridin-2- yl)phenyl)isophthalamide (150 mg, 0.21 mmol, 1.00 equiv) in HCHO (in water) (6 mL), NaBH ₃ CN (15 mg, 1.10 equiv), and acetic acid (5 drops). The resulting solution was stirred for 2 h at 25°C. The resulting solution was diluted with 5 mL of sodium bicarbonate, extracted with 2x5 mL of dichloromethane, and the organic layers combined. The resulting mixture was washed with 1x5 mL of water and 1x5 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product (80 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 13.3 mg

(9%) of a light yellow solid. 1H-NMR (300MHz, CD ₃ OD, ppm): δ 8.96(d, J=5.1Hz, 1H), 8.76(d, J=9.3Hz, 1H), 8.45(s, 1H), 8.15(s, 1H), 8.05(s, 2H), 7.89~7.87(m, 1H), 7.71~7.62(m, 5H), 7.59~7.56(m, 2H), 4.72(s, 2H), 3.79(s, 2H), 3.66(d, J=5.1Hz, 4H), 3.50~3.34(m, 2H), 3.15~3.04(m, 6H), 2.89~2.85(m, 6H), 2.80~2.60(m, 2H), 2.04(d, J=4.5Hz, 4H), 1.83(d, J=5.4Hz, 2H). MS (ES, m/z): 742 [M+H] ⁺ .

EXAMPLE 83 1 -methyl-N 1 -(2-Γ4-Γ methylsulfonvnpiperazin- 1 -yl ethyl)-N3 -( 4-( piperidin- 1 -vD-2-( 4- (3-(trifluoromethyl)benzylcarbamoyl)pyridin-2-yl phenyl isophthalamide

Into a 50-mL round-bottom flask, was placed a solution of Nl-methyl-Nl-(2- (piperazin- 1 -yl)ethyl)-N3 -(4-(piperidin- 1 -yl)-2-(4-(3 -

(trifluoromethyl)benzylcarbamoyl)pyridin-2-yl)phenyl)isop hthalamide (100 mg, 0.14 mmol, 1.00 equiv) in dichloromethane (3 mL), triethylamine (42 mg, 0.42 mmol, 3.00 equiv), and methanesulfonyl chloride (17 mg, 0.15 mmol, 1.05 equiv). The resulting solution was stirred for 40 min at 25°C. The reaction was then quenched by the addition of 3 mL of water. The resulting solution was extracted with 2x5 mL of dichloromethane and the organic layers combined. The resulting mixture was washed with 1x5 mL of water and 1x5 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product (90 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 55.8 mg (50%) of a light yellow solid. 1H-NMR (300MHz, CD ₃ OD, ppm): δ 8.97(d, J=5.1Hz, 1H), 8.764(d, J=9.0Hz, 1H), 8.45(s, 1H), 8.16~8.10(m, 3H), 7.89~7.87(m, 1H), 7.80(d, J=7.5Hz, 1H), 7.72~7.67(m, 4H), 7.62~7.53(m, 2H), 4.72(s, 2H), 4.00(s, 2H), 3.68~3.55(m, 14H), 3.1 l(s, 3H), 2.96(s, 3H), 2.04(d, J=4.8Hz, 1H), 1.83(d, J=5.1Hz, 1H). MS (ES, m/z) 806 [M+H] ⁺ .

EXAMPLES 84 THROUGH 119

The compounds listed in Table 6 were prepared by the procedures disclosed above as typified in Example 1.1 (Method 1), Example 8.1 (Method 2), Example 5.1 (Method 3), Example 71 (Method 4), Example 25 (Method 5), Example 37 (Method 6), Example 26 (Method 7), Example 4.22 (Method 8) or Example 8.25 (Method 9). Mass spectral data (ES, positive ion mode) is provided for each compound.

EXAMPLE 120

(4-( dimethylaminoV 2-(4-(3 -( ^" trifluoromethyl ^' )benzylcarbamoyl)pyridin-2- y phenylcarbamovDbenzylthio)propanoic acid

This compound was prepared according to the procedure described for the synthesis of 3 -((3 -((4-(Dipropylamino)-2-(4-((3 -(trifluoromethyl)benzyl)carbamoyl)pyridin-2- yl)phenyl)carbamoyl)benzyl)thio)propanoic acid Example 19, using dimethylamine in place of dipropylamine. (ES, m/z): 637 [M+H] ⁺

(300MHz, OMSO, ppm): 12.10 (s, 1H), 9.53 (t, J=6.0Hz, 1H), 8.97 (d, J=5.1Hz, 1H), 8.33 (s, 1H), 8.26 (d, J=8.7Hz, 1H), 7.85-7.87 (m, 2H), 7.72-7.77 (m, 2H), 7.45-7.69 (m, 5H), 7.35 (s, 1H), 7.09 (d, J=7.8Hz, 1H), 4.63 (d, J=5.7Hz, 2H), 3.87 (s, 2H), 3.04 (s, 6H), 2.53-2.64 (m, 4H).

EXAMPLE 121

Nl-(2-(4-((2-methoxy-4-(trifluoromethyl benzyl ^' )carbamoyl ^' )pyridin-2-ylV4-(piperidin-

Into a 50-mL round-bottom flask, was placed a solution of 2-(2-(3- (carbamoyl)benzamido)-5-(piperidin-l-yl)phenyl)isonicotinic acid (100 mg, 0.15 mmol, 1.00 equiv, 85%) in dichloromethane (6 mL), (2-methoxy-4- (trifluoromethyl)phenyl)methanamine (36 mg, 0.17 mmol, 1.00 equiv), EDC.HCl (67 mg, 0.35 mmol, 2.00 equiv), 4-dimethylaminopyridine (43 mg, 0.35 mmol, 2.00 equiv). The resulting solution was stirred for 2 h at 25°C. The resulting solution was diluted with 100 mL of ethyl acetate. The resulting mixture was washed with 2x20 mL of NH ₄ C1 aq. and 1x20 mL of 10% sodium bicarbonate. The resulting mixture was washed with 1x20 mL of Brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product (120 mg) was purified by Prep-HPLC with the following conditions (1#-Waters 2767-3): Column, SunFire Prep C18, 19* 150mm 5um; mobile phase, water with 0.05%TFA and CH ₃ CN (28% CH ₃ CN up to 39% in 5.5 min); Detector, Waters2545 UvDector 254&270nm. 79.9 mg product was obtained. This resulted in 79.9 mg (48%) of Nl-(2-(4-((2-methoxy-4- (trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin - 1 -yl)phenyl)-N3 -methyl - as a yellow solid.

(ES, m/z): 759 [M+H] ⁺

H'-NMR (300MHZ, DMSO d ₆ ,ppm) 12.41 (s, IH), 9.74 (s, IH), 9.39-9.43 (t, J=12Hz, IH), 8.91 (d, J=6Hz, IH), 8.30-8.35 (m, 2H), 7.48-8.03 (m, 2H), 7.85 (d, J=6Hz, IH), 7.57-7.71 (m, 3H), 7.24-7.42 (m, 3H), 4.53 (s, 2H), 4.17-4.21 (m, 3H), 3.85-3.93 (m, 6H), 3.67 (m, 4H), 3.46 (m, 2H), 3.32 (m, 4H), 3.19 (m, 2H), 2.96 (s, 3H), 1.73 (m, 4H), 1.59 (m, 2H).

EXAMPLE 122

N 1 -(2-(4-((4-tert-butylbenzyl)carbamoyl pyridin-2-yl -4-(piperidin- 1 -yl phenyl -N3 - methyl-N3-(2-morpholinoethyl isophthalamide

Into a 8-mL round-bottom flask, was placed a solution of 2-(2-(3- (carbamoyl)benzamido)-5-(piperidin-l-yl)phenyl)isonicotinic acid (125 mg, 0.19 mmol, 1.00 equiv, 85%) in dichloromethane (2 mL), (4-tert-butylphenyl)methanamine (36 mg, 0.22 mmol, 1.00 equiv), EDC.HC1 (84 mg, 0.44 mmol, 2.00 equiv), 4- dimethylaminopyridine (54 mg, 0.44 mmol, 2.00 equiv). The resulting solution was stirred for 2 h at 25°C. The resulting solution was diluted with 100 mL of ethyl acetate. The resulting mixture was washed with 2x20 mL of NH ₄ C1 aq. and 1x20 mL of 10% sodium bicarbonate. The resulting mixture was washed with 1x20 mL of Brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product (130 mg) was purified by Prep-HPLC with the following conditions (lift- Waters 2767-3): Column, SunFire Prep CI 8, 19* 150mm 5um; mobile phase, water with 0.05%TFA and CH ₃ CN (28% CH ₃ CN up to 39% in 6 min); Detector, Waters2545 UvDector 254&270nm. 85.8 mg product was obtained. This resulted in 85.8 mg (44%) of N 1 -(2-(4-((4-tert-butylbenzyl)carbamoyl)pyridin-2-yl)-4-(piper idin- 1 -yl)phenyl)-N3 - methyl-N3-(2-morpholinoethyl)isophthalamide as a yellow solid. (ES, m/z): 717 [M+H] ⁺ ;

H-NMR (300MHz, DMSO, ppm): 12.39 (s, IH), 9.71 (s, IH), 9.41 (t, J=12Hz, IH), 8.89 (d, J=3Hz, IH), 8.28 (m, 2H), 7.98-8.02 (m, 2H), 7.83 (d, J=6Hz, IH), 7.62-7.69 (m, 3H), 7.24-7.36 (m, 5H), 4.48 (s, 2H), 3.46 (m, 3H), 3.31 (m, 4H), 3.20 (m, 3H), 2.96 (s, 3H), 1.73 (m, 4H), 1.58 (m, 2H), 1.26 (s, 9H).

EXAMPLE 123

N 1 -(2-(4-((2-(trifluoromethoxy)benzyl carbamoyl)pyridin-2- yl -4-(piperidin- 1 - yl)phenyl)-N3 -methyl-N3 -(2-morpholinoethyl)isophthalamide

Into a 8-mL round-bottom flask, was placed a solution of 2-(2-(3- (carbamoyl)benzamido)-5-(piperidin-l-yl)phenyl)isonicotinic acid (100 mg, 0.15 mmol, 1.00 equiv, 85%) in dichloromethane (2 mL), (2- (trifluoromethoxy)phenyl)methanamine (33.45 mg, 0.17 mmol, 1.00 equiv), EDC.HC1 (67.25 mg, 0.35 mmol, 2.00 equiv), 4-dimethylaminopyridine (42.73 mg, 0.35 mmol, 2.00 equiv). The resulting solution was stirred for 2 h at 25°C. The resulting solution was diluted with 100 mL of ethyl acetate. The resulting mixture was washed with 2x20 mL of NH C1 aq. and 1x20 mL of 10% sodium bicarbonate. The resulting mixture was washed with 1x20 mL of Brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product (120 mg) was purified by Prep- HPLC with the following conditions (1#- Waters 2767-3): Column, SunFire Prep CI 8, 19* 150mm 5um; mobile phase, water with 0.05%TFA and CH ₃ CN (22% CH ₃ CN up to 40% in 6 min); Detector, Waters2545 UvDector 254&270nm. 62.2 mg product was obtained. This resulted in 62.2 mg (38%) of Nl-(2-(4-((2- (trifluoromethoxy)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidi n- 1 -yl)phenyl)-N3 - methyl-N3-(2-morpholinoethyl)isophthalamide as a yellow solid. (ES, m/z): 745 [M+H] ⁺ ;

H-NMR (300MHz, DMSO, ppm): 12.37 (s, IH), 9.65 (s, IH), 9.47 (t, J=12Hz, IH), 8.90 (d, J=6Hz, IH), 8.28-8.30 (m, 2H), 7.83-8.00 (m, 2H), 7.96 (d, J=6Hz, IH), 7.57- 7.71 (m, 3H), 7.34-7.48 (m, 4H), 7.27 (m, IH), 4.59 (s, 2H), 3.66 (m, 3H), 3.46 (m, 4H), 3.30 (m, 2H), 2.96 (s, 3H), 1.72 (m, 4H), 1.58-1.60 (m, 2H).

EXAMPLE 124 Nl-(2-(4-((2-methoxybenzvncarbamoyl)pyridin-2-yl)-4-(piperid in-l-yl)phenyl -N3- methyl-N3-(2-morpholinoethyl)isoplithalamide

Into a 8-niL round-bottom flask, was placed a solution of 2-(2-(3- (carbamoyl)benzamido)-5-(piperidin-l-yl)phenyl)isonicotinic acid (100 mg, 0.15 mmol, 1.00 equiv, 85%) in dichloromethane (2 mL), (2-methoxyphenyl)methanamine (30 mg, 0.22 mmol, 1.00 equiv), EDC.HC1 (67.25 mg, 0.35 mmol, 2.00 equiv), 4- dimethylaminopyridine (42.73 mg, 0.35 mmol, 2.00 equiv). The resulting solution was stirred for 2 h at 25°C. The resulting solution was diluted with 100 mL of ethyl acetate. The resulting mixture was washed with 2x20 mL of NH ₄ C1 aq. and 1x20 mL of 10% sodium bicarbonate. The resulting mixture was washed with 1x20 mL of Brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product (120 mg) was purified by Prep-HPLC with the following conditions (1#- Waters 2767-3): Column, SunFire Prep CI 8, 19* 150mm 5um; mobile phase, water with 0.05%TFA and CH ₃ CN (20% CH ₃ CN up to 33% in 6 min); Detector, Waters2545 UvDector 254&270nm. 85.8 mg product was obtained. This resulted in 85.8 mg (55%) of N 1 -(2-(4-((2-methoxybenzyl)carbamoyl)pyridin-2-yl)-4-(piperidi n- 1 -yl)phenyl)-N3 - methyl-N3-(2-morpholinoethyl)isophthalamide as a yellow solid.

LC-MS (ES, m/z): 691 [M+H] ⁺ ;

H-NMR (300MHz, CD ₃ OD, pprri : 12.48 (s, 1H), 9.81 (s, 1H), 9.29 (t, J=12Hz, 1H), 8.90 (d, J=6Hz, 1H), 8.35 (m, 2H), 8.03-7.99 (m, 2H), 7.86 (d, J=3Hz, 1H), 7.72-7.63 (m, 2H), 7.34-7.19 (m, 3H), 7.00 (m, 1H), 6.92-6.87 (t, J=15Hz, 1H), 4.49 (m, 4H), 4.36 (m, 5H), 4.24 (m, 3H), 4.03 (m, 5H), 3.66 (m, 4H), 3.34 (m, 6H), 3.20 (m, 2H), 2.96 (s, 3H), 1.74 (m, 6H).

EXAMPLE 125

N 1 -(2-(4-(Y2-methoxy-5 -(trifluoromethyl)benzyl ^' )carbamoyl pyridin-2-yl -4-(piperidin- 1 -yl phenyl)-N3 -methyl-N3 -(2-morpholinoethyl ^' )isophtlialaniide

Scheme 58. 1. NaN ₃ DMF 2. PPh ₃ ,THF, H ₂ 0 3. 37b EDC HCl, DMAP, DCM.

Intermediate 125a: Into a 50-mL round-bottom flask, was placed a solution of 2- (bromomethyl)-l-methoxy-4-(trifluoromethyl)benzene (230 mg, 0.86 mmol, 1.00 equiv) in N,N-dimethylformamide (5 mL), sodiumazide (167 mg, 2.57 mmol, 3.00 equiv). The resulting solution was stirred for 3 h at 75°C in an oil bath. The resulting solution was diluted with 100 mL of ethyl acetate. The resulting mixture was washed with 4x20 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This resulted in 160 mg (73%) of 2-(azidomethyl)-l- methoxy-4-(trifluoromethyl)benzene as brown oil.

Intermediate 125b: Into a 50-mL round-bottom flask, was placed a solution of 2- (azidomethyl)-l-methoxy-4-(trifluoromethyl)benzene (160 mg, 0.62 mmol, 1.00 equiv, 90%) in tetrahydrofuran/water (4/0.5 mL), triphenylphosphine (399 mg, 1.52 mmol, 2.20 equiv). The resulting solution was stirred for 3 h at 40°C in an oil bath. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column with ethylacetate:methanol (10:1). This resulted in 180 mg (70%) of (2- methoxy-5-(trifluoromethyl)phenyl)methanamine as a off-white solid.

Example 125: 1 -(2-( 4-((2-methoxy-5 -(trifluoromethyl ^' )benzyl)carbamoyl pyridin-2- yl)-4-(piperidin- 1 -yl)phenyl -N3 -methyl -N3 -(2 -morpholinoethvDisophthalamide. A solution of 2-(2-(3-(carbamoyl)benzamido)-5-(piperidin-l-yl)phenyl)isoni cotinic acid (100 mg, 0.15 mmol, 1.00 equiv, 85%) in dichloromethane (6 mL), (2-methoxy-5- (trifluoromethyl)phenyl)methanamine (120 mg, 0.29 mmol, 1.00 equiv, 50%), EDC.HC1 (67 mg, 0.35 mmol, 2.00 equiv), 4-dimethylaminopyridine (43 mg, 0.35 mmol, 2.00 equiv). The resulting solution was stirred for 2 h at 25°C. The resulting solution was diluted with 100 mL of ethyl acetate. The resulting mixture was washed with 2x20 mL of NH ₄ C1 and 1x20 mL of 10% sodium bicarbonate. The resulting mixture was washed with 1x20 mL of Brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product (120 mg) was purified by Prep-HPLC with the following conditions (1#- Waters 2767-3): Column, SunFire Prep C18, 19* 150mm 5um; mobile phase, water with 0.05%TFA and CH ₃ CN (26% CH ₃ CN up to 36% in 6 min); Detector, Waters2545 UvDector 254&270nm. 80.6 mg product was obtained. This resulted in 80.6 mg (48%) of Nl-(2-(4-((2-methoxy-5- (trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin - 1 -yl)phenyl)-N3 -methyl- N3-(2-morpholinoethyl)isophthalamide Example 125 as a yellow solid. LC-MS (ES, m/z): 759 [M+H] ⁺ ;

H-NMR (300MHz, DMSO, ppm): 12.48 (s, IH), 9.70 (s, IH), 9.38 (t, J=12Hz, IH), 8.90 (d, J=6Hz, IH), 8.32 (m, 2H), 7.98-8.03 (m, 2H), 7.84(d, J=6Hz, IH), 7.59-7.71 (m, 4H), 7.27 (m, IH), 4.54 (s, 2H), 3.31-3.86(m, 10H), 3.19 (m, 2H), 3.97 (s, 3H), 1.59-1.72 (m, 6H).

EXAMPLE 126

(SVN 1 -methyl-N 1 -(3 -morpholinopropylVN3-(4-(piperidin- 1 -ylV2-(4-( 1.2.3.4- tetrahvdronaphthalen-l-ylcarbamoyl pyridin-2-yl phenvnisophthalamide

126a 126b

Scheme 59. 1. (Boc) ₂ 0, Et ₃ N, DCM 2. LiAlH ₄ , THF 3. EDCHCl, DMAP, DCM, 4. Lie, Pd(PPh ₃ ) ₄ Na ₂ C0 ₃ , H ₂ 0,DME 5. Pd/C, H ₂ MeOH 6. EDC HCl, DMAP, DCM, 3- (methoxycarbonyl)benzoic acid 7. LiOH, THF, H ₂ 0 8. 126b EDC HCl, DMAP, DCM.

Intermediate 126a: Into a 100-mL round-bottom flask, was placed a solution of 3- morpholinopropan-1 -amine (5 g, 34.67 mmol, 1.00 equiv) in dichloromethane (50 mL), di-tert-butyl dicarbonate (7.56 g, 34.67 mmol, 1.00 equiv.), triethylamine (7 g, 70.00 mmol, 2.00 equiv). The resulting solution was stirred overnight at 25°C. The resulting mixture was concentrated under vacuum. This resulted in 6.8 g (80%) of tert-butyl 3- morpholinopropylcarbamate as light yellow oil.

Intermediate 126b: Into a 100-mL round-bottom flask, was placed a solution of tert- butyl 3-morpholinopropylcarbamate (3 g, 12.28 mmol, 1.00 equiv) in tetrahydrofuran (50 mL). This was followed by the addition of LiAlH ₄ (0.93 g, 24.60 mmol, 2.00 equiv) in several batches. The resulting solution was stirred for 1 h at 75°C in an oil bath. The reaction was then quenched by the addition of 8 mL of water. The solids were filtered out. The resulting mixture was concentrated under vacuum. This resulted in 1.3 g (67%) of N-methyl-3-morpholinopropan-l -amine as light yellow oil.

Intermediate 126c: Into a 250-mL round-bottom flask, was placed a solution of 2- bromoisonicotinic acid (10 g, 49.50 mmol, 1.10 equiv) in dichloromethane (60 mL), (S)-l,2,3,4-tetrahydronaphthalen-l-amine (6.6 g, 44.90 mmol, 1.00 equiv), EDC.HC1 (12.9 g, 67.29 mmol, 1.50 equiv), 4-dimethylaminopyridine (8.3 g, 68.03 mmol, 1.50 equiv). The resulting solution was stirred for 3 h at room temperature. The resulting solution was diluted with 20 mL of water. The resulting solution was extracted with 2x20 ml of dichloromethane and the organic layers combined. The resulting mixture was washed with 1x10 mL of hydrogen chloride (10%) and 1x20 ml of water. The resulting mixture was washed with 1x20 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This resulted in 13.2 g (89%) of (S)-2-bromo-N-(l,2,3,4-tetrahydronaphthalen-l-yl)isonicotina mide as a off- white solid.

Intermediate 126d: Into a 250-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of l-(4-nitro-3-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)phenyl)piperidine (6.5 g, 19.58 mmol, 1.00 equiv) in ethylene glycol dimethyl ether (100 mL), (S)-2-bromo-N-( 1,2,3, 4-tetrahydronaphthalen-l- yl)isonicotinamide (6.5 g, 19.64 mmol, 1.00 equiv), Pd(PPh ₃ ) ₄ (1.13 g, 0.98 mmol, 0.05 equiv), a solution of sodium carbonate (6.2 g, 58.49 mmol, 3.00 equiv) in water(20 mL). The resulting solution was stirred for 3 h at 80°C in an oil bath. The resulting solution was extracted with 2x30 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 1x20 mL of water and 1x20 ml of Brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (2:5-2:1). This resulted in 7.6 g (85%) of 2-(2-nitro-5-(piperidin-l-yl)phenyl)-N-((S)- 1,2,3 ,4-tetrahydronaphthalen- l-yl)isonicotinamide as a yellow solid.

Intermediate 126e: Into a 250-mL round-bottom flask, was placed a solution of 2-(2- nitro-5-(piperidin- 1 -yl)phenyl)-N-((S)- 1 ,2,3 ,4-tetrahydronaphthalen- 1 - yl)isonicotinamide (7.6 g, 16.67 mmol, 1.00 equiv) in methanol (120 mL), Palladium carbon (0.76 g). Hydrogen gas was introduced into the reaction vessel. The resulting solution was stirred overnight at room temperature. The solids were filtered out. The resulting mixture was concentrated under vacuum. This resulted in 5.3 g (75%) of 2-(2- amino-5-(piperidin- 1 -yl)phenyl)-N-((S)- 1 ,2,3 ,4-tetrahydronaphthalen- 1 - yl)isonicotinamide as a brown solid.

(ES, m/z): 427 [M+H] ⁺

(300MHz, CD ₃ OD, ppm): 8.726~8.745(m, 1H), 8.072(s, 1H), 7.630~7.682(m, 2H), 7.266~7.306(m, 2H), 7.145~7.198(m, 3H), 6.984~7.022(m, 1H), 6.831~6.86(d, J=8.7Hz, 1H), 5.378(m, 1H), 3.014~3.049(m, 4H), 2.837~2.885(m, 2H), 1.915~2.033(m, 4H), 1.721~1.796(m, 4H).

Intermediate 126f: Into a 250-mL round-bottom flask, was placed a solution of 2-(2- amino-5-(piperidin- 1 -yl)phenyl)-N-((S)- 1 ,2,3 ,4-tetrahydronaphthalen- 1 - yl)isonicotinamide (4.3 g, 10.09 mmol, 1.00 equiv) in dichloromethane (100 mL), 3- (methoxycarbonyl)benzoic acid (2.08 g, 11.56 mmol, 1.10 equiv), EDCI (2.87 g, 14.97 mmol, 1.50 equiv), 4-dimethylaminopyridine (1.83 g, 14.98 mmol, 1.50 equiv). The resulting solution was stirred for 2 h at room temperature. The resulting solution was diluted with 10 mL of water. The resulting solution was extracted with 2x20 ml of dichloromethane and the organic layers combined. The resulting mixture was washed with 1x20 mL of water and 1x20 ml of Brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This resulted in 5.8 g (98%) of methyl 3 -((2-(4-(((S)- 1 ,2,3 ,4-tetrahydronaphthalen- 1 -yl)carbamoyl)pyridin-2-yl)-4-(piperidin- l-yl)phenyl)carbamoyl)benzoate as a brown solid. Intermediate 126g: Into a 250-mL round-bottom flask, was placed a solution of methyl 3 -((2-(4-(((S)- 1 ,2,3 ,4-tetrahydronaphthalen- 1 -yl)carbamoyl)pyridin-2-yl)-4-(piperidin- l-yl)phenyl)carbamoyl)benzoate (5.8 g, 9.86 mmol, 1.00 equiv) in tetrahydrofuran (50 mL), a solution of lithium hydroxide hydrate (1.2 g, 28.57 mmol, 5.00 equiv) in water(20 mL). The resulting solution was stirred for 16 h at 70°C in an oil bath. The resulting mixture was concentrated under vacuum. The pH value of the solution was adjusted to 3-4 with hydrogen chloride (10 %). The solids were collected by filtration. The solid was dried in an oven under reduced pressure. This resulted in 5 g (88%) of 3- ((2-(4-(((S)- 1 ,2,3 ,4-tetrahydronaphthalen- 1 -yl)carbamoyl)pyridm-2-yl)-4-(piperidin- 1 - yl)phenyl)carbamoyl)benzoic acidas as a brown solid.

LC-MS (ES, m/z): 575 [M+H] ⁺ ;

H-NMR (300MHz, CDC1 ₃ , ppm): 13.36(s, 1H), 8.85(s, 1H), 8.59(s, 2H), 8.31(s, 1H), 8.1 l(s, 2H), 7.81~7.46(m, 4H), 7.08(d, J=13.5Hz, 4H), 5.38(s, 1H), 3.23(s, 4H), 2.74(s, 2H), 2.10~1.60(m, 10H).

Example 126 : (S)-N 1 -methyl-N 1 -(3 -morpholinopropyl -N3 -(4-(piperidin- 1 -vD-2-(4- ( 1 ,2,3 ,4-tetrahydronaphthalen- 1 -ylcarbamoyl pyridin-2-yl phenyDisophthalamide. A solution of 3-((2-(4-(((S)-l,2,3,4-tetrahydronaphthalen-l-yl)carbamoyl)p yridin-2-yl)-4- (piperidin-l-yl)phenyl)carbamoyl)benzoic acid (150 mg, 0.26 mmol, 1.00 equiv) in dichloromethane (3 mL), N-methyl-3-morpholinopropan-l -amine (42 mg, 0.27 mmol, 1.00 equiv), EDC.HC1 (75 mg, 0.39 mmol, 1.50 equiv), 4-dimethylaminopyridine (48 mg, 0.39 mmol, 1.50 equiv). The resulting solution was stirred for 2 h at 25°C. The resulting solution was diluted with 3 mL of water. The resulting solution was extracted with 2x5 mL of dichloromethane and the organic layers combined. The resulting mixture was washed with 1x5 mL of water and 2x5 mL of Brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product (120 mg) was purified by Prep-HPLC with the following conditions (1#- Waters 2767-3): Column, SunFire Prep C18, 19*150mm 5um; mobile phase, water with 0.05%TFA and CH ₃ CN (24% CH ₃ CN up to 34% in 6 min); Detector, Waters2545 UvDector 254&220nm. 97 mg product was obtained. This resulted in 97 mg (35%) of (S)-Nl- methyl-Nl-(3-morpholinopropyl)-N3-(4-(piperidin-l-yl)-2-(4-( l,2,3,4- tetrahydronaphthalen- 1 -ylcarbamoyl)pyridin-2-yl)phenyl)isophthalamide. Example 126 as a yellow solid.

(ES, m/z): 715 [M+H] ⁺

(400MHz, CO ₃ OO, ppm): 8.91(s, 1H), 8.73(d, J=8.8Hz, 1H), 8.41(s, 1H), 8.14~8.09(m, 3H), 7.873~7.857(m, 1H), 7.753~7.69(m, 3H), 7.27(d, J=7.2Hz, 1H), 7.19~7.13(m, 3H), 5.40(d, J=6.4Hz, 1H), 4.18(s, 2H), 3.90~3.50(m, 9H), 3.46-3.17(m, 5H), 3.07(s, 3H), 2.89~2.78(s, 2H), 2.26~2.03(m, 8H), 1.98~1.81(m, 4H).

EXAMPLE 127

N 1 -(4-(butyl(methyl amino)-2-(4-(3 -(trifluoromethvDbenzylcarbamoyl ^' )pyridin-2- vDphenylVNS -methyl-N3 -( ^" 2-morpholinoethyl)isophthalamide

Into a 50-mL round-bottom flask, was placed a solution of N-(3- (trifluoromethyl)benzyl)-2-(2-amino-5-(butyl(methyl)amino)ph enyl)isonicotinamide (250 mg, 0.55 mmol, 1.00 equiv) in dichloromethane (10 mL), 3-(methyl(2- morpholinoethyl)carbamoyl)benzoic acid (190 mg, 0.65 mmol, 1.19 equiv), 4- dimethylaminopyridine (133 mg, 1.09 mmol, 1.99 equiv), EDC.HC1 (210 mg, 1.09 mmol, 2.00 equiv). The resulting solution was stirred overnight at room temperature. The reaction progress was monitored by LCMS. The resulting solution was diluted with 100 mL of dichloromethane. The resulting mixture was washed with 2x50 mL of NH ₄ C1 aq. and 2x50 mL of brine. The mixture was dried over sodium sulfate and concentrated under vacuum. The crude product was purified by Prep-HPLC with the following conditions (1#- Waters 2767-3): Column, SunFire Prep CI 8, 5um, 19* 150mm; mobile phase, water with 0.05%TFA and CH ₃ CN (30% CH ₃ CN up to 42% in 6 min); Detector, UV 220&254 nm. This resulted in 87.2 mg (15%) of Nl-(4- (butyl(methyl)amino)-2-(4-(3-(trifluoromethyl)benzylcarbamoy l)pyridin-2-yl)phenyl)- N3-methyl-N3-(2-morpholinoethyl)isophthalamide as a yellow solid. LC-MS (ES, m/z): 731 [M+H] ⁺

H-NMR (300MHz, DMSO, ppm): 11.95(s, 1H), 9.75(s, 1H), 9.52(s, 1H), 8.88(d, J=5.1Hz, 1H), 8.27(s, 1H), 8.10(d, J=9.3Hz, 1H), 7.97-7.83(m, 2H), 7.82(d, J=5.1Hz, 1H), 7.70-7.54(m, 6H), 7.17(s, 1H), 6.95(d, J=7.5Hz, 1H), 4.61(d, J=5.7Hz, 2H), 4.02(s, 2H), 3.90(s, 2H), 3.65(s, 4H), 3.45-3.39(m, 4H), 3.20(s, 2H), 3.0(d, J=12.3Hz, 6H), 1.55-1.50 (m, 2H), 1.35-1.30(m, 2H), 0.93-0.88(m, 3H).

EXAMPLE 128

N 1 -(2-(4-((3 -(trifluoromethyl benzyl carbamoyl)pyridin-2-yl -4-

(ethyl(propyl)amino phenvD-N3-methyl-N3-(2-morpholinoethyl)isophthalamide

Into a 50-mL round-bottom flask, was placed a solution of N-(3- (trifluoromethyl)benzyl)-2-(2-amino-5-(ethyl(propyl)amino)ph enyl)isonicotinamide (150 mg, 0.30 mmol, 1.00 equiv, 90%) in dichloromethane (8 mL), 3-(methyl(2- morpholinoethyl)carbamoyl)benzoic acid (144 mg, 0.44 mmol, 1.50 equiv, 90%), EDC HC1 (126 mg, 0.66 mmol, 2.00 equiv), 4-dimethylaminopyridine (80 mg, 0.66 mmol, 2.00 equiv). The resulting solution was stirred overnight at room temperature. The resulting solution was diluted with 100 mL of ethyl acetate. The resulting mixture was washed with 2x20 mL of NH ₄ C1 aq. and 1x20 mL of sodium bicarbonate(10%). The resulting mixture was washed with 1x20 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product (250 mg) was purified by Prep-HPLC with the following conditions (1#-Waters 2767-3): Column, SunFire Prep CI 8, 19* 150mm 5um; mobile phase, water with 0.05%TFA and CH ₃ CN (25% CH ₃ CN up to 39% in 6 min); Detector, Waters2545 UvDector 254&270nm. 183.7 mg product was obtained. This resulted in 183.7 mg (56%) of Nl- (2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-

(ethyl(propyl)amino)phenyl)-N3 -methyl-N3 -(2-morpholinoethyl)isophthalamide as a yellow solid. LC-MS (ES, m/z) : 731 [M+H] ⁺ ;

H-NMR (300MHz, DMSO, ppm): 9.83 (s, IH), 9.52 ( t, J=18Hz, IH), 8.89 (d, J=3Hz, IH), 8.26 (s, IH), 8.13 (s, IH), 7.99 (m, 2H), 7.82 (d, IH), 7.54-7.69 ( m, 6H), 6.95- 7.54 (m, 2H), 4.60 (s, 2H), 3.85-4.02 (m, 4H), 3.64 ( m, 4H), 3.36-3.47 (m, 6H), 3.18 (m, 2H), 2.95 (s, 3H), 1.60 (m, 2H), 1.09-1.13 (m, 3H), 0.87-0.92 (m, 3H).

EXAMPLE 129

N ¹ -methyl-N ³ -(4-( ^' methyl(propyl amino)-2-(4-((3-(trifluoromethyl benzyl carbamoyl pyridin-2-yl phenyl -N ¹ -(2-mo holinoethyl iso hthalamide

This compound was prepared according to the procedure described for the synthesis of N ¹ -(4-(diethylamino)-2-(4-((3-(trifluoromethyl)benzyl)ca rbamoyl)pyridin-2-yl)phenyl)- N ³ -methyl - ³ -(2^ο ηο1ϊηθ6^1)ί8ο η^ΐ3η ίάε 25, using N-methylpropan-1 -amine in place of diethylamine. MS (ES, m/z): 717.3 [M+H] ⁺ .

EXAMPLE 130 (S -Nl-methyl-Nl-r2-morpholinoethylVN3-(2-( ^" 4-ri.2 ,4-tetrahvdronaphthalen-l- ylcarbamovDpyridin-2-yl)-4-(trifluoromethyl phenyl)isophthalamide

Scheme 60. 1. PdCl ₂ (dppf), KOAc, DMSO, 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(l,3,2- dioxaborolane) 2. 126c, Pd(PPh ₃ ) ₄ , Na ₂ C0 ₃ , H ₂ 0, DME 3. Py, DCM.

Intermediate 130a: Into a 50-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of 2-bromo-4- (trifluoromethyl)benzenamine (1 g, 4.17 mmol, 1.00 equiv) in DMSO (20 mL), 4,4,5,5- tetramethyl-2-(4,4,5 ,5 -tetramethyl- 1 ,3 ,2-dioxaborolan-2-yl)- 1 ,3 ,2-dioxaborolane (1.58 g, 6.22 mmol, 1.50 equiv), PdCl ₂ (dppf) (91 mg, 0.12 mmol, 0.03 equiv), potassium acetate (1 g, 10.40 mmol, 2.57 equiv). The resulting solution was stirred overnight at 80 °C in an oil bath. The resulting mixture was combined with the solution of the previous batch and then diluted with 100 mL of ethyl acetate. The resulting mixture was washed with 2x100 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:100). This resulted in 1.2 g of 2-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)-4-(trifluoromethyl)benzenamine as a yellow solid. Intermediate 130b: Into a 100-mL 3 -necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of 2-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)-4-(trifluoromethyl)benzenamine (1.2 g, 4.18 mmol, 1.00 equiv) in ethylene glycol dimethyl ether (40 mL), (S)-2-bromo-N-(l,2,3,4- tetrahydronaphthalen-l-yl)isonicotinamide (1.38 g, 4.17 mmol, 1.00 equiv), Pd(PPh ₃ ) (480 mg, 0.42 mmol, 0.10 equiv), a solution of sodium carbonate (2.22 g, 20.94 mmol, 5.00 equiv) in water (20 mL). The resulting solution was stirred for 1 h at 80°C in an oil bath. The resulting solution was diluted with 100 mL of ethyl acetate. The resulting mixture was washed with 2x100 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with petroleum ether/ethyl acetate (5:1). This resulted in 900 mg (65%) of (S)-2-(2-amino-5-(trifluoromethyl)phenyl)-N-(l,2,3,4-tetrahy dronaphthalen-l- yl)isonicotinamide as a yellow solid.

Example 130: Into a 25 -mL round-bottom flask, was placed a solution of (S)-2-(2- amino-5-(trifluoromethyl)phenyl)-N-(l,2,3,4-tetrahydronaphth alen-l- yl)isonicotinamide (200 mg, 0.49 mmol, 1.00 equiv) in dichloromethane (6 mL), pyridine (3 mL). This was followed by the addition of a solution of 3-(methyl(2- morpholinoethyl)carbamoyl)benzoyl chloride (230 mg, 0.74 mmol, 1.50 equiv) in dichloromethane (1 mL) drop wise with stirring. The resulting solution was stirred for 3 h at room temperature. The pH value of the solution was adjusted to 7 with 10% hydrochloric acid. The resulting solution was extracted with 2x100 mL of ethyl acetate and the organic layers combined and concentrated under vacuum. The crude product (200 mg) was purified by Prep-HPLC with the following conditions (1#- Waters 2767- 3): Column, SunFire Prep CI 8, 19* 150mm 5um; mobile phase, water with 0.05%TFA and CH ₃ CN (40% CH ₃ CN up to 54% in 6 min); Detector, Waters2545 UvDector 254&270nm. 93.7 mg product was obtained. This resulted in 93.7 mg (21%) of (S)-Nl- methyl-Nl -(2-morpholinoethyl)-N3 -(2-(4-( 1 ,2,3 ,4-tetrahydronaphthalen- 1 - ylcarbamoyl)pyridin-2-yl)-4-(trifluoromethyl)phenyl)isophtha lamide as a light yellow solid. LC-MS (ES, m/z): 686 [M+H] ⁺ ;

H-NMR (300MHz,DMSO, ppm): 13.29 (s, IH), 9.28 (d, J=8.7Hz, IH), 8.96 (d, J=5.1Hz, IH), 8.77 (d, J=8.7Hz, IH), 8.46 (s, IH), 8.34 (s, IH), 8.10 (m, 2H), 7.97 (m, 2H), 7.78 (m, 2H), 7.18(m, 4H), 5.29 (d, J=5.7Hz, IH), 3.69 (m, 10H), 3.2 l(s, 2H), 2.98 (s, 4H), 2.82(m, 2H), 2.03(m, 4H).

EXAMPLE 131

(S)-N ¹ -( 4-(diethylaminoV2-(4-(Yl ,2,3 ,4-tetrahvdronaphthalen- 1 -vDcarbamovDpyridin- 2-yl phenyl)-N ³ -methyl-N ³ -(2-morpholinoethyl isophthalamide

Scheme 61. Pd(PPh ₃ ) ₄ , Na ₂ C0 ₃ , DME, H ₂ 0 2. diethylamine, K ₂ C0 ₃ , DMF; 3. Pd/C, H ₂ , MeOH; 4. 3-(tert-butoxycarbonyl)benzoic acid, HATU, DIEA, DMF; 5. 4M HCl in dioxane; 6. N-methyl-2-morpholinoethanamine, HATU, DIEA, DMF. Intermediate 131a. Into a 1000-mL 3 -necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of 2-(5-fluoro-2- nitrophenyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (10.7 g, 40.07 mmol, 1.20 equiv) in ethylene glycol dimethyl ether (300 mL), (S)-2-bromo-N-(l,2,3,4- tetrahydronaphthalen-l-yl)isonicotinamide (11.05 g, 33.38 mmol, 1.00 equiv), Pd(PPh ₃ ) ₄ (3.86 g, 3.34 mmol, 0.10 equiv), a solution of sodium carbonate (17.69 g, 166.89 mmol, 5.00 equiv) in water(150 mL). The resulting solution was stirred for 18 h at 80°C in an oil bath. The resulting solution was diluted with 100 mL of water. The resulting solution was extracted with 2x100 mL of ethyl acetate and the organic layers combined and dried over sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with petroleum ether/ethyl acetate (10:1-1 :1). This resulted in 5.0014 g (32%) of (S)-2-(5-fluoro-2-nitrophenyl)-N-(l,2,3,4- tetrahydronaphthalen-l-yl)isonicotinamide as a yellow solid. LC-MS (ES, m/z):392 [M+H] ⁺

H-NMR (400MHz, CDC1 ₃ , ppm):S 3 (d, J=3.9Hz, 1H) , 8.02-7.98 (m, 1H), 7.83 (s, 1H) ,7.60-7.58 (m, 1H), 7.32-7.13 (m, 6H), 6.45 (d, J=9.0Hz, 1H), 5.42-5.38 (m, 1H), 2.89-2.77 (m, 2H), 2.20-2.13 (m, 1H), 2.01-1.90 (m, 3H).

Intermediate 131b: ( S )-2-( 5 -(diethylaminoV2-nitrophenylVN-f 1 ,2,3.4- tetrahvdronaphthalen- 1 -vDisonicotinamide. A mixture of (S)-2-(5-fluoro-2- nitrophenyl)-N-(l,2,3,4-tetrahydronaphthalen-l-yl)isonicotin amide (12.77 mmol, 5 g), diethylamine (25.55 mmol, 1.87 g), and K ₂ C0 ₃ (31.93 mmol, 4.41 g) in DMF (30 mL) was stirred at 60°C overnight. The mixture was diluted with ethyl acetate, and the resulting solution was washed with water (2x), and then with brine. The solution was dried (Na ₂ S0 ₄ ) and the solvent was removed at reduced pressure. The residue was purified by chromatography on silica gel to give a yellow solid. (4.73 g, 83%).

Intermediate! 31c: (SV2-(2-amino-5-(diethylamino ^' )phenyl ^' )-N-(l,2,3,4- tetrahydronaphthalen- 1 -vDisonicotinamide. A mixture of (S)-2-(5-(diethylamino)-2- nitrophenyl)-N-(l,2,3,4-tetrahydronaphthalen-l-yl)isonicotin amide (4.73 g) and 10% Pd/C (1.3 g) in methanol (20 mL) was stirred under a hydrogen atmosphere for 2 h. The mixture was filtered and concentrated to give a brown solid (4g, 91%).

Intermediate 13 Id: (SVtert-butyl 3 -((4-f diethylamino)-2-( 4-(( 1 ,2,3.4- tetrahvdronaphthalen-l-vDcarbamovf)pyridin-2-yl ^' )phenvDcarbamovnbenzoate. To a mixture of (S)-2-(2-amino-5 -(diethylamino)phenyl)-N-( 1 ,2,3 ,4-tetrahydronaphthalen- 1 - yl)isonicotinamide (7.1 mmol, 2.94 g), 3-(tert-butoxycarbonyl)benzoic acid (8.52 mmol, 1.89 g) and DIEA (35.5 mmol, 4.59 g) in DMF (16 mL) was added HATU (8.52 mmol, 3.24 g). The mixture was stirred at 60 °C for 1 h. The reaction mixture was diluted with ethyl acetate, washed with water (2x), brine (lx), dried and concentrated. The residue was purified by column to give a yellow solid (4.31 g, 98%).

Intermediate 131 e: ( S >3 -( ( -(diethylaminoV 2-(4-( ( 1.2.3 ,4-tetrahvdronaphthalen- 1 - vDcarbamoyl pyridin-2-yl)phenyl carbamoyl benzoic acid. To ((S)-tert-butyl 3-((4- (diethylamino)-2-(4-(( 1 ,2,3 ,4-tetrahydronaphthalen- 1 -yl)carbamoyl)pyridin-2- yl)phenyl)carbamoyl)benzoate (4.31 g)was added 4M HC1 in dioxane (20 mL). The mixture was stirred at room temperature for 5 h, concentrated to give a yellow solid which was used without further purification.

Example 131 ; ( ^' SVN ¹ -(4-(diethylaminoV2-(4-((1.2.3,4-tetrahvdronaphthalen- l- vDcarbamoyl) pyridin-2-yl)phenyl -N ³ -methyl-N ³ -( ^, 2-morpholinoethyl)isophthalamide. To a mixture of (S)-3-((4-(diethylamino)-2-(4-(( 1,2,3, 4-tetrahydronaphthalen-l- yl)carbamoyl)pyridin-2-yl)phenyl)carbamoyl)benzoic acid (1.81 mmol, 1.15 g), N- methyl-2-morpholinoethanamine (2.17 mmol, 0.313 g) and DIEA (12.67 mmol, 1.64 g) in DMF (5mL) was added HATU (2.17 mmol, 0.826 g), and the mixture was stirred at 60°C for 2 h. The reaction mixture was diluted with ethyl acetate, washed with water (2x), brine (lx), dried and concentrated. The residue was purified by column to give a yellow solid (0.98 g, 79%). MS (ESI, m/z) 689.28 [M+H] ⁺ .

EXAMPLE 132

Scheme 62. 1. Cyclobutanol DMF, NaH 2. Pd/C, H ₂ , MeOH 3. 80e, EDC. HC1, DMAP, DCM.

Intermediate 132a: To a suspension of sodium hydride (100 mg, 4.17 mmol, 2.04 equiv, 100%) in N,N-dimethylformamide (25 mL) under an inert atmosphere of nitrogen, was addedcyclobutanol (200 mg, 2.77 mmol, 1.36 equiv, 100%) dropwise with stirring at 0°C over 5 min. To the resulting solution was added 2-(5-fluoro-2- nitrophenyl)-N-((S)-l,2,3,4-tetrahydronaphthalen-l-yl)isonic otinamide (800 mg, 2.04 mmol, 1.00 equiv, 100%) at 0°C. The resulting solution was stirred for 3 h at room temperature. The reaction was then quenched by the addition of 15 mL of water. The resulting solution was extracted with 3x20 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 1x20 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This resulted in 0.92 g (95%) of 2-(5-cyclobutoxy-2-nitrophenyl)-N-((S)- 1,2,3, 4-tetrahydronaphthalen- l-yl)isonicotinamide as yellow oil. Intermediate 132b: Into a 100-mL round-bottom flask, was placed a solution of 2-(5- cyclobutoxy-2-nitrophenyl)-N-((S)- 1 ,2,3 ,4-tetrahydronaphthalen- 1 -yl)isonicotinamide (920 mg, 2.07 mmol, 1.00 equiv, 100%) in methanol (30 mL), Palladium carbon (800 mg, 10%). Hydrogen gas was introduced to the reaction vessel The resulting solution was stirred overnight at room temperature. The solids were filtered out. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1 :5). This resulted in 0.42 g (48%) of 2-(2- amino-5-cyclobutoxyphenyl)-N-((S)- 1 ,2,3,4-tetrahydronaphthalen-l -yl)isonicotinamide as light yellow oil.

LC-MS (ES, m/z): 414 [M+H] ⁺

H-NMR (300MHz, DC\3, ppm): 8.71 ( d , J=5.1 Hz , 1H ) , 7.69 ( s , 1H ) , 7.52 ( d , J=1.5 Hz , 1H ) , 7.51-7.16 ( m , 4H ) , 7.09 ( d , J=2.7 Hz , 1H ) , 6.86-6.76 ( m , 2H ) , 6.47 ( d , J=8.1Hz , 1H ) , 5.44 ( d , J=7.2Hz , 1H ) , 4.65-4.60 ( m , 1H ) , 2.91-2.84 ( m , 2H ) , 2.49-2.39 ( m , 4H ), 2.23-2.14 ( m , 5H ) 2.06-1.88 ( m , 1H ).

Example 132: Into a 100-mL round-bottom flask, was placed a solution of 2-(2-amino- 5-cyclobutoxyphenyl)-N-((S)- 1 ,2,3 ,4-tetrahydronaphthalen- 1 -yl)isonicotinamide (100 mg, 0.24 mmol, 1.00 equiv, 100%) in dichloromethane (20 mL), 3-(methyl(2- morpholinoethyl)carbamoyl)benzoic acid (80 mg, 0.27 mmol, 1.13 equiv, 100%), 4- dimethylaminopyridine (44 mg, 0.36 mmol, 1.49 equiv, 100%), EDCI (69 mg, 0.36 mmol, 1.49 equiv, 100%). The resulting solution was stirred overnight at room temperature. The reaction progress was monitored by LCMS. The resulting mixture was washed with 2x10 mL of water. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product (0.15 g) was purified by Prep- HPLC with the following conditions (1#-Waters 2767-3): Column, SunFire Prep CI 8, 19* 150mm 5um; mobile phase, water with 0.05%TFA and CH ₃ CN (36% CH ₃ CN up to 52% in 6 min); Detector, Waters2545 UvDector 254&270nm. 84 mg product was obtained. This resulted in 108.4 mg (65%) of Nl-(2-(4-(((S)-l, 2,3,4- tetrahydronaphthalen- 1 -yl)carbamoyl)pyridin-2-yl)-4-cyclobutoxyphenyl)-N3 -methyl - N3-(2-morpholinoethyl)isophthalamide as a light yellow solid. LC-MS (ES, m/z) 688 [M+H] ⁺ H-NMR (300MHz, DMSO, ppm): 12.52 ( s , 1H ) , 9.27 ( d , J=8.7 Hz , 1H ) , 8.89 ( d , J=5.1Hz , 1H ) , 8.32 ( d , J=8.7Hz , 2H ) , 8.04-8.00 ( m , 2H ) , 7.89-7.87 ( m , 2H ) , 7.69-7.64 ( m , 1H ) , 7.58 ( d , J=3.0Hz , 1H ) , 7.22-7.12 ( m , 4H ) , 7.05-7.02 ( m , 1H ) , 5.26 ( d , J=6.0Hz , 1H ) , 4.78-4.76 ( t , 1H ) , 4.03 ( s , 2H ) , 3.87 ( s , 2H ) , 3.21 ( s , 2H ) , 2.97 ( s , 4H ) , 2.80 ( d , J=5.1Hz , 2H ) , 2.08 ( d . J=7.5Hz , 4H ) , 2.04-1.99 ( m , 4 H).

EXAMPLE 133

( ^, S)-N ¹ -( ^' 4-icvclopentyloxyV2-(4-(ri ,2,3,4-tetrahvdronaphthalen-l - vDcarbamovDpyridin-2-yl)phenyl -N ³ -meth^

Scheme 63a. 1. 3-(methyl(2-mo holinoethyl)carbamoyl)benzoic acid, HATU, DIEA, DMF.

Intermediate 133a ( ^, S)-2-(2-amino-5-(cyclopentyloxy phenyl)-N-(l,2.3.4- tetrahydronaphthalen- 1 -vDisonicotinamide. This intermediate was prepared according to the procedure described for the synthesis of (S)-2-(2-amino-5-cyclobutoxyphenyl)-N- (l,2,3,4-tetrahydronaphthalen-l-yl)isonicotinamide Example 132, using cyclopentanol in place of cyclobutanol.

Example 133: (S -N ¹ -( ^' 4-(cvclopentyloxy -2-r4-((1.2,3,4-tetrahvdronaphthalen-l- yl)carbamoyl ^' )pyridin-2-yl ^' )phenylVN ³ -methyl-N ³ -( ^, 2-morpholinoethyl ^' )isophthalamide. To a mixture of (S)-2-(2-amino-5-(cyclopentyloxy)phenyl)-N-(l, 2,3,4- tetrahydronaphthalen-l-yl)isonicotinamide (0.076 mmol, 32 mg), 3-(methyl(2- morpholinoethyl)carbamoyl)benzoic acid (0.083 mmol, 24 mg) and DIEA (0.38 mmol, 49 mg) in DMF (0.25 mL) was added HATU (0.083 mmol, 32 mg). The mixture was stirred at 60 °C overnight and purified by prep. HPLC to give Example 133 as a yellow solid (36 mg, 51%). MS (ES, m/z): 703.3[M+H] ⁺ .

EXAMPLE 134

2-(3-(3-(4-fpiperidin-l-yl -2-(4-(3-(trifluoromethyl benzylcarbamoyl pyridin-2- yl)phenylcarbamoyl benzylthio ^> )phenoxy acetic acid.

Scheme 63b. 1. 3-mercaptophenol, K2CO3, DMF; 2. ethyl 2-bromoacetate, sodium iodide, K ₂ C0 ₃ , DMF; 3. LiOH.

Intermediate 134a: 2-Γ2-Γ3 -((3 -hydroxyphenylthio)methyl benzamido -5-(piperidin- 1 - vDphenyD-N-CS-CtrifluoromethvDbenzvDisonicotinamide. A mixture of 8.1a (300 mg, 0.49 mmol), 3-mercaptophenol (66 μΕ, 0.59 mmol), and K ₂ C0 ₃ (75 mg, 1.5 mmol) in dry DMF (3 mL) was stirred at for 1 h and then filtered. The filtrate was poured into H ₂ 0 (50 mL), forming a yellow precipitate. The solid was filtered, then dissolved in DCM and washed with aqueous HCl, saturated aqueous NaHC0 ₃ , and H ₂ 0. The solvent was then removed to give 298 mg (87%) of the product 134a as a yellow solid.

Example 134: 2-(3-(3-(4-(piperidin-l-vn-2-(4-(3- (trifluoromethyl)benzylcarbamovDpyridin-2- vDphenylcarbamovDbenzylthiolphenoxy'jacetic acid. A mixture of 134a (74 mg, 0.11 mmol), ethyl 2-bromoacetate (21 mg, 0.13 mmol), sodium iodide (1 mg, 0.05 mmol), and K ₂ C0 ₃ (37 mg, 0.27 mmol) were combined in dry DMF and the suspension heated to 100 °C and stirred for 1 h. The suspension was poured into H ₂ 0 (100 mL), resulting in the formation of a yellow precipitate, which was filtered. The solid was dissolved in DCM and washed with aqueous HCl, saturated aqueous NaHC0 ₃ , and H ₂ 0, then dried over Na ₂ S0 ₄ and the solvent removed to give intermediate 134b. The residue was dissolved in dioxane (2 mL) and H ₂ 0 (1 mL), to which LiOH*H ₂ 0 (7 mg, 0.16 mmol) was added the solution stirred for 1 h. The solution was then acidified and purified by reverse-phase HPLC eluting with a water / acetonitrile gradient containing 0.1% TFA. The process resulted in 62 mg (60%) of the product Example 134 as the di-TFA salt. MS (ES, m/z) 755 [M+H] ⁺ .

EXAMPLE 135

3-(2-r2-( ^, 2-( ^{^} N-methyl-3-(3-(4-rpiperidin-l-ylV2-(4-(3- (trifluoromethyl benzylcarbamoyl ^N )pyridin-2- yl)phenylcarbamoyl benzylthio benzamido ethoxy)ethoxy)ethoxy propanoic acid

291 Scheme 64. 1. tert-butyl acrylate, Na, THF 2. 4-methylbenzene-l-sulfonyl chloride, pyridine 3. 2-methoxyethanamine 4. HATU, DIEA, DMF; 5. TFA, DCM.

Into a 1000-mL round-bottom flask, was placed a solution of 2,2'-(2,2'-oxybis(ethane- 2,l-diyl)bis,2-diylbis(oxy))diethanol (82 g, 546.05 mmol, 3.50 equiv) in tetrahydrofuran (300 mL), sodium (110 mg, 4.78 mmol, 0.03 equiv). This was followed by the addition of tert-butyl acrylate (20 g, 156.04 mmol, 1.00 equiv) dropwise with stirring at room temperature. The resulting solution was stirred overnight at room temperature. The pH value of the solution was adjusted to 7 with 1M hydrochloric acid. The resulting solution was extracted with 3x100 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 3x100 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This resulted in 36.6 g (84%) of tert-butyl 3-(2-(2-(2- hydroxyethoxy)ethoxy)ethoxy)propanoate as yellow oil.

Into a 250-mL round-bottom flask, was placed a solution of tert-butyl 3-(2-(2-(2- hydroxyethoxy)ethoxy)ethoxy)propanoate (10 g, 35.97 mmol, 1.00 equiv) in pyridine (40 mL). This was followed by the addition of 4-methylbenzene-l-sulfonyl chloride (6.8 g, 35.79 mmol, 1.00 equiv), in portions at 0°C. The resulting solution was stirred for 4 h at 0°C. The resulting mixture was concentrated under vacuum. The residue was dissolved in 30 ml of dichloromethane. The resulting mixture was washed with 3x20 mL of 3% hydrochloric acid (aq). The resulting mixture was washed with 20 mL of sodium chloride(aq). The mixture was dried over sodium sulfate and concentrated under vacuum. This resulted in 14 g (90%) of tert-butyl 3-(2-(2-(2- (tosyloxy)ethoxy)ethoxy)ethoxy)propanoate as yellow oil.

Into a 250-mL sealed bottle, was placed a solution of tert-butyl 3-(2-(2-(2- (tosyloxy)ethoxy)ethoxy)ethoxy)propanoate (14 g, 32.41 mmol, 1.00 equiv) in tetrahydrofuran (5 mL), CH ₃ NH ₂ (66.9 g, 712.16 mmol, 21.98 equiv, 33% in ethanol). The resulting solution was stirred overnight at 50°C. The resulting mixture was concentrated under vacuum. The residue was dissolved in 150 ml of dichloromethane. The resulting mixture was washed with 2x150 mL of water. The resulting mixture was washed with 1x150 mL of sodium chloride(aq). The mixture was dried over sodium sulfate and concentrated under vacuum. This resulted in 8.2 g (87%) of tert-butyl 3-(2- (2-(2-(methylamino)ethoxy)ethoxy)ethoxy)propanoate as yellow oil.

The following intermediates were prepared as depicted in scheme 64 by subtituting appropriate alcohols in place of 135a then displaceing the sulfonate in step 3 with amines, amides or potassium thioacetate with or without the addition of a suitable base.

*For intermediate 135c.5 the product was obtained after acidic deprotection of the displacement product. **For intermediate 135c.6 th product was obtained after catalytic hydrogenation of the displacement product.

This compound was prepared using the method described for the preparation of Example 10.1, using tert-butyl 3-(2-(2-(2-

(methylamino)ethoxy)ethoxy)ethoxy)propanoate 135c in place of tert-butyl 3-(2-(2-(2- aminoethoxy)ethoxy)ethoxy)propanoate. MS (ES, m/z) 942 [M+H] ⁺ .

EXAMPLE 136

2-(2-(3 -((3 -(2-(methyl(2-morpholinoethyl amino -2- oxoethvDphenylthio ^' jmethvDbenzamido^-S- piperidin-l-vDphenvD-N-fS- (trifluoromethyDbenzvDisonicotinamide

This compound was prepared using the method described for the preparation of Example 10.1a, using 8.18 in place of 8.1 and N-methyl-2-morpholinoethanamine in place of tert-butyl 3-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)propanoate. MS (ES, m/z) 865 [M+H] ⁺ . EXAMPLES 137-141

The compounds presented in Table 8 were prepared using the procedure described for the preparation of intermediate 10.1, using 8.18 in place of 8.1.

Table 8

EXAMPLE 1421 -(3- { r4-(piperidin- 1 -ylV2-(4- { ΓΠ S)- 1 ,2,3,4-tetrahvdronaphthalen- 1 - yllcarbamoyllpyridin^-vDphenyllcarbamovUphenylVS^J l J4-tetraoxa-2- thiaheptadecan-17-oic acid

Scheme 65. 1. 3-(chloromethyl)benzoyl chloride, diisopropylethylamine, DCM; 2. 1- mercapto-3,6,9,12-tetraoxapentadecan-15-oic acid, K ₂ C0 ₃ , DMF.

Intermediate 142a: (S)-2-(2-(3 -(chloromethyl)benzamidoV5-f piperidin- 1 -vDphenylVN- ( 1 ,2,3 ,4-tetrahydronaphthalen- 1 -yDisonicotinamide. To a stirring mixture of 126e (4.00 g, 9.38 mmol) and diisopropylethylamine (6.52 mL, 37.5 mmol) in DCM (50 mL) cooled to 0 °C was slowly added dropwise 3-(chloromethyl)benzoyl chloride (1.46 mL, 10.3 mmol). The solution was then allowed to warm to room temperature and stirred for 1 h, at which time it was washed with aqueous HCl, saturated aqueous NaHC0 ₃ , and H ₂ 0. The organic layer was dried over Na ₂ S0 ₄ and then the solvent removed to give 4.64 g of the product (85 %) as a yellow solid. Example 142 : (S 1 - (3 -(4-( piperidin- 1 -ylV2-f 4-( 123 ,4-tetrahydronaphthalen- 1 - ylcarbamoyl)pyridin-2-yl)phenylcarbamoyl ^' )phenyl ^' )-5,8J l,14-tetraoxa-2- thiaheptadecan-17-oic acid. A mixture of 142a (600 mg, 1.04 mmol), 1-mercapto- 3,6,9,12-tetraoxapentadecan-15-oic acid (322 mg, 1.14 mmol), and K2CO3 (431 mg, 3.12 mmol) in dry DMF was stirred for 3 h. The mixture was then poured into H ₂ 0 (150 mL) and the resulting suspension acidified with HCl and filtered. The solid was further purified by reverse-phase HPLC eluting with a water / acetonitrile gradient containing 0.1% TFA. The process resulted in 560 mg (51%) of Example 142 as the di- TFA salt. MS (ES, m/z) 825 [M+H] ⁺ .

EXAMPLE 143

2-(3 -(3 -(4-(diethylamino ^' )-2-(4-(3 -( ^" trifluoromethyl)benzylcarbamoyl)pyridin-2- yl phenylcarbamoyl benzylthio)phenyl acetic acid

Scheme 66. 1. 2-(3-mercaptophenyl)acetic acid, K ₂ C0 ₃ , DMF.

Intermediate 143a: 2-(2-(3-(chloromethyl)benzamido)-5-( ^' diethylamino)phenylVN-( ^' 3- (trifluoromethyl benzyl isonicotinamide. This compound was prepared using the method described for the preparation of Example 142a, using 25b in place of 126e. MS (ES, m/z) 886 [M+H] ⁺ .

Example 143: 2-(3 - (3 - (4-( diethylamino )-2-( 4-(3 -

( ^, trifluoromethyl)benzylcarbamoyl pyridin-2- yDphenylcarbamovDbenzylt1iio)phenyl acetic acid. A mixture of 143a (1.56 g, 2.62 mmol), 2-(3-mercaptophenyl)acetic acid (463 mg, 2.75 mmol), and K ₂ C0 ₃ (1.09 g, 7.86 mmol) in DMF (15 mL) was stirred for 16 h under an atmosphere of N ₂ . The mixture was poured into aqueous HC1 and the resulting precipitate was filtered. The solid was dissolved in DCM and washed with ¾0 and dried over Na ₂ S0 . The solvent was removed, yielding 1.26g (66%) of the product as a yellow solid. MS (ES, m/z) 727 [M+H] ⁺ . 1H NMR (400 MHz, cdcl3) δ 8.70 (d, J = 5.2 Hz, 1H), 8.20 (d, J = 9.2 Hz, 1H), 8.08 (s, 1H), 7.69 (s, 1H), 7.62 (d, J = 7.6 Hz, 2H), 7.61 - 7.55 (m, 2H), 7.55 - 7.48 (m, 3H), 7.46 - 7.40 (m, lH), 7.34 (t, J= 7.6 Hz, 2H), 7.28 (s, 1H), 7.16 - 7.10 (m, 2H), 7.01 - 6.94 (m, 1H), 6.78 (dd, J= 8.7, 2.6 Hz, 1H), 4.63 (d, J= 5.9 Hz, 2H), 4.13 (s, 2H), 3.48 (s, 2H), 3.29 (q, J= 7.0 Hz, 4H), 1.10 (t, J= 7.1 Hz, 6H).

EXAMPLE 144

3-(2-(2-(2-(2-Γ3-(3-(4-Γάί6ΦνΜηον2-(4-Γ3- (trifluoromethyl)benzylcarbamoyl pyridin-2-yl)phenylcarbamoyl benzylthio phenylV

N-methylacetamido)ethoxy ethoxy ethoxy)propanoic acid

Scheme 67. 1. tert-butyl 3-(2-(2-(2-(methylamino)ethoxy)ethoxy)ethoxy)propanoate, diisopropylethylamine, HATU, DMF; 2. TFA, DCM. Example 144j 3-( ^, 2-(2-(2-r2-(3-r3-(4-(diethylamino -2-( ^' 4-(3-

(trifluoromethyl benzylcarbamoyl pyridin-2-yl)phenylcarbamoyl benzylthio phenyl - N-methylacetamido ethoxy ethoxy)ethoxy)propanoic acid. To a mixture of 142 (1.72 g, 2.37 mmol), tert-butyl 3-(2-(2-(2-(methylamino)ethoxy)ethoxy)ethoxy)propanoate (827 mg, 2.84 mmol), and diisopropylethylamine (1.65 mL, 9.48 mmol) in dry DMF (5 mL) was added HATU (991 mg, 2.61 mmol) and the solution stirred for 2 h. The solution was then poured into aqueous HC1 and the resulting precipitate 144a was filtered. The solid was washed with H ₂ 0, then dissolved in EtOAc and washed with saturated aqueous NaHC0 ₃ , H ₂ 0, and brine, then dried over Na ₂ S0 ₄ and the solvent removed. The residue was purified by silica gel chromatography, using a gradient of 30% to 100% EtOAc in hexanes as eluent and the solvent removed to furnish intermediate 144a. The purified 144a was dissolved in DCM / TFA (1 :1). After 1 h. the solvent was removed with a stream of N ₂ and the resulting residue dissolved in a mixture of H ₂ 0 / MeCN (1 : 1) and lyophilized to give 2.70 g (96%) of Example 144 as this di-TFA salt. MS (ES, m/z) 944 [M+H] ⁺ . 1H NMR (400 MHz, dmso) δ 8.97 (s, 1H), 7.90 (s, 3H), 7.80 (s, 2H), 7.72 (s, 2H), 7.68 - 7.55 (m, 5H), 7.54 - 7.43 (m, 1H), 7.24 - 7.18 (m, 4H), 7.04 - 6.96 (m, 1H), 4.62 (d, J- 5.7 Hz, 2H), 4.36 (s, 2H), 3.65 (d, J= 14.7 Hz, 2H), 3.59 - 3.53 (m, 4H), 3.50 - 3.41 (m, 14H), 2.95 (s, 2H), 2.79 (s, 1H), 2.41 (q, J= 5.6 Hz, 2H), 1.10 (t, J= 7.0 Hz, 6H).

EXAMPLE 145

18-i2-i2-hydroxyethoxy)ethyl> 17-oxo- 1 -(3-(4-(piperidin- 1 -yl)-2-(4-(3- (trifluoromethyl)benzylcarbamoyl)pyridin-2- vDphenylcarbamoy Dphenyl)- 5 ,8,11,14- tetraoxa-2-thia-l 8-azaicosan-20-oic acid

Scheme 68. 1. Triethylamine, THF; 2. 8.7, 145a, diisopropylethylamine, HATU, DMF; 3. TFA, DCM.

Intermediate 145a: tert-butyl 2-(2-(2-hvdroxyethoxy ethylamino)acetate. 2-(2- aminoethoxy)ethanol (11 g, 104.62 mmol, 1.00 equiv) was dissolved in THF (300 mL) and cooled to 0°C. To the stirring solution was added dropwise tert-butyl 2- bromoacetate (20 g, 102.54 mmol, 1.00 equiv) and then triethylamine (15.5 g, 153.18 mmol, 1.50 equiv) dropwise The solution was then stirred for 16 h at room temperature. The solvent was removed and the residue then dissolved in DCM and washed twice with brine, then dried over anhydrous sodium sulfate and solvent removed. The residue was applied onto a silica gel column with dichloromethane / methanol (20:1) as eluent. This resulted in 5.25 g (16%) of the product as a yellow oil. MS (ES, m/z) 220 [M+H] ⁺

Example 145: 18-r2-r2-hvdroxyethoxy ^' )ethylV17-oxo-l-r3-( ^' 4-rpiperidin-l-ylV2-r4-(3- (trifluoromethyl benzylcarbamoyl)pyridin-2- vDphenylcarbamovDphenyl)- 5,8,11.14- tetraoxa-2-thia-l 8-azaicosan-20-oic acid. To a mixture of 8.7 (25 mg, 0.023 mmol), 145a (6 mg, 0.029 mmol), and diisopropylethylamine (16 μΐ,, 0.092 mmol) was added HATU (10 mg, 0.025 mmol). The solution was stirred for 2 h, the acidified with TFA and purified by reverse-phase HPLC eluting with a water / acetonitrile gradient containing 0.1% TFA and lyophilized to give intermediate 145b. The residue was dissolved in DCM / TFA (1 :1). After 1 h, the solvent was removed under a stream of N ₂ and the resulting residue dissolved in a mixture of H ₂ 0 / MeCN (1 :1) and lyophilized to give 20 mg (82 %) of Example 145 as the di-TFA salt. MS (ES, m/z) 998 [M+H] ⁺

EXAMPLE 146

2-(2-(3-(20-morpholino- 17-oxo-5,8 J 1 , 14-tetraoxa-2-thia- 18-azaicosyl benzamido -5- (piperidin- 1 -yl)phenyl)-N-(3 -ftrifluoromethvDbenzvDisonicotinamide

This compound was prepared using the method described for the preparation of Example 145b, using 2-morpholinoethanamine in place of tert-butyl 2-(2-(2- hydroxyethoxy)ethylamino)acetate. MS (ES, m/z) 965 [M+H] ⁺

EXAMPLE 147

2-(2-( 3 -( 17-(4-(2-(2-hvdroxyethoxy ethyl piperazin- 1 -ylV 17-oxo-5.8.11.14-tetraoxa-2- thiaheptadecyl benzamido -5-(piperidin-l-yl)phenyl)-N-(3- (trifluoromethvDbenzyl)isomcotinamide

This compound was prepared using the method described for the preparation of Example 145b, using 2-(2-(piperazin-l-yl)ethoxy)ethanol in place of tert-butyl 2-(2-(2- hydroxyethoxy)ethylamino)acetate. MS (ES, m/z) 1009 [M+H] ⁺

EXAMPLE 148

2-(2-r3-r27-oxo-2,5,8ai.l4.17.20.23.30.33.36.39-dodecaoxa-42 -thia-26- azatritetracontan-43-yDbenzamidoV5-(piperidin-l-ynphenyl ^' )-N-(3- (trifluoromethyl benzvnisonicotinamide

This compound was prepared using the method described for the preparation of Example 145b, using 2,5,8,1 l,14,17,20,23-octaoxapentacosan-25-amine in place of tert-butyl 2-(2-(2-hydroxyethoxy)ethylamino)acetate. MS (ES, m/z) 1218 [M+H] ⁺

EXAMPLE 149 2-(2-r3-r41-hvdroxy-17-oxo-5.8,l ia4,21,24,27,30,33.36.39-undecaoxa-2-thia-18- azahentetracontyl benzamido)-5-(piperidin-l-yl)phenyl -N-(3- (trifluoromethvDbenzyl)isonicotinamide

This compound was prepared using the method described for the preparation of Example 145b, using 23-amino-3,6,9,12,15,18,21-heptaoxatricosan-l-ol in place of tert- butyl 2-(2-(2-hydroxyethoxy)ethylamino)acetate. MS (ES, m/z) 1204 [M+H] ⁺

EXAMPLE 150

(3 -Π 8-methyl-20-morpholino- 17-oxo-5 ,8.11,14-tetraoxa-2-thia- 18

azaicosyl ^' )benzamido)-5-(piperidin-l-yl phenyl)-N-(3- (trifluoromethvDbenzvDisonicotinamide

This compound was prepared using the method described for the preparation of Example 145b, using N-methyl-2-morpholinoethanamine in place of tert-butyl 2-(2-(2- hydroxyethoxy)ethylamino)acetate. MS (ES, m/z) 979 [M+H] ⁺

EXAMPLE 151

2-(2-(3 -i20-hvdroxy- 18-C2-hvdroxyethvn- 17-oxo-5.8.11.14-tetraoxa-2-thia- 18- azaicosyl ^' )benzamido)-5-(piperidin-l-yl)phenyl ^' )-N-(3- (trifluoromethvnbenzyl)isonicotinamide

This compound was prepared using the method described for the preparation of Example 145b, using diethanolamine in place of tert-butyl 2-(2-(2- hydroxyethoxy)ethylamino)acetate. MS (ES, m/z) 940 [M+H] ⁺ .

EXAMPLE 152

2-(2-(3 -(21 -ethyl- 18-methyl- 17-oxo-5,8, 11.14-tetraoxa-2-thia- 18.21- diazatricosyl)benzamido)-5-Cpiperidin-l-yl phenylVN-(3- (trifluoromethvnbenzyDisonicotinamide

This compound was prepared using the method described for the preparation of Example 145b, using Nl,Nl-diethyl-N2-methylethane-l,2-diamine in place of tert- butyl 2-(2-(2-hydroxyethoxy)ethylamino)acetate. MS (ES, m/z) 965 [M+H] ⁺ .

EXAMPLE 153

2-(2-(3-(\ 7-f 4-acetyl- 1.4-diazepan- 1 -ylV 17-oxo-5.8.11.14-tetraoxa-2- thiaheptadecyl)benzamido)-5-(piperidin- 1 -yi)phenvD-N-(3 - (trifluoromethyl)benzyl)isonicotinamide

This compound was prepared using the method described for the preparation of Example 145b, using l-(l,4-diazepan-l-yl)ethanone in place of tert-butyl 2-(2-(2- hydroxyethoxy)ethylamino)acetate. MS (ES, m/z) 977 [M+H] ⁺

EXAMPLE 154 2-(2-(3-(\ 7-(4-morpholinopiperidin- 1 -ylV 17-oxo-5,8, 11,14-tetraoxa-2- thiaheptadecyl benzamido -5-(piperidin- 1 -yl phenyl -N-(3 - (trifiuoromethyl)benzyl)isonicotinamide

This compound was prepared using the method described for the preparation of Example 145b, using 4-( iperidin-4-yl)morpholine in place of tert-butyl 2-(2-(2- hydroxyethoxy)ethylamino)acetate. MS (ES, m/z) 1005 [M+H] ⁺

EXAMPLE 155

17-oxo- 1 -(3 -(4-(piperidin- 1 -ylV2-(4-C3 -(trifluoromethyl benzylcarbamoyl)pyridin-2- yl phenylcarbamoyl)phenyl)-5,8,l 1 ,14,21 ,24,27-heptaoxa-2-thia-l 8-azatriacontan-30- oic acid

This compound was prepared using the method described for the preparation of Example 145, using tert-butyl 3-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)propanoate in place of tert-butyl 2-(2-(2-hydroxyethoxy)ethylamino)acetate. MS (ES, m/z) 1056 [M+H] ⁺

EXAMPLE 157

(S 1 -(3-(4-(diethylamino>2-(4-( 1 ,2,3 ,4-tetrahydronaphthalen- 1 -ylcarbamovDpyridin-

2-yl)phenylcarbamovDphenyl)-5,8 J 1 4-tetraoxa-2-thiaheptadecan-17-oic acid

Scheme 69. 1. 3-(chloromethyl)benzoyl chloride, diisopropylethylamine, DCM; 2. 1- mercapto-3,6,9,12-tetraoxapentadecan-15-oic acid, K ₂ C0 ₃ , DMF; 3.

2,5,8,1 l,14,17,20,23-octaoxapentacosan-25-amine, HATU, diisopropylethylamine,

DMF.

Intermediate 157a: (S)-2-(2-amino-5-(diethylamino phenyl)-N-(l,2,3,4- tetrahydronaphthalen- 1 -vDisonicotinamide. To a stirring mixture of 131c (970 mg, 2.34 mmol) and diisopropylethylamine (1.63 mL, 9.36 mmol) in DCM (25 mL) cooled to 0 °C was slowly added dropwise 3-(chloromethyl)benzoyl chloride (365 μΐ,, 2.57 mmol). The solution was then allowed to warm to room temperature and stirred for 1 h, then the solvent was removed. The resulting residue was dissolved in EtOAc and washed with aqueous HCl, saturated aqueous NaHC0 ₃ , and brine, then dried over Na ₂ S0 ₄ . The solvent was removed and the residue purified by silica gel chromatography, using a gradient of 30% to 70% EtOAc in hexanes as eluent and the solvent removed. This gave 1.22 g (92%) of the product as a yellow solid.

Example 157: CSV 1 -Γ3 -(4-(diethylamino V2-( 4-( 1 ,2,3 ,4-tetrahvdronaphthalen- 1 - ylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)phenylV5,8, 11 , 14-tetraoxa-2- thiaheptadecan-17-oic acid. A stirring mixture of 157a (1.22 g, 2.15 mmol), 1- mercapto-3,6,9,12-tetraoxapentadecan-15-oic acid (668 mg, 2.37 mmol), and K ₂ C0 ₃ (891 mg, 6.45 mmol) in dry DMF (15 mL) was stirred for 2 h, then poured into H ₂ 0 (100 mL). The solution was acidified with aqueous HCl and extracted twice with DCM. The combined organic layers were washed thrice with H ₂ 0 and then dried over Na ₂ S0 ₄ . Removal of the solvent gave 1.61 g (92%) of the product Example 157 as a yellow foam. MS (ES, m/z) 813 [M+H] ⁺

EXAMPLE 157.1

(S -2-(5-(diethylamino -2-(3-r27-oxo-2.5,8.11.14.17.20.23.30.33.36.39-dodecaoxa-42- thia-26-azatritetracontan-43 -yl benzamido phenyl)-N-( 1,2,3 ,4-tetrahvdronaphthalen- 1 - yDisonicotinamide.

To a mixture of 157 (390 mg, 1.14 mmol), 2,5,8,1 l,14,17,20,23-octaoxapentacosan-25- amine (482 mg, 1.26 mmol), and diisopropylethylamine (793 μί, 4.56 mmol) was added HATU (479 mg, 1.26 mmol). The solution was stirred for 2 h, the acidified with TFA and purified by reverse-phase HPLC eluting with a water / acetonitrile gradient containing 0.1% TFA and lyophilized to give 1.40 g (87%) of the product Example 157.1 as the di-TFA salt. MS (ES, m/z) 1178 [M+H] ⁺

EXAMPLE 158

(SV2-(5-(dietfaylamino)-2-(3-(20-hvdroxy- 19.19-bis(hvdroxymethylV 17-oxo-5 ,8.11.14- tetraoxa-2-thia- 18-azaicosyl benzamido phenyl -N-(l ,2,3,4-tetrahydronaphthalen- 1 - vDisonicotinamide

This compound was prepared using the method described for the preparation of Example 157.1, using tris(hydroxymethyl)aminomethane»HCl in place of 2,5,8,1 l,14,17,20,23-octaoxapentacosan-25-amine. MS (ES, m/z) 916 [M+H] ⁺

EXAMPLE 159

fS V2-f5-(diethylamino )-2-(3-(20-hvdroxy- 19-(hvdroxymethylV 17-oxo-5.8.11.14- tetraoxa-2-thia- 18-azaicosyl benzamido phenylVN-( 1 ,2,3 ,4-tetrahydronaphthalen- 1 - vDisonicotinamide

This compound was prepared using the method described for the preparation of Example 157.1, using 2-aminopropane-l,3-diol»HCl in place of 2,5,8,11,14,17,20,23- octaoxapentacosan-25-amine. MS (ES, m/z) 886 [M+H] ⁺

EXAMPLE 160

f S)-2-(5-(dietfaylaminoV2-(3-(20-hvdroxy- 18-(2-hvdroxyefhylV 17-oxo-5,8J 1.14- tetraoxa-2-thia- 1 S-azaicosyDbenzamido ^' jphenv^-N-f 1 ,2,3 ,4-tetrahvdronaphthalen- 1 - vDisonicotinamide

This compound was prepared using the method described for the preparation of Example 157.1, using diethanolamine in place of 2,5,8,11,14,17,20,23- octaoxapentacosan-25-amine. MS (ES, m/z) 900 [M+H] ⁺

EXAMPLE 161 S )- 1 -(3-( 4-(diethylamino)-2-(4-( 1 ,2,3 ,4-tetrahydronaphthalen- 1 -ylcarbamovDpyridin-

2-yl)phenylcarbamoyDphenyl)-5 ,8, 11,14 , 17,20,23 ,26-octaoxa-2-thianonacosan-29-oic acid

This compound was prepared using the method described for the preparation of Example 157, using l-mercapto-3,6,9,12,15,18,21,24-octaoxaheptacosan-27-oic acid in place of l-mercapto-3,6,9,12-tetraoxapentadecan-15-oic acid. MS (ES, m/z) 989 [M+H] ⁺

EXAMPLE 162

1 -(3 -(4-(diethylamino -2-( ^' 4-(3 -(trifluoromethyl benzylcarbamoyl pyridin-2- yl)phenylcarbamoyl phenylV5 ,8, 11,14-tetraoxa-2-thiaheptadecan- 17-oic acid.

Scheme 70. 1. l-mercapto-3,6,9,12-tetraoxapentadecan-15-oic acid, K ₂ C0 ₃ , DMF; 2. tris(hydroxymethyl)aminomethane«HCl, HATU, diisopropylethylamine, DMF. Example 162: 1 -(3-(4-rdiethylaminoV2-r4-( ^, 3-

(trifluoromethyl)benzylcarbamoyl ^' )pyridin-2-yl phenylcarbamovDphenvn-5 _< 8, 11,14- tetraoxa-2-thiaheptadecan- 17-oic acid. A mixture of 143a (1.1 g, 1.8 mmol), 1- mercapto-3,6,9,12-tetraoxapentadecan-15-oic acid (0.5 g (1.8 mmol), and K ₂ C0 ₃ (250 mg) in DMF (18 mL) was stirred for 16 h. The mixture was acidified with TFA and purified by reverse-phase HPLC eluting with a water / acetoriitrile gradient containing 0.1% TFA and lyophilized to give 1.05 g (55%) of the product Example 162 as the di- TFA salt. MS (ES, m/z) 841 [M+H] ⁺ . 1H NMR (400 MHz, dmso) δ 9.83 (s, 1H), 9.02 (d, J= 5.2 Hz, 1H), 8.74 - 8.58 (m, 1H), 8.52 (s, 1H), 7.92 (d, J= 5.0 Hz, 2H), 7.82 (d, J = 1.6 Hz, 1H), 7.73 (s, 1H), 7.70 - 7.48 (m, 7H), 4.62 (d, J = 5.9 Hz, 2H), 3.92 (s, 2H), 3.55 (q, J= 6.4 Hz, 4H), 3.50 - 3.43 (m, 16H), 2.59 (t, J= 6.6 Hz, 2H), 2.41 (t, J- 6.4 Hz, 2H), 1.10 (t, J= 7.1 Hz, 6H).

EXAMPLE 163

2-( 5 -(diethylaminoV2-(3 -(20-hydroxy- 19, 19-bis(hydroxymethylV 17-oxo-5.8.11.14- tetraoxa-2-thia- 18-azaicosyl benzamido)phenyl)-N-(3- (trifluoromethvDbenzyl)isonicotinamide

Example 163 : 2-(5-(diethylamino)-2-(3-(20-hvdroxy- 19,19-bis(hydroxymethylV 17- oxo-5,8,1 L14-tetraoxa-2-thia-l 8-azaicosvDbenzamido)phenylVN-(3- (trifluoromethvnbenzvDisonicotinamide. To a mixture of Example 162 (1.02 g, 1.12 mmol), tris(hydroxymethyl)aminomethane»HCl (223 mg, 1.40 mmol), and diisopropylethylamine (0.97 mL, 5.6 mmol) in dry DMF (10 mL) was added HATU (468 mg, 1.23 mmol). The solution was stirred for 2 h, the acidified with TFA and purified by reverse-phase HPLC eluting with a water / acetonitrile gradient containing 0.1% TFA and lyophilized to give 880 mg (67%) of the product as the di-TFA salt. MS (ES, m/z) 944 [M+H] ⁺ .

EXAMPLE 164

2-( 5-idiethylaminoV2-i3 -(20-hvdroxy- 18-(2-hvdroxyethvn- 17-oxo-5.8.11 , 14-tetraoxa- 2-thia-18-azaicosyl benzamido^phenylVN-(3-(trifluoromethvnbenzyl)isonicotinamide

2-(5-(diethylamino)-2-(3 -(20-hydroxy- 18-(2-hydroxyethyl)- 17-oxo-5 ,8, 11 , 14-tetraoxa- 2-thia- 18-azaicosyl)benzamido)phenyl)-N-(3 -(trifluoromethyl)benzyl)isonicotinamide. This compound was prepared using the method described for the preparation of Example 163, using diethanolamine in place of tris(hydroxymethyl)aminomethane«HCl. MS (ES, m/z) 928 [M+H] ⁺ .

EXAMPLE 165

2-r5-(diethylamino)-2-(3-(27-oxo-2.5.8,l lJ4.17,20 _< 23.3033,36,39-dodecaoxa-42-thia- 26-azatritetracontan-43-yl)benzamido phenyl)-N-(3- (trifluoromethyl)benzyDisonicotinamide

2-(5-(diethylam _. ino)-2-(3-(27-oxo-2,5,8,l l,14,17,20,23,30,33,36,39-dodecaoxa-42-thia- 26-azatritetracontan-43 -yl)benzamido)phenyl)-N-(3 -

(trifluoromethyl)benzyl)isonicotinamide. This compound was prepared using the method described for the preparation of Example 163, using 2,5,8,11,14,17,20,23- octaoxapentacosan-25-amine in place of tris(hydroxymethyl)aminomethane«HCl. MS (ES, m/z) 1206 [M+H] ⁺ .

EXAMPLE 166

1 -(3 -(4-(diethylamino)-2-(4-(3 -( ^" trifluoromethyl)benzylcarbamoyDpyridin-2- yl)phenylcarbamoyl)phenyl)-5.,8,m4J7,20,23,26-octaoxa-2-thia nonacosan-29-oic acid

This compound was prepared using the method described for the preparation of Example 162, using l-mercapto-3,6,9,12,15,18,21,24-octaoxaheptacosan-27-oic acid in place of l-mercapto-3,6,9,12-tetraoxapentadecan-15-oic. MS (ES, m/z) 1017 [M+H] ⁺ . 1H NMR (400 MHz, dmso) δ 12.24 - 12.06 (m, 1H), 11.82 (s, 1H), 9.49 (t, J = 5.9 Hz, 1H), 8.95 (d, J = 5.1 Hz, 1H), 8.23 (s, 1H), 8.13 (d, J = 9.3 Hz, 1H), 7.85 - 7.77 (m, 2H), 7.75 - 7.67 (m, 2H), 7.64 (t, J= 7.3 Hz, 2H), 7.58 (d, J= 8.0 Hz, 1H), 7.53 - 7.41 (m, 3H), 7.06 (d, J = 2.6 Hz, 1H), 6.87 (dd, J = 9.2, 3.0 Hz, 1H), 4.61 (d, J = 6.0 Hz, 2H), 3.88 (s, 2H), 3.58 (t, J = 6.3 Hz, 2H), 3.54 (t, J = 6.6 Hz, 2H), 3.50 - 3.36 (m, 36H), 2.58 (t, J= 6.4 Hz, 2H), 2.43 (t, J= 6.3 Hz, 2H), 1.13 (t, J = 6.9 Hz, 6H).

EXAMPLE 167

1 -(((3 -((4-( diethylamino - 2- [4-((Y3 -(trifluoromethvDphenyllmethvDcarbamovDpyridin- 2-yl)phenvDcarbamoyl phenyl methane sulfonviy 3 ,6,9, 12-tetraoxapentadecan- 15-oic acid

A mixture of Example 162 (25 mg, 0.023 mmol) and Oxone® (71 mg, 0.12 mmol) in THF/MeOH/H ₂ 0 (1 mL: 0.5 mL: 0.5 mL) was stirred for 18 h and then filtered and the solid washed with EtOAc. The combined organic layers were washed with H ₂ 0 and brine, then dried over Na ₂ S0 ₄ and the solvent removed. The resulting residue was dissolved in MeOH, then 10 mol% Pd/C (5 mg) was added and the suspension stirred under an atmosphere of H ₂ for 0.5 h. The suspension was filtered through celite and the solvent removed then purified by reverse-phase HPLC eluting with a water / acetonitrile gradient containing 0.1% TFA and lyophilized to give 12 mg (47%) of the product as the di-TFA salt. MS (ES, m/z) 873 [M+H] ⁺ EXAMPLE 168

2-f5-(diejhylaminoV2-(3-(19-hydroxy-2.5.8,l 1,14,17- hexaoxanonadecyl benzamido)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicoti

Scheme 71. 1. 3,6,9,12,15-pentaoxaheptadecane-l,17-diol, sodium hydride, THF; 2. 4- nitrophenylchloroformate, diisopropylethylamine, DCM, then 2- morpholinoethanamine.

Example 168: 2-(5-(diethylaminoV2-(3-( 19-hvdroxy-2,5,8, 11 , 14, 17- hexaoxanonadecyDbenzamido phenyl -N-(3-(trifluoromethy benzyl)isonicotinamide. To a mixture of 143a (500 mg, 0.840 mmol) and 3,6,9,12,15-pentaoxaheptadecane- 1,17-diol (1.06 mL, 4.20 mmol) in dry THF (8 mL) was added a 60% sodium hydride dispersion in mineral oil (101 mg) and the mixture stirred at 50 °C for 1 h. The solution was then diluted with DCM and washed with aqueous HCl and H ₂ 0, then dried over Na ₂ S0 ₄ and the solvent removed to give 634 mg (90%) of the product as a yellow oil. MS (ES, m/z) 841 [M+H] ⁺

EXAMPLE 169

l-(3-(4-(diethylamino -2-(4-(3-(trifluoromethyl )benzylcarbamoyl ^' )pyridin-2- yl)phenylcarbamoyl)phenyiy2,5,8, 11,14,17-hexaoxanonadecan- 19-yl 2- morpholinoethylcarbamate.

Example 169j 1-Π-(4-Γ(1ί6ί1ινΜηον2-(4-Γ3-

(trifluoromethynbenzylcarbamoyl pyridin-2-yl)phenylcarbamovnphenylV

2,5,8,1 l,14,17-hexaoxanonadecan-19-yl 2-moφholinoethylcarbamate. To a mixture of Example 168 (50 mg, 0.060 mmol) and diisopropylethylamine (31 L, 0.18 mmol) in DCM (1 mL) was added 4-nitrophenylchloroformate (52 mg, 0.26 mmol) and the solution stirred for 1 h. 2-Morpholinoethanamine (46 μΐ,, 0.36 mmol) was then added and the solution stirred for 1 h, then the solvent removed and the residue purified by reverse-phase HPLC eluting with a water / acetonitrile gradient containing 0.1% TFA and lyophilized to give 20 mg (25%) of the product as the tri-TFA salt. MS (ES, m/z) 997 [M+H] ⁺ . 1H NMR (400 MHz, CDC1 ₃ ) δ 9.54 (t, J = 6.0 Hz, 1H), 9.25 (d, J = 2.6 Hz, 1H), 9.17 (d, J = 9.1 Hz, 1H), 8.92 - 8.83 (m, 2H), 8.08 (s, 1H), 8.03 (dd, J = 5.1, 1.4 Hz, 1H), 7.98 (dt, J= 7.0, 1.9 Hz, 1H), 7.69 (s, 1H), 7.62 (d, J= 7.6 Hz, 1H), 7.58 - 7.46 (m, 3H), 7.46 - 7.35 (m, 2H), 6.27 (s, 1H), 4.74 (d, J = 6.0 Hz, 2H), 4.68 (s, 2H), 4.23 - 4.12 (m, 2H), 4.02 - 3.82 (m, 4H), 3.74 - 3.50 (m, 22H), 3.25 (t, J= 5.6 Hz, 2H), 2.93 (t, J = 12.0 Hz, 2H), 1.27 (t, J= 7.2 Hz, 6H).

EXAMPLE 170

l-(3-(4-(diethylamino ^' )-2-( ^' 4-(3-(trifluoromethyl)benzylcarbamoyl pyridin-2- yDphenylcarbamoyl phenyl ^' )-2,5 ,8, 11,14,17-hexaoxanonadecan- 19-yl methyl(2- moφholinoethyl carbamate

This compound was prepared using the method described for the preparation of Example 169, using N-methyl-2-morpholinoethanamine in place of morpholinoethanamine. MS (ES, m/z) 1011 [M+H] ⁺

EXAMPLE 171

l-(3-( ^' 4-rdiethylamino)-2-( ^' 4-(3-( ^, trifluoromethynbenzylcarbamoyl)pyridin-2- yl)phenylcarbamoyl)phenyl)-2,5 ,8, 1 1 ,14,17-hexaoxanonadecan- 19-yl 4-(2-(2- hvdroxyethoxytethvDpiperidine- 1 -carboxylate H

This compound was prepared using the method described for the preparation of Example 169, using 2-(2-(piperidin-4-yl)ethoxy)ethanol in place of morpholinoethanamine. MS (ES, m/z) 1041 [M+H] ⁺

EXAMPLE 172

l-(3-(4-(diethylaminoV2-(4-(3-(trifluoromethvnbenzylcarbamov npyridin-2- yl)phenylcarbamoyDphenyl>2,5,,8, 11,14,17-hexaoxanonadecan- 19-yl bis(2- hvdroxyethvDcarbamate

This compound was prepared using the method described for the preparation of Example 169, using diethanolamine in place of mo holinoethanamine. MS (ES, m/z) 972 [M+H] ⁺ . 1H NMR (400 MHz, cdcl3) δ 9.53 (t, J = 5.9 Hz, 1H), 9.33 (d, J = 2.6 Hz, 1H), 9.20 (d, J= 9.2 Hz, 1H), 8.94 (s, 1H), 8.88 (d, J= 5.2 Hz, 1H), 8.13 - 8.08 (m, 1H), 8.04 (dd, J= 5.1, 1.4 Hz, 1H), 8.00 (dt, J= 7.3, 1.7 Hz, 1H), 7.71 (s, 1H), 7.63 (d, J= 7.5 Hz, 1H), 7.60 - 7.32 (m, 5H), 4.74 (d, J= 6.0 Hz, 2H), 4.69 (s, 2H), 4.29 - 4.22 (m, 2H), 3.82 (s, 4H), 3.76 - 3.54 (m, 26H), 3.47 (s, 4H), 1.27 (t, J- 7.2 Hz, 6H).

EXAMPLE 173

2-r2-(3-2,5,8a ia4J7,20.23.26-nonaoxaher)tacosylbenzamidoV5- (diethylamino phenylVN-(3-(trifluoromethynbenzynisonicotinamide

This compound can be prepared using the method described for the preparation of Example 169, using 2,5,8,1 1,14,17,20,23-octaoxapentacosan-25-ol in place of 3,6,9,12,15-pentaoxaheptadecane-l,17-diol. MS (ES, m/z) 943 [M+H] ⁺

EXAMPLE 174

1 -(3 -(4-(diethylamino V2-(4-(3 -(trifluoromethyl)benzylcarbamovDpyridin-2- yl)phenylcarbamoyl ^' )phenyl)-2,5 ,8, 11,14,17-hexaoxanonadecan- 19- yl

2,5,8, 11 , 14, 17,20-heptaoxadocosan-22-ylcarbamate

This compound was prepared using the method described for the preparation of Example 169, using 2,5,8,11,14,17,20,23 -octaoxapentacosan-25 -amine 135c.6 in place of morpholinoethanamine. MS (ES, m/z) 972 [M+H] ⁺

EXAMPLE 175 l-(3-(4-(diethylamino)-2-(4-(3-(trifluoromethvnbenzylcarbamo yl pyridin-2- yl phenylcarbamoyl phenyl)-2,5 ,8, 11 -tetraoxatridecan- 13-yl 2,5,8,11,14,17.20- heptaoxadocosan-22-ylcarbamate

Scheme 72. 1. 2,2'-(2,2'-oxybis(ethane-2,l-diyl)bis(oxy))diethanol, sodium hydride, THF; 2. 4-nitrophenylchloroformate, diisopropylethylamine, DCM; 3.

2,5,8,1 l,14,17,20,23-octaoxapentacosan-25-amine, DMAP, MeCN.

Intermediate 175a: 2-(5-(diethylaminoV2-(3-g3-hvdroxy-2.5.8.11 - tetraoxatridecvnbenzamido^phenylVN-(3-(trifluoromethyl benzyl)isonicotinamide. This compound was prepared using the method described for the preparation of Example 168, using 2,2'-(2,2'-oxybis(ethane-2,l-diyl)bis(oxy))diethanol in place of 3 ,6,9, 12, 15 -pentaoxaheptadecane- 1 , 17-diol.

Intermediate 175b: 1 -f 3 -(4-( diethylamino>2-f 4-Γ3 -

(trifluoromethyl benzylcarbamoyl pyridin-2-yl)phenylcarbamoyl)phenyl -2,5,8,l l- tetraoxatridecan- 13-yl 4-nitrophenyl carbonate. To a mixture of 175a (196 mg, 0.329 mmol) and diispropylethylamine (286 uL, 1.65 mmol) was added 4- nitrophenylchloroformate (266 mg, 1.32 mmol) and the mixture stirred for 2 h. The solution was diluted with DCM and washed with H ₂ 0, then dried over Na ₂ S0 and the solvent removed. The resulting residue was purified by silica gel chromatography, using a gradient of 50% to 100% EtOAc in hexanes as eluent and the solvent removed. This gave 80 mg (26%) of the product as a viscous, yellow oil.

Example 175j l-r3-( ^, 4-( ^, diethylaminoV2-r4-G-

(trifluoromethvnbenzylcarbamoyl pyridin-2-yl phenylcarbamoyl)phenyl)-2,5,8,l l- tetraoxatridecan- 13-yl 2,5,8,11,14,17,20-heptaoxadocosan-22-ylcarbamate. A mixture of 175b (20 mg, 0.022 mmol), 2,5,8,11,14,17,20,23 -octaoxapentacosan-25-amine (15 mg, 0.436 mmol) and catalytic DMAP in MeCN was stirred at 80°C for 2 h. The solution was acidified with acetic acid and purified by reverse-phase HPLC eluting with a water / acetonitrile gradient containing 0.1% TFA and lyophilized to give 15 mg (51%) of the product as the di-TFA salt. MS (ES, m/z) 1118 [M+H] ⁺

EXAMPLE 176

1 -(3 -(4-(diethylamino -2-(4-(3 -(trifluoromethyl benzylcarbamoyl pyridin-2- yl)phenylcarbamoyl)phenyl)-2,5,8,l l-tetraoxatridecan-13-yl bis(2- hydroxyethvDcarbamate

This compound was prepared using the method described for the preparation of Example 175, using diethanolamine in place of 2,5,8,11,14,17,20,23- octaoxapentacosan-25-amine. MS (ES, m/z) 884 [M+H] ⁺

EXAMPLE 177 1 -(3 -(4-(diethylaminoV-2-(4-(3 -(trifluoromethyl benzylcarbamoyl pyridin-2- yl)phenylcarbamovDphenylV2,5,8,l l-tetraoxatridecan-13-yl l,3-dihydroxy-2- (hydroxymethyl ^N )propan-2-ylcarbamate

This compound was prepared using the method described for the preparation of Example 175, using tris(hydroxymethyl)aminomethane»HCl in place of 2,5,8,1 l,14,17,20,23-octaoxapentacosan-25-amine. MS (ES, m/z) 900 [M+H] ⁺

EXAMPLE 178

2-( ^, 5-(diethylaminoV2-(3 -f22-hydroxy-20-(2-hvdroxyethyl>2,5,8, 11.14.17-hexaoxa-20- azadocosyDbenzamido ^' jphenvD-N-rS-CtrifluoromethvnbenzyDisonicotinamide

Scheme 73. 1. ?-Toluenesulfonyl chloride, triethylamine, DCM; 2. Diethanolamine, MeCN.

Intermediate 178a: 1 -r3-f4-rdiethylamino>2-(4-(3-

(trifluoromethyl benzylcarbamoyl)pyridin-2-yl)phenylcarbamoyDphenyl ^' )- 2,5,8,1 l,14,17-hexaoxanonadecan-19-yl 4-methylbenzenesulfonate. To a mixture of Example 168 (500 mg, 0.595 mmol) and triethylamine (167 nL, 1.19 mmol) in DCM (3 mL) was added /?-toluenesulfonyl chloride (136 mg, 0.714 mmol) in several portions and the solution stirred for 16 h. The solution was then diluted with DCM and washed with aquesous HC1 and H ₂ 0, then dried over Na ₂ S0 ₄ and the solvent removed. The residue was purified by silica gel chromatography, using a gradient of 20% to 100% EtOAc in hexanes as eluent and the solvent removed. This gave 560 mg (95%) of the product as a yellow oil.

Example 178: 2-(5-(diethylaminoV2-(3 - (22-hvdroxy-20-f 2-hvdroxyethylV 2,5, 8, 11, 14,17-hexaoxa-20-azadocosyl benzamido)phenyl -N-(3 - (trifluoromethvDbenzvDisonicotinamide. A mixture of 178a (85 mg, 0.085 mmol) and diethanolamine (18 mg, 0.17 mmol) in MeCN (1 mL) was heated to 80 °C and stirred for 18 h. The solution was diluted with H ₂ 0 and purified by reverse-phase HPLC eluting with a water / acetonitrile gradient containing 0.1% TFA and lyophilized to give 43 mg (40%) of the product as the tri-TFA salt. MS (ES, m/z) 928 [M+H] ⁺ . 1H NMR (400 MHz, cdcl3) δ 9.56 (t, J = 6.0 Hz, 1H), 9.31 (d, J = 2.5 Hz, 1H), 9.18 (d, J = 9.2 Hz, 1H), 8.94 (s, 1H), 8.87 (d, J = 5.1 Hz, 1H), 8.10 (s, 1H), 8.06 - 7.94 (m, 2H), 7.70 (s, 1H), 7.63 (d, J = 7.5 Hz, 1H), 7.58 - 7.37 (m, 5H), 4.72 (d, J = 5.9 Hz, 2H), 4.67 (s, 2H), 4.00 - 3.90 (m, 4H), 3.86 (d, J- 4.8 Hz, 2H), 3.70 (d, J= 5.3 Hz, 4H), 3.67 - 3.39 (m, 22H), 1.26 (t, J= 7.2 Hz, 6H).

EXAMPLE 179

2-(5-(diethylamino)-2-(3-(20-methyl-22-morpholino-2,5,8.11.1 4.17-hexaoxa-20- azadocosyl)benzamido)phenyl)-N-(3-(trifluoromethyl benzyl isonicotinamide

This compound was prepared using the method described for the preparation of Example 178, using N-methyl-2-morpholinoethanamine in place of diethanolamine. MS (ES, m/z) 967 [M+H] ⁺ .

EXAMPLE 180

N-( 2-(2-(2-hydroxyethoxytethoxy ethyr)- 1 - (3 - (4-( piperidin- 1 -ylV2-(4-( 3 - (trifluoromethyl)benzylcarbamoyl pyridin-2-yl)phenylcarbamoyl)benzyl ^' )-lH-indole-4- carboxamide.

Scheme 74. 1. tert-butyl 3-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)propanoate, HATU, diisopropylethylamine, DMF; 2. 8.1a, K ₂ C0 ₃ , DMF.

Intermediate 180a: tert-butyl l-(lH-indol-4-ylVl-oxo-5,8J l-trioxa-2-azatetradecan-14- oate. To a mixture of lH-indole-4-carboxylic acid (322 mg, 2.00 mmol), tert-butyl 3- (2-(2-(2-aminoethoxy)ethoxy)ethoxy)propanoate (554 mg, 2.00 mmol), and diisporopylethylamine (700 yL, 4.00 mmol) in DMF (3 mL) was added HATU (950 mg, 2.50 mmol) and the solutions stirred for 16 h. The solvent was removed and the resulting residue was purified by silica gel chromatography, using a gradient of 70% to 100% EtOAc in hexanes as eluent and the solvent removed. This gave 557 mg (66%) of the product.

Example 180: N-i2-(2-(2-hvdroxyethoxy)ethoxykthylV 1 -(3 -i4-(piperidin- 1 -yl>2-(4- (3 -(trifluoromethvnbenzylcarbamovnpyridin-2- vDphenylcarbamovDbenzyl)- 1 H-indole- 4-carboxamide. A mixture of 180a (524 mg, 1.25 mmol), 8.1a (755 mg, 1.25 mmol), and K ₂ C0 ₃ (510 mg, 3.70 mmol) in DMF (2 mL) was stirred for 3 days, then purified by reverse-phase HPLC eluting with a water / acetonitrile gradient containing 0.1% TFA and lyophilized to give 16 mg (1%) of the product as the di-TFA salt. MS (ES, m/z) 863 [M+H] ⁺

EXAMPLE 181

rS l -oxo- 1 -( 1 -( 3 -(4-( iperidin- 1 - ylV2-(4-( 1 ,2,3 ,4-tetrahvdronaphthalen- 1 - ylcarbamoyl)pyridin-2-yl ^> )phenylcarbamoyl ^N )benzyl)- 1 H-indol-4-ylV5,8, 11 -trioxa-2- azatetradecan-14-oic acid.

Scheme 75. 1. methyl lH-indole-4-carboxylate, Cs ₂ C0 ₃ , DMF; 2. LiOH»H ₂ 0, THF, H ₂ 0; 3. tert-butyl 3-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)propanoate, HATU, diisopropylethylamine, DMF; 4. HC1, dioxane.

Intermediate 181a. (SVmethyl l-(3-(4-(piperidin-l-yl>2-(4-(1.2.3.4- tetrahydronaphthalen- 1 -ylcarbamoyDpyridin-2-yl phenylcarbamoyl benzyl)- 1 H-indole- 4-carboxylate. A mixture of 142a (14.9 g, 25.7 mmol), methyl lH-indole-4-carboxylate (4.5 g, 25.7 mmol), and Cs ₂ C0 ₃ (16.7 g, 51.3 mmol) in DMF (50 mL) was stirred for 15 h under an atmosphere of N ₂ . The suspension was filtered and the solvent removed. The resulting residue was purified by silica gel chromatography to give 16.2 g (88%) of the product.

Intermediate 181b. (S)- 1 -(3 -(4-(piperidin- 1 - vD-2-f 4-( 1.2.3.4-tetrahydronaphthalen- 1 - ylcarbamoyl pyridin-2-yl phenylcarbamoyl benzyl - 1 H-indole-4-carboxylic acid. A mixture of 181a (16.0 g, 22.3 mmol) and ΠΟΗ·Η ₂ 0 (1.87 g, 44.5 mmol) in THF/H ₂ 0 (176 mL / 44 mL) was heated to 60 °C and stirred for 40 h. The solution was concentrated, then DCM added (300 mL) and washed with aqueous HC1, then dried over Na ₂ S0 ₄ and the solvent removed to give 15.4 g (98%) of the product. Intermediate 181c. fSVtert-butyl l-oxo-l-( ^, l-(3-r4-(piperidin-l-vn-2-(4-n.2.3.4- tetrahydronaphthalen- 1 -ylcarbamoyl pyridin-2-yl phenylcarbamoyl benzyiy 1 H-indol- 4-yl)-5 ,8, 11 -trioxa-2-azatetradecan- 14-oate. To a mixture of 181b (14.7 g, 20.9 mmol), tert-butyl 3-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)propanoate (6.06 g, 21.8 mmol), and diisopropylethylamine(14.5 mL, 83.4 mmol) in DMF (63 mL) was added HATU (9.93 g, 26.1 mmol), then the solution heated to 50 °C and stirred for 2 h. The solvent was removed and the resulting residue dissolved in EtOAc and washed thrice with H ₂ 0, then dried over Na ₂ S0 ₄ and the solvent removed. The resulting residue was purified by silica gel chromatography to give 10 g (50%) of the product.

Example 181 : fSVl -oxo- 1 -Π -(3 -(4-(piperidin- 1 - Y\)-2-(4-( 1 ,2,3 ,4-tetrahvdronaphthalen- 1 -ylcarbamovf)pyridin-2-yl phenylcarbamoyl)benzvn- 1 H-indol-4-yiy 5,8 , 11 -trioxa-2- azatetradecan-14-oic acid. A mixture of 181c (12.5 g, 13.0 mmol) in a 4M HCl solution of dioxane (120 mL) was stirred at 0 °C for lh and then the solvent removed. The resulting residue was dissolved in DCM and washed with H ₂ 0, then dried over Na ₂ S0 ₄ . The solvent was removed and the residue was purified by silica gel chromatography, using a gradient of 2% to 4% MeOH in DCM as eluent and the solvent removed. This gave 9.6 g (75%) of the product as the HCl salt. MS (ES, m/z) 907 [M+H] ⁺ . 1H NMR (400 MHz, dmso) δ 12.14 (s, 1H), 11.95 (s, 1H), 9.16 (d, J= 8.6 Hz, 1H), 8.68 (d, J= 5.1 Hz, 1H), 8.29 - 8.18 (m, 2H), 8.14 (d, J= 9.0 Hz, 1H), 7.84 - 7.66 (m, 3H), 7.61 (dd, J= 11.5, 5.7 Hz, 2H), 7.51 - 7.27 (m, 4H), 7.22 - 7.02 (m, 5H), 6.96 - 6.84 (m, 1H), 5.58 (s, 2H), 5.29 - 5.18 (m, 1H), 3.61 - 3.38 (m, 14H), 3.22 - 3.11 (m, 4H), 2.85 - 2.69 (m, 2H), 2.42 (t, J = 6.3 Hz, 2H), 2.06 - 1.88 (m, 2H), 1.87 - 1.70 (m, 2H), 1.70 - 1.58 (m, 4H), 1.54 (d, J= 5.0 Hz, 2H).

EXAMPLE 182

(S 1 -( 1 -(3-(4-( diefhylamino>2-(4-q ,2,3.4-tetrahvdronaphthalen- 1 - ylcarbamoyl pyridin-2-yl phenylcarbamoyl)benzvD-lH-indol-4-yl -l-oxo-5,8,l l- trioxa-2-azatetradecan- 14-oic acid

This compound was prepared using the method described for the preparation of Example 181, using 131c in place of 142a. MS (ES, m/z) 895 [M+H] ⁺

EXAMPLE 183

3 -((3 -(4-Cpiperidin- 1 -yl>2-(4-(3 -(trifluoromethyl benzylcarbamovnpyridin-2- vDphenylcarbamovDphenoxy methyl)benzoic acid.

Scheme 76. 1. 3-Hydroxybenzoic acid, HATU, diisopropylethylamine, DMF; 2. Methyl 3-(bromomethyl)benzoate, K ₂ C0 ₃ , DMF.

Intermediate 183 a: 2-(2-(3 -hydroxybenzamido)-5-(piperidin- 1 -yl)phenyl>N-(3 - (trifluoromethyl)benzvnisonicotinamide. To a mixture of 4.1c (91 mg, 0.20 mmol), 3- hydroxybenzoic acid (28 mg, 0.20 mmol), and diisopropylethylamine (104 DL, 0.60 mmol) in DMF (2 mL) was added HATU (76 mg, 0.20 mmol) and the solution stirred for 18 h. The solvent was removed and the resulting residue purified by reverse-phase HPLC eluting with a water / acetonitrile gradient containing 0.1% TFA and lyophilized to give 34 mg (30%) of the product.

Example 183: 3-((3-(4-(piperidin-l-ylV2-(4-(3-

(trifluoromethyl benzylcarbamoyl pyridin-2- yl phenylcarbamoyDphenoxy methyl benzoic acid. A mixture of 183a (34 mg, 0.059 mmol), methyl 3-(bromomethyl)benzoate (27 mg, 0.12mmol), and K ₂ C0 ₃ (24 mg, 0.18 mmol) was stirred for 16 h and then filtered. The solvent was removed and resulting residue purified by reverse-phase HPLC eluting with a water / acetonitrile gradient containing 0.1% TFA and lyophilized to give 18 mg (43%) of the product. MS (ES, m/z) 709 [M+H] ⁺

EXAMPLE 184

3-((2-(3-(4-(piperidin-l-yl)-2-(4-(3-(trifluoromethyl)benzyl carbamoyl)pyridin-2- vDphenylcarbamoyQphenyl l H-imidazol- 1 -yl)methyl)benzoic acid

This compound was prepared using the method described for the preparation of Example 183, using 3-(lH-imidazol-2-yl)benzoic acid in place of 3-hydroxybenzoic acid. MS (ES, m/z) 759 [M+H] ⁺ . 1H NMR (400 MHz, dmso) δ 12.21 (s, 1H), 9.51 (t, J = 5.8 Hz, 1H), 8.81 (d, J = 5.1 Hz, 1H), 8.30 (s, 1H), 8.23 - 8.14 (m, 2H), 8.11 (d, J = 7.6 Hz, 1H), 7.88 - 7.71 (m, 7H), 7.66 (s, 1H), 7.55 (dd, J= 18.5, 10.9 Hz, 4H), 7.41 (t, J= 7.7 Hz, 1H), 7.32 (d, J= 7.7 Hz, 2H), 5.51 (s, 2H), 4.57 (d, J= 5.8 Hz, 2H), 3.31 (s, 4H), 1.71 (s, 4H), 1.57 (s, 2H).

EXAMPLE 185

3-((3-(4-(piperidin-l-ylV2-(4-(3-(trifluoromethyl benzylcarbamoyl)pyridin-2- yl phenylcarbamoyl)benzyloxy methyl)benzoic acid.

Scheme 77. 1. Sodium hydride, DMF; 2. NaOH, MeOH, H ₂ 0; 3. 4.1c, HATU, diisopropylethylamine, DMF.

Intermediate 185a: dimethyl 3 '-oxybis(methylene dibenzoate. To a mixture of methyl 3-(hydroxymethyl)benzoate (500 mg, 3.01 mmol) in DMF (5 mL) cooled to 0 °C was added a 60% sodium hydride dispersion in mineral oil (180 mg). The mixture was stirred for 0.5 h at 0 °C, then methyl 3-(bromomethyl)benzoate (690 mg, 3.01 mmol) was added and the mixture stirred an additional 4 h at room temperature, then diluted with EtOAc. The solution was washed with aqueous HC1, saturated aqueous NaHC0 ₃ , H ₂ 0, and brine, then dried over Na ₂ C0 ₃ and the solvent removed. The resulting residue was purified by silica gel chromatography to give 450 mg (48%) of the product 185a.

Intermediate 185b: 3,3'-oxybis(methylene dibenzoic acid. A mixture of 185a (450 mg, 1.43 mmol) and three pellets of NaOH in MeOH/H ₂ 0 (4 mL : 4 mL) was stirred for 4 h at 0 °C, then diluted with EtOAc. The solution was washed with aqueous HC1, H ₂ 0, and brine, then dried over Na ₂ C0 ₃ and the solvent removed to give 370 mg (90 %) of the product 185b.

Example 185: 3-((3-(4-rpiperidin-l-yl -2-(4-(3-

(trifluoromethyl benzylcarbamoyl)pyridin-2-yl phenylcarbamoyl benzyloxy

methvDbenzoic acid. To a mixture of 4.1c (190 mg, 0.420 mmol), 185b (370 mg, 1.26 mmol) and diisopropylethylamme (660 μί, 3.80 mmol) in DMF (3 mL) was added HATU (240 mg, 0.630 mmol) and the solution stirred for 16 h. The solvent was removed and the residue purified by reverse-phase HPLC eluting with a water / acetonitrile gradient containing 0.1% TFA and lyophilized to give 25 mg (8%) of the product. MS (ES, m/z) 723 [M+H] ⁺

EXAMPLE 186

3 -((3 -(4-(piperidin- 1 -yl -2-(4-(3 -(trifluoromethyl)benzylcarbamoyl pyridin-2- yl phenylcarbamoyl phenylthio methyl)benzoic acid.

Scheme 78. 1. K ₂ C0 ₃ , DMF; 2. 4.1c, HATU, diisopropylethylamine, DMF; 3.

ΟΟΗ·Η ₂ 0, THF, H ₂ 0.

Intermediate 186a: 3-(3-(methoxycarbonyl benzylthio)benzoic acid. A mixture of 3- mercaptobenzoic acid (154 mg, 1.00 mmol), methyl 3-(bromomethyl)benzoate (229 mg, 1.00 mmol) and K ₂ C0 ₃ (414 mg, 3.00 mmol) in DMF (1 mL) was stirred for 16 h, then solvent removed. The resulting residue was purified by silica gel chromatography to give 300 mg (90%) of the product.

Intermediate 186b: methyl 3 -( ( 3 -(4-(piperidin- 1 - vD-2-i4-i 3 -

(trifluoromethyl benzylcarbamoyl)pyridin-2- yl)phenylcarbamoyl)phenylthio)methyl benzoate. To a mixture of 186a (300 mg, 0.991 mmol), 4.1c (454 mg, 1.00 mmol), and diisopropylethylamine (521 μί, 3.00 mmol) in DMF (3 mL) was added HATU (570 mg, 1.5 mmol) and then stirred for 18 h. The solvent was removed and the residue purified by silica gel chromatography to give 462 mg (63%) of the product.

Example 186j 3-((3-(4-(piperidin-l-vn-2-(4-(3-

(trifluoromethyl)benzylcarbamoyl ^' )pyridin-2- yl phenylcarbamoyl)phenylthio)methyl benzoic acid. A mixture of 186b (462 mg, 0.625 mmol) and LiOH»H ₂ 0 (40 mg, 0.953 mmol) in THF/H ₂ 0 (3 mL : 1 mL) was stirred for 4 h, then the solution concentrated and purified by reverse-phase HPLC eluting with a water / acetonitrile gradient containing 0.1% TFA and lyophilized to give 30 mg (7%) of the product. MS (ES, m/z) 725 [M+H] ⁺ . 1H NMR (400 MHz, dmso) δ 12.34 (s, 1H), 9.55 (t, J = 5.9 Hz, 1H), 8.87 (d, J = 5.1 Hz, 1H), 8.36 (s, 2H), 7.97 (s, 1H), 7.88 (d, J - 5.1 Hz, 2H), 7.83 - 7.73 (m, 3H), 7.73 - 7.45 (m, 8H), 7.41 (t, J= 7.7 Hz, 1H), 4.62 (d, J= 5.7 Hz, 2H), 4.40 (s, 2H), 3.45 (s, 4H), 1.85 (s, 4H), 1.63 (s, 2H).

EXAMPLE 187

(S Vtert-butyl 1 -(2-(N-methyl-3 -((4-(piperidin- 1 -vV\-2-( (($ V 1.2.3 ,4- tetrahydronaphthalen- 1 -yl)carbamovDpyridin-2- yl)phenvncarbamoyl benzamido)ethyl ^' )pyrrolidine-2-carboxylate

Scheme 79. 1. DMSO, (C0) ₂ C1 ₂ , DCM; 2. L-proline-t-butyl ester, NaCNBH ₃ , HO Ac, EtOH

Intermediate: 187a (SVN ¹ -methyl-N ¹ -(2-oxoethyl)-N ³ -(4-(piperidin-l-ylV2-r4- (( 1.2,3.4-tetrahydronaphthalen- 1 -y carbamovDpyridin-2-vDphenyl)isophthalamide. To a solution of DMSO (2.07 mmol, 162 mg) in DCM (1.6 mL) at -78 °C was added a solution of oxalyl chloride (1.04 mmol, 131 mg) in DCM (0.2 mL). The mixture was stirred at -78 °C for 15 minutes. Then a solution of (S)-N ¹ -(2-hydroxyethyl)-N ¹ - methyl-N ³ -(4-(piperidin- 1 -yl)-2-(4-((l ,2,3,4-tetrahydronaphthalen- 1 - yl)carbamoyl)pyridin-2-yl)phenyl)isophthalamide Example 115 (0.69 mmol, 435 mg) in DCM (0.5 mL) was added. The mixture was stirred at -78 °C for. 3 h. Triethylamine (0.5 mL) was added. The mixture was slowly warmed to room temperature. The mixture was diluted with aquaous 10% citric acid and extracted with DCM (3x). The combined organic layers was washed with water (lx), dried, concentrated to give a yellow solid which was used without purification.

Example 187. fSVtert-butyl l-r2-(N-methyl-3-((4-(piperidin-l-vn-2-(4-(((S VI.2,3,4- tetrahvdronaphthalen-l-yl carbamoyl pyridin-2-yl phenyl)carbamoyl)benzamido ethyl pyrrolidine-2-carboxylate. To a solution of L-proline-t-butyl ester (0.096 mmol, 16 mg) in ethanol (0.2 mL) were added (S)-N ¹ -methyl-N ¹ -(2-oxoethyl)-N ³ -(4-(piperidin-l-yl)- 2-(4-((l ,2,3,4-tetrahydronaphthalen-l -yl)carbamoyl)pyridin-2- yl)phenyl)isophthalamide (0.032 mmol, 20 mg) and HOAc (0.064 mmol, 4 mg). The mixture was stirred at room temperature for 25 minutes, and then sodium cyanoborohydride (0.16 mmol, 10 mg) was added. The mixture was stirred for an additional 20 minutes and quenched with water. The yellow solid was collected via filtration and was purified by prep HPLC to give a yellow solid (12 mg, 37%). MS (ES, m/z): 786.1 [M+H] ⁺ .

EXAMPLE 188

1 -(3 -((4-(diemylaminoV2-(4-((3 -(trifluoromethyl)benzyl carbamoyl pyridin-2- yl)phenyl carbamoyl)phenylV2-methyl- 1 -oxo-5,8 J 1 -trioxa-2-azatetradecan- 14-oic acid

Scheme 80. 1. 3-(tert-butoxycarbonyl)benzoic acid, HATU, DIEA, DMF; 2. 4M HCl in dioxane; 3. tert-butyl 5,8,1 l-trioxa-2-azatetradecan-14-oate, HATU, DIEA, DMF; 4. TFA.

Intermediate 188a: tert-butyl 3-((4-( diethylarninoV2-i4-i ( 3 -

(trifluoromethyl benzyl)carbamoyl) pyridin-2-yl ^' )phenyl ^' )carbamoyl)benzoate. To a mixture of 2-(2-amino-5-(diethylamino ^' )phenvD-N-r3-

(trifluoromethvDbenzvDisonicotinamide (25a, 6.33 mmol, 2.8 g), 3-(tert- butoxycarbonyl)benzoic acid (7.60 mmol, 1.69 g) and DIEA (31.65 mmol, 4.09 g) in DMF (15 mL) was added HATU (7.6 mmol, 2.89 g). The mixture was stirred at 60 °C for 2 hours. The reaction mixture was diluted with ethyl acetate, washed with water (2x), sat. aquaous NaHC0 ₃ (lx), brine (lx), dried and concentrated. The residue was purified by column to give a yellow solid (3.9 g, 95%).

Intermediate 188b: 3 -(( 4-(diethylamino >2-( 4-f (3 -

(trifluoromethyl)benzyl ^' )carbamoyl pyridin-2-yl phenyl carbamoyl benzoic acid. To tert-butyl 3 -((4-(diethylamino)-2-(4-((3 -(trifluoromethyl)benzyl)carbamoyl)pyridin-2- yl)phenyl)carbamoyl)benzoate was added 4M HCl in dioxane (25 mL). The mixture was stirred at room temperature for 3 hours, concentrated to give a light yellow solid which was used without further purification. Intermediate 188c: tert-butyl 1 -f 3 -(( 4-( diethylamino -2-( 4-(Y 3 -

(trifluoromethyDbenzvDcarbamoyl) pyridin-2-yl)phenyl)carbamoyl)phenyl)-2-methyl- 1 -oxo-5.,8 Λ 1 -trioxa-2-azatetradecan- 14-oate. To a mixture of 3-((4-(diethylamino)-2- (4-((3-(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl )carbamoyl)benzoic acid (1.81 mmol, 1.2 g), tert-butyl 5,8,1 l-trioxa-2-azatetradecan-l 4-oate (1.9 mmol, 554 mg) and DIEA (12.67 mmol, 1.64 g) in DMF (5 mL) was added HATU (2.17 mmol, 826 mg). The mixture was stirred at 60 °C for 1 hour. The reaction mixture was diluted with ethyl acetate, washed with water (2x), sat. aquaous NaHC0 ₃ (lx), brine (lx), dried and concentrated. The residue was purified by column to give a syrup (1.17 g, 75%).

(trifluoromethyl benzyl carbamoyl)pyridin-2-yl phenvDcarbamoyl)phenyl)-2-methyl-l- oxo-5,8 J l-trioxa-2-azatetradecan-14-oic acid. To a mixture of tert-butyl l-(3-((4- (diethylamino)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl) pyridin-2- yl)phenyl)carbamoyl)phenyl)-2-methyl-l-oxo-5,8,l l-trioxa-2-azatetradecan-14-oate (1.17 g) in DCM (20 mL) was added TFA (20 mL). The mixture was stirred for 1 hour, concentrated and lyophilized to give a think brown syrup. MS (ES, m/z): 808.3 [M+H] ⁺ .

EXAMPLE 189

(S)-2-( ^" 5-(diethylamino -2-(3-(3-((2-methoxyethyl)carbamoyl)piperidine-l- carbonyl)benzamido phenyl -N-( ^' 3-(trifluoromethyl benzyl isonicotinamide

This compound was prepared according to the procedure described for the synthesis of tert-butyl 1 -(3 -((4-(diethylamino)-2-(4-((3 -(trifluoromethyl)benzyl)carbamoyl)pyridin- 2-yl)phenyl)carbamoyl)phenyl)-2-methyl- 1 -oxo-5 ,8, 11 -trioxa-2-azatetradecan- 14-oate Example 188, using (S)-N-(2-methoxyethyl)piperidine-3-carboxamide 4.14a in place of tert-butyl 5,8,1 l-trioxa-2-azatetradecan-l 4-oate. MS (ES, m/z): 759 A [M+H] ⁺ .

EXAMPLE 190

tert-Butyl 2-methyl- 1 -(TS 1 -(2-(N-methyl-3 -(Y4-fpiperidin- 1 -yl -2-(4-((TS )- U2.3.4- tetrahvdronaphthalen-l-yl ^N )carbamovDpyridin-2-yl)phenyl carbamoyl benzamido ethyl)pyrrolidin-2-ylV 1 -oxo-5 ,8, 11 -trioxa-2-azatetradecan- 14-oate

Scheme 81. 1. TFA; 2. tert-butyl 5,8,1 l-trioxa-2-azatetradecan-l 4-oate 135c, HATU, DIEA, DMF.

Intermediate 190a: ( ^, S l-(2-(N-methyl-3-((4-(piperidin-l-vn-2-(4-(((S 1.2.3.4- tetrahydronaphthalen- 1 -yl ^' )carbamovDpyridin-2- yl ^' )phenyl ^' )carbamoyl ^' )benzamido ^' )ethyDpyrrolidine-2-carboxylic acid. To (S)-tert-butyl 1 -(2-(N-methyl-3 -((4-(piperidin- 1 -yl)-2-(4-(((S)- 1 ,2,3,4-tetrahydronaphthalen- 1 - yl)carbamoyl)pyridin-2-yl)phenyl)carbamoyl)benzamido)ethyl)p yrrolidine-2- carboxylate (90 mg) was added TFA (5 mL). The mixture was stirred at room temperature for 6 h, concentrated and purified by column to give a yellow solid (75 mg, 90%).

Example 190: tert-Butyl 2-methyl-l-r(S)-l-(2-rN-methyl-3-(r4-(piperidin-l-vn-2-(4- ((YSy 1 ,2,3 ,4-tetrahydronaphthalen- 1 -vDcarbamoyl)pyridin-2- yl)phenvDcarbamoyl)benzamido ethyl) pyrrolidin-2-yl - 1 -oxo-5 ,8 , 11 -trioxa-2- azatetradecan- 14-oate. To a mixture of (S)-l-(2-(N-methyl-3-((4-(piperidin-l-yl)-2-(4- (((S)- 1 ,2,3 ,4-tetrahydronaphthalen- 1 -yl)carbamoyl)pyridin-2- yl)phenyl)carbamoyl)benzamido)ethyl)pyrrolidine-2-carboxylic acid (0.035 mmol, 25.7 mg), tert-butyl 5,8,1 l-trioxa-2-azatetradecan-l 4-oate 135c (0.042 mmol, 12.4 mg) and DIEA (0.212 mmol, 27 mg) in DMF (0.15 mL) was added HATU (0.042 mmol, 16 mg). The mixture was stirred at 60 °C for 1 h. The reaction mixture was diluted with ethyl acetate, washed with water (2x), brine (lx), dried and concentrated. 23% of the residue was purified by prep. HPLC to give a yellow solid (4 mg, 37%). MS (ES, m/z): 1002.36 [M+H] ⁺ .

EXAMPLE 191

2-Methyl- 1 -((S)- 1 -(2-(N-methyl-3-(Y4-ipiperidin- 1 - _y l)-2-f 4-((TSV 1 ,2.3 ,4- tetrahydronaphthalen- 1 -yl carbamoyl)pyridin-2- yl)phenyl carbamoyl)benzamido ethyl)pyrrolidin-2-yl)-l-oxo-5,8J l-trioxa-2- azatetradecan-14-oic acid

Example 191 : 2-Methyl- 1 - ((S 1 - f 2-(N-methyl-3 -((4-(piperidin- 1 - _y lV2-(4-(((S 1.2.3.4- tetrahydronapht alen- 1 -yl)carbamoyl)pyridin-2- yl)phenyl)carbamoyl)benzamido)ethyl pyrrolidin-2-yl)- 1 -oxo-5,8 J 1 -trioxa-2- azatetradecan-14-oic acid. To tert-Butyl 2-methyl-l-((S)-l-(2-(N-methyl-3-((4- (piperidin- 1 -yl)-2-(4-(((S)- 1 ,2,3 ,4-tetrahydronaphthalen- 1 -yl)carbamoyl)pyridin-2- yl)phenyl)carbamoyl)benzamido) ethyl) pyrrolidin-2-yl)-l-oxo-5,8,l l-trioxa-2- azatetradecan-14-oate (16 mg) was added TFA (2 mL). The mixture was stirred at rt for 30 minutes, concentrated and purified by prep. HPLC to give a yellow solid (17.6 mg, 86%). MS (ES, m/z): 946.34 [M+H] ⁺ .

EXAMPLE 192

tert-butyl 1 -(YSV 1 -f 2-(N-methyl-3-((4-ipiperidin- 1 -ylV2-(4-f ((SV1 ,2,3 ,4- tetrahydronaphthalen- 1 -yl)carbamoyl pyridin-2- yl)phenyl)carbamoyl)benzamido ^' )ethyl)pyrrolidin-2-yl)-l-oxo-5,8,l l-trioxa-2- azatetradecan- 14-oate

This compound was prepared according to the procedure described for the synthesis of tert-butyl 2-methyl- 1 -((S)- 1 -(2-(N-methyl-3 -((4-(piperidin- 1 -yl)-2-(4-(((S)- 1 ,2,3 ,4- tetrahydronaphthalen- 1 -yl)carbamoyl)pyridin-2- yl)phenyl)carbamoyl)benzamido)ethyl)pyrrolidin-2-yl)- 1 -oxo-5,8, 11 -trioxa-2- azatetradecan-14-oate Example 190, using tert-butyl 3-(2-(2-(2-aminoethoxy)ethoxy) ethoxy)propanoate in place of tert-butyl 5,8,1 l-trioxa-2-azatetradecan-l 4-oate. MS (ES, m/z): 988.34 [M+H] ⁺ . EXAMPLE 193

1 -(YS V 1 - (2-(N-mefliy 1-3 -((4-Cpiperidin- 1 -νΓ)-2-(4-(Γ (S 1.2,3 ,4-tetrahvdronaphthalen- 1 - yl)carbamoyl)pyridin-2-yl)phenyl)carbamoyl)benzamido)ethyl)p yrrolidin-2-yl)-l-oxo-

5,8,1 l-trioxa-2-azatetradecan-14-oic acid

This compound was prepared according to the procedure described for the synthesis of 2-Methyl-l-((S)-l-(2-(^-methyl-3-((4-(piperidin-l-yl)-2-(4-( ((S)-l,2,3,4- tetrahydronaphthalen- 1 -yl)carbamoyl)pyridin-2- yl)phenyl)carbamoyl)benzamido)ethyl)pyrrolidin-2-yl)-l-oxo-5 ,8,ll-trioxa-2- azatetradecan-14-oic acid Example 191, using tert-butyl 3-(2-(2-(2- aminoethoxy)ethoxy) ethoxy)propanoate in place of tert-butyl 5,8,11 -trioxa-2- azatetradecan-14-oate.. MS (ES, m/z): 932.38 [M+H] ⁺ .

EXAMPLE 194

(S)-N ¹ -(4-(diethylamino -2-(4-(( 1 ,2,3 ,4-tetrahvdronaphthalen- 1 -vDcarbamovDpyridin-

2-yl phenyl)-N ³ -( ^' 2-hvdroxyethylVN ³ -methylisophthalamide

This compound was prepared according to the procedure described for the synthesis of (S)-N ¹ -(4-(diethylamino)-2-(4-((l,2,3,4-tetrahydronaphthalen -l-yl)carbamoyl)pyridin- 2-yl)phenyl)-N ³ -methyl-N ³ -(2-morpholinoethyl)isophthalamide Example 131, using 2- (methylamino)ethanol in place of MS (ES, m/z): 620.32 [M+H] ⁺ .

EXAMPLE 195

N ¹ -(2-((S)-2-(2,5,8J l,14J7,20,23-octaoxapentacosan-25-ylcarbamovDpyrrolidin-l- yltemylVN ¹ -methyl-N ³ -( 4-fpiperidin- 1 -yl)-2-(4-( ((S)- 1 ,2,3 ,4-tetrahvdronaphthalen- 1 - vDcarbamoyl pyridin-2-yDphenvDisophthalamide

This compound was prepared according to the procedure described for the synthesis of tert-butyl 2-methyl- 1 -((S)- 1 -(2-(N-methyl-3 -((4-(piperidin- 1 -yl)-2-(4-(((S)- 1 ,2,3 ,4- tetrahydronaphthalen- 1 -yl)carbamoyl)pyridin-2- yl)phenyl)carbamoyl)benzamido)ethyl)pyrrolidin-2-yl)- 1 -oxo-5 ,8 , 11 -trioxa-2- azatetradecan-14-oate Example 190, using 2,5, 8,11, 14,17,20,23-octaoxapentacosan-25- amine in place of tert-butyl 5,8,1 l-trioxa-2-azatetradecan-14-oate. MS (ES, m/z): 1094.47 [M+H] ⁺ .

EXAMPLE 196

N ¹ -(2-(( ^' SV2-( ^' 2,5,8, 11,14,17,20,23-octaoxapentacosan-25-ylcarbamoyDpyrrolidin-l - yl ethyiyN ³ -(4-fdiethylamino>2-( 4-(TfS V 1.2,3 ,4-tetrahvdronaphthalen- 1 - vf)carbamoyDpyridin-2- yPphenvD-N ¹ -methylisophthalamide

This compound was prepared according to the procedure described for the synthesis of N ¹ -(2-((S)-2-(2,5 ,8, 11 , 14, 17,20,23 -octaoxapentacosan-25-ylcarbamoyl)pyrrolidin- 1 - yl)ethyl)-N ¹ -methyl-N ³ -(4-(piperidin-l-yl)-2-(4-(((S)-l,2,3,4-tetrahydronaph thalen-l- yl)carbamoyl) pyridin-2-yl)phenyl)isophthalamide Example 195, using (S)-N'-(4- (diethylamino)-2-(4-(( 1 ,2,3 ,4-tetrahydronaphthalen- 1 -yl)carbamoyl) pyridin-2- yl)phenyl)-N ³ -methyl-N ³ -(2-oxoethyl)isophthalamide in place of (S)-N ¹ -methyl-N ¹ -(2- oxoethyl)-N ³ -(4-(piperidin- 1 -yl)-2-(4-(( 1 ,2,3 ,4-tetrahydronaphthalen- 1 - yl)carbamoyl)pyridin-2-yl)phenyl)isophthalamide. MS (ES, m/z): 1082.52 [M+H] ⁺ .

EXAMPLE 197

N ³ -(4-(diethylamino )-2-(4-((l 23 ,4-tetrahydronaphthalen- 1 -vDcarbamovOpyridin-2- yl)phenyl -N ¹ -methylisophthalamide

Scheme 82. 1. DMSO, (CO) ₂ Cl ₂ , DCM; 2. tert-butyl 1,4-diazepane-l-carboxylate, NaCNBH ₃ , HO Ac, EtOH; 3. 4M HC1 in dioxane; 4. m-dPEG ₈ -NHS ester, TEA, DMF.

Intermediate 197a: (SVN ¹ -(4-( diethylamino -2-i 4-(( 1.2.3.4-tetrahvdronaphthalen- 1 - yPcarbamoyl) pyridin-2-vDphenyl)-N ³ -methyl-N ³ -( ^' 2-oxoethyl)isophthalamide. To a solution of DMSO (4.8 mmol, 375 mg) in DCM (3 mL) at -78 °C was added a solution of oxalyl chloride (2.4 mmol, 305 mg) in DCM (0.4 mL). The mixture was stirred at -78 °C for 15 minutes. Then a solution of (S)-N ¹ -(4-(diethylamino)-2-(4-((l,2,3,4- tetrahydronaphthalen- 1 -yl)carbamoyl)pyridin-2-yl)phenyl)-N -(2-hydroxyethyl)-N - methylisophthalamide Example 194 (1.2 mmol, 742 mg) in DCM (1.7 mL) was added dropwise. The mixture was stirred at -78 °C for 3 h and quenched with triethylamine (0.85 mL). The mixture was stirred at -78 °C for 10 minutes, at 0 °C for 10 minutes, then diluted with water, and extracted with DCM (2x). The combined organic layers was washed with water (lx), dried, and concentrated. The residue was used without furthur purification.

Intermediate 197b: iSVtert-butyl 4-(2-( ^' 3-(( ^, 4-(diethylaminoV2-(4-i( ^' 1.2.3.4- tetrahvdronaphthalen-l-yl carbamoyl)pyridin-2-yl)phenyl)carbamoyl)-N- methylbenzamido ethyl)- 1 ,4-diazepane- 1 -carboxylate. To a mixture of (S)-N ¹ -(4- (diethylamino)-2-(4-(( 1 ,2,3 ,4-tetrahydronaphthalen- 1 -yl)carbamoyl) pyridin-2- yl)phenyl)-N ³ -methyl-N ³ -(2-oxoethyl)isophthalamide (0.162 mmol, 100 mg) in ethanol (1 mL) were added tert-butyl 1,4-diazepane-l-carboxylate (0.324 mmol, 65 mg) and HO Ac (0.324 mmol, 19.4 mg). The mixture was stirred at room temperature for 20 minutes, and then sodium cyanoborohydride (0.81 mmol, 51 mg) was added. The mixture was stirred for an additional 1 h, diluted with ethyl acetate, washed with sat. aqueous NaHCO ₃ and brine, dried, concentrated and purified by column to give a product (70 mg, 54%).

Intermediate 197c: (SVN ¹ -(2-(T.4-diazepan-l-ynethyl -N ³ -(4-(diethylamino -2-(4- ((1,2,3 ,4-tetrahydronaphthalen- 1 -yl carbamoyl)pyridin-2-yl)phenyl)-N ¹ - methylisophthalamide. To (S)-tert-butyl 4-(2-(3-((4-(diethylamino)-2-(4-((l,2,3,4- tetrahydronaphthalen- 1 -yl)carbamoyl) pyridin-2-yl)phenyl)carbamoyl)-N- methylbenzamido)ethyl)-l,4-diazepane-l -carboxylate was added 4M HCl in dioxane (3 mL). The mixture was stirred at room temperature for 2 h, concentrated to give a light yellow solid which was used without furthur purification.

Example 197. (S VN ¹ -(2-(4-(2,5.8.11.14,17.20.23 -octaoxahexacosan-26-oylV 1.4- diazepan- 1 -yl ethyl -N ³ -(4-(diethylaminoy 2-(4-(( 1 ,2,3.4-tetrahydronaphthalen- 1 - yDcarbamoyl pyridin-2-yl)phenyl)-N ¹ -methylisophthalamide. To a mixture of (S)-N ¹ - (2-(l,4-diazepan-l-yl)ethyl)-N ³ -(4-(diethylamino)-2-(4-((l,2,3,4-tetrahydronaphthalen - l-yl)carbamoyl)pyridin-2-yl)phenyl)-N ^I -methylisophthalamide (0.024, 20 mg) and m- dPEGg-NHS ester (0.024 mmol, 12.2 mg) in DMF (0.15 mL) was added triethylamine (0.144 mmol, 14.6 mg). The mixture was stirred at 60 °C for 1 h and purified by prep. HPLC to give a brown gel (6.3 mg, 18%). MS (ES, m/z): 1096.55 [M+H] ⁺ .

EXAMPLE 198

N ¹ -(2-((S)-2-(2,5,8a iJ4a7,20-heptaoxadocosan-22-yl( ^' methvncarbamoyl)pyrrolidin- 1 -yltethvn-N ¹ -methyl-N ³ -(4-(piperidin- 1 -ylV2-(4-( (YSV1.2.3.4-tetrahvdronaphthalen- 1 - yl carbamoyl)pyridin-2-yl phenyf)isophthalamide

This compound was prepared according to the procedure described for the synthesis of tert-butyl 2-methyl- 1 -((S)- 1 -(2-(N-methyl-3-((4-(piperidin- 1 -yl)-2-(4-(((S)- 1 ,2,3 ,4- tetrahydronaphthalen- 1 -yl)carbamoyl)pyridin-2- yl)phenyl)carbamoyl)benzamido)ethyl)pyrrolidin-2-yl)- 1 -oxo-5,8, 11 -trioxa-2- azatetradecan-14-oate Example 190, using N-methyl-2,5,8, 11, 14,17,20- heptaoxadocosan-22-amine in place of tert-butyl 5,8,1 l-trioxa-2-azatetradecan-14-oate. MS (ES, m/z): 1064.42 [M+H] ⁺ .

EXAMPLE 199

( ^' SV2,5,8,l l,14J7,20.23.26.29.32-undecaoxatetratriacontan-34-yl 4-( ^' 2-(3-(r4- (diethylamino)-2-( ^, 4-((l,2,3,4-tetrahydronaphthalen-l-yl ^' )carbamoyl ^' )pyridin-2- vDphenvDcarbamoylVN-methylbenzamido^ethyl V 1 ,4-diazepane- 1 -carboxylate

This compound was prepared according to the procedure described for the synthesis of (S)-N ¹ -(2-(4-(2,5,8, 11 , 14, 17,20,23-octaoxahexacosan-26-oyl)- 1 ,4-diazepan- 1 -yl)ethyl)- N -(4-(diethylamino)-2-(4-(( 1 ,2,3 ,4-tetrahydronaphthalen- 1 -yl)carbamoyl)pyridin-2- y^pheny^-N ¹ -methylisophthalamide Example 197, using m-dPEGn-NHS carbonate in place of m-dPEGg-NHS ester. MS (ES, m/z): 1244.49 [M+H] ⁺ .

EXAMPLE 200

2-(2-(3-(2,5,8,l 1,14,17,20,23 ,26-nonaoxaheptacosyl benzamidoV5- (dipropylamino)phenylVN-(3-(trifluoromethvnbenzyl)isonicotin amide

Example 200. 2-(2-(3-(2,5,8,l 1,14, 17,20,23.26-nonaoxaheptacosyl benzamidoV5- (dipropylamino phenyl)-N-(3-(trifluoromethyl)benzyl isonicotinamide. To a mixture of 2-(2-amino-5-(dipropylamino)phenyl)-N-(3-(trifluoromethyl)be nzyl)isonicotinamide (19b, 1.27 mmol, 600 mg), 3-(2,5,8,l l,14,17,20,23,26-nonaoxaheptacosyl)benzoic acid (prepared as in Example 185 2,5,9,12,15, 18,21,24-octaoxahexacosan-26-ol in place of methyl 3-(hydroxymethyl)benzoate) (1.40 mmol, 729 mg) and DIEA (7.66 mmol, 990mg) in DMF (4 mL) was added HATU (1.40 mmol, 534 mg). The mixture was stirred at 60 °C for 1 h, diluted with DCM, washed with water (3x), dried, concentrated and purified by column to give a yellow syrup (1.01 g, 82%). MS (ES, m/z): 971.42 [M+H] ⁺ .

EXAMPLE 201

(S -N ¹ -(2-(2-(2,5,8, 11,14.17.20.23-octaoxapentacosan-25-ylcarbamoyl piperidin- 1 - yl ethyl -N ³ -(4-(diethylamino)-2-(4-((3-(trifluoromethyl)benzyl)ca rbamoyl pyridin-2

Scheme 83. 1. (S)-methyl piperidine-2-carboxylate, Na(OAc) ₃ BH, TEA, DCE; 2. 2,5,8,1 l,14,17,20,23-octaoxapentacosan-25-amine, HATU, DIEA; 3. Pd/C, H ₂ , MeOH; 4. 3-((4-(diethylamino)-2-(4-((3-(trifluoromethyl)benzyl)carbam oyl)pyridin-2- yl)phenyl)carbamoyl) benzoic acid, HATU, DIEA, DMF.

Intermediate 201 a: (S)- 1 -(2-(((benzyloxy carbonyl)( ^' methynamino)ethv piperidine-2- carboxylic acid. To a mixture of benzyl methyl(2-oxoethyl)carbamate ( 0.47 mmol, 98 mg) and triethylamine (0.47 mmol, 48 mg) in DCE (1.7 mL) was added (S)-methyl piperidine-2-carboxylate (0.47 mmol, 85 mg), followed by addition of sodium triacetoxyborohydride (0.71 mmol, 150 mg). The mixture was stirred at rt for 1 h, concentrated under reduced pressure and purified by column to give a solid product (70 mg, 47%) and a clear syrup ((S)-methyl l-(2- (((benzyloxy)carbonyl)(methyl)amino)ethyl)piperidine-2-carbo xylate, 30 mg).

Intermidiate 201b: (SVbenzyl (2-(2-f2.5.8.11 J4J7,20,23-octaoxapentacosan-25- ylcarbamoyl) piperidin- 1 -vDethylXmethvDcarbamate. To a mixture of (S)-l-(2- (((benzyloxy)carbonyl) (methyl)amino)ethyl)piperidine-2-carboxylic acid (0.145 mmol, 46.4 mg), 2,5,8,1 l,14,17,20,23-octaoxapentacosan-25-amine (0.145 mmol, 55.6 mg), DIEA (0.725 mmol, 94 mg) in DMF (0.3 mL) was added HATU (0.16 mmol, 61 mg). The mixture was stirred at at 60 °C for 1 h. The crude mixture was used in next step without purification.

Intermediate 201c: (SVl-g-(metfaylaniino¼thvn-N-(2.5.8.11.14.17.20.23- octaoxapentacosan-25-yl)piperidine-2-carboxamide. To a solution of the above crude mixture ((S)-benzyl (2-(2-(2,5,8, 11,14,17,20,23-octaoxapentacosan-25-ylcarbamoyi) piperidin-l-yl)ethyl)(methyl) carbamate) in methanol (2 mL) was added 10% Pd/C (30 mg). The mixture was stirred at rt under hydrogen atmosphere for 1 h. The mixture was filtered and the filtrate was concentrated under high vacuum which was used without further purification.

Example 201 : (SVN 2-i2-(2,5,8.11.14,17.20.23-octaoxapentacosan-25- ylcarbamovDpiperidin- 1 -yl ethyl)-N ³ -( ^' 4-(diethylamino)-2-(4-((3 - (trifluoromethyl benzyl carbamoyl)pyridin-2-yl phenyl -N ¹ -methylisophthalamide. To a mixture of (S)-l-(2-(methylamino) ethyl)-N-(2,5,8,l 1,14,17,20,23- octaoxapentacosan-25-yl)piperidine-2-carboxamide (0.145 mmol), 3-((4- (diethylamino)-2-(4-((3-(trifluoromethyl)benzyl)carbamoyl)py ridin-2-yl)phenyl) carbamoyl) benzoic acid (0.12 mmol, 80 mg) and DIEA (0.6 mmol, 78 mg) in DMF (0.4 mL) was added HATU (0.145 mmol, 55 nig). The mixture was stirred at at 60 °C for 1 h and purified by prep. HPLC to give a yellow solid (91 mg, 52%). MS (ES, m/z): 1124.38 [M+H] ⁺ .

EXAMPLE 202

2-(2-(3 -(2,5.8.11,14,17,20,23 ,26-nonaoxaheptacosyl)benzamido -5 - cvclobutoxyphenyl)-N-(3-(trifluoromethyl benzyl)isonicotinamide

Compound: 2-(2-(3-(2,5,8.11.14.17,20,23,26-nonaoxaheptacosvnbenzamidoV 5- cvclobutoxyphenyl -N-(3-(trifluoromethyl benzvDisonicotinamide. To a mixture of 2- (2-amino-5 -cyclobutoxyphenyl)-N-(3 -(trifluoromethyl)benzyl)-isonicotinamide 26b (1.5 mmol, 662 mg), 3-(2,5,8,l l,14,17,20,23,26-nonaoxaheptacosyl)benzoic acid (prepared as in Example 185 2,5,9,12,15,18,21,24-octaoxahexacosan-26-ol in place of methyl 3-(hydroxymethyl)benzoate) (1.65 mmol, 857 mg) and DIEA (9.0 mmol, 1.16 g) in DMF (5 mL) was added HATU (1.65 mmol, 627 mg). The mixture was stirred at 60 °C for 1 h, diluted with DCM, washed with water (4 x), dried, concentrated and purified by column to give a yellow syrup. To a solution of the syrup in DCM (4 mL) at 0 °C was added 4M HCl in dioxane (0.35 mL) drop wise. The mixture was concentrated and triturated with dry ether to give an orange solid (955 mg, 65%). MS (ES, m/z): 942.56 [M+H] ⁺ .

EXAMPLE 203

(S)-N ¹ -(2- 2-(2,5,8J 1,14.17.20.23-octaoxapentacosan-25-ylcarbamoyl)pyrrolidin- 1 - yl)ethyl -N ³ -(4-(diethylamino -2-(4-((3-(trifluoromethyl benzvncarbamovnpyridin-2- vDphenvD-N^methylisophthalamide

Scheme 84. 1. (S)-tert-butyl l-(2-(methylamino)ethyl)pyrrolidine-2-carboxylate, HATU, DIEA, DMF; 2. 4M HC1; 3. 2,5,8,1 l,14,17,20,23-octaoxapentacosan-25-amine, HATU, DIEA, DMF.

Intermediate 203a. (S)-tert-butyl l-(2-(3-(i4-idiethylamino -2-(4-(T3- ftrifluoromethvPbenzvQ carbamov pyridin-2-yl)phenyl carbamoylVN- methylbenzamido ethyl ^' )pyrrolidine-2-carboxylate. To a mixture of 2-(2-amino-5- (diethylamino)phenyl)-N-(3-(trifluoromethyl)ben2yl)isonicoti namide 188b (2.01 mmol, 1.33 g), 3(S)-tert-butyl l-(2-(methylamino)ethyl)pyrrolidine-2-carboxylate (2.41 mmol, 0.551 g) and DIEA (14.08 mmol, 1.82 g) in DMF (6 mL) was added HATU (2.41mmol, 0.918 g). The mixture was stirred at 60 °C for 1 h. The reaction mixture was diluted with ethyl acetate, washed with water (2x), brine (lx), dried and concentrated. The residue was purified by column to give a yellow solid (1.57 g, 98%).

Intermediate 203b. (S -i2-(3-((4-(diethylaminoV2-(4-(Y3-

(trifluoromethvDbenzvDcarbamoyl) pyridin-2-yl phenyl carbamoyl)-N- methylbenzamido)ethyl)pyrrolidine-2-carboxylic acid. To a mixture of (S)-tert-butyl 1- (2-(3-((4-(diethylamino)-2-(4-((3-(trifluoromethyl)benzyl) carbamoyl)pyridin-2- yl)phenyl)carbamoyl)-N-methylbenzamido)ethyl)pyrrolidine-2-c arboxylate in DCM (3 mL) was added 4M HC1 in dioxane (40 mL). The mixture was stirred at room temperature for 3 h and concentrated to give a yellow solid, which was used without further purification.

Example 203, rSVN ¹ -( ^' 2-r2-( ^, 2,5,8.11.14,17.20.23-octaoxapentacosan-25- ylcarbamovDpyrrolidin- 1 -vDethvD-N -(4-(diethylaminoV2-(4-((3- (trifluoromethyl benzyl)carbamovnpyridin-2-yl ^' )phenyl ^' )-N ¹ -methylisophthalamide. To a mixture of (S)-l-(2-(3-((4-(diethylamino)-2-(4-((3-

(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)phenyl)car bamoyl)-N- methylbenzamido)ethyl) pyrrolidine-2-carboxylic acid (1.32 mmol, 1.12 g), 2,5,8,11,14,17,20,23 -octaoxapentacosan-25 -amine (1.38 mmol, 530 mg) and DIEA (9.21 mmol, 1.19 g) in DMF (4 mL) was added HATU (1.45 mmol, 0.551 g). The mixture was stirred at 60 °C for 1 h and purified by prep. HPLC to give a syrup (1.18 g, 62%). MS (ES, m/z): 1110.42 [M+H] ⁺ .

EXAMPLE 205

(S)-2-(2-(3-(2,5,8J L14a7,20.23.26-nonaoxaheptacosyl)benzamido -5- cvclobutoxyphenyl -N-(l ,2,3 ,4-tetrahydronaphthalen- 1 -vDisonicotinamide

This compound was prepared according to the procedure described for the synthesis of (S)-tert-butyl 16-(3 -((4-cyclobutoxy-2-(4-(( 1 ,2,3 ,4-tetrahydronaphthalen- 1 - yl)carbamoyl)pyridin-2-yl)phenyl)carbamoyl)phenyl)-4,7, 10,13 -tetraoxahexadecan- 1 - oate Example 284, using intermediate 3-(2,5, 8, 11, 14,17,20,23,26- nonaoxaheptacosyl)benzoic acid in place of 3-(2,2-dimethyl-4-oxo-3,7,10,13,16- pentaoxanonadecan-19-yl)benzoic acid. MS (ES, m/z): 914.6 [M+H] ⁺ .

EXAMPLE 207

N 1 -f 2-(4-( (2-methoxyethyl carbamoyl piperazin- 1 -yr)ethylVN3 -(2-( 4-((3 - (trifluoromethyl benzyl)carbamoyl ^' )pyridin-2-yl -4-( ^' piperidin- 1 -vDphenylVN 1 - methylisophthalamide

Scheme 85a. 1. EDC.HC1,DMAP, Et ₃ N 2. TFA/DCM 3. 4-nitrophenyl

carbonochloridate, DCM 4. 2-methoxyethanamine.

Intermediate 207a: Into a 100-mL round-bottom flask, was placed a solution of 3-(4- (piperidin- 1 -yl)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2- yl)phenylcarbamoyl)benzoic acid (900 mg, 1.49 mmol, 1.00 equiv) in dichloromethane (30 mL), tert-butyl 4-(2-(methylamino)ethyl)piperazine-l-carboxylate (468 mg, 1.92 mmol, 1.30 equiv), EDC.HC1 (432 mg, 2.25 mmol, 1.50 equiv), 4- dimethylaminopyridine (279 mg, 2.28 mmol, 1.50 equiv). The resulting solution was stirred for 2 h at 25°C. The resulting solution was diluted with 10 mL of water. The resulting solution was extracted with 2x10 mL of dichloromethane and the organic layers combined. The resulting mixture was washed with 1x5 mL of water and 2x5 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This resulted in 800 mg (65%) of tert-butyl 4-(2-(N-methyl-3-(4-(piperidin-l- yl)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2- yl)phenylcarbamoyl)benzamido)ethyl)piperazine-l-carboxylate as a light yellow syrup.

Intermediate 207b: Into a 100-mL round-bottom flask, was placed a solution of tert- butyl 4-(2-(N-methyl-3-(4-(piperidin-l-yl)-2-(4-(3- (trifluoromethyl)benzylcarbamoyl)pyridin-2- yl)phenylcarbamoyl)benzamido)ethyl)piperazine-l-carboxylate (800 mg, 0.97 mmol, 1.00 equiv) in dichloromethane (30 mL), trifluoroacetic acid (5 g). The resulting solution was stirred for 3 h at 25°C. The resulting mixture was concentrated under vacuum. This resulted in 550 mg of crude product and 400 mg was added to the next step. The crude product (150 mg) was purified by Prep-HPLC with the following conditions (1#-Waters 2767-3): Column, SunFire Prep CI 8, 19* 150mm 5um; mobile phase, water with 0.05%TFA and CH3CN (20% CH3CN up to 38% in 6 min); Detector, Waters2545 UvDector 254&270nm. 95.2 mg product was obtained. This resulted in 95.2 mg of Nl-methyl-Nl-(2-(piperazin-l-yl)ethyl)-N3-(4-(piperidin-l-yl )- 2-(4-(3 -(trifluoromethyl)benzylcarbamoyl)pyridin-2-yl)phenyl)isopht halamide as a light yellow syrup.

LC-MS (ES, m/z): 728 [M+H] ⁺ ;

H-NMR (300MHz, CD ₃ OD, ppm): 8.97(d, J=5.4Hz, 1H), 8.82(d, J=9.0Hz, 1H), 8.48(s, 1H), 8.25(d, J=2.7Hz, 1H), 8.12~8.09(m, 2H), 7.90~7.88(m, lH), 7.77~7.67(m, 5H), 7.62~7.53(m, 2H), 4.72(s, 2H), 3.83(s, 2H), 3.72~3.70(m, 4H), 3.68(s, 1H), 3.13~2.96(m, 10H), 2.64~2.52(m, 2H), 2.07(d, J=4.8Hz, 4H), 1.85(d, J=5.4Hz, 2H). Intermediate 207c: N 1 -(2-(4-((2-methoxyethyl)carbamoyl)piperazin- 1 -yl)ethyl)-N3 -(2- (4-((3 -(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidi n- 1 -yl)phenyl)-N 1 - methylisophthalamide. Into a 50-mL round-bottom flask, was placed a solution of 207b (250 mg, 0.21 mmol, 1.05 equiv) in sodium bicarbonate aq. (10 mL). The mixture was stirred for 20 minutes at room temperature. The resulting solution was extracted with 3x10 mL of ethyl acetate and the organic layers combined. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This resulted in 150 mg of N 1 -(2-(4-((3 -(trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidi n- 1 - yl)phenyl)-N3-methyl-N3-(2-(piperazin-l-yl)ethyl)isophthalam ide free base used without purification in the next reaction.

Into a 50-mL round-bottom flask, was placed a solution of Nl-(2-(4-((3- (trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin - 1 -yl)phenyl)-N3 -methyl- N3-(2-(piperazin-l-yl)ethyl)isophthalamide (100 mg, 0.14 mmol, 1.00 equiv) in dichloromethane (3 mL), triethylamine (42 mg, 0.42 mmol, 3.00 equiv). This was followed by the addition of 4-nitrophenyl carbonochloridate (31 mg, 0.15 mmol, 1.10 equiv) dropwise with stirring at 0°C. The resulting solution was stirred for 40 min at 25°C. The resulting solution was diluted with 3 mL of sodium bicarbonate. The resulting solution was extracted with 2x5 mL of dichloromethane and the organic layers combined. The resulting mixture was washed with 1x5 mL of water and 2x5 mL of Brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This resulted in 110 mg (90%) of 4-nitrophenyl 4-(2-(N-methyl-3-(4- (piperidin- 1 -yl)-2-(4-(3 -(trifluoromethyl)benzylcarbamoyl)pyridin-2- yl)phenylcarbamoyl)benzamido)ethyl)piperazine-l-carboxylate as a yellow solid.

Example 207: Into a 50-mL round-bottom flask, was placed 4-nitrophenyl 4-(2-(N- methyl-3 -(4-(piperidin- 1 -yl)-2-(4-(3 -(trifluoromethyl)benzylcarbamoyl)pyridin-2- yl)phenylcarbamoyl)benzamido)ethyl)piperazine-l-carboxylate 207c (100 mg, 0.11 mmol, 1.00 equiv), 2-methoxyethanamine (1 ml). The resulting solution was stirred for 4 h at 25oC. The resulting solution was diluted with 5 ml of water. The resulting solution was extracted with 2x5 ml of dichloromethane and the organic layers combined. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product (100 mg) was purified by Prep-HPLC with the following conditions (1#- Waters 2767-3): Column, SunFire Prep C18, 19*150mm 5um; mobile phase, water with 0.05%TFA and CH3CN (20% CH3CN up to 40% in 6 min); Detector, Waters2545 UvDector 254&270nm. 72.8mg product was obtained. This resulted in 72.8 mg (78%) of Nl-(2-(4-((2-methoxyethyl)carbamoyl)piperazin-l- yl)ethyl)-N3-(2-(4-((3-(triiluoromethyl)benzyl)carbamoyl)pyr idin-2-yl)-4-( iperidin-l- yl)phenyl)-Nl-methylisophthalamide as a light yellow solid. LC-MS (ES, m/z): 829 [M+H] ⁺

H-NMR (300MHz, CD30D, ppm): 8.96(d, .7=5.1 Hz, lH), 8.74(d, J=9.0Hz, 1H), 8.45(s, 1H), 8.17~8.15(m, 3H), 7.88~7.86(s, 1H), 7.80(d, J=7.5Hz, 1H), 7.72~7.64(m, 4H), 7.62~7.55(m, 2H), 4.72(s, 2H), 4.00(s, 2H), 3.90~3.54(m, 16H), 3.48~3.33(m, 5H), 3.11(s, 3H), 2.03(d, J=4.8Hz, 1H), 1.82(d, J=5.1Hz, 1H).

EXAMPLE 208

N-(2-methoxyethyl -4-(2-(methyl(3-(4-(piperidin-l-yl -2-(4-(3- (trifluoromethyl benzylcarbamoyl)pyridin-2- yl phenylcarbamoyl)benzyl)amino)ethvDpiperazine- 1 -carboxamide

This compound was prepared according to the procedure described for the synthesis of N-(2-methoxyethyl)-4-(2-(methyl(3-(4-(piperidin- 1 -yl)-2-(4-(3- (trifluoromethyl)benzylcarbamoyl)pyridin-2- yl)phenylcarbamoyl)benzyl)amino)ethyl)piperazine- 1 -carboxamide Example 207 substituting tert-butyl 4-(2-(methyl(3 -(4-(piperidin- 1 -yl)-2-(4-(3 -

(trifluoromethyl)benzylcarbamoyl)pyridin-2- yl)phenylcarbanioyl)benzyl)amino)ethyl)piperazine-l-carboxyl ate Example 38 in place of tert-butyl 4-(2-(N-methyl-3-(4-(piperidin-l-yl)-2-(4-(3-

(trifluoromethyl)benzylcarbamoyl)pyridin-2- yl)phenylcarbamoyl)benzamido)ethyl)piperazine- 1 -carboxylate 207a LC-MS (ES, m/z): 815 [M+H] ⁺

H-NMR (300MHz, DMSO, ppm): 12.30(s, IH), 9.55-9.59 (t, J=6.6Hz, IH), 8.92- 8.94(d, J=6Hz, IH), 8.28-8.34(sd, J=9Hz, 2H), 8.11-8.14(m, IH), 8.04(s, IH), 7.94- 7.96(d, J=6Hz, IH), 7.85-7.86(d, J=3Hz, IH), 7.56-7.71(m, 7H), 7.3 l(s, IH), 6.92- 6.95(m, IH), 6.73(s, IH), 4.63-4.64(d, J=3Hz, 2H), 4.28(s, 2H), 3.46(s, 3H), 3.31- 3.35(m, 7H), 3.17-3.23(m, 9H), 2.94(s, 4H), 2.63(s, 3H), 1.60-1.74(m, 6H).

EXAMPLE 209

N-(2-methoxyethylVN-methyl-4-f 2-(methyli3 -( 4-i iperidin- 1 -vD-2-(4-( 3 -

(trifluoromethyl benzylcarbamoyl pyridin-2- yl phenylcarbamoyl benzyl amino ethyl)piperazine-l-carboxamide

This compound was prepared according to the procedure described for the synthesis of N-(2-methoxyethyl)-4-(2-(methyl(3 -(4-(piperidin- 1 -yl)-2-(4-(3 - (trifluoromethyl)benzylcarbamoyl)pyridin-2- yl)phenylcarbamoyl)benzyl)amino)ethyl)piperazine- 1 -carboxamide Example 208 substituting 2-methoxy-N-methylethanamine in place of 2-methoxyethanamine.

LC-MS (ES, m/z): 829 [M+H] ⁺

H-NMR (300MHz, OMSO, ppm): 12.31(s, IH), 9.56(t, J=3.6Hz, IH), 8.93(d, J=6Hz, IH), 8.3 l(d, J=6Hz, 2H), 8.04(s, IH), 7.94(d, J=9Hz, IH), 7.84-7.86(m, IH), 7.56- 7.7 l(m, 7H), 7.30(d, J=9Hz, 1H), 4.63(d, J=3Hz, 2H), 4.26(s, 2H), 3.45(t, J=6.6Hz, 2H), 3.23-3.32(m, 16H), 3.17(s, 1H), 3.00(s, 4H), 2.80(s, 3H), 2.63(s, 3H), 1.60- 1.74(m, 6H).

EXAMPLE 210

N-(2-methoxyethyl)-N-methyl-4-(2-rmethvir( ^' 6-( ^' 4-(piperidin-l-vn-2-(4-(3- (trifluoromethvDbenzylcarbamoyl)pyridin-2-vnphenylcarbarnovD pyridin-2- yl)methyl¼mino)ethyl)piperazine- 1 -carboxamide

This compound was prepared according to the procedure described for the synthesis of N-(2-methoxyethyl)-N-methyl-4-(2-(methyl((6-(4-(piperidin- 1 -yl)-2-(4-(3 - (trifluoromethyl)benzylcarbamoyl)pyridin-2-yl)phenylcarbamoy l)pyridin-2- yl)methyl)amino)ethyl)piperazine-l -carboxamide Example 208 substituting 2-methoxy- N-methylethanamine in place of 2-methoxyethanamine. LC-MS (ES, m/z): 830 [M+H] ⁺ H-NMR (300MHz, DMSO, ppm): 12.81 (s, 1H), 9.57-9.55 (m, 1H), 9.05-9.03 (m, 1H), 8.50-8.47 (m, 1H), 8.27 (m, 1H), 8.10-8.06 (m, 2H), 7.89-7.87 (m, 1H), 7.79-7.52 (m, 6H), 7.27 (m, 1H), 4.65-4.63 (d, J=5.7Hz, 3H), 4.09 (m, 3H), 3.43-3.01 (m, 22H), 2.74 (m, 3H), 1.72-1.59 (m, 6H).

EXAMPLE 211

Nl -(2-(4-((2-methoxyethvn(methyDcarbamoyl)piperazin- 1 -vDethvD-Nl -methyl-N3-(4-

(piperidin- 1 -yD-2-(4-(3 -(trifluoromethyl ^' )benzylcarbamoyl ^' )pyridin-2- vDphenvDisophthalamide

This compound was prepared according to the procedure described for the synthesis of N 1 -(2-(4-((2-methoxyethyl)carbamoyl)piperazin- 1 -yl)ethyl)-N3 -(2-(4-((3 - (trifluoromethyl)benzyl)carbamoyl)pyridin-2-yl)-4-(piperidin - 1 -yl)phenyl)-N 1 - methylisophthalamide Example 207 substituting methoxy-N-methylethanamine in place of 2-methoxyethanamine. LC-MS (ES, m/z): 843 [M+H] ⁺

H-NMR (300MHz, iOO,ppm) 8.99(d, J=5.1Hz, IH), 8.77(d, J=9.0Hz, IH), 8.46(s, IH), 8.19(m, 3H), 7.90(m, IH), 7.81(d, J=7.8Hz, IH), 7.74~7.67(m, 4H), 7.62~7.53(m, 2H), 4.72(s, 2H), 4.00(s, 2H), 3.90~3.65(m, 9H), 3.57(d, J=5.1Hz, IH), 3.47(d, J=4.8Hz, IH), 3.34(s, 3H), 3.12(s, 3H), 2.97(s, 3H), 2.04(d, J=4.8Hz, 4H), 1.83(d, J=4.2Hz, 2H).

EXAMPLE 212

tert-butyl 3-Γ2-(2-(2-Γ(4- (2-Π -(3-{ K-idiethylamino^^^-i \(l SV1 ,2,3 ,4- tetrahydronaphthalen- 1 - yl] carbamoyl 1 pyridin-2- vDphenyl] carbamoyl I phenylVN- methylformamidol ethyl 1 piperazin- 1 - yDcarbonyKmethyDaminolethoxylethoxy^ethoxylpropanoate

Scheme 85b. 1. EDC.HC1,DMAP, Et ₃ N 2. TFA/DCM 3.i. triphosgene ii.tert-butyl 5,8,1 l-trioxa-2-azatetradecan-14-oate 135c.

Intermediate 212a: Into a 100-mL round-bottom flask, was placed a solution of 3-((2- (4-(((S)- 1 ,2,3 ,4-tetrahydronaphthalen- 1 -yl)carbamoyl)pyridin-2-yl)-4- (diethylamino)phenyl)carbamoyl)benzoic acid (880 mg, 1.56 mmol, 1.00 equiv) in dichloromethane (10 mL), tert-butyl 4-(2-(methylamino)ethyl)piperazine-l-carboxylate (570 mg, 2.35 mmol, 1.50 equiv), EDC.HCl (0.60 g, 3.14 mmol, 2.00 equiv), 4- dimethylaminopyridine (0.19 g, 1.56 mmol, 1.00 equiv). The resulting solution was stirred overnight at room temperature. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:5-1:1). This resulted in 0.8 g (65%) of tert-butyl 4-(2-(3-(carbamoyl)-N- methylbenzamido)ethyl)piperazine-l-carboxylate as a yellow solid.

Intermediate 212b: Into a 50-mL round-bottom flask, was placed a solution of tert-butyl 4-(2-(3-(carbamoyl)-N-methylbenzamido)ethyl)piperazine-l-car boxylate (800 mg, 1.02 mmol, 1.00 equiv) in dichloromethane (5 mL), trifluoroacetic acid (6 mL). The resulting solution was stirred overnight at room temperature. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 10 mL of water. The pH value of the solution was adjusted to 8-9 with sodium bicarbonate. The resulting solution was extracted with 3x30 mL of dichloromethane and the organic layers combined. The resulting mixture was washed with 3x30 mL of Brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This resulted in 0.65 g (93%) of Nl-(2-(4-(((S)-l,2,3,4-tetrahydronaphthalen-l- yl)carbamoyl)pyridin-2-yl)-4-(diethylamino)phenyl)-N3 -methyl-N3 -(2-(piperazin- 1 - yl)ethyl)isophthalamide as a yellow solid.

Example 212: Into a 50-mL round-bottom flask, was placed a solution of (S)-4- nitrophenyl 4-(2-(3 -(4-(diethylamino)-2-(4-( 1 ,2,3 ,4-tetrahydronaphthalen- 1 - ylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)-N-methylbenzamido) ethyl)piperazine-l- carboxylate (400 mg, 0.47 mmol, 1.00 equiv) in dichloromethane (3 mL), triethylamine (2 mL). This was followed by the addition of a solution of bis(trichloromethyl) carbonate (80 mg, 0.27 mmol, 0.50 equiv) in dichloromethane (4 mL) dropwise with stirring at 0°C. The resulting solution was stirred for 0.5 h at room temperature. To this was added triethylamine (2 mL), a solution of tert-butyl 3-(2-(2-(2- (methylamino)ethoxy)ethoxy)ethoxy)propanoate (224 mg, 0.77 mmol, 1.50 equiv) in dichloromethane (3 mL). The resulting solution was stirred for 2 h at room temperature. The reaction progress was monitored by LCMS. The resulting mixture was concentrated under vacuum. The crude product (0.1 g) was purified by Prep-HPLC with the following conditions (1#- Waters 2767-3): Column, SunFire Prep CI 8, 19* 150mm 5um; mobile phase, water with 0.05%TFA and CH ₃ CN (5% CH ₃ CN up to 30% in 1 min, up to 40% in 5 min); Detector, Waters2545 UvDector 254&270nm. 21.8 mg product was obtained. This resulted in 21.8 mg (4%) of Example 212 as a yellow solid. LC-MS (ES, m/z): 1006 [M+H] ⁺

H-NMR (300MHz, DMSO, ppm): 9.14(m, 1H), 8.87(m, 1H), 8.24(m, 2H), 7.96(m, 2H), 7.83(m, 1H), 7.63(m, 2H), 7.13(m, 6H), 5.76(m, 1H), 3.45(m, 18H), 2.98(m, 15H), 2.46(m, 3H), 1.87(m, 5H), 1.38(m, 11H), 1.12(m, 7H).

EXAMPLE 213

(SVNl^^^^^a LH.n^O^-octaoxapentacosane-l^-diazepan-l-vDethylVNl- methyl-N3 -(4-( iperidin- 1 -vD-2-(4-( 1 ,2,3 ,4-tetrahydronaphthalen- 1 - ylcarbamovDpyridin-2-vDphenyl sophthalamide

Scheme 86. NaH, tert-butylbromoacetate 2. HC1/DCM 3. EDC, DMAP, DCM. Intermediate 213a: Into a 50-mL round-bottom flask, was placed a solution of 2-(2-(2- (2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy )ethanol (500 mg, 1.47 mmol, 1.00 equiv) in tetrahydrofuran (15 mL). This was followed by the addition of sodium hydride (135 mg, 5.62 mmol, 3.83 equiv) in several batches at 0-5°C. The resulting solution was stirred for. 15 min at room temperature. To this was added tert- butyl 2-bromoacetate (345 mg, 1.78 mmol, 1.21 equiv). The resulting solution was allowed to react, with stirring, for an additional 4 h at room temperature. The reaction was then quenched by the addition of 50 mL of water/ice. The resulting solution was extracted with 3x20 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 3x20 mL of sodium chloride. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This resulted in 500 mg (75%) of tert-butyl-2-(2-(2-(2-(2-(2-(2-(2- methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)acet ate as colourless oil.

Intermediate 213b: Into a 100-mL round-bottom flask, was placed a solution of tert- butyl 2-(2-(2-(2-(2-(2-(2-(2- methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)acet ate (500 mg, 1.10 mmol, 1.00 equiv) in dichloromethane (20 mL). The gas of hydrochloric acid was introduced in. The resulting solution was stirred for 3 h at room temperature. The resulting mixture was concentrated under vacuum. This resulted in 400 mg (91%) of 2- (2-(2-(2-(2-(2-(2-(2- methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)acet ic acid as yellow oil.

Example 213 (SVNl-(2-(4-2,5,8,l 1,14, 17,20,23 -octaoxapentacosane- 1,4-diazepan-l - vnethyl -Nl-methyl-N3-(4-(piperidin-l-yl)-2-(4-(L2,3,4-tetrahvdronap hthalen-l- ylcarbamoy pyridin-2-yl)phenyl ^' )isophthalamide. This compound was prepared according to the procedure described for the synthesis of Example 197 using 2-(2-(2-(2- (2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy )ethoxy)acetic acid 213b in place of m-dPEG ₈ -NHS ester and 187a in place of 197a LC-MS (ES, m/z): 1094 [M+H] ⁺ H-NMR (300MHz, COCk, ppm): 8.93(d, J=5.1Hz, IH), 8.68-8.65(m, IH), 8.41(s, IH), 8.16-8.07(m, 3H), 7.87-7.85(m, 1H), 7.78-7.65(m, 3H), 7.25-7.14(m, 4H), 5.38(m, 1H), 4.31(s, 2H), 3.99-3.86(m, 3H), 3.66-3.51(m, 39H), 3.37-3.31(m, 3H), 3.13-3.09(m, 3H), 2.91-2.84(m, 2H), 2.32-1.80(m, 12H).

EXAMPLE 214

(SV2,5,8,11 ,14, 17.20-heptaoxadocosan-22-yl 4-(2-( -methyl-3-(4-fpiperidin- 1 -ylV2- (4-( 1 ,2,3 ,4-tetrahvdronaphthalen- 1 - ylcarbamoyl pyridin-2- yl phenylcarbamoyl benzamido)ethyiy 1 ,4-diazepane- 1 -carboxylate

Scheme 87. 1. 4-nitrophenyl carbonochloridate, TEA, DCM 2. DMAP, CH ₃ CN.

Intermediate 214a: Into a 100-mL round-bottom flask, was placed a solution of 4- nitrophenyl carbonochloridate (200 mg, 1.00 mmol, 1.00 equiv) in dichloromethane (10 mL), 2-(2-(2-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxy)ethox y)ethoxy)ethanol (338 mg, 0.99 mmol, 1.00 equiv), triethylamine (301 mg, 2.98 mmol, 2.99 equiv). The resulting solution was stirred for 3 h at room temperature. The resulting solution was diluted with 10 mL of dichloromethane. The resulting mixture was washed with 2x10 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This resulted in 240 mg (48%) of 2-(2-(2-(2-(2-(2-(2- methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl 4-nitrophenyl carbonate as yellow oil.

Example 214: Into a 100-mL round-bottom flask, was placed a solution of (S)-Nl-(2- (l,4-diazepan-l-yl)ethyl)-Nl-methyl-N3-(4-(piperidin-l-yl)-2 -(4-(l,2,3,4- tetrahydronaphthalen-l-ylcarbamoyl)pyridin-2-yl)phenyl)isoph thalamide (150 mg, 0.21 mmol, 1.00 equiv) in acetonitrile (1 mL), 2-(2-(2-(2-(2-(2-(2- methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl 4-nitrophenyl carbonate (106 mg, 0.21 mmol, 1.00 equiv), 4-dimethylaminopyridine (39 mg, 0.32 mmol, 1.51 equiv). The resulting solution was stirred overnight at 80°C in an oil bath. The resulting mixture was washed with 2x20 mL of sat. NH ₄ C1. The mixture was dried over sodium sulfate and concentrated under vacuum. The crude product (100 mg) was purified by Prep-HPLC with the following conditions (1#- Waters 2767-3): Column, SunFire Prep CI 8, 19* 150mm 5um; mobile phase, water with 0.05%TFA and CH ₃ CN (25% CH ₃ CN up to 38% in 6 min); Detector, Waters2545 UvDector 254&270nm. 35.2 mg product was obtained. This resulted in 35.2 mg (12%) of (S)-2,5,8,l 1,14,17,20- heptaoxadocosan-22-yl 4-(2-(N-methyl-3-(4-(piperidin-l-yl)-2-(4-(l,2,3,4- tetrahydronaphthalen-l-ylcarbamoyl)pyridin-2-yl)phenylcarbam oyl)benzamido)ethyl)- 1,4-diazepane-l -carboxylase as yellow oil.

LC-MS (ES, m/z): 1081 [M+H] ⁺

H-NMR (400MHz, CD ₃ OD, ppm): 8.93~8.92(d, J=4.8Hz, 1H), 8.61~8.59(d, J=8.8Hz, 1H), 8.38(s, 1H), 8.15~8.10(t, 2H), 7.97(s, 1H), 7.86~7.84(d, J=5.2Hz, 1H), 7.79~7.70(m, 2H), 7.59~7.56(d, J=9.2Hz, 1H), 7.28~7.26(d, J=7.2Hz, 1H), 7.18~7.14(m, 3H), 5.39(s, 1H), 4.27(s, 2H), 4.00(s, 3H), 3.80~3.72(m, 5H), 3.63 (s, 24H), 3.57~3.46(m, 10H), 3.33(s, 2H), 3.13(s, 3H), 2.91~2.86(m, 2H), 2.24~2.16(m, 3H), 2.04-1.90(m, 7H),1.78(s, 2H).

EXAMPLE 215

rS)-Nl-methyl-Nl-r2-r3-oxopiperazin-l-vnethylVN3-(4-(piperid in-l-ylV2-(4-fl.2.3.4- tetrahydronaphthalen-l-ylcarbamovnpyridin-2-vnphenyl isophthalamide

This compound was prepared according to the procedure described for the synthesis of Example 187 using piperazin-2-one in place of L-proline-tert-butyl ester. Into a 50-mL round-bottom flask, was placed a solution of (S)-Nl-methyl-Nl-(2-oxoethyl)-N3-(4- (piperidin- 1 -yl)-2-(4-( 1 ,2,3 ,4-tetrahydronaphthalen- 1 -ylcarbamoyl)pyridin-2- yl)phenyl)isophthalamide (100 mg, 0.16 mmol, 1.00 equiv) in ethanol (5 mL), piperazin-2-one (20 mg, 0.20 mmol, 1.20 equiv). This was followed by the addition of acetic acid (20 mg, 0.33 mmol, 2.20 equiv). The mixture was allowed to react with stirring for 1 h at room temperature. To this was added NaBH ₃ CN (22 mg, 0.35 mmol, 2.20 equiv). The resulting solution was stirred overnight at room temperature. The resulting mixture was concentrated under vacuum. The pH value of the solution was adjusted to 7 with sodium bicarbonate (2 mol/L). The resulting solution was extracted with 3x20 mL of dichloromethane and the organic layers combined and dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product (120mg ) was purified by Prep-HPLC with the following conditions (1#-Waters 2767-3): Column, SunFire Prep CI 8, 19* 150mm 5um; mobile phase, water with 0.05%TFA and CH ₃ CN (20% CH ₃ CN up to 40% in 6 min); Detector, Waters2545 UvDector 254&270nm. 91.4mg product was obtained. This resulted in 91.4 mg (54%) of (S)-Nl- methyl-N 1 -(2-(3 -oxopiperazin- 1 -yl)ethyl)-N3 -(4-(piperidin- 1 -yl)-2-(4-( 1 ,2,3 ,4- tetrahydronaphthalen- l-ylcarbamoyl)pyridin-2-yl)phenyl)isophthalamide as a yellow solid.

LCMS (ES, m/z): 714 [M+H] ⁺

H-NMR (300MHz, CO ₃ OO, ppm): 8.94(m, IH), 8.70(m, IH), 8.40(s, 2H), 8.12(m, 3H), 7.85(m, 1H), 7.72(m, 3H), 7.17(m, 3H), 5.39(s, 1H), 3.94(m, 3H), 3.56(m, 7H), 3.09(m, 3H), 2.86(m, 3H), 1.95(m, 8H).

EXAMPLE 216

iSVNl-methyl-Nl-( ^" 2-i4-me^

(4-( 1 ,2,3 ,4-tetrahydronaphthalen- 1 -ylcarbamoyl pyridin-2- yl phenyl isophthalamide

This compound was prepared according to the procedure described for the synthesis of Example 187 using methylpiperazin-2-one in place of L-proline-tert-butyl ester. Into a 50-mL round-bottom flask, was placed a solution of (S)-Nl-methyl-Nl-(2-oxoethyl)- N3 -(4-(piperidin- 1 -yl)-2-(4-( 1 ,2,3 ,4-tetrahydronaphthalen- 1 -ylcarbamoyl)pyridin-2- yl)phenyl)isophthalamide (100 mg, 0.16 mmol, 1.00 equiv) in ethanol (2 mL). This was followed by the addition of a solution of l-methylpiperazin-2-one (18 mg, 0.16 mmol, 1.00 equiv) in ethanol (2 mL), two drop of acetic acid. To this was added NaBH ₃ CN (20 mg, 0.32 mmol, 2.00 equiv). The resulting solution was stirred for 2 h at room temperature. The resulting solution was diluted with 50 mL of ethyl acetate. The resulting mixture was washed with 2x20 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product (lOOmg ) was purified by Prep-HPLC with the following conditions (1#-Waters 2767-3): Column, SunFire Prep CI 8, 19* 150mm 5um; mobile phase, water with 0.05%TFA and CH ₃ CN (22% CH ₃ CN up to 38% in 6 min); Detector, Waters2545 UvDector 254&270nm. 70mg product was obtained. This resulted in 70 mg (61%) of (S)-Nl- methyl-N 1 -(2-(4-methyl-3 -oxopiperazin- 1 -yl)ethyl)-N3-(4-(piperidin- 1 -yl)-2-(4- (1,2,3 ,4-tetrahydronaphthalen- 1 -ylcarbamoyl)pyridin-2-yl)phenyl)isophthalaniide as a yellow solid. LC-MS (ES, m/z): 728 [M+H] ⁺

H-NMR (300MHz, DMSO, ppm): 12.25(s, 1H), 9.18(d, J=8.4Hz, 1H), 8.80(d, J=5.1Hz, 1H), 8.29 (d, J=13.8Hz 2H), 7.99(t, J=6.9Hz, 2H), 7.86(d, J=4.8Hz, 1H), 7.57~7.67(m, 3H), 7.10~7.28(m, 5H), 5.25(d, J=5.4Hz, 1H), 3.92~3.85(m, 4H), 3.30~3.54(m, 10H), 2.78~2.95(m, 9H), 1.99(d, J=3.6Hz, 2H), 1.72~1.80(m, 6H), 1.60(s, 2H).

EXAMPLE 217

( S VN 1 -(2-(bisr2-methoxyethyl amino ethvn-N 1 -methyl-N3 -(4-fpiperidin- 1 -νΓ)-2-(4-

(1 ,2,3,4-tetrahydronaphthalen- 1 -ylcarbamoyl pyridin-2-yl)phenyl isophthalamide

This compound was prepared according to the procedure described for the synthesis of Example 187 using bis(2-methoxyethyl)amine in place of L-proline-tert-butyl ester. Into a 25-mL round-bottom flask, was placed a solution of (S)-Nl-methyl-Nl-(2- oxoethyl)-N3-(4-(piperidin- 1 -yl)-2-(4-(l ,2,3 ,4-tetrahydronaphthalen- 1 - ylcarbamoyl)pyridin-2-yl)phenyl)isophthalamide (100 mg, 0.16 mmol, 1.00 equiv) in ethanol (1 mL), bis(2-methoxyethyl)amine (25 mg, 0.19 mmol, 1.20 equiv), NaBH ₃ CN (20 mg, 0.32 mmol, 2.00 equiv), acetic acid (1.0 mg, 0.02 mmol, 0.10 equiv). The resulting solution was stirred for 2 h at 25°C. The reaction was then quenched by the addition of 10 mL of water. The resulting solution was extracted with 2x10 mL of ethyl acetate and the organic layers combined and dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product (lOOmg ) was purified by Prep-HPLC with the following conditions (1#-Waters 2767-3): Column, SunFire Prep CI 8, 19* 150mm 5um; mobile phase, water with 0.05%TFA and CH ₃ CN (25% CH ₃ CN up to 38% in 6 min); Detector, Waters2545 UvDector 254&270nm. 47.9mg product was obtained. This resulted in 47.9 mg (40%) of (S)-Nl-(2-(bis(2- methoxyethyl)amino)ethyl)-N 1 -methyl-N3 -(4-(piperidin- 1 -yl)-2-(4-( 1 ,2,3 ,4- tetrahydronaphthalen-l-ylcarbamoyl)pyridin-2-yl)phenyl)isoph thalamide as a yellow solid.

LC-MS (ES, w/z):747[M+H] ⁺

H-NMR (300MHz, DMSO, ppm): 12.24(s, IH), 9.50(s, IH), 9.20(d, J=9Hz, IH), 8.89(d, J=3Hz, IH), 8.24-8.32(m, 2H), 7.99(d, J=6Hz, 2H), 7.86(d, J=6Hz, IH), 7.60- 7.69(m, 3H), 7.30(s, IH), 7.10-7.24(m, 4H), 5.25(t, J=6.9Hz, IH), 3.80(d, J=33Hz, 5H), 3.63(s, 6H), 3.33(s, 12H), 2.97(s, 4H), 2.74(s, 2H), 1.96-2.00(m, 2H), 1.73- 1.88(m, 6H), 1.60(d, J=6Hz, 2H).

EXAMPLE 218

(S)-N 1 -(2-( -( dimethylcarbamovDpiperidin- 1 -vDethvD-N 1 -methyl-N3-(4-(piperidin- 1 - yl)-2-(4-( 1 ,2,3 ,4-tetrahydronaphthalen- 1 - ylcarbamoyl)pyridin-2- vDphenvDisophthalamide

This compound was prepared according to the procedure described for the synthesis of Example 187 using N,N-dimethylpiperidine-4-carboxamide in place of L-proline-tert- butyl ester. Into a 100-mL round-bottom flask, was placed a solution of (S)-Nl-methyl- N 1 -(2-oxoethyl)-N3 -(4-(piperidin- 1 -yl)-2-(4-( 1 ,2,3 ,4-tetrahydronaphthalen- 1 - ylcarbamoyl)pyridin-2-yl)phenyl)isophthalamide (100 mg, 0.16 mmol, 1.00 equiv) in ethanol (10 mL), N,N-dimethylpiperidine-4-carboxamide (50 mg, 0.32 mmol, 2.02 equiv), acetic acid (22 mg, 0.37 mmol, 2.31 equiv). The resulting solution was stirred for 0.5 h at room temperature. To the above was added NaBH ₃ CN (22 mg, 0.35 mmol, 2.20 equiv). The resulting solution was allowed to react, with stirring, for an additional 4 h at room temperature. The resulting mixture was concentrated under vacuum. The pH value of the solution was adjusted to 8 with sodium bicarbonate.aq. The resulting solution was extracted with 3x20 mL of ethyl acetate and the organic layers combined. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product (100 mg) was purified by Prep-HPLC with the following conditions (1#-Waters 2767-3): Column, SunFire Prep C18, 19* 150mm 5um; mobile phase, water with 0.05%TFA and CH ₃ CN (22% CH ₃ CN up to 38% in 6 min); Detector, Waters2545 UvDector 254&270nm. 51.5 mg product was obtained. This resulted in 51.5 mg (42%) of (S)-N 1 -(2-(4-(dimethylcarbamoyl)piperidin- 1 -yl)ethyl)-N 1 -methyl-N3 -(4-(piperidin- 1 -yl)-2-(4-( 1 ,2,3 ,4-tetrahydronaphthalen- 1 -ylcarbamoyi)pyridin-2- yl)phenyl)isophthalamide as a light yellow solid.

LC-MS (ES, m/z): 770[M+H] ⁺

H-NMR (400MHz, DMSO, ppm): 12.26(s, 1H), 9.18~9.16(m, 2H), 8.90~8.88(d, J=3.9Hz, 1H), 8.32~8.25(m, 2H), 8.02~7.98(t, 2H), 7.88~7.87(d, J=3.9Hz, 1H), 7.71~7.64(m, 2H), 7.60(s, 1H), 7.28(s, 1H), 7.20~7.10(m, 4H), 5.26(s, 1H), 3.85(s, 11H), 3.38~3.30(m, 8H), 3.04(s, 5H), 2.96(s, 5H), 2.83~2.78(m, 5H), 2.00-1.91(m, 4H), 1.86~1.72(m, 9H), 1.60~1.59(d, J=3.3Hz, 2H).

EXAMPLE 219

(SVtert-butyl 4-(2-(Tvf-methyl-3-(4-(piperidin-l-yl -2-(4-( 2,3.4-tetrahvdronaphthalen- 1 -ylcarbamoyl pyridin-2-yl phenylcarbamoyl ^' )benzamido ethyl - 1 ,4-diazepane- 1 - carboxylate

This compound was prepared according to the procedure described for the synthesis of Example 187 using tert-butyl 1,4-diazepane-l-carboxylate in place of L-proline-tert- butyl ester. Into a 50-mL round-bottom flask, was placed a solution of (S)-Nl-methyl- N 1 -(2-oxoethyl)-N3-(4-(piperidin- 1 -yl)-2-(4-( 1 ,2,3 ,4-tetrahydronaphthalen- 1 - ylcarbamoyl)pyridin-2-yl)phenyl)isophthalamide (100 mg, 0.16 mmol, 1.00 equiv) in ethanol (5 mL), tert-butyl 1,4-diazepane-l-carboxylate (50 mg, 0.25 mmol, 1.57 equiv), acetic acid (20 mg, 0.33 mmol, 2.10 equiv). The resulting solution was stirred for 0.5 h at room temperature. To the above was added NaBH ₃ CN (20 mg, 0.32 mmol, 2.00 equiv). The resulting solution was allowed to react, with stirring, for an additional 3 h at room temperature. The resulting mixture was concentrated under vacuum. The pH value of the solution was adjusted to 8-9 with sodium bicarbonate. The resulting solution was extracted with 3x20 mL of ethyl acetate and the organic layers combined. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product (lOOmg ) was purified by Prep-HPLC with the following conditions (1#- Waters 2767-3): Column, SunFire Prep C18, 19*150mm 5um; mobile phase, water with 0.05%TFA and CH ₃ CN (25% CH ₃ CN up to 43% in 6 min); Detector, Waters2545 UvDector 254&270nm. 60.2 mg product was obtained. This resulted in 60.2 mg (47%) of (S)-tert-butyl 4-(2-(N-methyl-3-(4-(piperidin-l-yl)-2-(4-(l,2,3,4- tetrahydronaphthalen-l-ylcarbamoyl)pyridin-2-yl)phenylcarbam oyl)benzamido)ethyl)- 1,4-diazepane-l-carboxylate as a light yellow solid.

LC-MS (ES, m/z):814 [M+H] ⁺

H-NMR (300MHz, OMSO, ppm): 12.23 (s, IH), 9.38 (s, IH) ,9.18 (d, J=8.4Hz, IH), 8.88 (d, J=5.1Hz, IH), 8.31 (s, IH) ,8.23 (d, J=7.8Hz, IH), 7.98 (d, J=6.3Hz, 2H), 7.85(d, J=5.1Hz, 1H), 7.68-7.56 (m, 3H), 7.28-7.12 (m, 5H), 5.25 (d, J=6.0Hz, 1H), 3.82-3.46 (m, 12H), 3.30 (s, 3H), 2.96-2.51 (m, 2H), 2.07-1.99 (m, 4H), 1.83-1.72 (m, 6H), 1.59 (d, J=4.2Hz, 1H), 1.42 (s, 9H).

EXAMPLE 220

Yl)-2-(4-(l,2,3,4-tetrahvdronaphthalen-l-ylcarbamoynpyridin- 2- vPphenvDisophthalamide

Scheme 88. 1.Methanesulfonylcholoride,TEA,DCM.

Example 220: Into a 50-mL round-bottom flask, was placed a solution of (S)-Nl-(2- ( 1 ,4-diazepan- 1 -yl)ethyl)-N 1 -methyl-N3 -(4-(piperidin- 1 -yl)-2-(4-( 1 ,2,3 ,4- tetrahydronaphthalen-l-ylcarbamoyl)pyridin-2-yl)phenyl)isoph thalamide (150 mg, 0.21 mmol, 1.00 equiv) in dichloromethane (5 mL), methanesulfonyl chloride (40 mg, 0.35 mmol, 1.50 equiv), triethylamine (43 mg, 0.43 mmol, 2.00 equiv). The resulting solution was stirred for 1 h at room temperature. The resulting mixture was washed with 1x20 mL of water. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product (120mg ) was purified by Prep-HPLC with the following conditions (1#-Waters 2767-3): Column, SunFire Prep C18, 19* 150mm 5um; mobile phase, water with 0.05%TFA and CH ₃ CN (25% CH ₃ CN up to 36% in 6 min); Detector, Waters2545 UvDector 300&270nm. 43.5mg product was obtained. This resulted in 43.5 mg (18%) of (S)-Nl-methyl-Nl-(2-(4-(methylsulfonyl)- 1 ,4-diazepan- 1 -yl)ethyl)-N3 -(4-(piperidin- 1 -yl)-2-(4-( 1 ,2,3 ,4-tetrahydronaphthalen- 1 - ylcarbamoyl)pyridin-2-yl)phenyl)isoplit]ialamide as a yellow solid. LCMS (ES, m/z): 792 [M+H] ⁺

H-NMR (300MHz, CD ₃ OD, ^w): 8.94(m, IH), 8.68(m, IH), 8.39(s, IH), 8.12(m, 3H), 7.86(m, IH), 7.77(m, 3H), 7.25(m, IH), 7.17(m, 3H), 5.38(m, IH), 3.99(m, 2H), 3.56(m, 14H), 3.11(s, 3H), 2.91(s, 3H), 2.86(m, 2H), 2.28(m, 2H), 2.02(m, 8H), 1.81(m, 2H).

EXAMPLE 221

5-{2-| -methyl-l-n-(r4-(piperidin- ^

yl] carbamoyl }pyridin-2-yl)phenyl1 carbamoyl >phenyl formamidol ethyl) -2,8, 11,14- tetraoxa-5-azaheptadecan- 17-oic acid

Scheme 89. 1. 2-methoxyethanamine 2. NaBH ₃ CN, AcOH, EtOH 3. TFA, DCM.

Intermediate 221c: Into a 50-mL sealed tube, was placed tert-butyl 3-(2-(2-(2- (tosyloxy)ethoxy)ethoxy)ethoxy)propanoate (3 g, 6.94 mmol, 1.00 equiv), 2- methoxyethanamine (30 mL). The resulting solution was stirred overnight at 50°C. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 200 mL of ethyl acetate. The resulting mixture was washed with 2x200 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This resulted in 2 g (86%) of 221c as light yellow oil.

Intermediate 22 Id: Into a 50-mL round-bottom flask, was placed a solution of (S)-Nl- methyl-N 1 -(2-oxoethyl)-N3 -(4-(piperidin- 1 -yl)-2-(4-( 1 ,2,3 ,4-tetrahydronaphthalen- 1 - ylcarbamoyl)pyridin-2-yl)phenyl)isophtlialamide (200 mg, 0.32 mmol, 1.00 equiv) in ethanol (4 mL), amine 221c (160 mg, 0.48 mmol, 1.50 equiv), acetic acid (34 mg, 0.71 mmol, 2.20 equiv). The mixture was stirred overnight at room temperature. To the above was added NaBH ₃ CN (44 mg, 0.70 mmol, 2.20 equiv). The resulting solution was stirred for 1 h at room temperature. The reaction was then quenched by the addition of 20 ml of water. The resulting solution was extracted with 2x100 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 2x100 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This resulted in 300 mg (100%) 22 Id as yellow oil.

Example 221 : Into a 50-mL round-bottom flask, was placed a solution of 22 Id (100 mg, 0.1 1 mmol, 1.00 equiv) in dichloromethane (3 mL), trifluoroacetic acid (1.5 mL). The resulting solution was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum. The crude product (100 mg) was purified by Prep-HPLC with the following conditions (1#- Waters 2767-3): Column, SunFire Prep CI 8, 19* 150mm 5um; mobile phase, water with 0.05%TFA and CH ₃ CN (25% CH ₃ CN up to 37% in 6 min); Detector, Waters2545 UvDector 254&270nm. 46.6 mg product was obtained. This resulted in 46.6 mg (39%) Example 221 as a yellow solid.

LC-MS (ES, m/z): 893 [M+H] ⁺

H-NMR (300MHz, CD ₃ OD ppm): 8.94(d, J=5.1Hz, 1H), 8.67(d, J=9Hz, 1H), 8.40(s, 1H), 8.15~8.16(m, 2H), 8.06-8.1 l(m, 1H), 7.86~7.87(m, 1H), 7.78 ~7.85(m, 2H), 7.63~7.67(m, 1H), 7.14~7.28(m, 4H), 5.39~5.40(m, 1H), 3.99(s, 4H), 3.84(s, 1H), 3.57~3.64(m, 20H), 3.44(s, 3H), 3.14(s, 3H), 2.84~2.91(m, 2H), 2.52(t, J=6Hz, 2H), 2.14~2.17(m, 1H), 2.03~2.07(m, 7H), 1.96~2.00(m, 2H).

EXAMPLE 222

(S VN 1 -( 14-azido-3-methyl-6,9, 12-trioxa-3 -azatetradecyl)-N3-(4-( diethylamino )-2-( 4-

( 1 ,2,3 ,4-tetrahydronaphthalen- 1 -ylcarbamoyl)pyridin-2-y0phenyiyN 1 - methylisophthalamide

Intermediate 222a: Into a 250-mL round-bottom flask, was placed a solution of 2-(2-(2- (2-azidoethoxy)ethoxy)ethoxy)ethanamine (3 g, 13.75 mmol, 1.00 equiv) in tetrahydrofuran (100 mL), triethylamine (4.17 g, 41.21 mmol, 3.00 equiv). This was followed by the addition of di-tert-butyl dicarbonate (9 g, 41.24 mmol, 3.00 equiv), in portions at 0°C. The resulting solution was stirred overnight at 25°C. The mixture was concentrated under vacuum. The resulting solution was diluted with 100 mL of dichloromethane. The resulting mixture was washed with 2x100 mL of Brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:1). This resulted in 4 g (91%) of tert-butyl 2-(2-(2-(2- azidoethoxy)ethoxy)ethoxy)ethylcarbamate as colorless oil.

Intermediate 222b: Into a 100-mL 3 -necked round-bottom flask, was placed a solution of tert-butyl 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethylcarbamate (3.0 g, 9.43 mmol, 1.00 equiv) in N,N-dimethylformamide (40 mL). This was followed by the addition of sodium hydride (876 mg, 21.9 mmol, 2.00 equiv, 60%), in portions at 0°C in 5 min. The resulting solution was stirred for 0.5 h at 0°C. To this was added iodomethane (16.2 g, 114.08 mmol, 10.00 equiv) dropwise with stirring at 0°C in 20 min. The resulting solution was stirred for 18 h at room temperature. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 50 mL of dichloromethane. The resulting mixture was washed with 2x20 mL of water. The resulting mixture was washed with 2x20 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This resulted in 2200 mg (70%) of tert-butyl 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl(methyl)carbamate as yellow oil.

Intermediate 222c: Into a 50-mL round-bottom flask, was placed a solution of tert-butyl 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl(methyl)carbamate (2200 mg, 6.63 mmol, 1.00 equiv) in dichloromethane (5 mL). This was followed by the addition of 2,2,2- trifluoroacetic acid (3 mL) dropwise with stirring at 0°C. The resulting solution was stirred for 1 h at 25°C in an oil bath. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 5 mL of methanol. The pH value of the solution was adjusted to 12 with sodium hydroxide (0.5 mol/L). The resulting mixture was concentrated under vacuum. The residue was dissolved in 10 mL of dichloromethane. The solids were filtered out. The resulting mixture was concentrated under vacuum. This resulted in 1230 mg (80%) of 2-(2-(2-(2- azidoethoxy)ethoxy)ethoxy)-N-methylethanamine as yellow oil. LC-MS (ES, m/z) : 233 [M+H] ⁺

H-NMR (300MHz, CO ₃ OO, ppm): 3.78-3.74 (m, 2H), 3.70-3.67 (m, 10H), 3.42-3.39 (m, 2H), 3.23-3.20 (m, 2H), 2.74 (s, 3H).

Example 222: Into a 100-mL round-bottom flask, was placed a solution of (S)-Nl-(4- (diethylamino)-2-(4-(l ,2,3 ,4-tetrahydronaphthalen- 1 -ylcarbamoyl)pyridin-2-yl)phenyl)- N3-formyl-N3-(2-oxoethyl)isophthalamide (160 mg, 0.27 mmol, 1.00 equiv) in ethanol (3 mL), 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)-N-methylethanamine (90 mg, 0.39 mmol, 1.50 equiv), acetic acid (27 mg, 0.56 mmol, 2.20 equiv). The resulting solution was stirred overnight at room temperature. To the above was added NaBH ₃ CN (36 mg, 0.57 mmol, 2.20 equiv). The resulting solution was stirred for 2 h at room temperature. The mixture was concentrated under vacuum. The crude product (160 mg) was purified by Prep-HPLC with the following conditions (1#- Waters 2767-3): Column, SunFire Prep C18, 19*150mm 5um; mobile phase, water with 0.05%TFA and CH ₃ CN (hold 30% CH ₃ CN in 6 min); Detector, Waters2545 UvDector 254&270nm. 20 mg product was obtained. This resulted in 20 mg (6%) of (S)-Nl-(14-azido-3-methyl-6,9,12-trioxa- 3 -azatetradecyl)-N3 -(4-(diethylamino)-2-(4-( 1 ,2,3 ,4-tetrahydronaphthalen- 1 - ylcarbamoyl)pyridin-2-yl)phenyl)-Nl-methylisophthalamide as a yellow solid. LC-MS (ES, m/z): 834 [M+H] ⁺

H-NMR (400MHz, CD ₃ OD, ppm): 8.806(s, IH), 8.515(d, J=8.4Hz, IH), 8.246(s, IH), 7.987~8.032(m, 2H), 7.734~7.767(m, 2H), 7.600~7.676(m, 2H), 7.369(d, J=8Hz, IH), 7.146(d, J=7.2Hz, IH), 7.016~7.067(m, 3H), 5.258(t, J=5.6Hz, IH), 3.883(s, IH), 3.808(s, 2H), 3.544~3.599(m, 8H), 3.514(s, 10H), 3.209-3.244(m, 8H), 3.000(d, J=8.8Hz, 6H), 2.716~2.783(m, 2H), 1.775~2.039(m, 4H), 1.558(d, J=6.8Hz, IH), 1.113(t, J=6.8Hz, 6H).

EXAMPLE 223

(S -N 1 -(4-(diethylamino -2-(4-( 1 ,2,3 ,4-tetrahydronaphthalen- 1 - ylcarbamoyl)pyridin-2- vnphenylVN3 -methyl-N3 -( 17-methyl- 1 -morpholino-4-oxo-8, 11 , 14-trioxa-3.5.17- triazanonadecan- 19-yDisophthalamide

Scheme 91. 1. PPh ₃ , H ₂ 0,THF 2. 3. 4-nitrophenyl carbonochloridate, DCM, TEA 4. 2- moφholinoethanamine, DMAP, CH ₃ CN.

Intermediate 223a: Into a 100-mL round-bottom flask, was placed a solution of (S)-Nl- ( 14-azido-3 -methyl-6,9, 12-trioxa-3-azatetradecyl)-N3 -(4-(diethylamino)-2-(4-(l ,2,3 ,4- tetrahydronaphthalen- 1 -ylcarbamoyl)pyridin-2-yl)phenyl)-N 1 -methylisophthalamide (500 mg, 0.60 mmol, 1.00 equiv) in tetrahydrofuran/water (20/2 mL), triphenylphosphine (350 mg, 1.34 mmol, 2.23 equiv). The resulting solution was stirred overnight at 40°C. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column with dichloromethane:methanol (10:1). This resulted in 350 mg (72%) of (S)-Nl-(14-amino-3 -methyl-6,9, 12-trioxa-3- azatetradecyl)-N3 -(4-(diethylamino)-2-(4-( 1 ,2,3 ,4-tetrahydronaphthalen- 1 - ylcarbamoyl)pyridin-2-yl)phenyl)-Nl -methylisophthalamide as a yellow solid.

Intermediate 223b: Into a 100-mL round-bottom flask, was placed a solution of (S)-Nl- (14-amino-3-methyl-6,9,12-trioxa-3-azatetradecyl)-N3-(4-(die thylamino)-2-(4-(l,2,3,4- tetrahydronaphthalen- 1 -ylcarbamoyl)pyridin-2-yl)phenyl)-N 1 -methylisophthalamide (300 mg, 0.37 mmol, 1.00 equiv) in dichloromethane (30 mL), triethylamine (112.5 mg, 1.11 mmol, 3.00 equiv), 4-nitrophenyl carbonochloridate (74.6 mg, 0.37 mmol, 1.00 equiv). The resulting solution was stirred overnight at room temperature. The resulting mixture was washed with 2x30 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This resulted in 320 mg (89%) of (S)-4- nitrophenyl 1 -(3 -(4-(diethylamino)-2-(4-( 1 ,2,3 ,4-tetrahydronaphthalen- 1 - ylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)phenyl)-2,5-dimethy l- 1 -oxo-8, 11,14-trioxa- 2,5-diazahexadecan-16-ylcarbamate as a yellow solid.

Example 223: Into a 25-mL round-bottom flask, was placed a solution of (S)-4- nitrophenyl 1 -(3 -(4-(diethylamino)-2-(4-( 1 ,2,3 ,4-tetrahydronaphthalen- 1 - ylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)phenyl)-2,5-dimethy l- 1 -oxo-8, 11,14-trioxa- 2,5-diazahexadecan-16-ylcarbamate (200 mg, 0.21 mmol, 1.00 equiv) in acetonitrile (5 mL). This was followed by the addition of 2Tmorpholinoethanamine (26 mg, 0.20 mmol, 0.97 equiv) and 4-dimethylaminopyridine (38 mg, 0.31 mmol, 1.51 equiv). The resulting solution was stirred for 4 h at 80°C in an oil bath. The resulting mixture was concentrated under vacuum. The crude product (200 mg) was purified by Prep-HPLC with the following conditions (l#-PreP-HPLC-001(SHIMADZU)): Column, SunFire Prep CI 8, 19* 150mm 5um; mobile phase, CH3CN and water with 0.05%TFA (20% CH3CN up to 35% in 6 min, up to 100% in 1 min,down to 20% in 0.7 min); Detector, Waters2545 UvDector 254&220nm. This resulted in 80.3 mg (28%) of (S)-Nl-(4- (diethylamino)-2-(4-( 1 ,2,3 ,4-tetrahydronaphthalen- 1 -ylcarbamoyl)pyridin-2-yl)phenyi)- N3-methyl-N3-(l 7-methyl- 1 -morpholino-4-oxo-8, 11,14-trioxa-3,5, 17-triazanonadecan- 19-yl)isophthalamide as yellow oil.

LC-MS (ES, m/z): 965 [M+H] ⁺

H-NMR (300MHz, CD30D, ppm): 8.899(d, J=5.1Hz, 1H), 8.304(s, 1H), 8.080-8.109(m, 2H), 7.815~7.837(m, 1H), 7.707~7.755(m, 3H), 7.188-7.196(m, 2H), 7.130~7.175(m, 3H), 5.348~5.389(m, 1H), 3.916-3.993 (m, 6H), 3.500~3.715(m, 22H), 3.209~3.482(m, 2H), 3.110(d, J=6.3Hz, 6H), 2.837-2.91 l(m, 3H), 2.131~2.200(m, 1H), 1.204-1.25 l(m, 6H).

EXAMPLE 224 (SVNl -0 -amino- 14-methyl- 1 -oxo-5 ,8, 11 -trioxa-2, 14-diazahexadecan- 16- vD-N3 -( 4-

(diethylamino)-2-(4-n ,3,4-tetrahvdronaphthalen-l-ylcarbamoyl pyridin-2-yl phenvn-

N 1 -methylisophthalamide

This compound was prepared according to the procedure described for the synthesis of (S)-N 1 -(4-(diethylamino)-2-(4-( 1 ,2,3 ,4-tetrahydronaphthalen- 1 -ylcarbamoyl)pyridin-2- yl)phenyl)-N3-methyl-N3-(l 7-methyl- 1 -morpholino-4-oxo-8, 11 , 14-trioxa-3 ,5,17- triazanonadecan-19-yl)isophthalamide Example 223 substituting ammonia in methanol in place of 2-morpholinoethanamine. Into a 100-mL round-bottom flask, was placed a solution of (S)-4-nitrophenyl l-(3-(4-(diethylamino)-2-(4-(l,2,3,4- tetrahydronaphthalen-l-ylcarbamoyl)pyridin-2-yl)phenylcarbam oyl)phenyl)-2,5- dimethyl-l-oxo-8,l l,14-trioxa-2,5-diazahexadecan-16-ylcarbamate (100 mg, 0.10 mmol, 1.00 equiv) in NMP(5 mL), methanol (saturated with NH ₃ ) (5 mL). The resulting solution was stirred for 3 h at room temperature. The resulting mixture was washed with 2x30 mL of water. The resulting mixture was concentrated under vacuum. The crude product (100 mg) was purified by Prep-HPLC with the following conditions (1#- PreP-HPLC-OOl(SHIMADZU)): Column, SunFire Prep C18, 19*150mm 5um; mobile phase, water with 0.05%TFA and CH ₃ CN (22% CH ₃ CN up to 38% in 6 min, up to 100% in 1 min,down to 22% in 0.7 min); Detector, Waters2545 UvDector 254&220nm. This resulted in 26 mg (21%) of (S)-Nl-(l-amino-14-methyl-l-oxo-5,8,l l-trioxa-2,14- diazahexadecan- 16-yl)-N3 -(4-(diethylamino)-2-(4-( 1 ,2,3 ,4-tetrahydronaphthalen- 1 - ylcarbamoyl)pyridin-2-yl)phenyl)-Nl -methylisophthalamide as yellow oil. LC-MS (ES, m/z): 851 [M+H] ⁺

H-NMR (300MHz, CD ₃ OD, ppm): 8.96~8.94(d, J=5.1Hz, 1H), 8.71~8.68(m, 1H), 8.38(s, 1H), 8.16~8.12(m, 2H), 7.88(s, 1H), 7.87~7.86(m, 1H), 7.78~7.73(m, 2H), 7.58~7.54(m, 1H), 7.25~7.15(m, 4H), 5.39(s, 1H), 3.93(s, 5H), 3.76~3.61(m,. 12H), 3.57~3.48(m, 3H), 3.27~3.23(m, 2H), 3.13~3.09(m, 5H), 2.91~2.84(m, 3H), 2.05-1.91 (m, 5H), 1.31~1.22(m, 6H).

EXAMPLE 225

(S)-N 1 -(4-(diethylaminoV2-(4-( 1 ,2,3 ,4-tetrahydronaphthalen- 1 -ylcarbamoyl)pyridin-2- vnphenvD-NS-il-hvdroxy-S- -hvdroxyethvn-n-methyl^-oxo-S.l l.H-trioxa-S.S.n- triazanonadecan- 19-yl)-N3-methylisophthalamide

This compound was prepared according to the procedure described for the synthesis of (S)-N 1 -(4-(diethylamino)-2-(4-( 1 ,2,3 ,4-tetrahydronaphthalen- 1 -ylcarbamoyl)pyridin-2- yl)phenyl)-N3 -methyl-N3 -(17-methyl- 1 -morpholino-4-oxo-8, 11,14-trioxa-3 ,5 , 17- triazanonadecan-19-yl)isophthalamide Example 223 substituting 2,2'- azanediyldiethanol in place of 2-morpholinoethanamine. Into a 100-mL round-bottom flask, was placed a solution of (S)-4-nitrophenyl l-(3-(4-(diethylamino)-2-(4-(l,2,3,4- tetrahydronaphthalen- 1 -ylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)phenyl)-2,5 - dimethyl- l-oxo-8,11,14-trioxa-2,5-diazahexadecan-16-ylcarbamate (150 mg, 0.15 mmol, 1.00 equiv) in acetonitrile (10 mL), 2,2'-azanediyldiethanol (20 mg, 0.19 mmol, 1.24 equiv), 4-dimethylaminopyridine (28 mg, 0.23 mmol, 1.49 equiv). The resulting solution was stirred for 4 h at 80°C in an oil bath. The resulting mixture was concentrated under vacuum. The residue was dissolved in 20 mL of dichloromethane. The resulting mixture was washed with 2x30 mL of NFL;C1 (aq). The mixture was dried over sodium sulfate and concentrated under vacuum. The crude product (150 mg) was purified by Prep-HPLC with the following conditions (l#-PreP-HPLC- OOl(SHIMADZU)): Column, SunFire Prep CI 8, 19* 150mm 5um; mobile phase, CH ₃ CN and water with 0.05%TFA (22% CH ₃ CN to 38% in 6 min, up to 100% in 1 min,down to 22% in 0.7 min); Detector, Waters2545 UvDector 254&220nm. This resulted in 11.7 mg (6%) of (S)-Nl-(4-(diethylamino)-2-(4-(l,2,3,4- tetrahydronaphthalen- 1 -ylcarbamoyl)pyridin-2-yl)phenyl)-N3-(l -hydroxy-3-(2- hydroxyethyl)- 17-methyl-4-oxo-8, 11 , 14-trioxa-3 ,5 , 17-triazanonadecan- 19-yl)-N3 - methylisophthalamide as yellow oil.

LC-MS (ES, m/z): 939 [M+H] ⁺

H-NMR (300MHz, CD ₃ OD, ppm) 8.96~8.94(d, J=5.1Hz, 1H), 8.74~8.72(m, 1H), 8.39(s, 1H), 8.17~8.12(m, 2H), 7.89~7.87(m, 2H), 7.78~7.73(m, 2H), 7.61~7.56(m, 1H), 7.25(s, 1H), 7.18~7.16(m, 3H), 5.41~5.37(m, 1H), 4.05~3.92(m, 4H), 3.80~3.39(m, 26H), 3.13~3.10(m, 6H), 2.94~2.9(m, 3H), 2.19~1.86(m, 4H), 1.26~1.22(m, 6H).

EXAMPLE 226

3 -N- [4-(diethylamino)-2-(4- { [(1 S)- 1 ,2,3 ,4-tetrahydronaphthalen- 1 - yl]carbamoyl}pyridin-2-yl)phenyl]- 1 -N-(l -methanesulfonamido- 12-methyl-3 ,6,9- trioxa- 12-azatetradecan- 14-yl)- 1 -N-methylbenzene- 1 ,3-dicarboxamide

o

Scheme 92. 1.Methanesulfonylcholoride,TEA,DCM.

Example 266: Into a 50-mL round-bottom flask, was placed a solution of (S)-N1-(14- amino-3 -methyl-6,9, 12-trioxa-3 -azatetradecyl)-N3 -(4-(diethylamino)-2-(4-( 1 ,2,3 ,4- tetrahydronaphthalen- 1 -ylcarbamoyl)pyridin-2-yl)phenyl)-Nl -methylisophthalamide (40 mg, 0.05 mmol, 1.00 equiv) in dichloromethane (2 mL), methanesulfonyl chloride (8.5 mg, 0.07 mmol, 1.50 equiv), triethylamine (10 mg, 0.10 mmol, 2.00 equiv). The resulting solution was stirred for 1 h at room temperature. The resulting solution was diluted with 10 mL of dichloromethane. The resulting mixture was washed with 1x20 mL of water and 1x20 mL of brine. The mixture was dried over sodium sulfate and concentrated under vacuum. The crude product (50 mg) was purified by Prep-HPLC with the following conditions (l#-PreP-HPLC-001(SHIMADZU)): Column, SunFire Prep C18, 19* 150mm 5um; mobile phase, CH ₃ CN and water with 0.05%TFA (22% CH ₃ CN up to 38% in 6 min, up to 100% in 1 min,down to 22% in 0.7 min); Detector, Waters2545 UvDector. This resulted in 29 mg (48%) of 3-N-[4-(diethylamino)-2-(4- { [( 1 S)- 1 ,2,3 ,4-tetrahydronaphthalen- 1 -yl]carbamoyl } pyridin-2-yl)phenyl] - 1 -N-( 1 - methanesulfonamido- 12-methyl-3 ,6,9-trioxa- 12-azatetradecan- 14-yl)- 1 -N- methylbenzene- 1 ,3 -dicarboxamide,

Example 226 as brown oil.

LC-MS (ES, m/z): 886 [M+H] ⁺

H-NMR (300MHz, CD ₃ OD, ppm): 8.94~8.92(d, J=5.1Hz, 1H), 8.60(s, 1H), 8.35(s, 1H), 8.15~8.10(m, 2H), 7.86~7.70(m, 4H), 7.41(s, 1H), 7.27~7.25(m, 1H), 7.20~7.16(m, 3H), 5.40~5.36(m, 1H), 3.94(s, 5H), 3.73~3.62(m, 12H), 3.58~3.54(m, 3H), 3.24~3.21(t, 3H), 3.21~3.08(m, 6H), 2.95(s, 3H), 2.91~2.86(m, 2H), 2.21-1.85(m, 5H), 1.26-1.21 (t, 6H).

EXAMPLE 227

(diethylamino)-2-(4-( 1,2,3, 4-tetrahydronaphthalen-l-ylcarbamoyl pyridin-2-yl)phenylV

N 1 -methylisophthalamide

This compound was prepared according to the scheme for the synthesis of Example 213 substituting 212b in place of 213c. Into a 50-mL round bottom flask, was placed a solution of N 1 -(2-(4-(((S)- 1 ,2,3 ,4-tetrahydronaphthalen- 1 -yl)carbamoyl)pyridin-2-yl)- 4-(diethylamino)phenyl)-N3-methyl-N3-(2-(piperazin-l-yl)ethy l)isophthalamide (100 mg, 0.15 mmol, 1.00 equiv) in dichloromethane (10 mL), EDC.HC1 (43 mg, 0.22 mmol, 1.50 equiv), 4-dimethylaminopyridine (35.5 mg, 0.29 mmol, 2.00 equiv), 2-(2-(2-(2-(2- (2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)et hoxy)acetic acid 213b (70 mg, 0.18 mmol, 1.21 equiv). The resulting solution was stirred for 2 h at room temperature. The resulting mixture was washed with 5x20 mL of NH ₄ C1. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product (100 mg) was purified by Prep-HPLC with the following conditions (1#- Waters 2767-3): Column, Xbridge Prep C18, 5um, 19*100mm; mobile phase, water with 0.05% TFA and CH ₃ CN (5% CH ₃ CN up to 48% in 1 min, up to 59% in 5 min); Detector, Waters2545 UV Detector 254&270nm. 58 mg product was obtained.This resulted in 58 mg (37%) of (S)-Nl-(2-(4-2,5,8,l 1,14,17,20,23- octaoxapentacosanepiperazin- 1 -yl)ethyl)-N3-(4-(diethylamino)-2-(4-(l ,2,3 ,4- tetrahydronaphthalen- 1 -ylcarbamoyl)pyridin-2-yl)phenyl)-N 1 -methylisophthalamide as yellow oil. LC-MS (ES, m/z):1068 [M+H] ⁺

H-NMR (400MHz, CO ₃ OO, ppm) 8.94(s, 1H), 8.38(m, 1H), 8.17(s, 1H), 8.13(m, 2H), 7.95(m, 1H), 7.87-7.79(m, 3H), 7.74(m, 1H), 7.27-7.14(m, 4H), 5.40(t, 1H), 4.30- 4.0(m, 7H), 3.7-3.6(m, 46H), 3.35(m, 4H), 3.13(s, 3H), 2.87(m, 2H), 2.16-1.92(m, 4H), 1.30-1.22(m, 6H).

EXAMPLE 228

(S -Nl-(2-(4-2.5.8.11J4a7,20,23-octaoxapentacosanepiperazin-l-y l ethyl -Nl- methyl-N3 -(4-( piperidin- 1 -yl)-2-(4-( 1 ,2,3 ,4-tetrahydronaphthalen- 1 - ylcarbamoyl pyridin-2-yl)phenyl isophthalamide

Scheme 93. 1. EDC.HC1,DMAP, Et ₃ N 2. HC1/DCM.

Intermediate 228a: Into a 100-mL round-bottom flask, was placed a solution of 3-((2- (4-(((S)- 1 ,2,3,4-tetrahydronaphthalen- 1 -yl)carbamoyl)pyridin-2-yl)-4-(piperidin- 1 - yl)phenyl)carbamoyl)benzoic acid (2 g, 3.48 mmol, 1.00 equiv) in dichloromethane (20 mL), EDCHC1 (1 g, 5.22 mmol, 1.50 equiv), 4-dimethylaminopyridine (640 mg, 5.25 mmol, 1.51 equiv), tert-butyl 4-(2-(methylamino)ethyl)piperazine-l-carboxylate (1.02 g, 4.20 mmol, 1.21 equiv). The resulting solution was stirred for 3 h at room temperature. The resulting mixture was washed with 3x20 mL of NH ₄ Cl(aq). The mixture was dried over sodium sulfate and concentrated under vacuum. This resulted in 1.5 g (54%) of tert-butyl 4-(2-(3-(carbamoyl)-N-methylbenzamido)ethyl)piperazine-l- carboxylate as a yellow solid.

Intermediate 228b: Into a 50-mL round-bottom flask, was placed a solution of tert-butyl 4-(2-(3-(carbamoyl)-N-methylbenzamido)ethyl)piperazine-l-car boxylate (1.4 g, 1.75 mmol, 1.00 equiv) in dichloromethane (15 mL). To the above hydrogen chloride(g) was introduced in. The resulting solution was stirred for 3 h at room temperature. The resulting mixture was concentrated under vacuum. This resulted in 1.3 g (88%) of Nl- (2-(4-(((S)- 1 ,2,3 ,4-tetrahydronaphthalen- 1 -yl)carbamoyl)pyridin-2-yl)-4-(piperidin- 1 - yl)phenyl)-N3-methyl-N3-(2-(piperazin-l-yl)ethyl)isophthalam ide(4HCl salt) as a yellow solid.

This compound was prepared according to the procedure described for the synthesis of Example 227 substituting 228b in place of 212b. Into a 50-mL round bottom flask, was placed a solution of Nl-(2-(4-(((S)- 1,2,3 ,4-tetrahydronaphthalen-l- yl)carbamoyl)pyridin-2-yl)-4-(piperidin- 1 -yl)phenyl)-N3 -methyl-N3 -(2-(piperazin- 1 - yl)ethyl)isophthalamide (100 mg, 0.14 mmol, 1.00 equiv) in dichloromethane (12 mL), EDC.HC1 (40 mg, 0.20 mmol, 1.49 equiv), 4-dimethylaminopyridine (50 mg, 0.41 mmol, 3.01 equiv), 2-(2-(2-(2-(2-(2-(2-(2- methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)acet ic acid 213b (65 mg, 0.16 mmol, 1.20 equiv). The resulting solution was stirred for 2 h at room temperature. The resulting mixture was washed with 5x20 mL of NH ₄ C1. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product (100 mg) was purified by Prep-HPLC with the following conditions (1#-Waters 2767-3): Column, Xbridge Prep CI 8, 5um, 19* 100mm; mobile phase, water with 0.05% TFA and CH ₃ CN (5% CH3CN up to 48% in 1 min, up to 59% in 5 min); Detector, Waters2545 UvDector 254&270nm. 22.5 mg product was obtained. This resulted in 22.5 mg (15%) of Example 228 as yellow oil. LC-MS (ES, m/z): 1081 [M+H] ⁺

H-NMR (300MHz, CD ₃ OD, ppm): 8.82(s, 1H), 8.24(m, 2H), 8.00(s, 2H), 7.77(m, 1H), 7.64(m, 2H), 7.43(s, 1H), 7.24(m, 1H), 7.15-7.07(m, 4H), 5.34(m, 1H), 4.23-4.07(m, 2H), 3.74-3.50(m, 32H), 3.33(m, 4H), 3.18-3.02(m, 7H), 2.83-2.58(m, 6H), 2.19(m, 3H), 2.01-1.60(m, 3H), 1.60-1.58(m, 6H), 1.30(m, 1H).

EXAMPLE 229tert-butyl 3-r2-(2-{2-rmethvir4-{2-rN-methyl-l-r3-{r4-(piperidin-l-ylV

2-(4- { | ^" ( 1 S - 1 ,2,3 ,4-tetrahydronaphthalen- 1 -yl] carbamoyl} pyridin-2- yDphenyl] carbamoyl ) phenyl formamido] ethyl > piperazin- 1 - vDcarbonylaminolethoxylethoxy^ethoxylpropanoate

This compound was prepared according to the procedure described for the synthesis of Example 207 substituting 228b in place of 207b. Into a 100-mL round-bottom flask, was placed a solution of 4-nitrophenyl 4-(2-(3-(carbamoyl)-N- methylbenzamido)ethyl)piperazine-l-carboxylate (1.34 g, 1.55 mmol, 1.00 equiv) in acetonitrile (1 mL), tert-butyl 3-(2-(2-(2-

(methylamino)ethoxy)ethoxy)ethoxy)propanoate 135c (900 mg, 3.09 mmol, 1.99 equiv), 4-dimethylaminopyridine (189 mg, 1.55 mmol, 1.00 equiv). The resulting solution was heated to reflux overnight. The resulting mixture was concentrated under vacuum. The residue was dissolved in 30 mL of dichloromethane. The resulting mixture was washed with 3x30 mL of NH ₄ C1 (aq) and 5x30 mL of water. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This resulted in 1.4 g of crude product and 1.3 g was added to the next step. The crude product (100 mg) was purified by Prep-HPLC with the following conditions (1#-Waters 2767-3): Column, SunFire Prep CI 8, 19* 150mm 5um; mobile phase, water with 0.05%TFA and CH ₃ CN (31% CHsCN up to 46% in 5 min); Detector, Waters2545 UvDector 254&270nm. 50.2 mg product was obtained. This resulted in 1.3 g (82%) of tert-butyl 3-(2-(2-(2-(l-(2-(3- (carbamoyl)-N-methylbenzamido)ethyl)-N-methylpiperazine-4- carboxamido)ethoxy)ethoxy)ethoxy)propanoate as yellow oil.

LC-MS (ES, m/z): 1039 [M+Na] ⁺ .

H-NMR (300MHz, CD ₃ OO, ppm): 8.964-8.947(m, IH), 8.821-8.791(d, J=9.0Hz, IH), 8.418(s, IH), 8.192(s, IH), 8.145-8.088(s, 2H), 7.885-7.880(m, IH), 7.867-7.862(m, IH), 7.786-7.662(m, 2H), 7.225(m, IH), 7.177-7.158(m, 3H), 5.425-5.320(m, IH), 4.009(s, 2H), 3.866-3.848(m, IH), 3.736-3.433(m, 30H), 3.124(s, 3H), 2.987-2.972(m, 3H), 2.909-2.862(m, 2H), 2.519-2.450(m, 3H), 2.068-1.809 (m, 10H), 1.473-1.448 (m, 13H). EXAMPLE 230

(S)-2,S,8aia4,17,20-heptaoxadocosan-22-yl 4-(2-(3-(4-(diethylaminoV2-(4-(l,2.3.4- tetrahvdronaphthalen- 1 -ylcarbamovDpyridin^-yOphenylcarbamovD-N- methylbenzamidolethyllpiperazine- 1 -carboxylate

This compound was prepared according to the procedure described for the synthesis of Example 214 substituting 212b in place of 213c. Into a 8-mL sealed tube, was placed a solution of (S)-Nl-(4-(diethylamino)-2-(4-(l _> 2,3,4-tetrahydronaphthalen-l- ylcarbamoyl)pyridin-2-yl)phenyl)-N3 -methyl-N3 -(2- (piperazin- 1 - yl)ethyl)isophthalamide (150 mg, 0.22 mmol, 1.00 equiv) in acetonitrile (5 mL), 2,5,8,1 l,14,17,20-heptaoxadocosan-22-yl 4-nitrophenyl carbonate (165 mg, 0.33 mmol, 1.50 equiv), 4-dimethylaminopyridine (53 mg, 0.43 mmol, 2.00 equiv). The resulting solution was stirred for 5 h at 90°C in an oil bath. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 10 ml of water. The resulting solution was extracted with 3x30 mL of dichloromethane and the organic layers combined. The resulting mixture was washed with 3x30 mL of NH4CI aq. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product (100 mg) was purified by Prep-HPLC with the following conditions (1#- U V 1 -SHIM AD ZU- SPD-20 A) : Column, SunFire Prep C18, 19*150mm 5um; mobile phase, water with 0.05%TFA and CH ₃ CN (30% CH ₃ CN up to 50% in 6 min); Detector, Waters2545 UvDector 254&220nm. 85.6 mg product was obtained. This resulted in 85.6 mg (28%) of (S)-2,5,8,ll,14,17,20-heptaoxadocosan-22-yl 4-(2-(3-(4- (diethylamino)-2-(4-(l,2,3,4-tetrahydronaphthalen-l-ylcarbar noyl)pyridin-2- yl)phenylcarbamoyl)-N-methylbenzamido)ethyl)piperazine-l-car boxylate as a yellow solid.

LC-MS (ES, m/z): 1055 [M+H] ⁺

H-NMR (300MHz, CD ₃ OD, ppm): 8.92 (d, J= 5.1Hz, 1H), 8.60 (s, 1H), 8.35 (s, 1H), 8.13 (t, J= 7.5Hz, 2H), 7.69-7.85 (m, 4H), 7.44-7.46 (m, 1H), 7.26 (d, J= 6.6Hz, 1H), 7.14-7.19 (m, 3H), 5.38 (s, 1H), 4.26-4.86 (m, 3H), 3.99 (s, 2H), 3.63-3.74 (m, 31H), 3.52-3.61 (m, 6H), 3.31-3.34 (m, 5H), 3.09-3.12 (m, 3H), 2.84-2.91 (m, 2H), 1.90-1.97 (m, 4H), 1.21-1.26 (m, 6H).

EXAMPLE 2313-N-r4-(diethylaminoV2-(4-{raSVl,2,3.4-tetrahvdronaphthal en-l- yllcarbamoyllpyridin-2-vnphenvn-l-N-(2-{4-fr2-{2-r2-n-f4-r2- r2- hvdroxyethoxytethyllpiperazin- l-yl>-3- oxopropoxykthoxylethoxylethvnfmethvncarbamovnpiperazin-l-yll ethylVl-N-

Scheme 94. 1. TFA DCM 2. EDC.HC1, DMAP, 2-(2-(piperazin-l-yl)ethoxy)ethanol 2. HC1 DCM.

Intermediate 231a: Into a 50-mL round-bottom flask, was placed a solution of (S)-tert- butyl l-(4-(2-(3-(4-(diethylamino)-2-(4-(l,2,3,4-tetrahydronaphtha len-l- ylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)-N-memylbenzamido)e thyl)piperazin-l-yl)- 2-methyl-l-oxo-5,8,ll-trioxa-2-azatetradecan-14-oate (200 mg, 0.20 mmol, 1.00 equiv) in dichloromethane (10 mL), trifluoroacetic acid (2 mL). The resulting solution was stirred for 2 h at room temperature. The reaction progress was monitored by LCMS. The resulting mixture was concentrated under vacuum. The crude product (0.1 g) was purified by Prep-HPLC with the following conditions (1#- Waters 2767-3): Column, SunFire Prep C18, 19*150mm 5um; mobile phase, water with 0.05%TFA and CH ₃ CN (23% CH ₃ CN up to 35% in 6 min); Detector, aters2545 UvDector 254&270nm. 20 mg product was obtained. This resulted in 18.1 mg (7%) of Example 231a as a yellow solid.

LC-MS (ES, m/z): 950[M+H] ⁺

H-NMR (300MHz, DMSO, ppm): 11.88 (s, IH), 9.56(s, IH), 9.15(m, IH), 8.87(m, IH), 8.25(m, 2H), 8.12(m, 2H), 7.97(m, IH), 7.83(m, 2H), 7.67(m, 5H), 5.23(m, IH), 2.37- 2.73(m, 32H), 2.45(m, 3H), 1.81(m, 5H) , 1.23(m, 6H).

Example 231: Into a 50-mL sealed tube, was placed a solution of (S)-l-(4-(2-(3-(4- (diemylamino)-2-(4-(l,2,3,4-tetrahytonaph1halen-l-ylcarbamoy l)pyridin-2- yl)phenylcarbamoyl)-N-methylbenzamido)ethyl)piperazin- 1 -yl)-2 -methyl- 1 -oxo- 5,8,1 l-trioxa-2-azatetradecan-14-oic acid (1000 mg, 0.32 mmol, 1.00 equiv, 30%) in dichloromethane (20 mL), 2-(2-(piperazin-l-yl)ethoxy)ethanol (110 mg, 0.63 mmol, 2.00 equiv), EDC.HC1 (120 mg, 0.63 mmol, 2.00 equiv), 4-dimethylaminopyridine (38 mg, 0.31 mmol, 1.00 equiv). The resulting solution was stirred for two days at room temperature. The resulting solution was diluted with 30 mL of dichloromethane. The resulting mixture was washed with 4x50 mL of NH4CI aq.. The resulting mixture was concentrated under vacuum. The crude product (100 mg) was purified by Prep-HPLC with the following conditions (1#-Waters 2767-3): Column, SunFire Prep C18, 5um, 19*150mm; mobile phase, water with 0.05%TFA and CH ₃ CN (25% CH ₃ CN up to 40% in 6 min); Detector, UV 220&254 nm. This resulted in 9.8 mg (2%) of Example 231 as a yellow solid.

LC-MS (ES, w/z):1106 [M+H] ⁺

H-NMR (300MHz, CD3OD, j¾9m):8.94-8.95 (d, J=3Hz, IH), 8.70-8.72 (d, IH), 8.38 (s, IH), 8.11-8.16 (m, 2H), 7.71-7.94 (m, 4H), 7.49-7.51 (d, IH), 7.19-7.27 (m, IH), 7.12- 7.17 (m, 3H), 5.36-5.40 (m, IH), 5.45 (m, IH), 3.82-3.86 (m, 2H), 3.55-3.78 (m, 28H), 3.39-3.41 (m, 7H), 3.11 (s, 3H), 2.97 (s, 3H), 2.83-2.90 (m, 2H), 2.69-2.71 (m, 2H), 1.87-2.23 (m, 4H), 1.21-1.25 (t, 6H).

EXAMPLE 2323-N- 4-(diethylaminoV2-(4-{r(lS)-l,2.3.4-tetrahvdronaphthalen-l- yllcarbamoyl}pyridin-2-yl)phenyll-l-N-methyl-l-N-(2-i4-rmeth yl(2-i2-r2-( ^' 2- pentahvdroxyhexyl1carbamovUemoxy ethoxylemoxy>ethvDcarbamoyl1piperazin-l- yl I ethvDbenzene- 1 ,3 -dicarboxamide

This compound was prepared according to the procedure described for the synthesis of Example 231 substituting (2R,3R,4R,5S)-6-(methylamino)hexane-l,2,3,4,5-pentaol in place of 2-(2-(piperazin-l-yl)ethoxy)ethanol. Into a 8-mL sealed tube, was placed a solution of (S)-l-(4-(2-(3-(4-(diethylamino)-2-(4-(l,2,3,4-tetrahydronap hthalen-l- ylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)-N-methylbenzamido) ethyl)piperazin-l-yl)- 2-methyl-l-oxo-5,8,ll-trioxa-2-azatetradecan-14-oic acid (100 mg, 0.11 mmol, 1.00 equiv) in dichloromethane (5 mL), (2R,3R,4R,5S)-6-(methylamino)hexane-l,2,3,4,5- pentaol (30 mg, 0.15 mmol, 1.50 equiv), EDC.HC1 (40 mg, 0.21 mmol, 2.00 equiv), 4- dimethylaminopyridine (20 mg, 0.16 mmol, 1.50 equiv). The resulting solution was stirred overnight at room temperature. The resulting mixture was concentrated under vacuum. The crude product (lOOmg ) was purified by Prep-HPLC with the following conditions (1#-Waters 2767-3): Column, SunFire Prep C18, 19*150mm 5um; mobile phase, water with 0.05%TFA and CH ₃ CN (22% CH ₃ CN up to 34% in 6 min); Detector, Waters2545 UvDector 254&220nm. 7.1mg product was obtained. This resulted in 7.1 mg (5%) of Example 232 as a Pale-yellow solid. LC-MS (ES, m/z): 1127 [M+H] ⁺

H-NMR (300MHz, CD ₃ OD, ppm): 8.94 (d, J = 5.1Hz, 1H), 8.61 (s, 1H), 8.36 (s, 1H), 8.10-8.16 (m, 2H), 7.86 (dd, J = 5.1Hz, 2H), 7.69-7.80 (m, 2H), 7.46-7.49 (m, 1H), 7.14-7.27 (m, 4H), 5.38 (t, J = 6.0Hz, 1H), 4.00 (d, J = 6.3Hz, 3H), 3.41-3.81 (m, 37H), 3.09-3.14 (m, 5H), 2.67-2.97 (m, 10H), 1.91-1.98 (m, 4H), 1.21-1.26 (m, 6H). EXAMPLE 233

(SVl-oxo -G-f3-i4-fpiperidin-l-yl^

ylcarbamoyDpyridm-2-yl)phenylcarbamoyD^

azatetradecan-14-oic acid

This compound was prepared according to the procedure described for the synthesis of Example 10.1 substituting 142a in place of 4.1c. LC-MS (ES, m/z): 900 [M+H] ⁺ .

H-NMR (300MHz, CD ₃ OD, pprvi): 8.91 l-8.895(s, IH), 8.821-8.791(d, J=9.0Hz, IH), 8.422(s, IH), 8.203-8.195(s, IH), 7.950(s, IH), 7.839-7.81 l(m, 3H), 7.756-7.725(m, IH), 7.624-7.470(m, 4H), 7.365-7.314(m, IH), 7.246(s, IH), 7.143(s, 3H), 5.377(s, IH), 4.326(s, 2H), 3.715-3.465(m, 18H), 2.843(m, 2H), 2.504-2.463(m, 2H), 2.078- 1.836(s, 4H).

EXAMPLE 234

(S)-2-(3-(3-(4-(piperidin-l-yl')-2-(4-(1.2.3.4-tetrahvdronap hthalen-l- ylcarbamoyl Dyridin-2-yl phenylcarbamoyl)benzylthio)phenyl)acetic acid

This compound was prepared according to the procedure described for the synthesis of Example 143 substituting 142a in place of 143a. LC-MS (ES, m/z):711,88 [M-2HC1+H] ⁺

H-NMR (300MHz, OMSO, ppm): 12.69 (s, 1H), 9.28 (s, 1H), 8.95 (d, 7= 5.1Hz, 1H), 8.50 (d, J= 18.6Hz, 1H), 7.94-7.90 (m, 2H), 7.78 (d, J= 7.8Hz, 2H), 7.60 (d, J=7.5Hz, 1H), 7.52-7.46 (m, 1H), 7.24-7.05 (m, 8H), 5.26(d, J = 4.8Hz, 1H), 4.37 (s, 1H), 2.75 (d, J=13.5Hz, 1H), 1.98-1.67 (m, 2H).

EXAMPLE 235

(SV3-methyl-2-oxo-l-(3-(3-f4-(piperidin-l-yl'l-2-(4-fl.2.3.4 -tetrahvdronaphthalen-l- ylcarbamoyl)pyridm-2-vnphenylcarbamovnberizyltMo^phenylV6.9, 12-trioxa-3- azapentadecan-15-oic acid

This compound was prepared according to the procedure described for the synthesis of Example 144 substituting 142a in place of 143 a. LC-MS (ES, m/z): 928 [M-2HC1+H] ⁺ H-NMR (300MHz, CDC1 ₃ , ppm): 13.64(s, 1H), 8.99(s, 2H), 8.84(s, 1H), 8.50(s, 1H), 7.95(d, J=20.7Hz, 4H), 7.48~7.62( _m> 3H), 7.33(s, 1H), 7.14~7.28(m, 6H), 5.49(s, lH), 4.2 l(s, 2H), 3.47~3.74(m, 20H), 2.78 3.1 l(m, 5H), 2.35~2.71(m, 4H), 1.80~2.30(m, 7H).

EXAMPLE 236

(S>2-(2-(3-((3-(15-(4-(2-(2-hvdroxyem^^

6.9.12-1rioxa-3-azapen1adecyl)phenylmio)memyD^ 1 - vnphenyl -N-il.2.3.4 etrahvdronaphmaleri-l-vnisonicotinarnide

This compound was prepared according to the procedure described for the synthesis of Example 231 substituting Example 235 in place of 231a. A solution of (S)-3-methyl-2-oxo-l-(3-(3-(4-(piperidin-l-yl)-2-(4-(l,2,3,4 - tetrahydronaphthalen- 1 -ylcarbamoyl)pyridin-2- yl)phenylcarbamoyl)benzylthio)phenyl)-6,9,12-trioxa-3-azapen tadecan-15-oic acid (120 mg, 0.13 mmol, 1.00 equiv) in dichloromethane (5 mL), 2-(2-(piperazin-l- yl)ethoxy)ethanol (33.7 mg, 0.19 mmol, 1.50 equiv), N-(3-dimethylaminopropyl)-Nj ^~ - ethylcarbodiimide hydrochloride (49.7 mg, 0.26 mmol, 2.00 equiv). The resulting solution was stirred overnight at room temperature. The resulting solution was diluted with 50 mL of ethyl acetate. The resulting mixture was washed with 2x20 mL of brine. The mixture was dried over sodium sulfate and concentrated under vacuum. The crude product (100 mg) was purified by Prep-HPLC with the following conditions (1#- Waters 2767-3): Column, SunFire Prep C18, 19*150mm 5um; mobile phase, water with 0.05%TFA and CH ₃ CN (30% CH ₃ CN up to 42% in 6 min); Detector, Waters2545 UvDector 254&270nm. 20 mg product was obtained. This resulted in 20 mg (14%) of (S)-2 2 3-((3^15-(4-(2 2-hyoioxyethoxy)e l)piperazin-l-yl)-3-methyl-2,15-dioxo- 6,9,12-trioxa-3-azapentadecyl)phenylmio)methyl)benzamido)-5- (piperidin-l- yl)phenyl)-N-(l,2,3,4-tetrahydronaphthalen-l-yl)isonicotinam ide as a yellow solid. LC-MS (ES, m/z): 1084 [M+H] ⁺

H-NMR (300MHz, OMSO,ppm): 12.19(s, IH), 9.65(s, IH), 9.19(d, J=8.4Hz, IH), 8.91 (d, J=15.1Hz, IH), 8.28(d, J=12.9Hz, 2H), 7.90(s, IH), 7.85(d, J=4.8 Hz, IH), 7.75(d, .7=7.5 Hz, IH), 7.44~7.57(m, 8H), 7.10~7.22(m, 8H), 7.01(d, .7=2.4 Hz, IH), 5.25(d, .7=6.6 Hz, IH), 4.34(s, IH), 4.05(s, IH), 3.50~3.80(m, 8H), 3.30~3.40(m, 8H), 1.95(s, 2H), 1.80(s, 2H), 1.90~2.10(m, 2H), 1.50~1.80(m, 8H).

EXAMPLE 237

(S)-l-(3-(4-chloro-2-(4-(l,2,3,4-tetrahvdronaphthalen-l-ylca rbamoyl)pyridin-2- yl)phenylcarbamoyl ^' )phenylV2-methyl-l-oxo-5.8.11-trioxa-2-azatetradecan-1 4-oic acid

Scheme 95. 1. Pd(dppf)Cl ₂ /KOAc DMSO, 4,4,4 ^, ,4 ^, ,5,5,5',5'-octamethyl-2,2'-bi(l,3,2- dioxaborolane) 2. Pd(dppf)Cl ₂ /Na ₂ C03/H ₂ 0/Dioxane. Intermediate 237a: Into a 100-mL three-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of 2-bromo-4- chlorobenzenamine (10 g, 48.43 mmol, 1.00 equiv) in DMSO (30 mL), 4,4,5,5- tetramethyl-2-(4,4,5 ,5 -tetramethyl- 1 ,3 ,2-dioxaborolan-2-yl)- 1 ,3 ,2-dioxaborolane (18.5 g, 72.86 mmol, 1.50 equiv), potassium acetate (12.2 g, 124.36 mmol, 2.57 equiv), Pd(dppf)Cl2 (1.1 g, 1.50 mmol, 0.03 equiv). The resulting solution was stirred overnight at 80°C in an oil bath. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:50). This resulted in 5 g (41%) of 4-chloro-2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)benzenamine as a white solid.

LC-MS (ES, m/z): 254 [M+H] ⁺

H-NM (400MHz, CDC1 _3> ppm): 1.5 l(s, 12H), 6.53(d, > =6.6Hz, IH), 7.15(m, IH), 7.73(m, IH).

Intermediate 237b: Into a 500-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of 4-chloro-2-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)benzenamine (5.75 g, 22.72 mmol, 1.25 equiv) in dioxane (240 mL), (S)-2-bromo-N-(l,2,3,4-tetrahydronaphthalen-l-yl)isonicotina mide (6 g, 18.18 mmol, 1.00 equiv), Pd(dppf)Cl2 (1.81 g, 2.47 mmol, 0.14 equiv), a solution of sodium carbonate (9.6 g, 90.57 mmol, 4.98 equiv) in water(96 mL). The resulting solution was stirred overnight at 80°C in an oil bath. The resulting mixture was concentrated under vacuum. The resulting mixture was diluted with 50 mL of water. The resulting solution was extracted with 2x100 mL of ethyl acetate and the organic layers combined. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:5-1:2). This resulted in 3.5 g (48%) of (S)-2-(2-amino-5-chlorophenyl)-N-(l,2,3,4- tetrahydronaphthalen-l-yl)isonicotinamide as a yellow solid. LC-MS (ES, m/z): 378 [M+H] ⁺

H-NMR (300MHz, CDC1 ₃ , ppm): 8.72(d, J=5.1Hz, IH), 7.96(s, IH), 7.56-7.51 (m, 2H), 7.36 (d, J=8.1Hz, IH), 7.23~7.12(m, 4H), 6.72(d, =8.7Hz, IH), 6.48(d, J=8.1Hz, IH), 6.3~5.65(m, 2H), 5.45~5.41(m, IH), 2.94~2.80(m, 2H), 2.23-2.19 (m, IH), 2.05~1.91(m, 3H).

Example 237: This compound was prepared according to the procedure described for the synthesis of Example 188 substituting 237b in place of 25b. LC-MS (ES, m/z): 743 [M-HC1+H] ⁺

H-NMR (300MHz, CDC1 ₃ , ppm): 13.15(s, IH), .86(s, IH), 8.66 (d, J=8.1Hz, IH), 8.24(s, IH), 8.07 (m, 2 H), 7.828(s, IH), 7.821(s, IH), 7.75~7.56(m, 2H), 7.54(d, J=21.3Hz, IH), 7.47-7.43 (m, IH), 7.22-7.14 (m, 3H), 7.02-6.92 (m, IH), 5.46-5.44 (m, IH), 3.81-3.58 (m, 16H), 3.17-3.10 (m, 3H), 2.86-2.85 (m, 2H), 2.51-2.47 (t, 2H), 2.20-2.03 (m, 2H), 2.01-1.91 (m, 3H).

EXAMPLE 2383 2-r2-(2-{l-r3-({4-chloro-2-r4-({r3- ( ^" trifluoromethvnphenyllmethv carbamovnpyridin^-yllphenyllcarbaniovnphenyll-N- methylformamido|ethoxy)ethoxy]ethoxy}pr6panoic acid

This compound was prepared according to the procedure described for the synthesis of Example 188 substituting 21b in place of 25b. LC-MS (ES, m/z):771.30 [M+H] ⁺

EXAMPLE 239

(S V 1 -(3 -(3 -(4-chloro-2-( 4-( 1.2.3.4-tetrahydronaphthalen- 1 -ylcarbamo yl1pyridin-2- yllphenylcarbamovDbenzylthio ^' iphenylVS-methyl^-oxo-e.g.n-trioxa-S- azapentadecan-15-oic acid

This compound was prepared according to the procedure described for the synthesis of Example 144 substituting 237b in place of the aniline starting material 4c. (LC-MS (ES, m/z): 879 [M-HC1+H] ⁺

H-NMR (300MHz, DMSO, ppm): 12.94(s, IH), 12.08(s, IH), 9.26(d, J=8.4Hz, IH), 8.96(d, J=5.1Hz, IH), 8.60(d, J=8.7Hz, IH), 8.412(s, IH), 8.09(s, IH), 8.08~7.91(m, 2H), 7.91(d, J=7.5Hz, IH), 7.61~7.48(m, 3H), 7.22~7.13(m, 2H), 7.01 (d, J=5.1Hz, IH), 5.27(s, IH), 4.36(s, 2H), 3.66 ~3.48(m, 7H), 3.45 ~3.32(m, 15H), 3.29(s, 2H), 2.84 ~2.80(m, 4H), 2.44 -2.38(m, 3H), 2.02-1.80(m, 4H).

EXAMPLE 240

teit-butyl 2-methyl- 1 -((SV 1 -(2-(N-methyl-3 -(4-(piperidin- 1 -yl -2-(4-f (SV 1.2.3.4- tetrahvdronaphthalen- 1 -ylcarbamo yllpyridin-2- yllphenylcarbamoynbenzamido^ethv piperidin- -ylV 1 -oxo-5.8.11 -trioxa-2- azatetradecan-14-oate

Scheme 96. 1. NaBH ₃ CN, EtOH, AcOH 2. tert-butyl 3-(2-(2-(2- (methylamino)ethoxy)ethoxy)ethoxy)propanoate 135c, EDC.HC1, DMAP, DCM.

Intermediate 240a: Into a 100-mL round-bottom flask, was placed a solution of (S)-Nl- me l-Nl-(2-oxoe l)-N3-(4-(piperidin-l-yl)-2-(4-(l,2,3,4-tetrahya>orMphtha len-l- ylcarbamoyl)pyridin-2-yl)phenyl)isophthalamide (350 mg, 0.56 mmol, 1.00 equiv) in ethanol (20 mL), (S)-piperidine-2-carboxylic acid (216 mg, 1.67 mmol, 2.00 equiv). This was followed by the addition of acetic acid (2 mL). The mixture was stirred for overnight at room temperature. To this was added NaB¾CN (77 mg, 1.22 mmol, 2.20 equiv). The resulting solution was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was dissolved in 50 mL of ethyl acetate. The resulting mixture was washed with 1x20 mL of water. The mixture was dried over sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with methanohdichloromethane (1:5). This resulted in 300 mg (73%) of (S)- 1 -(2-(N-methyl-3 -(4-(piperidin- l-yl)-2-(4-((S)- 1 ,2,3,4- tetrahydronaphthalen- 1 -y lcarbamoyl)pyridin-2- yl)phenylcarbamoyl)benzamido)ethyl)piperidine-2-carboxylic acid as a yellow solid. Example 240: Into a 50-mL round-bottom flask, was placed a solution of (S)-l.-(2-(N- methyl-3-(4-(piperidin-l-yl)-2-(4-((S)-l,2,3,4-tetrahydronap hthalen-l- ylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)beiizamido)ethyl)pi peridine-2-carboxylic acid (140 mg, 0.19 mmol, 1.00 equiv) in dichloromethane (3 mL), EDC.HC1 (73 mg, 0.38 mmol, 2.00 equiv), 4-dimethylaminopyridine (47 mg, 0.38 mmol, 2.00 equiv), tert- butyl 3-(2-(2-(2-(methylamino)ethoxy)ethoxy)ethoxy)propanoate 135c (110 mg, 0.38 mmol, 2.00 equiv). The resulting solution was stirred overnight at room temperature. The resulting mixture was washed with NH4CI aq.. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product (140mg ) was purified by Prep-HPLC with the following conditions (1#-Waters 2767-3): Column, Xbridge Prep CI 8, 5um, 19* 100mm; mobile phase, water with 0.03%NH ₃ H ₂ O and CH3CN (65% CH3CN up to 78% in 6 min); Detector, Waters2545 UvDector 254&270nm. 49.3mg product was obtained. This resulted in 49.3 mg (26%) of tert- butyl 2-methyl-l -((S)- 1 -(2-(N-methyl-3-(4-(piperidin- 1 -yl)-2-(4-((S)- 1 ,2,3,4- tetrahydronaphthalen- 1 -ylcarbamoyl)pyridin-2- yl)phenylcarbamoyl)benzamido)ethyl)piperidin-2-yl)- 1 -oxo-5 ,8,11 -trioxa-2- azatetradecan-14-oate as a yellow solid.

LC-MS (ES, m/z): 1016 [M+H] ⁺

H-NMR (300MHz, CD ₃ OD, pprri): 8.84(s, IH), 8.29-8.22(m, 2H), 8.03-8.01(m, 2H), 7.79-7.78(m, IH), 7.66-7.64(m, 2H), 7.47(s, IH), 7.28-7.26(m, IH), 7.18-7.12(m, 4H), 5.36-5.35(m, IH), 3.67-3.53(m, 16H), 3.26-3.22(m, 5H), 3.12-3.03(m, 4H), 2.90- 2.80(m, 5H), 2.70-2.60(m, IH), 2.46-2.42(m, 2H), 2.30-2.20(m, IH), 2.19-2.10(m, IH), 2.05-1.85(m, 3H), 1.77-1.76(m, 5H), 1.65-1.63(m, 4H), 1.44-1.42(m, 11H).

EXAMPLE 241

fe^butyl 3-{2-r2-(2-f l-r(2S,4R)-4-hvdroxy-l-{2-rN-methyl-l-(3-{[4-(piperidin-l-yl V 2-i4- { Kl SI- 1.2.3.4-tetrahvdronaphthalen- 1 -yl] carbamoyl }pyridin-2- vDphenyllcarbamoyUphenvDformamidol ethyl } pyrrolidin-2-yll -N- methylformamido } ethoxy)ethoxy1ethoxy ) propanoate

This compound was prepared according to the procedure described for the synthesis of Example 240 substituting (2S,4R)-4-hydroxypyrrolidine-2-carboxylic acid in place of (S)-piperidine-2-carboxylic acidLC-MS (ES, m/z): 1018 [M+H] ⁺ H-NMR (300MHz, DMSO, ppm): 12.25~12.09(m, IH), 9.19~9.16(d, J=8.4Hz, IH), 8.86(s, IH), 8.28(s, IH), 8.19~8.18(m, IH), 7.92~7.84(m, 3H), 7.62(s, 2H), 7.38(s, IH), 7.19~7.10(m, 6H), 5.24(s, IH), 3.58~3.51(m, 4H), 3.45(s, 12H), 3.22~3.18(m, 5H), 3.00~2.72(m, 10H), 2.41~2.27(m, 3H), 1.99~1.78(m, 7H) ,1.66~1.56(m, 7H), 1.33(s, J=3.3Hz, 10H), 1.25(s, 2H).

EXAMPLE 242

tert-butyl 2-methyl -r(S)-4- -nsr-methyl-3-(4-(piperidin-l-yl)-2-(4-((S)-l,2.3.4- tetrahydronaphthalen- 1 -ylcarbamoyl)pyridin-2- yl)phenylcarbamoyl)benzamido)ethyl)morpholin-3-yl)-l-oxo-5.8 .11-trioxa-2- azatetradecan- 14-oate

This compound was prepared according to the procedure described for the synthesis of Example 240 substituting (S)-morpholine-3-carboxylic acid in place of (S)-piperidine- 2-carboxylic acid.

LC-MS (ES, m/z): 1018 [ +H] ⁺

H-NMR (300MHz, CD ₃ OD, ppm): 8.93~8.91(d, J=5.4Hz, IH), 8.58~8.55(d, 8.7Hz, IH), 8.36(s, IH), 8.23(s, IH), 8.13~8.11(d, 7=6.9Hz, IH), 7.90~7.83(m, 3H), 7.75~7.70(m, IH), 7.54~7.52(d, J=6.6Hz, IH), 7.28~7.26(d, J=7.8Hz, IH), 7.20~7.14(m, 3H), 5.40~5.37(m, IH), 4.51~4.45(m, 2H), 4.25~4.21(m, IH), 4.09~ .04(m, IH), 3.88(s, IH), 3.69~3.54(m, 23H), 3.53~3.52(m, 2H), 3.15~3.12(m, IH), 3.10~3.08(m, 4H), 3.00(s, 2H), 2.89~2.86(m, 3H), 2.49~2.45(m, 2H), 2.00(s, IH), 1.95-1.94(m, 8H), 1.78~1.76(m, 2H), 1.44(s, 9H).

EXAMPLE 243

2-methyl-l-(rSV4-f2-(N-methyl-3-(4-(Diperidin-l-ylV2-(4-f(SV 1.2.3,4- tetrah ydronaphthalen- 1 -ylcarbamoyr)pyridin-2- v phenYlcarbamovnbenzamidokthyllmorpholin-S-vn-l -oxo-5.8.1 l-trioxa-2- azatetradecan-14-oic acid

A solution of tert-butyl 2-methyl-l-((S)-4-(2-(N-methyl-3-(4-(piperidin-l-yl)-2-(4-(( S)- 1 ,2 ,3 ,4-tetrahydronaphthalen- 1 -ylcarbamoyl)pyridin-2- yl)phenylcarbamoyl)benzamido)ethyl)morpholin-3 -yl)- 1 -oxo-5 ,8,11 -trioxa-2- azatetradecan-14-oate Example 242 (100 mg, 0.10 mmol, 1.00 equiv) in dichloromethane (4 mL), trifluoroacetic acid (2 mL). The resulting solution was stirred for 1 h at room temperature. The resulting mixture was concentrated under vacuum. The crude product (80mg ) was purified by Prep-HPLC with the following conditions (1#- Waters 2767-3): Column, SunFire Prep C18, 19*T50mm 5um; mobile phase, water with 0.05%TFA and C¾CN(5% C¾CN up to 28% in 1 min, up to 38% in 6 min); Detector, Waters2545 UvDector 254&270nm. 8.4mg product was obtained. This resulted in 8.4 mg (7%) of 2-methyl-l-((S)-4-(2-(N-methyl-3-(4-(piperidin-l-yl)-2-(4- ((S)-l,2,3,4-tetrahydr0naphthalen-l-ylcarbamoyl)pyridin-2- yl)pheny lcarbamoyl)benzamido)ethyl)morpholin-3 -y 1)- 1 -oxo-5 ,8 , 11 -trioxa-2- azatetradecan-14-oic acid as a yellow solid.

LC-MS (ES, m/z) 962 [M+H] ⁺

H-NMR (300MHz, CD ₃ OD,ppm): 8.93(d, J=5.1Hz, IH), 8.65(d, J=9.3Hz, IH), 8.39(s, IH), 8.24(s, IH), 8.14-8.11(m, IH), 8.03-8.02(m, IH), 7.86-7.84(m, 2H), 7.76-7.72(m, IH), 7.64-7.61(m, IH), 7.28-7.25(m, IH), 7.18-7.14(m, 3H), 5.39(m, IH), 4.50-4.45(m, 2H), 4.30-4.20(m, IH), 4.09-4.05(m, IH), 3.86-3.43(m, 25H), 3.21(s, IH), 3.10-3.08(m, 3H), 3.00(s, IH), 2.91-2.84(m, 2H), 2.57-2.51(m, 2H), 2.04-1.79(m, 10H).

EXAMPLE 244

(SVtert-butyl l-q-nSf-methyl-3-(4-fDiperidin-l-yl ^' )-2-r4-( ^' 1.2.3,4-tetrahvdronaphthalen- l-ylcarbamoyDpyridin-2-yl ^' )phenyIcarbamoyl ^' )benzamido ethyl)piperidine-4- carboxylate

This compound was prepared according to the procedure described for the synthesis of Example 187 substituting tert-butyl piperidine-4-carboxylate in place of L-proline-t- butyl ester.

LC-MS (ES, m z): 799 [M+H] ⁺

H-NMR (300MHz, DMSO, ppm): 12.19(s,lH), 9.19~9.17(d, J=7.8Hz, IH), 9.03(s, IH), 8.89~8.87(d, =5.1Hz, IH), 8.30 (s, IH), 8.23~8.20(d, J=9.3Hz, IH), 8.00-7.97 (d, J=9.0Hz, 2H), 7.86-7.84 (d, J=4.8Hz, IH), 7.68-7.63 (m, 2H), 7.49 (s, IH), 7.20-7.13(m, 5H), 5.25(s, IH), 3.84(s, 3H), 3.39 (s, 3H), 3.31-3.26 (m, 5H), 2.96 (s, 6H), 2.78-2.73 (m, 2H), 2.12-1.98 (m, 5H) , 1.84-1.59 (m, 11H), 1.44~1.40(m, 10H).

EXAMPLE 245

S ^' )-2- 2-(3-(3-methyl-3-( ^' 2-moφholinoethyl ^' )ureido)benzamido 5-( iperidi -l- vnphenylVN-fl^ ^-tetrahvdronaphthalen-l-vnisonicotinamide

Scheme 97. 1. N-methyl-2-morpholinoethanamine, TEA, DCM 2. Aq. NaOH, THF 3. EDC.HC1, DMAP, DCM.

Intermediate 245a: Into a 25-mL round-bottom flask, was placed a solution of N- methyl-2-morpholinoethanamine (162.8 mg, 1.13 mmol, 1.00 equiv) in dichloromethane (5 mL), triethylamine (114.1 mg, 1.13 mmol, 1.00 equiv). This was followed by the addition of methyl 3-isocyanatobenzoate (200 mg, 1.13 mmol, 1.00 equiv), in portions. The resulting solution was stirred for 0.5 h at room temperature. The residue was applied onto a silica gel column with dichloromethane/methanol (500:1- 100:1). This resulted in 333 mg (92%) of methyl 3-(3-methyl-3-(2- morpholinoethyl)ureido)benzoate as a yellow semi-solid.

Intermediate 245b: Into a 50-mL round-bottom flask, was placed a solution of methyl 3- (3-methyl-3-(2-morpholinoethyl)ureido)benzoate (479 mg, 1.49 mmol, 1.00 equiv) in tetrahydrofuran (6 mL), a solution of sodium hydroxide (477.6 mg, 11.94 mmol, 8.00 equiv) in water(3 mL). The resulting solution was stirred for 4 h at room temperature. The reaction progress was monitored by TLC.LCMS (dichloromethane/methanol = 2:1). The resulting mixture was concentrated under vacuum. The pH value of the solution was adjusted to 6-7 with hydrogen chloride (2 mol/L). The resulting solution was extracted with 2x20 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 2x20 mL of sodium chloride(aq). The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with dichloromethane/methanol (400:1-20:1). This resulted in 600 mg (92%) of 3-(3-methyl-3-(2-morpholinoethyl)ureido)benzoic acid as a light yellow solid.

Example 245: Into a 50-mL round-bottom flask, was placed 2-(2-amino-5-(piperidin-l- yl)phenyl)-N-((S)-l,2,3,4-tetrahydronaphthalen-l-yl)isonicot inamide (200 mg, 0.47 mmol, 1.00 equiv), 3-(3-methyl-3-(2-morpholinoethyl)ureido)benzoic acid (143 mg, 0.47 mmol, 0.99 equiv), EDC.HC1 (135 mg, 0.70 mmol, 1.50 equiv), 4- dimethylaminopyridine (86 mg, 0.70 mmol, 1.50 equiv), dichloromethane (5 mL). The resulting solution was stirred for 2 h at room temperature. The reaction progress was monitored by LCMS/TLC (dichloromethane/methanol = 10:1). The resulting solution was diluted with 20 mL of water. The resulting solution was extracted with 3x20 mL of dichloromethane and the organic layers combined. The resulting mixture was washed with 2x20 mL of NH4CI (aq). The mixture was dried over anhydrous sodium sulfate. The crude product was purified by Prep-HPLC with the following conditions (1#- Waters 2767-3): Column, SunFire Prep CI 8, 19* 150mm 5um; mobile phase, water with 0.05%TFA and CH ₃ CN (24% CH ₃ CN up to 34% in 6 min); Detector, Waters2545 UvDector 254&270nm. This resulted in 95.8 mg (19%) of Example 245 as a white solid.

LC-MS (ES, m/z): ^■ 716 [M+H] ⁺

H-NMR (300MHz, CD ₃ OD , pw):8.95-8.93(d, J=5.1Hz, 1H), 8.718.68(d, J=9Hz, 1H), 3.39(s, 1H), 8.20-8.1 l(m, 1H), 7.86-7.84(m, 1H), 7.72-7.64(m, 1H), 7.53-7.48(m, 2H), 7.27-7.25(d, J=6.9Hz, 1H), 7.17-7.13(m, 4H), 5.38(s, 1H), 4.00(s, 2H), 3.83-3.80(m, 4H), 3.69-3.65(t, =5.4Hz, 6H), 3.44-3.40(m, 2H), 3.18(s, 4H), 2.87-2.85(d, ^6.6Hz, 2H), 2.04-1.8 l(m, 10H).

EXAMPLE 246

(S -Nl-(2-(4-(2-(2-hvdroxyethoxy ^' )ethvnpiperazin-l-yl ^' l-2-oxoethyl ^' )-Nl-methYl-N3-(4-

(piperidin-1 -yl -2-(4-(l .2.3.4-tetrahvdronaphthalen- 1 -ylcarbamoyl r>yridin-2- yllphenvDisophthalamide

Into a 100-mL round-bottom flask, was placed a solution of (S)-2-(N-methyl-3-(4- (piperidin-l-yl)-2-(4-(l,2,3,4-tetrahydronaphthalen-l-ylcarb amoyl)pyridin-2- yl)phenylcarbamoyl)benzamido)acetic acid (200 mg, 0.31 mmol, 1.00 equiv) in dichloromethane (10 mL), EDC.HC1 (113 mg, 0.59 mmol, 1.90 equiv), 4- dimethylaminopyridine (80 mg, 0.65 mmol, 2.1 1 equiv), 2-(2-(piperazin-l- yl)ethoxy)ethanol (103 mg, 0.59 mmol, 1.91 equiv). The resulting solution was stirred overnight at room temperature. The resulting solution was diluted with 30 mL of dichloromethane. The resulting mixture was washed with 2x30 mL of NHtCl.aq. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product (200 mg) was purified by Prep-HPLC with the following conditions (1#- Waters 2767-3): Column, SunFire Prep C18, 19*150mm 5um; mobile phase, water with 0.05%TFA and CH ₃ CN (23% CH ₃ CN up to 34% in 6 min); Detector, Waters2545 UvDector 254&270nm. 57.6 mg product was obtained. This resulted in 57.6 mg (23%) of (S)-Nl-(2-(4-(2-(2½droxyemoxy)ethyl)piperazin-l-yl)-2-oxoet hyl)-Nl-methyl-N3- (4-^iperidin-l-yl)-2-(4-(l,2,3,44etrahydronaphthalen-l-ylcar bamoyl)pyridin-2- yl)phenyl)isophthalamide as a yellow solid.

LC-MS (ES, m/z): 802 [M+H] ⁺

H-NMR (300MHz, DMSO, ppm): 12.38(s, 1H), 9.94(s,lH), 9.21~9.19(d, J=8.4Hz, 1H), 8.95~8.90(m, 1H), 8.00~7.95(m, 2H), 7.87~7.84(m, 3H), 7.67~7.54(m, 3H), 7.30~7.13(m, 5H), 5.27~5.25(m, 1H), 3.79~3.69(m, 3H), 3.57-3.1 l(m, 16H), 3.00~2.92(m, 4H), 2.78(s, 2H), 2.00(s, 2H), 1.85~1.79(m, 6H), 1.55(s, 2H).

EXAMPLE 247

3-(2-(2-(2-(3-(3-((30S)-3-((2-(4- (SV1.2,3.4-tetrahvdronaphthalen-l- yDcarbamoynpyridin^-vD^-Cpiperidin-l- vnphenyl)carbamoyl)benzyltMo)Dhenyl)propoxy)ethoxy)ethoxy ^' )ethoxy ^' )pro ^p anoic acid

Br 1 ·

7a

Scheme 98. 1. Na, THF 2. Na, tert-butyl acrylate, THF 3. 3-iodophenol, copper(I)iodide, Pd(PPh ₃ ) ₂ Cl ₂ , triethylamine 4. Pd/C, H ₂ , MeOH 5. trifluoromethanesulfonyl trifluoromethanesulfonate, TEA, DCM 6. 3- (mercaptomethyl)benzoic acid, K2CO3, Pd ₂ (dba)3, Xantphos, xylene 7. 126e, EDC.HC1, DMAP, DCM. 8. HC1/DCM.

Intermediate 247a: Into a 1 -L round-bottom flask, was placed a solution of Triethylene glycol (56.76 g, 378.40 mmol, 0.90 equiv) in tetrahydrofuran (400 mL). This was followed by the addition of sodium hydride (10 g, 416.67 mmol, 1.00 equiv), in portions at 0-5°C in 10 min. To this was added a solution of 3-bromoprop-l-yne (50 g, 420.17 mmol, 1.00 equiv) in toluene (50 mL) dropwise with stirring at room temperature. The resulting solution was stirred for 2 h at room temperature. The reaction progress was monitored by LCMS. The solids were filtered out. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column with petroleum ether/ethyl acetate (10:1-1:1). This resulted in 30.1 g (37%) of 2-(2-(2-(prop-2-ynyloxy)ethoxy)ethoxy)ethanol as yellow oil.

Intermediate 247b: Into a 1000-mL round-bottom flask, was placed a solution of 2-(2- (2-(prop-2-ynyloxy)ethoxy)ethoxy)ethanol (22.5 g, 119.68 mmol, 1.00 equiv) in tetrahydrofuran (200 mL), sodium (83 mg, 3.61 mmol, 0.03 equiv). This was followed by the addition of a solution of tert-butyl acrylate (15.3 g, 119.53 mmol, 1.00 equiv) in tetrahydrofuran (100 mL) dropwise with stirring. The resulting solution was stirred for 3 h at room temperature. The reaction progress was monitored by LCMS. The pH value of the solution was adjusted to 7-8 with IN hydrochloric acid. The resulting solution was diluted with 300 mL of water. The resulting solution was extracted with 3x200 ml of ethyl acetate and the organic layers combined. The resulting mixture was washed with 1x200 mL of water. The resulting mixture was washed with 1x200 mL of sodium chloride(aq). The resulting mixture was concentrated under vacuum. This resulted in 31.3 g (79%) of tert-butyl 3-(2-(2-(2-(prop-2- ynyloxy)ethoxy)ethoxy)ethoxy)propanoate as yellow oil.

Intermediate 247c: Into a 1000-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of 3-iodophenol (7 g, 31.82 mmol, 1.01 equiv) in tetrahydrofuran (200 mL), copper(I) iodide (600 mg, 3.16 mmol, 0.10 equiv), Pd(PPh ₃ ) ₂ Cl ₂ (2.22 g, 3.16 mmol, 0.10 equiv), triethylamine (6.4 g, 63.37 mmol, 2.00 equiv). This was followed by the addition of tert-butyl 3-(2-(2-(2-(prop-2- ynyloxy)ethoxy)ethoxy)ethoxy)propanoate (10 g, 31.65 mmol, 1.00 equiv) dropwise with stirring at 0-5°C in 20 min. The resulting solution was stirred for 2 h at room temperature. The reaction progress was monitored by TLC/LCMS (1:1 ethyl acetate/petroleum ether). The reaction was then quenched by the addition of 200 ml of water. The resulting solution was extracted with 3x200 ml of ethyl acetate and the organic layers combined. The resulting mixture was washed with 1x100 mL of water. The resulting mixture was washed with 3x100 mL of sodium chloride(aq). The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column with petroleum ether/ethyl acetate (10:1-1:2). This resulted in 7 g (43%) of tert-butyl 3-(2-(2-(2-(3-(3-hydroxyphenyl)prop-2- ynyloxy)ethoxy)ethoxy)ethoxy)propanoate as a brown oil.

Intermediate 247d: Into a 250-mL round-bottom flask, was placed a solution of tert- butyl 3-(2-(2-(2-(3-(3-hydroxyphenyl)prop-2- ynyloxy)ethoxy)ethoxy)ethoxy)propanoate (5 g, 12.25 mmol, 1.00 equiv) in methanol/dichloromethane (20/20 mL). This was followed by the addition of Palladium carbon (5 g, 47.17 mmol, 3.85 equiv) and hydrogen gas The resulting solution was stirred overnight at 35°C in an oil bath. The reaction progress was monitored by LCMS. The solids were filtered out. The resulting mixture was concentrated under vacuum. This resulted in 4.5 g (86%) of tert-butyl 3-(2-(2-(2-(3-(3- hydroxyphenyl)propoxy)ethoxy)ethoxy)ethoxy)propanoate as yellow oil.

Intermediate 247e: Into a 1000-mL round-bottom flask, was placed a solution of tert- butyl 3-(2-(2-(2-(3-(3-hydroxyphenyl)propoxy)ethoxy)ethoxy)ethoxy) propanoate (6 g, 14.53 mmol, 1.00 equiv) in dichloromethane (100 mL), triethylamine (9 g, 89.11 mmol, 6.13 equiv). This was followed by the addition of a solution of (trifluoromethane)sulfonyl trifluoromethanesulfonate (12 g, 42.54 mmol, 2.93 equiv) in d chloromethane (50 mL) dropwise with stirring at 0-5°C in 5 min. The resulting solution was stirred for 1 h at 0-5°C in a water/ice bath. The reaction progress was monitored by LCMS. The reaction was then quenched by the addition of 100 ml of water. The resulting solution was extracted with 3x100 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 4x100 mL of sodium chloride(aq). The resulting mixture was concentrated under vacuum. This resulted in 10 g (crude) of tert-butyl 3-(2-(2-(2-(3-(3- (trifluoromethylsulfonyloxy)phenyl)propoxy)ethoxy)ethoxy)eth oxy) propanoate as a brown oil.

Intermediate 247f: Into a 50-mL 3 -necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of 3- (mercaptomethyl)benzoic acid (2.5 g, 0.015 mol, 1.01 equiv) in xylene (12.5 mL), potassium carbonate (1.01 g, 0.9 mmol, 0.50 equiv). The resulting solution was stirred for 30 min at 25°C. Into another 250-mL 3-necked round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was added a solution of tert-butyl 3- (2-(2-(2-(3-(3-

(trifluoromethylsulfonyloxy)phenyl)propoxy)ethoxy)ethoxy) ethoxy)propanoate (8 g, 0.015 mol, 1.00 equiv) in xylene (40 mL), Pd ₂ (dba) ₃ (1 g), Xantphos (1 g). The resulting solution was stirred for 20 min at 25°C and then added to the above reacting solution. The resulting solution was stirred overnight at 135°C in an oil bath. The reaction progress was monitored by LCMS. The resulting mixture was concentrated under vacuum. The pH value of the solution was adjusted to 5~6 with IN hydrochloric acid. The resulting solution was extracted with 3x50 ml of ethyl acetate and the organic layers combined and concentrated under vacuum. The residue was applied onto a silica gel column with petroleum ether/ethyl acetate (10:1-1:1). This resulted in 2.6 g (28%) of 3-((3-(3-(2-(2-(2-(3-tert-butoxy-3- oxopropoxy)ethoxy)ethoxy)ethoxy)propyl)phenylthio)methyl)ben zoic acid as a brown solid.

LC-MS (ES, m/z): 561 [M-H]

H-NMR (300MHz, CDC1 ₃ , ppm): 7.965-7.940(d, J=7.5Hz,lH), 7.882(s, 1H), 7.561- 7.535(d, J=7.8Hz, 1H), 7.418-7.366(m, 1H), 7.177-7.161(d, J=4.8Hz, 2H), 7.052(s, 1H), 7.026-6.997(m, 1H), 4.117(s, 2H), 3.748-3.566(m, 15H), 3.428-3.383(t, J=6.6Hz, 2H), 2.607-2.495(m, 4H), 1.859-1.763(m, 2H), 1.454(s, 9H).

Intermediate 247g: Into a 100-mL round-bottom flask, was placed a solution of 2-(2- amino-5-(piperidin-l-yl)phenyl)-N-((S)-l,2,3,4-tetrahydronap hthalen-l- yl)isonicotinamide (909.6 mg, 2.14 mmol, 1.00 equiv) in dichloromethane (15 mL), 3- ((3-(3-(2-(2-(2-(3-tert-butoxy-3- oxopropoxy)ethoxy)ethoxy)emoxy)propyl)phenylthio)methyl)benz oic acid (1.2 g, 2.14 mmol, 1.00 equiv), EDC.HC1 (614.0 mg, 3.20 mmol, 1.50 equiv), 4- dimethylaminopyridine (390.7 mg, 3.20 mmol, 1.50 equiv). The resulting solution was stirred overnight at room temperature. The reaction progress was monitored by LCMS/TLC (petroleum ethenethyl acetate = 1:1). The resulting solution was diluted with 20 mL of NH4CI aq.. The resulting solution was extracted with 2x20 mL of dichloromethane and the organic layers combined. The resulting mixture was washed with 2x20 mL of brine. The mixture was dried over anhydrous sodium sulfate. The solids were filtered out. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column with petroleum ether/ethyl acetate (20:1-4:1). This resulted in 1.6 g (70%) of tert-butyl 3-(2-(2-(2-(3-(3-((22S)-3-((2-(4- (((S)-l,2,3,4 etrahydronaphmalen -yl)carbamoyl)pyridin-2-yl)-4-(piperidin-l- yl)phenyl)carbamoyl)benzylthio)phenyl)propoxy)ethoxy)ethoxy) ethoxy)propanoate as brown oil.

Example 247: Into a 250-mL round-bottom flask, was placed a solution of tert-butyl 3- (2-(2-(2-(3-(3-((30S)-3-((2-(4-(((S)-l,2,3,4-tetrahydronapht halen-l- yl)carbamoyl)pyridin-2-yl)-4-(piperidin- 1 - yl)phenyl)carbamoyl)benzylthio)phenyl)propoxy)ethoxy)ethoxy) ethoxy)propanoate (1.2 g, 1.24 mmol, 1.00 equiv) in dichloromethane (20 mL), trifluoroacetic acid (20 mL). The resulting solution was stirred for 2 h at room temperature. The reaction progress was monitored by LCMS. The resulting mixture was concentrated under vacuum. The pH value of the solution was adjusted to 5~6 with sat. sodium carbonate. The resulting solution was extracted with 3x10 mL of dichloromethane and the organic layers combined and concentrated under vacuum. The residue was dissolved in 20 mL of acetonitrile, 20 mL of water, 1 mL of hydrochloric acid and lyophilized. This resulted in 0.67 g (50%) of 3-(2-(2-(2-(3-(3-((30S)-3-((2-(4-(((S)-l,2,3,4- tetrahydronaphmalen-l-yl)carbamoyl)pyridin-2-yl)-4-(piperidi n-l- yl)phenyl)carbamoyl)benzylthio)phenyl)propoxy)ethoxy)ethoxy) ethoxy)propanoic acid dihydrochloride as a brown semi-solid. LC-MS (ES, m/z): 915[M-2HC1+H] ⁺ .

H-NMR (300MHz, CD ₃ OD, p/wi): 8.969-8.951(d,J=5.4Hz,lH), 8.798-8.768(m, 1H), 8.481(s, 1H), 8.296-8.287(m, 2H), 7.918-7.90 l(m, 4H), 7.867-7.837(m, 2H), 7.517- 7.469(m, 1H), 7.255-7.110(m, 6H), 7.031-7.009(m, 1H), 5.393(m, 1H), 4.250(s, 2H), 3.793-3.757(m, 4H), 3.694-3.600(m, 2H), 3.589-3.546(m, 10H), 3.490-3.460(m, 2H), 3.351-3.314(m, 2H), 2.886-2.857(m, 2H), 2.596-2.492(m, 4H), 2.128(s, 5H), 2.026- 1.999(d, 2H), 1.874(s, 3H), 1.756-1.730(m, 2H).

EXAMPLE 248

3-r2-r2-{2-rN-methyl-l-(3-{r4-(piperidin-l-ylV2-r4-» r3- ftrifluoromethyl ^' )pheriyl1methvncarbamoyl ^' )pyridin-2- vl]phenyl]carbamoyl|phenYnformamido1ethoxy)e1faoxy)ethoxy]pr opanoic acid

This compound was prepared according to the procedure described for the synthesis of Example 188 substituting 4.1e in place of 25b.

LC-MS (ES, m/z): 820 [M+H] ⁺ .

H-NMR (300MHz, CDCI ₃ , ppm): 8.976-8.959(d, 1H), 8.830-8.800(d, J=9.0Hz,lH), 8.457(s,lH), 8.161-8.095(d, 3H), 7.903-7.881(m, 1H), 7.727-7.567(m, 7H), 4.724(s, 2H), 3.826(s, 2H), 3.709-3.492(m, 16H), 3.177-3.096(m, 3H), 2.513-2.444(m, 3H), 2.059-2.043(s, 4H), 1.846-1.828(s, 2H).

EXAMPLE 249 3-r2-f2-{2-[N-methyl-l-f3-f r4-(piperidin-l-ylV2-f4-ir(lSV .3.4- tetrahvdronaphthalen-l-yl1carbamoyl pyridin-2- v phenyllcarbamoyl phenyl^fomiamidolethoxylethoxytethoxylpTopanoic acid

This compound was prepared according to the procedure described for the synthesis of Example 188 substituting 126e in place of 25b.

LC-MS (ES, m/z): 792[M-2HC1+H] ⁺

H-NMR (400MHz, CDC1 ₃ , ppm): 12.90(s, 1H), 11.725-11.778 (m, 1H) , 8.677~8.861(m, 3H), 7.888~8.222(m, 5H), 7.445~7.658(m, 2H), 7.245~7.262(m, 1H), 7.062~7.147(m, 3H), 5.412(s, 1H), 3.394~3.748(m, 18H), 2.740~3.072(m, 5H), 2.246~2.875(m, 4H), 2.043-2.104(m, 5H), 1.853~1.992(m, 3H), 1.230~1.929(m, 2H).

EXAMPLE 250

l-N-f2-{2-r2-( ^" 3-{4-r2-f2-hvdroxyethoxy ^' )ethyllrjit)erazin-l-yl)-3- oxopropoxylethoxyl ethoxy) ethylV 1 -N-methyl-3 -N-f4-( ^" piperidin- 1 - vD-2-(4- ί \( 1 SV l^ ^-tetrahvdronaphthalen-l-yllcarbamovUpyridin^-yllphenyllbenz ene-LS- dicarboxamide

This compound was prepared according to the procedure described for the synthesis of Example 231 substituting Example 249 in place of 231a. LC-MS (ES, m/z): 948 [M+H] ⁺

H-NMR (300MHz, CD ₃ OD,£pm): 8.914~8.931(m, 1H), 8.676(d, =9Hz, 1H), 8.398(s, 1H), 8.033~8.084(m, 3H), 7.851~7.872(m, 1H), 7.615~7.771(m, 3H), 7.263-7.286(m, 1H), 7.136~7.220(m, 3H), 8.369~5.410(m, 1H), 3.824(s, 4H), 3.538~3.736(m, 23H , 3.338~3.398(m, 3H), 3.090~3.171(m, 4H), 2 865~2.888(m, 2H), 2.650(s, 2H), 1.989~2.007(m, 1H), 1.795-1.922(m, 9H).

EXAMPLE 251

16-(3-(4-(diethylarninoV2-(4-(3-ftrifluoromethyl ^' )benzylcarbamoyl ^' )pyridin-2- vDphenylcarbamoyr)phenyiy4.7,l 0, 13 -tetraoxahexadecan- 1 -oic acid

Scheme 99. 1. 1. Benzyl bromide, K ₂ C0 ₃ 2. copper(I)iodide, Pd(PPh ₃ ) ₂ Cl ₂ , triethylamine, 247b 3. Pd/C, H ₂ , MeOH.

Intermediate 251a: Into a 500-mL round-bottom flask, was placed a solution of 3- iodobenzoic acid (9.92 g, 40.00 mmol, 1.00 equiv) in DMF (100 mL), 1- (bromomethyl)benzene (6.84 g, 40.00 mmol, 1.00 equiv), potassium carbonate (11.04 g, 80.00 mmol, 2.00 equiv). The resulting solution was stirred for 2 h at room temperature. The solids were filtered out and the filtrate was concentrated under vacuum. The residue was diluted with 50 mL of water and extracted with 2x50 mL of ethyl acetate. The combined organic layers were washed with 2x50 mL of sodium chloride, dried over anhydrous sodium sulfate and concentrated under vacuumto give 13.1 g (97%) of benzyl 3-iodobenzoate as light brown oil

Intermediate 251b: Into a 250-mL three-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of benzyl 3-iodobenzoate (10.7 g, 31.66 mmol, 1.00 equiv) in THF (100 mL), tert-butyl 3-(2-(2-(2-(prop-2- - ynyloxy)ethoxy)ethoxy)ethoxy)propanoate (10 g, 31.65 mmol, 1.00 equiv), copper(I) iodide (601 mg, 3.16 mmol, 0.10 equiv), Pd(PPh ₃ ) ₂ Cl ₂ (2.222 g, 3.17 mmol, 0.10 equiv), triethylamine (6.39 g, 63.27 mmol, 2.00 equiv). The resulting solution was stirred for 3 h at room temperature. The resulting mixture was concentrated under vacuum and the residue was diluted with 50 mL of water. The resulting solution was extracted with 3x50 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 3x50 mL of brine. The mixture was dried over anhydrous sodium sulfate. The solids were filtered out. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column with petroleum ether/ethyl acetate (20:1-2:1). This resulted in 10.7 g (64%) of benzyl 3-(3-(2-(2-(2-(3- tert-butoxy-3-oxopropoxy)ethoxy)ethoxy)ethoxy)prop-l-ynyl)be nzoate as brown oil.

Intermediate 251c: Into a 100-mL round-bottom flask, was placed a solution of benzyl 3 -(3 -(2-(2-(2 -(3 -tert-butoxy-3 -oxopropoxy)ethoxy)ethoxy)ethoxy)prop- 1 -yny l)benzoate (5.8 g, 11.03 mmol, 1.00 equiv) in methanol (50 mL) followed by Palladium on carbon (2.8 g). The mixture was stirred under one atmosphere of hydrogen for 24 h at 35°C. The solids were filtered out and the filtrate was concentrated under vacuum. The residue was applied onto a silica gel column with petroleum ether/ethylacetate (10:1- 1 :1). This resulted in 2.8 g (58%) of 3-(3-(2-(2-(2-(3-tert-butoxy-3- oxopropoxy)ethoxy)ethoxy)ethoxy)propyl)benzoic acid as light yellow oil. LC-MS (ES, m/z): 463 [M+Na] ⁺

H-NMR (300MHz,CDC13, ppm): 7.96 (m, 2H), 7.42(m, 2H), 3.75-3.59(m, 14H), 3.48(t, /=6.3Hz, 2H), 2.78(t, J=7.2Hz, 2H), 2.52(t, J=6.6Hz, 2H), 1.99-1.90(m, 2H), 1.45(s, 9H).

Scheme 100. 1. HATU, DIPEA, DMF; 2. TFA, DCM.

Intermediate 25 Id: ferf-butyl 16-(3-(4-(diethylamino ^' )-2-(4-(3-

(trifluoromemyl benzylcarbamoyl')pyridin-2-yl ^' )phenylcarbamoyl ^' lphenylV4.7.10.13- tetraoxahexadecan- 1 -oate. To a solution of 2-(2-amino-5-(diethylamino)phenyl)-N-(3- (trifluoromethyl)benzyl)isonicotinamide (1.77 g, 4.0 mmol), 3-(2,2-dimethyl-4-oxo- 3,7, 10,13, 16-pentaoxanonadecan-19-yl)benzoic acid (1.70 g, 3.86 mmol) and DIPEA (1.47 g, 11.4 mmol) in DMF (20 ml) was added HATU (1.56 g, 4.10 mmol). The reaction mixture was stirred for 30 minutes, at which time additional 2-(2-amino-5- (diethylartnno)phenyl)-N-(3-(1rifluoromethyl)benzyl)isonicot inamide (0.06 g, 0.14 mmol) was added. After stirring an additional 25 minutes, the reaction mixture was concentrated under vacuum. The residue was dissolved in DCM (200 mL), washed with water (4 x 50 mL), dried (Na ₂ S04) and concentrated to dryness. Purification by flash chromatography on silica gel (50% to 100% EtOAc in hexanes) gave the title compound (2.58 g) as an oil.

Example 251 TFA salt: 16-(3-(4-(diethylaminoV2-(4-G-

(trifluoromemvnbenzylcarbamoyl pyridin-2-yl)phenylcarbarnoyl ^' )phenvn-4,7,10.13- tetraoxahexadecan- 1 -oic acid. fert-Butyl 16-(3-(4-(diethylamino)-2-(4-(3-

(trifluoromemyl)berizylcarbamoyl)pyridin-2-yl)phenylcarba moyl)phenyl)-4,7,10,13- tetraoxahexadecan-l-oate (2.58 g, 2.67 mmol) was dissolved in DCM (5 mL) and TFA (5 mL) was added dropwise. The resulting solution was stirred for 20 minutes and then concentrated at reduced pressure. The residue was dissolved in 50% ACN/ water (6 mL) and freeze-dried. Toluene (10 mL) was added and the mixture concentrated under reduced pressure. ACN (100 mL) was added to the mixture, concentrated under reduced pressure and died under vacuum to give a TFA salt of the title compound (3.18 g) as an orange oil. MS (ES, m z): 809.4 [M+H] ⁺ .

Example 251 HCl salt: 16-(3-(4-(diethylaminoV2-(4-(3-

( fluoromemyllberizylcarbamovnpyridin-2-yl ^' )phenylcarbamovnphenyl ^' )-4.7.10.13- tetraoxahexadecan-l-oic acid. To ierf-butyl 16-(3-(4-(diethylamino)-2-(4-(3- (trifluoromemyl)benzylcarbamoyl)pyridin-2-yl)phenylcarbamoyl )phenyl)-4,7, 10,13- tetraoxahexadecan-l-oate (1.31 g, 1.51 mmol) was added 4N HCl in dioxane (5.68 mL, 22.7 mmol). After stirring for 1 hour, the solvent was removed under a stream of nitrogen. Dioxane (5 mL) was added and then removed under a stream of nitrogen. The residue was then dried under vacuum. The resulting oil was combined with the product of another run (0.17 mmol), dissolved in 50% ACN/water (20 mL) and freeze- dried to give a HCl salt of the title compound (1.41 g) as a light pink solid. ¾ NMR (400MHz, CD ₃ OD, ppm) δ 9.52 (m, 0.3H), 8.96 (d, J=5.3 Hz, IH), 8.79 (d, J=9.0 Hz, IH), 8.44 (s, IH), 5.15 (d, Hz, J _A c=1.6 Hz, IH), 7.80- 7.77 (m, 2H), 7.69 (d, J=2.6 Hz, IH), 7.68-7.64 (m, 2H), 7.56-7.50 (m, 2H), 7.48-7.46 (m, 2H), 4.68 (s, 2H), 3.77 (quar,

Hz, J _A c=7.4, 2H), 2.47 (t, J=6.2 Hz, 2H), 1.94-1.90 (m, 2H), 1.22 (t, J=7.2 Hz, 6H). MS (ES, m/z): 809.5 [M+H] ⁺ . Example 251 Na salt: 16-(3-(4-(diethylamino)-2-f4-f3-

(trifluoromethvnbenzylcarbamoyl)pyridin-2-yl)phenylcarbam oyl)phenvn-4JJ0,13- tetraoxahexadecan-l-oic acid. A hydrochloide salt of 16-(3-(4-(diethylamino)-2-(4-(3- (trifluoromemyl)benzylcarbamoyl)pyridin-2-yl)phenylcarbamoyl )phenyl)-4,7, 10,13- tetraoxahexadecan-l-oic acid (4.20 g, 4.76 mmol) was partitioned between EtOAc (70 mL) and water (50 mL). The pH was adjusted to 5.5 with IN NaOH (7.5 mL), the layers were separated and the aqueous layer was extracted with EtOAc (2 x 50 mL). The combined orgamc layers were washed with water (25 mL) and brine (25 mL), then dried (Na2S04 and concentrated to give the free base of the title compound as a yellow oil (3.96 g). The free base was dissolved in ACN (25 mL) and water (15 mL). IN NaOH (4.75 mL) was added and the resulting solution was freeze-dried to give the sodium salt of the title compound as a yellow powder. ¾ NMR (400MHz, CD3OD, ppm) δ 8.80 (d, .7=5.3 Hz, 1H), 8.16 (s, 1H), 8.00 (d, J=9. Hz, 1H), 7.74 (dd, JAB=5.0 Hz, J _A c=1.5 Hz, 1H), 7.69-7.65 (m, 3H), 7.61 (d, J=7.5 Hz, 1H), 7.53 (d, J=9.2 Hz, 1H), 7.50-7.48 (m, 1H), 7.39-7.37 (m, 2H), 7.07 (d, J=6.0 Hz, 1H), 6.87 (dd, AB=9.2 Hz, Ac=2.9 Hz, 1H), 4.65 (s, 2H), 3.65 (t, J=6.9 Hz, 2H), 3.62-3.52 (m, 12H), 3.50- 3.41 (m, 6H), 2.76 (t, J=7.3 Hz, 2H), 2.39 (t, J=6.8 Hz, 2H), 1.94-1.87 (m, 2H), 1.18 (t, J=7.0 Hz, 6H). MS (ES, m/z): 809.4 [M+H] ⁺ .

EXAMPLE 252

3-(2-(2-(2-(3-(3-((2-(4-(((S)-1.2.3.4-tetrahvdronaphthalen-l -yl)carbamoyl)pYridin-2- yl)-4-(piperidin- 1 - yl)phenyl carbamoyl)phenyl ^' )propoxY)ethoxy)ethoxy)ethoxy)propanoic acid

This compound was prepared according to the procedure described for the synthesis of Example 251 substituting 126e in place of 25b. Into a 50-mL round-bottom flask, was placed a solution of 3-(3-(2-(2-(2-(3-tert-butoxy-3- oxopropoxy)ethoxy)ethoxy)ethoxy)propyl)benzoic acid (1.308 g, 2.97 mmol, 1.00 equiv) in dichloromethane (15 mL), 2-(2-ammo-5-(piperidin-l-yl)phenyl)-N-((S)- l,2,3,4-tetrahydronaphthalen-l-yl)isonicotinamide (1.26 g, 2.96 mmol, 0.99 equiv), EDC.HG1 (854.8 mg, 4.46 mmol, 1.50 equiv), 4-dlmethylaminopyridine (544 mg, 4.46 mmol, 1.50 equiv). The resulting solution was stirred overnight at room temperature. The reaction progress was monitored by LCMS TLC (DCM:MeOH = 10:1). The resulting mixture was washed with 2x20 mL of NH4CI aq. The resulting mixture was washed with 2x20 mL of Brine. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1 :10-1 :1). This resulted in 2.0 g (79%) of tert-butyl 3-(2-(2-(2-(3-(3-((2-(4-(((S)- 1,2,3 ,4-tetrahy dronaphthalen- 1 -yl)carbamoyl)pyridin-2-yl)-4-(piperidin- 1 - yl)phenyl)carbamoyl)phenyl)propoxy)ethoxy)ethoxy)ethoxy)prop anoate as yellow oil.

Example 252: Into a 100-mL round-bottom flask was placed a solution of tert-butyl 3- (2-(2-(2 3-(3-((2-(4-(((S)-l,2,3,4-tetrahydronaphthalen-l-yl)carbamoy l)pyridin-2-yl)- 4-( iperidin-l-yl)phenyl)carbamoyl)phenyl)propoxy)ethoxy)ethoxy) ethoxy)propanoate (2.3 g, 2.71 mmol, 1.00 equiv) in dichloromethane (20 mL), trifluoroacetic acid (20 mL). The resulting solution was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 20 mL of dichloromethane. The gas of HCl was introduced in. The mixture was stirred for 0.5 h, then concentrated under vacuum. This resulted in 1.60 g (68%) of 3-(2-(2-(2-(3-(3- ((2-(4-(((S)- 1 ,2,3,4-tetrahydronaphthalen- 1 -yl)carbamoyl)pyridin-2-yI)-4-(piperidin- 1 - yl)phenyl)carbamoyl)phenyl)propoxy)ethoxy)ethoxy)ethoxy)prop anoic acid (HCl salt) as a yellow solid.

LC-MS (ES, mJz): 793 [M-2HC1+H] ⁺

H-NM (300MHz, CD30D, ppm): 9.03 (d, J=5.7Hz, 1H), 8.58(s, 1H), 8.35(s, 1H), 8.12(m, 1H), 8.08(m, 2H), 7.70 (m, 2H), 7.46 (m,2H), 7.15(m,4H), 5.33(t, =6.0Hz, 1H), 3.80-3.47(m, 20H), 2.81-2.76 (m, 4H), 2.56-2.52 (t, J^6.0Hz, 2H), 2.16(m, 5H), 1.94-1.87(m, 7H).

EXAMPLE 253

Example A.2 (S)-l 6-(3-(4-(chloro)-2-(4-( 1.2.3.4-tetrahvdronaphthalen-l - ylcarbamoyl pyridin-2-yl)phenylcarbamoyl)phenyl)-4.7.10.13 -tetraoxahexadecan- 1-oic acid

Scheme 101. 1. HATU, DIPEA, DMAP, DMF, 65°C; 2. TFA, DCM.

(S)-tert-butyl 16-(3-(4-chloro-2-(4-(l,2,3,4-tetrahydronaphthalen-l- ylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)phenyl)-4,7, 10, 13 -tetraoxahexadecan- 1 - oate. To a solution of (S)-2-(2-amino-5-chlorophenyl)-N-(l,2,3,4-tetrahydronaphthal en- l-yl)isonicotinamide 237b (1.02 g, 2.7 mmol), 3-(2,2-dimethyl-4-oxo-3,7,10,13,16- pentaoxanonadecan-19-yl)benzoic acid 251c (1.19 g, 2.7 mmol), DIPEA (1.04 g, 8.1 mmol) and DMAP (190 mg, 1.55 mmol) in DMF (20 ml) was added HATU (1.13 g, 2.97 mmol). The reaction mixture was heated at 65°C for 24 hours, then cooled and concentrated. The residue was combined with another run (0.28 mmol scale), dissolved in DCM (150 mL), washed with water (4 x 50 mL), dried and concentrated to dryness. Purification by flash chromatography on silica gel (10% to 30% EtOAc in DCM) gave the title compound (1.44 g).

(S)-16-(3-(4-(chloro)-2-(4-(l,2,3,4 etrahyaronaphthalen-l-ylcarbamoyl)pyridin-2- yl)phenylcarbamoyl)phenyl)-4,7,10,13-tetraoxahexadecan-l-oic acid. Following the procedures described in Example 251, using (S)-tert-butyl 16-(3-(4-chloro-2-(4- (l,2,3,4 etrahydronaphthalen-l-ylcarbamoyl)pyridin-2-yl)phenylcarbamo yl)phenyl)- 4,7,10,13-tetraoxahexadecan-l-oate gave a HC1 salt of the title compound. MS (ES, m/z): 744.2 [M+H] ⁺ .

EXAMPLE 254

2-(2-(3-((S)-3-(2-methoxyethylcarbamoyl)DiDeridine-l-carbony l)benzamido -5-

(piperidin-l-v phenylVN-((SV1.23.4-tetrahvdronaphthalen-l-yl ^' )isonicotinarnide

This compound was prepared using the method described for the preparation of Example 4.14 using (S)-3-(4-(piperidin-l-yl)-2-(4-(l ,2,3,4-tetrahydronaphthalen-l- ylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)benzoic acid 126g in place of 4.1e. Purification by reverse-phase HPLC eluting with a water/ACN gradient containing 0.1% TFA gave a TFA salt of the title compound. MS (ES, m/z): 743.7 [M+H] ⁺ .

EXAMPLE 255

2-(2-r3-((S)-3-(2,5.8.11.14.17.20-heptaoxadocosan-22-yl(meth yl1carbamoyl)DiDeridine- 1 -carbonyl)benzamido)-5-(Diperidin- 1 - ypphenyll-N-ff S 1.2.3.4-tetrahvdronaphthalen-

1 -yPisonicotinamide

This compound was prepared using the method described for the preparation of Example 4.14 using (S)-3 4-( iperidin-l-yl)-2-(4-(l,2,3,4-tetrahydronaphthalen-l- ylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)benzoic acid 126g in place of 4.1e and N- methyl-2,5,8,l l,14,17,20-heptaoxadocosan-22-amine 135c.l in place of 2- methoxyethanamine. Purification by reverse-phase HPLC eluting with a water/ ACN gradient containing 0.1% TFA gave a TFA salt of the title compound. MS (ES, m/z): 1021.5 [M+H] ⁺ .

EXAMPLE 256

2-(2-(3-((SV3 -(2,5.8.11.14,17,20-heptaoxadocosan-22-ylcarbamoyl1piperidin e- 1 - carbonyl)benzamidoV5-(piperidin-l-yl)phen^

vDisonicotinamide

This compound was prepared using the method described for the preparation of Example 4.14 using (S)-3-(4-(piperidin-l-yl)-2-(4-(l,2,3,4-tetrahydronaphthalen -l- ylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)benzoic acid 126g in place of 4.1e and 2,5,8,11,14, 17,20-heptaoxadocosan-22-amine 135c.6 in place of 2-methoxyethanamine. Purification by reverse-phase HPLC eluting with a water/ACN gradient containing 0.1% TFA gave a TFA salt of the title compound. MS (ES, m/z): 1007.5 [M+H] ⁺ .

EXAMPLE 257

(Sy2-(2-(3-(16-(3-(2,5.8.11.14.17.20-heptaoxadocosan-22- yltoemvDcarbamovDpiperidin- 1 -vD-16-oxo-4.7.10, 1 S-tetraoxahexadecyllbenzamidol- 5-(diethylamino)phenyl)-N-(3-(trifluoromethyl ^' )benzyl')isonicotinamide

Scheme 102. 1. HATU, DIPEA, 135c.l, DMF; 2. TFA, DCM 3. HATU, DIPEA, 257b, DMF.

Intermediate 257a: To a solution of Boc-(S)-nipecotic acid (137 mg, 0.60 mmol), N- methyl-2,5,8,ll,14,17,20-heptaoxadocosan-22-amine 135c.l (310 mg, 0.88 mmol) and DIPEA (335 mg, 2.6 mmol) in DMF (3 mL) was added HATU (285 mg, 0.75 mmol). The reaction was stirred for 1 hour and then the DMF was removed under vacuum. The residue was added to saturated aqueous NaHC0 ₃ (10 mL) and extracted with DCM (3 x 20 mL). The combined organic layers were dried (Na2S04) and concentrated to give (S)-tert-butyl 3-(2,5,8,l l,14,17,20-heptaoxadocosan-22- yl(methyl)carbamoyl)piperidine-l-carboxylate (720 mg).

Intermediate 257b: Trifluoroacetic acid (2 mL) was added to a solution of (S)-tert-butyl 3-(2,5,8, 11 , 14, 17,20-heptaoxadocosan-22-yl(methyl)carbamoyl)piperidine- 1 - carboxylate (720 mg) in DCM (2 mL) and stirred at RT for 30 minutes. The solvents were removed under vacuum to give a TFA salt of (S)-N-(2,5,8,l 1,14,17,20- heptaoxadocosan-22-yl)-N-methylpiperidine-3-carboxamide (760 mg).

Example 257: (SV2-(2-(3-(16-(3-(2,5.8.11.14.17,20-heptaoxadocosan-22- yl( ^' memyl ^" )carbamoyl ^' )piperidin-l-yl ^' )-16-oxo-4.7.10.13-tetraoxahexadecyl)benzamidoV S-Cdiethylamino^phenvn-N-n-ftrifluoromethylftenzvDisonicotin amide. To a solution of 16-(3-(4-(diethylarmno)-2-(4-(3-(trifluoromethyl)benzylcarba moyl)pyridin-2- yl)phenylcarbamoyl)phenyl)-4,7,10,13-tetraoxahexadecan-l-oic acid Example 251 in place of 4.1e and 2,5,8,1 l,14,17,20-heptaoxadocosan-22-amine in place of 2- methoxyethanamine. To a solution of 16-(3-(4-(diethylamino)-2-(4-(3- (trifluoromethyl)benzylcarbamoyl)pyridin-2-yl)phenylcarbamoy l)phenyl)-4,7,10,13- tetraoxahexadecan-l-oic acid (50 mg, 0.062 mmol), intermediate 257b(50 mg, 0.086 mmol) and DIPEA (31 uL, 0.18 mmol) in DMF (1.0 mL) was added HATU (27 mg, 0.070 mmol). The reaction was stirred for 90 minutes and then the DMF was removed under vacuum. Purification by reverse-phase HPLC eluting with a water/ ACN gradient containing 0.1% TFA gave a TFA salt of the title compound (65 mg). MS (ES, m/z): 1255.5 [M+H] ⁺ .

EXAMPLE 258

2-(2-(3-(16-(-4-(2.5.8.11,14,17,20-heptaoxadocosan-22-yl ^' )-3-oxopiperazin-l-vn-16- oxo-4.7.10, 1 S-tetiaoxahexadecvDbenzarmdoVS-t ^' diethylamino ^' tphenvn-N-n-

(trifluoromethvDbenzv isonicot amide

This compound was prepared using the same method described for the preparation of Example 257 using a TFA salt of 1-(2,5,8,1 l,14,17,20-heptaoxadocosan-22- yl)piperazin-2-one 135c.5 in place of intermediate 257b . Ή NMR (400MHz, CD3OD, ppm) δ 9.44 (t, J=6.0 Hz, 0.4 H), 8.92 (d, .7=5.0 Hz, 1H), 8.74 (d, J=8.6 Hz, 1H), 8.39 (s, 1H), 7.99 (br s, 1H), 7.87 (dd, ,7AB=5.1 HZ, J _A c=1.2 HZ, lH), 7.80-7.76 (m, 2H), 7.69 (s, 1H), 7.64 (d, .7=7.6 Hz, 1H), 7.58-7.50 (m, 3H), 7.46 (d, .7=5.0 Hz), 4.68 (s, 2H), 4.18 (s, 0.8 H), 4.09 (s, 1.2 H), 3.76-3.66 (m, 8H), 3.63-3.45 (m, 44H), 3.31 (s, 3H), 2.80 (t (J=7.4 Hz, 2H), 2.64-2.54 (m, 2H), 1.95-1.87 (m, 2H), 1.20 (t, .7=7.2 Hz, 6H). MS (ES, m/z): 1213.5 [M+H] ⁺ .

EXAMPLE 259

2-r5-fdiethylamino)-2-(3-C23-methyl-24-oxo-2.5.8.11.14.17.20 .27.30.33,36-iindecaoxa-

23 -azanonatriacontan-39-vDbenzamido)phenyl ^' )-N-(3 -

(trifluoromethvnbenzyltisonicotinamide

This compound was prepared using the same method described for the preparation of Example 257 using a N-methyl-2,5,8,l l,14,17,20-heptaoxadocosan-22-amine 135c.1 in place of a TFA salt of (S)-N-(2,5,8,l l,14,17,20-heptaoxadocosan-22-yl)-N- methylpiperidine-3-carboxamide. MS (ES, m/z): 1144.4 [M+H] ⁺ .

EXAMPLE 260 2-f5-(diethylaminoV2-(3-('24-oxo-2.5.8.11.14.17.20.27.30.33. 36-undecaoxa-23- azanonatriacontan-3 g-yDbenzamido^phenylVN-O - ftrifluoromethvDbenzvDisom^otinamide

This compound was prepared using the same method described for the preparation of Example 257 using 2,5,8,1 l,14,17,20-heptaoxadocosan-22-amine 135c.6 in place of a TFA salt of (S)-N-(2 _> 5,8,ll,14,17,20-heptaoxadocosan-22-yl)-N-methylpiperid ine-3- carboxamide. MS (ES, m/z): 1130.5 [M+H] ⁺ .

EXAMPLE 261

fSV2-r2-(3-(2,5,8,l l,14,17.20.23.26-nonaoxanonacosan-29-yl ^, )benzamido'l-5- (diemylammo^phenvn-N-fl^.S^-tetrahvtonaphthalen-l-yl ^' lisonicotinamide

Scheme 103. 1. Na, THF 2. copper(I)iodide, Pd(PPh ₃ ) ₂ Cl ₂ , triethylamine 3. Pd/C, H ₂ , MeOH. Intermediate 261a: Into a 500-mL round-bottom flask, was placed a solution of 2-(2-(2- (2-(2-(2-(2-(2-methoxyemoxy)ethoxy)ethoxy)ethoxy)elhoxy)etho xy)e1hoxy)ethanol (15 g, 39.06 mmol, 1.00 equiv) in tetrahydrofuran (150 inL). This was followed by the addition of sodium hydride (1.9 g, 79.17 mmol, 1.01 equiv), in portions at 0-5°C in 5 min. To this was added a solution of 3-bromoprop-l-yne (9.3 g, 78.81 mmol, 2.02 equiv) in toluene (20 mL) dropwise with stirring at 0-5°C in 5 min. The resulting solution was stirred for 1 h at 0-5°C in a water/ice bath. The reaction progress was monitored by LCMS TLC (ethyl acetate/petroleum ether = 1 :1). The solids were filtered out. The resulting mixture was concentrated under vacuum. This resulted in 15.9 g (96%) of 3-(2-(2-(2-(2-(2-(2-(2-(2- methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)etho xy)prop- 1 -yne as brown oil

Intermediate 261b: Into a 250-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of 3-(2-(2-(2-(2-(2-(2-(2-(2- methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)etho xy)prop- 1 -yne (12.7 g, 30.09 mmol, 1.00 equiv) in tetrahydrofuran (150 mL), benzyl 3-iodobenzoate (15.9 g, 47.04 mmol, 1.56 equiv), Cul (720 mg, 3.79 mmol, 0.13 equiv), Pd(PPh ₃ ) ₂ Cl ₂ (2.65 g, 3.77 mmol, 0.13 equiv), triethylamine (7.6 g, 75.25 mmol, 2.50 equiv). The resulting solution was stirred for 2 h at room temperature. The reaction progress was monitored by LCMS/TLC (ethyl acetate/petroleum ether = 4:1). The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 200 mL of water. The resulting solution was extracted with 3x150 of ethyl acetate and the organic layers combined. The resulting mixture was washed with 3x100 mL of sodium chloride(aq). The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1 :2- ethyl acetate). This resulted in 12.8 g (65%) of benzyl 3-(3-(2-(2-(2-(2-(2-(2-(2-(2- memoxyemoxy)emoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy) prop-l- ynyl)benzoate as brown oil. Intermediate 261c: Into a 1000-mL round-bottom flask, was placed a solution of benzyl 3-(3-(2-(2-(2-(2-(2-(2-(2-(2- methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)etho xy)prop-l- ynyl)benzoate (23 g, 36.39 mmol, 1.00 equiv) in methanol (200 mL), Palladium carbon (20 g). Hydrogen gas was introduced to the reaction vessel The resulting solution was stirred overnight at room temperature. The reaction progress was monitored by LCMS/TLC (ethyl acetate/petroleum ether = 4:1). The solids were filtered out. The resulting mixture was concentrated under vacuum. This resulted in 17.2 g (80%) of 3- (3-(2-(2-(2-(2-(2-(2-(2-(2- methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)etho xy)propyl)benzoic acid as brown oil.

LC-MS

(ES, m/z): 547[M+H] ⁺ .

H-NMR (300MHz, CDC1 ₃ , pprri): 7.948-7.920(m, 2H), 7.425-7.280(m, 2H), 5.763(s, 2H), 3.673-3.390(m, 38H), 2.801-2.750(t, J=7.8Hz, 2H), 1.985-1.893(m, 2H)

Scheme 104. 1. A) (COCl) ₂ , DMF, DCM b) 4. 131c TEA, DCM. Example 261: (SV2-(2-(3-(2.5.8.11.14,17.20.23,26-nonaoxanonacosan-29- vnbenzamidoVS-( ^' diethylamino pheriyl -N-(1.2 ^-tetrahvdronaphmalen-l- vDisonicotinarnide: To a solution of 261c (10.9g, 20.0mmol, 1.5eq) in DCM (lOOmL) under N ₂ was added oxalyl dichloride (3.04g, 23.9mmol, 1.8eq) and DMF (catalytic). After 1 hour, the solvent was removed and the crude acid chloride dissolved in dry DCM (30mL). The resulting solution was added dropwise to a solution of 131c (5.5g, 13.3mmol, leq) and TEA (5.4g, 53.2mmol, 4eq) in dry DCM (66mL) at 0°C. The reaction mixture was allowed to come to room temperature under an atmosphere of N2. After 1 hour, the resulting solution was diluted with DCM (40mL), washed with water (3x75mL) and brine, and dried over Na ₂ S0 to give 10.4g of (S)-2-(2-(3- (2,5 ,8, 11 , 14, 17,20,23 ,26-nonaoxanonacosan-29-yl)benzamido)-5- (diethylamino)phenyl)-N-(l ,2,3 ,4-tetrahydronaphthalen- 1 -yl)isomcotinamide (98% purity) as a yellow oil. MS (ES, m/z) 943.5 [M+H] ⁺ ; ¾ NMR (400 MHz, d ₆ DMSO) δ 11.57 (s, 1H), 9.13 (d, J= 8.6 Hz, 1H), 8.85 (d, J= 5.1 Hz, 1H), 8.21 (s, 1H), 8.04 (d, J= 9.0 Hz, 1H), 7.81 (dd, J= 5.1, 1.5 Hz, 1H), 7.70 - 7.63 (m, 2H), 7.46 - 7.37 (m, 2H), 7.22 - 7.02 (m, 5H), 6.85 (dd, J= 9.1, 2.9 Hz, 1H), 5.28 - 5.19 (m, 1H), 3.55 - 3.45 (m, 32H), 3.44 - 3.35 (m, 8H), 3.31 (s, 3H), 3.22 (s, 3H), 2.81 - 2.74 (m, 2H), 2.74 - 2.66 (m, 2H), 2.04 - 1.91 (m, 2H), 1.88 - 1.71 (m, 4H), 1.12 (t, J= 7.0 Hz, 6H).

EXAMPLE 262

2-(2-(3-(l 6-(4-(3-(2.5.8.11.14.17.20.23 ,26-nonaoxanonacosan-29-yDberizoyl)piperazin- 1 -ylV 16-0X0-4,7.10.13 etraoxahexadecvDbenzamidoV5-(diethylamino ^' lphenyl ^' )-N-(3- (trifluoromethynbenzyl sonicotinamide

Scheme 105. 1. fert-butyl piperazine-l-carboxylate, HATU, DIPEA, DMF; 2. TFA, DCM; 3. 261c HATU, DIPEA, DMF.

Intermediate 262b: 2-(5-(diemylamino)-2-(3-(16-oxo-16-(piperazm^^ tetraoxahexadecyl benzamido)phenyl)-N-Q-(1rifluoromemvnbenzvDisomcotinamide, To a mixture of 16-(3-(4-(diethylamino)-2-(4-(3-

(trifluoromethyl)benzylcarbamoyl)pyridin-2-yl)phenylcarba moyl)phenyl)-4,7, 10,13- tetraoxahexadecan-l-oic acid (292 mg, 0.36 mmol), fert-butyl piperazine-l-carboxylate (75 mg, 0.40 mmol) and DIPEA (142 mg, Ί.1 mmol) in DMF (3 mL) was added HATU (160 mg, 0.42 mmol). After 30 minutes, the solvent was removed under vacuum and the residue was dissolved in DCM (50 mL). This was washed with water (4 x 25 mL), dried and concentrated. The resulting oil was dissolved in DCM (2 mL) and TFA (2 mL) was added dropwise. After 30 minutes, the solvents were removed under vacuum. The residue was dissolved in 50% ACN/water (30 mL) and freeze dried to give the title compound (560 mg) as a TFA salt.

Example 262 2-(2-(3-( 16-(4-f3-(2.5.8.11.14.17.20.23„26-nonaoxanonacosan-29- vDbenzovDpiperazin-l -yl)- 16-oxo-4.7.10.13-tetraoxahexadecyl)benzamido)-5- (diethylamino phenyl)-N-0-(trifluoromemyl benzyl)isonicotinamide. To a solution of a TFA salt of 2-(5-(diethylamino)-2-(3-(16-oxo-16-(piperazin-l-yl)-4,7,10, 13- tetraoxahexadecyl)benzamido)phenyl)-N-(3-(trifluoromethyl)be nzyl)isonicotinamide (50 mg, 0.041 mmol), 3-(2,5,8,l l,14,17 _> 20,23,26-nonaoxanonacosan-29-yl)benzoic acid 261c (22 mg, 0.041 mmol) and DIPEA (26 mg, 0.20 mmol) in DMF (1.0 mL)was added HATU (27 mg, 0.070 mmol). The reaction was stirred for 90 minutes and then the DMF was removed under vacuum. Purification by reverse-phase HPLC eluting with a water/ ACN gradient containing 0.1% TFA gave a TFA salt of the title compound (33 mg). MS (ES, m/z): 1405.6 [M+H] ⁺ .

EXAMPLE 263

2-r5^diethylaminoV2-r3-(16-C4-(4-(2-(2-r2- methoxyethoxy ^' )ethoxy ^' )ethoxy)phenyl)piperazin-l -yl)- 16-oxo-4.7.10.13- tetraoxahexadecyl)berizamido phenyl)-N-(3-(trifluoromethyl)benzyl)isonicotinamide

Scheme 106. 1. 4-(piperazin-l-yl)phenol, HATU, DIPEA, DMF; 2. 2-(2-(2- methoxyethoxy)ethoxy)ethyl 4-methylbenzenesulfonate, K2CO3, DMF.

Intermediate 263a: 2-(5-(diethylamino)-2-(3-(16-(4-(4-hydroxyphenyl ^' )pir)erazin-l-ylV ^-oxo^JJO.lS-tetraoxahexadecv benzamidotphenylVN-O-

(trifluoromethvnbenzyllisonicotinamide. To a solution of 16-(3-(4-(diethylamino)-2- (4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2-yl)phenylca rbamoyl)phenyl)- 4,7,10,13-tetraoxahexadecan-l-oic acid (300 mg, 0.37 mmol), 4-(piperazin-l-yl)phenol (71 mg, 0.40 mmol) and DIPEA (142 mg, 1.1 mmol) in DMF (3 mL) was added HATU (160 mg, 0.42 mmol). After 30 minutes, the solvent was removed under vacuum and the residue was dissolved in DCM (50 mL). This was washed with water (4 x 25 mL), dried (Na ₂ SO,i) and concentrated to give the title compound (379 mg).

Example 263: 2-(5-(diethylamino)-2-(3-(16-(4-(4-(2-(2-(2- methoxyethoxy)ethoxy)ethoxy)phenyl)piperazin-l -ylV 16-0X0-4.7.10.13- tetraoxahexadecyl)benzamido phenyl)-N-(3-(trifluoromethyl benzvnisonicotinamide. Finely ground K2CO3 (54 mg, 039 mmol) was added to a solution of 2-(5- (diethylamino)-2-(3 -(16-(4-(4-hydroxypheny l)piperazin- 1 -yl)- 16-oxo-4,7, 10,13- tetraoxahexadecyl)benzamido)phenyl)-N-(3-(1iifluoromemyl)ben zyl)isonicotinamide (125 mg, 0.13 mmol) and 2-(2-(2-methoxyethoxy)ethoxy)ethyl 4- methylbenzenesulfonate (50 mg, 0.16 mmol) in DMF (0.30 mL), and was heated at 70°C for 3 hours with stirring. The reaction mixture was cooled to room temperature and another portion of 2-(2-(2-methoxyethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (75 mg, 0.34 mmol) was added. The mixture was stirred for 3 days at room temperature and then 5 hours at 70°C. Water (10 mL) was added to the cooled reaction mixture and extracted with DCM (3 x 10 mL). The combined organic layers were dried (Na ₂ SC> ₄ ) and concentrated. Purification by reverse-phase HPLC eluting with a water/ACN gradient containing 0.1% TFA gave a TFA salt of the title compound (80 mg). 'H NMR (400MHz, CD3OD, ppm) δ 9.44 (t, J=5.0 Hz, 0.6 H), 8.93 (dd, _Β =5.3 Hz, J _A c=0.6 HZ, IH), 8.84 (d, J=9.0 Hz, IH), 8.40 (s, IH), 8.09 (d, .7=2.5 Hz, IH), 7.88 (dd, HZ, lH), 7.80 (m, 2H), 7.69 (s, 1H), 7.65-7.52 (m, 4H), 7.47 (dd, Hz, 2H), 6.88 (d, J=9.2 Hz), 4.69 (d, .7=4.3 Hz 2H), 4.04 (m, 2H), 3.78-3.68 (m, 12H), 3.66-3.63 (m, 2H), 3.62-3.52 (m, 16H), 3.51-3.45 (m, 4H), 3.31 (s, 3H), 3.22 (t, .7=4.1 Hz, 2H), 3.16 (t, J=4.1 Hz, 2H), 2.80 (t, .7=7.4 Hz, 2H), 2.64 (t, 7=6.3 Hz, 2H), 1.91 (m, 2H), 1.20 (t, J=7.1 Hz, 6H). MS (ES, m/z): 1115.4 [M+H] ⁺ .

EXAMPLE 264

l-(3-(3-(4-chloro-2-(4-( ^" 3-(trifluoromethyl)benzylcarbamoyl)pyridin-2- yl)phenylcarbamoyl)benzylthio)phenyl - 1 -oxo-5 ,8 , 11 -trioxa-2-azatetradecan- 14-oic acid

This compound was prepared using the method described for the preparation of Example 10.1 using 3-(3-(4-cMoro-2-(4-(3-(trifluoromemyl)benzylcarbamoyl)pyridi n- 2-yl)phenylcarbamoyl)benzylthio)benzoic acid (Example 8.25) in place of 3-(3-(4- ( iperidin-l-yl)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl)pyri diri-2- yl)phenylcarbamoyl)benzylthio)benzoic acid (8.1) to give a TFA salt of the title compound. MS (ES, m/z): 879.3 [M+H] ⁺ .

EXAMPLE 265

2-Q-f3-(2.5.8.11J4.17.20.23-octaoxa-26-thiaheptacosan-27-vnb enzamido ^' )-5- (diethylamino)phenyl)-N-C3-(trifluoromethyl benzyl)isonicotinamide

Scheme 107. 1. MeONa, DMF.

Example 265: 2-(2-(3-(2,5,8.11.14.17.20,23-octaoxa-26-l aheptacosan-27- vDbenzamidoy5- iiemylamino)phenyl)-N-(3-(ta

To a solution of 2-(2-(3-(chloromethyl)benzamido)-5-(diethylamino)phenyl)-N-( 3- (trifluoromethyl)benzyl)isonicotinamide 143a (715 mg, 1.2 mmol) and S- 2,5,8,1 l,14,17,20,23-octaoxapentacosan-25-yl ethanethioate 135c.3 (590 mg, 1.33 mmol) in DMF (10 mL) was added 4.3 M NaOMe in MeOH (0.37 mL, 1.6 mmol) and stirred at room temperature for 15 minutes. The reaction mixture was added to water (35 mL) and extracted with DCM (3 x 50 mL). The combined organic layers were washed with water (25 mL), dried (Na2S04) and concentrated at reduced pressure. The residue was purified by flash chromatography on silica gel (1% to 5% MeOH in DCM). The purified product was dissolved in 50% ACN/water and TFA (410 mg, 3.6 mmol) was added. Lyophylization gave a TFA salt of the title compound (1.34 g) as a light yellow oil. MS (ES, m/z): 959.4 [M+H] ⁺ .

EXAMPLE 266

2-C5 -Cdiethylamino)-2-(3 -(1 -hydrox v-3.6.9.12-tetraoxapentadec- 14- vn- 15 - yl)benzamido)phenYlVN-f3-(ttifluoromethvDbenzyl ^' )isonicotinamide

Scheme 108. 1. NaH, propargyl bromide, THF; 2. 3-Iodobenzoic acid, HATU, DIPEA, DMF; 3., Pd(PPh ₃ ) ₂ Cl ₂ , Cul, Et ₃ N, THF.

Intermediate 266a.O: To a suspension of sodium hydride (60% in oil, 740 mg, 18.5 mmol) in THF (50 mL) at 0°C was added tetraethylene glycol (4.0 g, 20.6 mmol). After stirring for 15 minutes, propargyl bromide (80% in toluene, 2.00 mL, 18.0 mmol) was added slowly. The reaction was allowed to warm to RT and stirred 16 hours. Solids were removed by filtration and rinsed with MTBE (3 x 20 mL). The combined filtrates were concentrated and purified by flash chromatography on silica gel (EtOAc) to give 3,6,9,12-tetraoxapentadec-14-yn-l-ol (2.14 g).

Intermediate 266a: 2-(5-(diethylamino)-2-(3-iodobenzamido)phenyl)-N-(3-

(trifluoromethvDbenzvDisonicotinamide. To a solution of 2-(2-amino-5- (diemylamino)phenyl)-N-(3-(trifluoromemyl)benzyl)isonicotina mide (440 mg, 1.0 mmol), 3-iodobenzoic acid (248 mg, 1.0 mmol) and DIPEA (387 mg, 3.0 mmol) in DMF (5 mL) was added HATU (418 mg, 1.1 mmol). After one hour, the reaction mixture was added to EtOAc (150 mL) washed with water (5 x 50 mL) and saturated aqueous NaCl (25 mL), dried (Na ₂ S0 ) and concentrated. The residue was triturated with DCM (3 mL) to give a solid (718 mg) which was dried under vacuum.

Example 266: 2-(5-(diethylaminoV2-(3-(l-hydroxy-3.6.9.12-tetraoxapentadec -14-vn- 15-yl)ben2amido)phenylVN-(3-(trifluoromethyl ^' )benzyl ^' )isonicotinamide. To a slurry of 2-(5 -(diethy lamino)-2-(3 -iodobenzamido)phenyl)-N-(3 -

(trifluoromethyl)benzyl)isonicotinamide (385 mg, 0.57 mmol), 3,6,9,12- tetraoxapentadec-14-yn-l-ol (175 mg, 0.75 mmol), Et3N (3mL) and THF (2 mL) was added bis(triphenylphosphine)palladium(II)dichloride (12 mg, 0.017 mmol) and Cul (10 mg, 0.053 mmol) and purged well with nitrogen. The reaction mixture was stirred for 13 hours, then concentrated under vacuum and combined with the crude product from another run (0.15 mmol scale). Purification by flash chromatography on silica gel eluting (1% to 5% MeOH in DCM) gave the title compound (349 mg). Ή NMR (400MHz, CDCI3, ppm) 512.51 (s, IH), 8.83 (d, 7=5.3 Hz, IH), 8.42 (d, 7=9.0 Hz, IH), 8.21 (s, IH), 7.99 (t, 7=1.6 Hz, IH), 7.94 (d, .7=8.0 Hz, IH), 7.75-7.68 (m, 2H), 7.65 (s, IH), 7.60 (d, 7=7.3 Hz, 1Η),7.58-7.54 (m, 2H), 7.48 (t, 7=7.6 Hz, IH), 7.42 (t, 7=7.9 Hz, IH), 6.98 (d, 7=2.6 Hz, IH), 6.76 (d, 7=8.8 Hz, IH), 4.76 (d, 7=5.9 Hz, 2H), 4.48 (s, 2H), 3.82-3.80 (m, 2H), 3.72-3.70 (m, 2H), 3.67-3.63 (m, 4H), 3.60 (s, 4H), 3.53- 3.51 (m, 2H), 3.32 (quar, 7=7.2 Hz, 4H), 2.90 (s, IH), 1.13 (t, 7=6.8 Hz, 6H). MS (ES, m/z): 777.4 [M+H] ⁺ .

EXAMPLE 267

2-(5-(diethylamino ^' )-2-(3-(l-hvdroxy-3.6.9.12-tetraoxapentadecan-15- yl)berizamido phenylVN-(3-(trifluoromethvDbenzyl ^" )isonicotinamide

Scheme 109a. l. H ₂ , Pd/C.

Example 267: 2-(5-(diethylaminoV2-(3-(l-hydroxy-3,6,9.12-tetraoxapentadec an-15- vnbenzamido)phenylVN-( ^' 3-( ^' trifluQromethyl)benzyl ^' )isonicotinamide. A mixture of 2- (5-(diethylamino)-2-(3-(l-hydroxy-3,6,9,12-tetraoxapentadec- 14-yn-15- yl)berizamido)phenyl)-N-(3-(trifluoromethyl)benzyl)isonicoti namide (107 mg, 0.014 mmol) and 10% palladium on carbon (water content 50%, 40 mg) in methanol (3 mL) was stirred under one atmosphere of ¾ for 1 hour. The mixture was filtered and concentrated under vacuum to give the title compound (92 mg). Ή NMR (400MHz, CDCla, ppm) 612.13 (s, 1H), 8.81 (d, =5.2 Hz, 1H), 8.39 ,1=9.0 Hz, 1H), 8.15 (s, 1H), 7.78 (d, HZ, IH), 7.64 (s, 1H), 7.63-7.54 (m, 3H), 7.47 (t, J=7.5 Hz, IH), 7.37 (t, .7=7.6 Hz, IH), 7.32 (d, J=7.9 Hz, IH), 6.95 (d,

Hz, 2H), 3.66-3.56 (m, 14H), 3.53-3.51 (m, 2H), 3.48 (t, .7=6.5 Hz, 2H), 3.32 (quar, J=7.0 Hz, 4H), 2.96 (br s, IH), 2.77 (t, J=7.2 Hz, 2H), 1.98-1.91 (m, 2H), 1.13 (t, J=6.9 Hz, 6H). MS (ES, m/z): 781.4 [M+H] ⁺ .

EXAMPLE 268

2-(2-(3-(2.5.8.11.14.17.20.23.26-nonaoxanonacos-28-vn-29-yl) benzamidoV5- (diethylamino)phenylVN-(3-(lTifluoromethyl)benzyl)isonicotin amide

Example 268: This compound was prepared using the method described for the preparation of Example 266 using 2,5,8,1 l,14,17,20,23,26-nonaoxanonacos-28-yne 261a in place of 3,6,9,12-tetraoxapentadec-14-yn-l-ol. Purification by flash chromatography on silica gel (1% to 4% MeOH in DCM) gave the title compound. ¾ NMR (400MHz, CDC1 ₃ , ppm) £12.57 (s, IH), 8.82 (d, 7=5.3 Hz, IH), 8.41 (d, ,7=9.0 Hz, IH), 8.22 (s, IH), 7.99 (t, 7=1.5 Hz, IH), 7.93 (dt, 7AB=8.3 HZ, J _A C=1-8 Hz, IH), 7.75-7.80 (m, 2H), 7.66 (s, IH), 7.62 (d, 7=8.3 Hz, IH), 7.57-7.54 (m, 2H), 7.49 (d, 7=7.6 Hz, IH), 7.43 (t, J=7.8 Hz), 9.99 (d, 7=3.0 Hz, IH), 6.75 (dd, 7AB=8.5 Hz, HZ, IH), 4.75 (d, 7=5.9 Hz, 2H), 4.47 (s, 2H), 3.81-3.78 (m, 2H), 3.72-3.69 (m, 2H), 3.65-3.50 (m, 26H), 3.35 (s, 3H), 3.31 (quar, 7=7.0 Hz, 4H), 1.12 (t, 7=7.0 Hz, 6H). MS (ES, m/z) 96 '.4 [M+H] ⁺ .

EXAMPLE 269

2-(2-f 3-Γ2.5.8.11.14.17.20.23.26-nonaoxanonacosan-29-yl)benzamido ^' l-5- (diemylamino phenyl)-N-G-(trifluoromethyl)berizyl)isonicotinamide

Example 269: This compound was prepared using the method described for the preparation of Example 269 using 2-(2-(3-(2,5,8,l l,14,17,20,23,26-nonaoxanonacos- 28-yn-29-yl)benzamido)-5-(diethylamino)phenyl)-N-(3-

(trifiuoromethyl)benzyl)isonicotinamide (Example 267) in place of 2-(5- (diethylamino)-2-(3-(l-hydroxy-3,6,9,12-tetraoxapentadec-14- yn-15- yl)benzamido)phenyl)-N-(3-( fluoromethyl)benzyl)isomcotinamide. Ή NMR (400MHz, CDCI3, ppm) 812.30 (s, IH), 8.81 (m, IH), 8.46 (s, IH), 8.21 (s, IH), 7.79 (d, 7=7.4 Hz, IH), 7.76-7.68 (m, 3H), 7.65 (s, IH), 7.61 (d, 7=7.6 Hz, IH), 7.55 (d, 7=7.6 Hz, IH), 7.49-7.45 (t, 7=7.8 Hz, IH), 7.38 (t, 7=7.4 Hz, IH), 7.33 (d, 7=7.9 Hz, IH), 7.12 (s, IH), 6.83 (s, IH), 4.74 (d, 7=6.0 Hz, 2H), 3.65-3.45 (m, 34H), 3.40-3.30 (m, 4H), 3.35 (s, 3H), 2.78 (t, /=7.2 Hz, 2H), 1.96-1.92 (m, 2H), 1.15 (s, .7=7.0 Hz, 6H). MS (ES, m/z): 971.5 [M+H] ⁺ .

EXAMPLE 270

2-(2-(3-(l-amino-3.6.9.12-tetraoxapentadecan-15-vDbenzamido ^' )-5- (diethylarninolphenylVN-O-ftrifluoromethvDbenzyl sonicotinamide

Scheme 109b. 1. CopperQiodide, Pd(PPh ₃ ) ₂ Cl ₂ , triethylamine, 266a.O 3. methylbenzene-l-sulfonyl chloride, TEA, DCM 4. NaN ₃ 5. PPh ₃ , H ₂ 0, THF 5. di-tert- butyl dicarbonate 6. Pd/C, H ₂ . Intermediate 270a: benzyl S-O-f -f -f -f -hvdroxyethoxy ^' lethoxy ^' lethoxy ^' tethoxy ^' lprop- 1-vnvDbenzoate: Into a 500-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of benzyl 3-iodobenzoate (25.68 g, 66.19 mmol, 1.00 equiv) in tetrahydrofuran (300 mL), 2-(2-(2-(2-(prop-2- ynyloxy)ethoxy)ethoxy)ethoxy)ethanol (15.36 g, 66.21 mmol, 1.00 equiv), copper(I) iodide (1.26 g, 6.63 mmol, 0.10 equiv), Pd(PPh ₃ ) ₂ Cl ₂ (4.65 g, 6.62 mmol, 0.10 equiv), triethylamine (13.4 g, 132.67 mmol, 2.00 equiv). The resulting solution was stirred for 3 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column with petroleum ether/ethyl acetate (1:1). This resulted in 20 g (68%) of benzyl 3-(3-(2-(2-(2-(2- hydroxyethoxy)ethoxy)ethoxy)ethoxy)prop-l-ynyl)benzoate as a brown oil.

Intermediate 270b: benzyl S-d-ftosyloxyl-S^^.n-tetraoxapentadec-H-yn-lS- vDbenzoate: Into a 500-mL 3 neck round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of benzyl 3-(l-hydroxy-3,6,9,12- tetraoxapentadec-14-yn-15-yl)benzoate (25.2 g, 56.88 mmol, 1.00 equiv) in dichloromethane (300 mL), triethylamine (17.2 g, 170.30 mmol, 3.00 equiv). This was followed by the addition of a solution of 4-methylbenzene-l-sulfonyl chloride (16.3 g, 85.34 mmol, 1.50 equiv) in dichloromethane (100 mL) dropwise with stirring at 0°C. The resulting solution was stirred overnight at room temperature. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column with petroleum ether/ethyl acetate (5:1-1:1). This resulted in 31 g (91%) of benzyl 3-(l- (tosyloxy)-3,6,9,12-tetraoxapentadec-14-yn-15-yl)benzoate as a brown oil.

Intermediate 270c benzyl 3-(l-azido-3.6.9.12-tetraoxapentadec-14-yn-15-yl1benzoate: Into a 1000-mL round-bottom flask, was placed a solution of benzyl 3-(l-(tosyloxy)- 3,6,9,12-tetraoxapentadec-14-yn-15-yl)benzoate (35.4 g, 59.30 mmol, 1.00 equiv) in N,N-dimethylformamide (400 mL), sodium bicarbonate (10 g, 119.05 mmol, 2.00 equiv), sodium azide (11 g, 169.23 mmol, 3.00 equiv). The resulting solution was stirred overnight at 80°C. The resulting solution was diluted with 200 mL of water. The resulting solution was extracted with 3x100 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 3x100 mL of NaHCC>3 aq.. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This resulted in 25 g (90%) of benzyl 3-(l-azido-3,6,9,12-tetraoxapentadec-14-yn-15- yl)benzoate as brown oil.

Intermediate 270d: benzyl 3-(l-amino-3.6.9.12-tetaoxapentadec-14-vn-15-yl)beiizoate: Into a 500-mL round-bottom flask, was placed a solution of benzyl 3-(l-azido-3,6,9,12- tetraoxapentadec-14-yn-15-yl)benzoate (23 g, 49.15 mmol, 1.00 equiv) in tetrahydrofuran (200 mL), water(20 mL), triphen lphosphine (25.7 g, 98.09 mmol, 2.00 equiv). The resulting solution was stirred for 3 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column with dichloromethane:methanol(100:l-50:l). This resulted in 15 g (69%) of benzyl 3-(l-amino-3,6,9,12-tetraoxapentadec-14-yn-15-yl)benzoate as pale-yellow oil.

Intermediate 270e benzyl 3-(2.2-dimethyl-4-oxo-3.8.11.14.17-pentaoxa-5-azaicos-19- yn-20-yl)benzoate: Into a 500-mL round-bottom flask, was placed a solution of benzyl 3-(l-amino-3,6,9,12-tetraoxapentadec-14-yn-15-yl)benzoate (15 g, 33.94 mmol, 1.00 equiv) in dichloromethane (200 mL), triethylamine (6.85 g, 67.82 mmol, 2.00 equiv). This was followed by the additio of a solution of di-tert-butyl dicarbonate (13.7 g, 62.84 mmol, 2.00 equiv) in dichloromethane (50 mL) dropwise with stirring at 0°C. The resulting solution was stirred for 5 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column with petroleum ether/ethyl acetate(5: 1-1:1). This resulted in 16 g (87%) of benzyl 3-(2,2- dimethyl -4-0X0-3, 8,1 l,14,17-pentaoxa-5-azaicos-19-yn-20-yl)benzoate as pale-yellow oil.

Intermediate 270f 3-(2.2-dimethyl-4-oxo-3.8.11.14.17-pentaoxa-5-azaicosan-20- vDbenzoic acid: Into a 500-mL round-bottom flask, was placed a solution of benzyl 3- (2,2-dimethyl-4-oxo-3,8,l l,14,17-pentaoxa-5-azaicos-19-yn-20-yl)benzoate (16 g, 29.52 mmol, 1.00 equiv) in methanol (200 mL), Palladium carbon (10 g). Hydrogen gas was introduced into the reaction vessel. The resulting solution was stirred for 3 h at room temperature. The solids were filtered out. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1 :5-1:1). This resulted in 7 g (52%) of 3-(2,2-dimethyl-4-oxo- 3,8,1 l,14,17-pentaoxa-5-azaicosan-20-yl)benzoic acid as pale-yellow oil. LC-MS (ES, m/z): 456 [M+H] ⁺

H-NMR (300MHz, DMSO, ppm) 7.76 (dd, J= 6.0Hz, 2H), 7.37-7.47 (m, 2H), 6.73 (s, 1H), 3.35-3.52 (m, 16H), 3.05 (dd, J= 11.7Hz, 2H), 2.69 (t, J= 7.5Hz, 2H), 1.76-1.85 (m, 2H), 1.36 (s, 9H).

Scheme 110. 1. HATU, DIEA, DMF 2. TFA, DCM.

Intermediate 270g: tert-butyl 15-(3-(4-(diethylamino)-2-(4-(3-

(trifluoromethyl benzylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)phenyl)-3.6.9.1 2- tetraoxapentadecylcarbamate: To a solution of 25b (1.81g, 4.1mmol, l.Oeq) and 270f (1.96g, 4.3mmol, 1.05eq) in DMF (20mL) was added DIEA (2.2g, 16.4mmol, 4.0eq) and HATU (1.71g, 4.51mmol, 1.1 equiv). After 40 minutes the solvent was removed and the residue diluted with EtOAc (200mL). The resulting solution was washed with water (4x75mL), brine, and dried over Na ₂ S0 ₄ . Purification on Si0 ₂ (220g, 0-100% EtOAc) gave 3.45g (95%) of the product as a yellow oil. Example 270: 2-(2-Q-(\ -amino-3,6,9, 12-tetraoxapentadecm- lS-yDbenzamidoVS- fdiemylamino^henylVN-O-tMfluoromel^U^ To a solution of compound 270g (3.45g, 3.9mmol) in dichloromethane (15mL) was added TFA (5mL). The reaction was stirred overnight, diluted with dichloromethane (lOmL) and partitioned with water (25mL). NaOH was added to bring the resulting solution to pH 6 and obtain 2.69g of 2-(2-(3-(l-amino-3,6,9,12-tetraoxapentadecan-15-yl)benzamido )-5- (diethylamino)phenyl)-N-(3-(trifluoromethyl)ben2yl)isonicoti namide as the free base. MS (ES, m/z) 780.4 [M+H] ⁺ .

EXAMPLE 271

2-(2-(3-( 1 -(3-(2,5,8, 11.14, 17.20.23.26-nonaoxanonacosan-29-yl)phenvn- 1 -oxo-

5.8.11.14-tetraoxa-2-azaheptadecan- 17-yl benzamido ^' )-5 -CdiethylaminotehenylVN-G -.

(trifluoromethvnbenzvnisonicotinamide

Example 271 : This compound was prepared using the method described for the preparation of Example 262 sybstituting Example 270 in place of 262b in the reaction sequence. Purification by reverse-phase HPLC eluting with a water/ ACN gradient containing 0.1% TFA gave a TFA salt of the title compound. MS (ES, m/z): 1308.6 [M+H] ⁺ .

EXAMPLE 272

2-(2-Q-(l -(4-(2.5.8.11.14.17.20-heptaoxadocosan-22-yl(2- methoxyethvncarbamovnphenylsulfonamidoVS .6.9.12-tetraoxapentadecan- 15- yl)benzamido>5-idiemylamino phenyl>N-f3-irt^

Scheme 111. 1. TEA, DCM, 0°C 2. HATU, DIEA, DMF.

Intermediate 272a: 4-(N-d5-(3-(4-(diethylamino)-2-(4-( ^' 3-trifluoromemynbenzylcarbamovDpyridin^-yl ^' lphenylcarbamovnphenyl ^' l-S^.g.^- tetraoxapentadecyl)sulfamoyl)benzoic acid. A solution of Example 270 (200mg, 0.25mmol, l.Oeq) and triethylamine (50.5, 0.50mmol, 2.0eq) in dichloromethane (5mL) under N2 was cooled to 0°C. 4-(chlorosulfonyl)benzoic acid (55.15mg, 0.25mmol, l.Oeq) was added and the reaction warmed to room temperature and monitored by LCMS. After 2 hours, the resulting solution was diluted with dichloromethane (20mL) and washed with water (2x20mL). The organic layer was acidified to pH 5 with IN HC1 and washed with water (20mL), brine, and dried over Na2SC> . Removing the solvent resulted in 172mg of 4-(N-(15-(3-(4-(diethylamino)-2-(4-(3- (trifluoromethyl)benzylcarbamoyl)pyridin-2-yl)phenylcarbamoy l)phenyl)-3,6,9,12- tetraoxapentadecyl)sulfamoyl)benzoic acid as an oil.

Example 272: 2-Ώ-(3-(1-(4-(2,5.8,1 l,14.17.20-heptaoxadocosan-22-yl(2- memoxyethyDcarbamoyl)phenylsulfonamidoV3.6.9 2 efa

vDbenzamidoV5-(diemylamino)phenyl)-N-(3-(tt^

To a solution of 272a (50mg, 0.0518mmol, l .Oeq) in dimethylformamide (0.26mL) was added N-(2-methoxyethyl)-2,5,8,l l,14,17,20-heptaoxadocosan-22-amine 135c.2 (18.3mg, 0.0518mmol, l.Oeq), DIEA (33.4mg, 0.259mmol, 5.0eq) and HATU (21.7mg, 0.0569mmol, l.leq). The resulting solution was stirred for 1 hour at which LCMS indicated complete conversion. The reaction mixture was diluted with acetonitrile/water (1:1, 2mL), acidified with TFA, and purified by reverse phase HPLC eluting with a water/CH3CN gradient containing 0.05% TFA. The product was obtained as 26.5mg as an oil. MS (ES, m/z) 1343.4 [M+H] ⁺ ; ¾ NMR (400 MHz, CD ₃ OD) 8 8.98 (dd, J= 5.4, 0.7 Hz, 1H), 8.62 (d, J= 8.9 Hz, 1H), 8.49 (dd, J= 1.5, 0.8 Hz, 1H), 8.17 (d, J= 2.7 Hz, 1H), 8.01 (dd, J= 5.4, 1.6 Hz, 1H), 7.86 (d, 7= 8.4 Hz, 2H), 7.79 - 7.71 (m, 3H), 7.69 (s, 1H), 7.64 (d, J= 7.4 Hz, 1H), 7.62 - 7.48 (m, 4H), 7.48 - 7.40 (m, 2H), 4.68 (s, 2H), 3.85 - 3.68 (m, 7H), 3.68 - 3.54 (m, 31H), 3.54 - 3.33 (m, 18H), 3.22 (s, 1H), 3.00 (t, J= 5.4 Hz, 2H), 2.83 - 2.73 (m, 2H), 1.90 (tt, = 12.7, 6.3 Hz, 2H), 1.22 (t, J= 7.2 Hz, 6H).

EXAMPLE 273

2-(5-(diemylaminoV2-r3-(23-methyl-24-oxo-2.5.8.11.14.17.20,2 8.31.34,37-undecaoxa-

23.25-άί3ζ ΐ6ίταοοηί3η-40-ν1¾6ηζ3ΐηίάο^6ην1 ^" )-Ν- 3-

(trifluoromethvnbenzvnisonicotinamide

Scheme 112. 1. a) triphosgene, TEA, DCM b) N-methyl-2,5,8,11,14,17,20- heptaoxadocosan-22-amine (135c.l).

To a solution of triphosgene (2.0mg, 0.0069mmol, 0.3eq) in dry DCM (0.25mL) was added TEA (5.0mg, 0.05mmol, 2.0eq) and Example 270 (20mg, 0.025mmol, l.Oeq). After 15 minutes, a solution of N-methyl-2,5,8,1 l,14,17,20-heptaoxadocosan-22-amine (135c.l) in DCM (0,25mL) was added and the reaction stirred at room temperature. After 30 minutes the solvent was removed and the crude residue diluted with acetonitrile/water (1:1, 2mL). The resulting solution was purified by reverse phase HPLC elutmg with a water/C¾CN gradient containing 0.05% TFA to give 13.6mg of the title compound as an oil. MS (ES, m/z) 1159.4 [M+H] ⁺ .

EXAMPLE 274

2-(5-(diethylamino ^' )-2-(3-(l-hvdroxy-3-(2-hvdroxyethylV4-oxo-8.11.14.17-t etraoxa-

S.S-diazaicosan^O-yllbenzamidolphenylVN-O-

(trifluoromethvnbenCTllisonicotinamide

A solution of Intermediate 270 (20mg, 0.25mmol, l.Oeq) in dichloromethane (0.25mL) was added dropwise to a solution of CDI (4.5mg, 0.028mmol, l.leq) in dichloromethane (0.25mL). After 50 minutes the solvent was removed and the residue dissolved in acetonitrile (0.5mL). 2,2'-azanediyldiethanol (2.89mg, 0.0275mmol, l.leq) and DMAP (lmg) was added and the reaction heated to 50°C. After 45 minutes the reaction was removed from heat, diluted with acetonitrile/water (1:1, 1.5mL), and purified by reverse phase HPLC eluting with a water/CHsCN gradient containing 0.05% TFA to give 13.0mg of the title compound as an oil. MS (ES, m/z) 911.3 [M+H] ⁺ .

EXAMPLES 275-283

The compounds listed in Table 9 were prepared by the procedures described in Example 257 from acids Examples 251, 302 and 303 substituting appropriate amines in the coupling. Mass spectral data (ES, positive ion mode) is provided for each compound.

Table 9

EXAMPLE 284

(SVtert-butyl 16-(3-((4-cvclobutoxy-2-(4-((1.2.3.4-tetrahvdronaphthalen-l- yl¼arbamoyl pyridin-2-yl phenylkarbamoyl)phenylV4.7J0 3-tetraoxahexadecan-l- oate

Scheme 113. 1. 3-(2,2-dimethyl-4-oxo-3 ,7, 10,13 , 16-pentaoxationadecan- 19-yl)benzoic acid, HATU, DIEA, DMF.

Example 284: (SVtert-butyl 16-(3-r(4-cvclobutoxy-2-(4-((1.2.3.4-tetrahvdronaphthalen- 1 -yDcarbamovDpyridin^-yDphenyllcarbamovDphenyl .?.10.13-tetraoxahexadecan- 1-oate. To a mixture of (S)-2-(2-amino-5-cyclobutoxyphenyl)-N-(l,2,3 _> 4- tetrahydronaphthalen-l-yl)isonicotinamide 132b (0.048 mmol, 20 mg), 3-(2,2-dimethyl- 4-oxo-3,7,10,13, 16-pentaoxanonadecan-19-yl)benzoic acid (0.053 mmol, 24 mg) and DIEA (0.29 mmol, 38 mg) in DMF (0.16 mL) was added HATU (0.053 mmol, 20 mg). The mixture was stirred at 60 °C for 1 h and purified by prep. TLC to give a yellow syrup (13.8 mg, 34%). MS (ES, m/z): 836.07 [M+H] ⁺ .

EXAMPLE 285

( ^" SV16-(3-((4-cvclobutoxy-2-(4-((1.2.3.4-tetrahvdronaDht halen-l-yl)carbamoyl)pyridin-

2-yl phenyl)carbamoyl)phenyl)-4.7.10.13-tetraoxahexadecan-l -oic acid

Example 285. (S)-16-(3-((4-cvclobutoxy-2-(4-((1.2.3.4-tetralivdronaphthal en-l- vDcarbamoyl) pyridin-2-yl ^' )phenyl)carbamoyl ^' )Dhenyl)-4.7.10.13-tetraoxahexadecan-l - oic acid. To (S)-tert-butyl 16-(3-((4-cyclobutoxy-2-(4-((l ,2,3,4-tetrahydronaphthalen-l- yl)carbamoyl)pyridin-2-yl)phenyl)carbamoyl)phenyl)-4,7,10,13 -tetraoxahexadecan-l- oate Example 284 was added trifluoracetic acid (1 mL). The mixture was stirred for 5 minutes, concentrated and purified by prep. TLC to give a yollow syrup (7.2 mg, 64%). MS (ES, m/z): 780.5 [M+H] ⁺ .

EXAMPLE 286

rSV2-(2-r3-(2.5.8.11.14.17.20.23-octaoxa-26-thiaheptacosan-2 7-yl)benzamido)-5- (diethylamino)phenyl ^' )-N-(1.2.3.4-tetrahvdronaphthalen-l-yl)isonicotinamide :

Example 286: (SV2-(2-(3-(2.5,8,l l,14.17,20.23-octaoxa-26-thiaheptacosan-27- yl)benzamido ^" )-5 -(diemylamino ^" )phenyr)-N-( 1.2.3.4-tetrahvdronaphthalen- 1 - vnisonicotinamide. This compound was prepared from Compound 131c according to the procedure described in Example 265 using S-2,5,8,11,14,17,20,23- octaoxapentacosan-25-yl ethanethioate as the protected thiol. MS (ES, m/z) 931.5 [M+H] ⁺ .

EXAMPLE 287

2-(2-(3-(l -( -(2,5,8,l 1.14.17.20-heptaoxadocosan-22- virmethvDcarbamovDphenylsulfonamidoVS .6.9.12-tetraoxapentadecan- 15- yl)benzamidoy5-(die ylamino phenyiyN-(3-(¾

This compound was prepared from 4-(N-(15-(3-(4-(diethylamino)-2-(4-(3- (trifluoromemyl)benzylcarbamoyl)pyridin-2-yl)phenylcarbamoyl )phenyl)-3,6 _> 9,12- tetraoxapentadecyl)sulfamoyl)benzoic acid 272a by following the procedure described in Example 272 using N-methyl-2,5,8,l l,14,17,20-heptaoxadocosan-22-amine 135c.l as the amine component in this coupling. MS (ES, m/z) 1299.5 [M+H] ⁺ .

EXAMPLE 288 2-(2-G-n-(4-(4-(2.5.8.11.14.17.20-heptaoxadocosan-22-ylV3-ox opiperazine-l- carbonvDphenylsulfonamidoV3.6.9.12-tetraoxapentadecan ^

(diemylamino)phenyl)-N-(3-(¾fluorom

This compound was prepared from 4-(N-(15-(3-(4-(diethylamino)-2-(4-(3- (trifluoromethyl)benzylcarbamoyl)pyridin-2-yl)phenylcarbamoy l)phenyl)-3,6,9,12- tetraoxapentadecyl)sulfamoyl)benzoic acid 272a by following the procedure described in Example 272 using l-(2,5,8,l l,14,17,20-heptaoxadocosan-22-yl)piperazin-2-one 135c.5 as the amine component in this coupling. MS (ES, m/z) 1368.4 [M+H] ⁺ .

EXAMPLE 289

3-( -(15-(3-(4-fdiethylamino>2-(4-f3-(tri^

vnphenylcarbamovnphenyll-S^.g.^-tetraoxapentadecvnsulfamovnb enzoic acid

This compound was prepared from Intermediate 270 according to the procedure described in Example 272 using 3-(chlorosulfonyl)benzoic acid as the sulfonyl chloride. MS (ES, m/z) 964.6 [M+H] ⁺ . EXAMPLE 290

4-f4-n6-(3-(4-fdiethylammoV2-(4-(3-(1rifluo

yDphenylcarbamoyl ^' lphenyl ^' I^J.lO.B-tetraoxahexadecane'tpiperazin-l- ylsulfonyl)benzoic acid

Scheme 114. 1. DIEA, DMF.

Example 290: 4-(4-fl6-G- 4-idiethylaminoV2-( ^' 4-(3-

( fluoromemyl benzylcarbamoyl pyridin-2-vDphenylcarbarnovnphenyl')-4.7.10.13- tetraoxahexadecanetpiperazin- 1 -ylsulfonvDbenzoic acid: To a solution of 2-(5- (diethylamino)-2-(3 -( 16-oxo- 16-(piperazin- 1 -yl)-4,7, 10,13- tetraoxahexadecyl)ben2ajnido)phenyl)-N-(3-(trifluoromethyl)b enzyl)isomcotinamide 262b (50mg, 0.0505mmol, l.Oeq) in DMF (ImL) was added TEA (19.5mg, 0.152mmol, 3.0eq) and finally 4-(chlorosulfonyl)benzoic acid (l l.lmg, 0.0505mmol, l.Oeq). After 2 hours, the resulting solution was diluted with acetonitrile/water solution (1:1, 2mL), acidified with TFA and purified by reverse phase HPLC eluting with a water/C¾CN gradient containing 0.05% TFA. The product was obtained as 15.8mg of an oil. MS (ES, m z) 1061.5 [M+H] ⁺ .

EXAMPLE 291

2-(5-( ^' diethylaminoV2-( ^' 3-(16-oxo-16-f4-tosylDiperazin-l-ylV4.7,10.13- tetraoxahexadecvnbenzamido)phenylVN-r3-(trifluoromethvnbenzy l sonicotinamide

This compound was prepared from 262b according to the procedure described in Example 290 using 4-methylbenzene-l -sulfonyl chloride as the sulfonyl chloride. MS (ES. m/z) 1031.4 [M+H] ⁺ .

EXAMPLE 292

2-(5-(άί6Φνΐ3∞ίηο 2-(3-(16-(4-(ί5θΡΓο νΐ5η1&ηνΠρί 6Γ3ζίη-1-νΐνΐ6-οχο-4.7.10.13- tetraoxahexadecvnbenzamido^phenylVN-(3-(trifluoromethvnbenCT l sorncothamide

This compound was prepared from 262b according to the procedure described in Example 290 using propane-2-sulfonyl chloride as the sulfonyl chloride. MS (ES, m/z) 983.9 [M+H] ⁺ .

EXAMPLE 293

16-G-i4-(16-f3-(4-(diethylaminoV2-(4-f3-(te^

yl)phenylcarbamovnphenyl'>-4.7.10.1 S-tetraoxahexadecanelpiperazine- 1 - carbonyl)phenyl>4.7.10.13-tetraoxahexadecan- 1 -oic acid

To a solution of 2-(5-(diethylamino)-2-(3-(16-oxo-16-(piperazin-l-yl)-4,7,10, 13- tetraoxahexadecyl)benzamido)phenyl)-N-(3-(trifluoromethyl)be nzyl)isoriicotinamide 262b (56.1mg, 0.072mmol, l.Oeq) and 4-(2,2-dimethyl-4-oxo-3,7,10,13,16- pentaoxanonadecan-19-yl)benzoic acid 251c (31.7mg, 0.72mmol, l.Oeq) in DMF (0.5mL) was added DIEA (46.5mg, 0.36mmol, 5.0eq) and HATU (30.1mg, 0.0792mmol, l.leq). After 4 hours the resulting solution was diluted with EtOAc (lOmL) and washed with water (3x5mL) and brine, and dried over The solvent was removed and the resulting crude material diluted with dichloromethane (2mL). TFA (0.5mL) was added and the reaction stirred for 30 minutes to remove the ester. The solvent was removed and the resulting residue diluted with acetonitrile/water (1:1, 2mL) and purified by reverse phase HPLC eluting with a water/C¾CN gradient containing 0.05% TFA. The product was obtained as 55.2mg of an oil. MS (ES, m/z) 1243.5 [M+H] ⁺ .

EXAMPLE 294 3-i4-fN-n5-f3-i4-(diethylamino>2-(4-G^

vDphenylcarbamovDphenvD-S .6.9.12-tetraoxapentadecyl ^' )sulfamoyl ^' >phenyl1propanoic acid

Example 294j 3-(4-(N-fl5-(3-(4-(diethylaminoV2-(4-(3- itrifluoromethvnbenzylcarbamovnpyridin-2-vnphenylcarbamovnph enylV3.6,9.12- tetraoxapentadecvDsulfamovDphenvDpropanoic acid. This compound was prepared from Example 270 according to the procedure described in Example 272 using 3-(4- (chlorosulfonyl)phenyl)propanoic acid as the sulfonyl chloride. MS (ES, m/z) 992.9 [M+H] ⁺ ; Ή NMR (400 MHz, CD ₃ OD) δ 9.42 (t, J= 5.9 Hz, 1H), 8.92 (d, J= 5.2 Hz, 1H), 8.80 (d, 7= 9.2 Hz, 1H), 8.39 (s, 1H), 8.04 (s, 1H), 7.87 (dd, J= 5.2, 1.5 Hz, 1H), 7.83 - 7.75 (m, 2H), 7.71 - 7.66 (m, 3H), 7.64 (d, J= 7.5 Hz, 1H), 7.60 - 7.48 (m, 3H), 7.46 (d, J= 5.0 Hz, 2H), 7.35 (d, J= 8.5 Hz, 2H), 4.68 (s, 2H), 3.72 (q, /= 7.1 Hz, 4H), 3.65 - 3.53 (m, 9H), 3.52 - 3.46 (m, 5H), 3.42 - 3.37 (m, 2H), 3.36 - 3.31 (m, 2H), 2.98 - 2.89 (m, 4H), 2.83 - 2.75 (m, 2H), 2.59 (t, J= 7.5 Hz, 2H), 1.91 (dq, J= 12.8, 6.3 Hz, 2H), 1.20 (t, J= 7.2 Hz, 6H).

EXAMPLE 295

2-Γ5-(άΪ6ΐ1ιν^ίηον2-(·3-η-(4-(23-Γ2^6Φοχν6� �ινη-24-οχο-2.5.8.11.14.17.20- heptaoxa-23-azahexacosan-26-vDphenylsulfonamidoV3.6.9.12-tet raoxapentadecan-15- yl)benzanTido)phenylVN-(3-flTifluoroniethyl')benzyl')isonico tinamide

This compound was prepared from compound Example 294 according to the procedure described in Example 272 using N-(2-methoxyethyl)-2,5,8,l 1,14,17,20- heptaoxadocosan-22-amine as the amine component in this coupling. MS (ES, m/z) 1371.6 [M+H] ⁺ .

EXAMPLE 296

2-(5-(diethylamino ^, )-2-(3-(l-( ^' 4-(24-oxo-2.5.8.11.14.17.20-het)taoxa-23-azahexacosan- 26-yl)phenylsulfonamidoV3.6.9.12-tetraoxapentadecan-15-yl1be nzamido ^' )rihenyl1-N-( ^' 3- (trifluoromethvnbenzyllisonicotinamide

This compound was prepared from compound Example 294 according to the procedure described in Example 272 using 2,5,8,1 l,14,17,20-heptaoxadocosan-22-amine as the amine component in this coupling. MS (ES, m/z) 1313.6 [M+H] ⁺ .

EXAMPLE 297

16-( ^' 4-(15-(3-(4-(diemylarmno>-2-(4- -ftrifluoromethvnberizylcarbamoyl)pyridin-2- yl1phenylcarbamoyl ^' )phenylV3.6.9.12-tetraoxapentadecylcarbamoyl ^' )phenyl ^' l -4.7.10.13- tetraoxahexadecan-l-oic acid

Example 297 16-(4-(15-(3-(4-(die ylaminoy2-(4-(3-

(ttifluoromethvPbenzylcarbamo

tetraoxapentadecylcarbamovnphenvD^^-lO-lS-tetraoxahexadec an-l-oic acid: This compound was prepared from Example 270 the procedure described in Example 293 using 4-(2,2-dimethyl-4-oxo-3,7,10,13,16-pentaoxanonadecan-19-yl)b enzoic acid as the acid component in the coupling. MS (ES, m/z) 1146.6 [M+H] ⁺ .

EXAMPLE 298

31-(3-(4-fdiethylarninoy2-(4-(3-(trifm^

yl)phenylcarbamoyl)phenyD-4.7, 10, 13 ,16.19.22.25.28-nonaoxahentriacontan- 1 -oic acid

Intermediate 298a: 3.6.9.12.15.18.21.24-octaoxaheptacos-26-vn-l-ol. Into a 500-mL round-bottom flask, was placed a solution of 3,6,9,12,15, 18,21-heptaoxatricosane-l,23- diol (6.7 g, 18.11 mmol, 1.00 equiv) in tetrahydrofuran (200 mL). This was followed by the addition of sodium hydride (724 mg, 18.10 mmol, 1.00 equiv, 60%) in several batches at 0-5°C in 30 min. The resulting solution was stirred for 30 min at 0°C. To this was added a solution of 3-bromoprop-l-yne (2.24 g, 18.82 mmol, 1.04 equiv) in tetrahydrofuran (100 mL) dropwise with stirring at 0-5°C in 1 h. The reaction progress was monitored by LCMS. The resulting solution was allowed to react, with stirring, for an additional 1 h at room temperature. The solids were filtered out. The residue was applied onto a silica gel column with dichloromethane:methanol (50:1). This resulted in 3 g (40%) of intermediate 298a as light yellow oil. Intermediate 298b: tert-butyl 3-(2-C2-(2-(2-(2-(2-(2-(2-(prop-2- vnyloxy¼thoxy)ethoxy ^' )ethoxy')ethoxy ^' )ethoxy ethoxy ^' )ethoxy ^' )ethoxy ^' )propanoate. Into a 500-mL round-bottom flask, was placed a solution of 2-(2-(2-(2-(2-(2-(2-(2-(prop-2- ynyloxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)eth anol (22.3 g, 54.66 mmol, 1.00 equiv) in tetrahydrofuran (100 mL), Na (75 mg, 3.26 ^' mmol, 0.06 equiv). This was followed by the addition of a solution of tert-butyl acrylate (8.4 g, 65.62 mmol, 1.20 equiv) in tetrahydrofuran (100 mL) dropwise with stirring. The resulting solution was stirred overnight at room temperature. The pH value of the solution was adjusted to 7 with hydrogen chloride (1 mol L). The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column with dichloromethane/methanol (200:1). This resulted in 14.5 g (49%) of intermediate 298b as yellow oil.

Intermediate 298c: Into a 250-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of tert-butyl 3-(2-(2-(2-(2-(2-(2-(2- (2-(prop-2- ynyloxy)emoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)etho xy)propanoate (10.1 g, 18.84 mmol, 1.00 equiv) in tetrahydrofuran (200 mL), benzyl 3-iodobenzoate (7 g, 20.71 mmol, 1.00 equiv), copper(I) iodide (358 mg, 1.88 mmol, 0.10 equiv), Pd(PPh ₃ )Cl ₂ (1.32 g, 1.88 mmol, 0.10 equiv), triethylamine (3.8 g, 37.62 mmol, 2.00 equiv). The resulting solution was stirred for 3 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was dissolved in 100 mL of ethyl acetate. The solids were filtered out. The filtrate was washed with 3x100 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with dichloromethane/methanol (100: 1). This resulted in 6.4 g (46%) of intermediate 298c as red oil.

Intermediate 298d: 3-(2,2-dimethyl-4-oxo-3,7,10.13.16.19.22.25.28.31- decaoxatetratriacontan-34-yl benzoic acid. Into a 250 mL roundbottom flask, was placed a solution of intermediate 298c (6.4 g, 8.58 mmol, 1.00 equiv) in methanol (100 mL), Palladium carbon (6.5 g, 60.19 mmol, 7.02 equiv). Hydrogen gas was introduced into the reaction vessel. The resulting solution was stirred overnight at room temperature. The solids were filtered out. The resulting mixture was concentrated under vacuum. This resulted in 5.6 g (99%) of intermediate 298d as dark green oil. LC-MS (ES, m/z): 683 [M+Na] ⁺

H-NMR (300MHz, CDC1 ₃ , ppm): 7.93(m, 2H), 7.38(m, 2H), 3.75-3.60(m, 36H), 3.48(t, 2H), 3.13(m, 4H), 2.79(t, 2H), 2.53(t, 2H), 1.95(m, 2H), 1.47(s, 9H).

Intermediate 298e: tert-butyl 31-(3-(4-(diethylamino)-2-r4-(3-

(trifluoromethyl)benzylcarbamoyl)pyridin-2-yl)phenylcarba moyl phenyl)- 4.7.10.13.16.19.22.25.28-nonaoxahentriacontan-l-oate: To a solution of 2-(2-amino-5- (diethylamino)phenyl)-N-(3 -(trifluoromethyl)benzyl)isonicotinamide 25b 1.4g, 3.16mmol, l.leq) and 3-(2,2-dimethyl-4-oxo-3,7,10,13,16,19,22,25,28,31- decaoxatetratriacontan-34-yl)benzoic acid (1.95g, 2.95mmol, l.Oeq) in DMF (15mL) was added DIEA (1.63g, 12.64mmol, 4.3eq) and HATU (1.32g, 3.48mmol, 1.2eq). After 1 hour the solvent was removed and the resulting residue diluted with EtOAc (150mL), washed with water (4x75mL) and brine, and dried over Na2SC>4. The crude reaction mixture was purified by flash column chromatography (80g S1O2, 0 to 4% MeOH in DCM) to give 2.28g of intermediate 298e as a yellow oil.

Example 298j 31 -(3-(4-(diethylaminoV2-(4-(3-

(trifluoromemvnbergylcarbamoyl ^' )pyridin-2-yl ^' )phenylcarbamoyl')phenvn- 4.7.10.13.16.19.22.25.28-nonaoxahentriacontan-l -oic acid. Intermediate 298e (2.28g, 2.1mmol) was dissolved in dichloromethane (lOmL) and TFA (5mL) was added. The reaction was stirred at room temperature for one hour at which point solvent was removed. The TFA salt was dissolved in EtOAc (15mL) and partitioned with water (lOmL). The pH was adjusted to 5.5 with IN HCl and the organic layer diluted with EtOAc (75mL), washed with water (50mL). The aqueous layer was extracted with additional EtOAc (3x5 OmL) until no color remained. The combined organic layers were washed with brine and dried over Na ₂ SC>4 to give 1.99g of the free base. This was dissolved in acetonitrile (5mL) and water (2mL), NaOH was added (leq), and the resulting solution lyophilized to give the 1.81g of Example 298 as a yellow powder. MS (ES, m/z) 1029.6 [M+H] ⁺ . Ή NMR (400 MHz, CD ₃ OD) δ 8.99 (dd, J= 5.5, 0.7 Hz, 1H), 8.54 - 8.49 (m, 2H), 8.20 (d, J= 2.7 Hz, 1H), 8.07 (dd, J= 5.5, 1.6 Hz, 1H), 7.79 (dd, = 8.9, 2.7 Hz, 1H), 7.76 - 7.70 (m, 2H), 7.69 (s, 1H), 7.64 (d, J= 7.5 Hz, 1H), 7.57 (d, J= 7.9 Hz, 1H), 7.53 (d, J= 7.6 Hz, 1H), 7.46 - 7.41 (m, 2H), 4.67 (s, 2H), 3.77 (q, J= 7.2 Hz, 4H), 3.68 (t, J= 6.3 Hz, 2H), 3.63 - 3.53 (m, 31H), 3.47 ( = 6.2 Hz, 2H), 3.29 (dt, J= 3.3, 1.7 Hz, 8H), 2.81 - 2.74 (m, 2H), 2.50 (t, J= 6.3 Hz, 2H), 1.23 (t, = 7.2 Hz, 6H).

EXAMPLE 299 22-Q-(4-(diethylarrunoV2-(4-(3-(trifl

vDphenylcarbamoyl)phenyr)-4,7 J 0,13.16.19-hexaoxadocosan- 1 -oic acid

Intermediate 299a: 3.6.9.12.15-pentaoxaoctadec-17-vn-l-ol. Into a 1000-mL 3 -necked round-bottom flask, was placed a solution of 3,6,9,12-tetraoxatetradecane-l,14-diol (60 g, 251.78 mmol, 0.90 equiv) in tetrahydrofuran (300 mL). This was followed by the addition of sodium hydride (6.7 g, 0.66 equiv, 60%) at 0-10°C. The mixture was stirred for 0.5 h at 0-10°C. To this was added a solution of 3-bromoprop-l-yne (33.32 g, 280.00 mmol, 1.00 equiv) in tetrahydrofuran (100 mL) dropwise with stirring in 1.5 h. The resulting solution was stirred for 2 h at 0-10°C. The solids were filtered out. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (4:1-2:1). This resulted in 32.1 g (41%) of intermediate 299a as light yellow oil.

Intermediate 299b: Into a 1000-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of 3,6,9,12,15-pentaoxaoctadec-17- yn-l-ol (62.2 g, 225.12 mmol, 1.00 equiv) in tetrahydrofuran (500 mL), sodium (155.3 mg, 6.75 mmol, 0.03 equiv). The mixture was stirred for 30 minutes at room temperature. This was followed by the addition of a solution of tert-butyl acrylate (28.8 g, 224.65 mmol, 1.00 equiv) in tetrahydrofuran (100 mL) dropwise with stirring. The resulting solution was stirred overnight at room temperature. The pH value of the solution was adjusted to 7 with hydrogen chloride (1 ,2N mol/1). The resulting mixture was concentrated under vacuum. The residue was dissolved in 500 ml of ethyl acetate. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with petroleum ether/ethyl acetate (8:1-1:1). This resulted in 44 g (48%) of intermediate 299b as light yellow oil. 11 043263

Intermediate 299c: tert-butyl 22-(3-(berayloxycarbonyl)phenYl)-4.7.10,13.16.19- hexaoxadocos-21 -vn- 1 -oate. Into a 500-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of tert-butyl

4,7,10,13,16,19-hexaoxadocos-21-yn-l -oate (37.48 g, 92.66 mmol, 1.00 equiv) in tetrahydrofuran (200 mL), benzyl 3-iodobenzoate (34.5 g, 102.04 mmol, 1.10 equiv), copper(I) iodide (1.77 g, 9.29 mmol, 0.10 equiv), Pd(PPh ₃ ) ₂ Cl ₂ (6.50 g, 9.26 mmol,

0.10 equiv), triethylamine (18.72 g, 185.35 mmol, 2.00 equiv). The resulting solution was stirred for 4 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was dissolved in 200 ml of ethyl acetate. The solids were filtered out. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column with petroleum ether/ethyl acetate (2:1~1 :2). This resulted in

19.2 g (34%) of intermediate 299c as brown oil.

Intermediate 299d: 3-(2.2-dimethvl-4-oxo-3.7.10J3,16,19,22-heptaoxapentacosan-2 5- yl)benzoic acid. Into a 250-mL round-bottom flask, was placed a solution of tert-butyl

22-(3 -(benzyloxycarbonyl)phenyl)-4,7, 10,13,16,19-hexaoxadocos-21 -yn- 1 -oate (12.5 g,

20.36 mmol, 1.00 equiv) in methanol (200 mL), Palladium on carbon (25 g). Hydrogen gas was introduced into the reaction vessel. The resulting solution was stirred for 5 h at room temperature. The solids were filtered out. The resulting mixture was concentrated under vacuum. The crude product was washed with 2x30 mL of n-hexane. This resulted in 9.8 g (87%) of intermediate 299d as brown oil.

LC- S (ES, m/z): 551 [M+Na] ⁺

H-NMR (400MHz, CDC1 ₃ , ppm):T.93 ~7.90(m, 2H), 7.37-7.3 l(m, 2H), 4.68(s, 2H), 3.72~3.56(m, 22H), 3.48~3.42(m, H), 2.75(tri, Jl=5.4Hz^r=5.7Hz, 2H), 2.50(tri,

Example 29j½ 22-(3-(4-( ^' diethylaminoV2-(4-(3- ftoifluoromethvnbenzylcarbamovDpyridin-2-vnphenylcarbamoyl') phenyl ^' )- 4.7.10.13.16, 19-hexaoxadocosan-l -oic acid. This compound was prepared from 2-(2- amino-5-(diemylamino)phenyl)-N-(3-(t^ 25b using the procedures described in Example 251 using 3-(2,2-dimethyl-4-oxo- 3,7,10,13, 16,19,22-heptaoxapentacosan-25-yl)benzoic acid 299d as the protected acid component in the coupling. MS (ES, m/z) 897.9 [M+H] ⁺ ; Ή NMR (400 MHz, d ₆ DMSO) δ 11.77 (s, 1H), 10.60 (t, J= 5.9 Hz, 1H), 8.78 (d, /= 5.2 Hz, 1H), 8.50 (s, 1H), 7.81 (d, J= 5.1 Hz, 1H), 7.76 (s, 2H), 7.73 (s, 1H), 7.68 (s, 1H), 7.65 - 7.58 (m, 3H), 7.58 - 7.53 (m, 2H), 7.49 (t, J= 7.9 Hz, 1H), 7.36 - 7.26 (m, 2H), 6.99 (d, J= 3.0 Hz, 1H), 6.79 (dd, J= 9.0, 3.0 Hz, 1H), 4.57 (d, J= 6.0 Hz, 2H), 3.56 - 3.30 (m, 43H), 2.68 - 2.58 (m, 2H), 2.07 (t, /= 7.5 Hz, 2H), 1.77 (p, J= 6.1 Hz, 2H), 1.09 (t, J= 7.0 Hz, 6H).

EXAMPLE 300

19-( ^' 3-(4-< ^' diethylamino)-2-(4-(3-(trifluoromethvnbenzylcarbamoyl) pyridin-2- yl)phenylcarbamovOphenyr)-4.7.10.13.16-pentaoxanonadecan- 1 -oic acid

This compound was prepared according to the procedure described for the synthesis of Example 251 substituting 2,2'-(2,2 ^l -oxybis(ethane-2,l-diyl)bis(oxy))diethanol for tnethylene glycol as a starting material. MS (ES, m/z) 853.6 [M+H] ⁺ . ¾ NMR (400 MHz, <¾DMSO) 8 11.81 (s, 1H), 10.76 (s, 1H), 8.77 (d, J= 5.1 Hz, 1H), 8.55 (s, 1H), 7.82 (d, J= 5.0 Hz, 1H), 7.78 (s, 1H), 7.72 - 7.66 (m, 2H), 7.64 - 7.52 (m, 4H), 7.48 (t, J= 7.7 Hz, 1H), 7.35 - 7.24 (m, 2H), 6.98 (d, J= 3.0 Hz, 1H), 6.78 (dd, J= 8.8, 3.0 Hz, 1H), 4.57 (d, J= 5.7 Hz, 3H), 3.57 - 3.30 (m, 37H), 2.67 - 2.57 (m, 3H), 2.08 (t, .7= 7.5 Hz, 2H), 1.82 - 1.71 (m, 2H), 1.09 (t, J= 7.0 Hz, 7H).

EXAMPLE 302

('SV16-(3-(4-(diemylamirioV2-(4-(1.2.3.4-tetrahvdronaphthale n-l- ylcarbamoyl ^' )pyridin-2-yl)phenylcarbamoyl ^' )phenyl ^' )-4,7, 10, 13-tetraoxahexadecan- 1 -oic acid

Example 302: (SV16-(3-(4-(diethylaminoV2-(4-q,2.3.4-tetrahvdronaphthalen- l- ylcarbamoyl)pyridin-2-yl ^' )phenylcarbamoyl)phenyl ^' )-4.7.10.13-tetraoxahexadecan- 1 -oic acid. This compound was prepared according to the procedure described for the synthesis of Example 251 substituting 131c in place of 25b. MS (ES, m/i) 781.4 [M+H] ⁺ .

EXAMPLE 303 ,

16-(3-(4- piperidin-l-yl)-2-(4-(3-(trifluoromethvnbenzylcarbamoyl pyridin-2- yl)phenylcarbamoyl)phenyl1-4.7.10.13 -tetraoxahexadecan- 1 -oic acid

Example 303j 16-(3-(4-(piperidin- 1 -yl -2-(4-f 3-

(trifluoromemyl)berizylcarbamovnpyridin-2-yl ^' )phenylcarbamoyl ^' )phenyl ^' )-4.7.10.13- tetraoxahexadecan-l-oic acid. This compound was prepared according to the procedure described for the synthesis of Example 251 substituting 4.1c in place of 25b. MS (ES, m/z) 821.5 [M+H] ⁺ .

EXAMPLE 304

(SV22-('3-(4-(diethylamino')-2-(4-a.2.3.4-tetrahvdronaphthal en-l- ylcarbamoyl)pyridin-2-yl ^' )phenylcarbamoyl)phenYl')-4.7.10.13.16.19-hexaoxadocos an-

1-oic acid

This compound was prepared from 131c according to the procedures described in Example 251 using 3-(2,2-dimethyl-4-oxo-3,7,10,13,16,19,22-heptaoxapentacosan- 25- yl)benzoic acid 299d as the protected acid component. MS (ES, m/z) 869.6 [M+H] ⁺ ; Ή NMR (400 MHz, ^ DMSO) 6 11.63 (s, 1H), 9.38 (d, J= 8.3 Hz, 1H), 8.79 (d, J= 5.2 Hz, 1H), 8.29 (s, 1H), 7.88 (d, J= 9.0 Hz, 1H), 7.79 (d, J= 6.3 Hz, 1H), 7.69 (s, 1H), 7.65 - 7.58 (m, 1H), 7.39 - 7.31 (m, 2H), 7.17 - 6.97 (m, 6H), 6.79 (dd, J= 10.2, 1.5 Hz, 1H), 5.23 - 5.12 (m, 1H), 3.53 - 3.31 (m, 36H), 2.78 - 2.70 (m, 2H), 2.68 - 2.59 (m, 3H), 2.03 - 1.87 (m, 5H), 1.84 - 1.73 (m, 4H), 1.09 (t, J= 6.9 Hz, 6H).

EXAMPLE 306

(SV19-(3-r4-fdiethylaminoV2-(4-n.2.3,4 etrahvdronaphthalen-l-ylcarbamoyl ^' )Dyridin- 2-yl)phenylcarbamoy nphenyll-4.7.10.13.16-pentaoxanonadecan- 1 -oic acid

This compound was prepared from 131c according to the procedures described in Example 251 and Example 300 using 3-(2,2-dimethyl-4-oxo-3,7,10,13, 16,19- hexaoxadocosan-22-yi)benzoic acid as the protected acid component. MS (ES, m/z) 825.9 [M+H] ⁺ .

EXAMPLES 320-326

The compounds listed in table 10 were prepared by the procedures described in Examples 262 and 272 from amine 270 and 270.1. Mass spectral data (ES, positive ion mode) is provided for each compound.

Intermediate 270.1 (SV2-f2-(3 -(1 -amino-3.6.9.12-tetraoxapentadecan- 15- ynbenzamidoVS- diethylamino ^' iDhenylVN-fl^.S^-tetrahvdronaphthalen-l- vDisonicotinamide. This compound was prepared from (S)-2-(2-amino-5- (diethylamino)phenyl)-N-( 1 ,2,3 ,4-tetrahy dronaphthalen- 1 -yl)isonicotinamide 131c according to the procedures described in Example 270 using 270f as the protected acid. MS (ES, m/z) 752.4 [M+H] ⁺ .

Table 10

EXAMPLE 327

(S)-Nl-f2-(4-( ^' 2.5.8.11.14.17.20-heptaoxadocosan-22-ylV3-oxoriiperazi n-l-vnethvn- N3 -(4-(diethylamino)-2-(4-n ,2.3.4-tetrahydronaphthalen- 1 -ylcarbamo yl)pyridin-2- yllphenylVN 1 -methylisophthalamide

(S)-N 1 -(2-(4-(2,5,8, 11 ,14, 17,20-heptaoxadocosan-22-yl)-3-oxopiperazin- 1 -yl)ethyl)- N3 -(4-(diethylamino)-2-(4-( 1 ,2,3 ,4-tetrahydronaphthalen- 1 -ylcarbamoy l)pyridin-2- yl)phenyl)-Nl-methylisophthalamide: This compound was prepared from 197a according to the procedure described in Example 197 using 1-(2,5,8,11,14,17,20- heptaoxadocosan-22-yl)piperazin-2-one 135c.5 as the amine. MS (ES, m/z) 1024.4 [M+H] ⁺ .

EXAMPLE 328

f SVN 1 -(4-f diethylamino ^' )-2-(4-f 1.2.3 ,4-tetrahydronaphthalen- 1 -ylcarbamoynpyridin-2- vnphenylVN3-C23-( ^' 2-methoxyethyl ^' )-2.5,8.11.14.17.20-heptaoxa-23-azapentacosan-25- yl)-N3-methylisophthalamide

Example 328: (SVNl-(4-( ^' diethylaminoV2-(4-a.2 ^-tetrahvdronaphthalen-l- ylcarbamoyl ^' )pyridin-2-yl ^' )phenyl ^' )-N3-(23 -Q-methoxyethyr)-2.5.8.11.14.17.20- heptaoxa-23 -azapentacosan-25-ylVN3 -methylisophthalamide : This compound was prepared from 197a according to the procedure described in Example 197 using N-(2- methoxyethyl)-2,5,8,l l,14,17,20-heptaoxadocosan-22-amine as the amine. MS (ES, m/z) 999.4 [M+H] ⁺ .

EXAMPLE 329

tert-butyl 3-methyl-l-[ -methyl-l-r3-(r4-(piperidin-l-vn-2-( ^' 4-(r( ^' lS)-1.2.3.4- tetrahvdronaphthalen-l-yl1carbamoyl)pyridin-2- vDphenyllcarbamoy phenvDformamidol^.g.^-trioxa-S-azapentadecan-lS-oate

Example 329: This compound was prepared from intermediate 187a according to the procedure described in Example 197 using tert-butyl 5,8,1 l-trioxa-2-azatetradecan-14- oate as the amine. MS (ES, m/z) 905.3 [M+H] ⁺ .

EXAMPLE 330

2-(2-(2-(3-(3-r4-( ^' diethylammoV2-(4-n-(n-ifluoromemvnbenzylcarbamovnpyrid in-2- vnphenylcaTbamovDphenvnpropoxy^emoxy¼moxyVN.N.N-triethyleth anaminium

Scheme 115. 1. Triethylamine, butanone, ethanol 2.H ₂ , Pd/C, MeOH 3. EDC.HC1, DMAP, DCM.

Intermediate 330a.O. Benzyl 3-(3-(2-(2-f2-(tosyloxy)emoxy)emoxy ethoxy)prop-l- ynyPbenzoate: This compound was prepared in a manner analogous to that described in Example 270b from benzyl 3-iodobenzoate by substituting 2-(2-(2-(2-(prop-2- ynyloxy)ethoxy)ethoxy)ethoxy)ethanol for the alkyne.

Intermediate 330a: Into a 100-mL round-bottom flask, was placed a solution of benzyl 3-(3-(2-(2-(2-(tosyloxy)ethoxy)ethoxy)ethoxy)prop-l-ynyl)ben zoate (300 mg, 0.54 mmol, 1.00 equiv) in butanone (5 mL), a solution of triethylamine (2 mL) in ethanol (2 mL). The resulting solution was stirred overnight at 80°C in an oil bath. The resulting mixture was concentrated under vacuum. This resulted in 250 mg (96%) of 2-(2-(2-(3- (3-(benzyloxycarbonyl)phenyl)prop-2-ynyloxy)ethoxy)ethoxy)-N ,N,N- triethylethanaminium as brown oil.

Intermediate 330b: Into a 100-mL round-bottom flask, was placed a solution of 2-(2-(2- (3-(3-(benzyloxycarbonyl)phenyl)prop-2-ynyloxy)ethoxy)ethoxy )-N,N,N- triethylethanaminium (250 mg, 0.52 mmol, 1.00 equiv) in methanol (20 mL), Palladium carbon (250 mg). Hydrogen gas was introduced into the reaction vessel. The resulting solution was stirred overnight at room temperature. The solids were filtered out. The resulting mixture was concentrated under vacuum. This resulted in 200 mg (97%) of 2- (2-(2-(3-(3-carboxyphenyl)propoxy)ethoxy)ethoxy)-N,N,N-triet hylethanaminium as brown oil.

Example 330: Into a 100-mL round-bottom flask, was placed a solution of 2-(2-(2-(3- (3-carboxyphenyl)propoxy)e1hoxy)ethoxy)-N,N,N-triethylethana miriium (107 mg, 0.27 mmol, 1.19 equiv) in dichloromethane (20 mL), EDC.HC1 (65 mg, 0.34 mmol, 1.50 equiv), 4-dimethylaminopyridine (42 mg, 0.34 mmol, 1.52 equiv), 2-(2-amino-5- (diethyIamino)phenyl)-N-(3-(trifluoromethyl)ber^l)isonicotin amide (100 mg, 0.23 mmol, 1.00 equiv). The resulting solution was stirred overnight at room temperature. The resulting solution was diluted with 30 mL of dichloromethane. The resulting mixture was washed with 2x100 mL of NH4CI (aq). The mixture was dried over sodium sulfate and concentrated under vacuum. The crude product (150 mg) was purified by Prep-HPLC with the following conditions (1#-Pre-HPLC-001(SHIMADZU)): Column, SunFire Prep C18, 19*150mm 5um; mobile phase, water with 0.05%TFA and CH3CN (27% CH3CN up to 45% in 6 min, up to 100% in 1 min,down to 27% in 0.7 min); Detector, Waters2545 UvDector 254&220nm.. This resulted in 28.1 mg (15%) of 2-(2- (2-(3-(3-(4-(diemylamino)-2-(4-(3-(trifluoromethyl)benzylcar bamoyl)pyridin-2- yl)phenylcarbamoyl)phenyl)propoxy)emoxy)ethoxy)-N,N,N-trieth ylemanarninium as yellow oil. LC-MS (ES, m/z): 820 [M+H] ⁺

H-NMR (400MHz, CD30D, ppm): 8.95(s, IH), 8.82(d, J=9.2Hz, IH), 8.46(s, IH), 8.14(s, IH), 7.92~7.91(m, IH), 7.85~7.83(m, 2H), 7.72~7.67(m, 2H), 7.62~7.51(m, 5H), 4.72(s, 2H), 3.86(s, 2H), 3.78~3.72(m, 4H), 3.66~3.60(m, 8H), 4H), 3.43~3.37(m, 6H), 2.85~2.83(m, 2H), 1.99~1.95(m, 2H), 1.30~1.23(m, 14H).

EXAMPLE 331

l-(2-(2-(2-(3-(4-(4-(diemylaminoV2-(4-(3-( fluoromemvnbenzylcarbamovnpyridin-2- yltphenylcarbamovnphenvDpropoxy^ethoxytethoxytethylV 1 -azonia- bicvclor2.2.21octane

Scheme 116. 1. H ₂ , Pd C, eOH 2. 331a, EDC.HC1, DMAP, DCM 3. quinuclidine, butanone.

Intermediate 331a: Into a 50-mL round-bottom flask, was placed a solution of benzyl 3- (3-(2-(2-(2-(tosyloxy)ethoxy)ethoxy)ethoxy)prop-l-ynyl)benzo ate (300 mg, 0.54 mmol, 1.00 equiv) in methanol (3 niL), Palladium carbon (1.0 g). Hydrogen gas was introduced into the reaction vessel. The resulting solution was stirred for 2 days at 25°C. The reaction progress was monitored by LCMS,TLC (ethyl acetate/petroleum ether = 1:1). The solids were filtered out. The resulting mixture was concentrated under vacuum. This resulted in 0.2 g (79%) of 3-(3-(2-(2-(2- (tosyloxy)ethoxy)ethoxy)ethoxy)propyl)benzoic acid as a yellow crude solid.

Intermeidate 331b: Into a 50-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed 2-(2-amino-5-(diethylamino)phenyl)-N-(3- (trifluoromethyl)benzyl)isonicotinamide (150 mg, 0.34 mmol, 1.00 equiv), 3-(3-(2-(2- (2-(tosyloxy)ethoxy)ethoxy)ethoxy)propyl)benzoic acid (190 mg, 0.41 mmol, 1.20 equiv), EDC1 (97.6 mg, 0.51 mmol, 1.50 equiv), 4-dimemylarninopyridine (62.2 mg, 0.51 mmol, 1.50 equiv), dichloromethane (2 mL). The resulting solution was stirred overnight at 25°C. The resulting mixture was washed v> .... x2 mL of brine. The miAtuie Was \? ^A anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:2). This resulted in 200 mg (66%) of 2-(2-(2-(3-(3-(4-(diethylamino)-2-(4-(3- (trifluoromethyl)benzylcarbamoyl)pyridin-2- yl)phenylcarbamoyl)phenyl)propoxy)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate as yellow oil.

Example 331 : Into a 25-mL round-bottom flask, was placed a solution of 2-(2-(2-(3-(4- (4-(a¾ethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl) pyridin-2- yl)phenylcarbamoyl)phenyl)propoxy)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (200 mg, 0.22 mmol, 1.00 equiv) in butanone (2 mL), quinuclidine (5 g, 44.97 mmol, 200.00 equiv). The resulting solution was stirred overnight at 25°C. The resulting mixture was concentrated under vacuum. The crude product (200mg ) was purified by Prep-HPLC with the following conditions (1#-Pre-HPLC-001(SHIMADZU)): Column, SunFire Prep C18, 19*150mm 5um; mobile phase, water with 0.05%TFA and CH ₃ CN (27% C¾CN up to 47% in 6 min, up to 100% in 1 min.down to 27% in 0.7 min); Detector, Waters2545 UvDector 254&220nm.. This resulted in 97.4 mg (52%) of l-(2- (2-(2-(3-(4-(4-(diemylammo)-2-(4-(3-(trifluoromethyl)benzylc arbamoyl)pyridin-2- yl)pheny lcarbamoyl)phenyl)propoxy)ethoxy)ethoxy)ethyl)- 1 -azonia- bicyclo[2.2.2]octane as a yellow semi-solid.

LC-MS (ESI, m/z):831 [ +H] ⁺

H-NMR (300MHz, CD ₃ OD, ppm): δ 8.97(d, J=3Hz, 1H), 8.84(d, J=9Hz, 1H), 8.45(s, 1H), 8.16(s, 1H), 7.91-7.93(m, 1H), 7.83-7.86(m, 2H), 7.56-7.73(m, 5H), 7.51-7.53(m, 2H), 4.73(s, 2H), 3.89(s, 2H), 3.73-3.80(m, 4H), 3.61-3.66(m, 8H), 3.49-3.56(m, 8H), 3.34-3.36(m, 2H), 2.85(t, J=9Hz, 2H), 2.12-2.14(m, 1H), 1.94-2.01(m, 8H), 1.25(t, =7.2Hz, 6H). EXAMPLE 332

N-(3-(trifluoromemyl)benzv^

bis(hydroxymemyl)propoxy)emoxy emoxy e oxy eto

onicotinamide

Scheme 117, 1. 1,1,1-triethoxyethane, methylbenzenesulfonic acid 2. 4-methylbenzene- 1-sulfonyl chloride, pyridine 3. NaH, DMF 4. Pd(PPh ₃ ) ₂ Cl ₂ , Cul, TEA, THF 5. H _2> Pd/C, TEA, MeOH 6. EDC.HC1, DMAP, DCM 7. HC1, MeOH.

Intermediate 332a: Into a 100-mL round-bottom flask, was placed 2,2- bis(hydroxymethyl)propane-l,3-diol (15 g, 110.29 mmol, 1.00 equiv), 1,1,1- triethoxyethane (20.2 mL, 1.00 equiv), 4-methylbenzenesulfonic acid (947 mg, 5.51 mmol, 0.05 equiv). The resulting solution was stirred for 0.5 h at 100 ^D C in an oil bath. The temperature was increased to 130°C and the mixture was stirred for 0.5 h. The solids were filtered out. The resulting mixture was concentrated under vacuum. The residue was applied onto a AI2O3 column with ethyl acetate/petroleum ether (1 :10-1:1). This resulted in 2 g (10%) of (l-methyl-2,6,7-trioxa-bicyclo[2.2.2]octan-4-yl)methanol as a white solid.

Intermediate 332b: Into a 100-mL 3-necked round-bottom flask, was placed a solution of 266a.O (2 g, 8.19 mmol, 1.00 equiv, 95%) in dichloromethane (10 mL), pyridine (15 mL). This was followed by the addition of 4-methylbenzene-l-sulfonyl chloride (3.27 g, 17.21 mmol, 2.00 equiv), in portions at 0-10°C. The resulting solution was stirred overnight at room temperature. The resulting solution was diluted with 200 mL of ethyl acetate. The resulting mixture was washed with 1x30 mL of water and 2x30 mL of 10% hydrogen chloride. The resulting mixture was washed with 1x30 mL of sodium bicarbonate and 1x30 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1 :1). This resulted in 1.2 g (32%) of 2-(2-(2- (2-(prop-2-ynyloxy)ethoxy)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate as light brown oil.

Intermediate 332c: Into a 50-mL 3-necked round-bottom flask, was placed a solution of (l-methyl-2,6,7-trioxa-bicyclo[2.2.2]octan-4-yl)methanol (750 mg, 3.75 mmol, 1.50 equiv, 80%) in N,N-dimethylformamide (10 mL). This was followed by the addition of sodium hydride (150 mg, 6.25 mmol, 2.00 equiv), in portions at 0-5°C. To this was added 2-(2-(2-(2-(prop-2-ynyloxy)ethoxy)ethoxy)ethoxy)ethyl 4- methylbenzenesulfonate (1.2 g, 2.64 mmol, 1.00 equiv, 85%). The resulting solution was stirred overnight at room temperature. The resulting solution was diluted with 150 mL of ethyl acetate. The resulting mixture was washed with 3x20 mL of Brine. The mixture was dried over sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:2). This resulted in 690 mg (63%) of l-methyl-4-((2-(2-(2-(2-(prop-2- ynyloxy)ethoxy)ethoxy)ethoxy)ethoxy)methyl)-2,6,7-trioxa-bic yclo[2.2.2]octane as brown oil. Intermediate 332d: Into a 50-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of l-methyl-4-((2-(2-(2-(2-(prop-2- ynyloxy)ethoxy)ethoxy)ethoxy)ethoxy)methyl)-2,6 _> 7-trioxa-bicyclo[2.2.2]octane (690 mg, 1.66 mmol, 1.00 equiv, 90%) in tetrahydrofuran (10 mL), benzyl 3-iodobenzoate (623 mg, 1.75 mmol, 1.00 equiv, 95%), Pd(PPh ₃ ) ₂ Cl ₂ (130 mg, 0.1 mmol, 0.10 equiv), copper(I) iodide (35 mg, 0.18 mmol, 0.10 equiv), triethylami'- - . mg, 3.69 mmol, 2.00 equiv). The resulting solution ,.ώ stirred for 4 h at room temperature. The resulting solution was diluted with 150 mL of ethyl acetate. The resulting mixture was washed with 3x30 mL of Brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a AI2O3 column with ethyl acetate/petroleum ether (1:2). This resulted in 270 mg (25%) of benzyl 3-(3-(2-(2- (2-(2-((l-fnethyl-2,6,7-trioxa-bicyclo[2.2.2]octan-4- yl)methoxy)ethoxy)ethoxy)ethoxy)ethoxy)prop-l-ynyl)benzoate as a brown oil.

Intermediate 332e: Into a 50-mL round-bottom flask, was placed a solution of benzyl 3- (3-(2-(2-(2-(2-((l-methyl-2,6,7-trioxa-bicyclo[2.2.2]octan-4 - yl)methoxy)ethoxy)ethoxy)ethoxy)ethoxy)prop-l-ynyl)benzoate (270 mg, 0.42 mmol, 1.00 equiv, 90%) in methanol (5 mL), Palladium carbon (270 mg), triethylamine (3 drops). Hydrogen gas was introduced into the reaction vessel. The resulting solution was stirred overnight at room temperature. The solids were filtered out. The resulting mixture was concentrated under vacuum. This resulted in 200 mg (86%) of 3-(3-(2-(2- (2-(2-((l-methyl-2,6,7-trioxa-bicyclo[2.2.2]octan-4- yl)methoxy)ethoxy)ethoxy)ethoxy)ethoxy)propyl)benzoic acid as brown oil.

Intermediate 332f: Into a 50-mL round-bottom flask, was placed a solution of N-(3- (trifluoromethyl)berizyl)-2-(2-ammo-5-(diemylammo)phenyl)iso mcotinamide (190 mg, 0.39 mmol, 1.00 equiv, 90%) in dichloromethane (8 mL), 3-(3-(2-(2-(2-(2-((l-methyl- 2,6,7-trioxa-bicyclo[2.2.2]octan-4- yl)methoxy)ethoxy)ethoxy)ethoxy)ethoxy)propyl)benzoic acid (200 mg, 0.32 mmol, 1.00 equiv, 80%), EDC.HC1 (154 mg, 0.80 mmol, 2.00 equiv), 4- dimethylaminopyridine (98 mg, 0.80 mmol, 2.00 equiv). The resulting solution was stirred for 4 h at room temperature. The resulting solution was diluted with 200 mL of ethyl acetate. The resulting mixture was washed with 3x20 mL of Brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with dichloromethane/methanol (100:1). This resulted in 260 mg (51%) of intermediate 232f as brown oil.

Example 332: Into a 50-mL round-bottom flask, was placed a solution of N-(3-

(trifluoromethyl)benzyl)-2-(5-(diethylamino)-2-(3-(3-(2-( 2-(2-(2-((l-methyl-2,6,7- trioxa-bicyclo[2.2.2]octan-4- yl)memoxy)emoxy)emoxy)ethoxy)ethoxy)propyl)benzamido)phenyl) isonicotinamide (250 mg, 0.19 mmol, 1.00 equiv, 70%) in methanol (8 mL), hydrogen chloride (12M) (1 mL). The resulting solution was stirred for 4 h at room temperature. The pH value of the solution was adjusted to 5-6 with sodium carbonate. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 20 mL of methanol. The solids were filtered out. The resulting mixture was concentrated under vacuum. The crude product (200 mg) was purified by Prep-HPLC with the following conditions (1#-Pre-HPLC-001(SHIMADZU)): Column, SunFire Prep C18, 19*150mm 5um; mobile phase, water with 0.05%TFA and CH ₃ CN (30% C¾CN up to 48% in 6 min, up to 100% in 1 min,down to 30% in 0.7 min); Detector, Waters2545 UvDector 254&220nm. This resulted in 137.4 mg (79%) of N-(3-(trifluoromethyl)benzyl)-2-(5- (diethylamino)-2-(3-(3-(2-(2-(2-(2-(3-hydroxy-2,2- bis(hydroxymethyl)propoxy)ethoxy)ethoxy)ethoxy)ethoxy)propyl )benzamido)phenyl)is ©nicotinamide as brown oil.

LC-MS (ES, m/zy. [M+H] ⁺

H-NMR (300MHz, CD ₃ OD, ppm): 8.97 (d, /=3Hz, 1H), 8.82 (d, J=9Hz, 1H), 8.43 (s, 1H), 8.06 (s, 1H), 7.91-7.93 (m, 1H), 7.82-7.84 (m, 2H), 7.56-7.72 (m, 5H), 7.50-7.52 (m, 2H), 4.72 (s, 2H), 3.73-3.80 (m, 4H), 3.59-3.65 (m, 22H), 3.45 (s, 2H), 2.82-2.87 (m, 2H), 1.93-1.99 (m, 2H), 1.22-1.27 (m, 6H).

EXAMPLE 333 (^-Af'-Methyl-^ ^,1 -(23-methyl-2.5.8.11.14,17,20-heptaoxa-23-azapentacosa n-25-vn-N3- (4-(piperidin-l -vD-2-(4-( 1.2.3.4-tetrahvdronaphthalen-l -ylcarbamoyl ^' )pyridin-2- vDphenyBisophthalamide

(5 -JV'-Methyl-A ¹ -(23-methyl-2.5.8J iq4J7 0-heptaoxa-23-azapentacosan-25-vn-N3- ( ^" 4-(piperidin- 1 -ylV2-(4-( 1.2.3.4-tetrahvdronaphthalen- 1 - ylcarbamo γ1Ίρντϊάϊη-2- vPphenvDisophthalamide. Sodium cyanoborohydride (0.75 g, 11.9 mmol) was added portionwise to (5)-Ν ^! -methyl- jV'-(2-oxoe ^^

tetrahydronaphthalen-l-ylcarbamoyl)pyridiii-2-yl)phenyl)i sophthalamide 187a (1.5 g, 2.38 mmol), AT-memyl-2,5,8,l l,14,17,20-heptaoxadocosan-22-amine 135c.l (2.52 g, 7.14 mmol) and acetic acid (0.41 mL, 7.14 mmol) in ethanol (15 mL) and the mixture stirred overnight at room temperature. The reaction was diluted with ethyl acetate, washed with saturated aqueous sodium bicarbonate and brine, dried (MgS0 ₄ ). The residue was purified by PTLC (10% MeOH 20% ethyl acetate/dichloromethane) to give product as an orange oil (0.85 g, 37%); MS (ES, m/z): 969 [M+H] ⁺ ; NM (400MHz, CDC , ppm): δ 12.8 (s, 1H); 8.80 (s, 1H); 8.55 (d, J = 8.8 Hz, 1H); 8.10 (s, 1H); 7.98- 8.02 (m, 2H); 7.47-7.55 (m, 3H); 7.06-7.24 (m, 5H); 6.69 (m, 1H); 5.41 (m, 1H).

EXAMPLE 334

(^-A '-(2-(4-(2.5.8.11.14.17.20-Heptaoxadocosan-22-yl(methvncarba moyl)piperidin- 1 -vDethylVN 1 -methyl-N3-(4-(piperidin-l -yl>2-i4-il .2.3.4-tetrahvdronaphthalen-l - ylcarbamoyl ^' )pyridin-2-yl ^' )phenyl ^' )isophthalamide

Example 334: DIEA (0.068 mL, 0.392 mmol) was added to (S)-l-(2-(JV-methyl-3-(4- (piperidin- 1 -yl)-2-(4-(l ,2,3 ,4-tetrahydronaphthalen- 1 -ylcarbamoyl)pyridin-2- yl)phenylcarbamoyl)benzamido)ethyl)piperidine-4-carboxylic acid (prepared from Example 244 by acidic hydrolysis) (58.1 mg, 0.0783 mmol), JV-methyl- 2,5,8,11, 14,17,20-heptaoxadocosan-22-amine 135c.l (35.9 mg, 0.102 mmol), and HATU (38.7 mg, 0.102 mmol) in DMF (2 mL) and the mixture stirred for 2 hours at room temperature. The reaction was diluted with water and extracted with ethyl acetate. The extract was washed with water and brine, dried (MgSOi), and evaporated. The residue was purified by PTLC (10% methanol/20% ethyl acetate/dichloromethane) to give product as an orange foam (1.2 g, 73%); MS (ES, m/z): 1080 [M+H] ⁺ ; NMR (400MHz, OMSO-d ₆ ,ppm): δ 12.05 (m, 1H); 9.16 (d, / = 8.8 Hz, 1H); 8.85 (d, J = 4.8 Hz, 1H); 8.27 (s, 1H); 8.16 (d, J = 8.8 Hz, 1H); 7.95 (m, 1H); 7.85 (d, J = 4.8 Hz, 1H); 7.60 (m, 2H); 7.40 (s, 1H); 7.09-7.20 (m, 4H); 5.20-5.30 (m, 1H); 3.40-3.65 (m, 21H); 3.18-3.24 (m, 5H); 2.75-3.20 (m, 7H); 1.99 (m, 2H); 1.80 (m, 2H); 1.65 (m, 4H); 1.56 (m, 2H); 1.23-1.28 (m, 6H).

EXAMPLE 335

JV ¹ -(4-(Diemylamino)-2-(4-(3-ftrifluoromemyl)berizylcarba moyl)pyridin-2-yl)phenvn- iV ³ -(23-r2-methoxyethyl)-2.5.8.11.14.17.20-heptaoxa-23-az apentacosan-25-vn-JV ³ - methylisophthalamide. trifluoroacetate

Scheme 118. 1. Na(OAc) ₃ BH, Acetic acid, THF N-(2-methoxyethyl)-2,5,8,l 1,14,17,20- heptaoxadocosan-22-amine 2. Pd C, ¾, MeOH; 3. HATU, DIEA, DMF.

Intermediate 335a. Benzyl 23-r2-methoxyethylV2.5.8.11.14.17.20-heptaoxa-23- azapentacosan-25-yl(methyl carbamate. Sodium triacetoxyborohydride (2.21 g, 10.4 mmol) was added portionwise at room temperature to benzyl methyl(2- oxoethyl)carbamate (1.66 g, 8.03 mmol), N-(2-methoxyethyl)-2,5,8,l l, 14,17,20- heptaoxadocosan-22-amine 135c.2 (3.19 g, 8.03 mmol), and acetic acid (0.92 mL, 16.1 mmol) in THF (50 mL). The mixture was stirred for 2 hours, diluted with ethyl acetate, washed with saturated aqueous sodium bicarbonate and brine, dried (Mg2S<¾) and evaporated. The residue was purified by PTLC (10% methanol/20% ethyl acetate/dichloromethane) to give product as an oil (2.58 g, 55%); MS for C2 H52N2O10 m/z 589 (M+H) ⁺ .

Intermediate 335b. N ¹ -(2.5,8,1 l,14a7.20-Heptaoxadocosan-22-ylVJV ¹ -(2- methoxyethylVA^-methylethane- 1.2-diamine. Benzyl 23-(2-methoxyethyl)- 2,5,8,11, 14,17,20-heptaoxa-23-azapentacosan-25-yl(methyl)carbamate 335a (2.58 g, 4.38 mmol) and palladium on carbon (10%, wet, 0.6 g) in methanol (30 mL) were stirred under a hydrogen atmosphere (balloon) for 2 hours. The mixture was filtered through celite and evaporated to give product as an oil (1.9 g, 99%); MS (ES, m/z): 455 [M+H] ⁺ .

Example 335: DIEA (1.40 mL, 8.05 mmol) was added to a mixture of the 3-(4- (diethylammo)-2-(4-(3-(trifluoromethyl)beKylcarbamoyl)pyridi n-2- yl)phenylcarbamoyI)benzoic acid25b (1.07 g) , ^'-(2,5,8,11,14,17,20- heptaoxadocosan-22-yl)-JV ¹ -(2-methoxyethyl)-Af ² -methylethane-l,2-diamine 335b (1.07 g, 1.61 mmol) and HATU (0.80 g, 2.09 mmol) in DMF (8 mL) and the reaction stirred for 2 hours at room temperature. The reaction was diluted with water and extracted with ethyl acetate. The extract was washed with water and brine, dried (MgSO^, and evaporated. The residue was purified by PTLC (10% methanol/20% ethyl acetate/dichloromethane) to give the title compound as an orange oil (1.2 g, 73%); MS (ES, m/z): 1029 [M+H] ⁺ ; NMR (400MHz, DMSO-4, ppm): δ 9.52 (m, 2H); 8.90 (d, J = 5.2 Hz, 1H); 8.25 (s, 1H); 7.98 (m, 2H); 7.84 (m, 2H); 7.54-7.70 (m, 6H); 4.62 (d, J = 5.6 Hz, 2H); 3.80-3.88 (m, 4H); 3.74 (m, 2H); 3.60 (m, 2H); 3.42-3.56 (m, XH); 3.38-3.41 (m, 2H); 3.32 (m, 2H); 3.22 (s, 3H); 1.12 (t, J = 6.8 Hz, 6H).

EXAMPLE 336

memylcarbamoyll-2-pyridyl1phenyl]carbamoyl1benzoyl1-methyl-a mino1ethyl-(2- memoxyemvnaminolethoxylethoxylethoxylpropanoate

Example 336 was prepared as described in Example 335 substituting tert-butyl 2,8,1 l,14-tetraoxa-5-azaheptadecan-17-oate 135c.4 in place of N-(2-methoxyethyl)- 2,5,8,1 l,14,17,20-heptaoxadocosan-22-amine to prepare tert-butyl 5-(2-methoxyethyl)- 8,l l,14-trioxa-2,5-diazaheptadecan-17-oate DIEA (2.04 mL, 11.7 mmol) was added to a mixture of the 3-(4-(diethylamino)-2-(4-(3-(trifluoromethyl)benzylcarbamoyl )pyridin- 2-yl)phenylcarbamoyl)benzoic acid 25b (2.34 mmol), tert-butyl 5-(2-methoxyethyl)- 8,ll,14-trioxa-2,5-diazaheptadecan-17-oate (0.92 g, 2.34 mmol) and HATU (1.15 g, 3.04 mmol) in DMF (15 mL) and the reaction stirred for 2 hours at room temperature. The reaction was diluted with water and extracted with ethyl acetate. The extract was washed with water and brine, dried (MgSOi), and evaporated. The residue was purified by PTLC (10% methanol/20% ethyl acetate/dichloromethane) to give product as an orange oil (2.13 g, 94%); MS (ES, m/z): 967 [M+H] ⁺ ; NMR (400MHz, DMSO-rf ₆ , ppm): δ 11.8 (m, 1H); 9.49 (m, 1H); 8.87 (d, J = 5.2 Hz, 1H); 8.23 (s, 1H); 8.03 (s, 1H); 7.95 (m, 1H); 7.79 (m, 1H); 7.69 (s, 1H); 7.55-7.65 (m, 5H); 7.06 (d, J = 2.8 Hz, 1H); 6.86 (dd, J = 2.8 and 9.2 Hz, 1H); 4.60 (d, J = 5.6 Hz, 2H); 3.83 (m, 2H); 3.52 (m, 2H); 3.36-3.60 (m, 20H); 3.06 (m, 2H); 3.01 (m, 2H); 2.95 (m, 2H); 2.88 (m, 3H); 2.73 (s, 3H); 2.38 (m, 2H); 1.37 (s, 9H); 1.13 (t, J = 6.8 Hz, 6H).

EXAMPLE 337

iV ^j -(4-(Diemylamino)-2-(4-( ^' 3-(trifluorometfayl)benzylcarbamoyl)pyridin-2-vnphenyl ^' )- N3-(3-(2-methoxyethyl)-17.17-dimethyl-15-oxo-6.9.12-trioxa-3 ,16-diazaoctadecylV ³ - methylisophthalamide

Scheme 119. 1. a. 4M HCl Dioxane; b. HATU, DIEA, iert-butylamine DMF. tert-Butyl 3-[2-[2-[2-[2-[[3-[[4 diethylamino)-2-[5-[[3-(trifluoromethyl)phenyl] memylcarbamoyl]-2-pyridyl]phenyl]carbamoyl]benzoy

methoxyethyl)amino]ethoxy]ethoxy]ethoxy]propanoate (0.101 g, 0.105 mmol) Example 336 and hydrochloric acid (4N in dioxane, 3 mL) were stirred for 4 hours at room temperature and then evaporated to give the carboxylic acid, 3-[2-[2-[2-[2-[[3-[[4- (diemylamino)-2-[5-[[3-(trifluoromethyl)phenyl]methylcarbamo yl]-2- pyridyl]phenyl]carbamoyl]benzoyl]-methyl-amino]ethyl-(2- methoxyethyl)amino]ethoxy]ethoxy]ethoxy]propanoic acid, as a white solid. DIEA (0.091 mL, 0.525 mmol) was added to a mixture of the acid, tert-butylamine (7.65 mg, 0.105 mmol) and HATU (48 mg, 0.126 mmol) in DMF (1 mL) and the reaction stirred for 2 hours at room temperature. The reaction was diluted with water and extracted with ethyl acetate. The extract was washed with water and brine, dried (MgSOii), and evaporated. The residue was purified by PTLC (10% methanol/20% ethyl acetate/dichloromethane) to give product as an orange foam (30 mg, 30%); MS (ES, m z): 966 [M+H] ⁺ ; NMR (400MHz, DMSO-i¾, ppm): δ 11.8 (m, 1H); 9.53 (m, 1H); 8.85 (d, J = 5.2 Hz, 1H); 8.23 (m, 1H); 8.06 (m, 1H); 7.91 (m, 1H); 7.86 (s, 1H); 7.81 (m, 1H); 7.70 (m, 1H); 7.54-7.66 (m, 5H); 7.37 (m, 1H); 7.06 (d, J = 2.8 Hz, 1H); 6.86 (dd, J = 2.8 and 9.2 Hz, 1H); 4.61 (d, J = 6.0 Hz, 2H); 3.36-3.56 (m, 15H); 3.22 (m, 3H); 3.14 (m, 1H); 3.06 (m, 2H); 3.01 (m, 2H); 2.92 (m, 2H); 2.72 (m, 2H); 2.60 (m, 1H); 2.40 (m, 2H); 2.23 (m, 2H); 1.21 (s, 9H); 1.12 (t, J = 6.8 Hz, 6H).

EXAMPLE 338

A^ ¹ -(4-(DiethylaminoV2-(4-(3-(trifluoromemyl)benzylcarbam ovnpyridin-2-yl ^' )phenyl ^' )- JV ³ -(3-(2-methoxyethyl)-16-methyl-18-morpholino-15-oxo-6. 9.12-trioxa-3.16- diazaoctadecylVJV^-methylisophthalamide

Example 338 was prepared as described in Example 337 substituting N-methyl-2- morpholinoethanamine in place of feri-butylamine. MS (ES, m/z): 1035 [M+H] ⁺ ; NMR (400MHz, DMSO-<¾, ppm): δ 11.8 (m, 1H); 9.49 (m, 1H); 8.86 (d, J = 5.2 Hz, 1H); 8.23 (s, 1H); 8.05 (m, 1H); 7.91 (m, 1H); 7.86 (m, 1H); 7.80 (m, 1H); 7.70 (m, 1H); 7.55-7.66 (m, 4H); 7.06 (d, = 2.8 Hz, 1H); 6.86 (dd, J = 2.8 and 9.2 Hz, 1H); 4.61 (d, J = 6 Hz, 2H); 3.30-3.3.64 (m, 25H); 3.23 (m, 4H); 3.14 (m, 2H); 3.11 (m, 1H); 3.01 (m, 1H); 2.90-2.94 (m, 4H); 2.79 (s, 3H); 2.71 (m, 2H); 2.60 (m, 1H); 2.38 (m, 6H); 1.13 (t, J = 6.8 Hz, 6H).

EXAMPLE 339

(SVfe -Butyl l-(3-f4-fdiethylaminoV2-(4-(K2.3.4-tetrahvdronaphthalen-l- ylcarbamoyl ^' )Dyridin-2-yl ^' )phenylcarbamoyl ^' )phenyl ^' )-2.5-dimethyl-l-oxo-8.11.14-trioxa-

2,5 -diazahexadecan- 16-y lcarbamate

Scheme 120. 1. Na(OAc) ₃ BH, Acetic acid, THF 222c; 2. a. PPh ₃ , H ₂ 0, THF; b. di-ferf- butyl dicarbonate, DCM, DIEA 3. Pd/C, H ₂ , MeOH; 4. HATU, DIEA, DMF.

Intermediate 339a: Benzyl 14-azido-3-methyl-6.9.12-trioxa-3- azatetradecvKmethyllcarbamate. Sodium triacetoxyborohydride (3.55 g, 16.8 mmol) was added portionwise at room temperature to benzyl methyl(2-oxoethyl)carbamate (2.68 g, 12.9 mmol), 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)-N-methylethanamine 222c (3.00 g, 12.9 mmol), and acetic acid (2 equiv.) in THF (20 mL). The mixture was stirred for 2 hours, diluted with ethyl acetate, washed with saturated aqueous sodium bicarbonate and brine, dried (Mg2SO<t) and evaporated. The residue was purified by Combiflash purification system (ethyl acetate/dichloromethane) to give product as an oil (3.19 g, 58%); MS (ES, m/z): 424 [M+H] ⁺ .

Intermediate 339b: fert-Butyl iV- 2-[2-[2-r2-f2-(benzyloxycarbonylamino)ethyl-(2- methoxyethyl)aminolethoxy ^" |ethoxylethoxylethvncarbamate. Triphenylphosphine (1.80 g, 6.89 mmol) was added to benzyl 14-azido-3-methyl-6,9,12-trioxa-3- azatetradecyl(methyl)carbamate (2.92 g, 6.89 mmol) in THF (30 mL) and the mixture stirred for 5 hours at room temperature. Water (0.25 mL) was added, the mixture stirred at 50 °C overnight, and then evaporated under vacuum. The residue was dissolved in DCM (30 mL) and DIEA (1.80 mL, 10.3 mmol), and di-/ert-butyl dicarbonate (1.65 g, 7.58 mmol) in DCM (3 mL) added dropwise at 0 °C. The mixture was allowed to warm to room temperature, washed with water and brine, dried (Mg2SC>4) and evaporated. The residue was purified by Combiflash purification system (ethyl acetate/dichloromethane) to give product as an oil (2.99 g, 87%); MS (ES, m/z): 498 [M+H] ⁺ .

Intermediate 339c: ferf-Butyl 5-methyl-8.11.14-trioxa-2.5-diazahexadecan-16- ylcarbamate. fert-Butyl W-[2-[2-[2-[2-[2-(benzyloxycarbonylamino)ethyl-(2- methoxyethyl)amino]-ethoxy]ethoxy]ethoxy]ethyl]carbamate (2.99 g, ) and palladium on carbon (10%, wet, 0.6 g) in methanol (30 mL) were stirred under a hydrogen atmosphere (balloon) for 2 hours. The mixture was filtered through celite and evaporated to give product as an oil (2.18 g, quantitative).

Example 339: (S)-iert-Butyl 3 -(4-(diethylamino)-2-(4-( 1,2,3 ,4-tetrahydronaphthalen- 1 - ylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)benzoate (1.48 g, 2.39 mmol) and hydrochloric acid (4M in dioxane, 10 mL) were stirred at room temperature for 4 hours and then evaporated to dryness to give product as a white solid . DIEA (2.08 mL, 11.9 mmol) was added to (5)-3-(4-(diethylamino)-2-(4-(l,2,3,4-tetrahydronaphthalen-l - ylcarbamoyl)pyridin-2-yl)phenylcarbamoyl)benzoic acid (1.48 g, 2.3 ^r ,.„αοΠ rerr-butyl 5-methyl-8,l l,14-trioxa-2,5-diazahexadecan-16-v1f"il mate (0.87 g, i.jy mmol) and HATU (1.09 g, 2.87 ηττηοΠ in ΐ,ίΓ (15 mL) and the mixture stirred for 2 hours at room temperature. The mixture was diluted with water and extracted with ethyl acetate. The extract was washed with water and brine, dried (Mg ₂ S0 ₄ ) and evaporated. The residue was purified by PTLC (10% methanol/20% ethyl acetate/dichloromethane) to give product as a yellow oil ();MS (ES, m/z): 909 [M+H] ⁺ ; NMR (400MHz, DMSO-i¼, ppm) δ 9.13 (d, J = 8.4 Hz, 1H); 8.83 (d, J = 5.2 Hz, 1H); 8.21 (s, 1H); 8.03 (m, 1H); 7.90-7.92 (m, 1H); 7.86 (s, 1H); 7.81 (d, J = 4.4 Hz, 1H); 7.58-7.61 (m, 2H); 7.09-7.19 (m, 4H); 7.06 (d, J = 2.8 Hz, 1H); 6.85 (dd, J = 2.8 and 9.2 Hz, 1H); 6.72 (m, 1H); 5.23 (m, 1H); 3.33-3.57 (m, 19H); 2.96-3.08 (m, 4H); 2.91 (m, 1H); 2.72-2.80 (m, 2H); 2.24- 2.38 (m, 2H); 1.92-2.02 (m, 2H); 1.90 (m, 1H); 1.72-1.84 (m, 2H); 1.35 (s, 9H); 1.12 (t, J = 7.2 Hz, 6H).

EXAMPLE 340

iy ¹ -f2-f2-r2-r2-r2-(Adamantane-l-carbonylamino ^' )ethoxy1ethoxy1ethoxylethyl-methyl- amino1ethvn-jV ³ -[4-(diethylamino ^' )-2- [5 - Γ Γ3 -( ^" trifluoromethv phenyllmethylcarbamoyll - 2-pyridyl ^' |phenyll-jV'-methyl-benzene-1.3-dicarboxamide

2011/043263

Scheme 121. 1. 4M HC1, Dioxane 2. 1-adamantanecarboxylic acid HATU, DIEA,

DMF.

Intermediate 340a: (S)-ieri-Butyl l-(3-(4-(diethylamino)-2-(4-(l,2,3,4- tetrahydronaphthalen-l-ylcarbamoyl)pyridin-2-yl)phenylcarbam oyl)phenyl)-2,5- dimethyl-l-oxo-8,l l,14-trioxa-2,5-diazahexadecan-16-ylcarbamate Example 339 (1.08 g, 1.23 mmol) and hydrochloric acid in dioxane (4N, 20mL) were stirred for 4 hours at room temperature and then evaporated to dryness to give the intermediate (^-^-(H- arrimo-3-methyl-6,9,12-trioxa-3-azatetradecyl)-A' -(4-(diemylamino)-2-(4-(l,2,3,4- tetrahy dronaphthalen- 1 -ylcarbamoy^pyridin^-y^pheny^-JV ¹ -methylisophthalamide

tetrahydrochloride 340a as a foam (1.2 g, quantitative); MS (ES, m/z): 808 [M+H] ⁺ .

Example 340: DIEA (0.12 mL, 0.666 mmol) was added to (^-^-(M-amino-S-methyl- 6,9,12-trioxa-3-azatetradecyl)-A ^r3 -(4-(diethylamino)-2-(4-(l,2,3,4-tetrahydronaphthalen- 1 -ylcarbamoyl)pyridin-2-yl)phenyl)-A^' -methylisophthalamide tetrahydrochloride 340a

(0.106 g, 0.111 mmol), 1-adamantanecarboxylic acid (20.1 mg, 0.111 mmol) and

HATU (51 mg, 0.133 mmol) in DMF (2 mL) and the mixture stirred for 2 hours at room temperature. The reaction was diluted with ethyl acetate, washed with water and brine, dried (MgSC ) and evaporated. The residue was purified by PTLC (10% 2011/043263

methanol/20% ethyl acetate/dichloromethane) to give product as a yellow foam (0.076 g, 70%); MS (ES, m/z): 972 [M+H] ⁺ ; NMR (400MHz, DMSO-ife ppm): δ 11.8 (m,

1H); 9.13 (d, J = 8.8 Hz, 1H); 8.83 (d, J = 5.2 Hz, 1H); 8.21 (s, 1H); 8.03 (m, 1H); 7.95

(s, 1H); 7.91 (m, 1H); 7.86 (m, 1H); 7.81 (d, J = 4.8 Hz, 1H); 7.58 (m, 2H); 7.29 (t, J =

5.2 Hz, 1H); 7.09-7.19 (m, 4H); 7.05 (m, 1H); 6.85 (dd, J = 2.8 and 9.2 Hz, 1H); 5.22

(m, 1H); 3.30-3.52 (m, 16H); 3.25 (m, 2H); 2.88-3.05 (m, 6H); 2.70-2.83 (2H); 2.33 (m,

2H); 1.70-2.04 (m, 15); 1.56-1.68 (m, 6H); 1.12 (t, J= 6.8 Hz, 6H).

EXAMPLE 341

(^-Af'-(4-(Diethylamino ^' )-2-(4-(1.2.3.4-tetrahvdronaphthalen-l-ylcarbamoyl)Dyr idin-2- vnphenyl)- ⁱ -methyl-jV ³ -(3 -methyl- 16-oxo-6.9, 12-trioxa-3 , 15 - diazaheptadecvDisophthalamide

Example 341: DIEA (0.12 mL, 0.66 mmol) was added to (^-^-(M-amino-S-methyl- 6,9,l2-trioxa-3-azate1radecyl)-iV ³ -(4-(diemylarM^

l-ylcarbamoyl)pyridin-2-yl)phenyl)- -methylisophthalamide tetrahydrochloride 340a

(0.105 g, 0.11 mmol) and acetic anhydride (0.0125 mL, 0.132 mmol) in DCM (5 mL) and the mixture stirred for 2 hours at room temperature. The reaction was diluted with

DCM, washed with water and brine, dried (MgSO^ and evaporated. The residue was purified by PTLC (10% methanol/20% ethyl acetate/dichloromethane) to give product as a yellow foam (0.089 g, 95%); MS (ES, m/z) 852 [M+H] ⁺ ; NMR (400MHz, DMSO- d ₆ , ppm): 5 11.4 (m, 1H); 9.13 (d, J = 8.8 Hz, 1H); 8.83 (d, J = 5.6 Hz, 1H); 8.21 (s,

1H); 8.02 (m, 1H); 7.91 (m, 1H); 7.85 (m, 1H); 7.81 (d, J= 4.4 Hz, 1H); 7.58-7.59 (m,

2H); 7.09-7.19 (m, 4H); 7.06 (d, J = 3.2 Hz, 1H); 6.85 (dd, J = 3.2 and 9.2 Hz, 1H);

5.23 (m, 1H); 3.24-3.56 (m, 18H); 3.15 (q, J= 5.6 Hz, 2H); 3.00 (m, 2H); 2.91 (m, 2H); 2.76-2.79 (m, 2H); 2.63 (m, 1H); 2.57 (m, 1H); 2.46 (m, 1H); 2.33 (m, 1H); 2.29 (m, 2H); 1.93-2.04 (m, 2H); 1.89 (m, 1H); 1.70-1.84 (m, 2H); 1.77 (s, 3H); 1.12 (t, J = 6.8 Hz, 6H).

EXAMPLE 342

ffl-A ^fl -(4-(Diethylamino)-2-(4-n2 .4-tetrahvdronaphthalen-l-ylcarbam

diazahexadecan- 16-yl)isophthalamide

Example 342: DIEA (0.11 mL, 0.654 mmol) was added to (S)-/V^14-ainino-3-methyl- 6,9, 12-trioxa-3-azatetradecyl)-W ³ -(4-(diethylamino)-2-(4-(l ,2,3 ,4-tetrahydronaphthalen- 1 -ylcarbamoylJpyridin^-y pheny -JV'-methylisophthalamide tetrahydrochloride 340a (0.104 g, 0.109 mmol), nicotinic acid (13.4 mg, 0.109 mmol) and HATU (49 mg, 0.131 mmol) in DMF (2 mL) and the mixture stirred for 2 hours at room temperature. The reaction was diluted with ethyl acetate, washed with water and brine, dried (MgSC>4) and evaporated. The residue was purified by PTLC (10% methanol/20% ethyl acetate/dichloromethane) to give product as a yellow foam (0.079 g, 80%); MS (ES, m/∑): 915 [M+H] ⁺ ; NMR (400MHz, DMSO-<¼, ppm) δ 11.7 (m, 1H); 9.13 (d, J = 8.4 Hz, 1H); 8.98 (m, 1H); 8.83 (d, J = 4.4 Hz, 1H); 8.68-8.70 (m, 2H); 8.21 (s, 1H); 8.15- 8.18 (m, 1H); 8.02 (m, 1H); 7.92 (m, 1H); 7.86 (m, 1H); 7.80 (d, J = 4.8 Hz, 1H); 7.59 (m, 2H); 7.47-7.50 (m, 1H); 7.11-7.19 (m, 4H); 7.06 (d, J = 2.8 Hz, 1H); 6.85 (dd, J = 2.8 and 9.2 Hz, 1H); 5.22 (m, 1H); 3.32-3.64 (m, 18H); 3.14 (m, 1H); 3.00 (m, 2H); 2.92 (m, 2H); 2.77 (m, 2H); 2.32 (m, 1H); 1.70-2.04 (m, 5H); 1.12 (t, J = 6.8 Hz, 6H).

EXAMPLE 343 (,S^-Ar 4-fDiethylaminoV2-(4-fl.2.3.4-tett^

vnphenylVA^-methyl-A^-fH-methyl-l-oxo-l-ftetrahvdro^H -pyran-4-ylV5.8.11 -trioxa- 2.14-diazahexadecan-16-yl sophthalamide

Example 343: DIEA (0.11 mL, 0.654 mmol) was added to (S)-iV^14-amino-3-methyl- 6,9,12-trioxa-3-azatetradecyl)-JV ³ -(4-(diemylami∞

1 -ylcarbamoyl)pyridin-2-yl)phenyl)- -methylisophthalamide tetrahydrochloride 340a (0.101 g, 0.106 mmol), tetrahydropyran-4-yl-carboxylic acid (13.8 mg, 0.106 mmol) and HATU (48 mg, 0.127 mmol) in DMF (2 mL) and the mixture stirred for 2 hours at room temperature. The reaction was diluted with ethyl acetate, washed with water and brine, dried (MgSO-i) and evaporated. The residue was purified by PTLC (10% methanol/20% ethyl acetate/dichloromethane) to give product as a yellow foam (0.071 g, 73%); MS (ES, m/z): 921 [M+H] ⁺ ; NMR (400MHz, DMSO-rf ₆ , ppm): δ 11.7 (m, lH); 9.13 (d, J = 8.4 Hz, 1H); 8.83 (d, J = 5.2 Hz, 1H); 8.21 (s, 1H); 8.02 (m, 1H); 7.92 (m, 1H); 7.87 (m, 1H); 7.76-7.84 (m, 1H); 7.60 (m, 1H); 7.08-7.20 (m, 4H); 7.06 (d, J = 2.8 Hz, 1H); 6.84 (dd, J = 2.8 and 9.2 Hz, 1H); 5.22 (m, 1H); 3.80-3.84 (m, 2H); 3.20- 3.66 (m, 17H); 3.12-3.20 (m, 2H); 3.00 (m, 3H); 2.93 (m, 2H); 2.72-2.82 (m, 2H); 2.26- 2.38 (m, 2H); 1.98 (m, 2H); 1.79 (m, 2H); 1.51-1.56 (m, 4H); 1.12 (t, J = 6.8 Hz, 6H).

EXAMPLE 344

(jS^-A^-(4-( ^" DiemylaminoV2-(4-(1.2.3.4-tetrahvdronaphthalen-l-ylcar bamoyl)Dyridin-2-

diazahexadecan- 16-vnisophthalamide

Example 344: DIEA (0.11 mL, 0.654 mmol) was added to (^-^-(H-amino-S-methyl- 6,9,12-trioxa-3-azatetradecyl)-A' ³ -(4-(diethylamino)-2-(4-(l,2,3,44etrahydronaphmden^ 1 -ylcarbamoy pyridm^-y^pheny -W'-memylisophmalamide tetrahydrochloride 340a (0.101 g, 0.106 mmol), thiazole-5-carboxylic acid (14.2 mg, 0.110 mmol) and HATU (50 mg, 0.132 mmol) in DMF (2 mL) and the mixture stirred for 2 hours at room temperature. The reaction was diluted with ethyl acetate, washed with water and brine, dried (MgSO^ and evaporated. The residue was purified by PTLC (10% methanol/20% ethyl acetate/dichloromethane) to give product as a yellow foam (0.073 g, 75%); MS (ES, m/z): 921 [M+H] ⁺ ; NMR (400MHz, OMSO-d ₆ , ppm): δ 11.7 (m, 1H); 9.19 (s, 1H); 9.13 (d, J = 8.4 Hz, 1H); 8.83 (d, J = 4.4 Hz, 1H); 8.80 (m, 1H); 8.46 (s, 1H); 8.21 (s, 1H); 8.03 (m, 1H); 7.90 (m, 2H); 7.81 (d, J = 4.8 Hz, 1H); 7.60 (m, 2H); 7.08-7.20 (m, 4H), 7.05 (d, J = 2.8 Hz, 1H); 6.85 (dd, J = 2.8 and 9.2 Hz, 1H); 5.22 (m, 1H); 3.20-3.66 (m, 20H); 3.13 (m, 2H); 3.00 (m, 2H); 2.93 (m, 2H); 2.76 (m, 2H); 1.97 (m, 2H); 1.78 (m, 2H); 1.12 (t, J = 6.8 Hz, 6H).

EXAMPLE 345

(i^-Af ¹ -(4-(Diemylammo ^' )-2-(4-(1.2.3.4-tetrahvdronaphthalen-l-ylcarbamoyl Dyridin-2- yl DhenylVW ³ -( 1 -(4-hvdroxyphenyl ^" )- 14-methy 1- 1 -oxo-5.8.11 -trioxa-2.14- diazahexadecan-16-yl)-A^-methylisophthalamide

Example 345: DIEA (0.11 mL, 0.654 mmol) was added to (5)- -(14-amino-3-methyl- 6,9,12-trioxa-3-azatetradecyl)-A^-(4-(diemylam^

1 -ylcarbamoy Opyridin^-y phenyl)-/ ¹ -methy lisophthalamide tetrah drochloride 340a (0.101 g, 0.106 mmol), 4-acetoxybenzoic acid (19.1 mg, 0.106 mmol) and HATU (48 mg, 0.127 mmol) in DMF (2 mL) and the mixture stirred for 2 hours at room temperature. The reaction was diluted with ethyl acetf* ·;, ,»<«,iicu wuii waier and brine, dried (MgS0 ) and evaporated. ±ne residue was purified by PTLC (10% methanol/20% ethyl acetate/dichloromethane) to give the intermediate (S)-4-(l-(3-(4- (diemylammo)-2-(4-(l,2,3,4-tetrahydronaphmalen -ylcarbamoyl)pyridin-2- yl)phenylcarbamoyl)phenyl)-2,5-dimethyl- 1 -oxo-8, 11,14-trioxa-2,5-diazahexadecan- 16-ylcarbamoyl)phenyl acetate as a yellow foam (0.082 g, 75%); MS (ES, m/z): 972 [M+H] ⁺ . Ammonia in methanol (2M, 4 mL) was added and the mixture stirred overnight at room temperature. The reaction was evaporated and the residue purified by PTLC (10% methanol/20% ethyl acetate/dichloromethane) to give product as a yellow foam (0.065 g, 83%); MS (ES, m/z): 928 [M+H] ⁺ ; NMR (400MHz, DMS0-< ppm): δ 11.7 (m, 1H); 9.93 (s, 1H); 9.13 (d, J = 8.4 Hz, 1H); 8.83 (d, J = 5.2 Hz, 1H); 8.21 (m, 2H); 7.96-8.06 (m, 1H); 7.84-7.94 (m, 2H); 7.80 (d, J = 4.8 Hz, 1H); 7.70 (dd, J = 2.0 and 6.8 Hz, 2H); 7.60 (m, 2H); 7.09-7.19 (m, 4H); 7.06 (d, J = 3.2 Hz, 1H); 6.85 (dd, = 2.8 and 8.8 Hz, 1H); 6.77 (m, 2H); 5.23 (m, 1H); 3.35-3.60 (m, 25H); 2.99 (m, 3H); 2.92 (m, 2H); 2.33 (m, 1H); 1.90-2.04 (m, 3H); 1.70-1.86 (m, 2H); 1.12 (t, J = 6.8 Hz, 6H).

EXAMPLE 346

/vV4-(diemylamino)-2-(4-(3-(trifluorome^

A^-methyl-A^-0.17,17-trimethyl- 16-oxo-6.9 Λ 2-trioxa-3.15- diazaoctadecvDisophthalamide

Example 346: The compound was prepared as described in Examples 339 substituting 25b in place of 131c. DIEA (1.47 mL, 8.45 mmol) was added to 3-(4-(diethylamino)-2- (4-(3-(trifluoromethyl)benzylcarbamoyl)pyridin-2-yl)phenylca rbamoyl)benzoic acid, dihydrochloride(1.12 g, 1.69 mmol), tert-butyl 5-methyl-8,l l,14-trioxa-2,5- diazahexadecan-16-ylcarbamate 339c (0.61 g, 1.69 mmol) and HATU (0.77 g, 2.03 mmol) in DMF (8 mL) and the mixture stirred for 2 hours at room temperature. The mixture was diluted with water and extracted with ethyl acetate. The extract was washed with water and brine, dried (Mg ₂ SO< and evaporated. The residue was purified by Combiflash chromatography system (methanol/dichloromethane gradient) to give product as a yellow oil (1.46 g, 94%); MS (ES, m/z): 920 [M+H] ⁺ .

EXAMPLE 347

(S')-16-(3-(4-(cvclopentyloxy -2-(4-(1.2,3,4-tetrahvdronaphthalen-l- ylcarbamo vDpyridin-2-yl1phenylcarbamoyl ^' >phenyl)-4.7.10.13 -tetraoxahexadecan- 1 -oic acid

Example 347: This compound was prepared as described in Example 251 substituting 133a in place of 25b. MS (ES, m/z): 794 [M+H] ⁺ .

EXAMPLE 348

Procedure for the Measurement of NaP2b-Mediated P. Transport

Materials. HEK293 cells were obtained from the American Type Culture collection and propagated per their instructions. Expression clones for rat and human NaP2b (SLC34A2) were obtained from Open Biosystems (Catalog numbers MRN1768-9510282, and MHS1010-99823026, respectively). The sequence of the human protein was mutated to insert a threonine after residue 37, and to introduce a N39D mutation.

Inhibition of Pj Transport The rate of phosphate (Pi) uptake into HEK293 cells was measured using a modification of the method described by Mohrmann et al. (Mohrmann, I., Mohrmann, M., Biber, J., and Murer, H. (1 86) Am. J. Phys. 250(3 Pt l):G323-30.) Transfected HEK293 cells were treated with a pharmacological agent to minimize endogenous PiT-mediated phosphate transport activity, such that the only remaining sodium-dependent phosphate transport activity is that which was bestowed by introduction of the NaP2b genes.

Cells were seeded into 96-well plates at 25,000 cells/well and cultured overnight. Lipofectamine 2000 (Invitrogen) was used to introduce the NaP2b cDNA, and the cells were allowed to approach confluence during a second overnight incubation. Medium was aspirated from the cultures, and the cells were washed once with choline uptake buffer (14 mM Tris, 137 mM choline chloride, 5.4 mM KCl, 2.8 mM CaCl _¾ 1.2 mM MgS0 ₄ , 100 uM KH ₂ P0 , 1 mg/mL Bovine Serum Albumin, pH 7.4). Cells were then overlayed with either choline uptake buffer or sodium uptake buffer (14 mM Tris, 137 mM sodium chloride, 5.4 mM KCl, 2.8 mM CaCl ₂ , 1.2 mM MgS0 ₄ , 100 uM KH2PO4, PiT-silencing agent, 1 mg/mL Bovine Serum Albumin, pH 7.4) containing 6-9 uCi/mL ³³ P orthophosphoric acid (Perkin Elmer) and test compound. Each compound was tested at twelve concentrations ranging from 0.1 nM to 30 uM. Assays were run in duplicate.

After incubation for 3-30 minutes at room temperature, assay mixtures were removed, and the cells were washed twice with ice cold stop solution (137 mM sodium chloride, 14 mM Tris, pH 7.4). Cells were lysed by addition of 20 μΐ, 0.1% Tween 80 followed by 100 μ scintillation fluid, and counted using a TopCount (Perkin Elmer).

pIC50 (the negative log of the IC50) values of the test compounds were calculated using GraphPad Prism. Preliminary studies showed that under these conditions, sodium-dependent Pi uptake was linear for at least 30 min and tolerated 0.6 % (v/v) DMSO without deleterious effects.

To ascertain if an inhibitor was competitive for binding with phosphate, the procedure was repeated, but raising the concentration of the substrate in the assay mixture from 0.1 to 2.1 mM phosphate. Compounds that maintained their potency for inhibition of NaPi2b in the presence of 2.1 vs 0.1 mM phosphate were considered to not be competitive with respect to phosphate.

Table 11

Inhibitory activity of compounds against rat and human NaP2b Values reported as pIC50.

1.19 4.5-5

1.2 4.5-5

1.20 4.5-5

1.21 4.5-5

1.22 5.1-6.0

1.23 5.1-6.0

1.24 5.1-6.0

1.25 5.1-6.0

1.26 5.1-6.0

1.27 4.5-5

1.28 5.1-6.0

1.29 5.1-6.0

1.30 5.1-6.0

1.3 5.1-6.0

1.31 5.1-6.0

1.32 5.1-6.0

1.33 5.1-6.0

1.34 5.1-6.0

1.35 5.1-6.0

1.36 5.1-6.0

1.36 5.1-6.0

1.37 5.1-6.0

1.38 4.5-5

1.39 5.1-6.0

1.4 5.1-6.0

1.40 5.1-6.0

1.42 5.1-6.0

1.43 5.1-6.0

1.44 5.1-6.0

1.45 5.1-6.0

1.46 5.1-6.0

1.47 5.1-6.0

1.48 5.1-6.0

1.49 5.1-6.0

1.5 5.1-6.0

1.6 5.1-6.0

1.7 5.1-6.0

1.8 4.5-5 1.9 4.5-5

2 4.5-5

3.1 5.1-6.0 5.1-6.0

3.10 5.1-6.0 ^• 4.5-5

3.2 4.5-5

3.3 4.5-5

3.4 4.5-5

3.5 5.1-6.0

3.6 4.5-5 4.5-5

3.7 4.5-5 4.5-5

3.8 4.5-5

3.9 4.5-5

4.10 4.5-5

4.1 4.5-5

4.11 5.1-6.0

4.12 5.1-6.0

4.13 5.1-6.0

4.14 5.1-6.0

4.15 5.1-6.0

4.16 4.5-5

4.17 4.5-5

4.18 4.5-5

4.19 5.1-6.0 5.1-6.0

4.20.1 5.1- 6.0

4.2 5.1-6.0

4.20.2 5.1-6.0

4.21 5.1-6.0

4.22 4.5-5

4.23 4.5-5

4.24 5.1-6.0

4.25 5.1-6.0

4.26 5.1-6.0 >6.0

4.27 5.1-6.0

4.28 5.1-6.0

4.29 5.1-6.0

4.30 5.1-6.0

4.3 5.1-6.0

4.31 4.5-5 4.32 5.1-6.0

4.4 4.5-5

4.5 5.1-6.0

4.6 4.5-5

4.7 4.5-5

4.8 5.1-6.0

4.9 4.5-5

5.1 5.1-6.0

5.2 4.5-5

6.1 4.5-5

6.2 4.5-5

7 4.5-5

8.10 4.5-5

8.1 4.5-5

8.1 >6.0 >6.0 No

8.11 4.5-5

8.12 4.5-5

8.13 4.5-5

8.14 5.1-6.0

8.15 5.1-6.0

8.16 5.1-6.0

8.17 >6.0

8.18 >6.0 No

8.19 5.1-6.0

8.2 5.1-6.0

8.20 5.1-6.0

8.21 5.1-6.0 5.9

8.22 5.1-6.0

8.23 5.1-6.0

8.25 5.1-6.0 >6.0

8.26 4.5-5 No

8.27 4.5-5

8.3 5.1-6.0

8.4 5.1-6.0

8.5 5.1-6.0

8.6 5.1-6.0

8.7 5.1-6.0

8.8 >6.0 8.9 5.1-6.0

9.1 5.1-6.0

9.2 5.1-6.0 >6.0

9.3 5.1-6.0

10.10 5.1-6.0

10.1 5.1-6.0 >6.0 No

10.11 5.1-6.0

10.12 5.1-6.0

10.2 4.5-5

10.3 4.5-5

10.4 4.5-5

10.5 4.5-5

10.6 5.1-6.0

10.7 5.1-6.0

10.8 4.5-5

10.9 4.5-5

11.1 5.1-6.0

11.2 5.1-6.0

11.3 4.5-5

11.4 4.5-5

12.1 5.1-6.0

12.2 4.5-5

14 4.5-5

15 5.1-6.0

16 5.1-6.0

17 5.1-6.0

18 5.1-6.0

19 5.1-6.0

20 5.1-6.0

21 5.1-6.0

22 4.5-5

24 5.1-6.0

25 >6.0 >6.0

26 5.1-6.0

27 5.1-6.0

28 5.1-6.0

29 5.1-6.0

30 5.1-6.0 31 4.5-5

32 4.5-5

33 4.5-5

34 4.5-5

35 5.1-6.0

36 5.1-6.0

37 >6.0 >6.0 No

38 4.5-5

39 5.1-6.0

40 4.5-5

41 4.5-5

42 4.5 - 5

43 4.5-5

44 4.5-5

45 4.5-5

46 4.5-5

47 4.5-5

48 5.1-6.0

49 5.1-6.0

50 5.1-6.0

51 5.1-6.0

53 5.1-6.0

54 4.5-5

55 5.1-6.0

56 4.5-5

57 4.5-5

58 5.1-6.0

59 5.1-6.0

60 4.5-5

61 4.5-5

62 4.5-5

63 5.1-6.0

64 4.5-5

65 4.5-5

66 4.5-5

67 4.5-5

68 4.5-5

69 4.5-5 70 4.5-5

71 4.5-5

72 4.5-5

73 4.5-5

74 4.5-5

75 4.5-5

76 4.5-5

77 5.1-6.0

78 4.5-5

79 4.5-5

80 5.1-6.0 5.1-6.0 No

81 5.1-6.0

82 5.1-6.0

83 5.1-6.0

84 5.1-6.0

85 5.1-6.0

86 5.1-6.0

87 4.5-5

88 4.5-5

89 5.1-6.0

90 4.5-5

91 4.5-5

92 5.1-6.0

93 4.5-5

94 4.5-5

95 4.5-5

96 4.5-5

97 5.1-6.0 5.1-6.0

98 4.5-5

99 4.5-5

100 5.1-6.0

101 5.1-6.0

102 4.5-5

103 4.5-5

104 4.5-5

105 5.1-6.0

106 4.5-5

108 4.5 - 5 109 5.1-6.0

110 5.1-6.0

111 4.5-5

112 5.1-6.0

113 5.1-6.0

114 5.1-6.0

115 >6.0 >6.0

116 5.1-6.0

117 5.1-6.0 5.1-6.0

118 5.1-6.0

119 >6.0

270 5.1-6.0

331 5.1-6.0

330 5.1-6.0

332 >6.0 >6.0

263 5.1-6.0 >6.0

294 >6.0 >6.0

290 4.5- 5.0 5.1-6.0

291 5.1-6.0 >6.0

292 5.1-6.0 >6.0

295 5.1-6.0

296 5.1-6.0 5.1-6.0

293 5.1-6.0 5.1-6.0

297 5.1-6.0 5.1-6.0

272 5.1-6.0 5.1-6.0

287 5.1-6.0 5.1-6.0

288 5.1-6.0 5.1-6.0

257 5.1-6.0 >6.0

258 5.1-6.0

259 5.1-6.0 5.1-6.0

260 5.1-6.0 >6.0

262 5.1-6.0 5.1-6.0

271 5.1-6.0 >6.0

298 5.1-6.0 5.1-6.0

304 >6.0 >6.0

306 >6.0 >6.0

299 5.1-6.0 >6.0

300 5.1-6.0 >6.0 320 >6.0

321 5.1-6.0

322 5.1-6.0

323 >6.0

324 >6.0

326 >6.0

325 >6.0

225 4.5-5.0

224 5.1-6.0

344 >6.0

343 5.1-6.0

342 5.1-6.0

345 5.1-6.0

347 >6.0

133 5.1-6.0

346 5.1-6.0

341 5.1-6.0

340 5.1-6.0

289 5.1-6.0 5.1-6.0

226 >6.0 5.1-6.0

253 >6.0 >6.0

223 4.5-5.0 <4.5

339 >6.0 >6.0

273 5.1-6.0 5.1-6.0

274 5.1-6.0 5.1-6.0

338 5.1-6.0 5.1-6.0

247 5.1-6.0 5.1-6.0

239 >6.0 >6.0

261 >6.0 >6.0

337 5.1-6.0 5.1-6.0

179 5.1-6.0 5.1-6.0

178 5.1-6.0 5.1-6.0

182 >6.0 >6.0

285 >6.0 >6.0

205 >6.0 >6.0

284 5.1-6.0 5.1-6.0

232 4.5- 5.0 4.5-5.0

177 5.1-6.0 5.1-6.0 176 5.1-6.0 5.1-6.0

175 5.1-6.0 5.1-6.0

336 5.1-6.0 5.1-6.0

269 5.1-6.0 >6.0

266 5.1- 6.0 5.1-6.0

335 5.1-6.0 5.1-6.0

174 5.1-6.0 >6.0

172 5.1-6.0 >6.0

171 5.1-6.0 >6.0

170 5.1-6.0 >6.0

169 >6.0 >6.0

203 5.1-6.0 5.1-6.0

268 >6.0 >6.0

267 >6.0 >6.0

281 >6.0 >6.0

202 5.1-6.0 >6.0

275 5.1-6.0 5.1-6.0

276 5.1-6.0 5.1-6.0

277 5.1-6.0 5.1-6.0

278 5.1-6.0 5.1-6.0

303 5.1-6.0 >6.0

201 5.1-6.0 5.1-6.0

230 5.1-6.0 5.1-6.0

243 4.5- 5.0 4.5- 5.0

231 4.5- 5.0 4.5- 5.0

167 4.5-5.0 4.5- 5.0

251 5.1-6.0 >6.0

173 >6.0 >6.0

164 5.1-6.0 >6.0

163 5.1-6.0 5.1-6.0

222 >6.0 >6.0

214 5.1-6.0 5.1-6.0

213 4.5-5.0 5.1-6.0

242 >6.0 >6.0

200 5.1-6.0 >6.0

159 >6.0 >6.0

279 5.1-6.0 5.1-6.0

280 >6.0 >6.0 282 >6.0 5.1-6.0

283 >6.0 5.1-6.0

302 >6.0 >6.0

212 >6.0 >6.0

229 >6.0 >6.0

227 5.1-6.0 5.1-6.0

132 >6.0 >6.0

236 >6.0 >6.0

286 >6.0 >6.0

161 5.1-6.0 5.1-6.0

181 >6.0 >6.0

168 >6.0 >6.0

166 5.1-6.0 5.1-6.0

265 >6.0 >6.0

199 5.1-6.0

198 4.5- 5.0

334 4.5- 5.0

328 5.1-6.0 5.1-6.0

160 >e.o >6.0

158 >6.0 >6.0

255 5.1-6.0

245 4.5- 5.0

128 5.1-6.0

241 5.1-6.0

228 5.1-6.0

237 5.1-6.0

252 >6.0 >6.0

197 5.1-6.0

196 5.1-6.0 5.1-6.0

240 5.1-6.0

333 5.1-6.0

157.1 5.1-6.0

256 5.1-6.0

165 5.1-6.0

157 >6.0

195 5.1-6.0

194 >6.0

327 5.1-6.0 154 4.5-5.0

153 4.5-5.0

152 5.1-6.0

151 5.1-6.0

150 4.5- 5.0

155 4.5- 5.0

246 5.1-6.0

127 4.5-5.0

250 5,1- 6.0

149 5.1-6.0

148 5.1-6.0

142 >6.0 5.1-6.0

193 4.5-5.0

192 >6.0 >6.0

191 4.5-5.0

190 5.1-6.0 5.1-6.0

180 5.1-6.0

144 >6.0 >6.0

145 4.5- 5.0

147 5.1-6.0

221 4.5-5.0

131 >6.0

189 5.1-6.0

235 >6.0

146 5.1-6.0

329 5.1-6.0

254 >6.0 >6.0

244 5.1-6.0 5.1-6.0

220 >6.0 5.1-6.0

219 >6.0 >6.0

162 >6.0 >6.0

234 >6.0 >6.0

143 >6.0 >6.0

129 5.1-6.0

188 5.1-6.0 5.1-6.0

216 >6.0 >6.0

215 >6.0 >6.0

211 5.1-6.0 249 5.1-6.0

187 >6.0 5.1-6.0

233 5.1-6.0 5.1-6.0

218 5.1-6.0

141 5.1-6.0

140 5.1-6.0

139 4.5-5.0

264 4.5-5.0

217 >6.0

138 5.1-6.0 5.1-6.0

137 5.1-6.0

136 5.1-6.0

13 ₅ 5.1-6.0

134 5.1-6.0

185 5.1-6.0 >6.0

121 5.1-6.0

125 5.1-6.0

210 4.5-5.0

126 >6.0 5.1-6.0

186 5.1-6.0

124 5.1-6.0

123 5.1-6.0

122 . 5.1-6.0 5.1-6.0

208 4.5-5.0

207 4.5- 5.0

130 5.1-6.0

120 5.1-6.0

248 4.5-5.0

184 5.1-6.0

183 5.1-6.0 5.1-6.0

238 4.5-5.0

209 5.1-6.0

A blank indicates not tested

* Indicates compound is considered to not be competitive with respect to phosphate. A blank indicates not tested for competitive inhibition.

EXAMPLE 349 U 2011/043263

In vivo Assay: Bolus Phosphorus Challenge

It has been demonstrated that the hyperphosphatemia response to a single oral dose of phosphorus is significantly dampened in mice deficient in the Nap2b gene (Sabbagh et al, J. Am Soc Nephrol., 20(ll):2348-58 (2009)). By pretreating animals with a low phosphorus diet followed by the subsequent dosing of a phosphorus bolus, serum phosphorus levels were monitored after 30 minutes as a surrogate for intestinal phosphorus absorption. These investigators showed that as a result of Nap2b deletion, the rise in serum phosphorus was reduced by about 40%. This indicates that the theoretical maximum effect on phosphorus absorption a Nap2b inhibitor could have in mice is 40% as indicated by the serum Pi. The in vivo bolus phosphorus challenge model used here mimics this model in rats.

Male, 7-week-old Sprague-Dawley rats (Charles-River laboratories international, Hollister, CA) were allowed to acclimatize for a minimum of 3 days before switching to a synthetic low-phosphorus diet (TD.85010, Harlan Teklad,

Madison, WI) which contains 0.1% phosphorus and 0.6% calcium. At day 5, testing compounds or vehicle alone (as indicated) were orally administered at the indicated dose in a volume of 5 ml/kg, followed by a bolus gavage of monobasic sodium

phosphate (1 mmol in 1 ml ) 15 min after compound dosing. Serum was collected via retroorbital bleeding 30 min post phosphate bolus and phosphate levels were determined utilizing an ACE ALERA blood chemistry analyzer (Alfa Wassermann

Diagnostic Technologies, West Caldwell, NJ).

The extent of inhibition by test compounds on the elevation of serum phosphate levels in response to the bolus of phosphorus is shown in Table 12 (data are expressed as % Inhibition, with 6-10 animals per data point). The differences between groups were evaluated by one-way analysis of variance with Dunnett's post hoc tests.

Table 12

Inhibition of Uptake of Phosphorus from the Intestine

as Measured using the Bolus Phosphorus Challenge Model % inhibition of Serum P

Example Drug Dose elevation Significance

21 30 10-20 n.s.

1.32 30 20-30 ***

4.4 30 40-50 ***

51 30 10-20 n.s.

80 30 20-30 *#*

14 30 10-20 n.s.

1.1 30 20-30 **

* p < 0.05, versus vehicle by Dunnett's post hoc test.

** p < 0.01, versus vehicle by Dunnett's post hoc test.

*** p < 0.001, versus vehicle by Dunnett's post hoc test.

EXAMPLE 350

In vivo Evaluation Procedure: Co-Dosing in Chow Male, 7-week-old Sprague-Dawley rats (Charles-River laboratories international, Hollister, CA) were allowed to acclimate for a minimum of 3 days. The experiment was initiated by switching animals to a synthetic diet (0.6% phosphorus and 0.6% calcium, Harlan Teklad TD.84122) for four days. After this time, the animals were placed into metabolic cages for daily monitoring of food and water consumption, as well as urine and fecal collections. Test compounds were incorporated into the powdered diet listed above containing 3% chocolate flavoring (w/w, BioServ #7345) at 1.3 mg test compound per gram of diet to achieve an average daily nominal dose of 100 mg kg day. The actual dose received by each animal was later determined by measuring prepared diet consumption and body weight. Urine samples were collected in three daily periods from 24-48, 48-72, and 72-96 hours of drug dosing. Averaging these three 24 h periods allows for the more representative measurements of urination, fecal excretion, food consumption and water uptake for each animal. Phosphorus levels in the urine were determined by anion exchange chromatography using a Dionex ICS-3000 ion chromatography system. Urine samples were diluted 1:500 or 1 :1000 and injected onto an IonPac AS 18 analytical column (2 x 250 mm) using a potassium hydroxide eluent. Elution of urine phosphate ions was monitored via conductivity detector and reported as ppm relative to a standard ion solution containing phosphate. Daily urinary P output relative to the P consumed in the prepared diet for each animal was calculated. The percentage inhibition of phosphorus absorption was estimated by determining the reduction of this ratio compared to the control group (animals with no drug in chow). The differences between the means of control and treated groups were evaluated by t tests. In all experiments, one group was always included that had Renvela powder blended into their chow at 0.9% targeting a dose of 750 mg/kg. Typically this resulted in an approximately 15% inhibition of Urine Pout/P consumed.

Table 13

Inhibition of Uptake of Phosphorus from the Intestine as Measured using the Co-Dosing in Chow Model

299 so 10-30 **

298 50 10-30 ***

272 50 ≤ 10 ns

* p< 0.05 versus control ; ** p<0.01 versus control; *** p<0.001 versus control

EXAMPLE 351

Stability of Compounds in Simulated Gastric and Intestinal Fluid

Test compounds were incubated at 1-20 μΜ in simulated gastric fluid (SGF; standard USP solution with 3 mg mL pepsin) or simulated intestinal fluid (SIF; standard USP solution with 3 mg/mL pancreatin) for 3 hr or 6 hr. HPLC-UV or HPLC- MS were used to determine test compound levels using peak area %. Results (Table 14) were reported as the percentage of test compound remaining after incubation in a given condition relative to test compound present at t = 0 in the same condition.

Table 14

Percentage of Compound Remaining in Simulated Gastric and Intestinal Fluids

275 6 hr > 80% > 80%

202 6 hr > 80% > 80%

281 6 hr 20-40% > 80%

203 6 hr > 80% > 80%

169 6 hr 60-80% > 80%

170 6 hr 60-80% > 80%

171 6 hr > 80% > 80%

172 6 hr > 80% > 80%

174 6 hr > 80% > 80%

335 6 hr > 80% > 80%

269 6 hr > 80% > 80%

205 6 hr > 80% > 80%

285 6 r > 80% 60-80%

182 6 hr > 80% > 80%

261 6 hr 60-80% > 80%

261 6 hr > 80% > 80%

239 6 hr > 80% 60-80%

339 6 hr > 80% <20%

253 6 hr > 80% 60-80%

EXAMPLE 352

Determination of Compound Cmax and AUC Sprague-Dawley rats were orally gavaged with test article at a nominal dose of 2.5 or 10 mg/kg and blood was collected at 0.5, 1, 2 and 4 h. Blood samples were processed to plasma using K ₂ EDTA as an anticoaglulant. Plasma samples were treated with acetonitrile containing an internal standard, precipitated proteins removed by centrifugation. Supernatants were analyzed by LC-MS/MS and compound concentrations were determined by interpolation from a standard curve prepared in plasma. Table 15 illustrates data from the pharmacokinetic profiling of selected example compounds. All compounds were orally dosed at the dosage shown, and pharmacokinetic parameters determined.

Table 15

Pharmacokinetic Profiling of Selected Example Compounds Actual Oral Cmax AUC

Example

Dose (mg/kg) (ngmL) (ng x hr/mL)

8.1 3-15 <10 <30

37 3-15 <10 <30

26 3-15 <30 <30

2 ₅ 3-15 <30 <30

8.2 ₅ 3-15 <30 >50

8.6 3-15 <50 >50

1.1 3-15 <50 >50

8.21 3-15 <30 <30

80 3-15 <10 <10

80 3-15 <10 <30

209 3-15 <30 <30

238 3-15 <10 <10

248 3-15 <10 <10

126 3-15 < 10 <30

210 3-15 <10 <30

137 3-15 <10 <10

138 3-15 <10 <10

264 3-15 <10 <10

141 3-15 >50 >50

218 3-15 <10 <30

233 3-15 <10 <10

249 3-15 <10 <30

211 3-15 <10 <30

215 3-15 <10 <10

216 3-15 <10 <10

188 3-15 <10 <10

143 3-15 <10 <10

234 3-15 <10 <30

162 3-15 <10 <10

254 3-15 <10 <10

146 3-15 <10 <10

131 3-15 <30 <50

147 3-15 <10 <10

144 3-15 <10 <10

191 3-15 <10 <10

193 3-15 <10 <30

142 3-15 <10 <10

148 3-15 <10 < 10 149 3-15 <10 <10

2 ₅ 0 3-15 <10 <10

246 3-15 <10 <10

150 3-15 <10 <10

151 3-15 <10 <10

152 3-15 <10 <10

327 3-15 <10 <10

195 3-15 <10 <10

157 3-15 <10 <10

16 ₅ 3-15 <10 <30

256 3-15 <10 <10

157.1 3-15 <10 <30

333 3-15 <30 <50

240 3-15 <10 <10

196 3-15 >50 >50

252 3-15 <30 <30

255 3-15 <10 <10

158 3-15 <10 <10

160 3-15 < 10 <10

199 3-15 <10 <10

265 3-15 <30 <30

166 3-15 <10 <10

166 3-15 < 10 <10

166 15-40 >50 <50

168 3-15 <10 <30

181 3-15 <30 <30

161 3-15 <10 <10

161 3-15 <10 <10

286 3-15 <10 <10

286 3-15 <10 <10

200 3-15 <30 <30

251 3-15 <10 <10

281 3-15 < 10 <10

335 3-15 <10 >50

269 3-15 < 10 <10

285 3-15 <30 <50

261 3-15 <50 >50

239 15-40 <30 <30

339 3-15 < 10 <30

253 15-40 < 10 <10 300 15-40 < 10 < 30

299 15-40 < 30 < 30

298 15-40 < 30 < 30

271 15-40 < 30 > 50

262 15-40 < 10 < 50

272 15-40 < 10 < 10

297 3-15 < 10 < 30

294 3-15 < 10 > 50

LLOQ= Lower Limit of Quantification

EXAMPLE 353

Fecal Recovery of Orally Administered Compounds Quantitative determination of test compound level in feces after oral gavage was performed using the same set of animals used to determine test compound concentration in plasma (Example 352). The animals were kept in metabolic cages and feces were collected from the time of dosing until 48 hr after dosing. Upon collection, feces were dried by Iyophilization and ground to a visually homogenous powder. Duplicate samples of ground feces from each individual animal were weighed out and extracted using organic solvent. Extracted samples were then diluted into mobile phase and test compound levels were quantitatively determined by LC-MS MS analysis as described in Example 352 except that the standard curve was prepared in a feces matrix. Extraction conditions were not optimized for individual compounds, and thus may represent a minimal level of recovery.

Table 16

Fraction of Orally Administered Compound

Recovered in Feces 48 Hours after Dosing % recovered

Example 1 in feces

26 <20

25 20-80

8.3 <20

8.6 20-80

1.1 20-80

8.21 >80

80 20-80

137 <20

138 <20

264 <20

162 20-80

26 ₅ <20

166 >80

181 >80

161 >80

286 <20

200 20-80

251 >80

33 ₅ >80

269 <20

261 <20

300 20-80

299 20-80

298 >80

271 20-80

262 20-80

272 >80

294 >80

EXAMPLE 354

In vivo Evaluation Procedure: CKD rats

To assess the ability of selected example compounds to impact the progression of chronic kidney disease (CKD), 5/6 nephrectomy (5/6Nx) rat model of CKD was used. A commonly used model to study various aspects of CKD, the 5/6Nx rat is not normally hyperphosphatemia unless challenged with phosphate in the diet and co-administration of active vitamin D (Shobeiri et. al., Am J Nephrol 2010;31:471^t81, Vascular Calcification in Animal Models of CKD: A Review). (Lopez et al. 2006, J Am Soc Nephrol 17: 795-804. Calcimimetic R-568 Decreases Extraosseous Calcifications in Uremic Rats Treated with Calcitriol) . 5/6 Nx rats were obtained from Charles River Labs (CRL, Hollister, CA). Upon arrival, the surgeries and extent of kidney damage in the animals were assessed by measuring serum creatinine, P, Ca, and BUN. Based on this analysis, rats with inconsistent kidney function were removed from the study and the remainder of the cohort was divided in to evenly stratified test groups. The remaining animals were then placed on the same synthetic diet used in the drug-in- chow studies (Example 350), except the P levels were adjusted to 0.9% P. Drugs are blended into this chow to achieve the required dosing rate. At this time, rats were also started on an activated Vitamin D regimen in which they were injected intraperitoneally with calcitriol at 80ng kg three times a week. Once a week, serum was collected via retro orbital bleeding for analysis of serum P and creatinine utilizing an ACE ALERA blood chemistry analyzer. As reported by the Lopez group, substantial hyperphosphatemia was achieved after two weeks as well as measureable vascular and soft tissue calcification. Additionally, serum creatinine is doubled compared to untreated 5/6Nx rats and serum FGF-23 levels are significantly elevated. The data in Table 14 details the results for three independent studies in these 5/6 Nx rats. Unless otherwise indicated, the data shown is from the serum collected at 2 weeks after initiation of the treatment regimen. In addition, for study #3, during the third week of the study, the animals were placed in metabolic cages for two days, and urine collected for the final 24 hours. Using the measured levels of serum and urine creatinine, the creatinine clearance was calculated, and found to be 1.9 for vehicle, 1.9 for Renvela, 2.3 for Example 166 and 2.8 mL/min/kg for the combination group. The difference between the combination group and vehicle was statistically significant, with a p < 0.05.

These results support the concept that treatment of 5/6Nx kidney damaged animals with a NaP2b inhibitor results in a reduced rate of progression of loss of kidney function, as shown by the improved trends in accepted markers of kidney disease progression, including serum creatinine, and glomerular filtration rate (GFR; creatinine clearance). The improvement appears to be mediated by reductions in serum P as well as overall P homeostasis, as evidence^ by reduced levels of serum FGF23, a recognized indicator of whole-body P and recognized indicate of CKD progression (Zisman,A.L.and Wolf,M, Recent advances in the rapidly evolving field of fibroblast growth factor 23 in chronic kidney disease, Curr Opin Nephrol Hypertens. 2010 Jul;19(4):335-42.) It is worth noting that in study #3, the treatment with the combination of Example 166 with the P binder Renvela results in greater than expected improvement (statistically significant improvements in serum P, serum Cre,FGF-23 and GFR), suggesting that these agents may be working synergistically through distinct but overlapping mechanisms.

Table 14

Parameters for CKD rats after two weeks of treatment

Ser P = Serum P, mg/dL

Ser CRE = serum Creatinine, mg dL FGF23 = serum FGF23 levels, pg mL, measured using the Mouse FGF-23 (C-Terminal) ELISA kit from Immutopics (San Clemente, California) Avg % weight gain = average % body weight since initiation of studyData taken at 3 weeks after initiation of study

§ ^§ Data taken at 4 weeks after initiation of study

* p < 0.05, versus vehicle

**p < 0.01, versus vehicle

EXAMPLES FOR COMPOUNDS OF STRUCTURE (II)

EXAMPLE 1

Nl-Methyl-Nl-(2-morpholinoethvn-N3-(4-(piperidiii-l-vn-2- (f3-(3- itrifluoromethvnphenylVlH-l^^-triazol-S-vncarbamovftphenvnis ophthalamide

Scheme 1. l. oxalyl chloride, DMF; 2. Boc ₂ 0; 3. LAH; 4. intermediate la, Et ₃ N; 5. LiOH ¾0; 6. oxalyl chloride. DIVP ^" 7. SOCl ₂ , MeOH; 8. MeONa, MeOH, aminoguanidine carbonate; 9. NaH, THF, 5-chloro-2-nitrobenzoyl chloride; 10. piperidine, DMF; 11. Pd/C, MeOH; 12. pyridine, DCM, intermediate If.

Intermediate la: methyl 3-(chlorocarbonvnbenzoate. To 3-(methoxycarbonyl)benzoic acid (6.2 g, 34.44 mmol, 1.00 equiv) in dichloromethane (50 mL) was added oxalyl dichloride (8.74 g, 69.37 mmol, 2.00 equiv) and N,N-dimethylformamide (cat.) and the resulting solution was stirred for 1 h at 40°C in an oil bath. The mixture was concentrated under vacuum to yield 6.6 g (87%) of methyl 3-(chlorocarbonyl)benzoate as brown oil.

Intermediate lb: tert-butyl (2-morpholinoethyl)carbamate. To a solution of 2- morpholinoethanamine (10 g, 76.92 mmol, 1.00 equiv) in dichloromethane (50 mL) was added triethylamine (5.83 g, 57.72 mmol, 0.50 equiv) followed by the addition of di-tert-butyl dicarbonate (18.44 g, 84.59 mmol, 1.10 equiv) at 0-5°C and the resulting solution was stirred overnight at 25°C. The reaction was diluted with 200 mL of dichloromethane and washed with 1x30 mL of 10% sodium bicarbonate and 1 30 mL of brine. The organic layer was dried over sodium sulfate and concentrated under vacuum to afford 16 g (81%) of tert-butyl 2-morpholinoethylcarbamate as an off-white solid.

Intermediate lc: N-methyl-2-morpholinoethanamine. To a solution of LiAltL _t (7.72 g, 208.65 mmol, 3.00 equiv) in tetrahydrofuran (60 mL) at 0-5°C was added dropwise a solution of tert-butyl 2-morpholinoethylcarbamate (16 g, 62.61 mmol, l.Of miv, 90%) in tetrahydrofuran (40 mL). The resulting solution was then st^id υι _, h at 70°C in an oil bath bath. The reaction was then quencher* L-y the addition of 7.7 mL of water, 7.7 mL of 15% sodium hydrov'di, and 23.1 mL of water. The solids were filtered out. The mixture was dried over sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with dichloromethane:methanol (0.5% triethylamine) (20:1) to afford 4.2 g (42%) of N-methyl-2-morpholinoethanamine as a brown oil.

Intermediate Id: methyl 3- meth l(2-mo holinoethyl carbamoyl ^' )benzoate. To a solution of N-methyl-2-morpholinoethanamine (2.1 g, 13.12 mmol, 1.00 equiv, 90%) in dichloromethane (20 mL) at 0-5°C was added triethylamine (1.47 g, 14.55 mmol, 1.00 equiv) followed by dropwise addition of a solution of methyl 3- (chlorocarbonyl)benzoate (3.3 g, 15.00 mmol, 1.20 equiv, 90%) in dichloromethane (10 mL). The resulting solution was then stirred for 3 h at room temperature. The mixture was diluted with 100 mL of dichloromethane, washed with 1x30 mL of 10% sodium bicarbonate and 1x30 mL of brine, dried over sodium sulfate and then concentrated under vacuum. The residue was applied onto a silica gel column with dichloromethane:methanol (20:1) to afford 4.4 g (99%) of methyl 3-(methyl(2- morpholinoethyl)carbamoyl)benzoate as a brown solid.

Intermediate le: S- methv^-morpholinoethyltcarbamovDbenzoic acid. To a solution of methyl 3-(methyl(2-morpholinoethyl)carbamoyl)benzoate (4.4 g, 13.66 mmol, 1.00 equiv, 95%) in tetrahydrofuran water (15/10 mL) was added lithium hydroxide hydrate (1.77 g, 43.17 mmol, 3.00 equiv) and the resulting solution was stirred for 1 h at 25°C. The resulting mixture was concentrated under vacuum, diluted with 10 mL of water and then adjusted to pH 2-3 with hydrochloric acid. The resulting mixture was washed with 2x30 mL of ethyl acetate. The aqueous layers were concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate:methanol (4:1) to give 2.7 g (65%) of 3-(methyl(2-morpholinoethyl)carbamoyl)benzoic acid as a white solid. Ή-NMR (300MHz, D ₃ OO, ppm): δ 8.17 (m, 2H), 7.78 (m, 1H), 7.61 (m,

1H), 3.98 (m, 6H), 3.56 (m, 5H), 3.47 (m, 1H), 3.10 (s, 3H). MS (ES, m/z): 293

[M+H] ⁺ .

Intermediate If: S-fmethv^-morpholinoethv carbamovnbenzoyl chloride. To 3- (methyl(2-morpholinoethyl)carbamoyl)benzoic acid (1.37 g, 4.69 mmol, 1.00 equiv) in dichloromethane (17 mL) was added 2 drops of N,N-dimethylformamide followed by the addition of oxalyl dichloride (3.63 g, 28.14 mmol, 6.00 equiv). The resulting solution was stirred for 1 h at 50°C in an oil bath then concentrated under vacuum to afford 1.41 g (87%) of 3-(methyl(2-morpholinoethyl)carbamoyl)benzoyl chloride as a gray-yellow solid.

Intermediate lg: methyl S-ftrifluoromethvDbenzoate. To a solution of 3- (trifluoromethyl)benzoic acid (5 g, 26.30 mmol, 1.00 equiv) in methanol (25 mL) was added dropwise thionyl chloride (9.39 g, 78.93 mmol, 3.00 equiv) and the resulting solution was stirred for 2 h at 75°C in an oil bath. The mixture was concentrated under vacuum, diluted with 100 mL of ethyl acetate and then washed with 2x30 mL of sodium carbonate and 2x30 mL of brine. The organic layer was dried over anhydrous sodium sulfate and concentrated under vacuum to yield 4.6 g (86%) of methyl 3- (trifluoromethyl)benzoate as yellow oil

Intermediate 1 h: 5 -(3 -( ^" trifluoromethyllphenyll^H- 1.2.4-triazol-3 -amine. To a solution of sodium methanolate (1.05 g, 19.44 mmol, 4.00 equiv) in methanol (40 mL) at 0°C was added aminoguanidine bicarbonate (2.66 g, 19.54 mmol, 4.00 equiv) in several batches. To this was added dropwise a solution of methyl 3-(trifluoromethyl)benzoate (1 g, 4.90 mmol, 1.00 equiv) in methanol (10 mL) with stirring at 0°C. The resulting solution was then stirred overnight at 75°C in an oil bath. The reaction was then quenched with 10 mL of water/ice, the solution adjusted to pH 3-4 with hydrochloric acid (1 mol/L), and the solids were collected by filtration To afford 150 mg (13%) of 5- (3-(1rifluoromemyl)phenyl)-4H-l,2,4-triazol-3-arnine as a yellow solid.

Intermediate li: 5-chloro-2-nitro-N-( ^' 5-(3-(trifluoromethyl)Dhenyl)-2H-1.2.4-triazol-3- vD-benzamide. To a solution of 5-(3-(trifluoromethyl)phenyl)-2H-l,2,4-triazol-3-amine (100 mg, 0.44 mmol, 1.00 equiv) in tetrahydrofuran (1 mL) was added sodium hydride (35 mg, 0.88 mmol, 2.00 equiv, 60%) followed by the dropwise addition of a solution of 5-chloro-2-nitrobenzoyl chloride (96.49 mg, 0.44 mmol, 1.00 equiv) in tetrahydrofuran (1 mL) and the resulting solution was stirred for 2 h at room temperature. The mixture was diluted with 50 mL of ethyl acetate, washed with 2x20 mL of brine, dried over anhydrous sodium sulfate and concentrated under vacuum to afford 120 mg (67%) of a yellow solid.

Intermediate li: 2-nitro-5-rpiperidin-l-ylVN-(5-(3-(trifluoromethvnDhenylV2H- 1.2.4- triazol-3 -yHbenzamide. To a solution of 5-chloro-2-nitro-N-(5-(3- (trifluoromethyl)phenyl)-2H-l,2,4-triazol-3-yl)benzamide (120 mg, 0.29 mmol, 1.00 equiv) in Ν,Ν-dimethylformamide (1 mL) was added piperidine (1 mL) and the resulting solution was stirred for 2 h at 100°C in an oil bath. The mixture was diluted with 50 mL of ethyl acetate, washed with 2x20 mL of brine, dried over anhydrous sodium sulfate, and concentrated under vacuum to affordl30 mg (97%) of product as yellow oil.

Intermediate lk: 2-amino-5-(piperidin- 1 -yl)-N-(5-(3-(trifluoromethyl)phenyl ^" )-2H-

1.2.4-triazol-3-yl)benzamide. To a solution of 2-nitro-5-(piperidin-l-yl)-N-(5-(3- (trifluoromethyl)phenyl)-2H-l,2,4-triazol-3-yl)benzamide (130 mg, 0.28 mmol, 1.00 equiv) in methanol (3 mL) was added Pd/C (130 mg, 10%) and the suspension stirred under an atmosphere of hydrogen for 2 h at room temperature. The solids were filtered out and the resulting mixture was concentrated under vacuum to yield 50 mg (41%) of product as a yellow solid.

Example 1: Nl-me1i>yl-Nl-(2-mo^holinoetM^

(trifluoromethyDDhenylV2H-1.2.4 ri To a solution of 2-amino-5-(piperidm-l-yl)-N-(5-(3-(trifluoromethyl)phenyl)-2 H-l,2,4- triazol-3-yl)benzamide (50 mg, 0.12 mmol, 1.00 equiv) in dichloromethane (3 mL) was added pyridine (73 mg, 0.92 mmol, 8.00 equiv) followed by the dropwise addition of a solution of 3-(methyl(2-morpholinoethyl)carbamoyl)benzoyl chloride (54 mg, 0.17 mmol, 1.50 equiv) in dichloromethane (2 mL) and the resulting solution was stirred for 30 min at room temperature. The mixture was diluted with 50 mL of ethyl acetate, washed with 2x20 mL of NH ₄ C1 and 2x20 mL of brine, dried over anhydrous sodium sulfate and then concentrated under vacuum. The crude product (50 mg) was purified by reverse phase HPLC eluting with a water/CLljCN gradient containing 0.05% TFA. The product was obtained as 12 mg (10%) of a yellow solid. 'H- MR (300MHz, CO ₃ OO,ppm): δ 8.34(m, 3H), 8.17(t, J=7.8Hz, 2H), 7.73(m, 5H), 7.42 (m, 1H), 3.98(s, 2H), 3.55(m, 3H), 3.40(m, 5H), 3.29(m, 1H), 3.09(m, 3H), 1.86(d, J=4.8Hz, 4H), 1.71(t, J=5.1Hz, 2H). MS (ES, mlz): 705 [M+H] ⁺ .

EXAMPLE 2

Nl-Methyl-Nl-(2-morpholinDethvn-N3-(4-(piperidin-l-Yl)-2-(fl -(3-

(trifluoromethyl phenvL)-lH-l,2,4-triazol-3-yl)carbamoyl)phenyl)isophthalamid e

Scheme 2: 1. 3-(trifluoromethyl)phenyboronic acid, Cu(OAc)2, pyridine; 2. ¾, Pd/C; 3. 2-nitro-5-chIorobenzoyI chloride, pyridine; 4. piperidine, DMF, K2CO3; 5. H2, 6. Pd/C; pyridine, intermediate If.

Intermediate 2a: 3-nitro- 1 -n-ftrifluoromethyllphenyll- 1 H- 1.2.4-triazole. Into a 250- mL round bottom flask, was placed a solution of 3-nitro-lH-l,2,4-triazole (2 g, 17.54 mmol, 1.00 equiv) in dichloromethane (100 mL), 3-(trifluoromethyl)phenylboronic acid (6.66 g, 35.05 mmol, 2.00 equiv), Cu(OAc) ₂ (4.79 g, 26.32 mmol, 1.50 equiv), pyridine (2.77 g, 35.06 mmol, 2.00 equiv), and molecular sieves (5.2 g). The resulting solution was stirred overnight at 30°C. The solids were filtered out. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate/petroleum ether (1 :20-l : 10) to give 2.2 g (49%) of product as a white solid. Intermediate 2b: l-G-faifluorometfavnphenylVlH-L ^-triazol-S-arnine. Into a 100- mL round bottom flask, was placed a solution of 3-nitro-l-(3-(trifluoromemyl)phenyl)- lH-l,2,4-triazole (1 g, 3.88 mmol, 1.00 equiv) in methanol (20 mL). The mixture was treated with Pd/C (1 g) and stirred under an atmosphere of hydrogen for 3 h at 25°C in an oil bath. The solids were filtered out. The resulting mixture was concentrated under vacuum to yield 900 mg of crude product as a white solid.

Intermediate 2c: 5-chloro-2-nitro-N-(l-(3-( ^' trifluoromethyl)phenyl ^' )-lH-1.2.4-triazol-3- yPbenzamideas. Into a 100-mL round bottom flask, was placed a solution of l-(3- (trifluoromethyl)phenyl)-lH-l,2,4-triazol-3-amine (1 g, 4.39 mmol, 1.00 equiv) in dichloromethane (20 mL), and pyridine (1.15 g, 14.56 mmol, 3.00 equiv). This was followed by dropwise addition of a solution of 5-chloro-2-nitrobenzoyl chloride (1.04 g, 4.75 mmol, 1.10 equiv) in dichloromethane (5 mL) with stirring at 0-5°C. The resulting solution was stirred for 2 h at 0-5°C. The resulting solution was diluted with 50 mL of dichloromethane. The resulting mixture was washed with 2x50 mL of aqueous hydrochloric acid, dried over anhydrous sodium sulfate, and concentrated under vacuum. This resulted in 2 g of crude product as a white-yellow solid.

Intermediate 2d: 2-nitro-5-(piperidin-l-vn-N-(l-(3-(trifluoromethyl)phenyl)-l H-1.2.4- triazol-3-yl)benzamide. Into a 100-mL round bottom flask, was placed a solution of 5- chloro-2-nitro-N-(l -(3-(trifluoromethyl)phenyl)-l H- 1 ,2,4-triazol-3-yl)benzamide (500 mg, 1.21 mmol, 1.00 equiv) in N,N-dimethylformamide (10 mL), and piperidine (500 mg, 5.88 mmol, 4.84 equiv). The resulting solution was stirred overnight at 90 ^D C. The resulting mixture was concentrated under vacuum. The residue was dissolved in 30 mL of ethyl acetate. The resulting mixture was washed with 2x50 mL of brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. This resulted in 500 mg (90%) of product as white oil.

Intermediate 2e: 2-amino-5-(piperidin-l -ylVN-(l -(3-(trifluoromethyr>phenyri-lH-

1 ,2.4-triazol-3-yllberizamide. Into a 100-mL round bottom flask, was placed a solution of 2-nitro-5-(piperidm-l-yl)-N-(l-(3-(trifluoromethyl)phenyl)-l H-l,2,4-triazol-3- yl)benzamide (500 mg, 1.09 mmol, 1.00 equiv) in methanol (20 mL). The solution was treated with Pd/C (500 mg) and stirred under an atmosphere of hydrogen for 2 h at room temperature. The solids were filtered out. The resulting mixture was concentrated under vacuum to yield 450 mg (96%) of product as a brown solid.

Example 2: Nl-methyl-Nl-^-morpholinoethylVNS^^piperidin-l-vn^-ffl-G-

(rifluoromemvnphenylVlH-l^^-triazol-S-vncarbainovnphenvni sophthalamide. Into a 100-mL round bottom flask, was placed a solution of 2-amino-5-(piperidin-l-yl)-N- (l-(3-(trifluoromethyl)phenyl)-lH-l,2,4-triazol-3-yl)benzami de (150 mg, 0.35 mmol, 1.00 equiv) in dichloromethane (20 mL), and pyridine (83 mg, 1.05 mmol, 3.01 equiv). This was followed by dropwise addition of a solution of 3-(methyl(2- morpholinoethyl)carbamoyl)benzoyl chloride (130 mg, 0.42 mmol, 1.20 equiv) in dichloromethane (10 mL) with stirring at 0-5°C. The resulting solution was stirred for 3 h at room temperature. The resulting solution was diluted with 30 mL of dichloromethane. The resulting mixture was washed with 1x20 mL of NH4CI and 2x20 mL of brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. The crude product (200 mg) was purified by reverse phase HPLC eluting with a water/C¾CN gradient containing 0.05% TFA. The product was obtained as 36.7 mg (15%) of a yellow solid. Ή-NMR (400MHz, DMSO, ppm): δ 11.43-11.33(m, 2H), 9.70(s, 1H), 9.43(s, 1H), 8.77(s, 1H), 8.26-8.18 (m, 3H), 8.06-7.93 (m, 2H), 7.86- 7.79(m, 2H), 7.68-7.62(m, 2H), 7.52(s, 1H), 7.30-7.28(d, ^=6.9Hz, 1H), 4.59-4.57(m, 1H), 4.18-3.83(m, 27H), 3.44(s, 3H), 3.27-3.26 (m, 5H), 3.18 (s, 3H), 2.96(s, 4H), 1.69(s, 4H), 1.59-1.52(m, 3H). MS (ES, m/z): 705 [M+H] ⁺ .

EXAMPLE 3

Nl-Methyl-Nl-(2-morpholinoethvn-N3-(4-(piperidin-l-vn-2-((4- (3-

(trifluoromethyllphenyltthiazol^-yllcarbamovDphenvDisopht halamide

3

Scheme 3. 1. Br ₂ , ether; 2. MeOH, thiourea; 3. DIPEA, DCM, 5-chloro-2-nitrobenzoyl chloride; 4. K ₂ C0 ₃ , MeOH; 5. DMF, piperidirie; 6. ¾, Pd/C, MeOH; 7. DCM, pyridine intermediate If.

Intermediate 3a: 2-bromo-l-f3-ftrifluoromemvDphenvDethanone. Into a 250-mL round bottom flask, was placed a solution of l-(3-(trifluoromethyl)phenyl)ethanone (5 g,

26.57 mmol, 1.00 equiv) in ether (80 mL). To this was added dropwise a solution of !!¾

(4.26 g, 26.66 mmol, 1.00 equiv) in ether (20 mL) with stirring over 1 hr and the resulting solution was stirred an additional 1 h at room temperature. The mixture was washed with 2x30 mL of NaHSOj and 1x30 mL of brine, then dried over anhydrous sodium sulfate and concentrated under vacuum to give 5.2 g (crude) of 2-bromo-l-(3- (trifluoromethyl)phenyl)ethanone as yellow oil.

Intennediate 3b: S-( ^' 3-( ^' trifluoromethyl ^' )phenyl)thiazol-2-amine. Into a 100-mL round bottom flask, was placed a solution of 2-bromo-l-(3-(trifluoromethyl)phenyl)ethanone (2.5 g, 9.40 mmol, 1.00 equiv) in methanol (50 mL), and thiourea (710 mg, 9.33 mmol, 1.00 equiv). The resulting solution was stirred overnight at 75°C in an oil bath. The reaction mixture was cooled with a water/ice bath. The solids were collected by filtration. The residue was dissolved in 200 mL of ethyl acetate. The resulting mixture was washed with 1x50 mL of sodium hydroxide (1 N) and 2x50 mL of brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. This resulted in 2.2 g (96%) of 5-(3-(trifluoromethyl)phenyl)thiazol-2-amine as a white solid.

Intermediate 3 c: 5-chloro-N-(5-chloro-2-nitrobenzoyl)-2-nitro-N-f4-(3- ftrifluoromethyl)-phenyl thiazol-2-yl)ben2amide. Into a 100-mL round bottom flask, was placed a solution of 5-(3-(trifluoromethyl)phenyl)thiazol-2-amine (2 g, 8.19 mmol, 1.00 equiv) in dichloromethane (20 mL), and diisopropylethylamine (4.22 g, 32.65 mmol, 4.00 equiv). This was followed by dropwise addition of a solution of 5-chloro-2- nitrobenzoyl chloride (3.967 g, 18.03 mmol, 2.20 equiv) in dichloromethane (10 mL) with stirring. The resulting solution was stirred for 4 h at room temperature. The resulting solution was diluted with 50 mL of ethyl acetate. The resulting mixture was washed with 2x20 mL of brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. This resulted in 4.5 g (90%) of product as a yellow oil.

Intermediate 3d: 5-cMoro-2-ni1io-N- S-0-(trifluoromethvnphenv thiazol-2- vDbenzamide. Into a 100-mL roimd bottom flask, was placed a solution of 5-chloro-N- (5-cUoro-2-ru(iobenzoyl)-2-nitro-N-(4-(3-(trifluoromethyl)ph enyl)thiazol-2- yl)benzamide (4.5 g, 7.36 mmol, 1.00 equiv) in methanol (50 mL), and potassium carbonate (3.05 g, 22.07 mmol, 3.00 equiv). The resulting solution was stirred for 4 h at 40°C in an oil bath. The resulting solution was diluted with 200 mL of ethyl acetate. The resulting mixture was washed with 2x50 mL of brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. This resulted in 2.6 g (83%) of product as a yellow solid.

Intermediate 3e: 2-nitro-5-(piperidin-l-yl)-N-f5-(3-(trifluoromethyl ^' )phenyl)thiazol-2- vD-benzamide. To a solution of 5-chloro-2-nitro-N-(5-(3- (trifluoromethyl)phenyl)thiazol-2-yl)benzamide (2.6 g, 6.08 mmol, 1.00 equiv) in N,N- dimethylformamide (20 mL) was added and piperidine (20 mL) and the resulting solution was stirred for 3 h at 100°C in an oil bath. The mixture was diluted with 200 mL of ethyl acetate, washed with 2x50 mL of brine, dried over anhydrous sodium sulfate and then concentrated under vacuum to give 2.2 g (76%) of product as a yellow solid.

Intermediate 3f: 2-amino-5-fpiperidin-l -ylVN- S-O-drifluoromethvnphenvnthiazol^- vD-benzamide, Into a 100-mL round bottom flask, was placed a solution of 2-nitro-5- (piperidin-l-yl)-N-(5-(3-(ttifluoromem^ (2.2 g, 4.62 mmol, 1.00 equiv) in methanol (30 mL). The solution was treated with Pd/C (2 g, 10%), and stirred under an atmosphere of hydrogen for 2 h at room temperature. The solids were filtered out. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column and eluted with petroleum ether/ethyl acetate (7:1). This resulted in 1.2 g (58%) of product as a yellow solid.

Example 3; 1^6άιν1-Ν1- 2^οφ^1ΐηθ6Φν1 -Ν3-(4-( ί 6η(ϋη-1-νΐν2-((4-(3-

(trifluoromethyl)phenyl)thiazol-2-yl)carbamoyl)phenyl)iso phthalamide. Into a 50-mL round bottom flask, was placed a solution of 2-amino-5-(piperidin-l-yl)-N-(4-(3- (trifluoromethyl)phenyl)thiazol-2-yl)benzamide (287 mg, 0.64 mmol, 1.00 equiv) in dichloromethane (3 mL), and pyridine (406 mg, 5.13 mmol, 8.00 equiv). This was followed by dropwise addition of a solution of 3-(methyl(2- morpholinoethyl)carbamoyl)benzoyl chloride (300 mg, 0.97 mmol, 1.50 equiv) in dichloromethane (2 mL) with stirring. The resulting solution was stirred for 1 h at room temperature, then diluted with 50 mL of ethyl acetate. The resulting mixture was washed with 1x20 mL of hydrogen chloride (I N) and 2x20 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product (300 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 120 mg (20%) of as a yellow solid. Ή-NMR (300MHz, DMSO, ppm): δ 12.89(s, IH), 10.93(s, IH), 9.79(s, IH), 8.26 (m, 2H), 8.00(m, 4H), 7.69(m, 4H), 7.53(s, IH), 7.27(d, J=8.7Hz, IH), 4.01(s, 2H), 3.85(s, 2H), 3.63(s, 4H), 3.44(s, 2H), 3.17(m, 6H), 2.99(s, 3H), 1.70(m, 6H). MS (ES, m/z): 721 [M+H] ⁺ .

EXAMPLE 4

3-((3-f(4.ChLoro-2-f(l-f3.4-dimethylphenvn-lH-pyrazol-3- ylkarbamoyl)Dhenylk ^, arbamoyl)benz\'lHhio Dronanoic acid

Scheme 4. 1. KSAc, MeOH; 2. K ₂ C0 ₃ ; 3. tert-butyl acrylate, DBU; 4. oxalyl chloride, DMF; 5. 3,4-dimethylbromobenzene, Cul, L-proline, K ₂ C0 ₃ ; 6. ¾, Pd/C; 7. 2-nitro- 5-chlorobenzoyl chloride, pyridine; 8. Zn, AcOH; 9. intermediate 4d, pyridine; DCM; 10. DCM, TFA. Intermediate 4a: 3-(acetylmiomemyl1benzoic acid. Into a 250-mL round-bottom flask, was placed a solution of 3-(bromomethyl)benzoic acid (7 g, 32.56 mmol, 1.00 equiv) in ethanol (80 mL), and potassium thioacetate (9.65 g, 84.65 mmol, 2.60 equiv). The resulting solution was stirred overnight at room temperature. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 80 mL of water and adjusted to pH 3-4 with 10% hydrochloric acid. The resulting solution was extracted with 3x50 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 1x50 mL of brine, dried over sodium sulfate, and concentrated under vacuum. This resulted in 4.4 g (64%) of 3-(acetylthiomethyl)benzoic acid as a brown solid.

Intermediate 4b: 3-(mercaptomethyl)benzoic acid. Into a 500-mL round-bottom flask, was placed a solution of 3-(acetylthiomethyl)benzoic acid (16.4 g, 78.10 mmol, 1.00 equiv) in methanol (150 mL), and a solution of potassium carbonate (26.9 g, 194.93 mmol, 2.50 equiv) in water (70 mL). The resulting solution was stirred for 4 h at 60°C. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 200 mL of water and adjusted to pH 3 with 10% hydrochloric acid. The resulting solution was extracted with 3x (100/20 mL) of ethyl acetate/ tetrahydrofuran and the organic layers combined. The resulting mixture was washed with 1x100 mL of brine, dried over sodium sulfate, and concentrated under vacuum. This resulted in 12 g (91%) of 3-(mercaptomethyl)benzoic acid as a brown solid.

Intermediate 4c: 3-((3-tert-butoxy-3-oxopropylthio)methv benzoic acid Into a 500- mL round bottom flask, was placed a solution of 3-(mercaptomethyl)benzoic acid (12 g, 71.43 mmol, 1.00 equiv) in acetonitrile (200 mL), tert-butyl acrylate (60 mL), and DBU (21.7 g, 142.76 mmol, 2.00 equiv). The resulting solution was stirred overnight at 80°C in an oil bath. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 200 mL of water and adjusted to pH 2-3 with 10% hydrochloric acid. The resulting solution was extracted with 3x200 mL of ethyl acetate and the organic layers combined. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with petroleum ether/ethyl acetate (50:1) to give 10.5 g (47%) of 3-((3-tert- butoxy-3-oxopropylthio)methyl)benzoic acid as red oil. Ή-NMR (300MHz, CDCb, ppm): δ 8.08 (s, 1H), 8.04 (d, ,/=7.8Hz, 1H), 7.62 (d, J=7.8Hz, 1H), 7.46 (t, 1H), 3.81 (s, 2H), 2.68 (t, 2H), 2.50 (t, 2H), 1.48 (s, 9H). MS (ES, m/z): 295 [M-H] ^" .

Intermediate 4d: tert-butyl 3-((3-(c orocarbonvDbenzyl)thio)propanoate, Into a 100- mL round bottom flask, was placed a solution of 3-((3-tert-butoxy-3- oxopropylthio)methyl)benzoic acid 1.1c (3.00 g, 10.14 mmol, 1.00 equiv) in dichloromethane (50 mL). This was followed by dropwise addition of oxalyl dichloride (4.50 g, 35.43 mmol, 3.00 equiv) with stirring at 0°C. To this was added N,N- dimethylformamide (1 drop). The resulting solution was stirred for 1.5 h at room temperature. The resulting mixture was concentrated under vacuum to yield 3.18 g (99%) of tert-but l 3-(3-(chlorocarbonyl)benzylthio)propanoate as red oil.

Intermediate 4e: l-(3.4-cUmethylphenylV3-nitro-lH-pyrazole. Into a 250-mL round bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of 3-nitro-lH-pyrazole (6 g, 53.10 mmol, 1.00 equiv) in DMSO (80 mL), 4- bromo-l,2-dimethylbenzene (11.8 g, 64.13 mmol, 1.21 equiv), Cul (1.6 g, 8.42 mmol, 0.16 equiv), L-proline (1 g, 8.70 mmol, 0.16 equiv), and potassium carbonate (14.6 g, 105.80 mmol, 1.99 equiv). The resulting solution was stirred overnight at 85°C in an oil bath. The reaction progress was monitored by LCMS. The resulting solution was diluted with 300 mL of water. The resulting solution was extracted with 4x100 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 3x100 mL of water and 1x100 mL of brine. The mixture was dried over anhydrous sodium sulfate. The solids were filtered out. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate/petroleum ether (1:10) to give 1 g (9%) of l-(3,4-dimethylphenyl)-3-nitro-lH- pyrazole as a yellow solid.

Intermediate 4f: l-(3.4-dimethylphenyl)-lH-pyrazol-3-amine. Into a 100-mL round bottom flask, was placed a solution of l-(3,4-dimethylphenyl)-3-nitro-lH-pyrazole (900 mg, 4.15 mmol, 1.00 equiv) in methanol/ethyl acetate (20/10 mL). The solution was treated with Pd/C (500 mg) and stirred under an atmosphere of hydrogen overnight at room temperature. The reaction progress was monitored by LCMS. The solids were filtered out. The resulting mixture was concentrated under vacuum to yield 750 mg (97%) of l-(3,4-dimethylphenyl)-lH-pyrazol-3-amine as a yellow solid.

Intermediate 4g: 5-chloro-N-(l-(3.4-dimethylphenyl)-lH-t)yrazol-3-yl)-2- nitrobenzamide. Into a 100-mL round bottom flask, was placed a solution of l-(3,4- dimethylphenyl)-lH-pyrazol-3 -amine (408 mg, 2.18 mmol, 1.00 equiv) in dichloromethane (10 mL), pyridine (518 mg, 6.56 mmol, 3.00 equiv), and 5-chloro-2- nitrobenzoyl chloride (575 mg, 2.61 mmol, 1.00 equiv). The resulting solution was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum. The solution was adjusted to pH 7 with hydrochloric acid (1 mol/L). The resulting solution was extracted with 3x50 mL of ethyl acetate and the organic layers combined dried over anhydrous Sodium sulfate, and concentrated under vacuum. This resulted in 600 mg (59%) of 5-chloro-N-(l-(3,4-dimethylphenyl)-lH-pyrazol-3-yl)-2- nitrobenzamide as a yellow solid.

Intermediate 4h: 2-amino-5-chloro-N-(l-(3.4-dimethylphenyl ^' )-lH-pyrazol-3-vn- benzamide. Into a 100-mL round bottom flask, was placed a solution of 5-chloro-N-(l - (3,4-dimethylphenyl)-lH-pyrazol-3-yl)-2-nitrobenzamide (300 mg, 0.81 mmol, 1.00 equiv) in acetic acid (10 mL), and zinc (527 mg, 8.11 mmol, 9.96 equiv). The resulting solution was stirred for 1 h at 70°C. The resulting mixture was concentrated under vacuum. The solution was adjusted to pH 8 with ammonia (2 mol/L). The resulting solution was extracted with 4x50 mL of ethyl acetate and the organic layers combined, dried over anhydrous sodium sulfate, and concentrated under vacuum. The product was obtained as 200 mg (73%) of a solid.

Intermediate 4i: tert-butyl S-G-M-chloro^-d-O^-dimethylphenylVlH-pyrazol-S-yl- carbamoyl)phenylcarbamoyl)benzyltmo)propanoate. Into a 50-mL round bottom flask, was placed a solution of tert-butyl 3-(3-(chlorocarbonyl)benzylthio)propanoate (185 mg, 0.59 mmol, 1.00 equiv) in dichlpromethane (10 mL), and pyridine (140 mg, 1.77 mmol, 3.00 equiv). This was followed by dropwise addition of a solution of 2-amino-5- chloro-N-(l-(3,4-dimethylphenyl)-lH-pyrazol-3-yl)benzamide (200 mg, 0.59 mmol, 1.00 equiv) in dichloromethane (2 mL) with stirring. The resulting solution was stirred for 1 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column and eluted with petroleum ether/ethyl acetate (10:1) to yield 150 mg (33%) of product as a yellow solid.

Example 4: 3 -(3 -(4-chloro-2-( 1 -(3.4-dimethylphenyl ^' )- 1 H-pyrazol-3 -ylcarbamo ylV phenylcarbamoyl)benzylthio)propanoic acid. Into a 50-mL round bottom flask, was placed a solution of tert-butyl 3-(3-(4-chloro-2-(l-(3,4-dimethylphenyl)-lH-pyrazol-3- ylcarbamoyl)phenylcarbamoyl)benzylthio)propanoate (150 mg, 0.24 mmol, 1.00 equiv) in dichloromethane (4 mL), and 2,2,2-trifluoroacetic acid (2 mL). The resulting solution was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum. The crude product (100 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 36.3 mg (27%) ofa white solid. Ή-NMR (300MHz, DMSO,/¾WB): δ 11.82(s, 1H), 11.48(s, 1H), 8.52(d, J=8.70Hz, 1H), 8.41(s, 1H), 8.1 l(s, 1H), 7.92(s, 1H), 7.79(m, 1H), 7.67(m, 1H), 7.57(m, 4H), 7.26(m, 1H), 6.92(d, J=1.8Hz, 1H), 3.86(s, 2H), 2.60(m, 2H), 2.29(m, 6H). MS (ES, m/z) 563 [M+H] ⁺ . EXAMPLE 5

3-f(3-f(2-( ^, ( ^, l-f3.4-DimethylphenylVlH-Dyrazol-3-yl)carbamoylV4-(pii ieridin-l- yl)nhenyl)carbaiiioyl)ben/,ylHhio)proDanoic acid

Scheme 5. l . K ₂ C0 ₃ , DMF, piperidine; 2. Zn, HOAc; 3. EDC.HC1, DCM, DMAP, intermediate 4c; 4. DCM, TFA.

Intermediate 5a: N-f 1 -(3.4-dimethylphenyl)- 1 H-pyrazol-3-yl)-2-nitro-5-(piperidin- 1 - yll-benzamide. Into a 50-mL round bottom flask, was placed a solution of 5-chloro-N- (l-(3,4-dimethylphenyl)-lH-pyrazol-3-yl)-2-nitrobenzamide 4g (300 mg, 0.81 mmol, 1.00 equiv) in N,N-dimethylformamide (10 mL), potassium carbonate (330 mg, 2.39 mmol, 3.00 equiv), and piperidine (200 nig, 2.35 mmol, 3.00 equiv). The resulting solution was stirred for 4 h at 1 10°C. The resulting mixture was concentrated under vacuum. The residue was dissolved in 50 mL of ethyl acetate. The resulting mixture was washed with 2x30 mL of brine, dried over sodium sulfate, and concentrated under vacuum. This resulted in 300 mg (88%) of product as a yellow solid.

Intermediate 5b: 2-amino-N-d-C3.4-dimethylphenyl ^' )-lH-rJyrazol-3-yl ^' )-5-(iJiperidin-l- ylVbenzamide. Into a 50-mL round bottom flask, was placed a solution of N-(l-(3,4- dimethylphenyl)-lH-pyrazol-3-yl)-2-nitro-5-(piperidin-l-yl)b enzamide (400 mg, 0.95 mmol, 1.00 equiv) in acetic acid (8 mL), and zinc (600 mg, 9.23 mmol, 9.96 equiv). The resulting solution was stirred for 1 h at 70°C. The solids were filtered out. The resulting mixture was concentrated under vacuum. The solution was adjusted to pH 8 with ammonia (2 mol/L). The resulting solution was extracted with 2x50 mL of ethyl acetate and the organic layers combined, dried over anhydrous sodium sulfate, and concentrated under vacuum. This resulted in 300 mg (81%) of 2-amino-N-(l-(3,4- dimethylphenyl)-lH^yrazol-3-yl)-5-(piperidin-l-yl)benzamide as a green solid.

Intermediate 5c: tert-butyl 3-(3-(2-(l-(3.4-dimethylphenvD- 1 H-n yrazol-3 - ylcarbamoyl ^' )-4-fpiperidin-l-yl)phenylcarbamoyl ^' )benzylthio propanoate. Into a 100- mL round bottom flask, was placed a solution of 3-((3-tert-butoxy-3- oxopropylthio)methyl)benzoic acid (167 mg, 0.56 mmol, 1.10 equiv) in dichloromethane (10 mL), EDC.HC1 (148 mg, 0.77 mmol, 1.50 equiv), 4- dimethylaminopyridine (95 mg, 0.77 mmol, 1.50 equiv), and 2-amino-N-(l-(3,4- dimethylphenyl)-lH-pyrazol-3-yl)-5-(piperidin-l-yl)benzamide (200 mg, 0.51 mmol, 1.00 equiv). The resulting solution was stirred for 4 h at room temperature. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column and eluted with petroleum ether/ethyl acetate (10:1) to yield 150 mg (44%) of product as a green solid.

Example 5: 3-(3-(2-(l-r3.4-dimethylphenyl)-lH-pyrazol-3-ylcarbamoyl)-4- ( ^' piperidin- 1 -yl)phenylcarbamoyl ^' )benzylthio)propanoic acid. Into a 50-mL round bottom flask, was placed a solution of tert-butyl 3-(3-(2-(l-(3,4-dimethylphenyl)-lH-pyrazol-3- ylcarbamoyl)-4-(piperidin-l-yl)phenylcarbamoyl)benzylthio)pr opanoate (150 mg, 0.22 mmol, 1.00 equiv) in dichloromethane (4 mL), and tnfluoroacetic acid (2 mL). The resulting solution was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum. The crude product (100 mg) was purified by reverse phase HPLC eluting with a water/CHsCN gradient containing 0.05% TFA. The product was obtained as 85.3 mg (62%) of a white solid. Ή-NMR (300MHz, DMSO, ppm): δ 11.70(s, 1H), 11.44(s, 1H), 8.41(m, 2 H), 7.91(s, 1H), 7.78(m, 1H), 7.68(m, 1H), 7.62(m, 1H), 7.58(m, 3H), 7.40(m, 1H), 7.23(m, 1H), 6.92(s, 1H), 3.86(s, 2H), 3.36(m, 4H), 2.62(m, 2H), 2.29(m, 6H), 1.60(m, 6H). MS (ES, m/z): 612 [M+H] ⁺ .

EXAMPLE 6 3-(f3-f(4-Chloro-2-(a-f3-(trifluoroniethvnphenyl)-lH-pyrazol -3- yl)carbamoyl)i)henyl>carbamovnbenzv Hhio>Dropanoic acid

Scheme 6. 1. 3-(trifluoromethyl)iodobenzene, K2CO3, Cul, L-proline; 2. ¾, Pd C; 3. 2-nitro-5-chlorobenzoyl chloride, pyridine, DCM; 4. Zn, HOAc; 5. DCM, intermediate 4d, pyridine; 6. DCM, TFA.

Intermediate 6a: S-nitro-l-O-ftrifluoromethvDphenvn-lH-pyrazole, Into a 250-mL round-bottom flask, was placed a solution of 3-nitro-lH-pyrazole (10 g, 88.50 mmol, 1.00 equiv) in DMSO (100 mL), l-iodo-3-(trifluoromethyl)benzene (29 g, 106.62 mmol, 1.20 equiv), potassium carbonate (24 g, 173.91 mmol, 1.97 equiv), copper(I) iodide (2.6 g, 13.68 mmol, 0.15 equiv), and L-proline (2.5 g, 21.74 mmol, 0.25 equiv). The resulting solution was stirred overnight at 85°C in an oil bath. The reaction progress was monitored by LCMS. The resulting solution was diluted with 500 mL of water, extracted with 7x200 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 3x200 mL of water and 2x200 mL of brine. The mixture was dried over sodium sulfate. The solids were filtered out. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column and eluted with petroleum ether/ethyl acetate (10:1-5:1) to give 14 g (62%) of 3-nitro-l-(3-(trifluoromethyl)phenyl)-lH-pyrazole as a light yellow solid.

Intermediate 6b: l-(3-(trifluoromethvl)phenylVlH-pyrazol-3-amine. Into a 100-mL round-bottom flask, was placed a solution of 3-nitro-l-(3-(trifluoromethyl)phenyl)-lH- pyrazole (7 g, 27.24 mmol, 1.00 equiv) in methanol (30 mL). The mixture was treated with Pd C (3 g) and stirred under a hydrogen atmosphere overnight at room temperature. The solids were filtered out. The resulting mixture was concentrated under vacuum to yield 6 g (97%) of l-(3-(trifluoromethyl)phenyl)-lH-pyrazol-3-amine as a white solid.

Intermediate 6c : 5 -chloro-2-nitro-N-C 1 -(3 -(trifluoromethyltphenyl'l- 1 H-pyrazol-3-vD- benzamide. Into a 100-mL round bottom flask, was placed a solution of l-(3- (trifluoromethyl)phenyl)-lH-pyrazol-3 -amine (520 mg, 2.29 mmol, 1.00 equiv) in dichloromethane (5 mL), pyridine (540 mg, 6.84 mmol, 3.00 equiv), and 5-chloro-2- nitrobenzoyl chloride (500 mg, 2.27 mmol, 1.00 equiv). The resulting solution was stirred for 1 h at room temperature. The resulting mixture was washed with 2x50 mL of water, dried over anhydrous sodium sulfate, and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with petroleum ether/ethyl acetate (10:1). This resulted in 800 mg (85%) of product as a yellow solid.

Intermediate 6d: 2-amino-5 -chloro-N-( 1 -(3 -(trifluorometrryl)phenyl')- 1 H-pyrazol-3 -ylV benzamide. Into a 100-mL round bottom flask, was placed a solution of 5-chloro-2- nitro-N-(l-(3-(trifluoromethyl)phenyl)-lH-pyrazol-3-yl)benza mide (400 mg, 0.98 mmol, 1.00 equiv) in acetic acid (5 mL), and Zn (640 mg, 9.85 mmol, 10.00 equiv). The resulting solution was stirred for 1 h at 70°C. The solids were filtered out. The resulting mixture was concentrated under vacuum. The solution was adjusted to pH 8 with ammonia (2 mol/L). The resulting solution was extracted with 2x50 mL of ethyl acetate and the organic layers combined, dried over anhydrous sodium sulfate, and concentrated under vacuum. This resulted in 300 mg (81%) of product as a yellow solid.

Intermediate 6e: tert-butyl 3-(3-(4-chloro-2-(l-(3-(trifluoromethyl)phenyl')-lH-pyrazol- S-ylcarbamoyl ^' lphenylcarbamovDbenzylthio ^' tpropanoate. Into a 50-mL round bottom flask, was placed a solution of 2-amino-5-chloro-N-(l-(3-(trifluoromethyl)phenyl)-lH- pyrazol-3-yl)benzamide (191 mg, 0.50 mmol, 1.00 equiv) in dichloromethane (5 mL), pyridine (120 mg, 1.50 mmol, 3.00 equiv), and tert-butyl 3-(3- (chlorocarbonyl)benzylthio)propanoate (158 mg, 0.50 mmol, 1.00 equiv). The resulting solution was stirred for 1 h at room temperature. The resulting mixture was washed with 2x50 mL of water. The mixture was dried over sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with petroleum ether/ethyl acetate (20:1) to give 100 mg (30%) of product as yellow oil.

Example 6: 3 -(3 -(4-chloro-2-( 1 -(3 -(trifluoromethyl)phenyl)- 1 H-pyrazol-3 - ylcarbamovn-phenylcarbamoynbenzylth^propanoic acid. Into a 50-mL round bottom flask, was placed a solution of tert-butyl 3-(3-(4-chloro-2-(l-(3- (trifluoromethyl)pheny 1)- 1 H-pyrazol-3 - ylcarbamoyl)phenylcarbamoyl)benzylthio)propanoate (150 mg, 0.23 mmol, 1.00 equiv) in dichloromethane (4 mL), trifluoroacetic acid (2 mL). The resulting solution was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum. The crude product (100 mg) was purified by reverse phase HPLC eluting with a water/C¾CN gradient containing 0.05% TFA. The product was obtained as 48.9 mg (36%) of a white solid. Ή-NMR (300MHz, OMSO,ppm) δ 12.21(s, 1H), 11.73(s, 1H), 11.56(s, 1H), 8.68(m, 1H), 8.49(m, 1H), 8.10(m, 3H), 7.92(s, 1H), 7.73(m, 7H), 7.01(d, J=3Uz, 1H), 3.86(s, 2H), 2.59(m, 2H). MS (ES, m/z): 625 [M+Na] ⁺ .

EXAMPLE 7

3-((3-((4-(Piperidin-l-vn-2-((l-(3-(trifluoromethvnDhenyl )-lH-pyrazol-3- yl)carbamoyl)DhenylkarbamovDbcnzylHhio¾nronanoic acid

This compound was prepared from 5-chloro-2-nitro-N-(l-(3-(trifluoromethyl)phenyl)- lH-pyrazol-3-yl)benzamide 6c using the procedure described for the preparation of 3- (3 -(2-( 1 -(3 ,4-dimethylphenyl)- 1 H-pyrazol-3 -ylcarbamoyl)-4-(piperidin- 1 - yl)phenylcarbamoyl)-benzylthio)propanoic acid 5 from 5-chloro-N-(l-(3,4- dimethylphenyl)-lH-pyrazol-3-yl)-2-nitrobenzamide 4g. ^-NMR (300MHz, CD ₃ OD, ppm): δ 8.715(d, J=6.9Hz, IH), 8.390-8.397(m, IH), 8.180(s, IH), 8.057-8.077(m, IH), 8.020(s, 2H), 7.894-7.914(m, IH), 7.679-7.719(m, 2H), 7.591-7.642(m, 2H), 7.520- 7.558(m, IH), 7.147-7.154(m, IH), 3.889(s, 2H), 3.614-3.640(m, 4H), 2.690-2.725(m, 2H), 2.563-2.598(m, 2H), 2.002-2.055(m, 4H), 1.804-1.818(m, 2H). MS (ES, m/z): 652 [M+H] ⁺ .

EXAMPLE 9

2-MethvL-l-(6-((4-(piperidin-l-vn-2-(fl-(3-(trifluorometh Ynphenyn-lH-pyrazol-3- yl)carbamovnphenyl)carbamoyl)pyridiii-2-yl ^' )-5.8.11-trioxa-2-azatetradecaii-14-oic acid

Scheme 7. l. TsCl, pyridine; 2. MeN¾, EtOH; 3. 2-nitro-5-(piperidin-l-yl)benzoic acid, HATU, DIPEA; 4. H ₂ , Pd/C; 5. EDC.HC1, DCM, DMAP, 6-(chloromethyl)picolinic acid; 6. K ₂ C0 ₃ , DMF, KI, intermediate 8b; 7. DCM, TFA.

Intermediate 8a: tert-butyl 3-(2-(2-(2-(tosyloxytethoxy ethoxytethoxy^propanoate, Into a 250-mL round-bottom flask, was placed a solution of tert-butyl 3-(2-(2-(2- hydroxyethoxy)ethoxy)ethoxy)propanoate (10 g, 35.97 mmol, 1.00 equiv) in pyridine (40 mL). This was followed by the addition of toluenesulfonyl chloride (6.8 g, 35.79 mmol, 1.00 equiv), in portions at 0°C. The resulting solution was stirred for 4 h at 0°C. The resulting mixture was concentrated under vacuum. The residue was dissolved in 30 mL of dichloromethane. The resulting mixture was washed with 3x20 mL of 3% hydrochloric acid (aq) and 20 mL of brine. The mixture was dried over sodium sulfate and concentrated under vacuum to give 14 g (90%) of tert-butyl 3-(2-(2-(2- (tosyloxy)ethoxy)ethoxy)ethoxy)propanoate as yellow oil.

Intermediate 8b: tert-butyl 3-(2-(2-(2-(methylamino)ethoxy ^' )ethoxy)ethoxy ^' )propanoate. Into a 250-mL sealed bottle, was placed a solution of tert-butyl 3-(2-(2-(2- (tosyloxy)ethoxy)ethoxy)ethoxy)propanoate (14 g, 32.41 mmol, 1.00 equiv) in tetrahydrofuran (5 mL), and CH ₃ NH ₂ (66.9 g, 712.16 mmol, 21.98 equiv, 33% in ethanol). The resulting solution was stirred overnight at 50°C. The resulting mixture was concentrated under vacuum. The residue was dissolved in 150 mL of dichloromethane. The resulting mixture was washed with 2x150 mL of water and 1x150 mL of brine, dried over sodium sulfate, and concentrated under vacuum. This resulted in 8.2 g (87%) of product as a yellow oil.

Intermediate 8c: 2-nitro-5-(piperidin-l-yl ^' )-N-(l-(3-(trifluoromethyl ^' )phenyl ^' )-lH- pyrazol-3-v benzamide. Into a 250-mL round bottom flask, was placed a solution of 2- nitro-5-(piperidin-l-yl)benzoic acid (5 g, 20.00 mmol, 1.19 equiv) in N,N- dimethylformamide (50 mL), l-(3-(trifluoromethyl)phenyl)-lH-pyrazol-3-amine (3.8 g, 16.74 mmol, 1.00 equiv), HATU (9.5 g, 25.00 mmol, 1.49 equiv), and N,N- diisopropylethylamine (3.3 g, 25.58 mmol, 1.53 equiv). The resulting solution was stirred overnight at 50°C in an oil bath. The reaction progress was monitored by LCMS. The resulting solution was diluted with 200 mL of water, extracted with 4x50 mL of ethyl acetate, and the organic layers combined. The resulting mixture was washed with 2x50 mL of water and 2x50 mL of brine. The mixture was dried over sodium sulfate. The solids were filtered out. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column and eluted with petroleum ether/ethyl acetate (5 : 1) to yield 2.8 g (36%) of product as a yellow solid.

Intermediate 8d: 2-amino-5-(piperidin-l-ylVN-(l-(3-ftrifluoromethvnphenylVlH- pwazol-3-yl1benzamide. Into a 50-mL round-bottom flask, was placed a solution of 2- nitro-5-(piperidin-l-yl)-N-(l-(3-(trifluoromethyl)phenyl)-lH -pyrazol-3-yl)benzamide (900 mg, 1.96 mmol, 1.00 equiv) in methanol (15 mL) and ethyl acetate (15 mL). The mixture was treated with Pd/C (500 mg) stirred under a hydrogen atmosphere for 1 h at room temperature in an oil bath. The reaction progress was momtored by LCMS. The solids were filtered out. The resulting mixture was concentrated under vacuum to give 600 mg (71 %) of product as a brown solid.

Intermediate 8e: 6-(chloromethyl')-N-(4-(piperidin- 1 -νΓ)-2-(Υ 1 -(3 -

(trifluoromethvnphenvn-lH-Dyrazol-S-vncarbamovDphenvnpico linamide. Into a 50- mL round bottom flask, was placed a solution of 2-amino-5-(piperidin-l-yl)-N-(l-(3- (trifluoromethyl)phenyl)-lH-pyrazol-3-yl)benzamide (100 mg, 0.23 mmol, 1.00 equiv) in dichloromethane (3 mL), 6-(chloromethyl)picolinic acid (50 mg, 0.29 mmol, .1.25 equiv), EDC.HC1 (67 mg, 0.35 mmol, 1.50 equiv), and 4-dimethylaminopyridine (43 mg, 0.35 mmol, 1.51 equiv). The resulting solution was stirred overnight at 25°C in an oil bath. The mixture was concentrated under vacuum to give 170 mg (75%) of product as a

Intermediate 8f: tert-butyl 3-(2-(2-(2-(((6-((4-(piperidin- 1 -yl)-2-(( 1 -(3-

(trifluoromethyl)-phenyl)- 1 H-pyrazol-3 -yl)carbamoyl)phenyl)carbamo yl)p yridin-2- yl)methyl)(methyl)-amino)ethoxy)ethoxy)ethoxy)propanoate. Into a 50-mL round bottom flask, was placed a solution of 6-(chloromethyl)-N-(4-(piperidin-l-yl)-2-((l-(3- (trifluoromethyl)phenyl)- 1 H-pyrazol-3 -y l)carbamoyl)phenyl)picolinamide (170 mg, 0.29 mmol, 1.00 equiv) in N,N-dimethylformamide (5 mL), tert-butyl 3-(2-(2-(2- (methylamino)ethoxy)ethoxy)ethoxy)-propanoate (255 mg, 0.88 mmol, 3.00 equiv), potassium iodide (24.2 mg, 0.15 mmol, 0.50 equiv), and potassium carbonate (79.5 mg, 0.58 mmol, 1.97 equiv). The resulting solution was stirred for 2.5 h at 70°C in an oil bath. The reaction progress was monitored by LCMS. The resulting solution was diluted with 50 mL of water. The resulting solution was extracted with 3x50 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 3x50 mL of brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. This resulted in

Example 8: 2-methyn-(6-((4-(piperidin -yl^^

pyrazol-3 -vDcarbamo vnphenyncarbamo νΠρντίάίη-2- yll-5.8.11 -trioxa-2-azatetradecan- 14-oic acid. Into a 50-mL round bottom flask, was placed a solution of tert-butyl 3-(2- (2-(2-(((6-((4-(piperidin -yl)-2-((l 3 trifluoromethyl)phenyl)-lH-pyrazol-3- yl)carbamoyl)-phenyl)carbamoyl)pyridin-2- yl)methyl)(methyl)amino)ethoxy)ethoxy)ethoxy)propanoate (210 mg, 0.25 mmol, 1.00 equiv) in dichloromethane (4 mL), and trifluoroacetic acid (2 mL). The resulting solution was stirred for 2 h at room temperature. The reaction progress was monitored by LCMS. The resulting mixture was concentrated under vacuum. The crude product was purified by reverse phase HPLC eluting with a water/CH^CN gradient containing 0.05% TFA. The product was obtained as 32.9 mg (13%) of a brown solid. Ή-NMR (300MHz, CD ₃ OD, ppm): δ 8.81-8.78(d, J=9.3Hz, 1H), 8.48-8.47(d, =2.7Hz, 1H), 8.33-8.31(d, J=7.5Hz, 1H), 8.21-8.16(d, J=7.5Hz, 2H), 7.87-7.86(d, J=2.4Hz, 1H),

7.79- 7.72(m, 2H), 7.64-7.62(d, J=6.9Hz, 2H), 6.98-6.97(d, J=2.4Hz, IH), 4.75(s, 2H),

3.80- 3.77(t, J=4.5Hz, 2H), 3.66-3.47(m, 16H), 3.1 l-3.09(d, J=6.3Hz, 3H), 2.49-2.45(d, =6Hz, 2H), 1.94-1.75(m, 6H). MS (ES, m/z): 782 [M+H] ⁺ .

EXAMPLE 9

2-(4-(((2-(Dicthylaniino)cthvD(incthyl)amino)mcthvnbcnzai nido)-5-(pineridin-l- vD-N-fl-fS-CtrifluoromethvnDhenyn-lH-pyrazoI-S-y tbenzamide

Scheme 7. 1. Ν,Ν-diethyl-N-methylethylenediamine; 2 EDC.HC1, DMAP, DCM.

Intermediate 9a: 4-(f( ^' 2-(diethylamino ^' )ethyl ^' )(methvnamino ^' )methyl ^' )benzoic acid. Into a 1000-mL round bottom flask, was placed a solution of Nl,Nl-diethyl-N2- methylethane-l,2-diamine (10 g, 69.23 mmol, 1.20 equiv, 90%) in N,N- dimethylformamide (500 mL), 4-(chloromethyl)benzoic acid (11.5 g, 67.65 mmol, 1.00 equiv), potassium carbonate (10 g, 71.94 mmol, 3.00 equiv), and potassium iodide (1.95 g, 11.75 mmol, 0.20 equiv). The resulting solution was stirred for 2 h at 90°C in an oil bath. The solids were filtered out The resulting mixture was concentrated under vacuum. The crude product (10 g) was purified by reverse phase chromatography eluting with a water/methanol gradient. This resulted in 5 g (27%) of 4-(((2- (diethylamino)ethyl)(methyl)amino)methyl)benzoic acid as a white solid. Ή-NMR (300MHz, CDC1 ₃ , ppm): δ 8.00(d, =8.4Hz, 2H), 7.39(d, .7=8. lHz, 2H), 3.68(s, 2H), 3.23-3.15(m, 6H), 2.91(m, 2H), 2.33(s, 3H), 1.33-1.27(m, 6H). MS (ES, m/z): 265 [M+H] ⁺ .

Example 9: 2-(4-(((2-fdiethylamino)ethyl (memyl)a^

(piperidin- 1 -yl)-N-( 1 -(3 -(trifluoromethyDphenyri- 1 H-pyrazol-3 -vDbenzamide. Into a 5- mL vial, was placed a solution of 2-amino-5-(piperidin-l-yl)-N-(l-(3- (trifluoromethyl)phenyl)-l H-pyrazol-3 -yl)benzamide 8d (100 mg, 0.23 mmol, 1.00 equiv) in dichloromethane (5 mL), 4-(((2-

(diethylamino)ethyl)(methyl)amino)methyl)benzoic acid (74 mg, 0.28 mmol, 1.20 equiv), EDC.HC1 (90 mg, 0.47 mmol, 2.00 equiv), and 4-dimethylaminopyridine (43 mg, 0.35 mmol, 1.50 equiv). The resulting solution was stirred overnight at 30°C in an oil bath. The reaction progress was monitored by LCMS. The resulting mixture was washed with 3x10 mL of water and 1x10 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product (150 mg) was purified by reverse phase HPLC eluting with a water/C¾CN gradient containing 0.05% TFA. The product was obtained as 57.8 mg (31%) of a light yellow solid. Ή- NMR (300MHz, CD ₃ OD, ppm): δ 8.684(d, J=9Hz, 1H), 8.392-8.400(m, 1H), 8.179(s, 1H), 8.047-8.075(m, 3H), 7.991-7.999(m, 1H), 7.589-7.727(m, 5H), 7.078-7.087(m, 1H), 4.007(s, 2H), 3.556-3.615(m, 4H), 3.393-3.436(m, 2H), 3.171-3.263(m, 4H), 3.052-3.095(m, 2H), 2.538-2.560(m, 3H), 1.998(m, 4H), 1.788-1.804(m, 2H), 1.286- 1.334(m, 6H). MS (ES, m/z): 676 [M+H] ⁺ . EXAMPLE 10

Nl-(2-(2-Hvdroxyethoxy)ethYn-N3-f4-(piperidin-l-vn-2-fg-( 3- (trifluoromethyl)phenyl)-lH-imidazol-4-vncarbamoyl)phenvniso phthalamide

Scheme 8. 1. 2-(2-aminoethoxy)ethanol, HATU, DIEA; 2. LiOH H ₂ 0;

3. 3-(trifluoromethyl)iodobenzene, K ₂ C0 ₃ , Cul, proline; 4. ¾, Pd/C; 5. EDC.HC1, DMAP, DCM, 5-(l-piperidinyl)-2-nitrobenzoic acid; 5. Intermediate 10b; 6. ¾, Pd C; 7. 3-((2-(2-hydroxyethoxy)ethyl)carbamoyl)benzoic acid, EDC HC1, DMAP.

Intermediate 10a: methyl 3-(r2-(2-hvdroxyethoxy')ethyncarbamoyl')benzoate. Into a 1000-mL round bottom flask, was placed a solution of 3-(methoxycarbonyl)benzoic acid (20 g, 111.11 mmol, 1.00 equiv) in N,N-dimethylformamide (500 mL), HATU (63.2 g, 166.32 mmol, 1.50 equiv), N,N-diisopropylethylamine (21.5 g, 166.67 mmol, 1.50 equiv), and 2-(2-aminoethoxy)ethanol (23.3 g, 221.90 mmol, 2.00 equiv). The resulting solution was stirred overnight at 25°C. The resulting mixture was concentrated under vacuum. The resulting solution was dissolved in 200 mL of ethyl acetate. The resulting mixture was washed with 10x200 mL of brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with dichloromethane:methanol (100:1). This resulted in 15 g (51%) of methyl 3-((2-(2-hydroxyethoxy)ethyl)carbamoyl)benzoate as red oil.

Intermediate 10b: 3-f(2-(2-hvdroxyethoxy ethyl)carbamoyl)benzoic acid. Into a 500- niL round bottom flask, was placed a solution of methyl 3-((2-(2- hydroxyethoxy)ethyl)carbamoyl)benzoate (10 g, 37.45 mmol, 1.00 equiv) in tetrahydrofuran (40 mL), and a solution of lithium hydroxide hydrate (23.4 g, 558.33 mmol, 15.00 equiv) in water (30 mL). The resulting solution was stirred overnight at room temperature. The resulting mixture was concentrated under vacuum. The solution was adjusted to pH 3-4 with hydrochloric acid (2 mol/L), extracted with 3x10 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 2x10 mL of brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with dichloromethanemethanol (50:1). This resulted in 5 g (53%) of 3-((2-(2- hydroxyethoxy)ethyl)carbamoyl)benzoic acid as a yellowish solid. 'H-NMR

(300MHz, DMSO, ppm) δ 13.25(s, 1H), 8.71(m, 1H), 8.48(d, J=8.5Hz 1H), 8.06(m, 2H), 7.62(m, 1H), 4.59(s, 1H), 3.41-3.60 (m, 8H). MS (ES, m/z): 254 [M+H] ⁺ . Intermediate 10c: 4-nitJo -(3-(trifluoromethvl)phenyl ^' )-lH-imidazole. Into a 500-mL round bottom flask, was placed a solution of 4-nitro-lH-imidazole (10 g, 88.50 mmol, 1.00 equiv) in DMSO (50 mL), l-iodo-3-(trifluoromethyl)benzene (24 g, 88.24 mmol, 1.00 equiv), potassium carbonate (25 g, 181.16 mmol, 2.00 equiv), copper(I) iodide (2.5 g, 13.16 mmol, 0.15 equiv), and L-proline (1.53 g, 13.30 mmol, 0.15 equiv). The resulting solution was stirred overnight at 85°C in an oil bath. The resulting solution was diluted with 1000 mL of ethyl acetate. The solids were filtered out. The filtrate was washed with 2x500 mL of brine, dried over sodium sulfate, and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate/petroleum ether (1 :3) to yield 6.7 g (28%) of 4-nitro-l-(3- (trifluoromethyl)phenyl)-lH-imidazole as a pale solid.

Intermediate lOd: l-G-CtrifluoromethyDphenvD-lH-imidazol^-amine. Into a 100-mL round bottom flask, was placed a solution of 4-nitro-l-(3-(trifluoromethyl)phenyl)-lH- imidazole (1.5 g, 5.54 mmol, .1.00 equiv, 95%) in methanol (30 mL). The mixture was treated with Pd/C (1.5 g) and stirred under a hydrogen atmosphere for 4 h at room temperature. The solids were filtered out. The resulting mixture was concentrated under vacuum. This resulted in 1.2 g (88%) of l-(3-(trifluoromethyl)phenyl)-lH-imidazol-4- amine as a brown oil.

Intermediate lOe: 2-nitro-5 -(piperidin- 1 - vD-N-( 1 -(3 -(trifluoromethvDphenyl ^' )- 1 H- imidazol-4-vObenzamide, Into a 250-mL round-bottom flask, was placed a solution of l-(3-(trifluorome11iyl)phenyl)-lH-imidazol-4-amine (1.2 g, 4.49 mmol, 1.00 equiv, 85%) in dichloromethane (30 mL), 2-nitro-5-(piperidin-l-yl)benzoic acid (1.32 g, 5.07 mmol, 1.00 equiv, 96%), EDC.HC1 (2 g, 10.42 mmol, 2.00 equiv), and 4- dimethylaminopyridine (1.29 g, 10.57 mmol, 2.00 equiv). The resulting solution was stirred overnight at 28°C. The resulting solution was diluted with 200 mL of dichloromethane. The resulting mixture was washed with 1x30 mL of 10% sodium bicarbonate and 1x30 mL of brine, dried over sodium sulfate, and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate/petroleum ether (1:1) to give 600 mg (22%) of product as brown oil.

Intermediate 1 Of: 2-amino-5-(piperidin- 1 -yl)-N-(l -(3-(trifluoromethyl ^' )phenyl')- 1 H- imidazol-4-yl)benzamide . Into a 100-mL round-bottom flask, was placed a solution of 2-nitro-5-(piperidin- 1 -yl)-N-( 1 -(3 -(trifluoromethyl)phenyl)- 1 H-imidazol-4- yl)benzamide (600 mg, 1.11 mmol, 1.00 equiv, 85%) in methanol/dichloromethane (10/5 mL). The mixture was treated with Pd/C (600 mg) and stirred under an atmosphere of hydrogen overnight at room temperature. The solids were filtered out. The resulting mixture was concentrated under vacuum to give 450 mg (85%) of product as a brown solid.

Example 10: Nl-(2-(2-hvdroxyethoxy ^' )ethyl ^' )-N3-(4-(piperidin-l -yl1-2-((l-(3-(trifluoro- me yl)phenyl)-lH-imidazol-4-yl carbamovD^^

emoxy)ethyl)-N3 -i4-fpiperidin- 1 -ylV2-(d -(3 -ftrifluoromethyltphenyl)- 1 H-imidazol-4- yl)carbamoyl)phenyl isophthalamide. Into a 50-mL round bottom flask, was placed a solution of 2-amino-5 -(piperidin- 1 -yl)-N-( 1 -(3 -(trifluoromethyl)phenyl)- 1 H-imidazol- 4-yl)benzamide (150 mg, 0.32 mmol, 1.00 equiv, 92%) in dichloromethane (8 mL), 3- ((2-(2-hydroxyethoxy)ethyl)carbamoyl)benzoic acid (133 mg, 0.45 mmol, 1.50 equiv, 85%), EDC.HC1 (134 mg, 0.70 mmol, 2.00 equiv), and 4-dimethylaminopyridine (85 mg, 0.70 mmol, 2.00 equiv). The resulting solution was stirred overnight at 25°C. The resulting solution was diluted with 100 mL of dichloromethane. The resulting mixture was washed with 1x20 mL of 10% sodium bicarbonate and 1x20 mL of brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with dichloromethane/methanol (20:1). The crude product (120 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 67.8 mg (22%) of a light yellow solid. 'H-NMR (300MHZ, CD ₃ OD, ppm): δ 8.74 (d, J=9Hz, 1H), 8.53 (s, 1H), 8.35(s, lH), 8.01 (m, 6H), 7.74 (m, 3H), 7.44 (m, 1H), 3.66 (m, 12H), 2.06 (m, 4H), 1.83 (m, 2H). MS (ES, m/z): 665 [M+H] ⁺ .

EXAMPLE 11

Nl-Methyl-Nl-(2-morpholinoethyl)-N3-(4-(piperidin-l-vI)-2-(q -(3- (trifluoromethyl)phenyl)-lH-pyrazol-3-yl)carbamoyl)l)henvL)i sophthalamide

Into a 50-mL round bottom flask, was placed 2-amino-5-(piperidin-l-yl)-N-(l-(3- (trifluoromethyl)phenyl)-lH-pyrazol-3-yl)benzamide 8d (100 mg, 0.23 mmol, 1.00 equiv), 3-(methyl(2-morpholinoethyl)carbamoyl)benzoic acid (130 mg, 0.45 mmol, 1.91 equiv), EDC.HC1 (67 mg, 0.35 mmol, 1.50 equiv), 4-dimethylaminopyridine (43 mg, 0.35 mmol, 1.51 equiv), and dichloromethane (5 mL). The resulting solution was stirred for 4 h at 25°C in an oil bath. The reaction progress was monitored by LCMS. The resulting mixture was washed with 3x10 mL of water and 3x10 mL of aqueous N¾C1. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product was purified by reverse phase HPLC eluting with a water/CHsCN gradient containing 0.05% TFA. The product was obtained as 108.6 mg

(66%) of a white solid. Ή-NMR (400MHz, CD ₃ OD, ppm): δ 8.66-8.64(d, J=8.8Hz, 1H), 8.39(s, 1H), 8.16 (s, 3H), 8.07-8.05(d, J=7.6Hz, lH), 7.99(s, 1H), 7.79(s, 1H), 7.16-7.68 (m, 3H), 7.61(s, 1H), 7.07(s, 1H), 4.11-4.10(d, .7=3.2 Hz, 2H), 3.98 (s, 3H), 3.80-3.77(m, 4H), 3.59-3.54 (m, 6H), 3.14(m, 4H), 1.99-1.79(m, 6H). MS (ES, m/z): 704 [M+H] ⁺ .

EXAMPLE 12

2-(3-(((2-fDiethylamino)ethyl (methyllamino)methyl)benzamido ^' >-5-( ^' piperidiii-l- vD-N-d-O-ftrifluoromethvnphenyll-lH-pyrazol-S-vnbeiizainide

Scheme 9. 1. Nl,Nl-diethyl-N2-methylethane-l,2-diamine, K ₂ C0 ₃ ; 2. EDC.HC1, DMAP, dichloromethane.

Intermediate 12a: 3-(((2-(diethylamino ethyl¥methvDamino')methyl')benzoic acid. Into a 1000-mL round bottom flask, was placed a solution of Nl,Nl-diethyl-N2- methylethane-l,2-diamine (9.1 g, 63.00 mmol, 1.50 equiv, 90%) in N,N- dimethylformamide (500 mL), 3-(bromomethyl)benzoic acid (10 g, 46.51 mmol, 1.00 equiv), potassium carbonate (7.8 g, 56.12 mmol, 1.20 equiv), and potassium iodide (1.55 g, 9.34 mmol, 0.20 equiv). The resulting solution was stirred for 2 h at 90 ^C C in an oil bath. The solids were filtered out. The resulting mixture was concentrated under vacuum. The crude product (10 g) was purified by reverse phase HPLC eluting with 0.05% TFA in a water/CHCN gradient. The product was obtained as 6 g (46%) of a white solid. Ή-NMR (300MHz, CDCh, ppm): δ 8.01(m, 1H), 7.89-7.87(m, 1H), 7.28- 7.22(m, 2H), 3.99(s, 2H), 2.97-2.72(m, 8H), 2.28(s, 3H), 1.13-1.01(m, 6H). MS (ES, m/z): 265 [M+H] ⁺ .

Example 12: 2-(3-(((2-(diemylamino ethyn(memvDamino methyl ^' )benzamido ^' )-5-

(piperidin- 1 -yl)-N-( 1 -(3 -(trifluoromethyl)phenylV 1 H-pyrazol-3 -v benzamide. Into a 50-mL round bottom flask, was placed a solution of 2-amino-5-(piperidin-l-yl)-N-(l- (3-(trifluoromethyl)phenyl)-lH-pyrazol-3-yl)benzamide 8d (100 mg, 0.23 mmol, 1.00 equiv) in dichloromethane (5 mL), 3-(((2- (diethylamino)ethyl)(methyI)amino)methyl)benzoic acid (74 mg, 0.28 mmol, 1.20 equiv), EDC.HC1 (90 mg, 0.47 mmol, 2.01 equiv), and 4-dimethylaminopyridine (43 mg, 0.35 mmol, 1.51 equiv). The resulting solution was stirred overnight at 30°C in an oil bath. The reaction progress was monitored by LCMS. The resulting mixture was washed with 3x10 mL of water and 1x10 mL of brine. The mixture was dried over sodium sulfate. The solids were filtered out. The resulting mixture was concentrated under vacuum. The crude product (150 mg) was purified by reverse phase HPLC eluting with a water/C¾CN gradient containing 0.05% TFA. The product was obtained as 58.5 mg (32%) of a yellow solid. 'H-NMR (300MHz, CD ₃ OD, ppm): δ 8.502- 8.532(d, /=9.0Hz, 1H), 8.277-8.286(m, 1H), 8.060(s, 1H), 7.851-7.966(m, 4H), 7.475- 7.610(m, 5H), 6.949-6.958(m, 1H), 3.922(s, 2H), 3.450-3.485(m, 4H), 3.273-3.316(m, 2H), 3.035-3.108(m, 4H), 2.957-2.998(m, 2H), 2.449-2.475(m, 3H), 1.857-1.872(m, 4H), 1.666-1.683(m, 2H), 1.139-1.200(m, 6H). MS (ES, m/z): 676 [M+H] ⁺ .

EXAMPLE 13

Nl-(2-(2-Hvdroxyethoxy)ethvn-N3-(4-(piperidin-l-yl)-2-((l -(3- (trifluoromethYDphenvR-lH-pyrazol-S-vDcarbamovDphenYDisophth alamide

2- Amino-5 -(piperidin- 1 -yl)-N-( 1 -(3 -(trifluoromethyl)phenyl)- 1 H-pyrazol-3 - yl)benzamide 8d was converted to Nl-(2-(2-hydroxyethoxy)ethyl)-N3-(4-(piperidin-l- yl)-2-(( 1 -(3 -(trifluoromethyl)pheny 1)- 1 H-pyrazol-3 - yl)carbamoyl)phenyl)isophthalamide 13 using the procedure described for the preparation of Nl-(2-(2-hydroXyethoxy)ethyl)-N3-(4-(piperidin-l-yl)-2-((l-( 3- (trifluoromethyl)phenyl)-lH-imidazol-4-yl)carbamoyl)phenyl)- isophthalamide 10. ¾- NMR (300MHz, CD ₃ OD, pprri): δ 8.683(d, J=9Hz, IH), 8.498(s, IH), 8.382-8.391(m, IH), 8.151-8.171(m, 2H), 8.039-8.086(m, 3H), 7.655-7.715(m, 3H), 7.592(d, J=7.8Hz, IH), 7.128-7.136(m, IH), 3.579-3.710(m, 12H), 2.002-2.016(m, 4H), 1.803-1.818(m, 2H). MS (ES, m/z): 665 [M+H] ⁺ .

EXAMPLE 14

Nl-(4-Chloro-2-((l-(3-(trifluoromethyl)phenyl)-lH-pyrazol -3- ylkarbamoyl)nhenyn-N3-methyl-N3-(2-m()rph(>lin ethvnisi)nhthalamide 2.2.2- trifluoroacetate

Into a 50-mL round bottom flask, was placed a solution of 2-arnino-5-chloro-N-(l-(3- (trifluoromethyl)phenyl)-lH-pyrazol-3-yl)benzamide 6d (150 mg, 0.39 mmol, 1.00 equiv) in dichloromethane (6 mL), and pyridine (93.6 mg, 1.18 mmol, 3.00 equiv). To this was added dropwise, a solution of 3-(methyl(2- morpholinoethyl)carbamoyl)benzoyl chloride If (147 mg, 0.47 mmol, 1.20 equiv) in dichloromethane (2 mL) over 10 min with stirring at 0°C. The resulting solution was stirred for 1 h at room temperature. The resulting solution was diluted with 2 mL of water, and adjusted to pH 8 with NH ₃ .H ₂ 0 (2 mol/L). The resulting solution was extracted with 2x5 mL of dichloromethane and the organic layers combined, dried over sodium sulfate, and concentrated under vacuum. The crude product (150 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 67.2 mg (22%) of a white solid. ¾-NMR (300MHz, DMSO, pprri): δ 11.67 (s, IH) , 11.54 (s, IH), 9.62 (s, IH), 8.68-8.67 (d, J=2.7Hz, IH), 8.71-8.38 (d, /=9.0Hz, IH), 8.16-8.02 (m, 5H), 7.79-7.65 (m, 5H), 6.968-6.960 (d, /=2.4Hz, 1H), 4.01(s, 2H), 3.84 (s, 2H), 3.42 (s, 6H), 3.18 (s, 2H), 2.98(s, 3H). MS (ES, m/z): 655 [M +H] ⁺ .

EXAMPLE 15

2-MethYl-l-oxo-l-(3- 4-(piperidin-l-yl 2-f(l-f3-(trifluoromethvnphenyl)-lH- Pyrazol-S-vncarbamovDphenYDcarbamoYllphenylVS.S.ll-trioxa- -azatetradecan- 14-oic acid

Scheme 10: 1. methyl 3-(chlorocarbonyl)benzoate, Et ₃ N; 2. LiOH H ₂ 0; 3. tert-butyl 3- (2-(2-(2-(methylamino)ethoxy)ethoxy)ethoxy)prGpanoate 8b, EDC HCl, DMAP, then TFA/DCM.

Intermediate 15a: methyl 3-((4-fpiperidin-l-yl ^' )-2-(( ^' l-(3-( ^' trifluoromethyl ^' )phenylVlH- pyrazol-3-yl)carbamoyl)phenyl carbamoyl)benzoate. Into a 100-mL 3 -necked round bottom flask, was placed a solution of 2-amino-5-(piperidin-l-yl)-N-(l-(3- (trifluoromethyl)phenyl)-lH-pyrazol-3-yl)benzamide (260 mg, 0.61 mmol, 1.00 equiv) in dichloromethane (20 mL), and triethylamine (123 mg, 1.22 mmol, 2.01 equiv). This was followed by dropwise addition of a solution of methyl 3-(chlorocarbonyl)benzoate (144 mg, 0.73 mmol, 1.20 equiv) in dichloromethane (10 mL) with stirring at 0°C. The resulting solution was stirred for 2 h at room temperature, with reaction progress monitored by LCMS. The resulting mixture was washed with 3x20 mL of water and 20 mL of brine, then dried over anhydrous sodium sulfate. The solids were filtered out. The resulting mixture was concentrated under vacuum to give 300 mg of crude product as a brown solid.

Intermediate 15b: 3 -( (4-(piperidin- 1 -vD-2-(T 1 -(3 -(trifluoromethyl)phenyl)- 1 H-pyrazol- 3-yl)carbamoyl)phenyl)carbamoyl)benzoic acid. Into a 100-mL round bottom flask, was placed a solution of methyl 3-((4-(piperidin-l-yl)-2-((l-(3-(trifluoromethyl)phenyl)-lH- pyrazol-3-yl)carbamoyl)phenyl)carbamoyl)benzoate (300 mg, 0.51 mmol, 1.00 equiv) in tetrahydrofuran (30 mL), water (5 mL), and lithium hydroxide hydrate (300 mg, 12.50 mmol, 24,62 equiv). The resulting solution was stirred overnight at room temperature. The reaction progress was monitored by LCMS. The resulting mixture was concentrated under vacuum. The solution was adjusted to pH 2 with hydrochloric acid 1 mol L). The resulting solution was extracted with 3x30 mL of ethyl acetate and the organic layers combined, washed with 1x30 mL of brine, and dried over anhydrous sodium sulfate. The solids were filtered out. The resulting mixture was concentrated under vacuum. This resulted in 300 mg of crude product as a gray solid.

Example 15: 2-methyl- 1 -oxo- 1 -(3 -((4-(piperidin- 1 -yp-2-(( 1 -(3 -

(trifluoromethyl)phenyl')-lH-pyrazol-3-yl ^' )carbamoyl ^' )Dhenyl ^' )carbamoyl)phenyl ^' )- 5,8,1 l-trioxa-2-azatetradecan-14-oic acid. Into a 50-mL round bottom flask, was placed 3 -((4-(piperidin- 1 -yl)-2-(( 1 -(3 -(trifluoromethyl)phenyl)- 1 H-pyrazol-3 - yl)carbamoyl)phenyl)carbamoyl)benzoic acid 8d (150 mg, 0.26 mmol, 1.00 equiv), tert- butyl 3-(2-(2-(2-(methyIamino)ethoxy)ethoxy)ethoxy)propanoate 8b (75 mg, 0.26 mmol, 0.99 equiv), EDC.HC1 (75 mg, 0.39 mmol, 1.51 equiv), 4- dimethylaminopyridine (48 mg, 0.39 mmol, 1.52 equiv), and dichloromethane (5 mL). The resulting solution was stirred for 3 h at 25°C in an oil bath, with reaction progress monitored by LCMS. The resulting solution was diluted with 10 mL of dichloromethane. The resulting mixture was washed with 3x10 mL of water and 3x10 mL of aqueous NH4CI. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum to yield 190 mg (86%) of product as a yellow solid. Into a 50-mL round bottom flask, was placed a solution of this solid (170 mg, 0.20 mmol, 1.00 equiv) in dichloromethane (3 mL), and trifluoroacetic acid (1.5 mL). The resulting solution was stirred for 2 h at room temperature. The reaction progress was monitored by LCMS. The resulting mixture was concentrated under vacuum. The crude product was purified by reverse phase HPLC eluting with a water/CHsCN gradient containing 0.05% TFA. The product was obtained as 67.2 mg (42%) of a yellow solid. ¹ H-NMR (300MHz, CD ₃ OD, ppm): δ 8.74-8.71(d, J=9Hz, IH), 8.40-8.39(d, J=2.4Hz, IH), 8.17(s, IH), 8.09-8.05(m, 4H), 7.76-7.58(m, 5H), 7.11-7.10(d, J=2.7Hz, IH), 3.79(s, 2H), 3.68-3.53(m, 17H), 3.15-3.12(d, J=l l.lHz, 3H), 2.52-2.48(t, J=6.3Hz, 2H), 2.04- 1.81(m, 6H). MS (ES, m/z): 795 [M+H] ⁺ .

EXAMPLE 16

2-(3-(((3-((2-Melhoxyethvnamino)-3- oxopropyUdnethynaminotmethyDbenzamidoVS-fpiperidin-l-vn-N-fl -O- (trifluoromethyl)phenyl HHayrazo]-3-vDbenzamide

Scheme 11: 1. 3-(bromomethyl)benzoyl chloride, DIPEA; 1. N-(2-methoxyethyl)-3- (methylamino)propanainide, KI, K2CO3.

Intermediate 16a: 2-G-(bromomethvnberizamido ^' )-5-(piperidin-l-yl -N-(l-(3-

(trifluoromethyllphenyll-lH-pyrazol-S-vnbenzamide. Into a 50-mL round bottom flask, was placed 2-amino-5-(piperidin -yl)-N^l-(3-(triflupromethyl)phenyl)-lH- pyrazol-3-yl)benzamide 8d (100 mg, 0.23 mmol, 1.00 equiv) in tetrahydrofuran (5 mL), and N,N-diisopropylethylamine (60 mg, 0.47 mmol, 2.00 equiv). To this was added 3- (bromomethyl)benzoyl chloride (75 mg, 0.32 mmol, 1.39 equiv), in portions at 0°C. The resulting solution was stirred for 2.5 h at room temperature. The reaction progress was monitored by LCMS/TLC. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 10 mL of water, extracted with 3x10 mL of ethyl acetate, and the organic layers combined. The resulting mixture was washed with 3x10 mL of brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. This resulted in 160 mg (88%) of product as a brown solid.

Example 16: 2-(3-(((3-((2-methoxyethyl ^' )amino1-3-oxopropyl)(methv amino ^" )methyl ^' )- berizamido)-5-^iperidin -yl)-N-( ^' l-f3-( ^' trifluoromethyl)phenyl)-lH-pyrazol-3-ylV benzamide. Into a 50-mL round bottom flask, was placed intermediate 16a-2 (160 mg, 0.26 mmol, 1.00 equiv), (123 mg, 0.77 mmol, 3.01 equiv), potassium iodide (21.2 mg, 0.13 mmol, 0.50 equiv), potassium carbonate (70.1 mg, 0.51 mmol, 1.99 equiv), and N,N-dimethylformamide (5 mL). The resulting solution was stirred for 1.5 h at 70°C in an oil bath. The reaction progress was monitored by LCMS. The resulting solution was diluted with 20 mL of water. The resulting solution was extracted with 3x20 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 3x20 mL of brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. The crude product was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 88.2 mg (42%) of a yellow solid. Ή-NMR (300MHz, CD ₃ OD, pprri): δ 8.66-8.63(d, J=9.3Hz, 1H), 8.39-8.38(d, J=2.7Hz, 1H), 8.16-8.05(m, 3H), 7.98-7.97(d, J=2.4Hz, 1H), 7.82- 7.75(m, 1H), 7.73-7.59(m, 5H), 7.07-7.06 (d, =2.4Hz, 1H), 4.54-4.49(m, 2H), 3.60- 3.57(t, J=5.1Hz, 4H), 3.46-3.43(m, 3H), 3.39-3.36 (t, =5.1Hz, 2H), 2.88(s, 3H), 2.79- 2.74(t, J=6.6Hz, 2H), 1.99-l,78(m, 6H). MS (ES, m/z) 706 [M+H] ⁺ .

EXAMPLE 17

2-Methyl-l-(3-f(4-(piperidin-l-ylV2-(fl-(3-(trifluorometh vnphenylVlH-pyrazol-3- yl)carbamoyl)phenYncarbamoyl)nhcnyl)-5.8,ll-trioxa-2-azatetr adecan-14-oic acid

Into a 50-mL round bottom flask, was placed a solution of 2-(3- (bromomethyl)benzamido)-5 -(piperidin- 1 -y l)-N-( 1 -(3 -(trifiuoromethyl)phenyl)- 1 H- pyrazol-3-yl)benzamide 16a(120 mg, 0.19 mmol, 1.00 equiv) in N,N- dimethylformamide (3 mL), tert-butyl 3-(2-(2-(2-

(methylamino)ethoxy)ethoxy)ethoxy)propanoate 8b (168 mg, 0.58 mmol, 3.01 equiv), potassium iodide (18 mg, 0.11 mmol, 0.57 equiv), and potassium carbonate (54 mg, 0.39 mmol, 2.04 equiv). The resulting solution was stirred overnight at 70°C in an oil bath. The reaction progress was monitored by LCMS. The resulting solution was diluted with 20 mL of water. The resulting solution was extracted with 3x20 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 3x20 mL of brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. This resulted in 220 mg (96%) of product as a yellow solid.

Into a 50-mL round bottom flask, was placed a solution of 206 mg of this solid in dichloromethane (4 mL), and trifluoroacetic acid (2 mL). The resulting solution was stirred for 1 h at room temperature. The reaction progress was monitored by LCMS. The resulting mixture was concentrated under vacuum. The crude product was purified by reverse phase HPLC eluting with a water/CItCN gradient containing 0.05% TFA. The product was obtained as 58.1 mg (26%) of a yellow solid. Ή-NMR (300MHz, CD ₃ OD, ppm): δ 8.61-8.59(d, J=8.7Hz, 1H), 8.40-8.39(d, =2.4Hz, 1H), 8.16-8.12(m, 3H), 8.08-8.05(d, J=8.4Hz, 1H), 7.90(s, 1H), 7.81-7,67(m, 3H), 7.61-7.59(d, J=7.8Hz, 2H), 7.05-7.04(d, J=2.4Hz, 1H), 4.53(s, 2H), 3.89-3.85(t, J=4.8Hz, 2H), 3.69-3.53(m, 15H), 3.41(s, 2H), 2.92(s, 3H), 2.51-2.47(t, J=6Hz, 2H), 1.95-1.76(m, 6H). MS (ES, m/z): 781 [M+H] ⁺ .

EXAMPLE 18

3-f(3-(f4-(Piperidin-l-vn-2- i-(3-(triflnoromethvnphenvn-lH-pyrazol-3- yl)carbamoyOphenyl)carbamoyl)bengyl)thio)benzoic acid

Into a 250-mL round bottom flask, was placed a solution of 2-(3- (cUoromethyl)benzamido)-5-(piperidin-l-yl)-N-(l-(3-(trifluor omethyl)phenyl)-lH- pyrazol-3-yl)benzamide 21a (1.6 g, 2.56 mmol, 1.00 equiv) in tetrahydrofuran (100 mL), 3-mercaptobenzoic acid (390 mg, 2.53 mmol, 0.99 equiv), potassium iodide (21.2 mg, 0.13 mmol, 0.05 equiv), and N,N-diisopropylethylamine (660 mg, 5.12 mmol, 2.00 equiv). The resulting solution was stirred for 24 h at 40°C in an oil bath. The reaction progress was monitored by TLC/LCMS. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 20 mL of H ₂ 0, extracted with 3x20 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 1x20 mL of hydrochloric acid (1 mol/L) and 3x20 mL of brine. The mixture was dried over anhydrous sodium sulfate. The residue was applied onto a silica gel column and eluted with ethyl acetate/petroleum ether (1:20-1 :1). This resulted in 1.12 g (63%) of product as a yellow to green solid. Ή-NM (400MHz, CDCh,ppm): δ 11.68(s, 1H), 9.75(s, 1H), 8.60-8.56(d, J=9.2Hz, 1H), 8.00(s, 1H), 7.91(s, 3H), 7.88-7.81(m, 2H), 7.80-7.79(d, 2.1Hz, 1H), 7.66-7.65(d, J=2.4Hz, 4H), 7.53-7.38(m, 2H), 7.33-7.25(m, 1H), 7.10-7.08(m, 1H), 4.20(s, 2H), 3.17(s, 4H), 1.69-1.54(m ,6H). MS (ES, m/z): 700 [M+H] ⁺ .

EXAMPLE 19

3- 3-((4-(Piperidin-l-ylV2-((l-(3-(trifluoromethvnphenvn-lH-imi dazol-4- vDcarhamoyl)nhenyl)carbamov))bcnzyl^thio)proDanoic acid

Into a 50-mL round bottom flask, was placed a solution of 2-amino-5-(piperidin-l-yl)- N-(l-(3-(trifluoromethyl)phenyl)-lH-imidazol-4-yl)benzamide lOf (140 mg, 0.26 mmol, 1.00 equiv, 80%) in dichloromethane (6 mL), 3-((3-tert-butoxy-3- oxopropylthio)methyl)benzoic acid (97 mg, 0.29 mmol, 1.00 equiv, 90%), EDC.HC1 (125 mg, 0.65 mmol, 2.00 equiv), and 4-dimethylaminopyridine (80 mg, 0.66 mmol, 2.00 equiv). The resulting solution was stirred overnight at 28°C. The resulting solution was diluted with 60 mL of ethyl acetate. The resulting mixture was washed with 1x20 mL of 10% sodium bicarbonate and 1x20 mL of brine. The mixture was dried over sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate/petroleum ether (1:1). This resulted in 140 mg (64%) of product as brown oil. Into a 50-mL round bottom flask, was placed a solution of this solid (140 mg) in dichloromethane (5 mL), and 2,2,2-trifluoroacetic acid (1 mL). The resulting solution was stirred overnight at room temperature. The resulting mixture was concentrated under vacuum. The crude product (100 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 61.2 mg (51%) of a yellow solid. 'H-NMR (300MHz, CDC1 ₃ , ppm): δ 12.30 (s, 1H), 11.98 (s, 1H), 8.97 (d, J=9Hz, 1H), 8.19 (m, 3H), 7.91 (s, 1H), 7.74 (m, 1H), 7.60 (m, 6H), 7.47 (m, 2H), 3.82 (s, 2H), 3.49 (m, 4H), 2.70 (m, 2H), 2.49 (m, 2H), 2.02 (m, 4H), 1.69 (m, 2H). MS (ES, m/z): 652 [M+H] ⁺

EXAMPLE 20

4-((3-q4-(Piperidiii-l-yl)-2-((l-(3-(trifluoromethvnpheny l)-lH-pyrazol-3- ylkaibamuyl)nhenyl)carbamoyl)benzylHhio)ben/x>ic acid

Scheme 13. 1. 3-(chloromethyl)benzoyl chloride, DIPEA; 2 4-mercaptobenzoic acid, K ₂ C0 ₃ , DMF, rt.

Intermediate 21a: 2-(3 -(chloromemyl)benzamido>5 -(piperidin- 1 -yll-N-f 1 -(3 - ftrifluoromethvDphenyl ^' )- 1 H-pyrazol-3 -yllbenzamide. A mixture of 100 mg of 2- amino-5-(piperidin- 1 -yl)-N-(l -(3 -(trifluoromethyl)phenyl)- lH-imidazol-4- yl)benzamide and 119 mg of DIPEA, in 2 mL of 1 : 1 THF / dichloromethane was cooled to 0°C and treated with 48 mg of 3-(chloromethyl)benzoyl chloride. After 30 minutes the solvent was evaporated. The residue was dissolved in dichloromethane, and the solution was washed with 3 N hydrochloric acid, then with an aqueous solution of sodium bicarbonate. The solution was dried (Na ₂ SC> ₄ ) and the solvent was evaporated.

Example 21: 4-(n-( ^' r4-( ^, piperidin -ylV2-( ^" a-(3-ftrifluoromethyl ^' )phenyl ^' )-lH-pyrazol- S-vncarbamoyllphenvncarbamovDbenzvDthio'lbenzoic acid. Into a round bottom flask was placed a solution of intermediate 21a (0.0580 mmol, 1 equiv), 4-mercaptobenzoic acid (11 mg, 0.0696 mmol, 1.2 equiv), potassium carbonate (24 mg, 3 equiv), and DMF (1 mL). The solution was stirred at room temperature overnight. The solvent was evaporated at reduced pressure and the residue was partitioned between dichloromethane and water. The organic phase was dried (Na2SC>4). The solvent was evaporated and the residue was purified by reverse phase HPLC eluting with 0.05% TFA in a water / acetonitrile gradient to give 34 mg of product. ¹ H-NMR (400MHz, DMSO, ppm): δ 11.55(s, IH), 11.48(s, IH), 8.67(d, J=2.6Hz, IH), 8.32(d, J=8.3Hz, IH), 8.19(S, IH), 8.16(d, J=7.8Hz, IH), 8.01(s, IH), 7.85-7.71(m, 5H), 7.65(d, J=7.5Hz, 3H), 7.52(t, J=7.7Hz, IH), 7.44(d, J=8.7Hz, 2H), 7.04(d, J=2.7Hz, IH), 4.46(s, 2H), 3.30(s, 4H), 1.70(s, 4H), 1.59(s, 2H). MS (ES, m/z) 700 [M+H] ⁺ .

EXAMPLE 21

Nl-Methyl-Nl-(2-morpholmoethvU-N3-(2-( -(3-(triflnoromethvUphenvn-lH-

Pyrazol-3-yl)carbamoYnthiophen-3-yl)isophthalamide

Scheme 14, 1. 2-nitro-5-(piperidin-l-yl)benzoic acid, DIPEA, HATU; 2. H ₂ , Pd/C; 3. HATU, DMF, DIEA, 3-(methyl(2-morpholinoethyl)carbamoyl)benzoic acid le..

Intermediate 22a: 2-nitro-N-(S-phenyl- 1.3.4-thiadiazol-2-ylVS-(piperidin- 1 - vPbenzamide. A solution of 100 mg of 2-nitro-5-(piperidin-l-yl)benzoic acid, 78 mg of 2-amino-5-phenyl-l,3,4-thiazdiazole, and 153 μΐ _^ of DIPEA in 0.8 mL of DMF was treated with 182 mg of HATU. After stirring for 16 h at 60°C the mixture was diluted with ethyl acetate and washed with aqueous sodium bicarbonate solution and three times with water. The organic extracts were washed with brine and dried (Na ₂ SC>4). The solvent was evaporated and the residue was chromatographed on silica gel eluting with a gradient of 0% to 10% ethyl acetate in dichloromethane to give 137 mg of product. MS (ES, m/z) 410.0 [M+H] ⁺ . Intermediate 22b: 2-amino-N-(5 -phenyl- 1.3„4-thiadiazol-2- vD-5 -(piperidin- 1 -ylV benzamide. A solution of 130 mg of intermediate 22a in 2 mL of methanol and 6 mL of ethyl acetate was treated with 50 mg of 10% Pd/C (50% water by weight) and stirred under a hydrogen atmosphere for 3 hours. The mixture was diluted with dichloromethane and filtered. The solvent was evaporated to give 116 mg of yellow powder. MS (ES, m/z) 380.2 [M+H] ⁺ .

Example 22: Nl-methyl-Nl-(2-morpholinoethyl)-N3-(2-((l-(3-

(trifluoromemyl)phenyl)-lH-pyrazol-3-yl)carbamoyl miophen-3-yl)isophthalamide. Into a round bottom flask was placed a solution of aniline 22b (10 mg) and 3-(methyl(2- morpholinoethyl)carbamoyl)benzoic acid le (9 mg) in DMF (0.8 μΐ,) and DIEA (17 μΙ ). To this was added HATU at room temperature. The resulting solution was stirred overnight. The reaction progress was monitored by TLC/LCMS. The mixture was concentrated. The crude product was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA to yield 8.6 mg of product. Ή-NMR (400MHz, CDjOD, ppm): δ 8.46-8.30 (m, IH), 8.081-8.035(m, 2H), 7.97-7.92(b, IH), 7.876-7.849(m, 2H), 7.711-7.692(m, 1 H), 7.619(t, J= 8 Hz, IH), 7.522-7.470(m, IH), 7.460-7.435(m, 3H), 3.873-3.859(m, 3H), 3.82-3.49(b, 4H), 3.431-3.378(m, 6H), 3.051(s, 3H), 1.837-1.825(m, 4H), 1.668, 1.639(m, 2H). MS (ES, m/z): 654 [M+H] ⁺ .

EXAMPLE 22

2-(3-((3- 4-a ^> iperidin-l-yl -2-((l-r3-(trifluoromethvnphenvn-lH-pyrazol-3- yl)carbamoyl)phenyl)carbainovI)beiizyl)thio phenyl)acetic acid

Into a round bottom flask was placed a solution of 2-(3-(cWoromethyl)benzamido)-5- ( iperidln-l-yl)-N-(l-(3-( fluoromethyl)phenyl) H-pyrazol-3-yl)berizamide 21b (0.23 mmol, 1 equiv) in DMF (1.2 mL), potassium carbonate (127.1 mg, 0.92 mmol, 4 equiv), and (3-mercaptophenyl)acetic acid (42.6 mg, 0.253 mmol, 1.1 equiv). The solution was stirred overnight at room temperature. The reaction progress was monitored by LCMS. After 16.5 h, more (3-mercaptophenyl)acetic acid (7 mg) was added to the solution, and the solution was stirred another 1 h. The solvent was removed. The residue was dissolved with DCM, washed with ¾0 and brine, and dried over sodium sulfate. The product was purified by reverse phase HPLC, eluting with 0.05% TPA in a water / acetonitrile gradient. MS (BS, mJz) 714 [M+H] ⁺ .

EXAMPLE 23

2-(3-(f3- 4-Chloro-2-(fl-i3-(trifluoromethvnphenyl)-lH-pyrazoI-3- vDcarbamovnphenvDcarbamoyllbeiizvDthiolphenvDacetic acid

Scheme 15. 1. DIPEA, DCM/THF; 2. (3-mercaptophenyl)acetic acid, K ₂ C0 ₃ , DMF, rt.

Intermediate 24a: 2-amino-5-chloro-N-( 1 -(3 -(trifluoromethyl)phenyl ^' )- 1 H-pyrazol-3- ylVbenzamide. Into a round bottom flask was placed a solution of 2-amino-5-chloro-N- (l-(3-(trifluoromethyl)phenyl)-lH-pyrazol-3-yl)benzamide 6d (250 mg) in dichloromethane (2 mL) and tetrahydrofuran (2 mL), and DIPEA (378 mg). The solution was cooled to 0°C. To this was added dropwise 3-(chloromethyl)benzoyl chloride (726 mg). The solution was warmed to room temperature, and stirred for 30 min, and then diluted with dichloromethane. The resulting solution was washed with 5% hydrochloric acid, an aqueous solution of NaHC0 ₃ , and ¾0, then dried over sodium sulfate. The solvent was removed and the crude product was used directly in the next step.

Example 24: 2-(3-((3-((4-chloro-2-((l-(3-(trifluoromethyl phenyl -lH-rJyrazol-3-yl)- carbamoyl)phenyl)carbamoyl)benzyl)thio)phenyl)acetic acid. Into a round bottom flask was placed a solution of intermediate 24a (195 mg) in DMF (4 mL), potassium carbonate (152 mg), and (3-mercaptophenyl)acetic acid (68 mg). The solution was stirred overnight at room temperature. The mixture was filtered and the solvent was evaporated at reduced pressure. The product was purified by reverse phase HPLC, eluting with 0.05% TFA in a water / acetonitrile gradient to yield 84 mg (35%) of product. MS (ES, m/z) 663 [M+H] ⁺ .

EXAMPLE 24 l-f3-((4-Chloro-2-(il-(3-(trifluoromethvnphenvn-lH-pyrazol-3 - yl)carbamoyl)phenyl ^' )carhamoyl ^' )phenyl ^' )-l-oxo-5.8.11-trioxa-2-azatetradecan-1 - oic acid

Scheme 16. l . tert-butyl 3-(2-(2-(2-(tosyloxy)ethoxy)ethoxy)ethoxy)propanoate 8b, HATU, 2. oxalyl chloride, DIEA; 3. 2-amino-5-chloro-N-(l-(3- (trifluoromethyl)phenyl)-lH-pyrazol-3-yl)benzamide 6d, pyridine; 4. TFA, DCM.

Intermediate 25a: 3-(Y14.14-dimethyl- 12-oxo-3.6.9.13 -tetraoxapentadecyl)carbamoylV benzoic acid. Into a 50-mL round-bottom flask, was placed a solution of isophthalic acid (1.7 g, 10.24 mmol, 2.98 equiv) in dichloromethane (10 mL), EDC.HC1 (660 mg, 3.44 mmol, 1.00 equiv), 4-dime ylaminopyridine (420 mg, 3.44 mmol, 1.00 equiv), and tert-butyl 3-(2-(2-(2-(methylamino)ethoxy)ethoxy)ethoxy)propanoate 8b (1 g, 3.44 mmol, 1.00 equiv). The resulting solution was stirred for 2 h at room temperature. The resulting mixture was washed with 2x20 mL of water and 1x20 mL of NH ₄ CI (aq). The mixture was dried over sodium sulfate and concentrated under vacuum. The crude product (1 g) was purified by reverse phase chromatography with a water/methanol gradient to yield 500 mg (33%) of 3-((14,14-dimethyl-12-oxo-3,6,9,13- tetraoxapentadecyl)carbamoyl)benzoic acid, as yellow oil. 'H-NMR (300MHz, CD ₃ OD, ppm): δ 8.087(s, 2H), 7.664-7.560(m, 2H), 3.785-3.499(m, 14H), 3.144-3.705(m, 3H), 2.489-2.448(m, 2H), 1.469-1. 56(s, 9H). MS (ES, m/z): 440 [M+H] ⁺ .

Intermediate 25b: tert-butyl l-f3-(chlorocarbonvnphenylVl-oxo-5.8.1 l-trioxa-2- azatetradecan- 14-oate. A solution of 68 mg of intermediate 25a and 35 ih of diisopropylethylamine in 1 mL of dichloromethane was treated with 18 iL of oxalyl chloride followed by 5 ih of DMF. The mixture was stirred 30 minutes and then the solvent was evaporated at reduced pressure. The residue was dissolved in toluene, and the solvent was evaporated at reduced pressure.

Intermediate 25c: tert-butyl l-(3-((4-chloro-2-( ^' (l-(3-( ^' trifluoromethyl ^' )phenylVlH-

azatetradecan- 14-oate. The residue from the preceding step was dissolved in 1 mL of a 1 : 1 mixture of dichloromethane and THF. The solution was treated with 57 mg of 2- amino-5 -chloro-N-( 1 -(3 -(trifluoromethyl)phenyl)- 1 H-pyrazol-3 -y l)benzamide 6d followed by 78 μΐ _^ of diisopropylethylamine. After 1 hour the mixture was partitioned between dichloromethane and an aqueous solution of sodium bicarbonate. The solution was dried (Na ₂ SC> ) and the solvent was evaporated at reduced pressure. The residue was purified by silica gel chromatography eluting with a gradient of 0% to 100% ethyl acetate in dichloromethane. This gave 37 mg of product.

Example 25: l-G- ^-chloro^-Cd-O-ftrifluoromethvnphenvn-lH-pyrazol-S-ylV carbamoyDphenvDcarbamoyDphenylV 1 -oxo-5.8.11 -trioxa-2-azatetradecan- 14-oic acid. Into a round bottom flask was placed a solution of intermediate 25c (96 mg) in dichloromethane (0.5 mL). To this was added trifluoroacetic acid (0.5 mL). The solution was stirred for 30 min, and then diluted with dichloromethane. The solvent was evaporated and the residue was purified by reverse phase HPLC, eluting with 0.05% TFA in a water / acetonitrile gradient yielding 93 mg of product. 'H-NMR (400MHz, CD ₃ OD, ppm): δ 8.59 (d, .7=9.2 Hz, IH), 8.33 (d, .7=2.5 Hz, IH), 8.13 (s, IH), 8.04 (d, .7=8.2 Hz, 3H), 7.97 (d, .7=2.5 Hz, IH), 7.67-7.54 (m, 5H), 7.03 (d, .7=2.4 Hz, IH), 3.76 (s, 2H), 3.64-3.46 (m, 14H), 3.12-3.09 (m, 3H), 2.46 (t, .7=6.3 Hz, 2H). MS (ES, m/z) 768 [M+Na] ⁺ .

EXAMPLE 25 2-Oxo-l-f3-((3- 4-fpiperidin-l-vn-2-((l-(3-ftrifluoromethvnphenvn-lH-pyrazol -3- yl)carbamoyl)phenyl)carbamov])benzyl)thio)phenvn-6.9.12-trio xa-3- azapentadecan-15-oic acid

Into a round bottom flask was placed a solution of 2-(3-((3-((4-(piperidin-l-yl)-2-((l- (3-(trifluoromethyl)phenyl)-lH-pyrazol-3- yl)carbamoyl)phenyl)carbamoyl)benzyl)thio)-phenyl)acetic acid 23 (0.119 mmol, 1 equiv) in acetonitrile (0.5 mL), and DIPEA (78.9 mg, 0.612 mmol, 4 equiv). To this was added a solution of tert-butyl 3-(2-(2-(2-

(methylamino)ethoxy)ethoxy)ethoxy)propanoate 8b (33.08 mg, 0.127 mmol, 1.1 equiv) in acetonitrile (0.5 mL), followed by HATU (57.9 mg, 0.153 mmol, 1.2 equiv). The mixture was stirred at room temperature. The reaction progress was monitored by LCMS. After 1 h, more 8b (15 mg) was added to the solution, and the solution was stirred another 30 min. The solvent was removed by evaporation at reduced pressure. The residue was dissolved in DCM (1 mL). To this was added TFA (0.5 mL). The solution was stirred for 1 h and then the solvent was evaporated at reduced pressure. The crude product was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA, Lyophilization gave 37 mg of product. ¾ NMR (400 MHz, dmso) δ 11.55 (s, IH), 11.46 (s, IH), 8.65 (d, 7= 2.6 Hz, IH), 8.33 (d, J= 8.5 Hz, IH), 8.16 (s, IH), 8.12 (d, 7= 7.9 Hz, IH), 8.05 (t, J= 5.2 Hz, IH), 7.94 (s, IH), 7.78 - 7.67 (m, 3H), 7.61 (d, J = 7.5 Hz, 2H), 7.55 (d, J = 7.4 Hz, IH), 7.45 (t, / = 7.7 Hz, IH), 7.22 (s, IH), 7.17 (d, J = 4.9 Hz, 3H), 7.01 (s, 3H), 4.30 (s, 3H), 3.54 (t, J = 6.4 Hz, 4H), 3.43 (s, 14H), 3.41 - 3.16 (m, 15H), 3.16 - 3.09 (in, 3H), 2.39 (t, J= 6.4 Hz, 3H), 1.76 - 1.66 (m, 4H), 1.61 - 1.52 (m, 2H).MS (ES, m/z) 917 [M+H] ⁺ .

EXAMPLE 26

Procedure for the Measurement of NaP2b-Mediated P, Transport

Materials.- HEK293 cells were obtained from the American Type Culture collection and propagated per their instructions. Expression clones for rat and human NaP2b (SLC34A2) were obtained from Open Biosystems (Catalog numbers MRN1768-9510282, and MHS1010-99823026, respectively). The sequence of the human protein was mutated to insert a threonine after residue 37, and to introduce a N39D mutation.

Inhibition of P, Transport. The rate of phosphate (Pi) uptake into HEK293 cells was measured using a modification of the method described by Mohrmann et al. (Mohrmann, I., Mohrmann, M., Biber, J., and Murer, H. (1986) Am. J. Phys. 250(3 Pt l):G323-30.) Transfected HEK293 cells were treated with a pharmacological agent to minimize endogenous PiT-mediated phosphate transport activity, such that the only remaining sodium-dependent phosphate transport activity is that which was bestowed by introduction of the NaP2b genes.

Cells were seeded into 96-well plates at 25,000 cells/well and cultured overnight. Lipofectamine 2000 (Invitrogen) was used to introduce the NaP2b cDNA, and the cells were allowed to approach confluence during a second overnight incubation. Medium was aspirated from the cultures, and the cells were washed once with choline uptake buffer (14 mM Tris, 137 mM choline chloride, 5.4 mM KCl, 2.8 mM CaCl ₂ , 1.2 mM MgS0 ₄ , 100 uM KH ₂ P0 ₄ , 1 mg/mL Bovine Serum Albumin, pH 7.4). Cells were then overlayed with either choline uptake buffer or sodium uptake buffer (14 mM Tris, 137 mM sodium chloride, 5.4 mM KCl, 2.8 mM CaCl ₂ , 1.2 mM MgSC>4, 100 uM KH2PO4, PiT-silencing agent, 1 mg/mL Bovine Serum Albumin, pH 7.4) containing 6-9 uCi/mL ³³ P orthophosphoric acid (Perkin Elmer) and test compound. Each compound was tested at twelve concentrations ranging from 0.1 nM to 30 uM. Assays were run in duplicate.

After incubation for 3-30 minutes at room temperature, assay mixtures were removed, and the cells were washed twice with ice cold stop solution (137 mM sodium chloride, 14 mM Tris, pH 7.4). Cells were lysed by addition of 20 μΐ, 0.1% Tween 80 followed by 100 μΐ, scintillation fluid, and counted using a TopCount (Perkin Elmer).

pIC50 (the negative log of the IC50) values of the test compounds were calculated using GraphPad Prism. Preliminary studies showed that under these conditions, sodium-dependent Pi uptake was linear for at least 30 min and tolerated 0.6 % (v/v) DMSO without deleterious effects.

To ascertain if an inhibitor was competitive for binding with phosphate, the procedure was' repeated, but raising the concentration of the substrate in the assay mixture from 0.1 to 2.1 mM phosphate. Compounds that maintained their potency for inhibition of NaPi2b in the presence of 2.1 vs 0.1 mM phosphate were considered to not be competitive with respect to phosphate.

Table 2

Inhibitory Activity of Compounds Against Rat

and Human NaP2b Values Reported a pIC50.

* A blank indicates not tested

** Indicates compound is considered to not be competitive with respect to phosphate. A blank indicates not tested for competitive inhibition.

EXAMPLE 27

In vivo Assay: Bolus Phosphorus Challenge It has been demonstrated that the hyperphosphatemic response to a single oral dose of phosphorus is significantly dampened in mice deficient in the Nap2b gene (Sabbagh et al, J. Am Soc Nephrol, 20(11):2348-58 (2009)). By pretreating animals with a low phosphorus diet followed by the subsequent dosing of a phosphorus bolus, serum phosphorus levels were monitored after 30 minutes as a surrogate for intestinal phosphorus absorption. These investigators showed that as a result of Np2b deletion, the rise in serum phosphorus was reduced by about 40%. This indicates that the theoretical maximum effect on phosphorus absorption a Nap2b inhibitor could have in mice is 40% as indicated by the serum Pi. The in vivo bolus phosphorus challenge model used here mimics this model in rats.

Male, 7-week-old Sprague-Dawley rats (Charles-River laboratories international, Hollister, CA) were allowed to acclimatize for a minimum of 3 days before switching to a synthetic low-phosphorus diet (TD.85010, Harlan Teklad, Madison, WI) which contains 0.1% phosphorus and 0.6% calcium. At day 5, testing compounds or vehicle alone (as indicated) were orally administered at the indicated dose in a volume of 5 ml/kg, followed by a bolus gavage of monobasic sodium phosphate (1 mmol in 1 ml ) 15 min after compound dosing. Serum was collected via retroorbital bleeding 30 min post phosphate bolus and phosphate levels were determined utilizing an ACE ALERA blood chemistry analyzer (Alfa Wassermann Diagnostic Technologies, West Caldwell, NJ).

The extent of inhibition by test compounds on the elevation of serum phosphate levels in response to the bolus of phosphate is shown in Table 3 (data are expressed as % Inhibition, with 6-10 animals per data point). The differences between groups were evaluated by one-way analysis of variance with Dunnett's post hoc tests.

Table 3

Inhibition of Uptake of Phosphate from the Intestine as Measured using the Bolus Phosphate Challenge Model

% Inhibition of Serum Significance

Drug Dose P elevation

Example % Inhibition of Serum Significance

Drug Dose P elevation

Example

11 30.0 30.0 ***

7 30 49 *** p < 0.05, versus vehicle by Dunnett's post hoc test.

* p < 0.01, versus vehicle by Dunnett's post hoc test.

** p < 0.001, versus vehicle by Dunnett's post hoc test.

EXAMPLE 28

In vivo Evaluation Procedure: Co-Dosing in Chow Male, 7-week-old Sprague-Dawley rats (Charles-River laboratories international, Hollister, C A) were allowed to acclimate for a minimum of 3 days. The experiment was initiated by switching animals to a synthetic diet (0.6% phosphorus and 0.6% calcium, Harlan Teklad TD.84122) for four days. After this time, the animals were placed into metabolic cages for daily monitoring of food and water consumption, as well as urine and fecal collections. Test compounds were incorporated into the powdered diet listed above containing 3% chocolate flavoring (w/w, BioServ #7345) at 1.3 mg test compound per gram of diet to achieve an average daily nominal dose of 100 mg/kg/day. The actual dose received by each animal was later determined by measuring prepared diet consumption and body weight. Urine samples were collected in three daily periods from 24-48, 48-72, and 72-96 hours of drug dosing. Averaging these three 24 h periods allows for the more representative measurements of urination, fecal excretion, food consumption and water uptake for each animal. Phosphorous levels in the urine were determined by anion exchange chromatography using a Dionex ICS- 3000 ion chromatography system. Urine samples were diluted 1:500 or 1:1000 and injected onto an IonPac AS 18 analytical column (2 x 250 mm) using a potassium hydroxide eluent. Elution of urine phosphate ions was monitored via conductivity detector and reported as ppm relative to a standard ion solution containing phosphate. Daily urinary P output relative to the P consumed in the prepared diet for each animal was calculated. The percentage inhibition of phosphorus absorption was estimated by determining the reduction of this ratio compared to the control group (animals with no drug in chow). The differences between the means of control and treated groups were evaluated by t tests. In all experiments, one group was always included that had Renvela powder blended into their chow at 0.9% targeting a dose of 750 mg kg. Typically this resulted in an approximately 15% inhibition of Urine Pout/P consumed.

Table 4

Inhibition of Uptake of Phosphorus from the Intestine as Measured using the Co-Dosing in Chow Model

* p< 0.05 versus control ; ** pO.01 versus control; *** p<0.001 versus control

EXAMPLE 29

Stability of Compounds in Simulated Gastric and Intestinal Fluid

Test compounds were incubated at 1-20 μΜ in simulated gastric fluid (SGF; standard USP solution with 3 mg mL pepsin) or simulated intestinal fluid (SIF; standard USP solution with 3 mg/mL pancreatin) for 3 hr or 6 hr. HPLC-UV or HPLC- MS were used to determine test compound levels using peak area %. Results (Table 5) were reported as the percentage of test compound remaining after incubation in a given condition relative to test compound present at t = 0 in the same condition.

Table 5

Percentage of Compound Remaining in Simulated Gastric and Intestinal Fluids

Incubation % remaining, % remaining,

Example Time SIF SGF Incubation % remaining, % remaining,

Example Time SIF SGF

26 6 hr 95 91

14 6 hr 72 93

25 6 hr 95 58

15 6 hr 97 100

EXAMPLE 30

Determination of Compound Cmax and AUC Sprague-Dawley rats were orally gavaged with test article at a nominal dose of 2.5 or 10 mg kg and blood was collected at 0.5, 1, 2 and 4 h. Blood samples were processed to plasma using ₂ EDTA as an anticoaglulant. Plasma samples were treated with acetonitrile containing an internal standard, precipitated proteins removed by centrifugation. Supernatants were analyzed by LC-MS/MS and compound concentrations were determined by interpolated from a standard curve prepared in plasma. Table 6 illustrates data from the pharmacokinetic profiling of selected example compounds. All compounds were orally dosed at the dosage shown, and pharmacokinetic parameters determined.

Table 6

Pharmacokinetic Profiling of Selected Example Compounds

LLOQ= Lower Limit of Quantification

EXAMPLE 31

Fecal Recovery of Orally Administered Compounds Quantitative determination of test compound level in feces after oral gavage was performed using the same set of animals used to determine test compound concentration in plasma (Example 30). The animals were kept in metabolic cages and feces were collected from the time of dosing until 48 hr after dosing. Upon collection, feces was dried by lyophilization and ground to a visually homogenous powder. Duplicate samples of ground feces from each individual animal were weighed out and extracted using organic solvent. Extracted samples were then diluted into mobile phase and test compound levels were quantitatively determined by LC-MS/MS analysis as described in "Example 30" except that the standard curve was prepared in a feces matrix. Extraction conditions were not optimized for individual compounds, and thus may represent a minimal level of recovery.

Table 7

Fraction of Orally Administered Compound

Recovered in Feces 48 Hours after Dosing

* Dosed at 7.6 mg/kg (see Example 30) **Dosed at 1.9 mg/kg (see Example 30)

EXAMPLES FOR COMPOUNDS OF STRUCTURE (III)

EXAMPLE 1

S- O-^-^S-rS^-DimethylphenvDpyrazin^-vncarbamovn^^piperidin-l- ynphenyllcarbamoyDbenzyllthiolpropanoic acid

Scheme 1. l. KSAc, EtOH; 2. K ₂ C0 ₃ , H ₂ 0; 3. t-butyl acrylate, DBU; 4. Pd(PPh ₃ ) ₄ , MeOH, 1,4-dioxane, Na ₂ C0 ₃ H ₂ 0; 5. DCM, pyridine, 5-chloro-2-nitrobenzoyl chloride; 6. K ₂ C0 ₃ /DMF, piperidine; 7. Pd/C, H ₂ , MeOH; 8. DMF, HATU DIPEA, Intermediate lc, then. F ₃ CCOOH (TFA), DCM. Intermediate la: 3-(acetylthiomethyl)benzoic acid. Into a 250-mL round bottom flask, was placed a solution of 3-(bromomethyl)benzoic acid (7 g, 32.56 mmol, 1.00 equiv) in ethanol (80 mL), and potassium ethanethioate (9.65 g, 84.65 mmol, 2.60 equiv). The resulting solution was stirred overnight at room temperature. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 80 mL of water and adjusted to pH 3-4 with 10% hydrochloric acid. The resulting solution was extracted with 3x50 mL of ethyl acetate and the organic layers combined, washed with 1x50 mL of brine, dried over sodium sulfate, and concentrated under vacuum. This resulted in 4.4 g (64%) of 3-(acetylthiomethyl)benzoic acid as a brown solid.

Intermediate lb: 3-(mercaptomethyl benzoic acid. Into a 500-mL round bottom flask, was placed a solution of 3-(acetylthiomethyl)benzoic acid (16.4 g, 78.10 mmol, 1.00 equiv) in methanol (150 mL), and a solution of potassium carbonate (26.9 g, 194.93 mmol, 2.50 equiv) in water (70 mL). The resulting solution was stirred for 4 h at 60°C. The resulting mixture was concentrated under vacuum, diluted with 200 mL of water, and then adjusted to pH 3 with 10% hydrochloric acid. The mixture was extracted with 3x (100/20 mL) of ethyl acetate/ tetrahydrofuran and the organic layers combined, washed with 1x100 mL of brine, then dried over sodium sulfate and concentrated under vacuum. This resulted in 12 g (91%) of 3-(mercaptomethyl)benzoic acid as a brown solid.

Intermediate lc: 3-(i3-tert-butoxy-3-oxopropylMo memyl)berizoic acid. To a solution of 3-(mercaptomethyl)benzoic acid (12 g, 71.43 mmol, 1.00 equiv) in acetonitrile (200 mL) was added tert-butyl acrylate (60 mL) and DBU (21.7 g, 142.76 mmol, 2.00 equiv) and the solution was stirred overnight at 80°C in an oil bath. The resulting mixture was concentrated under vacuum, diluted with 200 mL of water and then adjusted to pH 2~3 with 10% hydrochloric acid. This was extracted with 3x200 mL of ethyl acetate and the organic layers combined, dried over anhydrous sodium sulfate and then concentrated under vacuum. The residue was applied onto a silica gel column and eluted with petroleum ether/ethyl acetate (50:1) to afford 10.5 g (47%) of 3-((3-tert-butoxy-3- oxopropylthio)methyl)benzoic acid as red oil. Ή-NMR (300MHz, CDCh,ppm): δ 8.08 (s, 1H), 8.04 (d, J=7.8Hz, 1H), 7.62 (d, =7.8Hz, 1H), 7.46 (t, 1H), 3.81 (s, 2H), 2.68 (t, 2H), 2.50 (t, 2H), 1,.48 (s, 9H). MS (ES, m/z): 295 [M-H]\

Intermediate Id: 5-(3.4-dimethylphenyl)pyrazin-2-amine. To a solution of 5- bromopyrazin-2-amine (4 g, 22.99 mmol, 1.00 equiv) in 1,4-dioxane (68 mL) and methanol (23 mL) was added 3,4-dimethylphenylboronic acid (3.52 g, 23.47 mmol, 1.02 equiv), sodium carbonate (4.872 g, 45.96 mmol, 2.00 equiv) in water (23 mL), and Pd(PPh ₃ (532 mg, 0.46 mmol, 0.02 equiv) and the resulting solution was stirred for 4.5 h at 110°C in an oil bath. The resulting mixture was concentrated under vacuum, diluted with 200 mL of ethyl acetate, washed with 2x100 mL of brine, dried over anhydrous sodium sulfate and then concentrated under vacuum. The residue was applied onto a silica gel column with petroleum ether/ethyl acetate=10:l~l :l, then with dichloromethane/methanol (10:1-5:1). The collected fractions were combined and concentrated under vacuum. This resulted in 4.82 g (crude) of 5-(3,4- dimethylphenyl)pyrazin-2 -amine as a yellow solid.

Intermediate 1 e: 5-cMoro-N-(5-n.4-dimemylphenvnpyrazin-2-yl)-2-nitrobenzamide . Into a 250-mL round bottom flask, was placed a solution of 5-(3,4- dimethylphenyl)pyrazin-2-amine (2 g, 10.04 mmol, 1.00 equiv) in dichloromethane (70 mL), pyridine (2.4 g, 30.34 mmol, 3.00 equiv), and a solution of 5-chloro-2- nitrobenzoyl chloride (2.21 g, 10.05 mmol, 1.00 equiv) in dichloromethane (20 mL). The resulting solution was stirred overnight at 25°C in an oil bath, then diluted with 150 mL of dichloromethane and washed with 2x100 mL of diluted hydrochloric acid, 2x200 mL of brine and 2x100 mL of sodium carbonate (sat.), and then 2x200 mL of brine. The organic layer was dried over sodium sulfate and concentrated under vacuum. The crude product was triturated with 40 mL of ethyl acetate/n-hexane (1:1). This resulted in 3.66 g (95%) of 5-chloro-N-(5-(3,4-dimethylphenyl)pyrazin-2-yl)-2- nitrobenzamide as an off-white solid.

Intermediate If: N-(5-(3.4-dimethylphenyl)pyrazin-2-yl)-2-nitro-5-(piperidin- l-yl)- benzamide. Into a 250-mL round bottom flask, was placed a solution of 5-chloro-N-(5- (3,4-dimethylphenyl)pyrazin-2-yl)-2-nitrobenzamide (3.66 g, 9.56 mmol, 1.00 equiv) in Ν,Ν-dimethylformamide (80 mL), piperidine (3.8 g, 44.71 mmol, 4.70 equiv), and potassium carbonate (3.96 g, 28.70 mmol, 3.00 equiv). The resulting solution was stirred for about 8 h at 85°C in an oil bath. The reaction was then quenched with 450 mL of water. The resulting solution was extracted with 3x300 mL of ethyl acetate and the organic layers combined, dried over anhydrous sodium sulfate, and concentrated under vacuum. This resulted in 3.86 g (crude) of N-(5-(3,4-dimethylphenyl)pyrazin-2- yl)-2-nitro-5-(piperidin-l-yl)benzamide as a yellow solid.

Intermediate lg: 2-amino-N-(S-n^-dimemYlDhenyl)pyrazin-2-yl ^' )-5-(piperidm-l-yl')- benzamide. Into a 500-mL round bottom flask, was placed a solution of N-(5-(3,4- dimemylphenyl)pyrazin-2-yl)-2-nitro-5-(piperidin-l-yl)benzam ide (3.66 g, 8.47 mmol, 1.00 equiv) in methanol (150 mL). The mixture was treated with Pd C (aqueous) (3.66 g) and stirred under a hydrogen atmosphere for 4 h at room temperature. The solids were filtered out. The resulting mixture was concentrated under vacuum. This resulted in 1.88 g (55%) of product as a yellow solid.

Example 1 : 3-(3-((2-((5-(3.4-dimethylphenyl ^' )pyrazin-2-yl ^' )carbamoylV4-(piperidin-l- ylYphenvDcarbamoyl)benzylt o)propanoic acid. Into a 50-mL round bottom flask, was placed a solution of 3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid (177.2 mg, 0.60 mmol, 1.20 equiv) in N,N-dimethylformamide (8 mL), HATU (567.7 mg, 1.49 mmol, 3.00 equiv), N,N-diisopropylethylamine (346.9 mg, 2.69 mmol, 5.40 equiv), and 2-amino-N-(5 -(3 ,4-dimethylphenyl)pyrazin-2-yl)- 5-(piperidin- 1 -yl)benzamide (200 mg, 0.50 mmol, 1.00 equiv). The resulting solution was stirred overnight at 25°C in an oil bath. The reaction was then quenched with 100 mL of water. The resulting solution was extracted with 3x50 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 2x50 mL of brine and dried over sodium sulfate. The solids were filtered out. The resulting mixture was concentrated under vacuum. This resulted in 0.51 g (crude) of tert-butyl 3-(3-((2-((5-(3,4-dimethylphenyl)pyrazin-2- yl)carbamoyl)-4-( iperidin-l-yl)phenyl)carbamoyl)benzylthio)propanoate as a dark brown syrup.

Into a 100-mL round bottom flask, was placed a solution of tert-butyl 3-(3-((2-((5-(3,4- dimethylphenyl)pyrazin-2-yl)carbamoyl)-4-(piperidin- 1 - yl)phenyl)carbamoyl)benzylthio)-propanoate (480 mg, 0.71 mmol, 1.00 equiv) in dichloromethane (25 mL), and trifluoroacetic acid (12.5 mL). The resulting solution was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum. The crude product (300 mg) was purified by reverse phase HPLC eluting with a water/C¾CN gradient containing 0.05% TFA to yield 56.1 mg (13%) of 3-(3-((2-((5- (3,4-dimethylphenyl)pyrazin-2-yl)carbamoyl)-4-(piperidin-l- yl)phenyl)carbamoyl)benzylthio)-propanoic acid as a yellow solid. Ή-NMR (300MHz, OMSO, ppm): δ 11.34(s, IH), 11.06(s, IH), 9.39(d, J=1.2Hz, IH), 9.03 (d, J=1.2Hz, IH), 8.13(d, J=9Hz, IH), 7.92 ~7.84(m, 3H), 7.78(d, J=7.2Hz, IH), 7.55~7.46(m, 3H), 7.29(d, J=8.1Hz, IH), 3.83(s, IH), 3.28(m, 4H), 2.73~2.72(m, 2H), 2.32 (s, 3H), 2.28~2.27(m, 4H), 1.61-1.58 (m, 6H). MS (ES, m/z): 624 [M+H] ⁺ .

EXAMPLE 2

3-((3-f(2-((2-PhenylpYrimidin-5-yl)carbamoylV4-( ^' piDeridiii-l- vDphenyllcarbamovDbenzvDthio ^' tpropanoic acid

Scheme 2. 1. methyl acrylate, DBU; 2. oxalyl chloride, DMF; 3. EDC · HC1, DMAP; 4. H _¾ Pd C, EtOAc, EtOH; 5. Intermediate 2b, pyridine, THF; 6. LiOH-H ₂ 0, THF, H ₂ 0.

Intermediate 2a: 3-f(Y3-methoxy-3-oxopropyl)trjo)memyl)benzoic acid. Into a 50-mL round bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of 3-(mercaptomethyl)benzoic acid (500 mg, 2.97 mmol,1.00 equiv) in acetonitrile (10.0 mL), then methyl acrylate (10.0 mL) and 1,8- diazabicyclo[5.4.0]undec-7-ene (1.0 g, 6.57 mmol, 2.00 equiv) were added in series. The resulting solution was heated to reflux overnight. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate/petroleum ether (0~1:6). This resulted in 220 mg (28%) of 3- ((3-methoxy-3-oxopropylthio)methyl)benzoic acid as a light-red oil.

Intermediate 2b: methyl S-Cn-fchlorocarbonyllbenzvnthio propanoate. Into a 50-mL round bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of 3-((3-methoxy-3-oxopropylthio)methyl)benzoic acid (61.6 mg, 0.24 mmol, 1.00 equiv) in dichloromethane (5 mL). This was followed by dropwise addition of oxalyl dichloride (121.76 mg, 0.96 mmol, 4.00 equiv) with stirring at room temperature. Then a few drops of N,N-dimethylformamide were added as catalyst. The resulting solution was heated to reflux for 30 min. The resulting mixture was concentrated under vacuum to yield 60 mg (crude) of methyl 3-(3- (chlorocarbonyl)benzylthio)propanoate as yellow oil. The crude was used directly in the next step.

Intermediate 2c: 2-nitro-N-(2-phenylpyrimidin-5-yl -S-(piperidin-l-yl)benzarnide. Into a 50-mL round-bottom flask, was placed a solution of 2-nitro-5-(piperidin-l-yl)benzoic acid (1.096 g, 4.38 mmol, 1.50 equiv) in dichloromethane (20 mL), 2-phenylpyrimidin- 5-amine (500 mg, 2.92 mmol, 1.00 equiv), N-(3-dimethylaminopropyl)-N'- ethylcarbodiimide hydrochloride (838 mg, 4.39 mmol, 1.50 equiv), and 4- dimethylaminopyridine (713 mg, 5.84 mmol, 2.00 equiv). The resulting solution was stirred overnight at 25°C. The reaction was diluted with 100 mL of water and the resulting mixture was extracted with 3x50 mL of dichloromethane. The organic layers were combined, washed with 1x100 mL of brine, dried over sodium sulfate, and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with PE:EA:CH ₂ C1 ₂ (20:1:0-3:1:1). The product was obtained as 150 mg (11%) of a yellow solid.

Intermediate 2d: l-amino-N-Q-phenylpyrimidm-S-ylVS-fpiperidin-l-vnbenzamide. Into a 100-mL round bottom flask, was placed a solution of 2-nitro-N-(2- phenylpyrimidin-5-yl)-5-(piperidin-l-yl)benzamide (100 mg, 0.25 mmol, 1.00 equiv) in EtOAc/EtOH (5/5 mL). The mixture was treated with Pd/C (10 mg) and stirred under a hydrogen atmosphere for 2 h at room temperature. The solids were filtered out. The resulting mixture was concentrated under vacuum to yield 90 mg (97%) of product as a yellow solid.

Intermediate 2e: methyl 3-( ^' G-((2-(( ^, 2-phenylpyrirnidin-5-yl ^' )carbamoyl)-4-(piperidin-l- yl)phenyl)carbamoyl)benzyl)thio)propanoate. To a solution of 2-amino-N-(2- phenylpyrimidin-5-yl)-5-(piperidin-l-yl)benzamide (138 mg, 0.37 mmol, 1.00 equiv) in tetrahydrofuran (6 mL) was added methyl 3-(3-(chlorocarbonyl)benzylthio)propanoate (112 mg, 0.41 mmol, 1.10 equiv) and pyridine (60 mg, 0.76 mmol, 2.00 equiv) and the resulting solution was stirred for 5 h at room temperature. The reaction progress was monitored by LCMS. The crude product was used directly in the next step.

Example 2: 3-(3-( (2-((2^henylpyrirnidm-5-yl)carbamovn-4-(piperidin- 1 -vDphenyr)- carbamovDbenzylthio propanoic acid. Into a 50 mL round-bottom flask was placed methyl 3-((3-((2-((2-phenylpyrimidin-5-yl)carbamoyl)-4-(piperidin-l - yl)phenyl)carbamoyl)-benzyl)tbio)propanoate (crude product of 1459-084), and a solution of lithium hydroxide (387 mg, 9.21 mmol, 24.98 equiv) in water (2 mL). The resulting solution was stirred overnight at room temperature. The reaction progress was monitored by LCMS. The resulting solution was diluted with 20 mL of water and adjusted to pH 4-5 with hydrochloric acid (2 N). The resulting solution was extracted with 4x30 mL of ethyl acetate and the organic layers combined, washed with 1x50 mL of brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. The resulting mixture was washed with 3x5 mL of ethyl ether. This resulted in 120 mg (55%) of product as a yellow solid. Ή-NMR (300MHz, DMSO, ppm): δ 12.21(s, 1H), 10.86-10.97(d, 2H), 9.21(s, 2H), 8.36-8.38(m, 2H), 8.1 l(m, 1H), 7.75-7.88(m, 2H), 7.39-7.52(m, 6H), 7.24(m, 1H), 3.84(s, 2H), 3.23-3.33(s, 4H), 2.56-2.61(m, 4H), 1.58- 1.67(d, 6H). MS (ES, m/z): 596 [M+H] ⁺ .

EXAMPLE 3

3-f(3-((2-((2-Phenylpyrimidin-5-vncarbamovn-4-(piperidiii -l- yl)nhen\ )carbamoyl)benzyl)thio)benzoic acid

Scheme 3, l. DCM, THF, pyridine, 3-(bromomethyl)benzoyl chloride; 2. Et3N, 3-mercaptobenzoic, DMF.

Intermediate 3 a: 2-(3-(¾romomethv berizarriido ^' )-N-(2-phenylpyrimidin-5-yl)-5-

(piperidin- 1 -vDbenzamide. To a solution of 2-amino-N-(2-phenylpyrimidin-5-yl)-5- (piperidin-l-yl)benzamide (300 mg, 0.80 mmol, 1.00 equiv) in tetrahydrofuran dichloromethane (10/3 mL) was added pyridine (190 mg, 2.41 mmol, 2.99 equiv) followed by 3-(chloromethyl)benzoyl chloride (181 mg, 0.96 mmol, 1.20 equiv) and the resulting solution was stirred overnight at room temperature. The mixture was concentrated under vacuum then applied onto a silica gel column and eluted with dichloromethane/methanol (10:1) to afford 160 mg (38%) of a yellow to green solid.

Example 3: 3-(3-((2-((2-phenylDyrimidin-5-yl)carbamoyl)-4-(piperidin-l- yl)Dhenyl)- carbamoyl)benzylthio)benzoic acid. To a solution of 2-(3-(bromomethyl)benzamido)- N-(2-phenylpyrimidin-5-yl)-5-(piperidin-l-yl)benzamide (120 mg, 0.23 mmol, 1.00 equiv) in N,N-dimethylformamide (10 mL) was added 3-mercaptobenzoic acid (42.12 mg, 0.27 mmol, 1.20 equiv) and triethylamine (46.08 mg, 0.46 mmol, 2.00 equiv) and the resulting solution was stirred for 3 h at room temperature. The mixture was diluted with 70 mL of water, extracted with 3x50 mL of ethyl acetate and the organic layers combined, dried over sodium sulfate, and concentrated under vacuum. The crude product (100 mg) was purified by reverse phase HPLC eluting with a water/CH3CN gradient containing 0.05% TFA to afford 24.7 mg (17%) of a light yellow solid. ¾- NMR (300MHz, DMSO, ppm): δ 10.94(m, 2H), 9.23(d, J=9.3Hz, 2H), 8.36(m, 2H), 8.12(d, J=9Hz, IH), 7.95(s, IH), 7.85(s, IH), 7.73(m, 2H), 7.45 (m, 9H) 4.39(s, 2H), 3.33(s, 4H), 1.72(s, 6H). MS (ES, m/z): 644 [M+H] ⁺ .

EXAMPLE 4

3-(0-((4-(Piperidin-l-ylV2-((2-(3-(trifluoromethvnphenvnp yriinidin-5- vIlcarbamovDphenYncarbamovDbenzylHhiolpropanoic acid

Scheme 4: 1. 3-(trifluoromethyl)phenylboronic acid, Pd(OAc)2, DPPF, toluene; 2. 2-nitro-5-(piperidin-l-yl)benzoic acid, EDC HQ, DMAP; 3. H ₂ , Pd C; 4, methyl 3- ((3-(chlorocarbonyl)benzyl)thio)propanoate, pyridine; 5. LiOH ^' H ₂ 0.

Intermediate 4a: 2-G-ftrifluoromemvnr)henyl rimidin-5-amine. To 2- chloropyrimidin-5-amine (1.7 g, 13.18 mmol, 1.00 equiv) was added 3- (trifluoromethyl) phenylboronic acid (3.8 g, 20.00 mmol, 1.50 equiv), Pd(OAc)2 (0.15 g, 0.05 equiv), dppf (0.37 g, 0.05 equiv) and potassium carbonate (3.6 g, 26.09 mmol, 2.00 equiv) and the mixture was stirred overnight at 100°C in an oil bath. The reaction was diluted with 300 mL of ethyl acetate and the solids were filtered out. The filtrate was was washed with water and the organic layer dried over anhydrous sodium sulfate and then concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate/petroleum ether (1:15) to afford 1.2 g (38%) of 2-(3- (trifluoromethyl)phenyl)pyrimidin-5 -amine as a white solid.

Intermediate 4b: 2-nitro-5-(piperidin-l-ylVN-(2-(3-(trifluoromethyl)phenyl)py rimidin- 5-y benzamide. To 2-(3-(trifluoromethyl)phenyl)pyrimidin-5-amine (750 mg, 3.14 mmol, 1.00 equiv) in dichloromethane (50 mL) was added 2-nitro-5-(piperidin-l- yl)benzoic acid (1.18 g, 4.72 mmol, 1.50 equiv), EDC.HCl (1.2 g, 6.28 mmol, 2.00 equiv) and 4-dimethylaminopyridine (770 mg, 6.31 mmol, 2.00 equiv) and the resulting solution was stirred for 48 h at room temperature. The reaction was diluted with 25 mL of water and then extracted with 2x25 mL of dichloromethane. The organic layers were combined, dried over sodium sulfate, concentrated, and the residue was applied onto a silica gel column and eluted with ethyl acetate/petroleum ether (1:30-1:5) to give 0.4 g (27%) of product as a yellow solid.

Intermediate 4c: 2-amino-5-(piperidin- 1 -ylVN-C2-G-

(trifluoromethvnphenyllpyrimidin-S-vnbenzamide. Into a 50-mL 3 -necked round bottom flask, purged and maintained with an inert atmosphere of nitrogen, was placed 2-nitro-5-(piperidin-l-yl)-N-(2-(3-(trifluoromemyl)phenyl)py rimi0¾^

(250 mg, 0.53 mmol, 1.00 equiv), methanol (15 mL), and ethyl acetate (5 mL). The mixture was treated with Pd/C (0.1 g, 0.10 equiv) and stirred under an atmosphere of hydrogen for 2 h at room temperature. The solids were filtered out. The resulting mixture was concentrated under vacuum to yield 0.23 g (98%) of product as a light yellow solid.

Intermediate 4d: methyl 3-rr3-r(4-fpiperidin-l-yl)-2-((2-(3-(trifluoromethyl)- phenyl)pyrimidin-5-vncarbamovnphenyl)carbamoyl)benzyl)thio)p ropanoate. Into a 50-mL 3-necked round-bottom flask, was placed 2-amrno-5-(piperidin-l-yl)-N-(2-(3- (trifluoromethyl)phenyl)pyrimidin-5-yl)benzamide (234 mg, 0.53 mmol, 1.00 equiv), tetrahydrofuran (5 mL), a solution of methyl 3-(3- (chlorocarbonyl)benzylthio)propanoate (145 mg, 0.53 mmol, 1.00 equiv) in tetrahydrofuran (5 mL), and pyridine (80 mg, 1.01 mmol, 2.00 equiv). The resulting solution was stirred for 4 h at room temperature. The reaction was diluted with 10 mL of water and then extracted with 2x20 mL of ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated under vacuum to afford 0.28 g (78%) of product as a yellow solid.

Example 4: 3-f(3-i(4-(piperidin-l-yl)-2-((2-(3-(trifluorome&^

vn-carbamoyllphenvDcarb-arnovnbenzvDthioteopanoic acid. To methyl 3-(3-((4- (piperidin-l-yl)-2-((2-(3-(trifluoromethyl)phenyl)pyrimidin- 5- yl)carbamoyl)phenyl)carbamoyl)-benzylthio)propanoate (280 mg, 0.41 mmol, 1.00 equiv) in tetrahydrofuran (8 mL) was added LiOH H ₂ 0 (500 mg, 11.90 mmol, 25.00 equiv) in water (2 mL) and the resulting solution was stirred overnight at room temperature. The reaction progress was monitored by LCMS. The solution was adjusted to pH 5-6 with hydrochloric acid and then extracted with 2x20 mL of ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated under vacuum until about 5 mL remained. The product was then precipitated with petroleum ether and the resulting solids were collected by filtration and washed with ether. This resulted in 0.22 g (80%) of product as a yellow to green solid. 'H-NMR

(400MHz, DMSO, ppm): δ 12.24(s, 1H), 10.92(s, 1H), 10.91(s, 1H), 9.27(s, 2H), 8.64(m, 2H), 68.06(d, 1H), 7.89(d, 2H), 7.75-7.80(m, 2H), 7.47-7.53(m, 2H), 7.39(s, 1H), 7.25(d, 1H), 3.83(s, 2H) 3.24(m, 4H), 2.58(t, 2H), 1.67(m, 4H). 1.58(m, 2H). MS (ES, m/z): 664 [M+H] ⁺ .

EXAMPLE 5

Nl-(2-((5-(3.4-DimethylphenvI ^' )PYrazin-2-yl ^' )carbamovn-4-(piperidin-l-vnphenvn- N3-(2-(2-hydroryethoxy)ethyl)isophthalamide

Scheme 5. 1. HATU, DIPEA, 2-(2-aminoethoxy)ethanol; 2. LiOH H ₂ 0, THF, water; 3. Intermediate 5b, HATU, DIPEA.

Intermediate Sa: methyl 3-((2-i2-hvdroxyemoxy ethyl)carbamoyl)benzoate. Into a 1000-mL round bottom flask, was placed a solution of 3-(methoxycarbonyl)benzoic acid (20 g, 111.11 mmol, 1.00 equiv) in N,N-dimethylformamide (500 mL), HATU (63.2 g, 166.32 mmol, 1.50 equiv), N,N-diisopropylethylamine (21.5 g, 166.67 mmol, 1.50 equiv), and 2-(2-aminoethoxy)ethanol (23.3 g, 221.90 mmol, 2.00 equiv). The resulting solution was stirred for overnight at 25°C. The resulting mixture was concentrated under vacuum. The resulting solution was dissolved in 200 mL of ethyl acetate. The resulting mixture was washed with 10x200 mL of brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with dichloromethane:methanol (100:1). This resulted in 15 g (51%) of methyl 3-((2-(2-hydroxyethoxy)ethyl)carbamoyl)benzoate as red oil. Intermediate 5b: 3-((2-(2-hydroxyethoxytethvDcarbamovObenzoic acid. Into a 500- mL round bottom flask, was placed a solution of methyl 3-((2-(2- hydroxyethoxy)ethyl)carbamoyl)benzoate (10 g, 37.45 mmol, 1.00 equiv) in tetrahydrofuran (40 mL), and a solution of lithium hydroxide hydrate (23.4 g, 558.33 mmol, 15.00 equiv) in water (30 mL). The resulting solution was stirred overnight at room temperature. The resulting mixture was concentrated under vacuum. The solution was adjusted to pH 3-4 with hydrochloric acid (2 mol/L). The resulting solution was extracted with 3x10 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 2x10 mL of brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with dichloromethaneimethanol (50:1). This resulted in 5 g (53%) of 3-((2-(2- hydroxyethoxy)ethyl)carbamoyl)benzoic acid as a yellowish solid. Ή-NMR (300MHz, OMSO,ppm): δ 13.25(s, 1H), 8.71 (m, 1H), 8.48(d, =8.5Hz 1H), 8.06(m, 2H), 7.62(m, 1H), 4.59(s, 1H), 3.41-3.60 (m, 8H). MS (ES, m/z): 254 [M+H] ⁺ .

Example 5: Nl-(2-((5-(3.4-dimethylphenyl)pyrazin-2-yncarbamoyl)-4-(pipe ridin- 1 - yn-phenyl)-N3-(2-(2-hydroxyethoxy)ethyl)isophthalamide. Into a 50-mL round bottom flask, was placed a solution of 3-((2-(2-hydroxyethoxy)ethyl)carbamoyl)benzoic acid (1893 mg, 0.75 mmol, 3.00 equiv) in N,N-dimethylformamide (5 mL), HATU (331.2 mg, 0.87 mmol, 3.50 equiv), N,N-diisopropylethylamine (160.6 mg, 1.24 mmol, 5.00 equiv), and 2-amino-N-(5-(3,4-dimemylphenyl)pyrazin-2-yl)-5-(piperidin-l - yl)benzamide (100 mg, 0.25 mmol, 1.00 equiv). The resulting solution was stirred overnight at 25°C in an oil bath. The reaction was then quenched with 50 mL of water. The resulting solution was extracted with 3x30 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 2x50 mL of brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. The crude product (120 mg) was purified by reverse phase HPLC eluting with a water/CHCN gradient containing 0.05% TFA. The product was obtained as 44.8 mg (28%) of a light yellow solid. Ή- NMR (300MHz, DMSO, ppm): δ 11.36(s, IH), 11.06(s, IH), 9.38 (d, J=1.5Hz, IH), 9.03 (d, J=1.5Hz, IH), 8.74-8.66 (m, IH), 8.39(s, IH), 8.10~8.01(m, 3H), 7.92(s, IH), 7.86(d, J=7.8Hz, IH), 7.66~7.51(m, 2H), 7.37(s, IH), 7.29(d, J=7.8Hz, IH), 3.56-3.34 (m, 13H), 2.32-2.28 (m, 6H), 1.72-1.61 (m, 6H). MS (ES, m/z): 637 [M+H] ⁺ .

EXAMPLE 6

Nl-(2- -Hvdroxyethoxy ethyl)-N3-(4-(piperidin-l-vn-2-((5-(3- ((rifluoromethyl)r)henyl)nyrazin-2-yl)carbamovnphenyl)isonht halamidc

Scheme 6. 1. 3-(trifluoromethyl)phenylboronic acid, Na ₂ C0 ₃ , (Ph3P)4Pd; 2. 2-nitro-5- chlorobenzoyl chloride, pyridine; 3. piperidine, K2CO3; 4. H ₂ , Pd C; 5. 3-((2-(2- hydroxyethoxy)ethyl)carbamoyl)benzoic acid, HATU. Intermediate 6a: 5-(3-(trifluoromemyl)phenyl)pwazin-2-amdne. Into a 500-mL sealed tube purged and maintained with an inert atmosphere of nitrogen, was placed a solution of 5-bromopyrazin-2-amine (4 g, 22.99 mmol, 1.00 equiv) in 1,4-dioxane (68 mL) and methanol (23 mL), 3-(trifluoromethyl)phenylboronic acid (4.46 g, 23.48 mmol, 1.02 equiv), a solution of sodium carbonate (4.88 g, 46.04 mmol, 2.00 equiv) in water (23 mL), and Pd(PPh ₃ ) ₄ (532 mg, 0.46 mmol, 0.02 equiv). The resulting solution was stirred overnight at 135°C in an oil bath. The resulting mixture was concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate/petroleum ether (1:5). This resulted in 4.4 g (80%) of 5-(3- (trifluoromethyl)phenyl)pyrazin-2-amine as a yellow solid.

Intermediate 6b: 5-chloro-2-nitro-N-(5-(3-(trifluoromethyl ^" )phenyl ^' )pyrazin-2-yl)- benzamide. Into a 50-mL round-bottom flask, was placed a solution of 5-(3- (trifluoromethyl)phenyl)pyrazin-2-amine (1.3 g, 5.43 mmol, 1.00 equiv) in dichloromethane (15 mL), and pyridine (2 mL). This was followed by dropwise addition of a solution of 5-chloro-2-nitrobenzoyl chloride (1.2 g, 5.45 mmol, 1.00 equiv) in dichloromethane (5 mL) with stirring. The resulting solution was stirred for 2 h at 25°C in an oil bath. The resulting solution was diluted with 100 mL of dichloromethane. The resulting mixture was washed with 2x50 mL of hydrogen chloride (aq), dried over anhydrous sodium sulfate, and concentrated under vacuum. This resulted in 2 g (87%) of 5-chloro-2-nitro-N-(5-(3-(trifluoromethyl)phenyl)pyrazin- 2-yl)benzamide as a yellow solid. Intermediate 6c: 2-nitro-5-(pipericUn -yl)-N-(5-(3-(trffl^

yll-benzamide. Into a 100-mL round bottom flask, was placed a solution of 5-chloro-2- nitro-N-(5-(3-(trifluoromethyl)phenyl)pyrazin-2-yl)benzamide (2.0 g, 4.73 mmol, 1.00 equiv) in N,N-dimethylformamide (30 mL), piperidine (1.0 g, 11.74 mmol, 2.50 equiv), and potassium carbonate (2 g, 14.47 mmol, 3.00 equiv). The resulting solution was stirred overnight at 100°C in an oil bath. The resulting solution was diluted with 150 mL of ethyl acetate. The resulting mixture was washed with 1x50 mL of water and 3x50 of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This resulted in 1.7 g (76%) of product as a yellow solid.

Intermediate 6d: 2-amino-5-(piperidin-l -ylVN-(5-(3-(trifluoromethyl)phenyl)pyrazin- 2-yl1-benzamide. Into a 50-mL round bottom flask, was placed a solution of 2-nitro-5- (piperi0¾n-l-yl)-N-(5-(3-(trifluoromemyl)phenyl)pyrazin-2-y l)benzamide (140 mg, 0.30 mmol, 1.00 equiv) in methanol/tetrahydrofuran (5 mL/2 mL). The mixture was treated with Pd/C and stirred under a hydrogen atmosphere for 1 h at room temperature. The solids were filtered out. The resulting solution was diluted with 50 mL of ethyl acetate. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This resulted in 100 mg (76%) of 2-amino-5-(piperidin-l-yl)-N-(5-(3- (trifluoromethyl)phenyl)pyrazin-2-yl)benzamide as a yellow solid.

Example 6: Nl-(2-(2-hydroxyethoxy ^' )ethyl)-N3-(4-(piperidin-l-yl ^' )-2-((-5-(3- ftrifluoromemynphenynpyrazin^-vncarbamoynphenvnisoplithalami de. Into a 50-mL round bottom flask, was placed a solution of 3-((2-(2-hydroxyethoxy)- ethyl)carbamoyl)benzoic acid (189.3 mg, 0.75 mmol, 1.10 equiv) in N,N- dimethylformamide (2.5 mL), HATU (1034 mg, 2.72 mmol, 4.00 equiv), and N-ethyl- N-isopropylpropan-2-amine (351 mg, 2.72 mmol, 4.00 equiv). This was followed by dropwise addition of a solution of 2-amino-5-(piperidin-l-yl)-N-(5-(3- (trifluoromethyl)phenyl)-pyrazin-2-yl)benzamide (300 mg, 0.68 mmol, 1.00 equiv) in N,N-dimethylformamide (2.5 mL) with stirring. The resulting solution was stirred overnight at 40°C in an oil bath. The resulting solution was diluted with 50 mL of ethyl acetate. The resulting mixture was washed with 2x20 mL of brine, dried over anhydrous sodium sulfate, and concentrated under vacuum. The crude product was purified by reverse phase HPLC eluting with 0.05% TFA in a water/C¾CN gradient. The product was obtained as 30 mg (7%) of a yellow solid. Ή-NMR (300MHz, DMSO, ppm): δ 11.45(s, 1H), 10.95(s, 1H), 9.46(s, 1H), 9.22(s, 1H), 8.67(m, l ^' H), 8.38(m, 3H), 8.01(m, 3H), 7.80(m, 3H), 7.77(m, 2H), 7.63(m, 1H), 7.48(m, 1H), 7.25(m, 1H), 3.52(m, 12H), 3.29(m, 5H), 2.98(s, 1H), 1.69(m, 6H). MS (ES, m/z): 677 [M+H] ⁺ .

EXAMPLE 7

2-f3-(f(2- Diethylamino)ethyl)fmethyl)amino)methvnbenzamido)-N-(5-(3.4- dimethylphenyl)pyrimidin-2-yl)-5-(piperidin-l-yl)benzainide

Scheme 7. 1. N,N-diethyl-N'-methylethylenediamine; 2. 3,4-dimethylphenylboromc acid, (Ph ₃ P) ₄ Pd, Na ₂ C0 ₃ , dioxane, methanol, water; 3. 2-nitro-5-chlorobenzoyl chloride, pyridine; 4. piperidine, K ₂ C0 ₃ ; 5. H ₂ , Pd/C; 6. 3-(((2- (diethylamino)ethyl)(methyl)amino)methyl)benzoic acid 7a, EDC HC1, DMAP.

Intermediate 7a: 3-(((2-(diemylamino ^' )ethvn(methvDamino ^' )methyl ^' )benzoic acid. Into a 1000-mL round bottom flask, was placed a solution of Nl,Nl-diethyl-N2- methylethane-l,2-diamine (9.1 g, 63.00 mmol, 1.50 equiv, 90%) in N,N- dimethylformamide (500 mL), 3-(bromomethyl)benzoic acid (10 g, 46.51 mmol, 1.00 equiv), potassium carbonate (7.8 g, 56.12 mmol, 1.20 equiv), and potassium iodide (1.55 g, 9.34 mmol, 0.20 equiv). The resulting solution was stirred for 2 h at 90°C in an oil bath. The solids were filtered out. The resulting mixture was concentrated under vacuum. The crude product (10 g) was purified by reverse phase HPLC eluting with 0.05% TFA in a water/CI¾CN gradient. The product was obtained as 6 g (46%) of a white solid. ^] H-NMR (300MHz, CDC1 ₃ , ppm): δ 8.0 l(m, 1H), 7.89-7.87(m, 1H), 7.28- 7.22(m, 2H), 3.99(s, 2H), 2.97-2.72(m, 8H), 2.28(s, 3H), 1.13-1.01(m, 6H). MS (ES, m/z): 265 [M+H] ⁺ .

Intermediate 7b: 5-G.4-dimethylphenyl)pyrimidin-2-amine. Into a 250-mL 3-necked round bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed 5-bromopyrimidin-2-amine (5 g, 28.74 mmol, 1.00 equiv), 3,4- dimethylphenylboronic acid (4.4 g, 29.33 mmol, 1.00 equiv), dioxane (85 mL), methanol (29 mL), sodium carbonate(6.1 g, 57.55 mmol, 2.00 equiv) in water (29 mL), and Pd(PPh3)4 (664 mg, 0.57 mmol, 0.02 equiv). The resulting solution was stirred overnight at 100°C in an oil bath. The mixture was concentrated under vacuum. The residue was applied onto a silica gel column and eluted with dichloromethane methanol (50: 1). This resulted in 6 g (crude) of 5-(3,4-dimethylphenyl)pyrimidin-2-amine as a yellow solid.

Intermediate 7c: 5-chloro-N-(5-(3.4-dimethylphenyl)pyrimidin-2-yl)-2-mtrobenz amide. Into a 250-mL round-bottom flask, was placed a solution of 5-(3,4- dimethylphenyl)pyrimidin-2-amine (1.41 g, 7.07 mmol, 1.00 equiv) in dichloromethane (90 mL), and pyridine (1.73 g, 3.00 equiv). This was followed by dropwise addition of a solution of 5-chloro-2-nitrobenzoyl chloride (1.60 g, 7.27 mmol, 1.00 equiv) in dichloromethane (30 mL) with stirring. The resulting solution was stirred overnight at 25°C in an oil bath. The resulting solution was diluted with 60 mL of dichloromethane. The resulting mixture was washed with 1x30 mL of hydrogen chloride (aq) and 3x200 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was dissolved in 100 mL of methanol, to this was added potassium carbonate (5.12 g). The mixture was stirred for 3 h at 30°C. The resulting mixture was concentrated under vacuum and dissolved in 100 mL of ethyl acetate. The resulting mixture was washed with 3x50 mL brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product was washed with ethyl acetate:n-hexane (30mL:30mL). This resulted in 0.78 g (29%) of 5- cUoro-N-(5-(3,4-dimethylphenyl)pyrirnidin-2-yl)-2-nitrobenza mide as a off-white solid.

Intermediate 7d: N-(5-(3 ^-dimethylphenvDpyrimidin-2-ylV2-mtro-5-fpiperidin- 1 -yl)- benzamide. Into a 50-mL round-bottom flask, was placed a solution of 5-chloro-N-(5- (3,4-dimethylphenyl)pyrimidin-2-yl)-2-nitrobenzamide (500 mg, 1.31 mmol, 1.00 equiv) in N,N-dimethylformamide (5 mL), and piperidine (330 mg, 3.88 mmol, 3.00 equiv). The resulting solution was stirred for 4 h at 85°C in an oil bath. The reaction was then quenched with 100 mL of water. The resulting solution was extracted with 2x100 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with 2x100 mL of brine. The mixture was dried over sodium sulfate and concentrated under vacuum to give 550 mg (98%) of product as a yellow solid.

Intermediate 7e: 2-amino-N-( ^' 5-(3.4-0^methylphenyl)pyrimidin-2-yl)-5-( ^' r)iperidin-l - yl)-benzamide. Into a 250-mL round-bottom flask, was placed a solution of N-(5-(3,4- dimethylphenyl)pyrimichn-2-yl)-2-nitro-5-(piperidin-l-yl)ben zamide (550 mg, 1.27 mmol, 1.00 equiv) in methanol (80 mL). The mixture was treated with Pd/C (550 mg) and stirred under a hydrogen atmosphere for ca. 4 h at room temperature. The solids were filtered out. The resulting mixture was concentrated under vacuum to yield in 420 mg (82%) of 2-amino-N-(5-(3,4-dimethylphenyl)pyrimidin-2-yl)-5-(piperidi n-l- yl)benzamide as a brown syrup

Example 7: 2-(3-(((2-(diethylamino)ethyl)(methyl)amino)methyl)benzamido )-N-(5- (3.4-dimethylphenyl)pyrimidin-2-yl)-5-(piperidin- 1 -yPbenzamide, Into a 10-mL round bottom flask, was placed a solution of 3 -(((2- (diethylamino)ethyl)(methyl)amino)methyl)benzoic acid (118.8 mg, 0.45 mmol, 1.50 equiv) in dichloromethane (24 mL), EDC.HC1 (171.6 mg, 0.90 mmol, 3.00 equiv), 4- dimethylaminopyridine (182.4 mg, 1.49 mmol, 5.00 equiv), and 2-amino-N-(5-(3,4- dimethylphenyl)pyrimidin-2-yl)-5-(piperidin-l-yl)benzamide (120 mg, 0.29 mmol, 1.00 equiv). The resulting solution was stirred for 8 h at 25°C in an oil bath. The resulting mixture was concentrated under vacuum. The crude product (200 mg) was purified by reverse phase HPLC eluting with a water/CI^CN gradient containing 0.05% TFA. The product was obtained as 139.2 mg (62%) of a yellow solid. Ή-NMR (300MHz, DMSO, ppm) δ 11.37(s, 1H), 11.30(s, 1H), 8.75 (d, J=6Hz, 2H), 8.22 (d, J=9Hz, 1H), 8.054(s, 1H), 7.93(d, /=6.3Hz, 1H), 7.68-7.60 (m, 2H), 7.53(s, 1H), 7.31-7.20 (m, 3H), 7.15(d, J=7.2Hz, 1H), 3.40~3.12(m, 13H), 2.59(s, 2H), 2.32~2.27(m, 4H), 2.16(s, 3H), 1.68 (m, 4H), 1.58~1.57(m, 2H), 1.21~1.16(m, 6H). MS (ES, m/z): 648 [M-H] ⁺ .

EXAMPLE 8

Nl-(2-(2-Hvdro3cvethoxy)ethyl)-N3-(4-(piperidin-l-yl)-2-( (5-i3-

(trifluoromethyl)phenvI pyrimtdin-2-yl)carbanioyl)phenyl)isophthalamide

2-Ammo-5-(piperidin -yl)-N-(5-(3-(trifiuoro^

was prepared according to the methods exemplified in the synthesis of intermediate lg, using 5-chloro-2-aminopyrimidine and 3-(trifluoromethyl)phenylboronic acid as starting materials. Into a 50-mL round bottom flask, was placed a solution of 2-amino- 5-(piperidin -yl)-N-(5-(3-(trifluoromemyl)phenyl)pyrimidin-2-yl)benzamide (200 mg, 0.45 mmol, 1.00 equiv) in N,N-dimethylformamide (5 mL), 3-((2-(2- hydroxyethoxy)ethyl)carbamoyl)benzoic acid (118 mg, 0.47 mmol, 1.00 equiv), HATU (345 mg, 0.91 mmol, 2.00 equiv), and N,N-diisopropylethylamine (234 mg, 1.81 mmol, 4.00 equiv). The resulting solution was stirred for 10 h at 25°C. The mixture was concentrated under vacuum. The crude product (200 mg) was purified by reverse phase HPLC eluting with a water/CI¾CN gradient containing 0.05% TFA. The product was obtained as 37.8 mg (12%) of a yellow solid. Ή-NMR (300MHz, CD ₃ OD, ppm): δ 8.92

(s, 2H), 8.44-8.47(d, /=9.3Hz, 1H), 8.32-8.33(m, 1H), 8.00-8.03(m, 2H), 7.87-7.95(m, 3H), 7.61-7.73(m, 3H), 7.51-7.56(m, 1H), 3.44-3.63(m, 15H), 1.94(s, 4H), 1.71 (s, 2H). MS (ES, m/z):677.00 [M+H] ⁺ .

EXAMPLE 9

2-G-(((2-(Diethylarninokthvn(rnethvhamino rnethyl)bcnzamido>-5-(piperidin-l- ylVN-CS-O-ftrifluoromethvnphenvnpyrimidin-l-vDbeiizamide

Into a 50-mL round bottom flask, was placed a solution of 2-amino-5-(piperidin-l-yl)- N-(5-(3-(Mfluoromethyl)phenyl)pyrimidin-2-yl)benzarnide (200 mg, 0.45 mmol, 1.00 equiv) in dichloromethane (5 mL), 3 -(((2-

(diethylamino)ethyl)(methyl)amino)methyl)benzoic acid (120 mg, 0.45 mmol, 1.00 equiv), EDCI (130 mg, 0.68 mmol, 1.50 equiv), and 4-dimethylaminopyridine (83 mg, 0.68 mmol, 1.50 equiv). The resulting solution was stirred for 10 h at 25°C. The crude product (200 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA. The product was obtained as 32.2 mg (9%) of a yellow solid. Ή-NMR (300MHz, DMSO-c¾, ppm): δ 11.45 (s, IH), 11.29 (s, IH), 9.18(s, 2H), 8.12-8.21 (m, 3H), 8.03 (s, IH), 7.89-7.91(d, J=6.6Hz, IH), 7.75-7.84(m, 2H), 7.62- 7.66(m, 2H), 7.51 (s, IH), 7.28-7.31(d, J=8.1Hz, IH), 3.37 (s, 2H), 3.26(s, 4H), 3.10- 3.18 (m, 4H), 1.58-1.68(m, 6H), 1.15-1.20(m, 6H). MS (ES, m/z): 688.00 [M +H] ⁺ .

EXAMPLE 10

Nl-MethvI-Nl-(2-morpholmoethyl)-N3-(4-(Diperidiii-l-yl)-2 -((2-(3-

(trifluoromethvDphenvDpyrimidin-S-ylkarbamoyltphenvDisoph thalaniide

Scheme 8. l. oxalyl chloride, DMF; 2. Boc ₂ 0, Et ₃ N; 3. LAH; 4. intermediate 10a; 5. LiOH H ₂ 0; 6. intermediate lOe, DCM, DMAP, EDC.HC1.

Intermediate 10a: methyl 3-icMorocarbonyr)benzoate. Into a 250-mL round bottom flask, was placed a solution of 3-(methoxycarbonyl)benzoic acid (6.2 g, 34.44 mmol, 1.00 equiv) in dichloromethane (50 mL), oxalyl dichloride (8.74 g, 69.37 mmol, 2.00 equiv), and N,N-dimethylformamide (cat.). The resulting solution was stirred for 1 h at 40°C in an oil bath. The resulting mixture was concentrated under vacuum. This resulted in 6.6 g (87%) of methyl 3-(chlorocarbonyl)benzoate as brown oil. a 250-mL round bottom flask, was placed a solution of 2-morpholinoethanamine (10 g, 76.92 mmol, 1.00 equiv) in dichloromethane (50 mL). To this was added triethylamine (5.83 g, 57.72 mmol, 0.50 equiv). This was followed by the addition of di-tert-butyl dicarbonate (18.44 g, 84.59 mmol, 1.10 equiv) at 0-5°C. The resulting solution was stirred overnight at 25°C. The resulting solution was diluted with 200 mL of dichloromethane. The resulting mixture was washed with 1x30 mL of 10% sodium bicarbonate and 1x30 mL of brine. The mixture was dried over sodium sulfate and concentrated under vacuum. This resulted in 16 g (81%) of tert-butyl 2-morpholinoethylcarbamate as an off-white solid.

Intermediate 10c: N-methyl -2-morpholinoethanamine. Into a 250-mL 3-necked round bottom flask, was placed a solution of LiAl¾ (7.72 g, 208.65 mmol, 3.00 equiv) in tetrahydrofuran (60 mL). To this was added dropwise a solution of tert-butyl 2- morpholinoethylcarbamate (16 g, 62.61 mmol, 1.00 equiv, 90%) in tetrahydrofuran (40 mL) with stirring at 0-5°C. The resulting solution was stirred for 2 h at 70°C in a oil bath bath. The reaction was then quenched by the addition of 7.7 mL of water, 7.7 mL of 15% sodium hydroxide, and 23.1 mL of water. The solids were filtered out. The mixture was dried over sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with dichloromethanemethanol (0.5% triethylamine) (20:1). This resulted in 4.2 g (42%) of N-methyl-2- morpholinoethanamine as brown oil.

Intermediate lOd: methyl 3-fmethyl(2-morpholinoethvncarbamoyl)benzoate. Into a 100-mL round bottom flask, was placed a solution of N-methyl-2- mo holinoethanamine (2.1 g, 13.12 mmol, 1.00 equiv, 90%) in dichloromethane (20 mL), and triethylamine (1.47 g, 14.55 mmol, 1.00 equiv). This was followed by dropwise addition of a solution of methyl 3-(chlorocarbonyl)benzoate (3.3 g, 15.00 mmol, 1.20 equiv, 90%) in dichloromethane (10 mL) with stirring at 0-5°C. The resulting solution was stirred for 3 h at room temperature. The resulting solution was diluted with 100 mL of dichloromethane. The resulting mixture was washed with 1x30 mL of 10% sodium bicarbonate and 1x30 mL of brine. The mixture was dried over sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with dichloromethane:methanol (20:1). This resulted in 4.4 g (99%) of methyl 3-(methyl(2-morpholinoethyl)carbamoyl)benzoate as a brown solid.

Intermediate lOe: 3-(methyl(2-morpholinoethyl ^' )carbamoyl)benzoic acid. Into a 100- mL round bottom flask, was placed a solution of methyl 3-(methyl(2- morpholinoethyl)carbamoyl)benzoate (4.4 g, 13.66 mmol, 1.00 equiv, 95%) in tetrahydrofuran/water (15/10 mL), and lithium hydroxide hydrate (1.77 g, 43.17 mmol, 3.00 equiv). The resulting solution was stirred for 1 h at 25°C. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 10 mL of water and adjusted to pH 2-3 with hydrochloric acid. The resulting mixture was washed with 2x30 mL of ethyl acetate. The aqueous layers were concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate:methanol (4:1). This resulted in 2.7 g (65%) of 3-(methyl(2-morpholinoethyl)carbamoyl)benzoic acid as a white solid. Ή-NMR (300MHz, CD ₃ OD, #pm): δ 8.17 (m, 2H), 7.78 (m, 1H), 7.61 (m, 1H), 3.98 (m, 6H), 3.56 (m, 5H), 3.47 (m, 1H), 3.10 (s, 3H). MS (ES, m/z): 293 [M+H] ⁺ .

(trifluoromethyl)phenyl pyrimidin-5-yl)cart Into a 50- mL round bottom flask, was placed a solution of 3-(methyl(2- morpholinoethyl)carbamoyl)benzoic acid (186 mg, 0.64 mmol, 2.00 equiv) in dichloromethane (10 mL), EDC.HC1 (92 mg, 0.48 mmol, 1.50 equiv), 4- dimethylaminopvridine (59 mg, 0.48 mmol, 1.50 equiv), and 2-amino-5-(piperidin-l- yl)-N-(2-(3-(1iifluoromemyl)phenyl)pyrirnidin-5-yl)benzamide (140 mg, 0.32 mmol, 1.00 equiv). The resulting solution was stirred for 4 h at 25°C. The resulting mixture was concentrated under vacuum. The crude product (200 mg) was purified by reverse phase HPLC eluting with a water/C¾CN gradient containing 0.05% TFA. The product was obtained as 191 mg (71%) of a yellow solid. Ή-NMR (300MHz, DMSO, ppm): δ 10.97(m, 2H), 9.66(s, 1H), 9.25(s, 2H), 8.63(m, 2H), 7.99(m, 4H), 7.79(m, 1H), 7.63(m, 2H), 7.42(s, 1H), 7.26(m, 1H), 3.99(m, 2H), 3.83(m, 2H), 3.61(m, 4H), 3.43(m, 2H), 3.24(m, 6H), 2.95(s, 3H), 1.59(m, 6H). MS (ES, m/z): 716 [M +H] ⁺ .

EXAMPLE 11

Nl-Methyl-Nl-(2-morpholinoethyl)-N3-(2-((2-phenylpYrimidiii- 5-yl)carbamoyl ^' )-4- (piperidin-l-yllphenvDisophthalamide Into a 50-mL round bottom flask, was placed a solution of 3-(methyl(2- morpholinoethyl)carbamoyl)benzoic acid (314 mg, 1.08 mmol, 2.00 equiv) in dichloromethane (10 mL), EDC.HC1 (155 mg, 0.81 mmol, 1.50 equiv), 4- dimethylaminopyridine (99 mg, 0.81 mmol, 1.50 equiv), and 2-amino-N-(2- phenylpyrimidin-5-yl)-5-(piperidin-l-yl)benzamide (200 mg, 0.54 mmol, 1.00 equiv). The resulting solution was stirred for 4 h at 25°C. The resulting mixture was concentrated under vacuum. The crude product (200 mg) was purified by reverse phase HPLC eluting with a water/CHsCN gradient containing 0.05% TFA. The product was obtained as 114 mg (28%) of a yellow solid. Ή-NMR (300MHz, DMSO, ppm): δ 10.98(m, 2H), 9.70(s, 1H), 9.29(s, 2H), 8.35(m, 2H), 8.01(m, 3H), 7.63(m, 2H), 7.52(m, 4H), 7.28 (m, 1H), 4.03(m, 2H), 3.82(m, 2H), 3.61(m, 4H), 3.43(m, 2H), 3.24(m, 6H), 2.95(s, 3H), 1.59(m, 6H). MS (ES, m/z): 648 [M+H] ⁺ .

EXAMPLE 12

_Y DcarbamoyDphenvBcarbamovItbenzyDth^propanoic acid

Scheme 9. 1. DMF, HATU, DIPEA, 3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid lc; 2. TFA, DCM.

Intermediate 12a: tert-butyl S-O-fH-f i eridin-l-vn^-ffS-O-

(trifluoromethyl ^' )phenyl ^' )pyrazin-2- yl1carbamoyl ^' )phenyl ^' lcarbamoyl ^' )benzylthio propanoate. To 3-((3-tert-butoxy-3- oxopropylthio)methyl)benzoic acid (53.7 mg, 0.18 mmol, 0.80 equiv) in N,N- dimethylformamide (2 mL) was added HATU (172.3 mg, 0.45 mmol, 2.00 equiv) and DIEA (117.0 mg, 0.91 mmol, 4.00 equiv) followed by the dropwise addition of a solution of 2-amino-5-(piperidin-l-yl)-N-(5-(3-(trifluoromethyl)phenyl)p yrazin-2- yl)benzamide 6d (100 mg, 0.23 mmol, 1.00 equiv) in N,N-dimethylformamide (1 mL). The resulting solution was stirred for 4 h at 25°C in an oil bath. The resulting solution was diluted with 50 mL of ethyl acetate. The resulting mixture was washed with 1x20 mL of water and 3x20 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum to yield 140 mg of crude product as a brown solid.

Example 12: 3-(3-((4-(piperidin-l-yl)-2-((5-(3-(trifluoromethyl ^' )phenyl ^' )Dyra2in-2- vDcarbamovnphenvDcarbamoyDbenzyltlu^propanoic acid. Into a 50-mL round bottom flask, was placed a solution of tert-butyl 3-(3-((4-(piperidin-l-yl)-2-((5-(3- (trifluoromethyl)phenyl)pyrazin-2- yl)carbamoyl)phenyl)carbamoyl)benzylthio)propanoate (140 mg, 0.19 mmol, 1.00 equiv) in dichloromethane (2 mL). This was followed by dropwise addition of 2,2,2- trifluoroacetic acid (1 mL) with stirring. The resulting solution was stirred for 2 h at 25°C in an oil bath. The resulting mixture was concentrated under vacuum. The crude product was purified by reverse phase HPLC eluting with a water/C¾CN gradient containing 0.05% TFA. The product was obtained as 11 mg (9%) of a yellow solid. ¾- NMR (300MHz, DMSO.ppm): δ 11.47(s, 1H), 11.01(s, 1H), 9.47(s, 1H), 9.23 (s, 1H), 8.44(d, J=4.5Hz, 2H), 8.10(d, =9Hz, 1H), 7.80(m, 4H), 7.51(m, 3H), 7.36(m, 1H), 3.83(s, 2H), 3.41(s, 4H), 2.60(d, 2H), 1.60(m, 6H). MS (ES, m/z): 644 [M+H] ⁺ .

EXAMPLE 13 tert-Butyl 3-((3-q2-((5-(3,4-dimethylphenvnpyrimidiii-2-yl)carbamovU-4- fpiperidin-l-ynphenvncarbamovUbenzyDthio ^' lpropanoate

Scheme 10. 1. 3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid lc, EDC.HC1, DMAP; 2. TFA, DCM.

Intermediate 13a: tert-butyl 3-(3-(2-(5-(3.4-dimemylphenvDpyrimidin-2-ylcarbamoylV 4-fpiperidin-l-yl')phenylcarbamoyl')benzylthio ^' )propanoate. In a round bottom flask was placed a solution of 3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid (88.6 mg, 0.30 mmol, 1.20 equiv) in dichloromethane (15 niL), EDC.HC1 (143.2 mg, 0.75 mmol, 3.00 equiv), 4-dimethylaminopyridine (152.1 mg, 1.24 mmol, 5.00 equiv), and 2- amino-N-(5-(3,4-dimethylphenyl)pyrimidin-2-yl)-5-( iperidin-l-yl)benzamide (100 mg, 0.25 mmol, 1.00 equiv). The resulting solution was stirred overnight at 25°C in an oil bath. The resulting solution was diluted with 50 mL of dichloromethane. The resulting mixture was washed with 1x20 mL of diluted hydrochloric acid and 2x30 mL of brine. The mixture was dried over sodium sulfate. The solids were filtered out. The resulting mixture was concentrated under vacuum to yield 340 mg of crude product as a brown syrup.

Example 13: 3 -(3 -(2-(5 -(3.4-dimethylphenyl pyrimidin-2-ylcarbamoyl)-4-(piperidin- 1 - yl)phenylcarbamoyl)benzylthio)propanoic acid. Into a 50-mL round bottom flask, was placed a solution of tert-butyl 3-(3-(2-(5-(3,4-dimethylphenyl)pyrimidin-2- ylcarbamoyl)-4-(piperidin-l-yl)phenylcarbamoyl)benzylthio)pr opanoate (340 mg, 0.5 mmol, 1.00 equiv) in dichloromethane (18 mL), and trifluoroacetic acid (8.9 mL). The resulting solution was stirred for ca. 5.5 h at room temperature. The resulting mixture was concentrated under vacuum. The crude product (200 mg) was purified by HPLC reverse phase HPLC eluting with a water/CHsCN gradient containing 0.05% TFA. The product was obtained as 25.3 mg (8%) of a yellow solid. Ή-NMR (300MHz, DMSO, ppm): 5 11.35(s, IH), 11.26(s, IH), 8.72(s, 2H), 8.25(d, J=9Hz, IH), 7.86(s, IH), 7.75(d, J=7.5Hz, IH), 7.56~7.741(m, 3H), 7.37(s, IH), 7.28~7.13(m, 3H), 4.34(s, IH), 3.84(s, 2H), 3.31(m, 4H), 2.60-2.55 (m, 2H), 2.32(s, 3H), 2.16(s, 3H), 1.71~1.58(m, 6H). MS (ES, m/z): 624 [M+H] ⁺ .

EXAMPLE 14

3-(P-((4-(Piperidin-l-ylV2-(f5-(3-(trifluoromethyl)phenvn Dyrimidin-2- ylkarbamovUnhenvDcarbam vDbenzvDthio^propanoic acid

Scheme 11. 1. 3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid lc, EDCI, DMAP, DCM; 2. TFA, DCM.

Intermediate 14b: tert-butyl 3-(3-( ^" 4-(piperidin-l-ylV2-f5-(3-(trifiuorQmethyl ^' )phenyl')- pyrimidin- -ylcarbamovnphenylcarbamovDbenzylthio^propanoate. 2-Amino-5- (piperidin-l-yl)-N-(5-(3-(trifluoromemyl)phenyl)pyrimidin-2- yl)beri2amide 14a was prepared from 2-amino-5-chloropyrimidine according to the procedure described from the preparation of 2-amino-5-(piperidin-l-yl)-N-(2-(3-

(trifluoromethyl)phenyl)pyrimidin-5-yl)benzamide 4c. Into a 50-mL round bottom flask, was placed a solution of 2-ammo-5-(piperidin-l-yl)-N-(5-(3- (trifluoromethyl)phenyl)pyrimidin-2-yl)benzamide (200 mg, 0.45 mmol, 1.00 equiv) in dichloromethane (8 mL), 3-((3-tert-butoxy-3-oxopropylthio)methyl)benzoic acid (134 mg, 0.45 mmol, 1.00 equiv), EDC (130 mg, 0.68 mmol, 1.50 equiv), and 4- dimethylaminopyridine (83 mg, 0.68 mmol, 1.50 equiv). The resulting solution was stirred for 2 h at 25°C. The resulting mixture was washed with 2x5 mL of water and 2x5 mL of 10% hydrochloric acid. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This resulted in 270 mg (83%) of product as a brown solid.

Example 14: 3-(3-(4-(piperidin-l-yl)-2-(5-(3-(trifluorome1hyl phenyl)pyrimidin-2-yl- carbamovDphenylcarbamovDbenzylthiotpropanoic acid. Into a 50-mL round bottom flask, was placed a solution of tert-butyl 3-(3-(4-(piperidin-l-yl)-2-(5-(3- (trifluoromethyl)phenyl)pyrimidin-2- ylcarbamoyl)phenylcarbarnoyl)benzylthio)propanoate (250 mg, 0.35 mmol, 1.00 equiv) in dichloromethane (3.5 mL), and 2,2,2-trifluoroacetic acid (1.7 mL). The resulting solution was stirred for 2 h at 25°C. The resulting mixture was concentrated under vacuum. The crude product (200 mg) was purified by reverse phase HPLC eluting with a water/C¾CN gradient containing 0.05% TFA. The product was obtained as 12.9 mg (6%) of a light yellow solid. Ή-NMR (300MHz, DMSO-t¾ ppm): δ 11.38 (s, 1H), 11.19 (s, 1H), 9.10(s, 2H), 8.04-8.20 (m, 3H), 7.62-7.79(m, 5H), 7.37-7.49 (m, 3H), 3.76 (s, 4H), 3.29 (s, 6H), 2.40-2.44 (m, 2H), 1.68(m, 4H),1.53-1.54(d, J=3.6Hz, 2H). MS (ES, m/z): 664.00 [M+H] ⁺ .

EXAMPLE 15

2-Methyl-l-oxo-l-(3-((2-((2-phenylpyrimidiii-5-yl)carbain ov -4-( ^, piperidiri-l- vDphenvDcarbamovnphenvn-S.S.ll-trioxa-l-azatetradecait-n-oic acid

Scheme 12. l. TsCl, pyridine; 2. MeNH ₂ , EtOH; 3. EDC HC1, DMAP, DCM, isophthalic acid monomethyl ester; 4. LiOH, THF, ¾0; 5. HATU, DIPEA, DMF, intermediate 15b; 6. TFA, DCM.

Intermediate 15a: tert-butyl 3-(2-( ^' 2-(2-(tosyloxy ^' )ethoxy ^" )ethoxy)ethoxy ^' )propanoate. To tert-butyl 3-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)propanoate (10 g, 35.97 mmol, 1.00 equiv) in pyridine (40 mL) was added 4-methylbenzene-l-sulfonyl chloride (6.8 g, 35.79 mmol, 1.00 equiv), in portions at 0°C. The resulting solution was stirred for 4 h at 0°C and then concentrated under vacuum. The residue was dissolved in 30 mL of dichloromethane, washed with 3x20 mL of 3% hydrochloric acid (aq) and 20· mL of brine, and then dried over sodium sulfate. The solution was concentrated under vacuum to afford 14 g (90%) of tert-butyl 3-(2-(2-(2- (tosyloxy)ethoxy)ethoxy)ethoxy)propanoate as a yellow oil.

Intermediate 15b: tert-butyl 3-(2-(2-(2-

(methylamino ^' lethoxylethoxy^ethoxylpropanoate. Into a 250-mL sealed bottle was placed a solution of tert-butyl 3-(2-(2-(2-(tosyloxy)ethoxy)ethoxy)ethoxy)propanoate (14 g, 32.41 mmol, 1.00 equiv) in tetrahydrofuran (5 mL) followed by CH ₃ H ₂ (66.9 g, 712.16 mmol, 21.98 equiv, 33% in ethanol) and the resulting solution was stirred overnight at 50°C. The resulting mixture was concentrated under vacuum, dissolved in 150 mL of dichloromethane and then washed with 2x150 mL of water and 1x150 mL of brine. The organic layer was dried over sodium sulfate and concentrated under vacuum to afford 8.2 g (87%) of tert-butyl 3-(2-(2-(2- (methylamino)ethoxy)ethoxy)ethoxy)propanoate as yellow oil.

Intermediate 15c: methyl 3-(2-(2^henylpyrimidin-5-ylcarbamoylV4-(piperidin-l-yl ^' l- phenylcarbamoyPbenzoate. To a solution of 2-amino-N-(2-phenylpyrimidin-5-yI)-5- (piperidin-l-yl)benzamide (2 g, 3.75 mmol, 1.00 equiv, 70%) in dichloromethane (30 mL) was added 3-(methoxycarbonyl)benzoic acid (1160 mg, 6.12 mmol, 1.20 equiv, 95%), EDC.HC1 (2040 mg, 10.20 mmol, 2.00 equiv, 95%), and 4- dimethylaminopyridine (660 mg, 5.14 mmol, 1.00 equiv, 95%) and the resulting solution was stirred for 3 h at 25°C in an oil bath. The mixture was concentrated under vacuum, diluted with 100 mL of ethyl acetate, washed with 1x100 mL of brine and then the organic layer was concentrated under vacuum. The residue was applied onto a silica gel column and eluted with petroleum ether/ethyl acetate (2:1) to afford 1200 mg (60%) of product as a green to yellow solid.

Intermediate 15d: 3 -(Y2-(Y2-phenylp yrimidin-5 -vDcarbamo yl)-4-(piperidin- 1 - vDphenvD-carbamovDbenzoic acid. To a solution of methyl 3-((2-((2-phenylpyrimidin- 5-yl)carbamoyl)-4-(piperidin-l-yl)phenyl)carbamoyl)benzoate (1200 mg, 2.02 mmol, 1.00 equiv, 90%) in tetrahydrofuran/water (5:1) (30 mL) was added lithium hydroxide hydrate (420 mg, 9.97 mmol, 8.00 equiv, 95%) and the resulting solution was stirred for 3 h at 40°C in an oil bath. The mixture was concentrated under vacuum and the residue was adjusted to pH 3-4 with hydrochloric acid. The mixture was extracted with 3x100 mL of tetrahydrofuran and the organic layers combined, washed with 1x100 mL of brine and then concentrated under vacuum to afford 1000 mg (95%) of a green to yellow solid.

Intermediate 15e: tert-butyl 3-(2-(2-(2-(3-(carbamoyl - -methylbenzamido)ethoxyV ethoxy)ethoxy)propanoate. To a solution of 3-((2-((2-phenylpyrimidin-5- yl)carbamoyl)-4-(piperidin-l-yl)phenyl)carbamoyl)benzoic acid (100 mg, 0.17 mmol, 1.00 equiv, 90%) in N,N-dimethylformamide (2 mL) was added tert-butyl 3-(2-(2-(2- (methylamino)ethoxy)ethoxy)ethoxy)propanoate (111 mg, 0.27 mmol, 1.50 equiv, 70%), HATU (109 mg, 0.28 mmol, 1.50 equiv, 99%), and N,N-diisopropylethylamine (37 mg, 0.28 mmol, 1.50 equiv, 99%) and the resulting solution was stirred for 3 h at room temperature. The mixture was diluted with 50 mL of water, extracted with 2x100 mL of ethyl acetate and the organic layers combined, dried over sodium sulfate, and then concentrated under vacuum to afford 135 mg (98%) of product as a yellow oil.

Example 15: 3-(2-(2-(2-(3-(carbamoyl)-N-methylben2amido)ethoxy)ethoxy)et hoxy)- propanoic acid. To a solution of tert-butyl 3-(2-(2-(2-(3-(carbamoyl)-N- methylbenzamido)ethoxy)ethoxy)ethoxy)propanoate (120 mg, 0.14 mmol, 1.00 ^' equiv, 90%) in dichloromethane (10 mL) was added trifluoroacetic acid (2 mL) dropwise with stirring and the resulting solution was stirred for 2 h at room temperature. The reaction progress was monitored by LCMS. The resulting mixture was concentrated under vacuum and the crude product (100 mg) was purified by reverse phase HPLC eluting with a water/CH ₃ CN gradient containing 0.05% TFA to afford 45 mg (45%) of a yellow solid. 'H-NMR (300MHz, DMSO, ppm): 10.95 (s, 1H), 10.87 (s, 1H), 9.19 (s, 2H), 8.35-8.38 (t, 2H), 8.04-8.07 (d, J=9Hz, 1H), 7.93 (s, 1H), 7.89 (s, 1H), 7.51-7.60 (m, 5H), 7.34 (s, 1H), 3.43-3.62 (m, 17 H), 3.98 (s, 3H), 2.38-2.42 (t, J=6, 6Hz, 2H), 1.51- 1.71 (m, 6H). MS (ES, mJz): 739 [M+H] ⁺ .

EXAMPLE 16

Nl-(2-(f5-(3.4-Dimethylphenyl)pyrimidin-2-yl)carbamoyl)-4 -(piperidin-l- vDphenyll-NS-d-^-hvdroxyethoxy ^' tethyl ^' Hsophthalaiiiide

Example 16: N 1 -(2-((5 -(3.4-dimethylphenyl)pYrimidin-2- yl)carbamoyl)-4-(piperidin- 1 -yl phenyl)-N3 -(2-(2-hvdroxyethoxy)ethyl)isophthalamide. Into a 10-mL round bottom flask, was placed a solution of 3-((2-(2-hydroxyethoxy)ethyl)carbamoyl)benzoic acid (227.1 mg, 0.90 mmol, 3.00 equiv) in N,N-dimethylformamide (6 mL), HATU (397.5 mg, 1.05 mmol, 3.50 equiv), N,N-diisopropylethylamine (192.8 mg, 1.49 mmol, 5.00 equiv), and 2-amino-N-(5-(3,4-dimethylphenyl)pyrimidin-2-yl)-5-(piperidi n-l- yl)benzamide (120 mg, 0.30 mmol, 1.00 equiv) and the resulting solution was stirred overnight at 25°C in an oil bath. The reaction was then quenched with 100 mL of water and the resulting solution was extracted with 3x50 mL of ethyl acetate and the organic layers combined, washed with 2x50 mL of brine and then dried over sodium sulfate. The solids were filtered out and the resulting mixture was concentrated under vacuum. The crude product (120 mg) was purified by reverse phase HPLC eluting with a water/CHCN gradient containing 0.05% TFA to afford 16.8 mg (9%) of a yellow solid. 'H-NMR (300MHZ, DMSO, ppm): δ 11.34(s, IH), 11.24(s, IH), 8.71~8.68(m, 3H), 8.38(s, IH), 8.19 (d, J=8.4Hz, IH), 8.04-7.99 (m, 2H), 7.66-7.58 (m, IH), 7.47-7.38 (m, IH), 7.28-7.19 (m, 2H), 7.15(d, J=6.3Hz, IH), 4.42(s, IH), 3.56~3.44(m, 9H), 3.31 (m, 4H), 2.32(s, 3H), 2.16(s, 3H), 1.71~1.58(m, 6H). MS (ES, m/z): 637 [M+H] ⁺ .

EXAMPLE 17

2-Oxo-l-(3-((3-((2-((5-phenYlpyrimidiii-2-Yl)carbamoyl ^' )-4-(piperidiii-l- yl)phenyl)carbamovI)benzYl)thio)plienYl)-6,9,12-trioxa-3-aza peiitadecan-lS-oic acid

Scheme 13. 1. 3-(chloromethyl)benzoyl chloride, DIEA; 2. 2-(3-mercaptophenyl)acetic acid, K ₂ C0 ₃ ; 3. DIPEA, HATU, 15b, then TFA/CH ₂ C1 ₂ .

Intermediate 17a: 2-(3-fchloromethvnbenzamidoVN-C5-phenylpyrimidin-2-ylV5-

( ^" piperidin-l-vDbenzamide. To a 0°C solution of 100 mg of 2-amino-N-(2- phenylpyrimidin-5-yl)-5-(piperidin-l-yl)benzamide 2d, and 138 mg of diisopropylethylamine in 2 mL of 1:1 THF/DCM was added dropwise 46 mg of 3- (chloromethyl)benzoyl chloride. The mixture was stirred overnight at room temperature and the solvent was evaporated. All of this material was used in the next step without further characterization.

Intermediate 17b: 2-(3-ir3-(r2-((5-phenylpyrimidin-2-yl')carbamoyl')-4-(piperi din-l-vn- phenvDcarbamoyl)benzyl¼hio^phenyDacefic acid. A mixture of all the product from the previous step, 148 mg of K2CO3, and 1.3 mL of DMF was treated with 68 mg of 2- (3-mercaptophenyl)acetic acid. The mixture was stirred 4 h and the solvent was evaporated at reduced pressure. The residue was partitioned between dichloromethane and water. The organic extracts were washed with brine and dried. The solvent was evaporated and the residue was purified by reverse phase HPLC eluting with 0.05% TFA in a water / acetonitrile gradient to give the product.

Example 17: 2-oxo-l-f3-( ^' (3-f( ^" 2-fr5-phenylpyrimidin-2-yl ^' )carbamoylV4-(piperidin-l- ylVphenyl carbamoyl ^' )benzyl ^" )thio')phenyl')-6.9.12-trioxa-3-azapentadecan-15-oic acid. A mixture of 82 mg of 17b, 40 mg of 15b, and 65 mg of DIEA in 0.2 mL of acetonitrile was treated with 57 mg of HATU. The mixture was stirred overnight and then the solvent was evaporated. The residue was dissolved in 1 mL of dichloromethane and treated with 1 mL of TFA. The solvent was evaporated and the residue was purified by reverse phase HPLC, eluting with a water/CH ₃ CN gradient containing 0.05% TFA. This procedure yielded 33 mg of product. MS (ES, m/z): 861 [M+H] ⁺ .

EXAMPLE 18

Procedure for the Measurement of NaP2b-Mediated Pi Transport

Materials. HEK293 cells were obtained from the American Type Culture collection and propagated per their instructions. Expression clones for rat and human NaP2b (SLC34A2) were obtained from Open Biosystems (Catalog numbers MRN 1768-9510282, and MHS1010-99823026, respectively). The sequence of the human protein was mutated to insert a threonine after residue 37, and to introduce a N39D mutation.

Inhibition of Pi Transport. The rate of phosphate (Pi) uptake into HEK293 cells was measured using a modification of the method described by Mohrmann et al. (Mohrmann, I., Mohrmann, M., Biber, J., and Murer, H. (1986) Am. J. Phys. 250(3 Pt l):G323-30.) Transfected HEK293 cells were treated with a pharmacological agent to minimize endogenous PiT-mediated phosphate transport activity, such that the only remaining sodium-dependent phosphate transport activity is that which was bestowed by introduction of the NaP2b genes.

Cells were seeded into 96-well plates at 25,000 cells/well and cultured overnight. Lipofectamine 2000 (Invitrogen) was used to introduce the NaP2b cDNA, and the cells were allowed to approach confluence during a second overnight incubation. Medium was aspirated from the cultures, and the cells were washed once with choline uptake buffer (14 mM Tris, 137 mM choline chloride, 5.4 mM KCl, 2.8 mM CaCl ₂ , 1.2 mM MgS0 ₄ , 100 uM KH ₂ P0 ₄ , 1 mg mL Bovine Serum Albumin, pH 7.4). Cells were then overlayed with either choline uptake buffer or sodium uptake buffer (14 mM Tris, 137 mM sodium chloride, 5.4 mM KC1, 2.8 mM CaCl ₂ , 1.2 mM MgSC>4, 100 uM KH2PO4, PiT-silencing agent, 1 mg/mL Bovine Serum Albumin, pH 7.4) containing 6-9 uCi/mL ³³ P orthophosphoric acid (Perkin Elmer) and test compound. Each compound was tested at twelve concentrations ranging from 0.1 nM to 30 uM. Assays were run in duplicate.

After incubation for 3-30 minutes at room temperature, assay mixtures were removed, and the cells were washed twice with ice cold stop solution (137 mM sodium chloride, 14 mM Tris, pH 7.4). Cells were lysed by addition of 20 μΐ, 0.1% Tween 80 followed by 100 μΐ, scintillation fluid, and counted using a TopCount (Perkin Elmer).

pIC50 (the negative log of the IC50) values of the test compounds were calculated using GraphPad Prism. Preliminary studies showed that under these conditions, sodium-dependent Pi uptake was linear for at least 30 min and tolerated 0.6 % (v/v) DMSO without deleterious effects.

To ascertain if an inhibitor was competitive for binding with phosphate, the procedure was repeated, but raising the concentration of the substrate in the assay mixture from 0.1 to 2.1 mM phosphate. Compounds that maintained their potency for inhibition of NaPi2b in the presence of 2.1 vs 0.1 mM phosphate were considered to not be competitive with respect to phosphate.

Table 2

Inhibitory Activity of Compounds Against Rat and Human NaP2b Values Reported a pIC50.

pIC50 range for pIC50 range for Competitive with

Example rat ap2b human Nap2b* respect to Pi?**

4 5.1- 6.0

2 5.1- 6.0

6 4.5 -5.0

7 5.1- 6.0

16 4.5 -5.0

8 4.5 -5.0

5 4.5 -5.0

13 5.1- 6.0

g 4.5 -5.0

1 5.1- 6.0

14 4.5 -5.0

12 5.1- 6.0

* A blank mdicates not tested

** Indicates compound is considered to not be competitive with respect to phosphate. A blank indicates not tested for competitive inhibition.

EXAMPLE 19

In vivo Assay: Bolus Phosphate Challenge

It has been demonstrated that the hyperphosphatemia response to a single oral dose of phosphorus is significantly dampened in mice deficient in the Nap2b gene (Sabbagh et al, J. Am Soc Nephrol., 20(l l):2348-58 (2009)). By pretreating animals with a low phosphorus diet followed by the subsequent dosing of a phosphorus bolus, serum phosphorus levels were monitored after 30 minutes as a surrogate for intestinal phosphorus absorption. These investigators showed that as a result of Np2b deletion, the rise in serum phosphorus was reduced by about 40%. This indicates that the theoretical maximum effect on phosphorus absorption a Nap2b inhibitor could have in mice is 40% as indicated by the serum Pi. The in vivo bolus phosphorus challenge model used here mimics this model in rats.

Male, 7-week-old Sprague-Dawley rats (Charles-River laboratories international, Hollister, CA) were allowed to acclimate for a minimum of 3 days before switching to a synthetic low-phosphorus diet (TD.85010, Harlan Teklad, Madison, WI) which contains 0.1% phosphorus and 0.6% calcium. At day 5, testing compounds or vehicle alone (as indicated) were orally administered at the indicated dose in a volume of 5 ml/kg, followed by a bolus gavage of monobasic sodium phosphate (1 mmol in 1 ml ) 15 min after compound dosing. Serum was collected via retroorbital bleeding 30 min post phosphate bolus and phosphate levels were determined utilizing an ACE ALERA blood chemistry analyzer (Alfa Wassermann Diagnostic Technologies, West Caldwell, NJ).

The extent of inhibition by test compounds on the elevation of serum phosphate levels in response to the bolus of phosphate is shown in Table 3 (data are expressed as % Inhibition, with 6-10 animals per data point). The differences between groups were evaluated by one-way analysis of variance with Dunnett's post hoc tests. Table 3

Inhibition of Uptake of Phosphorus from the Intestine as Measured using the Bolus Phosphorus Challenge Model

* p < 0.05, versus vehicle by Dunnett's post hoc test.

** p < 0.01, versus vehicle by Dunnett's post hoc test.

*** p < 0.001, versus vehicle by Dunnett's post hoc test.

EXAMPLE 20

In vivo Evaluation Procedure: Co-Dosing in Chow Male, 7-week-old Sprague-Dawley rats (Charles-River laboratories international, Hollister, CA) were allowed to acclimatize for a minimum of 3 days. The experiment was initiated by switching animals to a synthetic diet (0.6% phosphorus and 0.6% calcium, Harlan Teklad TD.84122) for four days. After this time, the animals were placed into metabolic cages for daily monitoring of food and water consumption, as well as urine and fecal collections. Test compounds were incorporated into the powdered diet listed above containing 3% chocolate flavoring (w/w, BioServ #7345) at 1.3 mg test compound per gram of diet to achieve an average daily nominal dose of 100 mg kg/day. The actual dose received by each animal was later determined by measuring prepared diet consumption and body weight. Urine samples were collected in three daily periods from 24-48, 48-72, and 72-96 hours of drug dosing. Averaging these three 24 h periods allows for the more representative measurements of urination, fecal excretion, food consumption and water uptake for each animal. Phosphorus levels in the urine were determined by anion exchange chromatography using a Dionex ICS-3000 ion chromatography system. Urine samples were diluted 1:500 or 1:1000 and injected onto an IonPac AS 18 analytical column (2 x 250 mm) using a potassium hydroxide eluent. Blution of urine phosphate ions was monitored via conductivity detector and reported as ppm relative to a standard ion solution containing phosphorus. Daily urinary P output relative to the P consumed in the prepared diet for each animal was calculated. The percentage inhibition of phosphorus absorption was estimated by determining the reduction of this ratio compared to the control group (animals with no drug in chow). The differences between the means of control and treated groups were evaluated by t tests. In all experiments, one group was always included that had Renvela powder blended into their chow at 0.9% targeting a dose of 750 mg/kg. Typically this resulted in an approximately 15% inhibition of Urine Pout/P consumed.

Table 4

Inhibition of Uptake of Phosphorus from the Intestine as Measured using the Co-Dosing in Chow Model

p< 0.05 versus control ; ** p<0.01 versus control; *** pO.001 versus control

EXAMPLE 21

Stability of Compounds in Simulated Gastric and Intestinal Fluid

Test compounds were incubated at 1-20 μΜ in simulated gastric fluid (SGF; standard USP solution with 3 mg mL pepsin) or simulated intestinal fluid (SIF; standard USP solution with 3 mg/mL pancreatin) for 3 hr or 6 hr. HPLC-UV or HPLC- MS were used to determine test compound levels using peak area %. Results (Table 5) were reported as the percentage of test compound remaining after incubation in a given condition relative to test compound present at t = 0 in the same condition. Table 5

Percentage of Compound Remaining in Simulated Gastric and Intestinal Fluids

EXAMPLE 22

Determination of Compound Cmax and AUC Sprague-Dawley rats were orally gavaged with test article at a nominal dose of 2.5 or 10 mg/kg and blood was collected at 0.5, 1, 2 and 4 h. Blood samples were processed to plasma using K ₂ EDTA as an anticoaglulant. Plasma samples were treated with acetonitrile containing an internal standard, precipitated proteins removed by centrifugation. Supernatants were analyzed by LC-MS/MS and compound concentrations were determined by interpolated from a standard curve prepared in plasma. Table 6 illustrates data from the pharmacokinetic profiling of selected example compounds. All compounds were orally dosed at the dosage shown, and pharmacokinetic parameters determined.

Table 6

Pharmacokinetic Profiling of Selected Example Compounds

LLOQ= Lower Limit of Quantification

EXAMPLE 23

Fecal Recovery of Orally Administered Compounds Quantitative determination of test compound level in feces after oral gavage was performed using the same set of animals used to determine test compound concentration in plasma (Example 22). The animals were kept in metabolic cages and feces were collected from the time of dosing until 48 hr after dosing. Upon collection, feces was dried by lyophilization and ground to a visually homogenous powder. Duplicate samples of ground feces from each individual animal were weighed out and extracted using organic solvent. Extracted samples were then diluted into mobile phase and test compound levels were quantitatively determined by LC-MS/MS analysis as described in "Example 22" except that the standard curve was prepared in a feces matrix. Extraction conditions were not optimized for individual compounds, and thus may represent a minimal level of recovery.

Table 7

Fraction of Orally Administered Compound Recovered in Feces 48 Hours after Dosing

EXAMPLES FOR COMPOUNDS OF STRUCTURE (IV)

EXAMPLE 1

3-(3-q4-(Piperidin-l-vn-2-(6-(trifluoromethvn-lH-indole-2 - carbonyl)phenyUcarbamoyl)beiizylthio)propanoic acid

Scheme 1, 1. HOCH ₂ CH ₂ OH, TsOH, toluene; 2. piperidine; 3. HC1; 4. PhS0 ₂ Cl, NaH; 5. LDA, intermediate lc; 6. DMSO, oxalyl dichloride; 7. ¾, Pd/C; 8. methyl acrylate, DBU, acetonitrile; 9. oxaloyl chloride, dichloromethane; 10. intermediates lg and li, pyridine; 11. Tetrabutylammonium fluoride; 11. LiOH.

Intermediate la: 2-f5 _' Chloro-2-nitrophenylV1.3-dioxolane. Into a 250 mL 3-neck round bottom flask was placed a solution of 5-chloro-2-nitrobenzaldehyde (7.6 g, 40.86 mmol, 1.00 equiv) in toluene (150 mL), ethane- 1,2-diol (2.9 g, 46.77 mmol), and p-toluenesulfonic acid monohydrate (350 mg, 2.03 mmol, 0.05 equiv). The resulting solution was heated to reflux under a Dean-Stark trap overnight. The resulting mixture was diluted with 300 mL of water. The solution was extracted with 3 x 100 mL of ethyl acetate and the organic layers combined. The resulting mixture was washed with l x 300 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This resulted in 9.3 g (99%) of intermediate la as a brown oil that was used without further characterization.

Intermediate lb, l-(3-( 1.3-Dioxolan-2-yl1-4-mttophenvnpiperidine. Into a 500 mL round bottom flask, was placed 2-(5-chloro-2-nitrophenyl)-l ,3-dioxolane (9.3 g, 40.43 mmol, l .OO equiv) and piperidine (172 g, 2.02 mol, 50.04 equiv). The resulting solution was heated to reflux overnight. The mixture was concentrated under vacuum. The resulting solution was diluted with 100 mL of dichloromethane and 200 mL of water. The phases were separated and the resulting solution was extracted with 3 x 100 mL of dichloromethane. The organic layers were combined. The mixture was washed with 1 x 200 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This resulted in 1 1 g (98%) of intermediate lb as brown oil.

Intermediate lc: 2-Nitro-5-(piperidin-l-yl)benzaldehvde, Into a 500 mL round bottom flask, was placed a solution of l-(3-(l,3-dioxolan-2-yl)-4-nitrophenyl) piperidine (11 g, 39.57 mmol, l.OO equiv) in tetrahydrofuran (250 mL), water (100 mL), and 3N hydrochloric acid (50 mL). The resulting solution was heated to reflux for 2 h in an oil bath. The mixture was concentrated under vacuum. The solids were collected by filtration. The filter cake was washed with 2 x 40 mL of water and 2 x 40 mL of hexane. This resulted in 9 g (97%) of intermediate lc as a yellow solid.

Intermediate Id: l-( ^" PhenylsulfonylV6-(trifluoromethylVlH-indole. Into a 100 mL 3-neck round bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of 6-(trifluoromethyl)-lH-indole (3.7 g, 20.00 mmol, 1.00 equiv) in N,N-dimethylformamide (50 mL). This was followed by the addition of sodium hydride (750 mg, 21.88 mmol, 1.09 equiv, 70%) in several batches at 0°C. The resulting solution was stirred for 1 h at 0°C in an ice/salt bath. To this was added benzenesulfonyl chloride (3.90 g, 22.03 mmol, 1.10 equiv) dropwise with stirring at 0°C. The resulting solution was stirred for 1 h at 0°C. The solution was diluted with 100 mL of water. The solids were collected by filtration. The residue was applied onto a silica gel column and eluted with ethyl acetate PE (1 :10). This resulted in 4 g (60%) of intermediate Id as a yellow solid.

Intermediate le: (2-Nitro-5-(piperidin-l-yl)phenyl)(l-(phenylsulfonyl)-6-(tri fluoro- methyl)- 1 H-indol-2-yl)methanol . Into a 50 mL 3-neck round bottom flask purged and maintained with an inert atmosphere of nitrogen was placed a solution of diisopropylamine (888 mg, 8.79 mmol, 1.90 equiv) in tetrahydrofuran (5 mL). This was followed by the addition of n-BuLi (3.7 mL, 2.5M) dropwise with stirring at -20°C. The mixture was warmed to 0°C slowly and stirred for 30 min. To this was added a solution of l-(phenylsulfonyl)-6-(trifluoromethyl)-lH-indole (1.5 g, 4.62 mmol, 1.00 equiv) in tetrahydrofuran (5 mL) dropwise with stirring at -80°C. The mixture was warmed to 0°C slowly and stirred for 1 h. To the mixture was added a solution of 2-nitro-5- (piperidin-l-yl)benzaldehyde (1.08 g, 4.62 mmol, 1.00 equiv) in tetrahydrofuran (5 mL) dropwise with stirring at -80°C. The mixture was stirred for 30 min at 80°C and then 4 h at room temperature. The reaction was then quenched by the addition of 5 mL of water. The resulting solution was extracted with 20 mL of ethyl acetate and the organic layers combined and dried over sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate PE (1 :10). This resulted in 1.2 g (46%) of intermediate le as a yellow solid.

Intermediate 1 f : (2-Nitro-5-(piperidin- 1 -yl)phenyl)( 1 -(phenylsulfonyl)-6-(trifluoro- methyl)- 1 H-indol-2-yl)methanone. Into a 50 mL 3 -neck round bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of dimethlysulfoxide (156 mg, 2.00 mmol, 3.73 equiv) in dichloromethane (5 mL). This was followed by the addition of oxalyl dichloride (127 mg, 1.00 mmol, 1.87 equiv) dropwise with stirring at -80°C. The resulting solution was stirred for 10 min at -80°C in a liquid nitrogen bath. To this was added a solution of (2-nitro-5-(piperidin-l- yl)phenyl)( 1 -(phenylsulfonyl)-6-(trifluoromethyl)- 1 H-indol-2-yl)methanol (300 mg, 0.54 mmol, 1.00 equiv) in dichloromethane (5 mL) dropwise with stirring at -80°C. The resulting solution was stirred for an additional 60 min at -80°C. To the mixture was added triethylamine (400 mg, 3.96 mmol, 7.39 equiv) dropwise with stirring at -80°C. The resulting solution allowed to warm to -20°C over 60 minutes. The solution was diluted with 50 mL of DCM. The mixture was washed with 1 x 30 mL of water and 1 x 30 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This resulted in 300 mg of intermediate If as orange oil.

Intermediate lg: f2-Amino-5-(piperidin-l-vDphenviyi-(phenylsulfonyl')-6-(trif luoro- methyl)- 1 H-mdol-2-yl)methanone. Into a 50 mL 3-neck round bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of (2-nitro-5- (piperidin- 1 -yl)phenyl)( 1 -(phenylsulfonyl)-6-(trifluoromethyl)- 1 H-indol-2- yl)methanone (300 mg, 0.51 mmol, 1.00 equiv, 95%) in methanol (10 mL), and wet palladium on carbon (0.15 g). The resulting solution was stirred overnight at 10°C under an atmosphere of hydrogen gas. The mixture was filtered. The filtrate was concentrated under vacuum. This resulted in 0.25 g (88%) of intermediate lg as a red solid.

Intermediate lh: (3-(Y3-Methoxy-3-oxopropylthio)memyl)benzoic acid. Into a 50-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was added a solution of 3-(mercaptomethyl)benzoic acid (500 mg, 2.97 mmol, 1.00 equiv) in acetonitrile (10.0 mL), followed by methyl acrylate (10.0 mL) and 1,8- Diazabicyclo[5.4.0]undec-7-ene (DBU; 1.0 g, 6.57 mmol, 2.00 equiv). The resulting solution was heated to reflux overnight, then concentrated under vacuum and the residue was applied onto a silica gel column, eluting with ethyl acetate/petroleum ether (0-1:6). This resulted in 220 mg (28%) of intermediate lh as light-red oil. Intermediate li: Methyl 3-(3-(cMorocarbonyl benzyl1mo)propanoate. Into a 50-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen, was placed a solution of 3-((3-methoxy-3-oxopropylthio)methyl)benzoic acid (61.6 mg, 0.24 mmol, 1.00 equiv) in dichloromethane (5 mL). This was followed by the addition of oxaloyl dichloride (121.76 mg, 0.96 mmol, 4.00 equiv) dropwise with stirring at room temperature. Then a few drops of Ν,Ν-dimethylformamide was addded as catalyst and the resulting solution was heated to reflux for 30 min. The reaction mixture was concentrated under vacuum to afford 60 mg (crude) of intermediate li as yellow oil.

Intermediate li: Methyl 3-(3-((2-(l-(phenylsulfonyl1-6-(trifluoromethyl)-lH-indole-2 - carbonylV4-(piperidin-l-vnphenvDcarbamovnbenzylthio)propanoa te. Into a 50 mL 3-neck round bottom flask was placed a solution of (2-amino-5-(piperidin-l-yl) phenyl)(l -(phenylsulfonyl)-6-(trifluoromethyl)- 1 H-indol-2-yl)methanone (300 mg, 0.57 mmol, 1.00 equiv) in tetrahydrofuran (10 mL) and a solution of methyl 3-(3- (chlorocarbonyl)benzylthio)propanoate (180 mg, 0.66 mmol, 1.16 equiv) in tetrahydrofuran (3 mL). This was followed by the addition of pyridine (80 mg, 1.01 mmol, 1.78 equiv) dropwise with stirring. The solution was stirred for 3 h at 10°C. The resulting solution was diluted with 50 mL of ethyl acetate. The mixture was washed with 1 x 30 mL of water and 1 x 30 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This resulted in 0.4 g intermediate lj as red oil,

Intermediate lk: Methyl 3-r3-( 4- Diperidin -ylV2-(6-(trifluoromemvn H-indole-2- carbonyllphenyl) carbamoyllbenzylthiolpropanoate. Into a 50 mL 3-neck round bottom flask, was placed a solution of methyl 3-(3-((2-(l-(phenylsulfonyl)-6-(trifluoromethyl)- 1 H-indole-2-carbonyl)-4-(piperidin- 1 -yl)phenyl)carbamoyl) benzylthio)propanoate (300 mg, 0.33 mmol, 1.00 equiv, 85%) in methanol (5 mL), and 5 mL of a 1M solution of tetrabutylammonium fluoride in THF. The resulting solution was heated to reflux for 6 h in an oil bath. The solution was diluted with 30 mL of ethyl acetate. The resulting mixture was washed with 1 x 20 mL of water and 1 x 20 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column and eluted with ethyl acetate/petroleum ether (1:5). This resulted in 150 mg (72%) of intermediate lk as a red solid.

Example 1 : 3-r3-(f4-fPiperidin -yl -2-f6-(trifluoromethyl)-lH-indole-2-carbonylV phenyll-carbamoyll benzylthio^propanoic acid. Into a 50 mL round bottom flask, was placed a solution of methyl 3-(3-((4-(piperidin-l-yl)-2-(6-(trifluoromethyl)-lH-indole- 2-carbonyl)phenyl)carbamoyl)benzylthio)-propanoate (60 mg, 0.10 mmol, l.OO equiv) in tetrahydrofuran (5 mL), and a solution of lithium hydroxide hydrate (100 mg, 2.50 mmol, 26.00 equiv) in water (2 mL). The solution was stirred overnight at 15°C. The solution was then diluted with 30 mL of water. The mixture was washed with 1 x 20 mL of ethyl acetate. The pH value of the solution was adjusted to 5 with IN hydrochloric acid. The resulting solution was extracted with 2 x 30 mL of ethyl acetate and the organic layers combined and dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was dissolved in 2 mL of ether. The product was precipitated by the addition of hexane. The solids were collected by filtration. This resulted in 20 mg (34%) of 3-(3-((4-(piperidin-l-yl)-2-(6-(trifluoromethyl)-lH-indole- 2-carbonyl)phenyl)-carbamoyl)-benzylthio)-propanoic acid as a orange solid. 'H-NM (300MHz, DMSO,ppm): δ 12.30 (IH, s), 10.36 (s, IH), 7.94-7.91 (d, IH), 7.76 (s, IH), 7.68-7.58 (m, 2H), 7.65 (s, IH), 7.47-7.44 (d, IH), 7.40-7.32 (m, 2H), 7.25-7.24 (d, 2H), 7.12 (s, IH), 3.74 (s, 2H), 3.19 (s, 4H), 2.5 (m, 4H), 1.56-1.64 (m, 6H), MS (ES, m/z): 610 [M+H] ⁺ .

EXAMPLE 2

Nl-Methyl-Nl-(2-morpholinoethvn-N3-(4-fpiperidiii-l-ylV2- (6-(trifluoromethyl)- lH-indole-2-carbonyl)phenyl)isophthalamide 2,2,2-tiifluoroacetate

2d

Scheme 2. 1. oxalyl dichloride, DCM, DMF; 2. (Boc) ₂ 0, TEA, DCM; 3. LiAltt,, THF; 4. Intermediate 2a, DCM, TEA; 5. LiOH, THF, H ₂ 0; 6. oxalyl dichloride, DMF; 7. Intermediate lg, pyridine; 8. Tetrabutylammonium fluoride.

Intermediate 2a: Methyl 3-(chlorocarbonvDbenzoate. To a solution of 3- (methoxycarbonyl)benzoic acid (6.2 g, 34.44 mmol, 1.00 equiv) in dichloromethane (50 mL) was added oxalyl dichloride (8.74 g, 69.37 mmol, 2.00 equiv) and N,N- dimethylformamide (DMF; cat.) and the resulting solution was stirred for 1 h at 40°C in an oil bath. The resulting mixture was concentrated under vacuum to afford 6.6 g (87%) of intermediate 2a as brown oil.

Intermediate 2b: Tert-butyl 2-morpholinoethylcarbamate. To 2-morpholino- ethanamine (10 g, 76.92 mmol, 1.00 equiv) in dichloromethane (50 mL) was added triethylamine (5.83 g, 57.72 mmol, 0.50 equiv). This was followed by the addition of Di-tert-butyl dicarbonate (18.44 g, 84.59 mmol, 1.10 equiv) at 0-5°C and the resulting solution was stirred overnight at 25°C. The reaction mixture was diluted with 200 mL of dichloromethane and then washed with 1x30 mL of 10% sodium bicarbonate and 1x30 mL of brine. The organic layer was dried over sodium sulfate and concentrated under vacuum to afford 16 g (81%) of intermediate 2b as an off-white solid.

Intermediate 2c: N-Methyl-2-morpholinoethanamine. To a solution of LiAlH4 (7.72 g, 208.65 mmol, 3.00 equiv) in tetrahydrofuran (THF; 60 mL) stirring at 0-5°C was added dropwise a solution of tert-butyl 2-morpholinoethylcarbamate (16 g, 62.61 mmol, 1.00 equiv, 90%) in THF (40 mL). The resulting solution was stirred for 2 h at 70°C in a oil bath bath, allowed to cool and then quenched by the addition of 7.7 mL of water, 7.7 mL of 15% sodium hydroxide and 23.1 mL of water. The solids were filtered out, then the mixture was dried over sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column, eluting with dichloromethaneimethanol (0.5% triethylamine) (20:1) to afford 4.2 g (42%) of intermediate 2c as brown oil. Intermediate 2d: Methyl 3-(memyl 2-moφholinoethyl carbamoyl benzoate■ To a solution of N-methyl-2-morpholinoethanamine (2.1 g, 13.12 mmol, 1.00 equiv, 90%) in dichloromethane (20 mL) at 0-5°C was added triethylamine (1.47 g, 14.55 mmol, 1.00 equiv) followed by the dropwise addition of a solution of methyl 3- (chlorocarbonyl)benzoate (3.3 g, 15.00 mmol, 1.20 equiv, 90%) in dichloromethane (10 mL). The resulting solution was stirred for 3 h at room temperature. The mixture was then diluted with 100 mL of dichloromethane and then washed with 1x30 mL of 10% sodium bicarbonate and 1x30 mL of brine. The organic layer was dried over sodium sulfate, concentrated under vacuum, and the residue was applied onto a silica gel column eluting with dichloromethane:methanol (20:1) to afford 4.4 g (99%) of intermediate 2d as a brown solid.

Intermediate 2e: 3-(Methyl(2-morpholinoethyl)carbamoyl)benzoic acid. To a solution of methyl 3-(methyl(2-morpholinoethyl)carbamoyl)benzoate (4.4 g, 13.66 mmol, 1.00 equiv, 95%) in tetrahydrofuran/water (15/10 mL) was added lithium hydroxide hydrate (1.77 g, 43.17 mmol, 3.00 equiv) and the resulting solution was stirred for 1 h at 25°C. The resulting mixture was concentrated under vacuum, diluted with 10 mL of water, and the pH value of the solution was adjusted to 2-3 with hydrogen chloride. The resulting mixture was washed with 2x30 mL of ethyl acetate, and then the aqueous layer was concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetatemethanol (4:1) to afford 2.7 g (65%) of intermediate 2e as a white solid.

Intermediate 2f: 3-(Methyl(2-morphoIinoethyl carbamoyl)benzoyl chloride. Into a 50 mL round bottom flask was placed 3-(methyl(2-morpholinoethyl)carbamoyl)benzoic acid (300 mg, 1.03 mmol, l.OO equiv), oxalyl dichloride (6 mL), and Ν,Ν-dimethylformamide (1 drop). The resulting solution was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum. This resulted in 300 mg (94%) intermediate 2f as a white solid.

Intermediate 2g: Nl-Methvl-Nl-(2-morpholinoethyl)-N3-(2-(l-(phenylsulfonyl)-6 - (trifluoromemyl)-lH-indole-2-carbonyl)-4-(piperidin-l-yl)phe nyl)isophthalamide. Into a 50 mL round bottom flask was placed a solution of (2-amino-5-(piperidin-l- yl)phenyl)(l -(phenylsulfonyl)-6-(trifluoromethyl)-lH-indol-2-yl)methanon e (20 mg, 0.04 mmol, l.OO equiv) in dichloromethane (5 mL), pyridine (30 mg, 0.38 mmol, 10.00 equiv), and 3-(methyl(2-morpholinoethyl)carbamoyl)benzoyl chloride (18 mg, 0.06 mmol, 1.50 equiv). The resulting solution was stirred for 2 h at room temperature. The mixture was washed with 1 x 50 mL of water. The mixture was concentrated under vacuum. The crude product was washed with water. This resulted in 20 mg (66%) of intermediate 2g as red oil.

Example 2 : N 1 -Methyl-N 1 -(2-morpholinoethyl ^' l-N3 -(4-(piperidin- 1 -ylV2-(6- trifluoro- methylVlH-indole-2-carbonvnphenvnisophthalamide 2,2.2 -trifluoroacetate. Into a 50 mL round bottom flask was placed a solution of Nl-methyl-Nl-(2- moφholinoethyl)-N3-(2-(l-( henylsulfonyl)-6-(trifluoromethyl)-lH-indole-2- carbonyl)-4-(piperidin-l-yl)phenyl)-isophthalamide (300 nig, 0.37 mmol, 1.00 equiv) in methanol (7 mL), and 7 mL of a IN solution of tetrabutylammonimu fluoride in THF. The resulting solution was stirred overnight at 85°C. The mixture was concentrated under vacuum. The residue was dissolved in 50 mL of ethyl acetate. The resulting mixture was washed with 4x50 mL of water. The mixture was dried over sodium sulfate and concentrated under vacuum. The crude product (300 mg) was purified by reverse phase (C18) HPLC, eluting with water (0.05% TFA) and C¾CN (0.05% TFA) gradient (25%-44% CH ₃ CN over 6 min) to afford 202 mg (68%) of Nl-methyl-Nl-(2- morpholinoethyl)-N3 -(4-(piperidin- 1 -yl)-2-(6-(trifluoromethyl)-l H-indole-2- carbonyl)phenyl)isophthalamide 2,2,2-trifluoroacetate as a yellow solid. Ή-NMR (300MHz, CD ₃ OD, ppm): δ 8.28 (d, J=9.0Hz, 1H), 8.02 (m, 2H), 7.94 (m, 2H), 7.84 (s, 1H), 7.71 (m, 2H), 7.62 (m, 1H), 7.35 (m, 1H), 7.26 (s, 1H), 4.11 (m, 2H), 3.93 (m, 3H), 3.77 (m, 3H), 3.53 (m, 6H), 3.32 (m, 2H), 3.06 (s, 3H), 1.94 (m, 4H), 1.77 (m, 2H). MS (ES, m/z): 662 [M+H] ⁺ .

EXAMPLE 3

N-(2-Methoxyethvn-3-(3-(4-(piperidm^^

carbonyl)phenylcarbamoyl)benzylthio)benzamide

Scheme 3, 1. Intermediate lg, pyridine, dichloromethane; 2. 3-mercaptobenzoic acid, Et ₃ N; 3. methoxyethylamine, EDC ' HCl, DMAP; 4. TBAF.

indole-2-carbonyl)-4-(piperidin- 1 -vnphenyllbenzamide. Intermediate 3a was prepared from 3-(bromomethyl)benzoylchloride and intermediate lg by a procedure similar to that used to prepare intermediate lh.

Intermediate 3b: 3-(3-(2-(l-(PhenylsulfonYlV6-ftrifluoromethyl'>-lH-indole -2- carbonvD-4-(piperidin- 1 -yltphenylcarbamovnbenzylthio benzoic acid. Into a 100-mL round-bottom flask was placed a solution of 3-(bromomethyl)-N-(2-(l- ( henylsulfonyl)-6-(trifluoromemyl)-lH-indole-2-carbonyl)-4-(p iperidin-l- yl)phenyl)benzamide (200 mg, 0.28 mmol, 1.00 equiv) in acetonitrile (20 mL), 3- mercaptobenzoic acid (50 mg, 0.32 mmol, 1.20 equiv), and triethylamine (90 mg, 0.89 mmol, 3.00 equiv). The resulting solution was stirred overnight at 45°C. The resulting mixture was concentrated under vacuum. The residue was dissolved in 60 ml of ethyl acetate. The resulting mixture was washed with 2x30 mL of water. The mixture was dried over sodium sulfate and concentrated under vacuum. This resulted in 200 mg of intermediate 3b as a red solid.

Intermediate 3c: N-(2-Methoxyethyl)-3-( ^, 3-(2-(l-(phenylsulfonyl ^' )-6-(trifluoromethyl ^" )- lH-indole-2-carbonylV4-(piperidin-l-yDphenylcarbamoylVbenzyl thio)benzarnide. Into a 100-mL round-bottom flask, was placed a solution of 3-(3-(2-(l-(phenylsulfonyl)-6- (trifluoromethyl)- 1 H-indole-2-carbonyl)-4-(piperidin-l - yl)phenylcarbamoyl)benzylthio)-benzoic acid (220 mg, 0.28 mmol, 1.00 equiv) in dichloromethane (20 mL), EDC HC1 (80 mg, 0.42 mmol, 1.50 equiv), 4- dimethylaminopyridine (51 mg, 0.41 mmol, 1.50 equiv), and 2-methoxyethanamine (42 mg, 0.56 mmol, 2.00 equiv). The resulting solution was stirred for 2 h at 25°C. The resulting mixture was washed with 2x10 mL of aqueous NH CI. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. This resulted in 200 mg (85%) of intermediate 3c as a red solid.

Example 3: N-(2-MemoxyemylV3-(3-(4-(piperidin-l-ylV2-(6-(trifluoromethy l)-lH- indole-2-carbonyl)phenylcarbamoyl)ben2ylthio)benzamide. Into a 50-mL round- bottom flask was placed a solution of N-(2-methoxyethyl)-3-(3-(2-(l-(phenylsulfonyl)- 6-(trifluoromethyl)-lH-indole-2-carbonyl)-4-(piperidin-l- yl)phenylcarbamoyl)benzylthio)-benzamide (200 mg, 0.23 mmol, 1.00 equiv) in methanol (3.5 mL), and 3.5 mL of a 1.0 N solution of tetrabutylammonium fluoride in THF. The resulting solution was stirred overnight at 80°C. The resulting mixture was concentrated under vacuum. The residue was dissolved in 50 mL of ethyl acetate. The resulting mixture was washed with 3x20 mL of water. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product (100 mg) was purified by HPLC with the following conditions (Waters 2767-3): Column, SunFire Prep C18, 19x150mm 5um; mobile phase, water with 0.05% TFA and CH ₃ CN (gradient of 49% to 61% CH3CN over 6 min); Detector, Waters 2545 LTV Detector 254 and 270 nm. This resulted in 38.1 mg (17%) of N-(2-methoxyethyl)-3-(3-(4-(piperidin-l- yl)-2-(6-(trifluoromethyl)-lH-indole-2-carbonyl)- phenylcarbamoyl)benzylthio)benzamide as a orange solid. Ή-NMR (300MHz, CD3OD, ppm): δ 8.38(d, J=9Hz, IH), 8.01(d, J=3Hz, IH), 7.91-7.87(m, 2H), 7.78-7.73(m, 4H), 7.62-7.59(m, IH), 7.53-7.51(m, IH), 7.47-7.26(m, 5H), 4.23(s, 2H), 3.62-3.57(m, 4H), 3.53(s, 3H), 3.35-3.34(m, 2H), 1.98-1.96(m, 4H), 1.79-1.77(m, 2H). MS (ES, m/z): 715 [M+H] ⁺ .

EXAMPLE 4

Procedure for the Measurement of NaP2b-Mediated Pi Transport Materials. HEK293 cells were obtained from the American Type Culture collection and propagated per their instructions. Expression clones for rat and human NaP2b (SLC34A2) were obtained from Open Biosystems (Catalog numbers MRN1768-9510282, and MHS1010-99823026, respectively). The sequence of the human protein was mutated to insert a threonine after residue 37, and to introduce a N39D mutation.

Inhibition of Pi Transport. The rate of phosphate (Pi) uptake into HEK293 cells was measured using a modification of the method described by Mohrmann et al. (Mohrmann, I., Mohrmann, M., Biber, J., and Murer, H. (1986) Am. J. Phys. 250(3 Pt l):G323-30.) Transfected HEK293 cells were treated with a pharmacological agent to minimize endogenous PiT-mediated phosphate transport activity, such that the only remaining sodium-dependent phosphate transport activity is that which was bestowed by introduction of the NaP2b genes.

Cells were seeded into 96-well plates at 25,000 cells/well and cultured overnight. Lipofectamine 2000 (Invitrogen) was used to introduce the NaP2b cDNA, and the cells were allowed to approach confluence during a second overnight incubation. Medium was aspirated from the cultures, and the cells were washed once with choline uptake buffer (14 mM Tris, 137 mM choline chloride, 5.4 mM KC1, 2.8 mM CaCl ₂ , 1.2 mM MgS0 ₄ , 100 uM KH2PO4, 1 mg/mL Bovine Serum Albumin, pH 7.4). Cells were then overlayed with either choline uptake buffer or sodium uptake buffer (14 mM Tris, 137 mM sodium chloride, 5.4 mM KC1, 2.8 mM CaCl ₂ , 1.2 mM MgS04, 100 uM KH2PO4, PiT-silencing agent, 1 mg/mL Bovine Serum Albumin, pH 7.4) containing 6-9 uCi/mL ³³ P orthophosphoric acid (Perkin Elmer) and test compound. Each compound was tested at twelve concentrations ranging from 0.1 nM to 30 uM. Assays were run in duplicate.

After incubation for 3-30 minutes at room temperature, assay mixtures were removed, and the cells were washed twice with ice cold stop solution (137 mM sodium chloride, 14 mM Tris, pH 7.4). Cells were lysed by addition of 20 μL 0.1% Tween 80 followed by 100 uL scintillation fluid, and counted using a TopCount (Perkin Elmer). pIC50 (the negative log of the IC50) values of the test compounds were calculated using GraphPad Prism. Preliminary studies showed that under these conditions, sodium-dependent Pi uptake was linear for at least 30 min and tolerated 0.6 % (v/v) DMSO without deleterious effects.

To ascertain if an inhibitor was competitive for binding with phosphate, the procedure was repeated, but raising the concentration of the substrate in the assay mixture from 0.1 to 2.1 mM phosphate. Compounds that maintained their potency for inhibition of NaPi2b in the presence of 2.1 vs 0.1 mM phosphate were considered to not be competitive with respect to phosphate.

Table 1

Inhibitory activity of compounds against rat and human NaP2b values reported as pIC50,

* A blank indicates not tested

** Indicates compound is considered to not be competitive with respect to phosphate. A blank indicates not tested for competitive inhibition.

EXAMPLE 5

In Vivo Evaluation Procedure: Co-Dosing in Chow

Male, 7-week-old Sprague-Dawley rats (Charles-River laboratories international, Hollister, CA) were allowed to acclimate for a minimum of 3 days. The experiment was initiated by switching animals to a synthetic diet (0.6% phosphorus and 0.6% calcium, Harlan Teklad TD.84122) for four days. After this time, the animals were placed into metabolic cages for daily monitoring of food and water consumption, as well as urine and fecal collections. Test compounds were incorporated into the powdered diet listed above containing 3% chocolate flavoring (w/w, BioServ #7345) at 1.3 mg test compound per gram of diet to achieve an average daily nominal dose of 100 mg kg/day. The actual dose received by each animal was later determined by measuring prepared diet consumption and body weight. Urine samples were collected in three daily periods from 24-48, 48-72, and 72-96 hours of drug dosing. Averaging these three 24 h periods allows for the more representative measurements of urination, fecal excretion, food consumption and water uptake for each animal. Phosphorus levels in the urine were determined by anion exchange chromatography using a Dionex ICS- 3000 ion chromatography system. Urine samples were diluted 1:500 or 1:1000 and injected onto an IonPac AS 18 analytical column (2 x 250 mm) using a potassium hydroxide eluent. Elution of urine phosphate ions was monitored via conductivity detector and reported as ppm relative to a standard ion solution containing phosphate. Daily urinary P output relative to the P consumed in the prepared diet for each animal was calculated. The percentage inhibition of phosphorus absorption was estimated by determining the reduction of this ratio compared to the control group (animals with no drug in chow). The differences between the means of control and treated groups were evaluated by / tests.

Table 2

Inhibition of uptake of phosphorus from the intestine as measured using the co-dosing in chow model

* p< 0.05 versus control; ** p<0.01 versus control; *** p<0.001 versus control

EXAMPLE 6

Determination of Compound Cmax and AUC

Sprague-Dawley rats were orally gavaged with test article at a nominal dose of 2.5 or 10 mg kg and blood was collected at 0.5, 1, 2 and 4 h. Blood samples were processed to plasma using K ₂ EDTA as an anticoaglulant. Plasma samples were treated with acetonitnle containing an internal standard, precipitated proteins removed by centrifugation. Supernatants were analyzed by LC-MS/MS and compound concentrations were determined by interpolated from a standard curve prepared in plasma. Table 3 illustrates data from the pharmacokinetic profiling of selected example compounds. All compounds were orally dosed at the dosage shown, and pharmacokinetic parameters determined.

Table 3

Pharmacokinetic profiling of representative compounds Example Actual Oral AUC

Dose LLOQ ¹ Cmax (ng x

(mg/kg) (ng mL) (ng mL) hr/mL)

1 7.5 10 299 433

2 11 0.5 91 < 97.0

¹ LLOQ= Lower Limit of Quantification

EXAMPLE 7

Fecal Recovery of Orally Administered Compounds

Quantitative determination of test compound level in feces after oral gavage was performed using the same set of animals used to determine test compound concentration in plasma (Example 6). The animals were kept in metabolic cages and feces were collected from the time of dosing until 48 hr after dosing. Upon collection, feces was dried by lyophilization and ground to a visually homogenous powder. Duplicate samples of ground feces from each individual animal were weighed out and extracted using organic solvent. Extracted samples were then diluted into mobile phase and test compound levels were quantitatively determined by LC-MS/MS analysis as described in Example 6 except that the standard curve was prepared in a feces matrix.

Table 4

Fraction of orally administered compound recovered in feces 48 hours after dosing

EXAMPLES FOR COMPOUNDS OF STRUCTURE (V) Example 1

Synthesis of (E)-l-(3-(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene) hydrazinecarbonyl)-4-(piperidin-l-yl)phenylcarbamoyl)phenyl) - 5,8,ll,14,17,20,23,26-octaoxa-2-thianonacosan-29-oic acid

Scheme 1. 1. Piperidine, K ₂ C0 ₃ DMF, 75 °C; 2. ¾, Pd/C, MeOH; 3. hydrazine hydrate; 4. Aldehyde, EtOH, RT; 5. DIEA, DCM, THF; 6. Thiol, K ₂ C0 ₃₎ DMF, RT.

Intermediate lb: methyl 2-nitro-5-(piperidin-l-yl) benzoate: A mixture of methyl-5- chloro-2-nitrobenzoate la (100 mmol, 21.5g), potassium carbonate (200 mmol, 28.0g), and piperidine (105 mmol, 8.95g) in Ν,Ν-dimethylformamide (DMF; 150 mL) was stirred at 75 °C for 6 hours. The solvent was evaporated and the residue diluted with dichloromethane (DCM; 200 mL) and then passed through a short plug of silica gel. After the solvent was removed the yellow solid was triturated twice with 100 mL of hexane/CH ₂ Cl ₂ (95/5) and then dried to afford 20.5 g (89%) of lb as bright yellow solid.

Intermediate lc: methyl 2-amino-5-(piperidin-l-yl)benzoate: To methyl 2-nitro-5- (piperidin-l-yl) benzoate lb (89 mmol, 20.5g) in methanol (30 mL) was added Pd/C (wet form, 5g) was and the suspension stirred under a hydrogen atmosphere for 1 hour. The resulting mixture was filtered and concentrated and the crude solid was then recrystallized from 3% methylene chloride in hexane to afford 17.8 g (86%) of lc.

Intermediate Id: 2-amino-5-(piperidin-l-yl)benzohydrazide: To methyl 2-amino-5- (piperidin-l-yl)benzoate lc (60 mmol, 14g) in ethanol (60 mL) was added hydrazine hydrate (60mL) and the mixture was heated to reflux for 7 hours. The solvent and excess hydrazine were removed by vacuum and the crude product was tntrated with 175 mL of 1:1 (CH ₂ Cl ₂ /hexane) to afford 13.5g (95%) of Id.

Intermediate le: (E)-2-amino-N'-(4-chlor6-3-(trifluoromethyl)benzylidene)-5- (piperidin-l-yl)benzohydrazide: To 2-amino-5-(piperidin-l-yl)benzohydrazide Id (11.3 mmol, 2.65g) in ethanol (22 mL) was added 4-chloro-3- (trifluoromethyl)benzaldehyde (12.5 mmole, 1.8mL) and the reaction was stirred for 4 hours. The resulting mixture was filtered and the isolated solid tritrated with methanol (lOOmL) twice and then dried to give 3.7g (77%) of le.

Intermediate If: (E)-N-(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene) hydrazinecarbonyl)-4-(piperidin-l-yl)phenyl)-3-(chloromethyl )benzamide: To a mixture of (E)-2-amino-N'-(4-chloro-3-(trifluoromethyl)benzylidene)-5-( piperidin-l- yl)benzohydrazide le (10 mmol, 4.24g) and diisopropylethylamine (3.48 mL) in tetrahydrofuran (THF; 40 mL) was added 3-(chloromethyl)benzoyl chloride dropwise and the resulting solution was then stirred for an additional 2 hours. After removing solvent the residue was triturated with 40 ml of ethyl acetate twice and 40 mL of water twice and then dried to afford 3.7 gram of If.

Example 1 : (E)-l-(3-(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene) hydrazinecarbonyl)-4-(piperidin-l-yl)phenylcarbamoyl)phenyl) - 5,8,ll,14,17,20,23,26-octaoxa-2-thianonacosan-29-oic acid: To (E)-N-(2-(2-(4- chloro-3-(trifluoromethyl)benzylidene) hydrazinecarbonyl)-4-(piperidin-l-yl)phenyl)-3- (chloromethyl)benzamide If (3.8 mmol, 1.89g) in DMF (15 mL) was added 1- mercapto-3,6,9,12,15,18,21,24-octaoxaheptacosan-27-oic acid (4.2 mmole, 1.5g) and potassium carbonate (1.8g) and the reaction stirred for 4 hours. The resulting mixture was then separated by preparative HPLC to afford 2.4g (63 %) of Example 1. 'H-NMR (300MHz, CD ₃ OD): δ 8.70 (d, J= 9.2 Hz, 1H), 8.42 (s, 1H), 8.30 (s, 1H), 8.08 (d, /= 2.8 Hz, 1H), 8.02 (d, J= 6.8 Hz, 1H), 7.96 (s, 1H), 7.86 (d, J= 7.8 Hz, 1H), 7.75 (dd, J = 2.7, 8.8 Hz, 1H), 7.69 (d, J = 8.4 Hz, 1H), 7.61 (d, J = 7.8 Hz, 1H), 7.50 (t, J = 7.8 Hz, lH), 3.90 (s, 2 H), 3.70 (t, J= 6.3 Hz, 2H), 3.52-3.69 (m, 34H), 2.59 (t, J= 6.5 Hz, 1H), 2.51 (t, J= 6.4 Hz, 2H), 2.02 (m, 4H), 1.79 (m, 2H). MS (ES, m/z): 999 [M+H] ⁺ .

Example 2

Synthesis of (E)-N-(2-(2-(4-chloro-3- (trifluoromethyl)benzylidene)hydrazinecarbonyl)-4-(piperidin -l-yl)phenyl)-3-(25- hydroxy-5,8,ll,14,i7,20,23-heptaoxa-2-thiapentacosyl)benzami de 2

Example 2 was prepared analogously to Example 1 from 23-mercapto- 3,6,9,12,15,18,21-heptaoxatricosyl acetate, and was isolated as a side product from the reaction mixture as a deacylation product in 17% yield. 'H-NMR (300MHz, CDCI3): δ 12.81 (s, 1H), 12.17 (s, 1H), 9.15 (m, 2H), 8.70 (s, 1H), 8.12 (s, 1H), 7.95 (m, 3H), 7.56 (m, 4H), 3.84 (s, 2 H), 3.40-3.70 (m, 34H), 2.62 (t, J= 3.6 Hz, 2H), 2.16 (m, 4H), 1.79 (m, 2H). MS (ES, m/z): 927 [M+H] ⁺ .

Example 3

Synthesis of (E)-l-(3-(2-(2-(4-chloro-3- (trifluoromethyl)benzylidene)hydrazinecarbonyl)-4-(piperidin -l- yl)phenylcarbamoyl)phenyl)-5,8,ll,14,17,20,23-heptaoxa-2-thi apentacosan- acetate

Example 3 was prepared analogously to Example 1 from 23-mercapto- 3,6,9,12,15,18,21-heptaoxatricosyl acetate, and isolated in 40% yield. Ή- MR (300MHz, CDC1 ₃ ): δ 12.82 (s, 1H), 12.18 (s, 1H), 9.15 (m, 2H), 8.70 (s, 1H), 8.11 (s, 1H), 7.95 (m, 3H), 7.56 (m, 4H), 4.19 (m, 2H), 3.84 (s, 2 H), 3.40-3.70 (m, 32H), 2.62 (t, J= 6.6 Hz, 2H), 2.16 (m, 4H), 1.79 (m, 2H). MS (ES, m/z): 969 [M+H] ⁺ .

Example 4

Synthesis of (E)-Nl-(2-(2-(4-chloro-3- (triflnoromethyl)benzylidene)hydrazinecarbonyl)-4-(piperidin -l-yl)phenyl)-N3-(3- hydroxypropyl)isophthaIamide

Scheme 2. 1. DIEA, HATU, DMF; 2. DIEA, HATU, DMF

Compound 4a: (E)-3-(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene) hydrazinecarbonyl)-4-(piperidin-l-yl)phenylcarbamoyl)benzoic acid: To a mixture of (E)-2-amino-N'-(4-chloro-3-(trifluoromethyl)benzylideae)-5-( piperidin-l- yl)benzohydrazide le (0.5 mmol, 212mg) and isophthalic acid (2.5mmol, 415mg) in DMF (3 mL) was added 0-(7-azabenzotriazol-l-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU; 1.1 equiv, 215mg) and diisopropylethylamine (DIEA; 2.0 mmol, 350 μί) and the resulting solution was stirred for 2 hours. After removing solvent the residue was triturated with 5 mL of methanol twice to furnish 226 mg (79%) of product after drying.

Compound 4: (E)-Nl-(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene) hydrazinecarbonyl)-4-(piperidin-l-yl)phenyl)-N3-(3- hydroxypropyl)isophthalamide To a mixture of (E)-3-(2-(2-(4-chloro-3- (trifluoromethyl)benzylidene) hydrazinecarbonyl)-4-(piperidin- 1 - yl)phenylcarbamoyl)benzoic acid 4a (0.05 mmol, 29mg) in DMF (0.5 mL) was added 3-aminopropan-l-ol (O.lmmol, 8μί), HATU (1.1 equiv, 25mg) and diisopropylethylamme (25μΙ_,) and the resulting solution was stirred for 2 hours. The reaction was purified by preparative HPLC to afford l lmg (35%) of product. Ή-NMR (300MHz, i¾-DMSO): δ 12.20 (s, 1H), 11.13 (s, 1H), 8.59 (m, 1H), 8.45 (s, 1H), 8.35 (s, 1H), 8.12 (m, 2H), 8.05 (m, 3H), 7.79 (d, J= 8.3 Hz, 1H), 7.62 (t, J = 7.8 Hz, 1H), 7.34 (m, 1H), 7.24 (m, 1H), 3.44 (t;J = 6.5 Hz, 2H), 3.30 (m, 2H), 3.23 (m, 4H), 1.66 (m, 4H), 1.55 (m, 2H). MS (ES, m/z): 630 [M+H] ⁺ .

Example 5

Synthesis of (E)-Nl-(2-(2-(4-chloro-3- (trifluoromethyl)benzyIidene)hydrazinecarbonyl)-4-(piperidin -l-yl)pheny])-N3-(2- (2-hydroxyethoxy)ethyl)isophthalamide

The title compound was prepared in 76% yield from Intermediate 4a and 2-(2- aminoethoxy)ethanol using similar procedures described for the preparation of Example 4. Ή-NMR (300MHz, c¾-DMSO): δ 12.19 (s, 1H), 11.12 (s, 1H), 8.65 (m, 1H), 8.45 (s, 1H), 8.36 (s, 1H), 8.13 (m, 2H), 8.00 (m, 3H), 7.79 (d, J = 8.5 Hz, 1H), 7.62 (t, J = 7.6 Hz, IH), 7.32 (m, IH), 7.25 (m, IH), 3.52 (t, J= 6.1 Hz, 2H), 3.47 (t, J= 6.4 Hz, 2H), 3.42 (m, 4H), 3.22 (m, 4H), 1.66 (m, 4H), 1.54 (m, 2H). MS (ES, m/z): 660 [M+H] ⁺ .

Example 6

Synthesis of (E)-tert-bufyl l-(3-(2-(2-(4-chloro-3- (trifluoromethyl)benzylidene)hydrazinecarbonyl)-4-(piperidii i-l- yl)phenylcarbamoyl)phenyl)-l-oxo-5,8,ll-trioxa-2-azatetradec an-14-oate

The title compound was prepared in 53% yield from Intermediate 4a and tert-butyl 3- (2-(2-(2-aminoethoxy)ethoxy)ethoxy)propanoate using the procedures described in Example 4. 'H-NMR (300MHz, <¾-DMSO): δ 12.20 (s, IH), 11.14 (s, IH), 8.67 (m, IH), 8.45 (s, IH), 8.36 (s, IH), 8.12 (m, 2H), 8.00 (m, 3H), 7.79 (d, J = 8.4 Hz, IH), 7.62 (t, J= 7.6 Hz, IH), 7.35 (m, IH), 7.26 (m, IH), 3.35-3.55 (m, 14H), 3.23 (m, 4H), 3.34 (t, J = 6.3 Hz, 2H), 1.66 (m, 4H), 1.54 (m, 2H), 1.34 (s, 9H). MS (ES, m/z): 832 [M+H] ⁺ .

Example 7

Synthesis of (E)-l-(3-(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene) hydrazinecarbonyl)-4-(piperidin-l-yl)phenylcarbamoyl)benzyl) -lH-l,2,3-triazole-

4,5-dicarboxylic acid

Example 7a: (E)-3-(azidomethyl)-N-(2-(2-(4-chloro-3-

(trifluoromethyl)benzylidene)hydrazinecarbonyl)-4-(piperi din-l- yl)phenyl)benzamide: To (E)-N-(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene) hydrazinecarbonyl)-4-(piperidin- 1 -y l)phenyl)-3 -(chloromethyl)benzamide If (6.42 mmol, 3.7g) in DMF (50 mL) was added sodium azide (3 equiv, 1.25g) and the mixture was stirred for 2 hours at 45 °C. After the solvent was removed the residue was triturated with 40 ml of ethyl acetate twice and 40 mL of water twice and then dried to afford 3.58 g of product.

Example 7: (E)-l-(3-(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene) hydrazinecarbonyl)-4-(piperidin-l-yl)phenylcarbamoyl)benzyl) -lH-l,2,3-triazole- 4,5-dicarboxylic acid: (E)-3-(azidomethyl)-N-(2-(2-(4-chloro-3-

(trifluoromethy])benzylidene) hydrazinecarbonyl)-4-(piperidin- 1 -yl)phenyl)benzamide 7a (0.119 mmol, 69mg) was fully dissolved in DMF (1.5mL) at an elevated temperature and then cooled to ambient temperature. To this was added but-2-ynedioic acid (0.15 mmol, 17mg), and copper iodide (5 mole %; lmg) and the mixture stirred for 18 hours. The crude mixture was then purified by preparative HPLG to afford 63 mg (76%) of Example 7. 'H-NMR (300MHZ, <¾-DMSO): δ 12.18 (s, 1H), 11.10 (s, 1H), 8.46 (s, 1H), 8.10 (m, 3H), 7.80 (m, 3H), 7.55 (m, 2H), 7.20 (m, 2H), 5.70 (s, 2H), 3.17 (m, 4H), 1.62 (m, 4H), 1.54 (m, 2H). MS (ES, m/z): 640 [M+H-C0 ₂ ] ⁺ .

Example 8

Synthesis of (E)-N-(2-(2-(4-chloro-3- (trifluoromethyl)benzyUdene)hydrazinecarbonyl)-4-(piperidin- l-yl)phenyl)-3-((4- (hydroxymethyl)-lH-l,2,3-triazol-l-yl)methyl)benzamide

The title compound was prepared in 40% yield from Intermediate 7a and prop-2-yn-l- ol using the procedures described in Example 7. Ή-NMR (300MHz, c¾-DMSO): δ 12.18 (s, 1H), 11.10 (s, 1H), 8.46 (s, lH), 8.14 (s, 1H), 8.09 (d, J= 9.2 Hz, 1H), 8.03 (s, 1H), 8.02 (d, J= 10.7 Hz, 1H), 7.80 (m, 3H), 7.25 (d, J= 2.4 Hz, 1H), 7.17 (dd, J= 2.4, 9.0 Hz, 1H), 5.65 (s, 2H), 5.11 (t, J = 5.7 Hz, 1H), 4.47 (d, J = 5.7 Hz, 2H), 3.17 (m, 4H), 1.62 (m, 4H), 1.54 (m, 2H). MS (ES, m/z): 640 [M+H] ⁺ .

Example 9

Synthesis of (E)-N-(2-(2-(4-chloro-3- (trifluoromethyl)benzylidene)hydrazinecarbonyl)-4-(piperidin -l-yl)phenyl)-3-((4- (2-hydroxyethyI)-lH-l,2,3-triazol-l-yl)methyl)benzamide

The title compound was prepared in 31% yield from Intermediate 7a and but-3-yn-l-ol using the procedures described in Example 7. Ή- MR (300MHz, CD ₃ OD): δ 8.36 (s, 1H), 8.30 (s, 1H), 8.25 d, J= 9.4 Hz, 1H), 8.02 (d, J= 8.1 Hz, 1H), 7.91 (m, 2H), 7.83 (s, 1H), 7.67 (d, J= 7.80 Hz, 1H), 7.52 (m, 2H), 7.36 (s, 1H), 7.22 (d, J= 9.1 Hz, 1H), 5.66 (s, 2H), 3.76 (t, J= 6.6 Hz, 2H), 3.23 (m, 4H), 2.87 (t, J = 6.3 Hz, 2H), 1.74 (m, 4H), 1.61 (m, 2H). MS (ES, m/z): 654 [M+H] ⁺ .

Example 10

Synthesis of (E)-3-((4-(aminomethyI)-lH-l,2,3-triazol-l-yl)methyl)-N-(2-( 2-(4- chloro-3-(trifluoromethyl)benzylidene)hydrazinecarbonyl)-4-( piperidin-l- yl)phenyl)benzamide

The title compound was prepared in 78% yield from Intermediate 7a and prop-2-yn-l- amine using the procedures described in Example 7. Ή-NMR (300MHz, CD3OD, TFA salt): δ 8.62 (d, / = 9.0 Hz, IH), 8.45 (s, IH), 8.32 (s, IH), 8.12 (s, IH), 8.01 (m, 2H), 7.95 (m, IH), 7.91 (s, IH), 7.70 (m, 2H), 7.58 (s, 2H), 5.75 (s, 2H), 4.22 (t, J= 6.2 Hz, 2H), 3.56 (m, 4H), 1.98 (m, 4H), 1.76 (m, 2H). MS (ES, m/z): 639 [M+H] ⁺ .

Example 11

Synthesis of (E)-2-amino-3-(l-(3-(2-(2-(4-chloro-3- (trifluoromethyl)benzylidene)hydrazmecarbonyl)-4-(piperidin- l- yl)phenylcarbamoyl)benzyl)-lH-l,2,3-triazol-4-yl)propanoic acid

The title compound was prepared in 5% yield from Intermediate 7a and 2-aminopent-4- ynoic acid using the procedures described in Example 7. Ή-NMR (300MHz, d6- DMSO): δ 12.21 (s, IH), 11.12 (s, IH), 8.47 (s, IH), 8.22 (br, 2H), 8.14 (s, IH), 8.10 (d, = 8.8 Hz, IH), 8.03 (m, 2H), 7.88 (s, IH), 7.82 (m, 2H), 7.53 (m, 2H), 7.27 (s, IH), 7.19 (d, J= 9.0 Hz, IH), 5.67 (s, 2H), 4.22 (m, IH), 3.17 (m, 6H), 1.53 (m, 4H), 1.47 (m, 2H). MS (ES, m/z): 697 [M+H] ⁺ .

Example 12

Synthesis of (E)-4-(l-(3-(2-(2-(4-chloro-3- (trifluoromethyl)benzylidene)hydrazinecarbonyI)-4-(piperidin -l- yl)phenylcarbamoyl)benzyl)-lH-l,2,3-triazol-4-yl)benzoic acid

The title compound was prepared in 40% yield from Intermediate 7a and 4- ethynylbenzoic acid using the procedures described in Example 7. Ή-NMR (300MHz, DMSO): δ 12.20 (s, IH), 11.18 (s, IH), 8.79 (s, IH), 8.46 (s, IH), 8.13 (m, 2H), 7.94 (m, 6H), 7.83 (m, IH), 7.77 (d, J = 8.6 Hz, IH), 7.58 (m, 2H), 7.32 (s, IH), 7.23 (m, IH), 5.79 (s, 2H), 3.20 (m, 4H), 1.64 (m, 4H), 1.53 (m, 2H). MS (ES, m z): 730 [M+H] ⁺ .

Example 13

Synthesis of (E)-3-amino-4-(l-(3-(2-(2-(4-chloro-3- (trifluoromethyl)benzylidene)hydrazineearbonyl)-4-(piperidin -l- yl)phenylcarbamoyl)benzyl)-lH-l,2,3-triazol-4-yl)butanoic acid

The title compound was prepared in 99% yield from Intermediate 7a and 3-aminohex- 5-ynoic acid using the procedures described in Example 7. Yield was 99%. Ή-NMR (300MHz, <¾-DMSO): δ 12.22 (s, IH), 11.15 (s, IH), 8.47 (s, IH), 8.12 (m, 2H), 8.06 (s, IH), 8.00 (d, J = 8.6 Hz, IH), 7.80 (m, 5H), 7.50 (m, 2H), 7.34 (s, IH), 7.23 (d, 9.2 Hz, IH), 5.66 (s, 2H), 3.68 (m, IH), 3.21 (m, 4H), 2.94 (d, J= 6.5 Hz, 2H), 2.54 (m, 2H), 1.65 (m, 4H), 1.54 (m, 2H). MS (ES, m/z): 711 [M+H] ⁺ .

Example 14

(E)-N-(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene)hydrazi necarbonyl)-4- (piperidin-l-yl)phenyl)-3-((4-((3,7-dimethyl-2,6-dioxo-2,3,6 ,7-tetrahydro-lH- purin-1 -yl)methyl)-l H-l ,2,3-triazol-l -yl)methyl)benzamide

The title compound was prepared in 48% yield from Intermediate 7a and 3,7-dimethyl- l-(prop-2-ynyl)-lH-purine-2,6(3H,7H)-dione using the procedures described in Example 7. NMR (300MHz, CDC1 ₃ ): σ 11.36(s, IH), 10.71(s, IH), 8.52(s, IH), 8.36- 8.39 (d, IH), 7.97-8.04 (m, 4H), 7.63 (s, IH), 7.47-7.57 (m, 5H), 7.10 (s, IH), 5.60 (s, 2H), 5.33 (s, 2H), 3.95 (s, 3H), 3.54 (s, 3H), 3.07 (s, 4H), 1.50-1.63 (d, 6H); MS (ES, m/z): 802 [ +H] ⁺ .

Example 15

Synthesis of (E)-N-(2-(2-(4-chloro-3- (trifluoromethyl)benzylidene)hydrazinecarbonyl)-4-(piperidin -l-yl)phenyl)-3-((4- (3-hydroxypropyl)-lH-l,2,3-triazol-l-yl)methyl)benzamide

The title compound was prepared in 32% yield from Intermediate 7a and pent-4-yn-l-ol using the procedures described in Example 7. Ή-NMR (300MHz, CD ₃ OD): δ 8.37 (s, 1H), 8.31 (s, 1H), 8.27 (d, /= 9.0 Hz, 1H), 8.02 (d, J= 7.9 Hz, 1H), 7.93 (m, 2H), 7.80 (s, 1H), 7.68 (d, J = 8.3 Hz, 1H), 7.51 (m, 2H), 7.38 (s, 1H), 7.24 (d, J = 9.2 Hz, 1H), 5.66 (s, 2H), 3.53 (d, J= 6.5 Hz, 2H), 3.21 (m, 4H), 2.74 (d, J= 7.9 Hz, 2H), 1.85 (tt, J = 6.5, 7.9 Hz, 2H), 1.75 (m, 4H), 1.63 (m, 2H). MS (ES, m/z): 668 [M+H] ⁺ .

Example 16

Synthesis of (E)-5-(l-(3-(2-(2-(4-chloro-3- (trifluoromethyl)benzylidene)hydrazinecarbonyl)-4-(piperidin -l- yl)phenylcarbamoyl)benzyl)-lH-l,2,3-triazol-4-yl)pentanoic acid

The title compound was prepared in 32% yield from Intermediate 7a and hept-6-ynoic acid using the procedures described in Example 7. Ή-NMR (300MHz, CD ₃ OD): δ 8.61 (d, J= 9.0 Hz, 1H), 8.39 (s, 1H), 8.32 (s, 1H), 8.03 (d, J = 9.0 Hz, 1H), 7.94 (m, 3H), 7.83 (s, 1H), 7.70 (m, 2H), 7.55 (m, 2H), 5.67 (s, 2H), 3.59 (m, 4H), 2.69 (t, J= 7.1 Hz, 2H), 2.26 (t, J= 7.2 Hz, 2H), 1.99 (m, 4H), 1.77 (m, 2H), 1.66 (m, 2H), 1.60 (m, 2H). MS (ES, m z): 710 [M+H] ⁺ .

Example 17

Synthesis of (E)-9-(l-(3-(2-(2-(4-chloro-3- (trifluoromethyl)benzylidene)hydrazinecarbonyl)-4-(piperidin -l- yl)phenylcarbamoyl)benzyl)-lH-l,2,3-triazol-4-yl)nonanoic acid

The title compound was prepared in 44% yield from Intermediate 7a and undec-10- ynoic acid using the procedures described in Example 7. 'H-NMR (300MHz, CDCI ₃ ): δ 12.79 (s, 1H), 12.11 (s, 1H), 9.08 (m, 2H), 8.66 (s, 1H), 8.12 (s, 1H), 8.04 (d, J = 7.8 Hz, 1H), 7.97 (s, 1H), 7.89 (d, J= 9.2 Hz, 1H), 7.54 (m, 3H), 7.42 (d, J= 7.3 Hz, 1H), 7.33 (s, 1H), 7.25 (s, 1H), 5.60 (s, 2H), 3.47 (m, 4H), 2.67 (t, J= 7.6 Hz, 2H), 2.26 (m, 2H), 2.17 (m, 4H), 1.60 (m, 2H), 1.50 (m, 4H), 1.23 (m, 8H). MS (ES, m/z): 766 [M+H] ⁺ .

Example 18

Synthesis of (E)-N-(2-(2-(4-chloro-3- (trifluoromethyl)benzylideiie)liydrazinecarbonyl)-4-(piperid in-l-yl)phenyl)-3-((4- (2-(2-(2-(2-chloroethoxy)ethoxy)ethoxy)ethyl)-lH-l,2,3-triaz ol-l- yl)methyl)benzamide

Scheme 4. 1.NaH, but-3-yn-l -ol; 2. Cul, DMF

Intermediate 18a: 4-(2-(2-(2-chloroethoxy)ethoxy)ethoxy)but-l-yne. To a solution of but-3-yn-l-ol (20 mmol, 1.51 mL) and l,2-bis(2-chloroethoxy)ethane (10 eq, 31.4 mL) cooled to 0 °C was added sodium hydride (1.25eq, lg, 60% pure) portionwise over a course of 5min. The reaction was stirred at 0 °C for 2 hours, then warmed to ambient temperature and stirred for an additional 16 hours. Methylene chloride (lOOmL) was then added followed by extraction with hexane (3xl00mL). The combined f actions were concentrated under vacuum to remove excess 1 ,2-bis(2-chloroethoxy)ethane, and the remaining residue was found to contain 3.2 g of a l-to-3 ratio of 18a and l,2-bis(2- chloroethoxy)ethane (20% yield), which was used in the next step without further purification.

Example 18: (E)-N-(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene)- hydrazinecarbonyl)-4-(piperidin-l-yl)phenyl)-3-((4-(2-(2-(2- (2-chloroethoxy)- ethoxy)ethoxy)ethyl)-lH-l,2,3-triazol-l-yl)methyl)benzamide. The title compound was prepared in 63% yield from Intermediate 7a and Intermediate 18a using the procedures described in Example 7. ^-NMR (300MHz, CD ₃ OD): δ 8.54 (d, J = 9.0 Hz, lH), 8.40 (s, 1H), 8.30 (s, 1H), 8.03 (d, J= 8.8 Hz, 1H), 7.93 (m, 3H), 7.83 (s, 1H), 7.67 (d, J= 8.0 Hz, 1H), 7.54 (m, 3H), 5.68 (s, 2H), 3.60 (m, 18H), 2.92 (m, 2H), 1.92 (m, 4H), 1.73 (m, 2H). MS (ES, m/z): 804 [M+H] ⁺ .

Example 19

Synthesis of (E)-N-(2-(2-(4-chloro-3- (trifluoromethyl)benzylidene)hydrazinecarbonyl)-4-(piperidin -l-yl)phen

(4-hydroxybutyl)-lH-l,2,3-triazol-l-yl)methyl)benzamide

The title compound was prepared in 57% yield from Intermediate 7a and hex-5-yn-l-ol using the procedures described in Example 7. Ή-NMR (300MHz, CD ₃ OD): δ 8.69 (d, J = 9.2 Hz, 1H), 8.42 (s, 1H), 8.31 (s, 1H), 8.11 (s, 1H), 8.02 (d, J= 8.2 Hz, 1H), 7.90 (m, 2H), 7.84 (s, 1H), 7.77 (dd, J= 2.7, 9.2 Hz, 1H), 7.79 (d, J= 8.2 Hz, 1H), 7.56 (m, 2H), 5.67 (s, 2H), 3.64 (m, 4H), 3.52 (t, J = 6.5 Hz, 2H), 2.69 (t, J= 6.4 Hz, 2H), 2.01 (m, 4H), 1.79 (m, 2H), 1.69 (m, 2H), 1.54 (m, 2H). MS (ES, m/z) 804 [M+H] ⁺ .

Example 20

Synthesis of (E)-3-((4-(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)-lH-l, 2,3- triazol-l-yl)methyl)-N-(2-(2-(4-chloro-3- (trifluoromethyl)benzylidene)hydrazinecarbonyl)-4-(piperidin -l- yl)phenyl)benzamide

Scheme 5. 1. NaN ₃ , DMF

To (E)-N-(2-(2-(4-chloro-3-(trifluoromethyl)berizylidene)hydraz inecarbonyl)-4- (piperidin-l-yl)phenyl)-3-((4-(2-(2-(2-(2-chloroethoxy)ethox y)ethoxy)ethyl)-lH-l,2,3- triazol-l-yl)methyl)benzamide (Example 18; 1.20 mmol, 960mg) in DMF (1.2 mL) was added sodium azide (5 equiv, 390mg) and the reaction was stirred for 4 hours at 90 °C. The crude mixture was then purified by preparative HPLC to afford 650mg (67%) of Example 20. 'H-NMR (300MHz, CD ₃ OD): δ 8.43 (d, J = 9.0 Hz, 1H), 8.37 (s, 1H), 8.29 (s, 1H), 8.01 (d, J= 8.2 Hz, 1H), 7.93 (m, 2H), 7.88 (s, 1H), 7.67 (m, 2H), 7.52 (m, 2H), 7.44 (d, J = 9.0 Hz, 1H), 5.67 (s, 2H), 3.69 (t, J = 6.5 Hz, 2H), 3.52 (m, 12H), 3.39 (m, 4H), 2.92 (d, J= 6.4 Hz, 2H), 1.85 (m, 4H), 1.69 (m, 2H). MS (ES, m/z): 811 [M+H] ⁺ .

Example 21 Synthesis of N-(2-((E)-2-(4-chloro-3- (trifluoromethyl)benzylidene)hydrazinecarbonyl)-4-(piperidin -l-yl)phenyl)-3-((4- (((3S,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro -2H-pyraii-2- yloxy)methyl)-lH-l,2,3-triazoI-l-yl)methyl)benzamide

Scheme 6. 1. prop-2-yn-l-ol, sulfuric acid-silica; 2. Cul, DMSO

Intermediate 21a: (2R,3R,4R,5R)-2-(hydroxymethyl)-6-(prop-2- ynyIoxy)tetrahydro-2H-pyran-3,4,5-triol. To glucose (3.0 g, 16.65 mmol, 1.00 equiv) was added prop-2-yn-l-ol (5 mL) and sulfuric acid-silica (100 mg) and the mixture was stirred for 3 h at 65°C. The residue was then purified by silica gel chromatography, eluting with petroleum ether/ethyl acetate (25:1~10:1) to afford 2.0 g (55%) of (3S,4S,5S,6S)-2-(hydroxymethyl)-6-(prop-2-ynyloxy)-tetrahydr o- 3,4,5-triol 21a as a light yellow syrup.

Example 21. N-(2-((E)-2-(4-chloro-3-(trifluoromethyl)benzylidene)hydrazi ne- carbonyl)-4-(piperidin-l-yl)phenyl)-3-((4-(((3S,4R,5R,6S)-3, 4,5-trihydroxy-6- (hydroxymethyl)tetrahydro-2H-pyran-2-yloxy)methyl)-lH-l,2,3- triazol-l- yl)methyl)benzamide. The title compound was prepared in 16 % yield from Intermediate 7a and Intermediate 21a using the procedures described in Example 7. Ή-NMR (300MHz, DMSO,ppm): 12.22(s, IH), 11.16(s, IH), 8.71(s, 2H), 8.50(s, IH), 8.04-8.21(m, 4H), 7.83-7.91(m, 3H), 7.51-7.62(m, 2H), 7.29(s, IH), 7.20-7.23(d, IH), 5.71(s, 2H), 4.84-4.85(d, IH), 4.76-4.77(d, IH), 4.65-4.72(m, 3H), 4.48-4.53(m, 2H), 3.61-3.64(m, IH), 3.38-3.49(m, 3H), 3.03-3.22(m, 6H), 1.58-1.66(d, 6H). MS (ES, m/z): 802 [M+H] ⁺ .

Example 22

Synthesis of (E)-3-(l-(3-(2-(2-(4-chloro-3- (trifluoromethyl)benzylidene)hydrazinecarbonyl)-4-(piperidin -l- yl)phenylcarbamoyl)benzyl)-lH-l,2,3-triazol-4-yl)propanoic acid

The title compound was prepared in 30% yield from Intermediate 7a and pent-4-ynoic acid using the procedures described in Example 7. Ή-NMR (300MHz, <¾-DMSO): δ 12.22 (s, 1H), 11.15 (s, 1H), 8.45 (s, 1H), 8.14 (m, 2H), 8.00 (d, J= 8.6 Hz, 1H), 7.91 (s, 1H), 7.82 (m, 3H), 7.54 (dd, J = 7.6, 7.7 Hz, 1H), 7.46 (d, J = 7.7 Hz, 1H), 7.41 (s, 2H), 7.31 (d, J= 8.2 Hz, 1H), 5.61 (s, 2H), 3.26 (m, 4H), 2.80 (t, J= 7.4 Hz, 2H), 2.53 (t, J= 7.4 Hz, 2H), 1.68 (m, 4H), 1.55 (m, 2H). MS (ES, m/z): 682 [M+H] ⁺ .

Example 23

Synthesis of (E)-4-(l-(3-(2-(2-(4-chloro-3- (trifluoromethyl)benzylidene)hydrazinecarbonyl)-4-(piperidin -l- yl)phenylcarbamoyl)benzyl)-lH-l,2,3-triazol-4-yl)butanoic acid

The title compound was prepared in 57% yield from Intermediate 7a and hex-5-ynoic acid using the procedures described in Example 7. Yield was 57%. ¾-NMR (300MHz, i¾-DMSO): 8 12.22 (s, 1H), 11.16 (s, 1H), 8.45 (s, 1H), 8.14 (m, 2H), 8.01 (d, J = 7.3 Hz, 1H), 7.93 (s, 1H), 7.80 (m, 3H), 7.54 (dd, J= 7.5, 7.8 Hz, 1H), 7.45 (m, 2H), 7.32 (d, J= 7.2 Hz, 1H), 5.61 (s, 2H), 3.26 (m, 4H), 2.58 (t, J= 7.6 Hz, 2H), 2.20 (t, J= 7.4 Hz, 2H), 1.78 (tt, J= 7.4, 7.6 Hz, 2H), 1.72 (m, 4H), 1.55 (m, 2H). MS (ES, m/z): 696 [M+H] ⁺ .

Example 24

Synthesis of (E)-2-(l-(3-(2-(2-(4-chloro-3- (trifluoromethyl)benzylidene)hydrazinecarbonyl)-4-(piperidin -l- yl)phenylcarbamoyl)benzyI)-lH-l,2,3-triazol-4-yl)-2-hydroxya cetic acid

The title compound was prepared in 79% yield from Intermediate 7a and 2-hydroxybut- 3-ynoic acid using the procedures described in Example 7. Ή-NM (300MHz, d6- DMSO): δ 12.19 (s, IH), 11.12 (s, IH), 8.45 (s, IH), 8.11 (m, 3H), 8.01 (d, J= 8.2 Hz, IH), 7.88 (s, IH), 7.79 (m, 2H), 7.54 (m, 2H), 7.32 (s, IH), 7.23 (d, J = 7.6 Hz, IH), 5.66 (s, 2H), 5.09 (s, IH), 3.21 (m, 4H), 1.65 (m, 4H), 1.53 (m, 2H). MS (ES, m/z): 684 [M+H] ⁺ .

Example 25

Synthesis of (E)-3-((4-(2r(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethyl)-lH-l, 2,3- triazol-l-yl)methyl)-N-(2-(2-(4-chloro-3- (trifluoromethyl)benzylidene)hydrazinecarbonyl)-4-(piperidin -l- yl)phenyl)benzamide

Scheme 7. 1. ¾, Pd C, MeOH

Example 25. To (E)-3-((4-(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)-lH-l, 2,3- triazol-l-yl)methyl)-N-(2-(2-(4-chloro-3-

(teifluoromethyl)beii2ylidene)hydra^

(Example 20; 0.802 mmol, 650 mg) in methanol (20 mL) was added Pd C (wet, 200 mg) and the reaction stired under a hydrogen atmosphere for 1 hour. The suspension was then filtered, concentrated and then purified by preparative HPLC to afford 350mg (55%) of Example 25. Ή-NMR (300MHz, c¾-D SO, TFA salt): δ 12.20 (s, 1H), 11.15 (s, 1H), 8.46 (s, 1H), 8.12 (m, 2H), 8.00 (d, J= 7.3 Hz, 1H), 7.94 (s, 1H), 7.81 (m, 3H), 7.70 (m, 3H), 7.52 (m, 2H), 7.30 (s, 1H), 7.20 (d, J = 8.5 Hz, 1H), 5.62 (s, 2H), 3.52 (m, 12H), 3.18 (m, 4H), 2.92 (m, 2H), 2.69 (d, J = 6.9 Hz, 2H), 1.62 (m, 4H), 1.53 (m, 2H). MS (ES, m/z): 785 [M+H] ⁺ .

Example 26

Synthesis of (E)-3-(l-(3-(2-(2-(4-chloro-3- (trifluoromethyl)benzylidene)hydrazinecarbonyl)-4-(piperidin -l- yl)phenylcarbamoyl)benzyl)-lH-l,2,3-triazol-4-yl)propylphosp honic acid

Scheme 8. 1. PBr ₃ , Et ₂ 0; 2. P(OEt) ₃ ; 3. 26b, Cul, DMSO; 4. TMSBr, DMF

26a

Intermediate 26a. 5-bromopent-l-yne. To pent-4-yn-l-ol (2.0 g, 23.81 mmol, 1.00 equiv) in ether (30 mL) was added tribromophosphine (3.2 g, 11.95 mmol, 0.50 equiv) dropwise with stirring at -10-0°C and the mixture was stirred for 2 h. The reaction was then quenched by the addition of 20 mL of saturated aqueous NH CI, the pH value of the solution was adjusted to 7-8 with 5% sodium bicarbonate, and then extracted with 3x50 mL of ether. The organic layers were combined, dried over anhydrous sodium sulfate and concentrated under vacuum to afford 1.8 g (51%) of Intermediate 26a as colorless oil

26b

Intermediate 26b: diethyl pent-4-ynylphosphonate. Into a 50-mL sealed tube purged and maintained with an inert atmosphere of nitrogen was placed 5-bromopent-l- yne 26a (1.8 g, 12.24 mmol, 1.00 equiv) and triethyl phosphite (3.0 g, 18.05 mmol, 1.47 equiv) and the resulting solution was stirred for 3 days at 160°C. The residue was purified via silica gel chromatography (ethyl acetateidichloromethane, 1:30~1:50) to afford 0.4 g (16%) of diethyl pent-4-ynylphosphonate 26b as colorless oil.

Intermediate 26c. (E)-diethyl 3-(l-(3-(2-(2-(4-c oro-3-(trifluoromethy])- benzylidene)hydrazinecarbonyl)-4-(piperidin-l-yl)phenylcarba moyl)benz l)-lH- l,2,3-triazol-4-yl)propylphosphonate. Intermediate 26c was prepared in 78% yield from Intermediate 7a and Intermediate 26b using the procedures described in Example 7.

Example 26: (E)-3-(l-(3-(2-(2-(4-chloro-3-

(trifluoromethyl)benzylidene)hydrazine-carbonyl)-4-(piper idin-l- yl)phenylcarbamoyl)benzyl)-lH-l,2,3-triazol-4-yl)propylphosp honic acid. To

Intermediate 26c (100 mg, 0.13 mmol, 1.00 equiv) in DMF (1 mL) was added bromotrimethylsilane (0.5 mL) and the resulting solution was stirred for 1 h. The reaction was then quenched by the addition of 15 ml of saturated aqueous NaHC(¾ and the solids were collected by filtration. The crude product was then purified by preparative reverse phase (CI 8) HPLC to afford 23.7 mg (26%) of Example 26 as a yellow solid. Ή NMR (400MHz , CD30D, ppm): 8.41(s, IH), 8.33(s, IH), 8.29- 8.31(d, IH), 8.05-8.07(d, IH), 7.94-7.97(m, 2H), 7.86(s, IH), 7.70-7.72(4 IH), 7.52- 7.58(m, 2H), 7.42(s, IH), 7.26-7.28(d, IH), 5.69(s, 2H), 3.26-3.28(m, 4H), 2.78-2.82(t, 2H), 1.95-2.00 (m, 2H), 1.48(m, 4H), 1.65-1.66(m, 4H). MS (ES, m/z): 732 [M+H] ⁺

Example 27

Synthesis of (E)-l-(l-(3-(2-(2-(4-chloro-3- (trifluoromethyI)benzylidene)hydrazinecarbonyl)-4-(piperidin -l- yl)phenylcarbamoyl)benzyl)-lH-l,2,3-triazol-4-yl)-14,15-dihy droxy-13-oxo-3,6,9- trioxa-12-azahexadecan-16-oic acid

Example 25

Scheme 9. 1. HATU, tartaric acid, DIEA, DMF.

To (E)-3-((4-(2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethyl)- 1 H- 1 ,2,3-triazol-l - yl)methyl)-N-(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene) hydrazinecarbonyl)-4- (piperidin-l-yl)phenyl)benzamide (Example 25; 0.07 mmol, 63mg) in DMF (1 mL) was added tartaric acid (0.7mmol, lOOmg), HATU (1.1 equiv, 30mg), and diisopropylethylamine (1.4 mmol, 230 μί) and the reaction stirred for 2 hours. The product was then isolated by preparative HPLC to afford 47mg (73%) of Example 27. Ή-NMR (300MHz, <¾-DMSO): δ 12.21 (s, 1H), 11.15 (s, 1H), 8.46 (s, 1H), 8.14 (m, 2H), 8.01 (d, J = 8.8 Hz, 1H), 7.93 (s, 1H), 7.81 (m, 3H), 7.60 (m, 1H), 7.54 (m, 1H), 7.49 (m, 1H), 7.41 (s, 1H), 7.30 (d, J= 6.8 Hz, 1H), 5.62 (s, 2H), 4.29 (d, J= 1.3 Hz, 1H), 4.15 (d, J = 1.3 Hz, 1H), 3.40-3.60 (m, 12H), 3.37 (t, J = 5.8 Hz, 2H), 3.24 (m, 4H), 2.81 (d, J= 6.9 Hz, 2H), 1.68 (m, 4H), 1.55 (m, 2H). MS (ES, m/z): 917 [M+H] ⁺ .

Example 28

l-(3-(2-((E)-2-(4-chloro-3-(trifluoromethyl)benz lidene)hydrazinecarbonyl)-4- (piperidin-l-yl)phenylcarbamoyl)phenyl)-N-((3R,4R,5S,6R)-2,4 ,5-trihydroxy-6- (hydroxymethyl)tetrahydro-2H-pyran-3-yl)-5,8,ll,14,17,20,23, 26-octaoxa-2- thianonacosan-29-amide

Scheme 10. 1. HATU, DIEA

Example 28: l-(3-(2-((E)-2-(4-chloro-3-

(trifluoromethyl)benzylidene)hydrazinecarbonyl)-4-(piperi din-l- yl)phenylcarbamoyl)phenyl)-N-((3R,4R,5S,6R)-2,4,5-trihydroxy -6- (hydroxymethyl)tetrahydro-2H-pyran-3-yl)-5,8,ll,14,17,20,23, 26-octaoxa-2- thianonacosan-29-amide: To a solution of Example 1 (34 mg, 0.036 mmol, 1 equiv) in DMF (1 mL) was added DIEA (25|JL, 0.14 mmol, 4 equiv), HATU (15 mg, 0.39 mmol, 1.1 equiv) and glucosamine 28a (8.5 mg, 0.039 mmol, 1.1 equiv) and the resulting solution was stirred at 25 °C for 2 h. The solvent was removed and the crude residue purified by reversed phase (C-18) HPLC using a gradient of 10 to 95% MeCN in water as eluent to afford 7 mg (32 %) of Example 28. Ή-NMR (300MHz, CD ₃ OD): δ 8.70 (d, J = 9.2- Hz, IH), 8.44 (s, IH), 8.34 (s, IH), 7.06 (m, 2H), 7.99 (s, IH), 7.88 (d, J = 8.4 Hz, IH), 7.77-7.71 (m, 2H), 7.64 (d, J = 7.6 Hz, IH), 7.52 (t, J = 7.6 Hz, IH), 5.09 (d, J= 3.6 Hz, 0.7 H), 4.59 (d, J= 8.0 Hz, 0.3H), 3.92-3.52 (m, 43H), 3.56 (t, J= 4.0 Hz, IH), 2.62 (t, J= 6.8 Hz, 2H), 2.50 (m, 2H), 2.03 (in, 4H), 1.80 (m, 2H). MS (ES, m/z): 1160 [M+H] ⁺ .

Example 29

(E)-l-(3-(4-chloro-2-(2-(4-chloro-3- (trifluoromethyl)benzylidene)hydrazinecarbonyl)phenylcarbamo yl)phenyl)- 5,8,11,14,17,20,23,26-octaoxa-2-thianonacosan-29-oic acid (£)-2-amino-5-chloro- N'-{4-chloro-3-(trifluoroniethyl)beiizylidene)benzohydrazide

Scheme 11. 1. EtOH, 50 °C ; 2. DIEA, DCM, THF; 3. K ₂ C0 ₃ , DMF, RT

Intermediate 29b: (E)-N'-(4-chloro-3-(trifluoromethyl)benzylidene)-2-amino-S- chlorobcnzohydrazide. To a solution of 2-atnino-5-chlorobenzohydrazide 29a (500mg, 2.69 mmol, 1.00 equiv) in ethanol (15 mL) was added dropwise a solution of 4-chloro-3-(trifluoromethyl)benzaldehyde (618mg, 2.96 mmol, 1.10 equiv) in ethanol (2 mL) and the reaction was stirred overnight at 50 °C. The resulting mixture was concentrated under vacuum. The crude product was then re-crystallized from ethyl acetate/petroleum ether (2:1) resulting in 900mg (89%) of 29b as a yellow solid.

Intermediate 29c: (E)-N'-(4-chloro-3-(trifluoromethyl)benzylidene)-2-(3- (bromomethyl)benzamido)-5-chlorobenzohydrazide. To a solution of (E)-N'-(4- chloro-3-(trifluoromethyl)benzylidene)-2-amino-5-chlorobenzo hydrazide 29b (500 mg, 1.33 mmol, 1.00 equiv) in dichloromethane (20 mL) and DIEA (257 mg, 1.99 mmol, 1.50 equiv) at 0 °C was added dropwise 3-(bromomethyi)benzoyl chloride (341 mg, 1.46 mmol, 1.10 equiv) and the reaction was stirred for 1 h at 0 °C. The resulting solution was diluted with 100 mL of dichloromethane, washed with 2x50 mL of brine, dried over anhydrous sodium sulfate and then concentrated under vacuum to afford 520 mg (68%) of 29c as a yellow solid.

Example 29: (E)-N'-(4-chloro-3-(trifluoromethyl)benzylidene)-2-(3-

(bromomethyl)benzamido)-S-chlorobeiizohydrazide. The title compound was prepared in 41% yield from Intermediate 29c and l-mercapto-3,6,9,12,15, 18,21,24- octaoxaheptacosan-27-oic acid using the procedures described in Example 1. Ή-NMR (300MHz, CDjOD): δ 8.61 (d, = 9.0 Hz, 1H), 8.37 (s, 1H), 8.29 (s, 1H), 8.02 (d, J = 6.7 Hz, 1H), 7.93 (m, 2H), 7.85 (d, J= 7.8 Hz, 1H), 7.67 (d, J= 8.4 Hz, 1H), 7.60 (m, 2H), 7.48 (dd, J = 7.6, 7.9 Hz, 1H), 3.89 (s, 2 H), 3.69 (t, J= 6.3 Hz, 2H), 3.59 (t, J = 6.6 Hz, 2H), 3.56 (m, 28H), 2.58 (t, J= 6.5 Hz, 1H), 2.50 (t, J= 6.3 Hz, 2H). MS (ES, m/z): 949 [M+H] ⁺ .

Example 30

(E)-N-(4-chloro-2-(2-(4-chloro-3- (trifluoromethyl)benzylidene)hydrazinecarboiiyl)phenyl)-3-(( 4-(2-hydroxyethyl)- lH-l,2,3-triazol-l-yl)methyl)benzamide

Scheme 12. 1. NaN ₃ , DMF; 2.

To a solution of (E)-3-(azidomethyl)-N-(4-chloro-2-(2-(4-cMoro-3- (trifluoromemyl)benzylidene)hyo¾azinecarbonyl)phenyl)benzam ide (0.5 g, 0.84 mmol, 1.00 equiv, 95%) in N,N-dimemylformamide (25 mL) was added sodiumazide (200 mg, 3.08 mmol, 3.50 equiv, 95%). The resulting solution was stirred for 2 h at 80°C in an oil bath. The reaction progress was monitored by TLC (dichloromethane/methanol = 20:1). The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 25 mL of water. The resulting solution was extracted with 3x30 mL of dichloromethane and the organic layers combined. The resulting solution was was washed with 3x30 mL of brine. The mixture was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product was washed with 30 mL of ethylacetate/petroleum ether=l:l. This resulted in 0.31 g (62%) of (E)-N'-(4-chloro-3- (trifluoromemyl)benzylidene)-2-(3-(azidom

Intermediate 30a as a light yellow solid. Compound 30: (E)-N-(4-chloro-2-(2-(4-chloro-3-

(trifluoromethyl)benzylidene)hydrazinecarbonyl)phenyl)-3- ((4-(2-hydroxyethyl)- lH-l,2,3-triazol-l-yl)methyl)benzamide: The title compound was prepared in 48% yield from Intermediate 30a and but-3-yn-l-ol using the procedures described in the preparation of Example 7. NMR (300MHz, <¾-DMSO): δ 12.40 (s, 1H), 11.58 (s, 1H), 8.50 (s, 1H), 8.41 (d, 1H), 8.20 (s, 1H), 8.08 (d, 1H), 7.96 (m, 2H), 7.87 (m, 3H), 7.73 (m, 2H), 7.62 (m, 2H), 5.67 (s, 1H), 4.67 (t, J= 5.1 Hz, 1H), 3.62(m, /= 5.1 Hz, 2H), 2.77 (t, J=6.9 Hz, 3H). MS (ES, m/z) 605 [M+H] ⁺ .

Example 31

(E)-N-(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene)hydrazi necarbonyl)-4- (piperidin-l-yl)phenyl)-3-(4-hydroxybut-l-yn-l-yl)benzamide

Scheme 13. 1. but-3-yn-l-ol, Pd(PPh ₃ )Cl ₂ , Copper(I)Iodide, TEA; 2. Aq. LiOH, THF; 3. Pyridine, Ac ₂ 0; 4. SOCl ₂ ; 5. DIEA, le , THF, DCM; 6. Aq. LiOH, THF. Intermediate 31a: methyl 3-(4-hydroxybut-l-yhyl)benzoate. To a stirred solution of methyl 3-iodobenzoate (2.16g, 8.24 mmol, 1.00 equiv), Pd(PPh ₃ ) ₂ Cl ₂ (145 mg, 0.21 mmol, 0.025 equiv), copper(I)iodide (78 mg, 0.41 mmol, 0.05 equiv) in TEA (20 mL) under an atmosphere of ti ₂ was added but-3-yn-l-ol (624 μL, 0.22 mmol, 1.5 equiv) and the resulting mixture was stirred for 18h. The mixture was concentrated under vacuum and the crude product was purified by column chromatography on silica using hexanes EtOAc 10% to 35% as the mobile phase. Concentration of the pooled fractions furnished 1.55 g (90 %) of 31a as a tan oil.

Intermediate 31b: 3-(4-hydroxybut-l-ynyl)benzoic acid. To a stirred solution of methyl 3-(4-hydroxybut-l-ynyl)benzoate (1.05 g, 5.14 mmol, 1.00 equiv), in THF (32 mL) was added de-ionized water (8 mL) followed by 1 aqueous LiOH solution (5.60 mL). The resulting solution was stirred 4h at room temperature, additional 1M aqueous LiOH solution (0.20 mL) was added, and stirring was continued for 1.5h. The reaction mixture was made acidic with 1 M HC1, concentrated under vacuum, diluted with 0.5 M aqueous a¾P04 and then extracted with 3 x 60mL EtOAc. The combined organic layers were washed with brine, dried over Na2SC>4, filtered and then concentrated under vacuum to provide 1.03 g (quantitative) of 31b as a tan solid.

Intermediate 31c: 3-(4-acetoxybut-l-ynyI)benzoic acid. A solution of 3-(4- hydroxybut-l-ynyl)benzoic acid (1.03 g, 5.42 mmol, 1.00 equiv) in pyridine (12 mL) was added dropwise over 5 min to 0°C acetic anhydride (3.9 mL, 37.9 mmol 7.00 equiv) and the resulting solution was stirred 30 min at 0°C h followed by 2 h at room temperature. The reaction mixture was cooled to 0°C and diluted cautiously with 4 M HC1 (50 mL) followed by de-ionized water (100 mL). The resulting precipitate was collected by filtration, washed with de-ionized water and dried under vaccume to provide 940 mg (75 %) of 31c as a cream colored solid.

Intermediate 31d: 4-(3-(chlorocarbonyl)phenyl)mit-3-ynyl acetate. 3-(4- acetoxybut-l-ynyl)benzoic acid (200 mg) was taken up in SO(¾ (2 mL) and stirred 1.5 h at room temperature. The reaction mixture was dried under vacuum and then co- evaporated from benzene 2 x 5 mL to provide 210 mg (97 %) of crude 31d as a yellow oil, which was used without further purification.

Intermediate 31e: (E)-4-(3-((2-(2-(4-chloro-3-(trifluoromethyl)benzyIidene) hydrazinecarbonyl)-4-(piperidin-l-yl)phenyl)carbamoyl)phenyl )but-3-yn-l-yl acetate. To (E)-2-amino-N'-(4-chloro-3 -(trifluoromethyl)benzylidene)-5-(piperidin- 1 - yl)benzohydrazide (300 mg, 0.71 mmol, 1 equiv) in THF (1 mL) at 0 °C was added drop wise a solution of 31d (190 mg) in DCM (2 mL) and the mixture was stirred at RT overnight. The mixture was then concentrated and purified by column chromatography (15% - 60% acetone/toluene) to give 31e as a a yellow solid 390 mg (83.6%).

Example 31: N-(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene) hydrazinecarbonyl)-4-(piperidin-l-yl)phenyl)-3-(4-hydroxybut -l-yn-l-yl) benzamide. To a solution of Intermediate 31e (390 mg, 0.61 mmol, 1 equiv) in THF (4 mL) at was added a solution of lithium hydroxide monohydrate (28.2 mg, 0.67 mmol, 1.1 equiv) in water (2 mL). The mixture was stirred at RT for 2 h. Additional solution of lithium hydroxide monohydrate (38.4 mg, 0.92 mmol, 1.5 equiv) in water (1 mL) was added and the resulting mixture was stirred at rt for 2 h. Additional lithium hydroxide monohydrate (20 mg) was added and the reaction mixture stirred at rt for 2 h. The organic solvent was removed under vacuum. The aqueous mixture was extracted with ethyl acetate twice and the combined organic layers were washed with brine, dried, concentrated and purified by column chromatography (2% methanol/dichloromethane) to give Example 31 as a yellow solid 280 mg (76.9 %) Ή-NMR (400MHz, DMSO, ppm): δ 12.21 (s, IH), 11.10 (s, IH), 8.48 (s, IH), 8.16 (m, IH), 8.10 (d, /=8.8Hz, IH), 8.04 (d, J=9.6Hz, IH), 7.89 (s, IH), 7.84 (t, J=7Hz, 2H), 7.60 (d, J=8Hz, IH), 7.54 (t, J=7.6Hz, IH), 7.28 (m, IH), 7.20 (dd, J=2.6Hz, J^9Hz , IH), 4.92 (t, J=5.6Hz, IH), 3.60 (q, J=6.4Hz, 2H), 3.20 (m, 4H), 2.58 (t, J=6.8Hz, 2H),1.66 (m, 4H), 1.56 (m, 2H). MS (ES, m/z): 597 [M+H] ⁺ .

Example 32

(E)-3-(13-azido-5,8,ll-trioxa-2-azatridecyl)-N-(2-(2-(4-chlo ro-3- (trifluoromethyl)benzylidene)hydrazinecarbonyl)-4-(piperidin -l- yl)phenyl)benzamide

Scheme 14. 1. DIEA, le , DMF, THF, DCM; 2. K ₂ C0 ₃ , DMF.

Intermediate 32a: (E)-3-(bromomethyl)-N-(2-(2-(4-cM ro-3-

(trifluoromethyl)benzylidene)hydrazinecarbonyl)-4-(piperi dm-l- yl)phenyl)benzamide. To Intermediate le (5.7 g, 13.4 mmol) in DMF (52 mL), THF (130 mL), and DCM (130 mL) was added DIEA (2.4 g, 18.57 mmol, 1.52 equiv) and the solution was colled to 0°C. To this was added dropwise a solution of 3- (bromomethyl)benzoyl chloride (3.12 g, 13.39 mmol, 1.10 equiv) in dichloromethane (20 mL) over 30 min. The reaction was stirred for 2.5 h at 0°C and then quenched by the addition of 20 mL of water. The mixture was concentrated under vacuum and the resulting solids were washed With 100 mL of dichloromethane, 100 mL of tetrahydrofuran and then 50 mL of dichloromethane to afford 6.05 g (80%) of Intermediate 32a as a yellow solid.

Compound 32: (E)-3-(13-azido-5,8,l l-trioxa-2-azatridecyl)-N-(2-(2-(4-chloro-3- (trifluoromethyl)benzylidene)taydrazinecarbonyl)-4-(piperidi n-l-yl)phenyl) benzamide. To a solution of 32a (50 mg, 0.08 mmol, 1 equiv) in DMF (1 mL) was added l l-azido-3,6,9-trioxaundecan-l-amine (19 ί, 0.10 mmol, 1.2 equiv) and potassium carbonate (16.6 mg, 0.12 mmol, 1.5 equiv) and the mixture was stirred overnight. The mixture was then diluted with ethylacetate, washed with water (2 x), brine, dried, concentrated and purified by silica gel chromatography (0-10 % MeOH DCM) to afford Example 32 as a yellow solid 20 mg (32.8 %). Ή-NMR (400MHz, CDC1 ₃ , ppm): δ 11.06 (bs, IH), 11.00 (bs, IH), 8.55 (s, IH), 8.09 (s, IH), 8.01 (m, 3H), 7.87 (d, J=8Hz, IH), 7.56 (d, J=8Hz, 2H)), 7.45 (t, J=7.6Hz, IH), 6.88 (m, 2H), 3.91 (s, 2H), 3.62 (m, 12H), 3.34 (t, J=5Hz, 2H), 2.84 (t, J=5.2Hz, 2H), 2.81 (m, 4H), 1.36 (m, 4H), 1.26 (m, 2H). MS (ES, m/z): 759 [M+H] ⁺ .

Example 33

(E)-3-(17-azido-5-oxo-9,12,15-trioxa-2-thia-6-azaheptadecyl) -N-(2-(2-(4-chloro-3- (trifluoromethyl)benzylidene)hydrazinecarbonyI)-4-(piperidin -l-yl)phenyl) benzamide

Scheme 15. 1. 3-mercaptopropanoic acid, K2CO3, KI; 2. N-hydroxysuccinimide, DCC 3. 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethanamine, THF.

Intermediate 33a: (E)-3-(3-(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene)- hydrazinecarbonyl)-4-(piperidin-l-yl)phenylcarbamoyl)benzylt hio)propanoic acid: To Intermediate 32a (500 mg, 0.80 mmol, 1.00 equiv) in acetone (50 mL) was added D F (50 mL), potassium carbonate (333 mg, 2.41 mmol, 3.00 equiv), potassium iodide (26.7 mg, 0.16 mmol, 0.20 equiv) and 3-mercaptopropanoic acid (128 mg, 1.21 mmol, 1.50 equiv) and the reaction was stirred for 3 h at 70 °C. The resulting mixture was concentrated, diluted with water (100 mL) and then washed with 1 x 50 mL of n- hexane and 4 x 150 mL of dichloromethane. The pH value of the aqueous layer was adjusted to 4 with diluted hydrochloric acid and it was then extracted with 2 x 100 mL of ethyl acetate. The organic layers were combined, washed with 3 x 150 mL of brine, dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product was triturated with 30 mL of methanol and 3 x 30 mL of n-hexane to afford 110 mg (21%) of Intermediate 33a as a yellow solid.

Intermediate 33b: (E)-2,5-dioxopyrrolidin-l-yl 3-((3-((2-(2-(4-chloro-3- (trifluoromethyI)benzylidene)hydrazinecarbonyl)-4-(piperidin -l-yl)phenyl) carbamoyl)benzyl)thio)propanoate: To a mixture of intermediate 33a (50 mg, 0.08 mmol, 1 equiv) and N-hydroxy-succinimide (9.3 mg, 0.08 mmol, 1.05 equiv) in THF (1 mL) was added dicyclohexyl carbodiimide (DCC; 16.7 mg, 0.08 mmol, 1.05 equiv) and the mixture was stirred for 1 h. DCM (0.5 mL) was added and the mixture was stirred at rt overnight. Additional N-hydroxy-succinimide (4.5 mg, 0.04 mmol, 0.5 equiv) and DCC (8 mg, 0.04 mmol, 0.5 equiv) were added and the resulting mixture was stirred at rt for 5h. The mixture was then concentrated and purified by silica gel chromatography (0 - 10 % MeOH/DCM) to give a yellow solid. The yellow solid was diluted with DCM, filtered to remove impurities, and the filtrate was concentrated to give 33b as a yellow solid 50 mg (87.0%).

Compound 33: (E)-3-(17-azido-5-oxo-9,12,15-trioxa-2-thia-6-azaheptadecyl) -N-(2- (2-(4-chIoro-3-(trifluoromethyl)benzylidene)hydrazinecarbony l)-4-(piperidin-l- yl)phenyl)benzamide. To a solution of Intermediate 33a (50 mg, 0.067 mmol, 1 equiv) in THF (0.7 mL) was added l l-azido-3,6,9-trioxaundecan-l-amine (20 uL, 0.10 mmol, 1.5 equiv) and the mixture was stirred for 1 h. The reaction was then filtered and the filtrate was concentrated and purified by silica gel chromatography (0 - 10% MeOH/DCM) followed by preparative HPLC to provide 33 as a yellow solid 17 mg (29.9 %). 'H-NMR (400MHz, COC , ppm): δ 11.47 (bs, 1H), 1 1.21 (bs, 1H), 8.34 (s, 1H), 7.97 (m, 5H), 7.47 (m, 3H), 7.05 (s, 1H)), 6.81 (d, J=8.8Hz, 1H), 6.24 (s, 1H), 3.63 (m, 12H), 3.51 (m, 2H), 3.37 (m, 4H), 2.92 (m, 5H), 2.59 (m, 2H), 1.96 (m, 6H), 1.31 (m, 6H). MS (ES, m/z): 870 [M+H] ⁺ .

Example 34

(E)-N-(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)-l-(3-((2- (2-(4-chloro-3- (trifluoromethyl)benzyHdene)hydrazinecarbonyl)-4-(piperidin- l-yl)

phenyl)carbamoyl)benzyl)piperidine-4-carboxamide

Scheme 16. K ₂ C0 _3> .

Intermediate 34a: (E)-ethyl l-(3-((2-(2-(4-chloro-3-(trifluoromethyl)ben2ylidene) hydrazmecarbonyl)-4-(pi eridin-l-yl)phenyl)carbamoyl)benzyl)piperidine-4- carboxylate: To a mixture of (E)-3-(bromomethyl)-N-(2-(2-(4-chloro-3- (trifluoromethyl) benzylidene)hydrazinecarbonyl)-4-(piperidin- 1 -y l)phenyl)benzamide (32a; 50 mg, 0.08 mmol, 1 equiv) in DMF (1 mL) was added ethyl isonipecotate (14.9 0.10 mmol, 1.2 equiv) and potassium carbonate (16.6 mg, 0.12 mmol, 1.5 equiv) and mixture was stirred at rt overnight. The mixture was then diluted with ethyl acetate, washed with water (2x), brine (lx), dried, concentrated and purified by silica gel chromatography (0 - 10 % MeOH/DCM) to give a yellow solid (58 mg).

Intermediate 34b: (E)-l-(3-((2-(2-(4-chloro-3-(trifluoromethyl)benzylidene) hydrazinecarbonyl)-4-(piperidin-l-yl)phenyl)carbamoyl)benzyl )piperidine-4- carboxylic acid: To a solution of Intermediate 34a (57 mg, 0.08 mmol, 1 equiv) in THF (1 mL) at rt was added a solution of lithium hydroxide monohydrate (5.1 mg, 0.12 mmol, 1.5 equiv) in water (0.5 mL) and the mixture was stirred at rt for 2 h. Additional lithium hydroxide monohydrate (5 mg, 0.12 mmol, 1.5 equiv) was added and the resulting mixture was stirred at rt for 2 h. Additional lithium hydroxide monohydrate (5 mg) was added and stirred continued at rt for 2 h. The mixture was then neutralized with 1 N HC1 to pH = 7, the organic solvent was removed under vacuum and the residue was then lyophilized to give a yellow solid (72 mg).

Compound 34: (E)-N-(2-(2-(2-(2-azidoethoxy)ethoxy)ethox )ethyl)-l-(3-((2-(2-(4- chloro-3-(trifluoromethyl)benzylidene)hydrazinecarbonyl)-4-( piperidin-l- yl)phenyl)carbamoyl)benzyl)piperidine-4-carboxamide: To a mixture of 34b (57 mg, 0.064 mmol) in DCM (0.6 mL) was added ll-azido-3,6,9-trioxaundecan-l -amine (15 nJ 0.077 mmol, 1.2 equiv) and triethylamine (TEA; 11 μΐ, 0.077 mmol, 1.2 equiv). The mixture was cooled to 0 °C and then N-hydroxybenzotriazole (HOBt; 13 mg, 0.096 mmol, 1.5 equiv) and l-emyl-3-N,N-diemylaminopropylcarbodiirnide hydrochloride (EDC.HC1; 14.7 mg, 0.077 mmol, 1.2 equiv) were added and the mixture was stirred at rt overnight. Additional l l-azido-3,6,9-trioxaundecan-l-amine (30 μΐ,, 0.15 mmol, 2.4 equiv), TEA (27 uL, 0.1 mmol, 3 equiv), HOBt (26 mg, 0.19 mmol, 3 equiv) and EDC-HCl (29.4 mg, 0.15 mmol, 2.4 equiv) were added and the mixture was stirred an additional 4h. The mixture was then concentrated and purified by silica gel chromatography (0 - 10% MeOH/DCM) to give a yellow solid (25 mg). 'H-NMR (400MHz, CDCh ppm): δ 11.47 (bs, 1H), 11.21 (bs, 1H), 8.34 (s, 1H), 7.97 (m, 5H), 7.47 (m, 3H), 7.05 (s, lH)), 6.81 (d, J=8.8Hz, 1H), 6.24 (s, 1H), 3.63 (m, 12H), 3.51 (m, 2H), 3.37 (m, 4H), 2.92 (m, 5H), 2.59 (m, 2H), 1.96 (m, 6H), 1.31 (m, 6H). MS (ES, m/z): 870 [M+H] ⁺ .

Example 35

(S,E)-2-acetamido-6-(3-((3-((2-(2-(4-chloro-3- (iriflnoromethyl)benzylidene)hydrazinecarbonyl)-4-(piperidin -l- yl)phenyl)carbamoyl)benzyl)thio)propanamido)hexanoic acid

Scheme 17. 1. HOBt, EDC, TEA. Compound 35: (S,E)-2-acetamido-6-(3-((3-((2-(2-(4-chloro-3-(trifluorometh yl) benzylidene)hydrazinecarbonyl)-4-(piperidin-l-yl)phcnyl)carb amoyl)benzy])thio) propanamido)hexanoic acid. To a mixture of (E)-3-((3-((2-(2-(4-chloro-3- (trifluoromemyl)benzylidene)hydrazinecarbonyl)-4-(piperidin- l-yl)phenyl)ca^^ benzyl)thio)propanoic acid 33a in DCM (0.6 mL) was added TEA (13 ί, 0.093 mmol, 1.2 equiv) and the mixture was cooled to 0 °C. HOBt (15.6 mg, 0.116 mmol, 1.5 equiv) was added, followed by the addition of EDC-HCl (17.8 mg, 0.093 mmol, 1.2 equiv) and the mixture was stirred at rt for 45 minutes. N-acetyl-L-lysine (17.5 mg, 0.093 mmol, 1.2 equiv) was added and the reaction mixture was stirred at rt overnight. The mixture was then concentrated and purified by silica gel chromatography (0 - 30% MeOH DCM) to give a yellow solid, which was further purified by preparative reverse phase (CI 8) HPLC to furnish a yellow solid (13 mg). Ή-NMR (400MHz, DMSO, ppm): δ 12.25 (s, 1H), 11.18 (s, 1H), 8.49 (s, 1H), 8.21 (d, =8.8Hz, 1H), 8.17 (s, 1H), 8.05 (d, J=8Hz, 2H), 7.84 (m, 3H), 7.77 (d, J=7.2Hz, 1H), 7.53 (m, 2H), 7.36 (m, 2H), 4.11 (m, 1H), 3.83 (s, 2H), 3.27 (m, 4H), 3.01 (q, /=6.4Hz, 2H), 2.59 (t, J=7Hz, 2H), 2.35 (t, ^7.6Hz, 2H),1.83 (s, 3H), 1.64 (m, 8H), 1.33 (m, 4H). MS (ES, m/z): 817 [M+H] ⁺ .

Example 36

(S,E)-2-amino-6-(3-((3-((2-(2-(4-chloro-3-(trilluoromethyl)b enzylidene) hydrazinecarbonyl)-4-(piperidiii-l-yl)phenyl)carbamoyl)benzy l)thio) propanamido)hexanoic acid

Scheme 18. 1. DIEA, DMF; 2. THF, TEA; 3. TFA

Intermediate 36a: ((E)-perfluorophenyl 3-((3-((2-(2-(4-chloro-3-(trifluoromethyl) benzylidene)hydrazinecarbonyl)-4-(piperidin-l-yl)phenyl)carb amoyl)benzyl)thio) propanoate. To a solution of (E)-3-((3-((2-(2-(4-chloro-3-

(trifluoromethyl)benzylidene)hydrazinecarbonyl)-4-(piperi din-l-yl)phenyl)carbam benzyl)thio)propanoic acid 33a in DMF (0.6 mL) was added pentafluorophenyl trifluoroacetate (20 _. μΐ,, 0.116 mmol, 1.5 equiv) and DIEA (27 μί, 0.155 mmol, 2 equiv) and the mixture was stirred overnight. The reaction was then diluted with ethyl acetate, washed with water (2 x) and brine, dried, concentrated and purified by silica gel chromatography (0 - 60% ethyl acetate hexane) to give a yellow solid (45 mg).

36b

Intermediate 36b: (S,E)-2-((tert-butoxycarbonyl)amino)-6-(3-((3-((2-(2-(4-chlo ro- 3-(trifluoromethyl)benzylidene)hydrazinecarbonyl)-4-(piperid in-l-yI)phenyl) carbamoyl)benzyl)thio)propanamido)hexaiioic acid. To a solution of Intermediate 36a (45 mg, 0.056 mmol, 1 equiv) in THF (1 mL) at rt was added N-Boc-lysine-OH (21 mg, 0.084 mmol, 1.5 equiv) and TEA (23.4 uL, 0.168 mmol, 3 equiv) and the reaction was stirred at rt overnight. The mixture was concentrated and purified by preparative thin-layer chromatography (TLC; 10% MeOH/DCM) to give a yellow solid (26 mg).

Compound 36: (S,E)-2-amino-6-(3-((3-((2-(2-(4-chloro-3-(trifluoromethyl) benzylidene)hydrazinecarbonyl)-4-(piperidin-l-yl)phenyl) arbamoyl)benzyl)thio) propanamido)hexanoic acid: To a mixture of Intermediate 36b (26 mg) in dichloroethane (DCE; 1 mL) was added trifluoroacetic acid (TFA; 1 mL) and the reaction was stirred for 1 h. The resulting mixture was then concentrated, co- evaporated with DCE (2 x) ,lyophilized and the residue was purified by preparative TLC (10% MeOH DCM) to give a yellow solid (26 mg). Ή-NMR (400MHz, DMSO, ppm): δ 12.24 (s, IH), 11.19 (s, IH), 8.50 (s, IH), 8.16 (m, 5H), 8.04 (d, J=9.6Hz, IH), 7.85 (m, 3H), 7.77 (d, J=7.2Hz, IH), 7.53 (m, 2H), 7.34 (s, IH), 7.25 (m, IH), 3.86 (m, IH), 3.83 (s, 2H), 3.23 (m, 4H), 3.03 (m, 2H), 2.59 (t, J=7.2Hz, 2H), 2.36 (t, J=7.2Hz, 2H), 1.71 (m, 6H), 1.57 (m, 2H), 1.39 (m, 4H). MS (ES, m/z): 115 [M+H] ⁺ .

Example 37

(E)-3-((4-(14-azido-2-oxo-6,9,12-trioxa-3-azatetradecyl)pipe ridin-l-yl)methyl)-N- (2-(2-(4-chloro-3-(triflBoromethyl)benzylidene)hydrazinecarb onyl)-4-(piperidin-l- yl)phenyl)benzamide

Example 37: (E)-3-((4-(14-azido-2-oxo-6,9,12-trioxa-3-azatetradecyl)pipe ridin-l- yl)methyl)-N-(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene) hydrazinecarbonyl)- 4-(piperidin-l-yl)phenyl)benzamide. Example 37 was synthesized via the same route as Example 34 except that ethyl isonipecotate was replaced with 2-(piperidine-4- yl)acetic acid ethyl ester in the first step to provide 37 7.0mg (9.9% yield 3 steps) ( ^! H- NMR (400MHz, CDC ,ppm): δ 11.15 (bs, IH), 11.02 (bs, IH), 8.54 (s, IH), 8.02 (m, 4H), 7.87 (d, J=8Hz, IH), 7.55 (d, J=8.4Hz, 2H), 7.43 (t, J=7.2Hz, IH), 6.91 (m, 2H), 6.13 (s, IH), 3.62 (m, 10H), 3.51 (t, J=5.2Hz, 2H), 3.41 (q, J=4.9Hz, 2H), 3.35 (t, /=5Hz, 2H), 2.86 (m, 4H), 1.94 (m, 4H), 1.67 (m, 2H), 1.30 (m, 13H). MS (ES, m/z): 884 [M+H] ⁺ .

Example 38

(E)-N-(2-(2-(4-chIoro-3-(trifluoromethyl)benzylidene)hydrazi necarbonyl)-4- (piperidin-l-yl)phenyl)-6-(4-hydroxybut-l-yn-l-yl)picolinami de

Scheme 19. 1. S0C1 ₂ ; 2. THF, DCM, le, DIEA; 3. Pd(PPh ₃ ) ₂ Cl ₂ , Cul, TEA.

Intermediate 38a: 6-bromopicolinoyl chloride. To 6-bromopicolinic acid (156 mg, 0.773 mmol) was added thionyl chloride (4 mL) and the mixture was stirred at 70 °C for 3 h. The mixture was concentrated and co-evaporated with toluene to give a yellow residue which was used without further purification.

Intermediate 38b: (E)-6-bromo-N-(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene ) hydrazinecarbonyl)-4-(piperidin-l-yl)phenyl)picolinamide. To a mixture of (E)-2- amino-N'-(4-cUoro-3-( fluoromethyl)benzylidene)-5-(piperidin-l-yl)benzohydrazide le (100 mg, 0.24 mmol, 1 equiv) in THF (0.3 mL) at 0 °C was added dropwise a solution (0.7 mL, 0.26 mmol) of Intermediate 38a in DCM (2 mL) and the reaction was stirred at rt overnight. The mixture was then concentrated and purified by silica gel chromatography (0% - 5% MeOH DCM) to give a yellow solid (132 mg).

Example 38: (E)-N-(2-(2-(4-chloro-3-(trifluoromethyl)beiizylidene) hydrazinecarbonyl)-4-(piperidin-l-yl)phenyl)-6-(4-hydroxybut -l-yii-l-yl) picolinamide: Intermediate 38c (132 mg, 0.216 mmol, 1.00 equiv) in DMF (1 mL) was purged with nitrogen and then &w(triphenylphosphine)palladium(II) dichloride (15.2 mg, 0.022 mmol, 0.1 equiv) and copper(I)iodide were added. The mixture was purged with nitrogen and then TEA (120 uL, 0.86 mmol, 4 equiv) and but-3-yn-l-ol (66 uX, 0.86 mmol, 4 equiv) were added. The mixture was purged with nitrogen again and then stirred at 50 °C overnight. The mixture was diluted with ethyl acetate, washed with water (2x) and brine (lx), dried, concentrated and purified by silica gel chromatography (0 - 7% MeOH/DCM) to give a yellow solid. The solid was purified again by preparativeTLC (5% MeOH/DCM) to afford Example 38 as a yellow solid (68 mg). Ή- NMR (400MHz, DMSO, ppm): δ 12.22 (s, IH), 11.76 (s, IH), 8.49 (s, IH), 8.39 (d, J=9.2Hz, IH), 8.20 (s, IH), 8.04 (m, 3H), 7.84 (d, J=8Hz, IH), 7.71 (d, J=7.6Hz, IH), 7.28 (s, IH), 7.22 (dd, J=2.4Hz, J=9.2Hz, IH), 4.98 (t, J^5.6Hz, IH), 3.66 (q, J=6.3Hz, 2H), 3.22 (m, 4H), 2.65 (t, =6.4Hz, 2H), 1.66 (m, 4H), 1.57 (m, 2H). MS (ES, mJz): 598 [M+H] ⁺ .

Example 39

(£)-N-(4-chloro-2-(2-(4-chloro-3- (trifluoromethyl)benzylidene)hydrazinecarbonyl)phenyl)-3-(4- hydroxybut-l- ynyl)benzamide

Scheme 20. 1. DIEA, 31d, THF, DCM; 2. Aq. LiOH, THF.

Intermediate 39e. (£)-4-(3-(4-chloro-2-(2-(4-chloro-3-

(trifluoromethyl)benzylidene)hydrazinecarbonyl)phenylcarb amoyl)phenyI)but-3- ynyl acetate: To a 0°C solution of Intermediate 31d (90.2 mg, 0.24 mmol, 1.0 equiv) and DIEA (131 μL, 0.79 mmol, 3.3 equiv) in THF (1.0 mL) was added dropwise over 5 minutes a solution of 29b (108 mg, 0.72 mmol, 3.0 equiv) in THF (0.5 mL). The resulting solution was stirred 10 min then allowed to warm to room temperature and stirred 2.5 h. The reaction mixture was then cooled to 0°C, diluted cautiously with saturated NaHCC>3, and then extracted with EtOAc (3 x 25 mL). The combined organics were washed with saturated NaHCC>3 (2 x 10 mL), 1M HCl (1 x 10 mL), and brine and then dried over Na2SC> . The mixture was then filtered and concentrated under vacuum to provide crude product (190 mg). A 100 mg portion of the crude product was purified by preparative TLC using 15% acetone in toluene as mobile phase to provide 17.4 mg 39e (23.4 %) as a clear oil.

Example 39: (£)-N-(4-chloro-2-(2-(4-chloro-3-(trifluoromethyl)benzylide ne)- hydrazinecarbonyl)phenyl)-3-(4-hydroxybut-l-ynyl)benzamide. To a stirred solution of (£)-4-(3-(4-chloro-2-(2-(4-chloro-3-

(trifluoromethyl)benzylidene)hydrazinecarbonyl)-phenylcar bamoyl)phenyl)bu^ acetate 39e (17.0 mg, 0.29 mmol, 1.0 equiv), in THF (2 mL) was added de-ionized water (0.5 mL) followed by 1M aqueous LiOH solution (32 μί,) and the resulting yellow solution was stirred 5h. Additional 1M aqueous LiOH solution (16 μΐ,) was added and stirring continued 2 h, and then additional 1M aqueous LiOH solution (16 μΐ,) was added and stirring continued another 2 h. The reaction mixture was then neutralized with 1 M HCl, diluted with de-ionized water and extracted with EtOAc. The combined organics were washed with brine, dried over a ₂ S0 , filtered, concentrated under vacuum and the crude product purified by preparative TLC (25% acetone in toluene) to provide 7.8 mg (49 %) of 39 as a colorless solid. 'H-NMR (400MHZ, CDC1 ₃ , ppm): δ 8.63 (d, J=9.2Hz, IH), 8.26 (s, IH), 8.10-7.90 (m, 2Η), 7.86 (d, J=7.6Hz, IH), 7.72 (s, IH), 7.53-7.45 (m, 3H), 7.37 (t, J=7.6Hz, IH), 3.75 (t, J=6.4Hz, 2H), 2.62 (t, J=6AHz, 2H). MS (ES, m/z): 547 [M] ⁺ .

Example 40

(E)-N-(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene)hydrazi necarbonyl)-4- (piperidin-l-yl)phenyl)-3-(5-(dimethylamino)pent-l-yiiyl)ben zamide

Scheme 21. 1. C1COCOC1 CH ₂ C1 ₂ , cat. DMF; 2. 40a, DIEA, THF; 3. but-3-yn-l-ol , Pd(PPh ₃ ) ₄ , Cul, DIEA, DMF; 4. Ms ₂ 0, CH ₂ C1 ₂ , TEA; 5. Dimethylamine hydrochloride, DMF

Intermediate 40a: 3-iodobenzoyl chloride. To 3-iodobenzoic acid (2 g, 8.06 mmol, 1.00 equiv) in DCM (100 mL) cooled to 0 °C was added dropwise a solution of oxalyldichloride (2.85 g, 22.44 mmol, 3.00 equiv) in dichloromethane (5 mL). To this was added DMF (0.1 mL) and the reaction was stirred for 2 h at room temperature. The mixture was then concentrated under vacuum to afford 2.1 g (98%) of 3-iodobenzoyl chloride 40a as yellow oil.

Intermediate 40b: (E)-N-(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene)- hydrazinecarbonyl)-4-(piperidin-l-yl)phenyl)-3-iodobenzamide : To Intermediate le (1.6 g, 3.76 mmol, 1.00 equiv) in THF (100 mL) was added DMF (1.45 g, 11.63 mmol, 3.00 equiv) and the solution cooled to 0°C. To this was added dropwise 3-iodobenzoyl chloride 40a (1 g, 3.76 mmol, 1.00 equiv) and the resulting solution allowed to warm to T and then stirred for 2 h. The mixture was concentrated under vacuum and then washed with MeOH resulting in 1.9 g (70%) of Intermediate 40b as a yellow solid.

Alternate synthesis of Example 31: (E)-N-(2-(2-(4-chloro-3- (trifluoromethyl)berizylidene)hydrazinecarbonyl)-4-(piperidi n-l-yl)phenyl)-3-(4- hydroxybut-l-ynyl)benzamide: To Intermediate 40b (500 mg, 0.76 mmol, 1.00 equiv) in DMF (5 mL) was added but-3-yn-l-ol (108 mg, 1.54 mmol, 3.00 equiv), Pd(PPh ₃ ) (88 mg, 0.08 mmol, 0.20 equiv), Copper (I) iodide (13 mg, 0.07 mmol, 0.10 equiv) and DIEA (150 mg, 1.16 mmol, 3.00 equiv) and the resulting solution was stirred overnight. The mixture was diluted with 100 ml of ethyl acetate, washed with 3x100 mL of brine, dried over anhydrous sodium sulfate and then concentrated under vacuum to afford 500 mg (crude) of Compound 31 as a yellow solid.

Intermediate 40c: (E)-4-(3-(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene)- hydrazinecarbonyl)-4-(piperidin-l-yl)phenylcarbamoyl)phenyl) but-3-ynyl methanesulfonate: To Example 31 (500 mg, 0.84 mmol, 1.00 equiv) in DCM (100 mL) was added TEA (254 mg, 2.51 mmol, 3.00 equiv) and the solution cooled to O'C. To this was added methanesulfonic anhydride (438 mg, 2.52 mmol, 3.00 equiv) portionwise and the reaction allowed to warm to rt and then stirred 2 h. The mixture was diluted with 100 mL of DCM, washed with 2 x 100 mL of brine, dried over anhydrous sodium sulfate and then concentrated under vacuum. The residue was purified by silica gel chromatography with ethyl acetate/petroleum ether (1:5-1:1) to afford 300 mg (53%) of Intermediate 40c as yellow oil.

Example 40: (E)-N-(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene)- hydrazinecarbonyl)-4-(piperidin-l-yl)pheny])-3-(5-(dimethyla mino)pent-l- ynyl)benzamide. To 40c (200 mg, 0.3 mmol, 1.00 equiv) in DMF (10 mL) was added dimethylamine hydrochloride (74 mg, 0.9 mmol, 3.00 equiv) and potassium carbonate (126 mg, 0.92 mmol, 3.00 equiv) and the reaction was stirred for 2 h at 80°C. The solution was then diluted with 100 ml of water, extracted with 3 x 100 ml of ethyl acetate and the organic layers combined, washed with 3x100 mL of brine, and then concentrated under vacuum. The crude product was purified by Preparative reverse phase (C18) HPLC with CH ₃ CN/H ₂ 0(with 0.5% HCOOH) to afford 30 mg (16%) of Example 40 as a yellow solid. Ή-NMR (300MHz, CD ₃ OO,ppni): δ 8.39 (m, 3H), 8.03 (m, 2H), 7.91 (d, J=7.5Hz, IH), 7.65 (d, J=7.8Hz, IH), 7.60 (d, J=4.8Hz, IH), 7.51 (m, IH), 7.38 (s, IH), 7.21 (d, J=8.1Hz, IH), 3.25 (s, 4H) , 2.84 (s, 2H) , 2.75 (m, 2H) , 2.48 (s, 6H) , 1.74(s, 4H) ,1.63 (s, 2H). LCMS (ES, m/z): 624 [M+H] ⁺

Example 41

(£)-N-(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene)hydraz inecarbonyl)-4- (piperidin-l-yl)phenyl)-3-(5-(dimethylamino)pent-l-ynyl)benz amide

Example 41: (£)-N-(2-(2-(4-chloro-3-(triffluoromethyl)benzylidene)- hydrazinecarbonyl)-4-(piperidiii-l-yl)phenyl)-3-(5-(dimethyl amino)pent-l- ynyl)benzamide. Example 41 was synthesized from Intermediate 40b and alkyne pent- 4-yn-l-ol using the procedures described in Example 40 to furnish 50 mg (27%) of Example 41 as a yellow solid. Ή NMR (300MHz, CO ₃ OO, ppm): 8.54 (d, J=9.1Hz, IH), 8.44 (s, IH), 8.38 (s, IH), 8.04 (t, 2H), 7.97 (d, J=9.1Hz, IH), 7.76 (m, 2H), 7.65 (d, =7.8Hz, 1H), 7.53 (t, 2H), 3.55 (s, 4H), 2.95 (s, 6H), 2.65 (t, 2H), 2.10 (m, 2H), 1.91(s, 4H), 1.75 (m, 2H). LCMS (ES, m/z): 638 [M+H] ⁺

Example 42

(E)-5-(3-(2-(2-(4-ch]oro-3-(trifluoromethyl)benz lidene)hydrazinecarbonyl)-4- (piperidin-l-yI)phenyIcarbamoyI)phenyI)pent-4-ynoic acid

Example 42. Example 42 was synthesized using the procedures described in Example 40, starting from intermediate 40b and substituting the alkyne pent-4-ynoic acid in the third step. To a 50-mL sealed tube purged and maintained with an inert atmosphere, of nitrogen, was placed a solution of (E)-N'-(4-chloro-3-(trifluoromethyl)benzylidene)-2- (3-iodobenzamido)-5-(piperidin-l-yl)benzohydrazide 40b (100 mg, 0.15 mmol, 1.00 equiv) in DMF (2 mL) followed by pent-4-ynoic acid (22 mg, 0.22 mmol, 1.50 equiv), Pd(PPh ₃ ) (18 mg, 0.02 mmol, 0.20 equiv), Copper (I) iodide (2 mg, 0.01 mmol, 0.10 equiv) and DIEA (59 mg, 0.46 mmol, 3.00 equiv) and the resulting mixture was stirred overnight at room temperature. The reaction was concentrated under vacuum and the crude product was purified by Preparative reverse phase (C18) HPLC (CH ₃ CN in ¾0 gradient + 0.1% HCOOH) to afford 30 mg (31%) of 42 as a yellow solid. Ή-NMR (300MHz, DMSO) δ 11.19 (s, 1H), 8.51 (s, 1H),8.22 (m, 2H), 8.18 (m, 2H), 8.07 (d, J=8.7Hz, 1H), 7.84 (m, 2H), 7.75 (m, 1H), 7.31 (s, 1H), 7.24 (d, J=8.4Hz, 1H), 8.76(s, 1H), 3.34 (m, 4H), 3.05(m, 2H),2.78 (m, 2H), 1.67-1.58 (m, 6H). LCMS (ES, m/z): 625 [M+H] ⁺ Example 43

(R,E)-3-(4-amino-17-azido-5-oxo-9,12,15-trioxa-2-thia-6-azah eptadecyl)-N-(2-(2- (4-chloro-3-(trifluoromethyI)benzylidene)hydrazinecarbonyl)- 4-(piperidin-l- yl)phenyl)benzamide

Scheme 22. 1. 32a, Boc-Cystine, Aq. NaOH, DMF; 2. EDC, HOBt, 2-(2-(2-(2- azidoethoxy)ethoxy)ethoxy)ethanamine, DMF; 3. TFA, DCE.

Intermediate 43a: (R,E) _: 2-(tert-butoxycarbonylamino)-3-(3-(2-(2-(4-chloro-3- (trifluoromethyl)benzylidene)hydrazinecarbonyl)-4-(piperidii i-l- yl)phenylcarbamoyl)benzylthio)propanoic acid: To Intermediate 32a (300 mg, 0.48 mmol, 1.0 equiv) and Boc-cystine (117 mg, , 0.53 mmol, 1.1 equiv) in DMF (2.4 mL) was added 1M NaOH (530 \xL, 0.53 mmol, 1.1 equiv) and the solution was stirred 1 h. Additional 1M NaOH (200 μΐ,, 0.20 mmol, 0.42 equiv) and DMF (2.4 mL) was added and the reaction mixture was heated to 45°C for 2h, cooled, and then diluted with EtOAc. The mixture was washed with 0.5M KH ₂ P0 ₄ , saturated NaHC<¾ (2 x 10 mL), and brine and then dried over Na ₂ SC>4. and the mixture was filtered, concentrated under vacuum was and then purified by silica gel chromatography (MeOH/DCM 0 to 10%) to afford 174 mg (48 %) of 43a as an oil.

Intermediate 43b: (R,E)-tert-butyl 17-azido-l-(3-(2-(2-(4-chloro-3- (trifluoromethyl)benzylidene)hydrazinecarbonyl)-4-(piperidin -l- yl)phenylcarbamoyl)phenyl)-5-oxo-9,12,15-trioxa-2-thia-6-aza heptadecaii-4- ylcarbamate. To a 0°C solution of 43a (155 mg, 0.21 mmol, 1.0 equiv), 2-(2-(2-(2- azidoethoxy)ethoxy)ethoxy)ethanamine (81 ί, 0.43 mmol, 2.0 equiv) and HOBt ( 41.2 mg, 0.32 mmol, 1.5 equiv) in DMF (1.0 mL) was added EDC ( 50.6 mg, 0.27 mmol, 1.3 equiv) and the reaction mixture was allowed to warm to room temperature and stirred overnight. The mixture was then diluted with EtOAc, washed with 0.5M KH2PO4, saturated NaHC0 ₃ , and brine. The organic layer was dried over Na ₂ S0 ₄ , filtered and then concentrated under vacuum to provide 133 mg (66 %) of 43b as a colorless oil.

Example 43: (R,E)-3-(4-amino-17-azido-5-oxo-9,12,15-trioxa-2-thia-6- azaheptadecyl)-N-(2-(2-(4-chloro-3-(trifluoromethyl)benzylid ene)- hydrazinecarbonyl)-4-(piperidin-l-yl)phenyl)benzamide. To 43b (37.0 mg, 0.29 mmol, 1.0 equiv) in DCE (2 mL) was added TFA (2 mL) and the reaction mixture was stirred 45 minutes. The solution was concentrated, the residue was co-evaporated 2x from DCE and then purified by Preparative reverse phase (CI 8) HPLC (CH ₃ CN/H ₂ 0 + 0.1% TFA) to afford Example 43 7.7mg (21 %) as a yellow solid. Ή-NMR (400MHz, CD ₃ On, ppm): 8.61 (d, J=10.0Hz, IH) 8.44 (s, IH), 8.34 (m, IH), 8.05-8.00 (m, IH), 7.96 (s, IH), 7.95-7.86 (m, 2H), 7.70 (d, /=10.0Hz, IH), 7.64-7.52 (m, 3H), 4.02 (t, J=6.8Hz, IH), 3.93 (d, J=2.4Hz, IH) 3.62-3.63-3.36 (m, 12H), 3.33-3.30 (m, 2H), 3.01- 2.95 (m, IH), 2.89-2.82 (m, IH), 1.96 (m, 4H), 1.78-1.70 (m, 2H). MS (ES, m/z): 862 [M+H] ⁺ .

Example 44

(E)-4-(((3-(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene)hy drazinecarboiiyl)-4- (piperidin-l-yl)phenylcarbamoyl)benzyl)(methyl)amino)methyl) phenylboroiiic acid

Scheme 23. 1. CH ₃ NH ₂ , DMF; 2. 4-(bromomethyl)phenylboronic acid, K ₂ C0 ₃ , DMF

Intermediate 44a: (E)-N-(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene)- hydrazinecarbonyl)-4-(piperidin-l-yl)phenyl)-3-((methylamino )methyl)benzamide.

To Intermediate 32a (600 mg, 0.96 mmol, 1.00 equiv) in DMF (60 mL) was bubbled methylamine gas for 20 min. The reaction was stirred for 2 h at room temperature and then quenched by the addition of 200 ml of ice-water. The mixture was extracted with 3x150 ml of ethyl acetate and the organic layers combined, washed with 2x150 mL of brine, and then dried over anhydrous sodium sulfate. The solution was filtered, concentrated under vacuum and the residue applied onto a silica gel column eluting with dichloromethane:methanol (20:1 increasing to 10:1) to afford 200 mg (36%) of (E)-N-(2-(2-(4-chloro-3-(1iifluoromemyl)benzylidene)hydrazin ecarbonyl)-4-(piperidin- l-yl)phenyl)-3-((methylamino)methyl)benzamide as a yellow solid.

Example 44: (E)-4-(((3-(2-(2-(4-chloro-3-(trifluoromethyI)benzylidene)- hydrazinecarbonyl)-4-(piperidin-l-yl)phenylcarbamoyl)benzyl) (methyl)- amino)methyl)phenylboronic acid. To intermediate 44a (160 mg, 0.28 mmol, 1.00 equiv) in DMF (15 mL) was added 4-(bromomethyl)phenylboronic acid (81 mg, 0.38 mmol, 1.35 equiv) and potassium carbonate (116 mg, 0.84 mmol, 3.00 equiv) and the resulting mixture was stirred for 24 h at room temperature. The reaction was then quenched by the addition of 100 ml of ice/water and the resulting solution was extracted with 3x100 ml of ethyl acetate. The organic layers were combined, washed with 2x50 mL of brine, dried over anhydrous sodium sulfate and then concentrated under vacuum. The crude product (210 mg) was purified by reverse-phase (C-18) HPLC eluting with a gradient of acetonitrile in water (0.1% HCOOH) to afford 47 mg of product. Ή-NMR (300MHz, DMSO): δ 12.22(s, IH), 11.21(s, IH), 8.50(s, IH), 8.22(d, J=9.0Hz, IH), 8.15(s,lH), 8.03(d, J=8.7Hz, IH), 7.945(m, 3H), 7.81(m, 4H), 7.59(m, 2H), 7.35(m, 3H), 7.23(d, J=8.7Hz, IH), 3.57 (s, 2H), 3.53 (s, 2H), 3.21(s, 4H), 2.09(s, 3H), 1.75- 1.57(m, 6H). LCMS (ES, m z): 706 [M+H] ⁺ .

Example 45

(E)-N-(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene)hydrazi necarbonyl)-4-(piperidin-l- yl)phenyl)-3-((4-(2-hydroxyethyl)thiazol-2-yl)methyl)benzami de

Scheme 24. 1, H ₂ S0 ₄ , MeOH; 2. NBS, CC1 ₄ ; 3. TMS-CN, TBAF, CH ₃ CN; 4. H ₂ S(g), EtjN, pyridine; 5. 45f, EtOH; 6. LiOH, THF, H ₂ 0; 7. le, EDC-HC1, DMAP, DCM; 8. AcCl, pyridine, DCM; 9. Br ₂ , A1C1 ₃ , Et ₂ 0

45a

Intermediate 45a: methyl 3-methylbenzoate. To 3-methylbenzoic acid (30 g, 220.51 mmol, 1.00 equiv) in methanol (300 mL) was added sulfuric acid (15 mL) dropwise and the solution heated to reflux overnight. The reaction mixture was concentrated, diluted with 100 mL of water and then extracted with 3x100 mL of ethyl acetate. The organic layers were combined, washed with 3x100 mL of brine, dried over anhydrous sodium sulfate and then concentrated under vacuum to afford 26 g (79%) of methyl 3- methylbenzoate (45a) as a colorless oil

45b Intermediate 45b: methyl 3-(bromomethyI)benzoate. To methyl 3-methylbenzoate (45a; 26 g, 173.14 mmol, 1.00 equiv) in dichloromethane (300 mL) was added benzoyl peroxide (850 mg, 3.51 mmol, 0.02 equiv) and the mixture heated to 90°C. N- Bromosuccinimide (33.9 g, 190.47 mmol, 1.10 equiv) was added in portions, and the mixture was stirred overnight at 90°C. The reaction was cooled to RT, the solids were filtered out and the filtrate was washed with 3x100 mL of brine. The solution was concentrated under vacuum and the crude product was purified by re-crystallization from ethyl ether to afford 15 g (38%) of methyl 3-(bromomethyl)benzoate (45b) as a white solid.

45c

Intermediate 45c: methyl 3-(cyanomethyl)benzoate. To methyl 3- (bromomethyl)benzoate (45b; 8 g, 35.09 mmol, 1.00 equiv) in acetonitrile (150 mL) at 0°C was added tetra-n-butyl ammonium fluoride (TBAF; 14 g, 53.55 mmol, 1.50 equiv) in portions. To this was added dropwise (trimethylsilyl)cyanide (5.22 g, 52.73 mmol, 1.50 equiv) and the reaction was warmed to 80°C and stirred overnight. The mixture was concentrated under vacuum, diluted with 200 ml of ethyl acetate and then washed with 2x200 mL of brine. The organic layer was dried over anhydrous sodium sulfate, concentrated, and the residue purified by silica gel chromatography (petroleum ether/ethyl acetate (5:1)) to afford 4 g (65%) of methyl 3-(cyanomethyl)benzoate (45c) as a yellow oil.

Intermediate 45d: methyl 3-(2-amino-2-thioxoethyl)benzoate. To methyl 3- (cyanomethyl)benzoate (45c; 4 g, 22.83 mmol, 1.00 equiv) in pyridine (200 mL) and triethylamine (12 mL) was bubbled ¾S gas for 3h and the solution then stirred overnight. The reaction was diluted with 100 ml of water, extracted with 2x200 mL of ethyl acetate and the combined organic layers washed with 10% hydrochloric acid (2x100 mL) and brine (2x100 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated to afford 4 g (84%) of methyl 3-(2-amino-2- thioxoethyl)benzoate (45d) as a yellow solid.

O O

^ ₀

45e

Intermediate 4Se: 3-oxobutyl acetate. To 4-hydroxybutan-2-one (5 g, 56.75 mmol, 1.00 equiv) in dichloromethane (30 mL) was added pyridine (5.97 g, 75.47 mmol, 1.33 equiv) and the solution cooled to 0°C. Acetyl chloride (4.9 g, 62.42 mmol, 1.10 equiv) was then added dropwise and the resulting solution was warmed to 40°C and stirred for 1 h. The reaction mixture was cooled to RT, washed with 10% hydrochloric acid and 2x50 mL of brine, then dried over anhydrous sodium sulfate and concentrated to afford 5.8 g (79%) of 3-oxobutyl acetate (4Se) as yellow oil.

45f

Intermediate 45f: 4-bromo-3-oxobutyl acetate. To 3-oxobutyl acetate (45e) (100 mg, 0.77 mmol, 1.00 equiv) in ethyl ether (2 mL) was added aluminum(III) chloride (102 mg, 0.77 mmol, 1.00 equiv) and the mixture cooled to 0°C. To this was added Br ₂ (123 mg, 123 mmol, 1.00 equiv) dropwise and the resulting solution was stirred for 1 h at 0°C. The reaction was diluted with 10 ml of ethyl acetate, washed with 2x10 mL of brine, dried over sodium sulfate and then concentrated under vacuum to afford 100 mg (62%) of 4-bromo-3-oxobutyl acetate (45f) as a yellow oil.

Intermediate 45g: methyl 3-((4-(2-acetoxyethyl)thiazol-2-yl)methyl)benzoate. To methyl 3-(2-amino-2-thioxoethyl)benzoate (45d; 100 mg, 0.48 mmol, 1.00 equiv) was added 4-bromo-3-oxobutyl acetate (45f; 100 mg, 0.48 mmol, 1.00 equiv) in efhanol (5 mL) and the reaction heated to reflux for 1 h. The mixture was concentrated and purified via silica gel chromatography (petroleum ether/ethyl acetate (3:1)) to afford 20 mg (13%) of methyl 3-((4-(2-acetoxyethyl)thiazol-2-yl)methyl)benzoate (45g) as a yellow solid.

Intermediate 45h: 3-((4-(2-hydroxyethyl)thiazol-2-yl)methyl)benzoic acid. To methyl 3-((4-(2-acetoxyethyl)thiazol-2-yl)methyl)benzoate (4Sg; 80 mg, 0.25 mmol, 1.00 equiv) in tetrahydrofuran (3 mL) was added a solution of lithium hydroxide hydrate (52.6 mg, 1.25 mmol, 5.00 equiv) in water(3 mL) and the resulting solution was stirred overnight. The pH value of the solution was adjusted to 6 with 10% hydrochloric acid and then it was extracted with 2x50 mL of dichloromethane. The organic were layers combined, dried over anhydrous sodium sulfate and then concentrated to afford 40 mg (61%) of 3-((4-(2-hydroxyethyl)thiazol-2- yl)methyl)benzoic acid (4Sh) as yellow oil.

Example 45 : (E)-N-(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene)h drazine- carbonyl)-4-(piperidin-l-yl)phenyl)-3-((4-(2-hydroxyethy])th iazol-2- yl)mctliyl)benzainide. To (E)-N'-(4-chloro-3-(trifiuoromethyl)benzylidene)-2-amino- 5-(piperidin-l-yl)benzohydrazide (Intermediate le; 48 mg, 0.11 mmol, 1.00 equiv) in dichloromethane (5 mL) was added 3-((4-(2-hydroxyethyl)thiazol-2-yl)methyl)benzoic acid (45h; 30 mg, 0.11 mmol, 1.00 equiv), l-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC.HC1; 32 mg, 0.17 mmol, 1.50 equiv) and 4- dimethylaminopyridine (DMAP; 21 mg, 0.17 mmol, 1.50 equiv) and the reaction was stirred overnight. The mixture was concentrated under vacuum and the crude product was purified by preparative reverse-phase (CI 8) HPLC (gradient of acetonitrile in water (0.1% NH40H)) to afford 8.6 mg (11%) of Example 45 as a yellow solid. 'H-NMR (300MHz,CD3OD, ppm): δ 8.36 (s, 1H), 8.31 (m, 2H), 8.06 (m, 1H), 7.95 (s, 1H), 7.88 (m, 1H), 7.72 (m, 1H), 7.56 (m, 2H), 7.39 (m, 1H), 7.24 (m, 1H), 7.10 (s, 1H), 4.44(s, 2H), 3.86 (m, 2H), 3.26 (m, 4H), 2.96 (m, 2H), 1.66 (m, 6H). LCMS (ES, m z): 670 [M+H] ⁺

Example 46

(E)-4-(3-(3-(2-(2-(4-chloro-3-(trifluoromethyl)beiizylidene) hydrazinecarbonyl)-4- (piperidin-l-yl)phenylcarbamoyl)benzylthio)propanamido)pheny lboronic acid

Example 46: (E)-4-(3-(3-(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene)- hydrazinecarbonyl)-4-(piperidin-l-yl)phenylcarbamoyl)benzylt hio)propaaamido)- phenylboronic acid. The synthesis of the title compound was conducted as described for compound 35 substituting 4-aminophenylboronic acid hydrochloride in place of N- a-acetyl lysine. To Intermediate 33a (108 mg, 0.17 mmol, 1.00 equiv) in dichloromethane (5 mL) was added 4-aminophenylboronic acid hydrochloride (28.9 mg, 0.17 mmol, 1.00 equiv), EDC.HC1 (48 mg, 0.25 mmol, 1.50 equiv) and DMAP (51 mg, 0.42 mmol, 2.50 equiv) and the mixture was stirred for 22 h. The reaction was diluted with 50 mL of water and then concentrated under vacuum to remove the organic solvents. The residue was purified by preparative HPLC (gradient of acetonitrile in water (0.1% HCOOH)) to afford 25 mg (20%) of Example 46 as a yellow solid. 'H- NMR (400MHz, DMSO, ppm): δ 12.22 (s, 1H), 11.17 (s, 1H), 9.98 (s, 1H), 8.49 (s, 1H), 8.20-8.14 (m, 2H), 8.05 (d, J=6.3Hz, 1H), 7.90-7.87 (m, 2H), 7.81-7.77 (m, 2H), 7.71 (d, J=6.3Hz, 2H), 7.58-7.52 (m, 4H), 7.30 (s, 1H), 7.23 (m, 1H), 3.88 (s, 2H), 3.22-3.20 (m, 4H), 2.70-2.64 (m, 4H), 1.66-1.56 (m, 6H). LCMS (ES, m/z): 766 [M+H] ⁺ .

Example 47

(E)-N-(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene)hydrazi necarbonyl)-4- (piperidin-l-yl)phenyl)-3-((4-(2-hydroxyethyl)-lH-imidazol-l - yl)methy])benzamide

Scheme 25. 1. MeOH, HCl(g); 2. a) NaHC(¾, MeOH, b) L1AIH4, THF; 3. 32a, NaH, DMF.

Intermediate 47a: methyl 2-(lH-imidazol-4-yl)acetate hydrochloride. To 2-(lH- imidazol-4-yl)acetic acid hydrochloride (1 g, 6.15 mmol, 1.00 equiv) in methanol (21 mL) was bubbled HQ gas for 30 min and the reaction was stirred for 3 h. The solution was concentrated under vacuum to afford 1.08 g (99%) of Intermediate 47a as yellow oil.

47b

Intermediate 47b: 2-(lH-imidazol-4-yl)ethanol. To Intermediate 47a (399 mg, 2.26 mmol, 1.00 equiv) in methanol (6 mL) was added sodium bicarbonate (190 mg, 2.26 mmol, 1.00 equiv) and the mixture stirred for 15 min. The solids were filtered out and the filtrate concentrated under vacuum to afford 317 mg of methyl 2-(lH-imidazol-4- yl)acetate (free base), which was added in portions to a suspension of lithium aluminum hydride (172 mg, 4.53 mmol, 2.01 equiv) in tetrahydrofuran (20 mL). The reaction was heated to reflux overnight and then cooled, quenched by the addition of 0.17 mL of water, 0.17 mL of 15% aqueous sodium hydroxide, and another 0.5 mL of water. The solids were filtered out and washed with ethyl acetate, and the combined filtrates were dried over anhydrous sodium sulfate and concentrated under vacuum to afford 180 mg (71 %) of Intermediate 47b as colorless oil.

Example 47: (E)-N-(2-(2-(4-chloro-3-(trifluoromethyl)ben2ylidene)hydrazi ne- carbonyJ)-4-(piperidin-l-yl)phenyl)-3-((4-(2-hydroxyethyl)-l H-imidazol-l- yl)methyl)benzamide. To Intermediate 47b (43 mg, 0.38 mmol, 1.20 equiv) in DMF (10 mL) at 0-5°C was added NaH (60%) (19 mg, 1.50 equiv) and the mixture was stirred for 30 mins. To this was Intermediate 32a (200 mg, 0.32 mmol, 1.00 equiv) and the reaction was stirred for 1 h. The reaction was then quenched by the addition of water and the resulting solution was extracted with 3x100 ml of dichloromethane. The organic layers were combined, washed with 2x50 mL of brine, dried over anhydrous sodium sulfate, concentrated under vacuum and then purified by preparative reverse- phase (CI 8) HPLC (gradient of acetonirile in water (0.05% NH ₄ OH) to afford 33.4 mg (16%) of Example 47 as a yellow solid. Ή-NMR (300MHz, CD ₃ OD, ppm): δ 8.39 (s, 1H), 8.31 (d, J=9.6Hz, 2H), 8.05 (d, J=8.1Hz, 1H), 7.94 (d, J=8.7Hz, 2H), 7.77 (s, 1H), 7.71 (d, J=8.1Hz, 1H), 7.57 (m, 2H), 7.46 (m, 1H), 7.26 (m, 1H), 6.98 (s, 1H), 5.29 (s, 2H), 3.76 (m, 2H), 3.25 (m, 4H), 2.75 (m, 2H), 1.65 (m, 6H). LCMS (ES, m z): 653 [M+H] ⁺ .

Example 48 (E)-l-(3-(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene)hydr azinecarbonyl)-4- (piperidin-l-yl)phenylcarbamoyl)benzyl)-3-(2-hydroxyethyl)-l H-imidazol-3-ium

Scheme 26. 1. l,3-dioxolan-2-one; 2. 32a, DMF

48a

Intermediate 48a: 2-(lH-imidazol-l-yl)ethanol. To IH-imidazole (3 g, 44.12 mmol, 1.00 equiv) was added l,3-dioxolan-2-one (6.05 g, 68.7 mmol, 1.55 equiv) and the reaction was stirred for 1 h at 125°C. The residue was purified via silica gel chromatography (dichloromethane/methanol (5:1)) to afford 1.8 g (36%) of Intermediate 48 a as a brown solid.

Example 48: (E)-l-(3-(2-(2-(4-chloro-3-

(trifluoromethyl)benzylidene)hydrazinecarbonyl)-4-(piperi din-l- yl)phenylcarbamoyl)benzyl)-3-(2-hydroxyethyl)-lH-imidazol-3- ium. To

Intermediate 32a (189 mg, 0.30 mmol, 1.00 equiv) in DMF (6 mL) was added Intermediate 48a (51.6 mg, 0.46 mmol, 1.50 equiv) and the reaction was stirred for 4 h at 80°C. The resulting mixture was concentrated under vacuum, diluted with 5 mL of 1 :1 water/methanol and purified by preparative reverse-phase (CI 8) HPLC (methanol gradient in water) affording 58 mg (26%) of Example 48 as a yellow solid. Ή-NMR (300MHz, DMSO, ppm): δ 12.25 (s, 1H), 11.19 (s, IH), 9.32 (s, 1H), 8.51 (s, 1H), 8.18-8.13 (m, 2H), 8.06-7.99 (m, 2H), 7.91-7.83 (m, 3H), 7.78 (s, IH), 7.65 (d, J=4.2Hz, 2H), 7.31 (s, IH), 7.24 (d, J=8.7Hz, IH), 5.56 (s, 2H), 5.22 (s, IH), 4.26-4.23 (m, 2H), 3.75-3.72 (m, 2H), 3.28-3.22 (m, 4H), 1.67-1.58 (m, 6H). LCMS (ES, m/z): 653 [M-Br] ^" .

Example 49

(E)-N-(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene)hydrazi necarbonyl)-4- (piperidin-l-yI)phenyl)-3-((3-(2-methoxyethylamino)-3- oxopropylthio)methyl)benzamide

Scheme 27. 1. oxaloyl chloride, DCM; 2. 2-methoxyethanamine, DIEA, DGM; 3. potassium thioacetate, EtOH; 4. LiOH, THF/H ₂ 0; 5. 32a, K ₂ C0 ₃ , KI, DMF

^Br ^Y CI

49a

Intermediate 49a: 3-bromopropanoyl chloride. To 3-bromopropanoic acid (10 g, 62.09 mmol, 1.00 equiv, 95%) in dichloromethane (100 mL) at 5°C was added oxaloyl chloride (9.13 g, 68.35 mmol, 1.00 equiv, 95%) dropwise with stirring over 15 min. To this was added N,N-dimethylformamide (3-4 drops) and the reaction was stirred for 2.5 h at room temperature. The resulting mixture was concentrated under vacuum to afford 9 g (85%) of 3-bromopropanoyl chloride as yellow oil.

49b

Intermediate 49b: 3-bromo-N-(2-methoxyethyl)propanamide. To 2- methoxyethanamine (2.9 g, 36.68 mmol, 1.00 equiv, 95%) in dichloromethane (30 mL) was added DIEA (7.5 g, 1.50 equiv) and the solution cooled to 0°C. To this was added dropwise a solution of 3-bromopropanoyl chloride (10 g, 55.43 mmol, 1.50 equiv, 95%) in dichloromethane (10 mL) and the reaction was stirred for 3 h at 0°C. The resulting mixture was concentrated under vacuum, diluted with 25 mL of water and then extracted with 3x30 mL of dichloromethane. The organic layers were combined, washed with 3x30 mL of brine, dried over sodium sulfate and then concentrated to afford 8 g of Intermediate 49b as yellow oil.

49c

Intermediate 49c: S-3-(2-methoxyethylamino)-3-oxopropyl ethanethioate. To

Intermediate 49b (250 mg, 1.19 mmol, 1.00 equiv) in ethanol (3 mL) at 5°C was added potassium ethanethioate (407 mg, 3.57 mmol, 3.00 equiv) and the reaction was then warmed to 70°C and stirred overnight. The resulting mixture was concentrated, diluted with 20 mL of water and extracted with 3x30 mL of ethyl acetate. The organic layers were combined, washed with 1 30 mL of brine, dried over anhydrous sodium sulfate, concentrated and then purified via silica gel chromatography (ethyl acetate/petroleum ether (1 :5)) to afford 200 mg (82%) of Intermediate 49c as light-yellow oil.

49d

Intermediate 49d: 3-mercapto-N-(2-methoxyethyl)propanamide. To Intermediate 49c (2.7 g, 13.17 mmol, 1.00 equiv) in tetrahydrofuran (20 mL) was added a solution of lithium hydroxide (2.16 g, 52.68 mmol, 4.00 equiv) in water (20 mL) and the reaction was stirred for 2 h. The resulting mixture was concentrated under vacuum, the pH value of the solution adjusted to 6-7 with acetic acid and the mixture extracted with 3x100 mL of ethyl acetate. The organic layers were combined, washed with 1x30 mL of brine, dried over anhydrous sodium sulfate and concentrated under vacuum to afford 2 g (93%) of Intermediate 49d as yellow oil.

Example 49: (E)-N-(2-(2-(4-chloro-3-(trifluoromethyl)benz lidene)hydrazine- carbonyl)-4-(piperidin-l-yl)phenyl)-3-((3-(2-methoxyethylami no)-3- oxopropylthio)methyl)benzamide. To Intermediate 32a (100 mg, 0.16 mmol, 1.00 equiv) in DMF (4 mL) was added Intermediate 49d (52 mg, 0.32 mmol, 1.00 equiv), potassium carbonate (66 mg, 0.48 mmol, 3.00 equiv) and potassium iodide (5.2 mg, 0.03 mmol, 0.20 equiv) and the resulting mixture was stirred overnight at 50°C in an oil bath. The reaction was diluted with 20 ml of water and the solids were collected by filtration and washed with 1x10 mL of acetone. The crude product was purified by preparative reverse-phase (C18) HPLC, eluting with methanol:water (1:1) to afford 37 mg (29%) of Example 49 as a yellow solid. 'H-NMR (300MHz, CDC13, ppm): δ 12.24 (m, 1H), 11.17 (m, 1H), 8.50 (m, 1H), 8.19 (m, 2H), 8.02 (m, 2H), 7.83 (m, 3H), 7.53 (m, 1H), 7.33 (m, 1H), 7.25 (m, 1H), 3.84 (s , 2H), 3.30 (m, 2H), 3.20(m, 9H), 2.39 (m , 2 H), 1.63 (m, 6H). LCMS (ES, m z): 705 [M+H] ⁺ .

Example 50

(E)-2-(3-(3-(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene)h ydrazinecarbonyl)-4- (piperidin-l-yl)phenylcarbamoyl)benzylthio)propanamido)aceti c acid

Scheme 28. 1. 32a, K ₂ C0 ₃ , KI, acetone; 2. LiOH, THF, H ₂ 0.

50a

Intermediate 50a: ethyl 2-(3-mercaptopropanamido)acetate. Intermediate 50a was prepared as a pale yellow oil in 13% overall yield from Intermediate 49a and ethyl glycine using the procedures described in Example 49.

Intermediate 50b: (E)-ethyl 2-(3-(3-(2-(2-(4-chloro-3-

(trifluoromethyi)benzylidene)hydrazinecarbonyl)-4-(piperi din-l- yl)phenylcarbamoyl)benzylthio)propanamido)acetate. To Intermediate 32a (100 mg, 0.15 mmol, 1.00 equiv, 95%) in acetone (10 mL) was added potassium carbonate (110 mg, 0.76 mmol, 3.00 equiv, 95%), potassium iodide (5 mg, 0.03 mmol, 0.20 equiv, 95%) and Intermediate 5Qa (110 mg, 0.55 mmol, 95%) and the reaction was stirred for 3 h at 70°C. The resulting mixture was then concentrated, diluted with 100 mL of water and then extracted with 3x30 mL of dichloromethane. The organic layers were combined, washed with 3x30 mL of brine, dried over anhydrous sodium sulfate, concentrated and then purified via silica gel chromatography (dichloromethane:methanol (60:1)) to afford 100 mg (85%) of Intermediate 50b as a yellow solid.

Example 50: (E)-2-(3-(3-(2-(2-(4-chloiO-3-(trifluoromethyl)benz lidene)- hydrazinecarbonyl)-4-(piperidin-l-yl)phenylcarbamoyl)benzylt hio)propanamido)- acetic acid. To Intermediate 50b (150 mg, 0.19 mmol, 1.00 equiv, 95%) in 1:1 THF/water (16 mL) was added lithium hydroxide hydrate (43 mg, 0.97 mmol, 5.00 equiv, 95%) and the reaction was stirred overnight. The resulting mixture was concentrated under vacuum and then washed with 3x10 mL of hexane and 3x10 mL of dichloromethane. The aqueous layer was diluted with 20 mL of water and the pH value of the solution was adjusted to 2-3 with aqueous hydrochloric acid (2 mol/L). The resulting solids were collected by filtration and then purified by preparative reverse- phase (C18) HPLC (acetonitrile gradient in water) to afford 28.8 mg (21%) of Example 50 as a yellow solid. 'H-NMR (300MHz, DMSO, ppm): δ 12.33 (s, 1H), 11.22 (s, 1H), 8.54 (s, 1H), 8.22-8.26 (m, 2H), 8.18 (s, 1H), 8.06 (d, 1H), 7.50-7.56 (m, 2H), 7.32-7.38 (m, 2H), 3.86 (s, 2H), 3.76 (d, 2H), 3.30-3.43 (m, 4H), 2.59-2.74 (m, 2H), 2.43-2.52 (m, 2H), 1.75 (d, 4H), 1.61(s, 1H). LCMS (ES, m/z): 704 [M+H] ⁺ .

Example 51

(E)-N-(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene)hydrazi necarbonyl)-4- (piperidin-l-yl)phenyl)-3-((3-(2-methoxyethylamino)-3- oxopropylsulfinyl)methyi)benzamidc Ό ^'

Example 51 : (E)-N-(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene)hydrazi ne- carbonyI)-4-(piperiditi-l-yl)phenyl)-3-((3-(2-methoxyethylan iino)-3- oxopropylsulfinyl)methyl)benzamide. Example 51 was isolated during the HPLC purification of Example 96. ^NMR (300MHz„CDC13, ppm): δ 11.32 (s, IH), 11.06 (s, IH), 8.42 (s, IH), 8.27 (d, IH), 7.96 (m, 4H), 7.51 (d, 3H), 7.23 (m, IH), 7.01 (d, IH), 6.53(s, IH), 4.09 (m, 2H), 3.42 (s, 3H), 3.29 (s, 4H), 3.10 (m, 5H), 2.88 (m, IH), 2.68 (m, 2H), 1.59 (m, 6H). LCMS (ES, m/z): 720 [M+H] ⁺ .

Example 52

(E)-N-(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene)liydraz inecarbonyl)-4- (piperidin-l-yl)p ethyl)benzamide

Example 52: (E)-N-(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene)hydrazi ne- carbonyl)-4-(piperidin-l-yl)phenyl)-3-((4-(2-hydroxyethyl)-l H-pyrazol-l- yl)methyl)benzamide. The synthesis of the title compound was conducted as described for compound 47 substituting 2-(lH-pyrazol-4-yl)ethanol in place of intermediate 47b in the third step. To Intermediate 32a (250 mg, 0.40 mmol, 1.00 equiv) in DMF (10 mL) at 0°C was added sodium hydride (24 mg, 0.60 mmol, 1.50 equiv) and the mixture was stirred for 1 h at 0°C. To this was added 2-(lH-pyrazol-4- yl)ethanol (45 mg, 0.40 mmol, 1.00 equiv) and the reaction was stirred for 1 h at 0°C. The reaction was then quenched by the addition of 20 mL of water and the mixture was extracted with 2x100 ml of ethyl acetate. The organic layers were combined, washed with 2x200 mL of brine, dried over sodium sulfate and concentrated under vacuum. The residue was purified via silica gel chromatography, eluting with dichloromethaneimethanol (15:1) to afford 58.1 mg (22%) of Example 52 as a yellow solid. ¾ N R (300MHz, CD ₃ OD, pprri): 8 8.39 (s, 1H), 8.301(m, 2H), 8.034(d, ^8.4Hz, 1H), 7.886(m, 1H), 7.851(s, 1H), 7.713(d, 7=8.4Hz, 1H), 7.621(s, 1H), 7.514(m, 1H), 7.253(m, 3H), 7.232(d, J=2.7Hz, 1H), 5.406(s, 2H), 3.690(m, 2H), 3.252(m, 4H), 2.690(m, 2H), 1.764(s, 4H), 1.654(m, 2H). LCMS (ES, m/z): 653 [M+H] ⁺

Example 53

(E)-N ¹ -(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene)hydraz inecarbonyl)-4- (piperidin-l-yl)phenyl)-N ³ -(2-morpholinoethyl)isophthalamide

Example 53: (E)-N ¹ -(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene)hydraz ine carbonyl)-4-(piperidin-l-yl)phenyl)-N ³ -(2-morpholinoethyl)isophthalamide. A solution of (E)-3-(2-(2-(4-chloro-3-(trifluoromethyl)benzylidene) hydrazinecarbonyl)- 4-(piperidin-l-yl)phenylcarbamoyl)benzoic acid 4a (200 mg, 0.35 mrnol, 1.00 equiv), (90 mg, 0.69 mrnol, 1.98 equiv), triethylamine (39.1 mg, 0.39 mrnol, 1.11 equiv), EDC HC1 (73.3 mg, 0.38 mrnol, 1.09 equiv) and HOBT (52 mg, 0.39 mrnol, 1.10 equiv) in N,N-dimethylformamide (5 mL) was stirred overnight at 25°C. The resulting solution was concentrated under vacuum and crude residue was purified by preparative HPLC (Waters 2767-3) using the following conditions: Column, SunFire Prep C18, 19*150mm 5pm; mobile phase, water with 0.05%TFA and CH ₃ CN (25% CH ₃ CN up to 40% in 6 min, up to 100% in 1 min, down to 25% in 1 min); detector, Waters 2545 Uv dectector 254nm. Purification provided 183 mg (57%) of Example 53 ditrifluoroacetate as a yellow solid. (300MHz, DMSO+D ₂ O, ppm): δ 11.18(s, 1H), 8.9(s, 1H), 8.45 (s, 1H), 8.38 (s, 1H), 8.18~8.00(m, 5H), 7.83~7.80(d, J=8.4Hz, 1H), 7.72~7.68(m, 1H), 7.55-7.49 (m, 1H), 7.42-7.39 (d, J=9.6Hz, 1H), 3.97 (s, 2H), 3.51 (s, 2H), 3.33-3.32 (d, J=4.8Hz, 6H), 3.13 (m, 2H), 1.76-1.72 (d, J=12Hz, 4H), 1.60~1.51(m, 2H). (ES, m/z): 684 [M-2CF ₃ COOH+H] ⁺ .

Example 54

Procedure for the Measurement of NaP2b-Mediated Pi Transport

Materials. HEK293 cells were obtained from the American Type Culture collection and propagated per their instructions. Expression clones for rat and mouse NaP2b (SLC34A2) cDNAs were obtained from Open Biosystems (Catalog numbers MKN 1768-9510282 and MMM1013-98478398 respectively).

Inhibition of P, Transport. The rate of phosphate uptake into HEK293 cells was measured using a modification of the method described by Mohrmann et al. (Mohrmann, I., Mohrmann, M., Biber, J., and Murer, H. (1986) Am. J. Phys. 250(3 Pt l):G323-30.) Transfected HEK293 cells were treated with a pharmacological agent to minimize endogenous PiT-mediated phosphate transport activity, such that the only remaining sodium-dependent phosphate transport activity is that which was bestowed by introduction of the NaP2b genes.

Cells were seeded into 96-well plates at 25,000 cells/well and cultured overnight. Lipofectamine 2000 (Invitrogen) was used to introduce the NaP2b cDNA, and the cells were allowed to approach confluence during a second overnight incubation. Medium was aspirated from the cultures, and the cells were washed once with choline uptake buffer (14 mM Tris, 137 mM choline chloride, 5.4 mM KC1, 2.8 mM CaCl ₂ , 1.2 mM MgS0 ₄ , 100 uM KH ₂ P0 , pH 7.4). Cells were then overlayed with either choline uptake buffer or sodium uptake buffer (14 mM Tris, 137 mM sodium chloride, 5.4 mM KC1, 2.8 mM CaCl ₂ , 1.2 mM MgS0 ₄ , 100 uM KH ₂ P0 ₄ , PiT-silencmg agent, 0.1% wt v bovine serum albumin, pH 7.4) containing 6-9 uCi/mL ³³ P orthophosphoric acid (Perkin Elmer) and test compound. Each compounds was tested at twelve concentrations ranging from 0.1 nM to 30 uM. Assays were run in duplicate.

After incubation for 3-30 minutes at room temperature, assay mixtures were removed, and the cells were washed twice with ice cold stop solution (137 mM sodium chloride, 14 mM Tris, pH 7.4). Cells were lysed by addition of 20 μΐ, 0.1% Tween 80 followed by 100 uL scintillation fluid, and counted using a TopCount (Perkin Elmer). pIC50 (the negative log of the IC50) values of the test compounds were calculated using GraphPad Prism. Preliminary studies showed that under these conditions, sodium-dependent Pi uptake was linear for at least 30 min and tolerated 0.6 % (v/v) DMSO without deleterious effects.

Table 2

Inhibitory activity of compounds against rat NaP2b

Ex.15 7.1-8.0 Ex.38 6.1-7.0

Ex.16 6.1-7.0 Ex.40 6.1-7.0

Ex.17 6.1-7.0 Ex.41 6.1-7.0

Ex.18 6.1-7.0 Ex.43 6.1-7.0

Ex.19 6.1-7.0 Ex.44 6.1-7.0

Ex.20 6.1-7.0 Ex.45 6.1-7.0

Ex.21 6.1-7.0 Ex.46 6.1-7.0

Ex.22 5.1-6.0 Ex.47 6.1 - 7.0

Ex.23 5.1-6.0 Ex.48 5.1-6.0

Ex.24 4.0-5.0 Ex.49 6.1-7.0

Ex.25 5.1-6.0 Ex.50 6.1-7.0

Ex.26 4.0-5.0 Ex.51 6.1-7.0

Ex.27 4.0-5.0 Ex.52 6.1-7.0

Ex.28 4.0-5.0 Ex.53 6.1-7.0

Example 55

Stability of Compounds in Simulated Gastric and Intestinal Fluid

Test compounds were incubated at 1-20 μΜ in simulated gastric fluid (SGF; standard USP solution with 3 mgmL pepsin) or simulated intestinal fluid (SIF; standard USP solution with 3 mg/mL pancreatin) for 3 hr. HPLC-UV or HPLC-MS were used to determine test compound levels using peak area %. Results (Table 3) were reported as the percentage of test compound remaining after incubation in a given condition relative to test compound present at t = 0 in the same condition.

Table 3

Percentage of Compound Remaining in Simulated Gastric and Intestinal Fluids

Incubation % remaining, % remaining,

Example Time SIF SGF

Ex. 49 3 hr 89 21

Ex. 31 3 hr 91 22

Ex. 40 3 hr 98 15

Ex. 5 3 hr 90 15

Ex. 53 3 hr 107 6

Example 56

In vivo Assay: bolus phosphate challenge

It has been demonstrated that in mice made genetically deficient for the Nap2b gene, the hyperphosphatemic response to single oral dose of phosphate is significantly dampened (Sabbagh et al, J. Am Soc Nephrol., 20(l l):2348-58 (2009)). This was demonstrated by placing animals on a low phosphate diet and then dosing with phosphate. Serum was collected 30 minutes after gavage, and phosphate levels measured. These investigators showed that as a result of the Np2b deletion, the rise in serum phosphate was reduced by about 40%. This indicates that the theoretical maximum effect a Nap2b inhibitor could have in this model is a reduction of serum Pi by 40%. The in vivo bolus phosphate challenge model used here mimics this model in rats.

Male, 7-week-old Sprague-Dawley rats (Charles-River laboratories international, Hollister, CA) were allowed to acclimatize for a minimum of 3 days before switching to a low-phosphorus diet (TD.85010, Harlan Teklad, Madison, WI) which contains 0.1% phosphorus and 0.6% calcium. At day 5, testing compounds or vehicle alone (as indicated) were orally administered at the indicated dose in a volume of 5 ml/kg, followed by a bolus gavage of monobasic sodium phosphate (1 mmol in 1 ml ) 15 min after compound dosing. Serum was collected via retroorbital bleeding 30 min post phosphate bolus and serum phosphate levels were determined utilizing an ACE ALERA blood chemistry analyzer (Alfa Wassermann Diagnostic Technologies, West Caldwell, NJ). The representative data on effects of test compounds on serum phosphate levels are shown in Table 4 (data are expressed as mean ± SD, with 6 animals per data point). The differences between groups were evaluated by one-way analysis of variance with Dunnett's post hoc tests.

Table 4

Inhbition of uptake of Phosphate from the instestine as measured using the bolus phosphate challenge model

* p < 0.05, versus vehicle by Dunnett's post hoc test.

** p < 0.01 , versus vehicle by Dunnett's post hoc test.

Exainpc 57

In vivo evaluation procedure: co-dosing in chow

Male, 7-week-old Sprague-Dawley rats (Charles-River laboratories international, Hollister, CA) were allowed to acclimatize for a minimum of 3 days. The experiment was initiated by switching animals to a diet in which the test agent was mixed into their chow (0.65% phosphorus, Harlan Teklad 2018c) for 2 days. Test compounds were incorporated at a level to achieve a dose of 100 mg/kg/day. Dietary phosphorus contents in experimental groups were maintained at 0.65% by adding various amount of high phosphorus diet (1.2% phosphorus, TD.85349 Harlan Teklad). The animals were housed in metabolic cages during the experiment for daily monitoring of food and water consumption, and urine and fecal collections for later analysis. Serum and urine chemistries (phosphate, Ca, Mg, creatinine, etc.) were analyzed by an ACE ALERA blood chemistry analyzer (Alfa Wassermann).

Representative data are shown in Table 5 (data are expressed as means ± SD, with 10 animals per data point). The differences between control and treated group were evaluated by t tests.

Table 5

Effects of NaPi2b inhibitors on serum and urine phosphate levels

* p< 0.05 versus control

** p<0.01 versus control

a: urine 24 h total phosphate excretion normalized by 24 h total phosphorus intake, assessed by measuring chow consumption.

ADDITIONAL BIOLOGICAL EXMAPLES

Example 1

Animal Models of Chronic Kidney Disease (CKD)

In one illustrative method, renal insufficiency is induced by 5/6 nephrectomy in 5 to 6 weeks-old male or female Sprague-Dawley rats, weighing 200 to 225 g. Several branches of the left renal artery are ligated and the right kidney is excised. This can be performed in one surgery, or preferably, in two separate surgeries. After being given one to two weeks to recover, the animals are then placed on diets that will enhance the progress of kidney damage as well increase serum phosphorus levels. These diets can include phosphorus at levels from 0.6 to 1.2% of chow weight. Optionally, the animals can be provided with activated forms of Vitamin D such as calcitriol that is dosed IP every other day, or it can be included in the chow in a dietary form. Animals are maintained on such a diet until they become hyperphosphatemic, that is, their serum P is greater than approximately 8 mg/dL P. Serum creatinine levels are also measured to estimate the level of kidney damage.

In a second illustrative method, male or female Sprague-Dawley rats are acclimated and fed a standard chow (for example, Harlan Teklad 5001 diet). To initiate renal insufficiency, rats are dosed orally with 500 or 600 mg/kg adenine sulfate for 10 consecutive days. After this time, the rats can be shifted to a diet that includes phosphorus at levels from 0.6 to 1.2% of chow weight. Optionally, the animals are provided with activated forms of Vitamin D such as Calcitriol that is dosed IP every other day, or it can be included in the chow in a dietary form. Animals are maintained on such a diet until they become hyperphosphatemic, that is, their serum P is greater than approximately 8 mg dL P. Serum creatinine levels are also measured to estimate the level of kidney damage.

In a third illustrative method, rodents are subjected to uninephrectomy (UNX) and renal artery cross-clamp of the contralateral kidney for a defined period of time (ischemic-reperfusion; IRI). The animals will then regain full kidney function but over about a two month period will develop chronic kidney disease (CKD) similar to human stage 2-4 CKD and will eventually reach end stage renal failure. One advantage of this model over existing ones is the well demarcated and consistent degree of renal dysfunction that enables one to detect even small changes (positive or negative) brought about by experimental manupulations. Another advantage of this method is the ability of the experimenter to control the speed of progression of CKD and the severity of its complications by changing the dietary sodium, protein, and phosphate.

Example 2 Measuring the Effects of NaPi2b Inhibitors on Serum Phosphorous Levels in Animal Models of CKD

Animals are treated as indicated in the example above to induce renal insufficiency. A subset of animals are selected that have similar levels of serum creatinine and phosphorus, and the animals are randomized. On the day of the experiment, compounds or vehicle alone are orally administered at the desired dose in a volume of 5 ml/kg, followed by a bolus gavage of monobasic sodium phosphate (0.6 to 1.0 mmol in 1 ml) from 15 to 120 minutes after compound dosing. Serum is then collected via tail or retroorbital bleeding 60 and/or 120 minutes after the phosphorus bolus and phosphorus levels are determined using a suitable blood chemistry analyzer, e.g., an ACE ALERA (Alfa Wassermann Diagnostic Technologies, West Caldwell, NJ).

Example 3

NaPi2b Inhibitors for Treating Hyperphosphatemia

Animals are treated as indicated in the example above to induce renal insufficiency. A subset of animals are selected that have similar levels or serum creatinine and phosphorus, and the animals are randomized. The animals are then switched to a diet containing a known high level of phosphorus, typically between 0.6 and 1.2% P, and the NaPi2b inhibitor is included in the chow at a desired level. The level of protein and NaCl in the chow can be varied to impact the rate of progression of kidney disease. Optionally, the animals are provided with activated forms of Vitamin D such as calcitriol that is dosed IP every other day, or it can be included in the chow in a dietary form. The animals are maintained on this diet from 1 to 12 weeks. On a weekly basis, serum is collected from the animals by tail or retro-orbital bleed. Serum is analyzed for P, creatinine, electrolytes and BUN. In addition, serum can be tested for one or more of the calciotropic and phosphate hormones, including l,25-OH2- Vitamin D3 and the phosphatonins PTH and FGF23. At various intervals, the animals can be placed in metabolic cages for up to four days, where urine and feces are collected every 24 hours, and where food and water consumption are monitored. By determination of phosphorus levels in the urine and feces, an assessment is made of the phosphorus balance status of the animals. In addition, other markers of CKD in the urine such as electrolytes, creatinine (to determine GF ) and Klotho protein may be monitored.

At the completion of the study, in addition to the above blood and urine tests, multiple organs can be harvested for the examination of, for example, soft tissue calcification. This can be assessed by any suitable method including whole body CT (computed axial tomography) scan, Von Kossa staining and/or quantitative OPC assay, performed in the heart, kidney and major large vessels. The method further allows for the examination of parathyroid histology to accompany the plasma PTH levels; bone quantitative histomorphometry and microCT; and renal and intestinal expression of phosphate transporter mRNA and protein.

Example 4

Use of NaPi2b inhibitors in the Treatment of CKD

Animals are treated as indicated in the example above to induce renal insufficiency. A subset of animals are selected that have similar levels or serum creatinine and phosphorus, and the animals are randomized. The animals are then switched to a diet containing a known high level of phosphorus, typically between 0.6 and 1.2% P. In addition, the level of protein and NaCl in the chow can be varied to impact the rate of progression of kidney disease. Optionally, the animals can be provided with activated forms of Vitamin D such as calcitriol that is dosed IP every other day, or it can be included in the chow in a dietary form. The animals are maintained on the selected diet until they reach the intended stage of kidney damage (models of CKD stage 2, 3, 4 or 5), as assessed, for example, by the reduction in levels of GFR (by measuring serum, and optionally, urine, creatinine). Once the animals are at the desired stage of CKD, they are switched to a treatment regimen. In this regard, NaPi2b inhibitor compound is included in the chow at a desired level. In addition, the level of phosphorus, protein and NaCl in the chow can be varied to impact the rate of further progression of kidney disease. Optionally, the animals can be provided with activated forms of Vitamin D such as calcitriol that is dosed IP every other day, or it can be included in the chow in a dietary form.

During the first week of treatment, serum is collected from the animals by tail or retro-orbital bleed. Serum is analyzed for P, creatinine, electrolytes, BUN, and one or more of the calciotropic and phosphate hormones (e.g., PTH, l,25-OH2- Vitamin D3, FGF23). After the first week, serum is collected once a week. At various intervals, the animals can be placed in metabolic cages for up to four days, where urine and feces are collected every 24 hours, and where food and water consumption may be monitored. By determination of phosphorus levels in the urine and feces, an assessment of the phosphorus balance status of the animals can be made, and other markers of CKD in the urine such as electrolytes, creatinine (to determine GFR) and Klotho protein, may also be assessed.

At the completion of the study, in addition to the above blood and urine tests, multiple organs can be harvested for the examination of soft tissue calcification, as assessed using a suitable method such as whole body CT scan, Von Kossa staining, and quantitative OPC assay. This can be performed in the heart, kidney, and several major large vessels. In addition, parathyroid histology to accompany the plasma PTH levels and bone quantitative histomorphometry and microCT are also assessed.

Example 5

Use of NaPi2b Inhibitors in Combination with Known Phosphate Binders in the

Treatment of CKD

It is common for patients with advanced CKD to be treated with phosphate binders to reduce serum P. These phosphate binders include aluminium hydroxide, calcium carbonate, calcium acetate (PhosLo), lanthanum carbonate (Fosrenol), sevelamer chloride (Renagel), sevelamer carbonate (Renvela), calcium acetate/magnesium carbonate (Renepho, OsvaRen), as well as various formulations of trivalent iron salts or polynuclear iron compounds. Specifically, the procedures described in Examples above can be carried out such that when the NaP2b inhibitor is blended into the chow, a P binder is also blended into the chow. The test compounds are blended into the chow in a series of experiments (often referred to as checkerboard experiments) at one half, one third or one tenth of each of their usual doses. In this way, synergistic effects between these two classes of compound may be evaluated.

Example 6

Use of NaPi2b inhibitors in Preventing Accelerated Aging due to

Hyperphosphatemia

The klotho protein forms a complex with multiple fibroblast growth factor (FGF) receptors and functions as an obligatory co-receptor for FGF23, a bone- derived hormone that induces negative phosphate balance. Defects in either Klotho or Fg£23 gene expression cause not only phosphate retention but also a premature-aging syndrome in mice, thus identifying a potential link between phosphate metabolism and aging (Kuro-o (2009), Biochim. Biophys. Acta 1790, 1049). Within their short life span of about nine weeks, klotho mutant homozygous mice show many characteristics similar to the senescence-related diseases of humans. These include ectopic calcification in the arterial wall and stomach, osteoporosis, abnormal bone formation and hyperphosphatemia. One of the consequences of phosphotoxicity is soft tissue calcification which occurs around 4-6 weeks of life and can be accelerated by escalating dietary phosphate content. In contrast, it has been shown that dietary phosphate restriction alleviates soft tissue calcification in these animals. NaPi2b inhibitor compounds of the invention may act similarly to reduce phosphate load via inhibition of NaPi2b, thereby altering the course of this accelerated senescence.

To evaluate NaPi2b inhibitors in such a model, after weaning (at about three weeks of age), klotho mice are fed chow containing sufficient levels of P to cause this rapid aging phenotype. An additional group is fed the same chow supplemented with test compound. After one or more weeks on these diets, the animals are compared with respect to progression of the premature aging-like phenotype. This comparison includes assessments of body weight, serum P, ectopic calcification in different tissues and prolonged survival. All of the U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications referred to in this specification are incorporated herein by reference, in their entirety to the extent not inconsistent with the present description.

From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.